"","nct_id","trial_title","Conditions","condition","Interventions","intervention_type","Sponsor_Collaborators","sponsor_class","fda.drug","fda.device","Gender","min.age","max.age","Enrollment","Start_Date","Completion_Date","title","p","p.desc","method","param.value","param.type","ci","ci.side","ci.l","ci.u"
"1","NCT00007020","Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid","Infantile Refsum's Disease",0,"Cholic Acids","Drug","Retrophin, Inc.","Industry",0,0,"All","N/A","N/A","79","January 1992","December 2009","Determination of changes in synthesis of atypical bile acids in urine by mass spectrometry (FAB MS)","0","0","0","0","0","0","0","0","0"
"2","NCT00036270","Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane","Breast Neoplasms",0,"exemestane (Aromasin)","Drug","Pfizer","Industry",0,0,"Female","50 Years","N/A","9779","August 2001","October 2008","Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years","0.118","0","Log Rank","0.89","Hazard Ratio (HR)","95","2-Sided","0.77","1.03"
"3","NCT00038948","Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients","Renal Transplantation",0,"Sirolimus","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","13 Years","N/A","830","January 2002","May 2008","Nankivell Glomerular Filtration Rate (GFR)","0.575","Analysis of covariance p-value","ANCOVA","-2.68","Weighted difference","95","0","-12.27","6.91"
"4","NCT00048724","Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)","Chronic Hepatitis C",0,"peginterferon alfa-2b (SCH 54031)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","631","June 2002","April 2008","Time to Observation of the First Clinical Event Experienced by a Subject","0.1439","0","Cox Proportional Hazards Model","1.452","Hazard Ratio (HR)","95","0","0.880","2.396"
"5","NCT00049842","Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)","Chronic Hepatitis C",0,"peginterferon alfa-2b (SCH 54031)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","540","October 2002","October 2009","Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3).","0","0","0","0","0","0","0","0","0"
"6","NCT00050011","Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy","Breast Neoplasms",0,"Zoledronic Acid","Drug","Novartis Pharmaceuticals","Industry",0,0,"Female","18 Years","85 Years","602","September 2002","January 2009","Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD)","0","0","0","0","0","0","0","0","0"
"7","NCT00065507","Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation","Hepatitis B",0,"Entecavir (ETV)","Drug","Bristol-Myers Squibb","Industry",0,0,"All","16 Years","N/A","195","August 2003","October 2008","Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24","<0.0001","0","Regression, Linear","-1.74","Mean Difference (Final Values)","95","2-Sided","-2.30","-1.18"
"8","NCT00069784","The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)","Diabetes Mellitus, Non-Insulin-Dependent",0,"insulin glargine (HOE901)","Drug","Sanofi","Industry",0,0,"All","50 Years","N/A","12537","August 2003","December 2011","Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke","0.6273","For the analysis of the two coprimary efficacy outcomes, the overall Type 1 error was partitioned. The first coprimary outcome was tested at 4.4%, whereas the second coprimary outcome was tested at 1% (weighted Hochberg procedure).","Log Rank","1.022","Cox Proportional Hazard","95","2-Sided","0.937","1.114"
"9","NCT00074906","Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)","Pneumonia",0,"Venticute","Drug","Takeda","Industry",0,0,"All","12 Years","85 Years","1200","November 2003","March 2008","Survival on day 28","0","0","0","0","0","0","0","0","0"
"10","NCT00075218","A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)","Gastrointestinal Stromal Tumor",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","361","December 2003","May 2008","Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase","<0.001","The nominal levels of significance for the interim and final analyses were determined at the time of the analyses using the Lan-DeMets procedure with an O’Brien-Fleming stopping rule.","Log Rank","0.329","Hazard Ratio (HR)","95","0","0.233","0.466"
"11","NCT00080470","An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence","Urinary Incontinence",0,"bion","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","148","June 2003","July 2008","Number of Leaks Per Day","0","0","0","0","0","0","0","0","0"
"12","NCT00082381","Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin","Diabetes Mellitus, Type 2",0,"Exenatide (AC2993)","Drug","AstraZeneca","Industry",0,0,"All","30 Years","75 Years","551","June 2003","July 2008","Change in Glycosylated Hemoglobin (HbA1c)","0.4602","0","ANCOVA","0.05","Mean Difference (Final Values)","95","0","-0.09","0.20"
"13","NCT00082407","Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin","Diabetes Mellitus, Type 2",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","30 Years","75 Years","505","November 2003","July 2008","Change in Glcosylated Hemoglobin (HbA1c)","0.2534","0","ANCOVA","-0.10","Mean Difference (Final Values)","95","0","-0.28","0.08"
"14","NCT00082433","Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","Cancer",0,"Ixabepilone + Capecitabine","Drug","R-Pharm","Industry",0,0,"Female","18 Years","N/A","1221","November 2003","March 2008","Overall Survival (OS)",".0005","0","Log Rank",".79","Hazard Ratio (HR)","95","0",".69",".90"
"15","NCT00083889","SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell",0,"Interferon-alfa","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","750","August 2004","September 2008","Progression-Free Survival (PFS), Core Radiology Assessment","<0.0001","p-value from 2-sided, unstratified test.","Log Rank","0.5268","Hazard Ratio (HR)","95","2-Sided","0.4316","0.6430"
"16","NCT00086346","Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients","Liver Transplantation",0,"Sirolimus (Rapamune)","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","13 Years","N/A","607","December 2002","July 2008","Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)","0.342","0","Rank ANCOVA","0","0","0","0","0","0"
"17","NCT00086580","Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients","B-Cell Chronic Lymphocytic Leukemia",0,"FluCAM [Fludara + Campath]","Biological","Genzyme, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","335","July 2004","June 2010","Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) Assessment","<0.001","0","Regression, Cox","0.610","Hazard Ratio (HR)","95","2-Sided","0.467","0.795"
"18","NCT00087022","Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer","Kidney Cancer",0,"girentuximab","Biological","Wilex","Industry",0,0,"All","18 Years","N/A","864","July 2004","October 2012","Disease-free survival","0","0","0","0","0","0","0","0","0"
"19","NCT00088010","Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer","Osteoporosis, Postmenopausal",0,"Arzoxifene","Drug","Eli Lilly and Company","Industry",0,0,"Female","60 Years","85 Years","9369","June 2004","June 2009","Effects of arzoxifene on bone fractures and bone mass","0","0","0","0","0","0","0","0","0"
"20","NCT00088166","XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors","Brain Edema",0,"hCRF","Drug","Celtic Pharma Development Services","Industry",0,0,"All","18 Years","N/A","200","May 2004","March 2008","The Proportion of Patients in Each Treatment Group Who Are Responders at Week 2 and Continue to be Responders at Week 5","0","0","0","0","0","0","0","0","0"
"21","NCT00088530","BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)","Lymphoma, Non-Hodgkin",0,"pixantrone, cyclophosphamide, vincristine, rituximab, prednisone","Drug","CTI BioPharma","Industry",0,0,"All","18 Years","N/A","140","July 2004","February 2010","Complete Response (CR) and Complete Response Unconfirmed (CRu)","0","0","0","0","0","0","0","0","0"
"22","NCT00089791","A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis","Osteoporosis",0,"placebo","Drug","Amgen","Industry",0,0,"Female","60 Years","90 Years","7808","August 1, 2004","May 1, 2008","Number of Participants With New Vertebral Fractures","<0.0001","Logistic regression was used to generate the p-value","Mantel Haenszel","0.32","Risk Ratio (RR)","95","0","0.26","0.41"
"23","NCT00089804","Study of LJP 394 in Lupus Patients With History of Renal Disease","Lupus Erythematosus, Systemic",0,"abetimus sodium (LJP 394) and/or placebo solution","Drug","La Jolla Pharmaceutical Company","Industry",0,0,"All","12 Years","70 Years","943","October 2004","February 2009","To determine whether abetimus sodium is more effective than placebo in delaying the time to renal flare in SLE patients with a history of SLE renal disease. Weekly administration with a 52-week treatment duration.","0","0","0","0","0","0","0","0","0"
"24","NCT00089895","EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)","Myocardial Ischemia",0,"Eptifibatide (Integrilin)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","9406","November 1, 2004","November 1, 2008","Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.","0","0","0","0","0","0","0","0","0"
"25","NCT00090051","FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients","Chronic Lymphocytic Leukemia",0,"Rituximab","Drug","Hoffmann-La Roche","Industry",0,0,"All","18 Years","N/A","552","July 2003","July 2008","Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC)","0.0218","0","Log Rank","0.76","Hazard Ratio (HR)","95","2-Sided","0.60","0.96"
"26","NCT00090220","A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)","Healthy Adult Female Participants",0,"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","24 Years","45 Years","3819","June 16, 2004","May 21, 2009","Incidence Rate of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer","0","0","0","88.7","Percent Relative Risk Reduction","95","0","78.1","94.8"
"27","NCT00090519","Reduction in the Occurrence of Center-Involved Diabetic Macular Edema","Diabetic Retinopathy",0,"ruboxistaurin","Drug","Chromaderm, Inc.","Industry",0,0,"All","18 Years","N/A","731","February 2004","April 2010","Mean Duration of Definite Center of Macula-involved Diabetic Macular Edema (DME)","0.969","0","ANOVA","-0.01","Mean Difference (Final Values)","95","2-Sided","-0.714","0.686"
"28","NCT00091442","A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer","Breast Cancer",0,"Docetaxel","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"Female","18 Years","N/A","751","September 2004","December 2008","Time to Progression","0.5988","Not adjusted for multiple comparison.","Log Rank","1.06","Hazard Ratio (HR)","95","0","0.86","1.3"
"29","NCT00091676","Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma","Non-Hodgkins Lymphoma",0,"FNHLId1","Biological","Biovest International","Industry",0,0,"All","18 Years","N/A","629","January 2000","December 2012","To demonstrate prolongation of the period of Disease Free Survival (significant prolongation of the period of complete remission) in idiotype vaccine treated patients","0","0","0","0","0","0","0","0","0"
"30","NCT00094458","Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC","Crohn Disease",0,"infliximab infusion; AZA placebo caps","Biological","Centocor Ortho Biotech Services, L.L.C.","Industry",0,0,"All","21 Years","99 Years","508","March 2005","April 2008","Percentage of Participants With Corticosteriod-free Clinical Remission","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"31","NCT00094653","MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma","Melanoma",0,"MDX-010 (anti-CTLA4) monoclonal antibody","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","1783","September 2004","August 2009","Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone","0.0004","0","Stratified Log Rank","0.68","Hazard Ratio (HR)","95","2-Sided","0.55","0.85"
"32","NCT00095199","Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer","Non Small Cell Lung Cancer",0,"Pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","939","January 2005","July 2011","Progression Free Survival (PFS)","0.756","The 2-sided unstratified log-rank test was employed at the 5% significance level.","Log Rank","1.03","Hazard Ratio (HR)","95","2-Sided","0.87","1.21"
"33","NCT00097370","Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome","Hypereosinophilic Syndrome",0,"mepolizumab","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","75 Years","78","September 2004","September 2010","Number of Participants With Any Adverse Event (AE) During the Treatment Phase","0","0","0","0","0","0","0","0","0"
"34","NCT00097500","Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","30 Years","75 Years","69","September 2004","December 2009","Beta-cell Function After 52 Weeks of Therapy","0.0001","0","ANCOVA","0","0","0","0","0","0"
"35","NCT00097695","Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema","Angioedema",0,"Icatibant","Drug","Shire","Industry",0,0,"All","18 Years","N/A","84","August 2004","March 2008","Time to Onset of Symptom Relief (TOSR)","0.142","0","Wilcoxon version of the log-rank test","0","0","0","0","0","0"
"36","NCT00097786","Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications","Diabetes Mellitus, Type 2",0,"Valsartan 160 mg + nateglinide 60 mg","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","50 Years","N/A","9306","January 2002","October 2009","Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan","0","0","0","0","0","0","0","0","0"
"37","NCT00101686","Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.","Colorectal Neoplasms",0,"Modified Bolus 5-FU/LV with Irinotecan","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","547","February 2003","October 2008","Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL","0.0152","p-value corresponds to the log-rank test for comparing Kaplan-Meier survival curves.","Log Rank","1.433","Hazard Ratio (HR)","95","0","1.09","1.89"
"38","NCT00101933","SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy","Epilepsy",0,"Medtronic DBS Therapy for epilepsy","Device","MedtronicNeuro","Industry",0,0,"All","18 Years","65 Years","157","December 2003","June 2008","Primary Analysis: Change in Seizure Rate","0.0017","Since a treatment-by-visit interaction remains in the final model, the results were analyzed by visit. The results shown are for the last month in the blinded phase (month 3-4).","Generalized Estimating Equations","0","0","0","0","0","0"
"39","NCT00104416","Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures","Epilepsy, Tonic-Clonic",0,"lamotrigine (LAMICTAL) extended-release","Drug","GlaxoSmithKline","Industry",0,0,"All","13 Years","N/A","153","December 2004","July 2008","Percent Change From Baseline in Weekly Primary Generalized Tonic-clonic (PGTC) Seizure Frequency During the Entire Double-Blind Treatment Phase","<0.0001","0","Cochran-Mantel-Haenszel","31.6","Median Difference (Final Values)","95","0","15.8","48.1"
"40","NCT00105027","The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study","Macular Edema, Cystoid",0,"Standard Care","Other","The EMMES Corporation","Industry",0,0,"All","18 Years","N/A","682","October 2004","February 2009","The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit","0","0","0","0","0","0","0","0","0"
"41","NCT00105183","EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection","Chronic Obstructive Pulmonary",0,"Placebo","Biological","Neovii Biotech","Industry",0,0,"All","18 Years","N/A","223","January 2005","January 2010","Number of Participants With the Event Death, Graft Loss, Acute Rejection and/or Loss to Follow-up (Whichever Occurred First)","0","0","0","0","0","0","0","0","0"
"42","NCT00105196","A Study of Aripiprazole in Patients With Major Depressive Disorder","Major Depressive Disorder",0,"Aripiprazole+ ADT","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","349","March 2005","March 2008","Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS)","<0.001","0","t-test, 2 sided","-3.73","Mean Difference (Final Values)","95","0","-5.44","-2.02"
"43","NCT00105443","A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma","Carcinoma, Hepatocellular",0,"Sorafenib (Nexavar, BAY43-9006)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","602","March 2005","November 2008","Overall Survival (OS)","0.00583","According to the pre-specified O’Brien-Fleming alpha spending function, the alpha value for this second interim analysis was 0.0073 (corresponding to a nominal value of 0.0077 after taking into account the first interim analysis).","Log Rank","0.6931","Hazard Ratio (HR)","95","0","0.5549","0.8658"
"44","NCT00106028","Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children","Osteogenesis Imperfecta",0,"risedronate sodium (Actonel)","Drug","Warner Chilcott","Industry",0,0,"All","4 Years","15 Years","143","November 2004","April 2008","Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 12, ITT Population","0.0625","0","ANCOVA","4.438","Mean Difference (Net)","95","2-Sided","-0.235","9.111"
"45","NCT00106691","Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)","Preneoplastic Conditions",0,"Toremifene 20 mg","Drug","GTx","Industry",0,0,"Male","30 Years","N/A","1590","January 2005","February 2010","To assess the efficacy of toremifene in the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN)","0","0","0","0","0","0","0","0","0"
"46","NCT00108082","The CLEVER Study - Coreg And Left Ventricular Mass Regression","Hypertrophy, Left Ventricular",0,"carvedilol MR","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","80 Years","287","January 2005","August 2008","Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12","0.7651","0","ANCOVA","0.33","Mean Difference (Final Values)","95","0","-1.83","2.49"
"47","NCT00109538","Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)","Myelodysplastic Syndromes",0,"Lonafarnib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","47","May 2005","August 2008","Proportion of subjects who achieved platelet transfusion independence for any 8-consecutive week period after randomization without worsening of RBC transfusion requirements or hemoglobin (untransfused) during the same 8-consecutive-week period.","0","0","0","0","0","0","0","0","0"
"48","NCT00110513","Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery","Antithrombin III Deficiency",0,"Recombinant human antithrombin (rhAT)","Biological","rEVO Biologics","Industry",0,0,"All","18 Years","80 Years","18","April 2005","May 2008","Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Venous Thrombosis (DVT)","0","0","0","0","0","0","0","0","0"
"49","NCT00113555","Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence","Urinary Incontinence",0,"ACT (Adjustable Continence Therapy)","Device","Uromedica","Industry",0,0,"Female","18 Years","N/A","221","December 2001","July 2008","Pad weight","0","0","0","0","0","0","0","0","0"
"50","NCT00113568","Safety Study of XP12B in Women With Menorrhagia","Menorrhagia",0,"Tranexamic acid tablets (XP12B)","Drug","Ferring Pharmaceuticals","Industry",0,0,"Female","18 Years","49 Years","784","June 2005","May 2009","Number of Subjects With at Least One Adverse Event During the Study","0","0","0","0","0","0","0","0","0"
"51","NCT00113607","An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer","Ovarian Cancer",0,"Trabectedin","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"Female","18 Years","N/A","672","April 2005","November 2010","Progression-Free Survival (PFS): Independent Radiologist Review","0.0190","0","Log Rank","0.79","Hazard Ratio, log","95","2-Sided","0.65","0.96"
"52","NCT00114777","Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant","Renal Transplantation",0,"CsA","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","580","February 2005","May 2008","subject and graft survival","0","0","0","0","0","0","0","0","0"
"53","NCT00114972","SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries","Coronary Artery Disease",0,"Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent","Device","Boston Scientific Corporation","Industry",0,0,"All","21 Years","N/A","1800","March 2005","April 2008","Primary Clinical Endpoint of 12-Month Binary MACCE.","0","0","0","0","0","0","0","0","0"
"54","NCT00116831","Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes","Atherosclerosis",0,"Glipizide","Drug","GlaxoSmithKline","Industry",0,0,"All","30 Years","80 Years","672","January 2005","August 2008","Change From Baseline in Percent Atheroma Volume (PAV) to Month 18","0","0","0","0","0","0","0","0","0"
"55","NCT00117286","Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","57","March 2005","September 2009","Participants With Markedly Abnormal Change in Vital Signs and Body Weight","0","0","0","0","0","0","0","0","0"
"56","NCT00119717","Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)","Cerebrovascular Accident",0,"NeuroFlo™ catheter","Device","CoAxia","Industry",0,0,"All","18 Years","N/A","515","June 2005","June 2010","The safety of the NeuroFlo device and procedure will be compared to medical management alone","0","0","0","0","0","0","0","0","0"
"57","NCT00120289","Niacin Plus Statin to Prevent Vascular Events","Cardiovascular Diseases",0,"Extended release niacin","Drug","Axio Research. LLC","Industry",0,0,"All","45 Years","N/A","3414","September 2005","September 2012","Composite End Point of CHD Death, Nonfatal MI, Ischemic Stroke, Hospitalization for Non-ST Segment Elevation Acute Coronary Syndrome (ACS), or Symptom-driven Coronary or Cerebral Revascularization","0.80","0","Regression, Cox","1.02","Hazard Ratio (HR)","95","2-Sided","0.87","1.21"
"58","NCT00120523","5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis","Atopic Dermatitis",0,"Pimecrolimus","Drug","MEDA Pharma GmbH & Co. KG","Industry",0,0,"All","3 Months","12 Months","2418","April 2004","October 2010","Safety Assessed by Adverse Events","0","0","0","0","0","0","0","0","0"
"59","NCT00121108","MEDI-524 (Motavizumab) for the Prevention of Respiratory Syncytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States","Healthy",0,"MEDI-524","Biological","MedImmune LLC","Industry",0,0,"All","1 Month","6 Months","2127","November 2004","December 2010","The incidence of RSV hospitalization from Study Day 0 through Study Day 150 of the 1st RSV season will be the primary endpoint.","0","0","0","0","0","0","0","0","0"
"60","NCT00122317","Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)","Paroxysmal Hemoglobinuria, Nocturnal",0,"eculizumab","Drug","Alexion Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","187","May 2005","September 2008","Incidence of Treatment-emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"61","NCT00122382","Remission and Joint Damage Progression in Early Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","1052","July 2005","February 2008","Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12","<0.001","p-value of <0.05: probability for testing the difference between ABA and PLA.","Chi-squared, Continuity-Corrected","15.1","Estimated Difference between ABA and PLA","95","2-Sided","6.0","24.2"
"62","NCT00125164","Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency","Growth Disorders",0,"rhIGF-1 (mecasermin, Tercica, Inc.)","Drug","Ipsen","Industry",0,0,"All","3 Years","12 Years","137","March 2004","July 2008","Height Velocity During the First Year - Intent to Treat (ITT)Population","<0.0001","The two-sided p-values for the comparisons are adjusted for multiple comparisons using Dunnett’s method.","ANCOVA","1.79","LS mean difference","95","0","1.19","2.39"
"63","NCT00125190","Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency","Insulin-Like Growth Factor-1 Deficiency",0,"rhIGF-1 (mecasermin) for a period of 86 weeks","Drug","Ipsen","Industry",0,0,"All","3 Years","N/A","45","July 2005","January 2009","Height Velocity Over the Study Period 0 - 34 Weeks [Intent to Treat Population]","0","0","0","0","0","0","0","0","0"
"64","NCT00126425","Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease","Heart Failure, Congestive",0,"123I-mIBG (meta-iodobenzylguanidine)","Drug","GE Healthcare","Industry",0,0,"All","18 Years","N/A","587","July 2005","July 2008","Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) Ratio","=0.004","At 0.025 level of significance.","Cox Proportional Hazards Model","0.44","Hazard Ratio (HR)","95","2-Sided","0.23","0.83"
"65","NCT00126438","Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease","Heart Failure, Congestive",0,"123I-mIBG (meta-iodobenzylguanidine)","Drug","GE Healthcare","Industry",0,0,"All","18 Years","N/A","515","July 2005","July 2008","Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) Ratio","0.001","At 0.025 level of significance.","Cox Proportional Hazards Model","0.36","Hazard Ratio (HR)","95","2-Sided","0.18","0.73"
"66","NCT00127166","Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)","Exercise Induced Asthma",0,"Montelukast sodium","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","6 Years","14 Years","154","December 2005","November 2008","Maximum Post-exercise Percent (%) Fall in FEV1","0.009","0","ANOVA","-3.25","Least squares mean difference","95","0","-5.66","-0.84"
"67","NCT00128102","Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)","Mesothelioma",0,"vorinostat","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","662","June 2005","July 2011","Overall survival","0","0","0","0","0","0","0","0","0"
"68","NCT00128492","Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)","Cystic Fibrosis",0,"AZLI 75 mg two times a day (BID)/ three times a day (TID)","Drug","Gilead Sciences","Industry",0,0,"All","6 Years","N/A","274","August 2005","November 2008","Number of Participants Reporting Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"69","NCT00131573","An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome","Overactive Bladder",0,"bion","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","118","May 2004","March 2008","Average Number of Voids Per Day","0","0","0","0","0","0","0","0","0"
"70","NCT00134537","Wallis Mechanical Normalization System for Low Back Pain","Low Back Pain",0,"Interspinous process and dynamic stabilization","Device","Zimmer Spine","Industry",0,0,"All","18 Years","60 Years","300","November 2004","April 2011","To provide a safety cohort for the Prospective, Multi-center, Randomized, Active-Controlled Study of the Wallis System for the Treatment of Mild to Moderate Degenerative Disc Disease of the Lumbar Spine","0","0","0","0","0","0","0","0","0"
"71","NCT00134563","Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis","Multiple Sclerosis",0,"Teriflunomide","Drug","Sanofi","Industry",0,0,"All","18 Years","55 Years","1088","September 2004","July 2010","Annualized Relapse Rate [ARR]: Poisson Regression Estimates","0.0005","Step down approach used to adjust for multiplicity:
H1 tested first
H2 tested only if the comparison H1 was statistically significant
A priori threshold for statistical significance for both comparisons ≤0.05","Regression, Poisson","31.5","Relative risk reduction (%)","0","0","0","0"
"72","NCT00135330","An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","18 Years","75 Years","137","October 2005","July 2008","Change in ASIiAUC During a Hyperglycemic Clamp Test.","0.282","0","ANCOVA","0","0","0","0","0","0"
"73","NCT00136916","Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes","Diabetes Mellitus",0,"Inhaled Insulin","Drug","Pfizer","Industry",0,0,"All","35 Years","75 Years","635","June 2002","December 2008","Change From Month 3 in Forced Expiratory Volume in 1 Second (FEV1)","0","0","0","0","0","0","0","0","0"
"74","NCT00137046","Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes","Diabetes Mellitus, Type 1",0,"Subcutaneous Insulin","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","582","May 2002","December 2008","Change From Baseline in Forced Expiratory Volume in One Second (FEV1)","0","0","0","-0.024","Mean Difference (Final Values)","90","0","-0.041","-0.007"
"75","NCT00137969","A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus","Lupus Erythematosus, Systemic",0,"Rituximab","Drug","Genentech, Inc.","Industry",0,0,"All","16 Years","75 Years","262","May 2005","August 2008","Number of Participants Who Achieved a Major Clinical Response (MCR), Partial Clinical Response (PCR), or Nonclinical Response (NCR) Defined by British Isles Lupus Assessment Group (BILAG) Scores Over The 52-week Treatment Period","0.4875","One-sided p-value.","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"76","NCT00138671","A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD","Diabetes Mellitus",0,"Subcutaneous Insulin","Drug","Pfizer","Industry",0,0,"All","30 Years","77 Years","105","January 2003","September 2008","Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)","0","0","0","0","0","0","0","0","0"
"77","NCT00139659","A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma","Asthma",0,"Inhaled Insulin","Drug","Pfizer","Industry",0,0,"All","18 Years","77 Years","288","January 2003","October 2008","Annualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1)","0","0","0","-0.034","Mean Difference (Final Values)","90","0","-0.080","0.011"
"78","NCT00139737","Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia","Schizophrenia",0,"Ziprasidone","Drug","Pfizer","Industry",0,0,"All","18 Years","60 Years","344","March 2002","June 2009","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"79","NCT00141011","Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke","Stroke",0,"Ancrod (Viprinex)","Drug","Neurobiological Technologies","Industry",0,0,"All","18 Years","N/A","277","September 2005","December 2008","Responder analysis based on Modified Rankin Scale (mRS)","0","0","0","0","0","0","0","0","0"
"80","NCT00141271","A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression","Bipolar Disorder",0,"Geodon (Ziprasidone)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","536","July 2005","February 2008","Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score","0.6409","Hochberg’s adjustment was used for multiple comparisons adjustment","Mixed Models Analysis","0","0","0","0","0","0"
"81","NCT00141921","Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis","Pediatric Plaque Psoriasis",0,"Etanercept","Drug","Amgen","Industry",0,0,"All","N/A","N/A","182","August 11, 2005","December 19, 2011","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"82","NCT00143390","Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer","Breast Neoplasms",0,"exemestane","Drug","Pfizer","Industry",0,0,"Female","20 Years","N/A","298","April 2005","December 2010","Time to Progression (TTP) - Expert Evaluation Committee Assessment","0","0","0","1.007","Hazard Ratio (HR)","95","2-Sided","0.771","1.317"
"83","NCT00143403","Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer","Colorectal Neoplasms",0,"Irinotecan + 5 FU + folinic acid","Drug","Pfizer","Industry",0,0,"All","18 Years","75 Years","321","December 2001","February 2008","Disease Free Survival (DFS)","0","0","0","0.90","Hazard Ratio (HR)","95","0","0.67","1.20"
"84","NCT00143455","Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer","Small Cell Lung Carcinoma",0,"Etoposide + cisplatin","Drug","Pfizer","Industry",0,0,"All","18 Years","75 Years","485","June 2002","December 2008","Overall Survival (OS) for the Full Analysis Population (FAP)","0.0556","0","Cox Proportional Hazard Model","1.236","Hazard Ratio (HR)","95","0","0.995","1.536"
"85","NCT00144547","Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP","Rheumatoid Arthritis",0,"MRA(Tocilizumab)","Drug","Chugai Pharmaceutical","Industry",0,0,"All","20 Years","N/A","241","April 2004","August 2008","Patients fron MRA Group of previous study:The frequency of amelioration of at least 20% in terms of the ACR criteria compared to the beginning of the treatment in previous study(MRA012JP)","0","0","0","0","0","0","0","0","0"
"86","NCT00145496","Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)","Schizophrenia",0,"Asenapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","468","December 2004","November 2008","Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total Score","0.7177","The test of hypothesis was a 2-tailed test with alpha=0.05 (0.049 to adjust for one interim analysis).","Mixed Model for Repeated Measurements","0","0","0","0","0","0"
"87","NCT00145535","SOLX Titanium Sapphire Laser for Trabeculoplasty","Glaucoma",0,"SOLX Titanium Sapphire Laser (TiSaLT)","Device","SOLX, Inc.","Industry",0,0,"All","18 Years","N/A","120","May 2004","June 2009","Intraocular Pressure (IOP)","0","0","0","0","0","0","0","0","0"
"88","NCT00150176","To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)","Schizophrenia",0,"Asenapine - Open Label","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","831","April 2005","June 2008","Time to Relapse or an Impending Relapse","0","0","0","0","0","0","0","0","0"
"89","NCT00150345","Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients","Possible Fungal Infection",0,"voriconazole (Vfend)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","147","January 2005","April 2009","Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis","0.258","0","Regression, Logistic","0.493","Odds Ratio (OR)","95","2-Sided","0.129","1.755"
"90","NCT00152516","Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures","Epilepsy, Partial",0,"levetiracetam (LEV)","Drug","UCB Pharma","Industry",0,0,"All","1 Month","16 Years","255","October 2004","June 2008","Percentage Change (Reduction) of Partial (Type I) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.","0","0","0","0","0","0","0","0","0"
"91","NCT00157014","Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens","Heart Diseases",0,"Tacrolimus","Drug","Astellas Pharma Inc","Industry",0,0,"All","N/A","N/A","111","May 10, 2004","July 18, 2008","The Change in the Markers of Growth, Apoptosis, Inflammation and Oxidation Measured in Endomyocardial Biopsies","0","0","0","0","0","0","0","0","0"
"92","NCT00157157","Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients","Hemophilia A",0,"Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)","Biological","Baxalta US Inc.","Industry",0,0,"All","N/A","6 Years","66","April 2004","September 2009","Factor VIII Inhibitor Development","0","0","0","0","0","0","0","0","0"
"93","NCT00157339","Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD","Diabetes Mellitus",0,"Human Insulin Inhalation Powder","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","299","August 2005","May 2008","To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c.","0","0","0","0","0","0","0","0","0"
"94","NCT00159822","Voriconazole For Chronic Bronchopulmonary Aspergillosis","Aspergillosis",0,"Voriconazole","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","48","July 2005","December 2008","Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis","0","0","0","31.7","Percent of subjects with success","95","0","18.08","48.09"
"95","NCT00159874","A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children","Pulmonary Arterial Hypertension",0,"Sildenafil citrate","Drug","Pfizer","Industry",0,0,"All","1 Year","17 Years","234","January 2004","December 2012","Number of Participants Reporting at Least One Adverse Event","0","0","0","0","0","0","0","0","0"
"96","NCT00159913","A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.","Pulmonary Arterial Hypertension, Children",0,"Sildenafil citrate","Drug","Pfizer","Industry",0,0,"All","1 Year","17 Years","235","August 2003","June 2008","Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population","0.056","No adjustments for multiple comparisons have been made.","ANCOVA","7.71","Mean Difference (Net)","95","0","-0.19","15.60"
"97","NCT00160524","A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]","Crohn's Disease",0,"Certolizumab Pegol (CDP870)","Biological","UCB Pharma SA","Industry",0,0,"All","18 Years","N/A","596","July 2004","August 2012","Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study CDP870-033 (up to 84 Months)","0","0","0","0","0","0","0","0","0"
"98","NCT00160641","A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Certolizumab Pegol","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","567","November 2005","February 2012","Percentage of Subjects With at Least One Adverse Event (AE) From First Certolizumab Pegol (CZP) Dose up to Approximately 6.8 Years","0","0","0","0","0","0","0","0","0"
"99","NCT00160693","Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Certolizumab Pegol","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","402","March 2003","February 2011","Percentage of Subjects With at Least One Adverse Event (AE) During the Study Period of 8 Years","0","0","0","0","0","0","0","0","0"
"100","NCT00160706","A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease","Crohn's Disease",0,"Certolizumab Pegol (CDP870)","Biological","UCB Pharma SA","Industry",0,0,"All","18 Years","N/A","310","February 2004","May 2012","Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of This Study CDP870-034 (up to 84 Months)","0","0","0","0","0","0","0","0","0"
"101","NCT00162032","A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease","Kawasaki Disease",0,"Sestamibi","Drug","Lantheus Medical Imaging","Industry",0,0,"All","4 Years","16 Years","445","August 2005","May 2010","Kawasaki Disease Population at High and Low Risk of Developing Cardiac Events Though Three Years Follow-up.","0","0","0","0","0","0","0","0","0"
"102","NCT00163020","17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies","Preterm Birth",0,"17-alpha-hydroxyprogesterone caproate injectable","Drug","Obstetrix Medical Group","Industry",0,0,"Female","18 Years","65 Years","321","November 2004","August 2009","Newborn Respiratory Distress Syndrome (RDS)","0","0","0","0","0","0","0","0","0"
"103","NCT00163215","Growth Retardation In Children With Special Pathological Conditions Or Disease","Endocrine System Diseases",0,"Somatropin","Drug","Pfizer","Industry",0,0,"All","11 Years","13 Years","46","January 2005","October 2011","Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population","0","0","0","0","0","0","0","0","0"
"104","NCT00163293","Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)","Asthma",0,"Ciclesonide","Drug","AstraZeneca","Industry",0,0,"All","4 Years","11 Years","240","January 1, 2005","June 1, 2009","Time to First Asthma Exacerbation","0.6625","0","Log Rank","0","0","0","0","0","0"
"105","NCT00168298","A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion","Macular Edema",0,"700 µg Dexamethasone","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","668","November 2004","March 2008","Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye","0","0","0","0","0","0","0","0","0"
"106","NCT00168324","A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion","Macular Edema",0,"700 µg Dexamethasone","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","599","October 2004","March 2008","Cumulative Response Rate of 15 or More Letter Improvement","0","0","0","0","0","0","0","0","0"
"107","NCT00168337","A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema","Diabetic Macular Edema",0,"Dexamethasone","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","554","May 2005","May 2012","Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye","0","0","0","0","0","0","0","0","0"
"108","NCT00168389","A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema","Diabetic Macular Edema",0,"Dexamethasone","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","494","February 2005","June 2012","Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye","0","0","0","0","0","0","0","0","0"
"109","NCT00171210","An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload","Transfusional Iron Overload in β-thalassemia",0,"Deferasirox","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","2 Years","N/A","506","October 2004","April 2008","Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse Event","0","0","0","0","0","0","0","0","0"
"110","NCT00171340","Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.","Bone Loss",0,"Zoledronic acid","Drug","Novartis Pharmaceuticals","Industry",0,0,"Female","N/A","N/A","1065","May 2003","February 2010","Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.","0","0","0","0","0","0","0","0","0"
"111","NCT00172185","Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)","Short Bowel Syndrome",0,"teduglutide 0.05 mg/kg/d","Drug","Shire","Industry",0,0,"All","18 Years","N/A","65","January 2005","January 2008","Number of Subjects Achieving a 20% Reduction at Week 28","0","0","0","0","0","0","0","0","0"
"112","NCT00174187","Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy","Endocrine System Diseases",0,"Somatropin","Drug","Pfizer","Industry",0,0,"All","11 Years","17 Years","30","September 2000","September 2011","Change From Baseline in Height Standard Deviation Score According to Chronological Age (SDS/CA) at Year 3","0","0","0","0","0","0","0","0","0"
"113","NCT00174252","Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age","Fetal Growth Retardation",0,"Genotonorm (Somatropin)","Drug","Pfizer","Industry",0,0,"All","4 Years","9 Years","57","February 2005","April 2009","Percentage of Children With Insulin Growth Factor-1 (IGF-1) > 2 Standard Deviation (SD) at 9 and 12 Months","0","0","0","0","0","0","0","0","0"
"114","NCT00174265","6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)","Schizophrenia",0,"asenapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","196","July 2005","April 2009","Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total Score","0.0148","The test of hypothesis was a 2-tailed test with alpha=0.05 (0.049 to adjust for one interim analysis).","Mixed Model for Repeated Measurements","0","0","0","0","0","0"
"115","NCT00174291","Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy","Endocrine System Diseases",0,"Somatropin","Drug","Pfizer","Industry",0,0,"All","4 Years","14 Years","21","March 2002","October 2011","Change From Baseline in Annual Rate of Growth Standard Deviation Score (SDS) at Year 3","0","0","0","0","0","0","0","0","0"
"116","NCT00174382","Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia","Dementia, Vascular",0,"Donepezil","Drug","Pfizer","Industry",0,0,"All","50 Years","N/A","149","June 2005","April 2008","Change in Total Score of Standardized Mini-Mental State Examination (sMMSE); Full Analysis Set","0.182","Baseline value, center, and week as fixed effects; subject was included as a random effect.","Mixed Models Analysis","0.44","Mean Difference (Net)","95","0","-0.21","1.09"
"117","NCT00174447","Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031","Schizophrenia",0,"Ziprasidone","Drug","Pfizer","Industry",0,0,"All","18 Years","70 Years","43","October 2001","October 2008","Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)","0","0","0","0","0","0","0","0","0"
"118","NCT00174785","A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation","Atrial Fibrillation",0,"dronedarone (SR33589)","Drug","Sanofi","Industry",0,0,"All","70 Years","N/A","4628","June 2005","March 2008","First Hospitalization for Cardiovascular Reason or Death From Any Cause","<0.0001","Cumulative incidence functions in each treatment group were calculated using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. The primary comparison was performed at the 5% level using a 2-sided Log rank test.","Log Rank","0.76","Hazard Ratio (HR)","95","0","0.69","0.84"
"119","NCT00174837","TRACE: Tirapazamine-Radiation And Cisplatin Evaluation","Head and Neck Squamous Cell Carcinoma",0,"Tirapazamine","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","317","April 2005","January 2008","Overall survival","0","0","0","0","0","0","0","0","0"
"120","NCT00175877","A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Certolizumab Pegol","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","857","June 2005","February 2012","Percentage of Subjects With at Least One Adverse Event (AE) From First Certolizumab Pegol (CZP) Dose up to Approximately 7 Years","0","0","0","0","0","0","0","0","0"
"121","NCT00179621","Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality","Myelodysplastic Syndromes",0,"Lenalidomide 5 mg","Drug","Celgene Corporation","Industry",0,0,"All","18 Years","N/A","205","July 2005","June 2008","Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days)","<0.001","To compare the response rates of Lenalidomide 5 mg QD vs. placebo, the Hochberg procedure was used to control the familywise error rate of 0.05.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"122","NCT00179647","Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma","Multiple Myeloma",0,"lenalidomide","Drug","Celgene Corporation","Industry",0,0,"All","18 Years","N/A","1913","September 2005","December 2008","Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.","0","0","0","0","0","0","0","0","0"
"123","NCT00180271","MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy","Tachycardia",0,"Cardiac resynchronization therapy with defibrillation","Device","Boston Scientific Corporation","Industry",0,0,"All","21 Years","N/A","1820","December 2004","June 2009","Mortality From Any Cause or First Heart Failure (HF) Event","0.05","The trial involved prespecified event monitoring at up to 20 successive periods by an independent DSMB to permit trial termination if the CRT-D was superior to, inferior to, or not different from ICD according to prespecified stopping rules.","Log Rank","0.66","Hazard Ratio (HR)","95","2-Sided","0.52","0.84"
"124","NCT00184548","Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding","Acquired Bleeding Disorder",0,"eptacog alfa (activated)","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","70 Years","554","October 2005","September 2008","Mortality","0.934","Two-sided significance level 5%","Regression, Logistic","0","0","0","0","0","0"
"125","NCT00184600","Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","Diabetes",0,"biphasic insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","708","November 2004","August 2009","HbA1c (Glycosylated Haemoglobin) at Month 12","0","0","0","0","0","0","0","0","0"
"126","NCT00185211","BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study","Multiple Sclerosis",0,"Interferon beta-1b (Betaseron, BAY86-5046)","Drug","Bayer","Industry",0,0,"All","18 Years","48 Years","468","August 2002","May 2008","Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time","0.0027","A 2-sided error level of 0.0253 was used for analyses at month 36 and 60 in order to keep the study-wise error level at 0.05. A conditional sequential testing approach was used for the family of null hypotheses of the primary efficacy variables.","Log Rank","0","0","0","0","0","0"
"127","NCT00185458","Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).","Menopause",0,"LNG IUS","Drug","Bayer","Industry",0,0,"Female","46 Years","51 Years","394","May 2000","May 2008","Number of Bleeding Days","0.128","0","Friedman's two-way ANOVA","0","0","0","0","0","0"
"128","NCT00191152","A Phase III Trial For Patients With Metastatic Breast Cancer","Breast Cancer",0,"gemcitabine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","475","February 2002","November 2008","Time to Disease Progression (Initial Treatment)","0.145","0","Log Rank","0","0","0","0","0","0"
"129","NCT00191165","Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency","Growth Hormone Deficiency",0,"Somatropin","Drug","Eli Lilly and Company","Industry",0,0,"All","N/A","14 Years","27","March 2004","April 2008","Height Velocity Standard Deviation Score (SDS) at 12-Month Endpoint","0.340","0","ANOVA","0.45","Mean Difference (Net)","95","0","-0.50","1.40"
"130","NCT00191386","Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)","Attention Deficit Hyperactivity Disorder",0,"Atomoxetine hydrochloride","Drug","Eli Lilly and Company","Industry",0,0,"All","6 Years","17 Years","228","May 2005","August 2009","Number of Participants With Adverse Events for Long Term Safety and Tolerability","0","0","0","0","0","0","0","0","0"
"131","NCT00191477","Instillation of Gemcitabine in Patients With Superficial Bladder Cancer","Bladder Neoplasms",0,"Gemcitabine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","355","January 2004","March 2008","Recurrence-Free Survival (RFS)","0.777","Only 87 recurrences and 7 deaths were documented at planned end of follow-up. The study was stopped early for futility reasons based on an interim analysis using pre-defined stopping boundaries for the hazard ratio (HR) of RFS.","Log Rank","0.946","Hazard Ratio (HR)","95","0","0.643","1.392"
"132","NCT00191646","An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy","Genital Neoplasms, Female",0,"Gemcitabine","Drug","Eli Lilly and Company","Industry",0,0,"Female","18 Years","N/A","919","October 2002","August 2009","Progression Free Survival (PFS)","0.199","0","Log Rank","0","0","0","0","0","0"
"133","NCT00191945","Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder",0,"Atomoxetine Hydrochloride","Drug","Eli Lilly and Company","Industry",0,0,"All","6 Years","15 Years","151","May 2005","February 2008","Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score at 12 Week Endpoint","<0.001","0","Mixed Models Analysis","-7.9","Mean Difference (Net)","95","0","-11.0","-4.8"
"134","NCT00193674","Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage","Recurrent Miscarriage",0,"Dydrogesterone","Drug","Abbott Products","Industry",0,0,"Female","18 Years","38 Years","71","September 2003","July 2009","Cytokine ratio IFN/IL-10","0","0","0","0","0","0","0","0","0"
"135","NCT00195273","Study Evaluating Sirolimus in Kidney Transplant Recipients","Graft vs Host Disease",0,"sirolimus","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","N/A","61","November 2004","July 2008","Mean Creatinine Clearance Rate","0.6081","Calculated for 12 month analysis","ANOVA","0","0","0","0","0","0"
"136","NCT00195650","Long Term Open Label Continuation Study","Rheumatoid Arthritis",0,"Adalimumab","Biological","Abbott","Industry",0,0,"All","18 Years","N/A","846","July 2000","May 2011","Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520","0","0","0","0","0","0","0","0","0"
"137","NCT00199381","An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001","Parkinson's Disease",0,"Istradefylline","Drug","Kyowa Kirin Pharmaceutical Development, Inc.","Industry",0,0,"All","30 Years","N/A","504","October 2005","October 2008","Safety as Measured by Adverse Events","0","0","0","0","0","0","0","0","0"
"138","NCT00205777","Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women","Osteoporosis",0,"Bazedoxifene Acetate","Drug","Pfizer","Industry",0,0,"Female","55 Years","80 Years","7609","December 2001","September 2010","Percentage of Participants With New Vertebral Fractures Through Month 36","0.22","0","Log Rank","0.647","Hazard Ratio (HR)","95","2-Sided","0.322","1.302"
"139","NCT00210639","A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection","Musculoskeletal Diseases",0,"No intervention","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","6 Months","16 Years","2233","August 2002","April 2010","Musculoskeletal Adverse Events During the Musculoskeletal Disorder Follow-up Phase","0","0","0","0","0","0","0","0","0"
"140","NCT00212355","Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.","Wilson's Disease",0,"NPC-02","Drug","Nobelpharma","Industry",0,0,"All","1 Year","N/A","37","March 2005","April 2008","Safety","0","0","0","0","0","0","0","0","0"
"141","NCT00214760","Polymethyl Methacrylate and (PEGT/PBT) Centralizer by the Uncemented BIHAPRO THP","Osteoarthritis",0,"PGET","Device","Biomet Nederland BV","Industry",0,0,"All","18 Years","75 Years","70","May 2005","August 2008","Alignment","0","0","0","0","0","0","0","0","0"
"142","NCT00215683","An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","137","February 2005","October 2009","Participants With Markedly Abnormal Change in Vital Signs and Body Weight","0","0","0","0","0","0","0","0","0"
"143","NCT00219544","Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.","Neuropathic Pain",0,"Pregabalin (Lyrica)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","158","November 2005","February 2008","Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase","0.0018","0","ANCOVA","-0.78","Mean Difference (Net)","95","0","-1.27","-0.30"
"144","NCT00225147","Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema","Hereditary Angioedema",0,"Recombinant Human C1 Inhibitor","Drug","Pharming Technologies B.V.","Industry",0,0,"All","12 Years","N/A","77","July 2005","October 2009","Time to Beginning of Relief of Symptoms","0.001","0","Log Rank","0","0","0","0","0","0"
"145","NCT00225186","Safety and Efficacy of SH T00660AA in Treatment of Endometriosis","Endometriosis",0,"Visanne (SH T00660AA , BAY86-5258)","Drug","Bayer","Industry",0,0,"Female","18 Years","45 Years","168","July 2004","March 2008","Safety assessment of the drug","0","0","0","0","0","0","0","0","0"
"146","NCT00225732","Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients","Pain",0,"Normal saline as placebo comparator","Other","Cumberland Pharmaceuticals","Industry",0,0,"Female","18 Years","70 Years","319","January 2005","January 2008","Change in the Patient Demand for the Narcotic Analgesic, Morphine, Post Surgery","0","0","0","0","0","0","0","0","0"
"147","NCT00226655","An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies","Brain Edema",0,"hCRF [XERECEPT (corticorelin acetate injection)]","Drug","Celtic Pharma Development Services","Industry",0,0,"All","18 Years","N/A","112","July 2005","March 2009","Long Term Safety and Tolerability of hCRF","0","0","0","0","0","0","0","0","0"
"148","NCT00226759","Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction","Knee Injuries",0,"OMS103HP","Drug","Omeros Corporation","Industry",0,0,"All","15 Years","65 Years","321","November 2004","September 2010","Improvement in knee function","0","0","0","0","0","0","0","0","0"
"149","NCT00226772","Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction","Knee Injuries",0,"OMS103HP","Drug","Omeros Corporation","Industry",0,0,"All","15 Years","65 Years","326","June 2005","September 2010","Improvement in knee function","0","0","0","0","0","0","0","0","0"
"150","NCT00228176","Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant","Carotid Artery Plaque",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","55 Years","N/A","661","August 2005","April 2009","Absolute change from baseline in averaged per patient carotid artery intima-media thickness (CIMT)","0","0","0","0","0","0","0","0","0"
"151","NCT00231153","Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters","Infection",0,"Omiganan 1% gel","Drug","Mallinckrodt","Industry",0,0,"All","13 Years","N/A","1859","August 2005","June 2008","Local Catheter Site Infection (LCSI)","0.082","The primary null hypothesis was tested using the CMH chi-square test stratified region: North America or Europe. Alpha for this test will be 0.05, tow-tailed. No adjustment for multiplicity was performed.","Cochran-Mantel-Haenszel","2.25","Net percentage difference","95","0","-0.30","4.81"
"152","NCT00231244","Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry (SECURE)","Coronary Artery Disease",0,"CYPHER Sirolimus-Eluting Coronary Stent","Device","Cordis Corporation","Industry",0,0,"All","18 Years","N/A","252","March 2002","May 2008","The primary endpoint of this study is a composite of Target Vessel Failure (TVF) defined as target vessel revascularization, myocardial infarction or cardiac death at 30 days, 6mo, 12mo, 2, 3, 4, and 5 years.","0","0","0","0","0","0","0","0","0"
"153","NCT00232180","A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines","Heart Failure",0,"Eplerenone","Drug","Pfizer","Industry",0,0,"All","55 Years","N/A","2743","March 2006","May 2010","Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date","<0.0001","Using an adaptation of Haybittle-Peto stopping criterion adjusting for two interim analyses, p-value for final primary analysis will be compared to alpha=0.049. No adjustment in alpha will be made on parameters/endpoints other than primary endpoint.","Cox proportional hazard model","0.630","Hazard Ratio (HR)","95","2-Sided","0.535","0.741"
"154","NCT00232596","Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy","Seizures",0,"Retigabine","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","75 Years","306","September 2005","January 2008","Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)","<0.001","Non-parametric rank analysis of covariance adjusted for baseline 28-seizure frequency and stratified by baseline seizure frequency category and region","Non-parametric rank ANCOVA","0","0","0","0","0","0"
"155","NCT00232830","The Study to Assess AMI Treated With Balloon Angioplasty.","Coronary Artery Disease",0,"drug-eluting stent","Device","Cordis Corporation","Industry",0,0,"All","18 Years","N/A","715","October 2003","February 2009","Composite of target vessel failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vesselpost-procedure.","0","0","0","0","0","0","0","0","0"
"156","NCT00233402","Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy","Bladder Cancer",0,"Hexvix","Drug","Photocure","Industry",0,0,"All","18 Years","N/A","789","January 2005","July 2008","Proportion of Patients With >= 1 Ta or T1 Tumor Detected With Blue Light and Not White Light","0","0","0","0","0","0","0","0","0"
"157","NCT00234533","Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq","Turner Syndrome",0,"Somatropin (rDNA origin)","Drug","Ipsen","Industry",0,0,"All","N/A","18 Years","250","June 2004","July 2008","Number of capillary blood spot IGF-1 measurements and optimal timing of samples to assess the IGF-1 status of NutropinAq treated patients","0","0","0","0","0","0","0","0","0"
"158","NCT00234832","A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients","Obesity",0,"Sibutramine hydrochloride","Drug","Abbott","Industry",0,0,"All","55 Years","N/A","10777","January 2003","March 2009","Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)","0.015","No adjustment for multiple testing or interim analysis was performed. The primary outcome was tested at a 2-sided alpha level of 0.05.","Log Rank","1.162","Cox Proportional Hazard","95","2-Sided","1.029","1.311"
"159","NCT00235443","A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy","Diabetic Neuropathy",0,"lacosamide","Drug","UCB Pharma","Industry",0,0,"All","32 Years","81 Years","451","September 2004","July 2008","Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator.","0","0","0","0","0","0","0","0","0"
"160","NCT00235755","Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy","Seizures",0,"Retigabine","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","75 Years","539","December 2005","April 2008","Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)","<0.001","Non-parametric rank analysis of covariance adjusted for baseline 28-seizure frequency and stratified by baseline seizure frequency category and region","Non-parametric rank ANCOVA","0","0","0","0","0","0"
"161","NCT00236899","Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC","Metastatic Breast Cancer (MBC)",0,"Gemcitabine","Drug","Eli Lilly and Company","Industry",0,0,"Female","18 Years","N/A","241","September 2005","August 2010","Time to Progressive Disease (TTPD) by Treatment Schedule","0.345","0","Regression, Cox","1.14","Hazard Ratio (HR)","95","0","0.87","1.50"
"162","NCT00237484","Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","Hepatitis C, Chronic",0,"Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","89","July 2005","June 2011","Proportion of subjects who have achieved sustained virological response (SVR) in the infliximab (induction dose) plus PEGETRON and the PEGETRON groups at 24 weeks post treatment end","0","0","0","0","0","0","0","0","0"
"163","NCT00239356","Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials","Schizophrenia",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","70 Years","119","March 2003","October 2012","Mean Clinical Global Impression Severity Score (CGI-S) From Baseline Through End of Study- - Safety Population.","0","0","0","0","0","0","0","0","0"
"164","NCT00239681","JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events","Elevated High-sensitivity C-Reactive Protein (hsCRP)",0,"Rosuvastatin","Drug","AstraZeneca","Industry",0,0,"All","50 Years","N/A","17802","February 2003","September 2008","Time to Major Cardiac Event (Cardiovascular Death, Stroke, Myocardial Infarction, Hospitalization Due to Unstable Angina or Arterial Revascularization)","<0.0001","0","Regression, Cox","0.56","Hazard Ratio (HR)","95","0","0.46","0.69"
"165","NCT00242710","Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women","Endometrial Hyperplasia",0,"Bazedoxifene/Conjugated Estrogen","Drug","Pfizer","Industry",0,0,"Female","40 Years","65 Years","1083","September 2005","September 2008","Percentage of Participants With Hyperplasia at Screening","0","0","0","0","0","0","0","0","0"
"166","NCT00243867","Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer","Non-Small Cell Lung Cancer",0,"Taxoprexin","Drug","Luitpold Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","519","November 2005","August 2008","Overall survival after 380 deaths","0","0","0","0","0","0","0","0","0"
"167","NCT00244140","Ultravist: Safety and Efficacy in Computed Tomography of Head and Body","Computed Tomography",0,"Iopromide 370 mg I/mL","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","435","October 2005","April 2008","The Quality of Visualization of the Contrast-Enhanced Computed Tomography (CECT) Images, Based on the Blinded Readers' Assessment.","0","0","0","95.8","Percent Images Rated Good/Excellent: BR1","95","0","93.3","97.6"
"168","NCT00244426","S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation","Atrial Fibrillation",0,"indobufen","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","1372","December 2000","April 2008","combined endpoints: cerebral ictus (ischemic or haemorragic), cardiovascular death, nonfatal acute myocardial infarction (AMI) or peripheral embolism. The first event occurring during the study will be considered.","0","0","0","0","0","0","0","0","0"
"169","NCT00245271","Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction","Anterior Cruciate Ligament Reconstruction",0,"OMS103HP","Drug","Omeros Corporation","Industry",0,0,"All","17 Years","65 Years","480","October 2004","March 2010","The overall incidence of adverse events regardless of relationship to study drug.","0","0","0","0","0","0","0","0","0"
"170","NCT00245505","The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active ""Drug: Crohn's Disease""","Crohn's Disease",0,"Mesalazine (Mesalamine)","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","3","February 2009","June 2009","Mucosal changes, (measured as number, type and localization of small bowel mucosal lesions detected by VCE) from baseline (i.e. < 7 days prior to inclusion), and after 6 and 12 weeks´ treatment with 4g Pentasa Sachet","0","0","0","0","0","0","0","0","0"
"171","NCT00247273","A Study of Monthly Risedronate for Osteoporosis","Postmenopausal Osteoporosis",0,"risedronate","Drug","Warner Chilcott","Industry",0,0,"Female","50 Years","N/A","1294","October 2005","March 2008","Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12-Endpoint in Women With Postmenopausal Osteoporosis, Primary Efficacy Population","0","0","0","-0.115","Least Square (LS) Mean Difference","95","2-Sided","-0.505","0.274"
"172","NCT00249795","Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)","Atrial Fibrillation",0,"Irbesartan","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","9016","June 2003","August 2009","First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke or Vascular Death as Per Adjudication","0.8570","The cumulative incidence function of this event was calculated for each treatment group using the non-parametric Kaplan-Meier method and the comparison was performed using a 2-sided Log Rank test at 4.5% level to account for multiplicity.","Log Rank","0.992","Hazard Ratio (HR)","95","2-Sided","0.907","1.085"
"173","NCT00249873","Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)","Atrial Fibrillation",0,"clopidogrel (SR25990C)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","7554","June 2003","March 2009","First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication","0.0133","Cumulative incidence functions in each treatment group were calculated using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. The primary comparison was performed at the 5% level using a 2-sided Log rank test.","Log Rank","0.89","Hazard Ratio (HR)","95","0","0.81","0.98"
"174","NCT00251641","The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)","Psoriasis",0,"infliximab","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","75 Years","868","September 1, 2005","June 1, 2008","Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16.","<0.001","0","Chi-squared","0","0","0","0","0","0"
"175","NCT00253968","Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia","Sleep Initiation and Maintenance Disorders",0,"Eplivanserin","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","967","November 2005","January 2008","Change from baseline of the mean pr-WASO (wake time after sleep onset using patient's sleep questionnaire)","0","0","0","0","0","0","0","0","0"
"176","NCT00254163","Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","B-Cell Chronic Lymphocytic Leukemia",0,"Fludarabine","Drug","US Oncology Research","Industry",0,0,"All","18 Years","N/A","184","December 2003","September 2011","Infection Rate","0","0","0","0","0","0","0","0","0"
"177","NCT00254566","A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)","Chronic Bronchitis",0,"Moxifloxacin Placebo","Other","Pfizer","Industry",0,0,"All","50 Years","N/A","398","February 2006","August 2008","Percentage of Clinical Cure (Success) at Test of Cure Visit(Clinical Per Protocol Population)","0","0","0","-0.9","Risk Difference (RD)","95","0","-5.8","3.9"
"178","NCT00254891","Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung",0,"PF-3512676 + Paclitaxel + Carboplatin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","828","November 2005","July 2008","Overall Survival","0","0","0","0","0","0","0","0","0"
"179","NCT00254904","Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC","Carcinoma, Non-Small-Cell Lung",0,"Cisplatin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","839","November 2005","June 2008","Overall Survival","0","0","0","0","0","0","0","0","0"
"180","NCT00254969","Immunogenicity and Safety of Pentaxim in South African Infants","Diphtheria",0,"Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib","Biological","Sanofi","Industry",0,0,"All","N/A","N/A","212","October 2005","May 2008","To provide information concerning the immunogenicity of DTacP-IPV//PRP~T combined vaccine.","0","0","0","0","0","0","0","0","0"
"181","NCT00255047","Safety and Immune Response of Different Pediatric Combination Vaccines.","Diphtheria",0,"DAPTACEL®. (DTaP), IPOL®., and ActHIB®.","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","42 Days","89 Days","2167","November 2005","July 2008","Percentage of Participant Responding to Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations.","0","0","0","0","0","0","0","0","0"
"182","NCT00255190","Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn","Gastroesophageal Reflux Disease",0,"Dexlansoprazole MR","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","591","January 2006","June 2008","Mean Change From Baseline to Month 12 for Hemoglobin Values","0.042","Statistical significance was determined at 0.05 level. All statistical tests were two-sided and the p-values were rounded to 3 decimal places prior to determining statistical significance.","ANOVA","0","0","0","0","0","0"
"183","NCT00255983","A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis","Chronic Bronchitis",0,"Faropenem medoxomil","Drug","Replidyne","Industry",0,0,"All","35 Years","N/A","491","December 2005","May 2008","• Clinical response at test of cure.","0","0","0","0","0","0","0","0","0"
"184","NCT00256204","A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease","Parkinson's Disease",0,"Rasagiline Mesylate","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","30 Years","80 Years","1174","November 2005","April 2008","Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline","0.0133","0","Repeated Measures Mixed Linear Model","0","0","0","0","0","0"
"185","NCT00256750","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)","Kidney Transplantation",0,"Cyclosporine (CsA)","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","738","March 2005","June 2008","Percent of Participants Surviving With a Functioning Graft by Month 12","0","0","0","3.7","Difference in Percent","97.3","2-Sided","-1.1","9.0"
"186","NCT00257192","Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia","Schizophrenia",0,"placebo","Drug","Pfizer","Industry",0,0,"All","13 Years","17 Years","284","April 2006","March 2009","Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total Score at Week 6","0.1530","Mixed effects repeated measures (MMRM) analysis of covariance model with subject as random effect, treatment, region, visit and visit-by-treatment interaction as fixed effects and baseline score as a covariate.","ANCOVA","-1.80","Least squares mean","95","2-Sided","-4.28","0.67"
"187","NCT00257205","CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy","Melanoma",0,"dacarbazine","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","655","March 2006","August 2010","overall survival","0","0","0","0","0","0","0","0","0"
"188","NCT00259012","Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD","Gastroesophageal Reflux",0,"pantoprazole sodium enteric-coated spheroid suspension","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","1 Month","11 Months","67","November 2005","March 2008","Peak Concentration (Cmax)","0","0","0","0","0","0","0","0","0"
"189","NCT00259272","Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine","Bipolar Disorder I or II",0,"olanzapine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","141","November 2005","May 2008","Mean Changes From Baseline to 6 Week and 24 Week Endpoints in the Multidimensional Assessment of THYmic States Scale (MATHYS) Total Score","0","0","0","0","0","0","0","0","0"
"190","NCT00259337","Immunogenicity and Safety of Pentaxim™ in an Indian Population","Diphtheria",0,"Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine","Biological","Sanofi","Industry",0,0,"All","42 Days","56 Days","226","February 2006","April 2008","To provide information concerning the safety of DTacP-IPV//PRP~T combined vaccine","0","0","0","0","0","0","0","0","0"
"191","NCT00261495","A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.","Pain",0,"OROS hydromorphone HCl","Drug","Janssen Pharmaceutica N.V., Belgium","Industry",0,0,"All","18 Years","N/A","504","March 2006","April 2008","Change From Baseline in Brief Pain Inventory (BPI) Questionnaire Item 6 ""Pain Right Now"" Score at Week 24 (Per Protocol [PP] Population)","0.011","Statistical significance level was 0.05. Two-sided 95% CI of the treatment difference based on LS means & error terms obtained from ANCOVA (covariate: baseline; factors: country, previous pain treatment, underlying disease, and treatment).","ANCOVA","0.29","Mean Difference (Net)","95","0","-0.27","0.84"
"192","NCT00261924","Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days","Thrombocytopenia",0,"Transfusion of Pathogen Inactivated Platelets stored for 6-7 days","Device","Cerus Corporation","Industry",0,0,"All","16 Years","N/A","211","October 2005","July 2009","1 hour corrected count increment for platelets","0","0","0","0","0","0","0","0","0"
"193","NCT00262106","Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection","HIV Infections",0,"PRO 2000/5","Drug","Endo Pharmaceuticals","Industry",0,0,"Female","16 Years","N/A","9404","October 2005","August 2008","Acquisition of HIV infection before or at the 12 month time point, confirmed in a central laboratory, in participants confirmed to be HIV negative at enrollment","0","0","0","0","0","0","0","0","0"
"194","NCT00262301","Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema","Hereditary Angioedema",0,"recombinant human C1 inhibitor","Drug","Pharming Technologies B.V.","Industry",0,0,"All","16 Years","N/A","75","June 2004","July 2009","Time to Beginning of Relief of Symptoms","0.003","0","Log Rank","0","0","0","0","0","0"
"195","NCT00262522","Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects","Human Immunodeficiency Virus Infections",0,"lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","664","November 2005","July 2008","Percentage of Subjects With Adverse Events of Diarrhea During the First 8 Weeks",">0.100","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"196","NCT00263042","Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes","Cardiovascular Disease",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","55 Years","N/A","18695","December 2005","April 2009","First occurrence of any of myocardial infarction, stroke or cardiovascular (CV) death","0","0","0","0","0","0","0","0","0"
"197","NCT00263575","Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients","Pain",0,"EN3267","Drug","Prostrakan Pharmaceuticals","Industry",0,0,"All","17 Years","N/A","97","January 2005","December 2008","The Study Objective is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid tolerant cancer patients who are using stable doses of opioid medication.","0","0","0","0","0","0","0","0","0"
"198","NCT00263640","Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma","Respiratory Hypersensitivity",0,"Acaroid","Biological","Allergopharma GmbH & Co. KG","Industry",0,0,"All","6 Years","40 Years","130","May 2005","April 2009","Inhalative dose of fluticasone propionate","0","0","0","0","0","0","0","0","0"
"199","NCT00264459","Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture","Grass Pollen Allergy",0,"Grass pollen formulation","Biological","Allergopharma GmbH & Co. KG","Industry",0,0,"All","18 Years","60 Years","160","February 2003","August 2008","Symptom and Medication Score (SMS)","0","0","0","0","0","0","0","0","0"
"200","NCT00264537","A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive","Rheumatoid Arthritis",0,"Placebo injections","Drug","Centocor, Inc.","Industry",0,0,"All","18 Years","N/A","637","December 2005","April 2008","Number of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24","0.053","A positive test is concluded if there is a significant difference between golimumab+MTX and placebo+MTX and at least one of the pair-wise comparisons at a 0.05 level.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"201","NCT00264810","RNS® System Pivotal Study","Epilepsy",0,"RNS® System implantation","Procedure","NeuroPace","Industry",0,0,"All","18 Years","70 Years","240","December 2005","October 2009","Acute SAE Rate","0","0","0","0","0","0","0","0","0"
"202","NCT00264875","Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy","Peripheral Neuropathy",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","220","February 2006","February 2008","Mean Visual Analogue Scale (VAS) Pain Scores","0","0","0","0","0","0","0","0","0"
"203","NCT00265330","Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)","Bipolar Disorder",0,"Ziprasidone oral capsules","Drug","Pfizer","Industry",0,0,"All","10 Years","17 Years","169","March 2006","January 2008","Young Mania Rating Scale (YMRS) Total Score Change From Baseline","0","0","0","0","0","0","0","0","0"
"204","NCT00265382","Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia","Schizophrenia",0,"Ziprasidone oral capsules","Drug","Pfizer","Industry",0,0,"All","13 Years","17 Years","221","June 2006","June 2009","Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"205","NCT00265395","Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)","Hepatitis C, Chronic",0,"Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","70 Years","1428","December 2004","May 2008","Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.","0.6445","0","Asymptotic Z-test","-4.9","SVR Rate Difference","95","0","-20.4","10.6"
"206","NCT00266032","Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles","Contraception",0,"Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)","Drug","Bayer","Industry",0,0,"Female","18 Years","35 Years","1166","December 2005","October 2008","Number of Days With Bleeding Including Spotting","<0.0001","0","t-test, 2 sided","-25","Mean Difference (Final Values)","95","0","-29","-20"
"207","NCT00266695","Treatment for Completers of the Study B7A-MC-MBCM","Diabetic Retinopathy",0,"Ruboxistaurin","Drug","Chromaderm, Inc.","Industry",0,0,"All","18 Years","N/A","203","January 2006","August 2008","Sustained Moderate Visual Loss (SMVL)","0","0","0","0","0","0","0","0","0"
"208","NCT00266799","The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)","Breast Cancer",0,"Pegylated liposomal doxorubicin (SCH 200746)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","N/A","210","January 13, 2006","September 29, 2010","Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST)","0.6686","0","Log Rank","1.08","Hazard Ratio (HR)","95","2-Sided","0.76","1.54"
"209","NCT00267371","ESCAPE Migraine Trial","Migraine Disorders",0,"PFO Closure with Premere investigational device.","Device","St. Jude Medical","Industry",0,0,"All","18 Years","70 Years","168","November 2005","March 2012","Primary Endpoint 1: Effectiveness","0","0","0","0","0","0","0","0","0"
"210","NCT00268879","Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)","Irritable Bowel Syndrome",0,"Renzapride","Drug","Alizyme","Industry",0,0,"Female","18 Years","65 Years","1821","December 2005","January 2008","Number of months a patient is a Responder for overall relief of IBS symptoms","0","0","0","0","0","0","0","0","0"
"211","NCT00268892","Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","278","January 2006","September 2009","Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight","0","0","0","0","0","0","0","0","0"
"212","NCT00268983","Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma","Lymphoma, Non-Hodgkin",0,"Tositumomab and Iodine I 131 Tositumomab","Biological","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","14","October 2004","September 2009","Event-free Survival (EFS)","0","0","0","0","0","0","0","0","0"
"213","NCT00270504","Memokath® 044TW Stent for Treatment of Urethral Stricture","Urethral Stricture",0,"Memokath stenting","Device","Pnn Medical DK","Industry",0,0,"Male","21 Years","N/A","92","December 2002","October 2009","Stent/control effectiveness - urethral patency","0","0","0","0","0","0","0","0","0"
"214","NCT00271284","Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients","Diabetes Mellitus, Type 1",0,"insulin glulisine / insulin glargine","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","88","October 2005","September 2008","Efficacy data : fasting blood glucose concentration","0","0","0","0","0","0","0","0","0"
"215","NCT00276380","A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke","Stroke, Acute",0,"EGb761 (Tanakan) and acetylsalicylic acid","Drug","Ipsen","Industry",0,0,"All","50 Years","N/A","204","February 2003","March 2009","Patients with Modified Rankin score 0 or 1 or 2 at the end of study period.","0","0","0","0","0","0","0","0","0"
"216","NCT00277095","ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males","Urinary Incontinence",0,"ProACT (Adjustable Continence Therapy)","Device","Uromedica","Industry",0,0,"Male","45 Years","N/A","123","August 2005","February 2009","Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction.","0","0","0","0","0","0","0","0","0"
"217","NCT00277537","Safety and Efficacy of Bronchitol in Bronchiectasis","Bronchiectasis",0,"Mannitol","Drug","Pharmaxis","Industry",0,0,"All","15 Years","80 Years","354","March 2006","July 2008","24 hour sputum clearance","0","0","0","0","0","0","0","0","0"
"218","NCT00277810","Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease","Alzheimer Disease",0,"lecozotan SR (SRA-333)","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","50 Years","N/A","250","March 2006","June 2008","All events and physical and neurological function and score change from baseline to 24 weeks in ratings for cognitive and global function scales","0","0","0","0","0","0","0","0","0"
"219","NCT00279448","Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer","Breast Neoplasms",0,"exemestane","Drug","Pfizer","Industry",0,0,"Female","50 Years","N/A","9779","January 2002","November 2008","To compare recurrence free survival between two treatment groups.","0","0","0","0","0","0","0","0","0"
"220","NCT00280059","Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy","Epilepsy, Partial",0,"Pregabalin","Drug","Pfizer","Industry",0,0,"All","16 Years","N/A","660","August 2006","December 2009","Percentage of Seizure-free Participants (Responders) During Efficacy Assessment Phase","0","0","0","-0.16","Mean Difference (Final Values)","95","2-Sided","-0.24","-0.09"
"221","NCT00280566","Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)","Bipolar Mania",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","584","December 2005","May 2008","Time to Intervention for a Mood Episode During Double Blind Period","0.0104","0","Log Rank","0","0","0","0","0","0"
"222","NCT00281320","Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)","Psychosis",0,"Asenapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","65 Years","N/A","122","February 2006","December 2008","Number of Participants Who Experienced an Adverse Event","0","0","0","0","0","0","0","0","0"
"223","NCT00281658","Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2","Neoplasms, Breast",0,"lapatinib (GW572016) oral tablets","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","444","January 2006","June 18, 2010","Overall Survival","0.0005","two-sided p-value","Wald Chi-squared","0.64","Hazard Ratio (HR)","95","2-Sided","0.49","0.82"
"224","NCT00282347","A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis","Lupus Nephritis",0,"Rituximab","Drug","Genentech, Inc.","Industry",0,0,"All","16 Years","75 Years","144","January 2006","January 2009","Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52","0.5538","0","Stratified Wilcoxon-Rank Sum Test","0","0","0","0","0","0"
"225","NCT00282464","A Six-Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.","Bipolar Disorder",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","392","February 2006","March 2008","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","0.0056","For all secondary efficacy analyses, no multiple comparison adjustment were made","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"226","NCT00282971","A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus","Diabetes Mellitus Type 2",0,"Standard of Care","Other","Pfizer","Industry",0,0,"All","35 Years","80 Years","354","March 2006","February 2008","Percentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","0","0","0","0","0","0","0","0","0"
"227","NCT00283842","Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy","Diabetic Neuropathies",0,"DVS SR","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","N/A","408","March 2006","June 2008","Change in Mean Pain Severity Score From Baseline to 13 Weeks","0.084","0","Hochberg","0","0","0","0","0","0"
"228","NCT00284128","AVE7688 in Patients With Mild to Moderate Blood Pressure","Hypertension",0,"AVE7688","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","1940","December 2005","March 2008","Change from baseline in trough diastolic blood pressure at the end of week 12.","0","0","0","0","0","0","0","0","0"
"229","NCT00284856","Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)","Asthma",0,"montelukast sodium","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","55 Years","1640","May 2006","April 2010","Percentage of Asthma-control Days Over the 6-month Treatment Period","0","0","0","5.92","Least Squares Mean Difference","95","0","0.28","11.56"
"230","NCT00284934","Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients","Kidney Diseases",0,"Enteric-coated mycophenolate sodium (EC-MPS)","Drug","Novartis","Industry",0,0,"All","18 Years","75 Years","94","December 2005","June 2008","Renal Function Assessed by Change in Estimated Glomerular Filtration Rate(eGFR)","0","0","0","0","0","0","0","0","0"
"231","NCT00285012","Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).","Smoking Cessation",0,"placebo","Drug","Pfizer","Industry",0,0,"All","35 Years","N/A","504","May 2006","July 2008","Number of Subjects With Four Week Continuous Quit Rate (CQR)","<0.0001","p-value obtained from a logistic regression model including the main effects of treatment and pooled center","Regression, Logistic","8.40","Odds Ratio (OR)","95","0","4.99","14.14"
"232","NCT00286078","Treatment for Migraines With an Implantable Device","Migraine",0,"Precision","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","179","February 2006","April 2009","Migraine Frequency at 12 Weeks","0","0","0","0","0","0","0","0","0"
"233","NCT00286091","Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer","Hormone Refractory Prostate Cancer",0,"Denosumab","Biological","Amgen","Industry",0,0,"Male","18 Years","N/A","1435","February 2006","July 2010","Bone Metastasis-free Survival","0.0284","0","Wald test","0.85","Hazard Ratio (HR)","95","2-Sided","0.73","0.98"
"234","NCT00287716","Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis",0,"Pirfenidone","Drug","Genentech, Inc.","Industry",0,0,"All","40 Years","80 Years","435","July 14, 2006","November 10, 2008","Absolute Change in Percent Predicted Forced Vital Capacity (FVC)","0","0","0","0","0","0","0","0","0"
"235","NCT00287729","Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis",0,"Pirfenidone","Drug","Genentech, Inc.","Industry",0,0,"All","40 Years","80 Years","344","April 2006","November 2008","Absolute Change in Percent Predicted Forced Vital Capacity(FVC)","0","0","0","0","0","0","0","0","0"
"236","NCT00288509","Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia","Cervical Dystonia",0,"abobotulinumtoxinA (Dysport) 250-1000 units","Drug","Ipsen","Industry",0,0,"All","18 Years","N/A","108","February 2006","January 2008","Change in Toronto Western Spasmodic Torticollis Rating Scale Total Score From Baseline","0","0","0","0","0","0","0","0","0"
"237","NCT00288704","Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)","Familial Cold Autoinflammatory Syndrome (FCAS)",0,"rilonacept 160 mg","Drug","Regeneron Pharmaceuticals","Industry",0,0,"All","7 Years","N/A","104","December 2005","June 2008","Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS)","<.0001","0","ANCOVA","0","0","0","0","0","0"
"238","NCT00289991","Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)","Antifungal Prophylaxis of Invasive Fungal Infections",0,"Itraconazole","Drug","Pfizer","Industry",0,0,"All","12 Years","N/A","489","March 2006","February 2009","Success at Day 180: Percent of Responders (Randomization Strata)","0","0","0","16.4","percent difference adjusted proportions","95","2-Sided","7.7","25.1"
"239","NCT00291655","Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).","Epilepsy",0,"Levetiracetam","Drug","UCB Pharma","Industry",0,0,"All","16 Years","N/A","130","June 2006","April 2008","Assessment of Safety of Levetiracetam as Per Adverse Event (AE) Reporting in Open-label Therapy Phase","0","0","0","0","0","0","0","0","0"
"240","NCT00293020","Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy","Pain",0,"BEMA Fentanyl","Drug","BioDelivery Sciences International","Industry",0,0,"All","18 Years","N/A","244","February 2006","June 2008","Percentage of Participants With Adverse Events.","0","0","0","0","0","0","0","0","0"
"241","NCT00293059","Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding","Metrorrhagia",0,"Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)","Drug","Bayer","Industry",0,0,"Female","18 Years","N/A","190","December 2005","May 2008","Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms","< 0.0001","0","inverting 2 one-sided tests","0","0","0","0","0","0"
"242","NCT00294619","Treatment of Adults With Growth Hormone Deficiency","Pituitary Disorders",0,"growth hormone","Drug","LG Life Sciences","Industry",0,0,"All","23 Years","70 Years","147","April 2006","March 2008","Changes in Fat Mass at the end of 26-week treatment from baseline","0","0","0","0","0","0","0","0","0"
"243","NCT00294723","To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c","Diabetes",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","80 Years","746","February 2006","November 2008","Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52","<0.0001","The statistical analysis of the primary endpoint was done in a hierarchal manner due to multiple comparisons. No other adjustments were made for multiplicity.
2-sided significance level 5%","ANCOVA","-0.62","Estimated treatment difference, LS Mean","95","0","-0.83","-0.42"
"244","NCT00295802","Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer","Prostate Cancer",0,"Integrated Imaging High Intensity Focused Ultrasound","Device","EDAP TMS S.A.","Industry",0,0,"Male","50 Years","N/A","141","April 2006","August 2012","Attainment achievement of prostate-specific antigen (PSA) nadir < 0.5 ng/ml and stability of PSA according to American Society for Therapeutic Radiology and Oncology (ASTRO) criteria through 24 month follow up without a positive biopsy","0","0","0","0","0","0","0","0","0"
"245","NCT00296348","Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation","Kidney Transplantation",0,"tacrolimus","Drug","Astellas Pharma Inc","Industry",0,0,"All","2 Years","18 Years","198","November 2005","February 2008","Growth, expressed as change in height SDS from baseline to end of study is chosen as the primary endpoint.","0","0","0","0","0","0","0","0","0"
"246","NCT00296504","A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects","Infection, Human Immunodeficiency Virus",0,"fosamprenavir (GW433908)","Drug","ViiV Healthcare","Industry",0,0,"All","13 Years","N/A","753","November 2001","October 2010","Number of Participants With Any Adverse Event (AE): Interim Analysis","0","0","0","0","0","0","0","0","0"
"247","NCT00297102","Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)","Chronic Obstructive Pulmonary Disease (COPD)",0,"Roflumilast","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","1523","February 2006","July 2008","Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)","0.0003","No adjustment of the significance level was done as a hierarchical approach for hypotheses testing was used.","ANCOVA","39","Mean Difference (Net)","95","2-Sided","18","60"
"248","NCT00297648","Mucosal Healing Study in Crohn's Disease (CD)","Crohn's Disease",0,"Certolizumab pegol","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","89","February 2006","January 2008","Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments","0","0","0","0","0","0","0","0","0"
"249","NCT00298038","A 6-month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy","Hepatic Encephalopathy",0,"Rifaximin","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","299","December 2005","August 2008","Time to treatment failure.","0","0","0","0","0","0","0","0","0"
"250","NCT00299013","Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis","Ulcerative Colitis",0,"COLAL-PRED®","Drug","Alizyme","Industry",0,0,"All","18 Years","75 Years","796","March 2006","April 2008","Disease activity index","0","0","0","0","0","0","0","0","0"
"251","NCT00299325","VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt","Metabolic Syndrome",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","35 Years","70 Years","254","February 2006","July 2008","Relative change in visceral fat area assessed by CT scan","0","0","0","0","0","0","0","0","0"
"252","NCT00299507","Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)","Macular Degeneration",0,"Anecortave Acetate Sterile Suspension, 30 mg/mL","Drug","Alcon Research","Industry",0,0,"All","50 Years","N/A","240","March 2005","April 2008","Mean change in best-corrected visual acuity (BCVA) at Month 12 from baseline","0","0","0","0","0","0","0","0","0"
"253","NCT00300118","Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)","Crohn's Disease",0,"budesonide","Drug","Dr. Falk Pharma GmbH","Industry",0,0,"All","18 Years","70 Years","311","September 2004","May 2008","Rate of remission","0","0","0","0","0","0","0","0","0"
"254","NCT00300131","ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation","Coronary Disease",0,"Bioabsorbable Everolimus Eluting Coronary Stent","Device","Abbott Vascular","Industry",0,0,"All","18 Years","N/A","30","March 2006","July 2011","Ischemia Driven MACE","0","0","0","0","0","0","0","0","0"
"255","NCT00300196","ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke","Stroke",0,"Ancrod (Viprinex)","Biological","Neurobiological Technologies","Industry",0,0,"All","18 Years","N/A","311","March 2006","December 2008","Modified Rankin Score - responder analysis","0","0","0","0","0","0","0","0","0"
"256","NCT00300430","Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.","Dyslipidemia",0,"ABT-335 and rosuvastatin calcium","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","1911","September 2006","March 2008","Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-Blind Studies or in This Open-Label Study","0","0","0","0","0","0","0","0","0"
"257","NCT00300755","Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)","Gastroesophageal Reflux",0,"pantoprazole sodium enteric-coated spheroid","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","1 Year","5 Years","60","May 2006","April 2008","Change in Weekly Gastroesophageal Reflux Disease (GERD) Symptom Scores (WGSS)","<0.001","0","t-test, 2 sided","0","0","0","0","0","0"
"258","NCT00302081","Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)","Hepatitis C, Chronic",0,"peginterferon alfa-2b (SCH 54031)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","70 Years","696","August 2003","April 2008","The Number of Participants Who Achieve a Sustained Virologic Response (SVR)","0.041","The Hochberg procedure was used to adjust for the multiple comparisons ([PEG2b 1.0/R(24 weeks)] - [PEG2b 1.5/R(24 weeks]) and ([PEG2b 1.5/R(16 weeks)]-[PEG2b 1.5/R(24 weeks)]).","z-test (non-inferiority margin=-0.1)","-0.02","Risk Difference (RD)","95","0","-0.10","1"
"259","NCT00302341","DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)","Pneumonia, Interstitial Plasma Cell",0,"Pafuramidine maleate (DB289)","Drug","Immtech Pharmaceuticals, Inc","Industry",0,0,"All","13 Years","65 Years","48","May 2006","December 2008","The primary efficacy endpoint will be the proportion of subjects with clinical success at the End of Treatment (Day 22) for the Modified Intent-to-Treat population (mITT).","0","0","0","0","0","0","0","0","0"
"260","NCT00304551","A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)","Liver Cirrhosis",0,"peginterferon alfa-2a 180μg","Drug","Chugai Pharmaceutical","Industry",0,0,"All","20 Years","75 Years","180","June 2006","December 2009","Sustained virological response, defined as undetectable hepatitis C virus (HCV)-RNA (< 50 IU per milliliter [IU/mL])","0","0","0","0","0","0","0","0","0"
"261","NCT00305162","A Clinical Trial to Demonstrate the Efficacy of Cangrelor","Myocardial Infarction (MI)",0,"Cangrelor (P2Y12 inhibitor)","Drug","The Medicines Company","Industry",0,0,"All","18 Years","N/A","8882","April 2006","May 2009","Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)","0","0","0","0","0","0","0","0","0"
"262","NCT00306163","Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)","Asthma",0,"Ciclesonide","Drug","AstraZeneca","Industry",0,0,"All","18 Years","60 Years","37","May 2006","August 2008","PC20 AMP (Post-treatment Compared to Baseline)","0","0","0","0","0","0","0","0","0"
"263","NCT00306384","Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus","Diabetes Mellitus",0,"Alogliptin","Drug","Takeda","Industry",0,0,"All","18 Years","80 Years","3323","March 2006","November 2011","Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","0","0","0","0","0","0","0","0","0"
"264","NCT00307047","SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System","Coronary Artery Disease",0,"XIENCE V® Everolimus Eluting Coronary Stent","Device","Abbott Vascular","Industry",0,0,"All","18 Years","N/A","3687","August 2006","August 2009","Ischemia Driven Target Lesion Failure (TLF)","0","0","0","0","0","0","0","0","0"
"265","NCT00307684","Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","Attention Deficit Disorder With Hyperactivity",0,"double blind placebo","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","65 Years","155","January 2006","July 2008","Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"266","NCT00307801","Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding","Metrorrhagia",0,"Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)","Drug","Bayer","Industry",0,0,"Female","18 Years","N/A","231","February 2006","May 2008","Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms","< 0.0001","0","inverting 2 one-sided tests","0","0","0","0","0","0"
"267","NCT00307931","Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab","Crohn's Disease",0,"Certolizumab pegol","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","16","April 2007","August 2008","Number of Patients With at Least a 100-point Decrease From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 6","0","0","0","0","0","0","0","0","0"
"268","NCT00308139","Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)","Type 2 Diabetes Mellitus",0,"exenatide, long acting release","Drug","AstraZeneca","Industry",0,0,"All","16 Years","N/A","303","April 2006","July 2008","Change in HbA1c From Baseline to Week 30","0.0023","0","ANOVA","-0.33","Least Squares Mean Difference","95","2-Sided","-0.54","-0.12"
"269","NCT00308581","Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab","Crohn's Disease",0,"Certolizumab pegol","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","539","April 2006","April 2008","Response Status With Response Defined as at Least 100 Point Decrease in Crohn's Disease Activity Score (CDAI Score) From Baseline in the Induction Phase","0","0","0","0","0","0","0","0","0"
"270","NCT00310492","Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis","Atopic Dermatitis",0,"subcutaneous immunotherapy","Biological","ALK-Abelló A/S","Industry",0,0,"All","18 Years","55 Years","154","April 2006","May 2009","Changes from baseline in SCORAD and topical medication consumption","0","0","0","0","0","0","0","0","0"
"271","NCT00311090","Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs","Deep Venous Thrombosis",0,"Idrabiotaparinux sodium","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","757","April 2006","January 2008","Bioequipotency sub-study: idrabiotaparinux/idraparinux ratio for pharmacodynamic exposure parameters","0","0","0","0","0","0","0","0","0"
"272","NCT00311311","Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients","Atherosclerosis",0,"tacrolimus","Drug","Pfizer","Industry",0,0,"All","35 Years","N/A","72","April 2006","December 2010","Annual Change Rate in Total Plaque Volume (TPV) From Pre-conversion Baseline to 12 Months Post-transplant","0","0","0","0","0","0","0","0","0"
"273","NCT00311415","Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children","Prevention of Meningococcal Infection",0,"Meningococcal C conjugate vaccine","Biological","Novartis Vaccines","Industry",0,0,"All","7 Weeks","16 Weeks","257","October 2005","April 2008","Demonstration of non-inferiority of memory antibody response after 1 dose of MenC Vaccine administered to healthy infants at 2 to 6 months of age and as first, second or third dose in the second year of life,as measured by rBCA.","0","0","0","0","0","0","0","0","0"
"274","NCT00312442","Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy","Prostate Cancer",0,"Treatment with WST09 Vascular Photodynamic therapy","Drug","STEBA France","Industry",0,0,"Male","18 Years","N/A","16","May 2006","July 2008","Prostate biopsy results at Month 6 after treatment.","0","0","0","0","0","0","0","0","0"
"275","NCT00312494","3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects","Bipolar Disorder",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","680","April 2006","December 2008","Change From Baseline to Week 3 in Young Mania Rating Scale (YMRS)","0.1077","The p-values reported are unadjusted for multiple comparisons. Dunnet's procedure for multiple dose comparisons to placebo was used for primary efficacy measure at Week 3.","Mixed Models Analysis","0","0","0","0","0","0"
"276","NCT00313911","Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.","Diphtheria",0,"DTaP-IPV-HB-PRP~T","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","50 Days","71 Days","2133","July 2006","January 2008","Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection.","0","0","0","0","0","0","0","0","0"
"277","NCT00314951","Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)","Clostridium Infections",0,"Fidaxomicin","Drug","Optimer Pharmaceuticals LLC","Industry",0,0,"All","16 Years","N/A","629","May 2, 2006","July 23, 2008","Cure Rate at End of Therapy","0","0","0","2.6","Risk Difference (RD)","95","2-Sided","-2.9","8.0"
"278","NCT00315237","Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract","Transitional Cell Carcinoma of the Urothelial Tract",0,"vinflunine and best supportive care","Drug","Pierre Fabre Medicament","Industry",0,0,"All","18 Years","N/A","364","July 2005","January 2008","duration of Overall Survival after Randomization","0","0","0","0","0","0","0","0","0"
"279","NCT00317642","A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)","Acute Myelogenous Leukemia",0,"clofarabine (IV formulation)","Drug","Genzyme, a Sanofi Company","Industry",0,0,"All","55 Years","N/A","326","August 2006","January 2012","Overall Survival - Overall and by Calculated Strata (CSR 7-April-11)","0.9951","0","Log Rank","1.00","Hazard Ratio (HR)","95","2-Sided","0.78","1.28"
"280","NCT00319020","Bosentan in Children With Pulmonary Arterial Hypertension Extension Study","Pulmonary Arterial Hypertension",0,"Bosentan","Drug","Actelion","Industry",1,0,"All","2 Years","11 Years","33","August 23, 2005","October 28, 2011","Change From Baseline to End of Study (EOS) in Height for Age.","0","0","0","0","0","0","0","0","0"
"281","NCT00319696","Bosentan in Digital Ulcers","Systemic Sclerosis",0,"bosentan","Drug","Actelion","Industry",0,0,"All","18 Years","N/A","116","July 2004","October 2008","Total Number of New Digital Ulcers (DUs) Per Patient Observed by the Investigator at Planned Visits","0","0","0","0","0","0","0","0","0"
"282","NCT00320489","Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia","Schizophrenia",0,"olanzapine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","65 Years","524","April 2006","September 2009","Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision)","0.612","0","Log Rank","0","0","0","0","0","0"
"283","NCT00320528","Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)","Attention Deficit Disorder With Hyperactivity",0,"atomoxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","6 Years","15 Years","269","April 2006","October 2008","Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain","0","0","0","0","0","0","0","0","0"
"284","NCT00321113","Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys","KIDNEY TRANSPLANTATION",0,"tacrolimus","Drug","Astellas Pharma Inc","Industry",0,0,"All","60 Years","N/A","142","September 2004","March 2008","Calculated creatinine clearance","0","0","0","0","0","0","0","0","0"
"285","NCT00321412","Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas","Inflammatory Bowel Disease",0,"AST-120","Drug","Ocera Therapeutics","Industry",0,0,"All","18 Years","70 Years","191","March 2006","March 2008","Efficacy: The proportion of patients considered to be ""treatment successes"" defined by a reduction of at least 50% in the number of draining fistulas at both week 4 and week 8 of an 8 week treatment period","0","0","0","0","0","0","0","0","0"
"286","NCT00321464","A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.","Bone Metastases",0,"Denosumab","Biological","Amgen","Industry",0,0,"All","18 Years","N/A","2049","April 2006","March 2009","Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)","<0.0001","0","Regression, Cox","0.82","Hazard Ratio (HR)","95","0","0.71","0.95"
"287","NCT00321620","Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer","Bone Metastases",0,"zoledronic acid","Drug","Amgen","Industry",0,0,"Male","18 Years","N/A","1904","April 2006","October 2009","Time to the First On-Study SRE (Non-inferiority)","0.0002","0","Regression, Cox","0.82","Hazard Ratio (HR)","95","0","0.71","0.95"
"288","NCT00322257","Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes","Diabetes",0,"inhaled human insulin","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","596","May 1, 2006","April 2, 2008","HbA1c","0","0","0","0","0","0","0","0","0"
"289","NCT00323037","A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure","Congestive Heart Failure",0,"carvedilol controlled release","Drug","CTI-1, LLC","Industry",0,0,"All","18 Years","N/A","318","March 2006","April 2008","Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI) Characterized by 2-D Echocardiography","0","0","0","0","0","0","0","0","0"
"290","NCT00323284","A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma","Open-Angle Glaucoma",0,"iStent plus Cataract Surgery","Device","Glaukos Corporation","Industry",0,0,"All","18 Years","N/A","240","June 2005","July 2009","Intraocular Pressure (Measured in mm Hg) Less or Equal to 21 mm Hg on no Topical Hypotensive Meds","0","0","0","0","0","0","0","0","0"
"291","NCT00323310","Safety and Efficacy of MultiHance in Pediatric Patients","Central Nervous System Diseases",0,"gadobenate dimeglumine","Drug","Bracco Diagnostics, Inc","Industry",0,0,"All","2 Years","17 Years","92","April 2006","September 2008","Delineation of Lesion Border (Change From Pre to Pre+Postdose) for Reader 1","<0.0001","H0: udiff = 0; Ha: udiff not = 0","t-test, 2 sided","1.3","Mean Difference (Final Values)","95","2-Sided","1.1","1.5"
"292","NCT00324155","Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma","Melanoma",0,"Ipilimumab","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","681","August 2006","January 2011","Overall Survival (OS)","0","0","0","0","0","0","0","0","0"
"293","NCT00324311","Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care","Burn",0,"DGD","Drug","MediWound Ltd","Industry",0,0,"All","4 Years","55 Years","182","December 2005","October 2009","Co-primary: % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, of deep partial wounds","0","0","0","0","0","0","0","0","0"
"294","NCT00325403","FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)","Pulmonary Hypertension",0,"Oral treprostinil (UT-15C) Sustained Release Tablets","Drug","United Therapeutics","Industry",0,0,"All","12 Years","75 Years","349","October 2006","April 2011","Six Minute Walk Distance (6MWD)","0.0125","P-Value","ANCOVA","23","Hodges-Lehmann (H-L)","95","2-Sided","4","41"
"295","NCT00325468","An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density","Low Bone Mineral Density",0,"AMG 162","Drug","Amgen","Industry",0,0,"Female","N/A","N/A","200","May 2006","March 2011","Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8","0","0","0","0","0","0","0","0","0"
"296","NCT00325650","Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes","Prediabetic State",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","35 Years","75 Years","2420","May 2006","March 2009","Time of progression to type 2 diabetes","0","0","0","0","0","0","0","0","0"
"297","NCT00327444","Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites","Ovarian Neoplasms",0,"aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)","Drug","Sanofi","Industry",0,0,"Female","18 Years","N/A","58","July 2006","October 2009","Time to Repeat Paracentesis (TRP)","0.0019","Estimated using Wilcoxon rank-sum test with stratification of baseline paracentesis (=<2 weeks versus >2 weeks) at randomization.","ANOVA","31.8","Least squares (LS) Mean difference","95","2-Sided","10.56","53.05"
"298","NCT00328627","Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.","Type 2 Diabetes Mellitus",0,"Alogliptin","Drug","Takeda","Industry",0,0,"All","18 Years","80 Years","1554","May 2006","March 2008","Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis)","<0.001","For the primary analysis, the overall average HbA1c response of the Alogliptin/pioglitazone combination groups was compared with that of the pioglitazone alone groups at the 2-sided 0.05 significance level with no adjustment for multiple comparisons.","ANCOVA","-0.54","LS Mean Difference","95","2-Sided","-0.67","-0.41"
"299","NCT00328692","PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function","Heart Failure, Congestive",0,"rolofylline","Drug","NovaCardia, Inc.","Industry",0,0,"All","18 Years","N/A","932","August 2006","July 2009","effect on heart failure signs and symptoms","0","0","0","0","0","0","0","0","0"
"300","NCT00330317","Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer","Breast Cancer",0,"letrozole","Drug","Novartis Pharmaceuticals","Industry",0,0,"Female","18 Years","80 Years","300","February 2006","March 2010","Optimum length of treatment with letrozole (2.5 mg daily) preoperatively, on tumour measured by clinical examination and breast ultrasound","0","0","0","0","0","0","0","0","0"
"301","NCT00330369","DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension","Hypertension",0,"Darusentan","Drug","Gilead Sciences","Industry",0,0,"All","35 Years","80 Years","352","June 2006","January 2009","Change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry","0","0","0","0","0","0","0","0","0"
"302","NCT00330668","Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency","Growth Disorders",0,"rh IGF-1 (mecasermin)","Drug","Ipsen","Industry",0,0,"All","4 Years","15 Years","114","November 2005","February 2010","Height Velocity in Modified Intent-to-Treat Population (ITT Patients Randomized to 120 Mcg/kg Twice Daily)","0","0","0","0","0","0","0","0","0"
"303","NCT00330681","Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","Amyotrophic Lateral Sclerosis (ALS)",0,"MCI-186","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","75 Years","206","May 2006","September 2008","Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks","0","0","0","0","0","0","0","0","0"
"304","NCT00330759","Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.","Bone Metastases",0,"Denosumab","Biological","Amgen","Industry",0,0,"All","18 Years","N/A","1779","June 2006","April 2009","Time to the First On-Study Skeletal-Related Event (Non-Inferiority)","0.0007","0","Regression, Cox","0.84","Hazard Ratio (HR)","95","0","0.71","0.98"
"305","NCT00331188","Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding","Esophageal Varices",0,"Sanvar® (vapreotide)","Drug","Debiovision","Industry",0,0,"All","18 Years","75 Years","70","May 2006","June 2008","To determine the efficacy of the early administration of Sanvar® (vapreotide) in association with endoscopic treatment for the control of bleeding at 5 days, i.e. control of initial bleeding and prevention of early re-bleeding, plus survival.","0","0","0","0","0","0","0","0","0"
"306","NCT00331604","Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes","Diabetes",0,"inhaled human insulin","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","99 Years","618","August 31, 2006","May 5, 2008","Treatment difference in HbA1c","0","0","0","0","0","0","0","0","0"
"307","NCT00331890","ICTUS Study: International Citicoline Trial on Acute Stroke","Acute Stroke",0,"Citicoline","Drug","Ferrer Internacional S.A.","Industry",0,0,"All","18 Years","N/A","2298","October 2006","February 2012","Total recovery at three months of onset, based on a global test analysis including NIHSS, mRS and Barthel Index","0","0","0","0","0","0","0","0","0"
"308","NCT00332241","Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","Autistic Disorder",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","6 Years","17 Years","98","June 2006","April 2008","Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score","0","0","0","0","0","0","0","0","0"
"309","NCT00332917","An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients","Early Stage Parkinson's Disease",0,"Pardoprunox","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","30 Years","N/A","224","February 2007","July 2008","Safety: laboratory data, adverse events, vital signs, ECG","0","0","0","0","0","0","0","0","0"
"310","NCT00333216","Anecortave Acetate Risk-Reduction Trial (AART)","AMD",0,"Anecortave Acetate Sterile Suspension, 30 mg/mL","Drug","Alcon Research","Industry",0,0,"All","50 Years","N/A","24","May 2005","December 2008","Proportion of patients with sight-threatening CNV in study eye","0","0","0","0","0","0","0","0","0"
"311","NCT00333359","XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.","Restless Legs Syndrome",0,"XP13512 (GEn)","Drug","XenoPort, Inc.","Industry",0,0,"All","18 Years","N/A","581","June 2006","December 2008","Change From Baseline in the International Restless Legs Syndrome Rating Scale (IRLS) at Week 52 Using Observed Case (OC)","0","0","0","0","0","0","0","0","0"
"312","NCT00333788","Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease","Crohn's Disease",0,"Certolizumab pegol (CDP870)","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","233","October 2006","April 2010","Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks)","0","0","0","0","0","0","0","0","0"
"313","NCT00334282","Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell",0,"Pazopanib","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","435","April 2006","May 2008","Progression-free Survival",".0000001","stratified log-rank test","Log Rank","0.46","Hazard Ratio (HR)","95","0","0.34","0.62"
"314","NCT00334958","Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures","Epilepsy",0,"Placebo","Drug","Eisai Inc.","Industry",0,0,"All","12 Years","80 Years","356","February 2006","May 2009","Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase","0","0","0","0","0","0","0","0","0"
"315","NCT00335153","Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease","Advanced Parkinson's Disease",0,"Levodopa-carbidopa intestinal gel","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","30 Years","N/A","354","January 2008","June 2012","Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs","0","0","0","0","0","0","0","0","0"
"316","NCT00335166","SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease","Early Stage Parkinson Disease",0,"Pardaprunox","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","30 Years","N/A","330","November 2006","February 2008","UPDRS part 3 (motor score)and change from baseline to 24 weeks maintenance treatment","0","0","0","0","0","0","0","0","0"
"317","NCT00335244","Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery","Heart Defects, Congenital",0,"L-citrulline","Drug","Asklepion Pharmaceuticals, LLC","Industry",0,0,"All","N/A","17 Years","77","May 2006","December 2009","Duration of postoperative mechanical ventilation in hours compared between treatment groups.","0","0","0","0","0","0","0","0","0"
"318","NCT00335374","An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients","Early Stage Parkinson's Disease",0,"Pardoprunox","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","30 Years","N/A","202","August 2007","September 2008","Safety: laboratory data, adverse events, vital signs, ECG","0","0","0","0","0","0","0","0","0"
"319","NCT00335452","Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS","Acute Coronary Disease",0,"Clopidogrel","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","25086","June 2006","September 2009","First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison","0.3037","The a priori threshold for statistical significance is ≤0.05.","Log Rank","6.1","Relative Risk Reduction (%)","95","2-Sided","-5.8","16.6"
"320","NCT00335985","Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)","Polymyositis",0,"GB-0998","Drug","Japan Blood Products Organization","Industry",0,0,"All","16 Years","75 Years","26","June 2006","March 2009","Changes in manual muscle strength (MMT) scores","0","0","0","0","0","0","0","0","0"
"321","NCT00336713","A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)","Depressive Disorder",0,"Saredutant (SR48968C)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","430","May 2006","April 2008","The time to relapse of depressive symptoms (in days) during the Maintenance Phase.","0","0","0","0","0","0","0","0","0"
"322","NCT00337467","Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression","Human Immunodeficiency Virus (HIV) Infections",0,"Atazanavir + Ritonavir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","61","June 2006","May 2008","Percentage of Participants With Treatment Failure Through Week 48","0","0","0","21.3","Percentage of Participants","95","2-Sided","11.9","33.7"
"323","NCT00337571","Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","Behavioral Symptoms",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","6 Years","17 Years","218","June 2006","June 2008","Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score","0","0","0","0","0","0","0","0","0"
"324","NCT00343252","Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis","Osteoporosis, Postmenopausal",0,"teriparatide","Drug","Eli Lilly and Company","Industry",0,0,"Female","45 Years","N/A","712","June 2006","June 2009","Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint","0.642","All comparisons were conducted using a 2-sided significance level of 0.05.","Chi-square","0","0","0","0","0","0"
"325","NCT00343421","Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers","Diphtheria",0,"PEDIACEL® and Prevenar®","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","55 Days","75 Days","588","July 2006","June 2008","To provide information concerning the immunogenicity of PEDIACEL® and Infanrix®-IPV+Hib","0","0","0","0","0","0","0","0","0"
"326","NCT00343460","APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","Nausea and Vomiting",0,"APF530","Drug","Heron Therapeutics","Industry",0,0,"All","18 Years","120 Years","1428","June 2006","September 2008","Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1","0","0","0","0","0","0","0","0","0"
"327","NCT00343980","Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes","Diabetes",0,"rosiglitazone","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","363","October 10, 2006","March 10, 2008","Treatment difference in HbA1c","0","0","0","0","0","0","0","0","0"
"328","NCT00344370","Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia","Type II Diabetes Mellitus",0,"Pitavastatin","Drug","Kowa Research Europe","Industry",0,0,"All","N/A","N/A","214","August 2006","April 2008","NCEP LDL-C Target Attainment","0","0","0","0","0","0","0","0","0"
"329","NCT00345618","Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","Embolism",0,"Idrabiotaparinux sodium","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","3202","June 2006","October 2010","Recurrence of symptomatic, fatal or not, VTE (PE or DVT) as confirmed by a Central Independent Adjudication Committee (CIAC)","0","0","0","0","0","0","0","0","0"
"330","NCT00345644","Risedronate in Osteopenic Postmenopausal Women","Osteoporosis",0,"risedronate","Drug","Sanofi","Industry",0,0,"Female","55 Years","75 Years","156","March 2006","June 2009","Efficacy data : 3-D-pQCT Data—Microarchitectural Parameters (Distal Radius BV/TV Measurements)","0","0","0","0","0","0","0","0","0"
"331","NCT00345839","E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events","Secondary Hyperparathyroidism",0,"Cinacalcet","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","3883","August 2006","January 2012","Time to Primary Composite Endpoint (All-cause Mortality, Myocardial Infarction, Hospitalization for Unstable Angina, Heart Failure or Peripheral Vascular Event)","0.112","p-value<0.044 considered significant","Log Rank","0","0","0","0","0","0"
"332","NCT00346034","This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia","Fibromyalgia",0,"Pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","357","December 2006","February 2008","Change From Baseline to Week 4 in Pain Visual Analog Scale (VAS) Score","0","0","0","0","0","0","0","0","0"
"333","NCT00347048","Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients","Ulcerative Colitis",0,"tacrolimus","Drug","Astellas Pharma Inc","Industry",0,0,"All","16 Years","64 Years","62","September 2006","April 2008","Improvement of Disease activity index score (DAI score)","0","0","0","0","0","0","0","0","0"
"334","NCT00347360","The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial","Hypertension",0,"lisinopril","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","654","July 2006","April 2008","Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure",">0.1","0","Hung AVE test, see comments","0","0","0","0","0","0"
"335","NCT00347412","Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer","Non Small Cell Lung Cancer",0,"Paclitaxel and Carboplatin","Drug","Cellectar Biosciences, Inc.","Industry",0,0,"All","18 Years","N/A","880","November 2006","January 2010","Overall survival during the length of the trial, length of the trial is approximately two years after last patient in","0","0","0","0","0","0","0","0","0"
"336","NCT00347425","Switch Study of Existing Atypical Antipsychotics to Bifeprunox","Schizophrenia and Schizoaffective Disorder",0,"Aripiprazole","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","286","December 2006","February 2008","Successful switch defined as those who complete the 4 weeks core study with no worsening of 2 successive post baseline assessments on the CGIS, exacerbation of EPS, or cardiovascular risk factors (body weight and fasting triglycerides) from baseline.","0","0","0","0","0","0","0","0","0"
"337","NCT00348140","Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease","Alzheimer's Disease",0,"Rosiglitazone Extended Release 2mg","Drug","GlaxoSmithKline","Industry",0,0,"All","50 Years","90 Years","1450","July 2006","March 2009","Change from Baseline in Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-Cog) total score at Week 48, as a function of APOE ε4 status in APOE4 negatives cohort","0","0","0","0","0","0","0","0","0"
"338","NCT00348283","Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon","Crohn's Disease",0,"adalimumab","Biological","Abbott","Industry",0,0,"All","18 Years","75 Years","135","August 2006","September 2008","Number of Subjects Without Mucosal Ulceration at Week 12","0.056","The P value is from Cochran-Mantel-Haenszel test with clinical response (CR-70 responder status) at Week 4 as the stratification factor.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"339","NCT00348374","Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes","Diabetes Mellitus",0,"Insulin Lispro","Drug","Pfizer","Industry",0,0,"All","18 Years","80 Years","191","June 2006","August 2008","Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at End of Treatment","0","0","0","0","0","0","0","0","0"
"340","NCT00348387","Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV","Poliomyelitis",0,"Poliomyelitis Vaccine inactivated","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","60 Days","70 Days","600","June 2006","September 2008","To provide information concerning the immunogenicity of IMOVAX Polio™ vaccine","0","0","0","0","0","0","0","0","0"
"341","NCT00348712","Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes","Diabetes",0,"rosiglitazone","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","301","October 30, 2006","March 5, 2008","Treatment difference in HbA1c","0","0","0","0","0","0","0","0","0"
"342","NCT00349752","Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease","Crohn's Disease",0,"certolizumab pegol 400 mg","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","174","November 2006","July 2009","Percentage of Subjects Who Have Been Withdrawn From Prednisone or Prednisolone Therapy According to the Corticosteroid Tapering Schedule and Have Remained Off Corticosteroids and in Disease Remission at Week 38","0","0","0","0","0","0","0","0","0"
"343","NCT00350948","Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer","Ovarian Neoplasms",0,"Telcyta","Drug","Telik","Industry",0,0,"Female","18 Years","N/A","244","May 2006","December 2008","To demonstrate superiority in progression-free survival of TLK286 in combination with liposomal doxorubicin as compared with the active control arm liposomal doxorubicin","0","0","0","0","0","0","0","0","0"
"344","NCT00352053","Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy","HIV Infections",0,"Tenofovir DF","Drug","Gilead Sciences","Industry",0,0,"All","12 Years","17 Years","87","June 2006","September 2008","Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA","0.55","No adjustments for multiple comparisons were made.","Van Elteren test","0","0","0","0","0","0"
"345","NCT00352183","Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy","Cardiovascular Diseases",0,"Fenofibrate/Simvastatin","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","450","January 2006","August 2008","Triglycerides","0","0","0","0","0","0","0","0","0"
"346","NCT00353574","DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension","Hypertension",0,"Darusentan","Drug","Gilead Sciences","Industry",0,0,"All","35 Years","80 Years","282","September 2006","February 2010","Change in trough sitting systolic and diastolic blood pressure","0","0","0","0","0","0","0","0","0"
"347","NCT00354458","PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function","Heart Failure, Congestive",0,"rolofylline","Drug","NovaCardia, Inc.","Industry",0,0,"All","18 Years","N/A","1102","October 2006","July 2009","effect on heart failure signs and symptoms","0","0","0","0","0","0","0","0","0"
"348","NCT00354627","The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs","HIV-1",0,"TMC125","Drug","Tibotec Pharmaceuticals, Ireland","Industry",0,0,"All","18 Years","N/A","5178","January 2006","February 2012","The primary objective of TMC125-C214 is to provide early access to TMC125 for treatment-experienced HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens and have limited treatment options with currently approved ARVs.","0","0","0","0","0","0","0","0","0"
"349","NCT00355082","Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy","Epilepsy, Partial",0,"lamotrigine, 300 mg/day","Drug","GlaxoSmithKline","Industry",0,0,"All","13 Years","N/A","226","May 2006","November 2008","The Percentage of Participants in the 300 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)","0","0","0","0","0","0","0","0","0"
"350","NCT00355134","Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis","Multiple Sclerosis",0,"Fingolimod","Drug","Novartis","Industry",0,0,"All","18 Years","55 Years","1083","June 2006","June 2011","Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24","0","0","0","0","0","0","0","0","0"
"351","NCT00355355","A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)","Carcinoma, Hepatocellular",0,"Talaporfin sodium","Drug","Light Sciences Oncology","Industry",0,0,"All","18 Years","N/A","208","July 2006","September 2012","Overall survival","0","0","0","0","0","0","0","0","0"
"352","NCT00356408","Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease","Crohn's Disease",0,"Certolizumab pegol","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","106","January 2007","February 2010","Occurrence of at Least One Treatment-emergent Adverse Event During This Study (Maximum 122 Weeks)","0","0","0","0","0","0","0","0","0"
"353","NCT00356915","Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.","Onychomycosis",0,"Itraconazole 100mg capsules","Drug","Stiefel, a GSK Company","Industry",0,0,"All","16 Years","75 Years","1381","July 2006","October 2008","Clinical and Mycological Cure of Target Toenail","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"354","NCT00357370","A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","75 Years","163","October 2006","March 2008","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2","0","0","0","-0.70","Mean Difference (Final Values)","95","2-Sided","-1.08","-0.32"
"355","NCT00357994","Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","Advanced Parkinson's Disease",0,"Levodopa carbidopa intestinal gel (LCIG)","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","30 Years","N/A","36","January 2009","October 2011","Change From Baseline to Week 12 in Average Daily Normalized ""Off"" Time","0.0015","Treatment comparisons are based on an ANCOVA model including effects for treatment, country, and with the corresponding baseline and the natural logarithm of the mean daily dose of rescue medication on valid symptom diary days as covariates.","ANCOVA","-1.91","Treatment Difference (LS Mean)","95","2-Sided","-3.05","-0.76"
"356","NCT00358215","RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial","Heart Failure",0,"Darbepoetin alfa","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","2278","June 2006","October 2012","Time to All Cause Death or First Hospitalization for Worsening Heart Failure","0.871","Stratification factors are: region and type of device (cardiac resynchronization therapy (CRT) with or without implantable cardioverter defibrillator (ICD), ICD without CRT, or none)","Stratified Log Rank","1.01","Hazard Ratio (HR)","95","2-Sided","0.90","1.13"
"357","NCT00358501","Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients","Severe Hepatic Veno-Occlusive Disease",0,"Defibrotide","Drug","Jazz Pharmaceuticals","Industry",0,0,"All","N/A","N/A","134","July 2006","September 2008","Survival at Day+100 Following Hematopoietic Stem Cell Transplant","0","0","0","0","0","0","0","0","0"
"358","NCT00358566","GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer","Advanced Unresectable Pancreatic Cancer",0,"GV1001","Biological","Pharmexa A/S","Industry",0,0,"All","18 Years","75 Years","360","June 2006","August 2008","Overall survival time","0","0","0","0","0","0","0","0","0"
"359","NCT00358670","Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)","Psoriasis",0,"infliximab","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","75 Years","441","May 2006","January 2009","Number of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI75) Response at Week 128","0","0","0","0","0","0","0","0","0"
"360","NCT00358917","Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects","Human Immunodeficiency Virus Infections",0,"lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","599","August 2006","November 2008","Percentage of Participants Responding at Week 48 Based on the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) Algorithm","0.413","0","normal approx. to binomial distribution","3.5","Diff. in Percentage of Subj. Responding","95","0","-4.5","11.5"
"361","NCT00359021","An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).","HIV-1",0,"TMC125","Drug","Tibotec Pharmaceuticals, Ireland","Industry",0,0,"All","18 Years","N/A","503","June 2006","January 2012","The Number of Participants Experiencing Adverse Events","0","0","0","0","0","0","0","0","0"
"362","NCT00359762","Exenatide Versus Glimepiride in Patients With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","18 Years","85 Years","1029","September 2006","March 2011","Number of Patients With Treatment Failure","0.0020","0","Regression, Cox","0.748","Hazard Ratio","95","2-Sided","0.623","0.899"
"363","NCT00360243","6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA","Sexual Dysfunctions, Psychological",0,"flibanserin","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","18 Years","50 Years","1385","July 2006","April 2008","Mean Change From Baseline to 24 Weeks in the Frequency of Satisfying Sexual Events as Measured by the eDiary.","0","0","0","0","0","0","0","0","0"
"364","NCT00360334","A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients","Type 2 Diabetes",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","30 Years","N/A","235","June 2006","April 2008","Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg)","<0.001","0","Regression, Logistic","4.71","Odds Ratio (OR)","95","0","2.62","8.46"
"365","NCT00360490","Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)","Menorrhagia",0,"Levonorgestrel IUS (Mirena, BAY86-5028)","Drug","Bayer","Industry",0,0,"Female","18 Years","N/A","165","July 2006","June 2008","The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6)","<0.001","0","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"366","NCT00360529","24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder","Sexual Dysfunctions, Psychological",0,"flibanserin","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","18 Years","N/A","880","July 2006","April 2008","Satisfying Sexual Event Monthly Change From Baseline at Final Visit","0.0454","Hierarchical ordering used for multiple endpoints, and Hochberg used for multiple dose comparisons. P-values ordered (p1≤p2). If p2≤0.05 then all doses significant. If p1≤0.025 then reject null for p1","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"367","NCT00360555","Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder","Sexual Dysfunctions, Psychological",0,"flibanserin","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","18 Years","55 Years","1584","July 2006","March 2008","Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary.","0","0","0","0","0","0","0","0","0"
"368","NCT00360568","Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects","Dyskinesias",0,"Levodopa-carbidopa intestinal gel","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","30 Years","N/A","62","June 2009","October 2012","Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs","0","0","0","0","0","0","0","0","0"
"369","NCT00361504","A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain","Osteoarthritis, Hip",0,"Oxycodone CR","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","1123","November 2006","July 2008","Number of Participants With Treatment-emergent Adverse Events (TEAE)","0","0","0","0","0","0","0","0","0"
"370","NCT00362206","Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin","Hyperlipidemia",0,"Fenofibrate/Simvastatin","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","423","September 2006","September 2008","Percent change from baseline to 12 weeks of treatment in Triglycerides","0","0","0","0","0","0","0","0","0"
"371","NCT00362323","Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO","Dyslipidemia/Glucose Metabolism Disorder",0,"fenofibrate (F) + metformin (M) hydrochloride fixed combination","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","482","October 2006","August 2008","TG / HDL-C ratio","0","0","0","0","0","0","0","0","0"
"372","NCT00362336","Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV","Hepatitis B",0,"DTaP-IPV-HB-PRP~T","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","N/A","3 Days","622","August 2006","May 2008","Number of Participants With Seroprotection After Primary Series Vaccination With DTaP-IPV-Hep B-PRT~T or CombAct Hib™ + Engerix B™ + Oral Polio Vaccine (OPV)","0","0","0","0","0","0","0","0","0"
"373","NCT00362349","Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients","Idiopathic Thrombocytopenic Purpura (ITP)",0,"IgNextGen 10%","Drug","CSL Limited","Industry",0,0,"All","18 Years","N/A","19","June 2007","October 2008","Efficacy","0","0","0","0","0","0","0","0","0"
"374","NCT00362466","A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy","Leukemia",0,"Dasatinib","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","3","April 2007","June 2008","Complete Cytogenetic Response (CCyR) Rate at Month 6","0","0","0","0","0","0","0","0","0"
"375","NCT00363415","Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer","Small Cell Lung Cancer",0,"pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","908","August 2006","June 2008","Overall Survival","<0.01","0","Log Rank","1.56","Hazard Ratio (HR)","95","0","1.27","1.92"
"376","NCT00363636","A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)","Lymphoma, Non-Hodgkin's",0,"Galiximab in combination with rituximab","Drug","Biogen","Industry",0,0,"All","18 Years","N/A","340","September 2006","January 2010","To assess efficacy as measured by progression free survival (PFS), and determine whether rituximab plus galiximab compared to rituximab plus placebo may extend PFS.","0","0","0","0","0","0","0","0","0"
"377","NCT00364013","PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy","Metastatic Colorectal Cancer",0,"Panitumumab","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","1183","August 2006","August 2009","Progression-free Survival","0.0234","P-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).","Stratified log-rank test","-2.27","Normal score","0","0","0","0"
"378","NCT00364182","Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B","Hemophilia B",0,"Recombinant Coagulation Factor IX (BeneFIX)","Drug","Pfizer","Industry",0,0,"Male","6 Years","65 Years","50","May 2007","October 2010","Annualized Number of Bleeding Episodes","<0.0001","P-values based on a model including terms for treatment regimen, treatment sequence, and the interaction of these terms with repeated measures on participants.","ANOVA","-30.5","Mean Difference (Final Values)","95","2-Sided","-36.5","-24.5"
"379","NCT00364845","STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients","Anemia",0,"Darbepoetin alfa","Drug","Amgen","Industry",0,0,"All","70 Years","N/A","51","September 2006","December 2008","Short Form 36 Health Survey Questionnaire (SF-36) Vitality Subscale Score at Week 24","0","0","0","0","0","0","0","0","0"
"380","NCT00365456","Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)","Osteoporosis",0,"Parathyroid Hormone (PTH)","Drug","Takeda","Industry",0,0,"Female","50 Years","N/A","407","July 2006","January 2011","Change in Lumbar Spine BMD From Start of Trial Period III Until End of Trial Period III.","0.010","No multiplicity correction of the significance level was performed as only one primary endpoint was planned.","ANCOVA","1.012","Mean Difference (Final Values)","95","2-Sided","1.003","1.021"
"381","NCT00365859","Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)","Autistic Disorder",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","6 Years","17 Years","330","September 2006","June 2009","Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs","0","0","0","0","0","0","0","0","0"
"382","NCT00366145","Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease","Graft Versus Host Disease",0,"Mesenchymal Stem Cells","Biological","Osiris Therapeutics","Industry",0,0,"All","6 Months","70 Years","240","July 2006","May 2009","Complete Response of greater than or equal to 28 days duration","0","0","0","0","0","0","0","0","0"
"383","NCT00366249","Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.","Bacterial Infections",0,"Tigecycline","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","N/A","1061","January 2007","March 2009","Number of Patients With Clinical Response of Cure Vs. Failure.","0","0","0","-5.5","Mehrotra and Railker","95","0","-11.0","0.1"
"384","NCT00366327","Study Evaluating Bifeprunox in Patients With Schizophrenia.","Schizophrenia",0,"Bifeprunox","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","66 Years","400","January 2007","March 2008","Change in weight from baseline/first dose of bifeprunox at each observation.","0","0","0","0","0","0","0","0","0"
"385","NCT00366548","Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants","Vaccines, Pneumococcal",0,"13 valent pneumococcal conjugate vaccine with Polysorbate 80","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","42 Days","98 Days","500","November 2006","June 2008","Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC+P80 Group Relative to 13vPnC-80 Group After the Infant Series","0","0","0","-0.8","Difference","95","0","-5.4","3.7"
"386","NCT00366678","Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants","Vaccines, Pneumococcal",0,"13-valent pneumococcal conjugate vaccine","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","42 Days","98 Days","613","October 2006","November 2008","Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin (PT) and Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group","0","0","0","0.0","Difference","95","0","-1.4","1.4"
"387","NCT00366704","Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint","Schizophrenia",0,"bifeprunox","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","65 Years","400","November 2006","March 2008","The primary analysis will be the change from baseline on body weight at the final evaluation.","0","0","0","0","0","0","0","0","0"
"388","NCT00367237","Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)","Arthritis, Psoriatic",0,"Infliximab + methotrexate (IFX + MTX)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","115","May 2006","March 2008","Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16","0.0210","Comparison of treatments (IFX + MTX versus MTX)","Chi-squared","19.61","Difference in percentages of respondents","95","0","3.27","35.95"
"389","NCT00367432","A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures","Epilepsies",0,"Levetiracetam","Drug","UCB Japan Co. Ltd.","Industry",0,0,"All","16 Years","65 Years","398","July 2006","December 2010","Occurrence of Treatment-emergent Adverse Events During the Study Period (Until the Time of Approval Granted)","0","0","0","0","0","0","0","0","0"
"390","NCT00368251","Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults","Unverricht-Lundborg Disease",0,"Placebo","Other","UCB Pharma","Industry",0,0,"All","16 Years","N/A","56","November 2006","January 2008","Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4)","=0.942","All hypotheses are tested at the 5 % level. The multiplicity scheme (hierarchical testing procedure) assures strong control of the type I error at the 5 % level.","stratified Wilcoxon Test","0.15","Hodges-Lehmann-estimator of difference","95","2-Sided","-26.12","24.96"
"391","NCT00368706","A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients","Urinary Bladder, Overactive",0,"solifenacin succinate","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","75 Years","246","September 2006","March 2008","Change from baseline in mean number of micturitions per 24 hours","0","0","0","0","0","0","0","0","0"
"392","NCT00368745","Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.","Generalized Anxiety Disorder",0,"Pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","108","September 2006","August 2008","Number of Subjects at Endpoint (Post Alprazolam Free Week 6 or Last Observation Carried Forward [LOCF] Post Alprazolam Free Week 1) Who Are Benzodiazepine Free","0.2838","significance determined using 2-tailed significance level of 0.05","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"393","NCT00369941","A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","HIV Infections",0,"MK-0518","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","566","August 2006","May 2009","Number of Participants Who Achieved Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) <50 Copies/mL at Week 48","0","0","0","0","0","0","0","0","0"
"394","NCT00370071","Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis","Multiple Sclerosis",0,"Interferon beta-1b (Betaseron, BAY86-5046)","Drug","Bayer","Industry",0,0,"All","16 Years","55 Years","39","November 2006","September 2008","Difference Between the Number of Newly Active Lesions in Magnetic Resonance Imaging (MRI) Per Three Months During the 6-month Treatment Period and the Number of Newly Active Lesions During 3-month Pre-treatment","<0.0001","one-sided p-value (one-sided test level 2.5%)","Wilcoxon-Signed-Rank test","0","0","0","0","0","0"
"395","NCT00371137","A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia","Fibromyalgia",0,"Xyrem®","Drug","Jazz Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","548","August 2006","September 2008","Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF).",">0.001","0","Chi-squared","0","0","0","0","0","0"
"396","NCT00371683","Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery","Deep Vein Thrombosis",0,"Enoxaparin + Placebo","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","3608","November 2006","May 2008","Event Rate of the Composite of Adjudicated Venous Thromboembolism (VTE) Events and All-Cause Death With Onset During the Intended Treatment Period - Primary Subjects","0.0635","If p-value is less than 0.025, it is statistically significant.","t-test, 1 sided","1.02","Risk Ratio (RR)","95","2-Sided","0.78","1.32"
"397","NCT00371761","PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)","Hepatitis B, Chronic (CHB)",0,"Pegylated interferon alfa-2b (PegIntron)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","70 Years","25","September 2006","February 2009","Number of Participants With a Combined Response Consisting of All Three Responses - (a) Serological Response, (b) Virological Response, and (c) Biochemical Response","0","0","0","0","0","0","0","0","0"
"398","NCT00372528","An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures","Epilepsy",0,"pregabalin (LYRICA)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","21","March 2007","October 2011","Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"399","NCT00372567","Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors","Gastrointestinal Stromal Tumor",0,"sunitinib malate","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","69","June 2007","November 2009","Progression-Free Survival (PFS)","0","0","0","1.040","Hazard Ratio (HR)","95","2-Sided","0.484","2.235"
"400","NCT00373113","A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine","Breast Neoplasms",0,"Capecitabine","Drug","Pfizer","Industry",0,0,"Female","18 Years","N/A","482","November 2006","October 2009","Progression-Free Survival (PFS)","0.002","2-sided log-rank test with the same set of stratification factors. The set of stratification factors included those used in the randomization except study sites.","Log Rank","1.470","Hazard Ratio (HR)","95","2-Sided","1.156","1.869"
"401","NCT00373256","A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer","Breast Neoplasms",0,"Sunitinib","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","488","November 2006","June 2009","Progression-Free Survival (PFS)","0.9986","p-value from 1-sided log-rank stratified for prior adjuvant chemotherapy, hormone receptor status, disease-free interval from prior adjuvant treatment. Stratification factors from Interactive Voice Randomization System.","Log Rank","1.6299","Hazard Ratio (HR)","95","2-Sided","1.1793","2.2527"
"402","NCT00374322","Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer","Neoplasms, Breast",0,"lapatinib","Drug","GlaxoSmithKline","Industry",0,0,"Female","18 Years","N/A","3166","August 2006","September 2011","Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])","0.286","The p-value was calculated from a stratified log-rank test, stratifying for hormone receptor status, time since initial diagnosis, and lymph node involvement.","Log Rank","0.91","Hazard Ratio (HR)","95","2-Sided","0.77","1.08"
"403","NCT00374777","A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients","Sleep Initiation and Maintenance Disorders",0,"zolpidem MR","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","64 Years","450","August 2006","May 2008","Mean wake time after sleep onset during the double-blind period","0","0","0","0","0","0","0","0","0"
"404","NCT00375401","A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety","Obesity",0,"CP-945,598 Treatment A","Drug","Pfizer","Industry",0,0,"All","18 Years","70 Years","2536","October 2006","January 2009","Proportion of subjects with 5% weight loss","0","0","0","0","0","0","0","0","0"
"405","NCT00375492","Effect on Weight Loss of Exenatide Versus Placebo","Type 2 Diabetes Mellitus",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","18 Years","75 Years","196","September 2006","February 2008","Change From Baseline in Body Weight","0.0030","0","Mixed Model Repeated Measures","0","0","0","0","0","0"
"406","NCT00376168","A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease","Gaucher Disease",0,"Plant cell expressed recombinant glucocerebrosidase (prGCD)","Drug","Protalix","Industry",0,0,"All","18 Years","N/A","32","August 2007","September 2009","Change From Baseline in Spleen Volume Measured by MRI.","<0.0001","0","one-sample t-test","0","0","0","0","0","0"
"407","NCT00377598","Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia","Neuralgia, Postherpetic",0,"TAK-583","Drug","Takeda","Industry",0,0,"All","50 Years","N/A","399","October 2006","February 2008","Change from Baseline in average daily pain intensity score for the previous 7 days","0","0","0","0","0","0","0","0","0"
"408","NCT00378378","Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)","Nasal Polyps",0,"Mometasone Furoate Nasal Spray (MFNS)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","6 Years","17 Years","127","July 2006","June 2008","Change From Baseline 24-hour Urinary Free Cortisol Level","0.258","0","ANOVA","0","0","0","0","0","0"
"409","NCT00378599","Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","Liver Transplantation",0,"Combination of (a) pegylated interferon alfa-2b and (b) rebetol","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","70 Years","125","May 2006","July 2009","A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment","0","0","0",".288","Binomial Approximation","95","2-Sided","0.21","0.38"
"410","NCT00378690","A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD","Prostate Cancer",0,"leuprorelin acetate","Drug","Astellas Pharma Inc","Industry",0,0,"Male","18 Years","80 Years","706","March 2006","June 2011","Time to PSA progression","0","0","0","0","0","0","0","0","0"
"411","NCT00379470","Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)","Recurrent Glioblastoma Multiforme",0,"NovoTTF-100A","Device","NovoCure Ltd.","Industry",0,0,"All","18 Years","N/A","236","September 2006","November 2009","Overall Survival","0","0","0","0","0","0","0","0","0"
"412","NCT00379769","RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","Diabetes Mellitus, Type 2",0,"Rosiglitazone","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","75 Years","4447","April 2001","December 2008","Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events","0","0","0","0.99","Hazard Ratio (HR)","95","0","0.85","1.16"
"413","NCT00380068","Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension","Pulmonary Hypertension",0,"Ambrisentan","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","224","August 2006","July 2008","Change From Baseline to Week 24 in 6 Minute Walk Distance (6MWD)","<0.001","0","t-test, 2 sided","20.5","Mean Difference (Net)","95","0","11.8","29.3"
"414","NCT00380367","Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)","Papillomavirus Infections",0,"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","9 Years","15 Years","110","May 3, 2007","February 4, 2008","Percentage of Participants Who Seroconvert to Each HPV Serotype (Types 6, 11, 16, 18) at Month 7","0","0","0","0","0","0","0","0","0"
"415","NCT00381303","GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.","HIV",0,"darunavir","Drug","Tibotec, Inc","Industry",0,0,"All","18 Years","N/A","429","November 2006","November 2008","Number of Viral Load (VL) < 50 HIV-1 RNA Copies/mL (Time to Loss of Virologic Response[TLOVR]) Subjects by Sex","0.30","P-Value for difference (Female - Male): Test for non-inferiority (Delta=15%)","Regression, Logistic","-9.6","Mean Difference (Final Values)","95","2-Sided","-19.85","0.68"
"416","NCT00381485","Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)","Asthma",0,"Mometasone furoate/formoterol (MF/F) combination","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","834","July 1, 2006","January 1, 2008","Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)","<0.001","0","ANCOVA","0","0","0","0","0","0"
"417","NCT00382031","Zalutumumab in Patients With Non-curable Head and Neck Cancer","Head and Neck Cancer",0,"Zalutumumab","Drug","Genmab","Industry",0,0,"All","18 Years","N/A","286","November 2006","December 2009","Overall Survival","0","0","0","0","0","0","0","0","0"
"418","NCT00382863","Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial","Heart Failure",0,"HeartNet Ventricular Support System","Device","Paracor Medical, Inc","Industry",0,0,"All","18 Years","74 Years","220","October 2006","May 2011","Responder Analysis - Peak Oxygen Uptake (Peak VO2)","0.502","0","Fisher Exact","0","0","0","0","0","0"
"419","NCT00383240","Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)","Asthma",0,"mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","781","September 2006","September 2008","Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F Versus MF","<.001","P-Value for Endpoint","ANCOVA","0","0","0","0","0","0"
"420","NCT00383422","Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis","Osteoporosis, Postmenopausal",0,"Arzoxifene","Drug","Eli Lilly and Company","Industry",0,0,"Female","50 Years","75 Years","320","October 2006","July 2008","Percent change in Lumbar Spine BMD","0","0","0","0","0","0","0","0","0"
"421","NCT00383435","Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)","Chronic Obstructive Pulmonary Disease (COPD)",0,"Mometasone furoate/formoterol (MF/F) combination","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","40 Years","N/A","1055","October 2006","July 2010","Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)","<0.001","0","ANCOVA","0","0","0","0","0","0"
"422","NCT00383526","Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly","Orthomyxoviridae Infection",0,"Inactivated, split-virion influenza vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","60 Years","N/A","3707","September 2006","June 2009","To provide information concerning the immunogenicity of Inactivated, Split-Virion Influenza vaccine","0","0","0","0","0","0","0","0","0"
"423","NCT00383552","Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)","Asthma",0,"Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","746","September 2006","August 2008","Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)","0.001","0","ANCOVA","0","0","0","0","0","0"
"424","NCT00383708","Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","Acromegaly",0,"lanreotide (Autogel formulation)","Drug","Ipsen","Industry",0,0,"All","18 Years","75 Years","125","October 2006","October 2008","The percentage of acromegalic patients with normalised (age and sex adjusted) IGF-1 level at the end of the co-treatment period.","0","0","0","0","0","0","0","0","0"
"425","NCT00383721","Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)","Chronic Obstructive Pulmonary Disease (COPD)",0,"Mometasone furoate/formoterol (MF/F) combination","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","40 Years","N/A","1196","September 2006","July 2010","Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)","<0.001","0","ANCOVA","0","0","0","0","0","0"
"426","NCT00384111","Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL","Follicular Lymphoma",0,"R-CVP + Zevalin Therapeutic Regimen","Drug","Spectrum Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","26","October 2006","March 2010","Safety","0","0","0","0","0","0","0","0","0"
"427","NCT00384150","Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)","Lymphoma, Non-Hodgkin's",0,"galiximab in combination with rituximab","Drug","Biogen","Industry",0,0,"All","18 Years","N/A","16","November 2007","January 2010","Safety measures include: adverse event rates, clinical laboratory results, development of anti-galiximab and human anti-chimeric antibodies","0","0","0","0","0","0","0","0","0"
"428","NCT00384397","A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers","Meningococcal Meningitis",0,"Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","249 Days","305 Days","1128","September 2006","August 2008","Percentage of Participants With Antibody Titers ≥ 8 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC)","0","0","0","0","0","0","0","0","0"
"429","NCT00385138","Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.","Atherosclerosis",0,"Cangrelor","Drug","The Medicines Company","Industry",0,0,"All","18 Years","N/A","5364","September 2006","May 2009","Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)","0","0","0","0","0","0","0","0","0"
"430","NCT00385697","The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus","Type 1 Diabetes Mellitus",0,"Teplizumab","Drug","MacroGenics","Industry",0,0,"All","8 Years","35 Years","554","October 2006","June 2010","The first primary endpoint is a composite endpoint at 52 weeks: the proportion of subjects with both a total daily insulin dose of less than 0.5 U/kg/day and HbA1c level of less than 6.5%.","0","0","0","0","0","0","0","0","0"
"431","NCT00385736","Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis","Ulcerative Colitis",0,"adalimumab","Biological","Abbott","Industry",0,0,"All","18 Years","N/A","576","November 2006","April 2009","Proportion of Participants With Clinical Remission Per Mayo Score at Week 8","0.031","The primary endpoint analysis was carried out in hierarchical order (as presented) to handle the multiplicity issues induced by the two adalimumab groups being compared to placebo and to control the overall alpha level of 0.05.","Chi-squared","0","0","0","0","0","0"
"432","NCT00386308","Efficacy and Safety Study of XP12B in Women With Menorrhagia","Menorrhagia",0,"Tranexamic acid tablets","Drug","Ferring Pharmaceuticals","Industry",0,0,"Female","18 Years","49 Years","196","October 2006","May 2008","Mean Reduction From Baseline in Menstrual Blood Loss (MBL)","0","0","0","0","0","0","0","0","0"
"433","NCT00386360","Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method","Osteopenia",0,"Placebo comparator","Drug","Warner Chilcott","Industry",0,0,"Female","40 Years","55 Years","161","April 2006","September 2009","Trabecular Bone Volume to Tissue Volume at Distal Radius, Percent Change From Baseline to Month 12","0.7096","0","ANOVA","0.231","LS Mean Difference","95","2-Sided","-0.995","1.458"
"434","NCT00387686","A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures","Fractures",0,"rhBMP-2/CPM","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","N/A","367","November 2006","July 2009","The primary objective of this study is to assess whether a single dose of rhBMP-2/CPM administered in combination with the SOC accelerates fracture union and return to normal function as indicated on radiographs and functional evaluations.","0","0","0","0","0","0","0","0","0"
"435","NCT00387881","TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)","Migraine, Without Aura",0,"sumatriptan succinate / naproxen sodium","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","65 Years","679","September 2006","February 2008","Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose.","<0.001","Endpoints were co-primary and both needed to have p-value of <0.05 to be considered indicative of efficacy.","Cochran-Mantel-Haenszel","18","Percent difference","95","0","10","25"
"436","NCT00389155","First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy","Bladder Cancer",0,"Vinflunine","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","34","January 2007","January 2008","Median Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria in Participants With Advanced Transitional Cell Carcinoma (TCC) of the Urothelium","0","0","0","0","0","0","0","0","0"
"437","NCT00389220","Limus Eluted From A Durable Versus ERodable Stent Coating","Coronary Disease",0,"Coronary stent placement","Device","Biosensors Europe SA","Industry",0,0,"All","18 Years","N/A","1707","November 2006","May 2008","Major adverse cardiac events (MACE) in the overall population according to the ARC definitions.","0","0","0","0","0","0","0","0","0"
"438","NCT00389597","LDR Spine USA Mobi-C(R) Cervical Disc Prosthesis IDE","Degenerative Disc Disease",0,"Cervical Artificial Disc","Device","LDR Spine USA","Industry",0,0,"All","18 Years","69 Years","599","April 2006","March 2010","Composite Definition of Study Success",".05","0","Farrington-Manning","0","0","0","0","0","0"
"439","NCT00389675","DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension","Hypertension",0,"Darusentan","Drug","Gilead Sciences","Industry",0,0,"All","35 Years","80 Years","661","May 2007","February 2010","Change from baseline in mean 24-hour systolic and diastolic ambulatory blood pressure","0","0","0","0","0","0","0","0","0"
"440","NCT00389779","DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension","Hypertension",0,"Darusentan","Drug","Gilead Sciences","Industry",0,0,"All","35 Years","80 Years","849","September 2006","August 2009","Change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry","0","0","0","0","0","0","0","0","0"
"441","NCT00390533","An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder","Generalized Anxiety",0,"Saredutant","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","428","September 2006","February 2008","Change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.","0","0","0","0","0","0","0","0","0"
"442","NCT00390702","Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System","Heart Septal Defects, Ventricular",0,"transcatheter implantation of a VSD occluder (Nitinol coil)","Device","pfm medical ag","Industry",0,0,"All","2 Years","N/A","338","October 2006","August 2012","a set of Performance Criteria (PC) deduced for VSD analogue to the set of Objective Performance Criteria (OPC) of the 'Multiorganization Advisory Panel to FDA for Pediatric Cardiovascular Devices' for PDAs","0","0","0","0","0","0","0","0","0"
"443","NCT00390806","Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer","Lung Cancer, Non-Small Cell",0,"HYCAMTIN, oral capsules","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","472","December 2006","July 2012","Overall Survival","0.1862","p-value from a stratified log-rank test is adjusted for Recursive Partitioning Analysis (RPA) class and the number of brain lesions at Screening.","Log Rank","0.88","Hazard Ratio (HR)","95","2-Sided","0.73","1.07"
"444","NCT00391079","Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS","Multiple Sclerosis",0,"Sativex","Drug","GW Pharmaceuticals Ltd.","Industry",0,0,"All","18 Years","N/A","339","September 2006","April 2008","Change in Mean Pain Due to MS NRS Score","0.468","0","ANCOVA","-0.17","Estimated treatment effect","95","2-Sided","-0.62","0.29"
"445","NCT00391196","A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients","Obesity",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","70 Years","975","November 2006","December 2008","Percent change in body weight from baseline.","0","0","0","0","0","0","0","0","0"
"446","NCT00391222","A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder","Bipolar Disorder",0,"Olanzapine","Drug","Janssen Pharmaceutica N.V., Belgium","Industry",0,0,"All","18 Years","65 Years","585","November 2006","April 2009","Time to Recurrence of a Mood Episode (Risperidone LAI Versus Placebo)","0.057","As defined in the protocol, the olanzapine arm was not included in the primary outcome comparison. Data on the olanzapine arm are presented in outcome measure 7.","Log Rank","0","0","0","0","0","0"
"447","NCT00391274","Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)","Non-Small Cell Lung Cancer",0,"pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","211","October 2006","December 2008","Overall Survival","0.1326","Logistic regression of best overall tumor response (complete response + partial response).","Regression, Logistic","2.50","Odds Ratio (OR)","95","0","0.76","8.25"
"448","NCT00391534","EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy","Partial Epilepsy",0,"modified release formulation of oxcarbazepine (OXC MR)","Drug","Desitin Arzneimittel GmbH","Industry",0,0,"All","18 Years","N/A","100","October 2006","November 2009","Maintenance dosage where dose up-titration has to be discontinued due to AEs","0","0","0","0","0","0","0","0","0"
"449","NCT00391807","Study of Safety and Efficacy of an Oral Contraceptive","Contraception",0,"Norethindrone acetate/ethinyl estradiol","Drug","Warner Chilcott","Industry",0,0,"Female","18 Years","45 Years","1683","November 2006","August 2008","Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population,","0","0","0","0","0","0","0","0","0"
"450","NCT00391976","Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis","Cystic Fibrosis",0,"Tobramycin solution for inhalation 300 mg","Drug","Novartis","Industry",0,0,"All","6 Months","N/A","123","November 2003","January 2008","Time to Recurrence of Pseudomonas (P.) Aeruginosa (Any Genotype) in Sputum or Deep Throat Cough Swab","0","0","0","0","0","0","0","0","0"
"451","NCT00392574","Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea","Acute Gastroenteritis in Adult Travelers",0,"Prulifloxacin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","282","August 2006","February 2008","Time to last unformed stool","0","0","0","0","0","0","0","0","0"
"452","NCT00393523","Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)","Hepatitis B",0,"Comparator: Modified Process Hepatitis B Vaccine","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","4 Years","8 Years","1478","September 2006","June 2008","Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy","<0.001","Adequate SPR required the lower bound of the 95.2% CI for the SPR for subjects in both Group 1 and Group 2 to be > 90% (P-Value < .024).
Since only one group met the criteria, that group was retested at α=.012.","Hochberg's step up","95.0","Seroprotection rate (SPR)","95.2","0","92.1","97.1"
"453","NCT00393744","Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children","Tonsillitis",0,"pristinamycin","Drug","Sanofi","Industry",0,0,"All","6 Years","25 Years","395","October 2006","March 2008","bacterial eradication","0","0","0","0","0","0","0","0","0"
"454","NCT00393939","Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer","Breast Neoplasms",0,"Sunitinib malate","Drug","Pfizer","Industry",0,0,"Female","18 Years","N/A","594","February 2007","February 2010","Progression-Free Survival (PFS)","0.2651","1-sided stratified log-rank test adjusted for baseline stratification factors (number of metastatic sites, estrogen receptor status, and disease-free interval from prior adjuvant treatment)","Log Rank","0.9222","Hazard Ratio (HR)","95","2-Sided","0.7156","1.1885"
"455","NCT00394212","Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass","Obesity",0,"Transoral Suturing","Device","C. R. Bard","Industry",0,0,"All","18 Years","N/A","77","November 2006","September 2008","Weight Loss (%)","0.066","P-value from non-parametric Mann-Whitney-Wilcoxon test comparing treatments.","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"456","NCT00394589","Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)","Rheumatoid Arthritis",0,"Infliximab Increased Frequency","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","43","March 2006","October 2008","Change in Disease Activity Score Based on 28 Joint Count (DAS28) Score.","0","0","0","0","0","0","0","0","0"
"457","NCT00395018","Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection","Hepatitis B, Chronic",0,"entecavir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","16 Years","N/A","109","April 2007","March 2011","Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72","0","0","0","0","0","0","0","0","0"
"458","NCT00395070","A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma","Metastatic Melanoma",0,"Allovectin-7®","Biological","Vical","Industry",0,0,"All","18 Years","N/A","390","October 2006","March 2012","To compare the overall response rate at ≥24 weeks after randomization in the Allovectin-7® arm versus the control (DTIC/TMZ) arm.","0","0","0","0","0","0","0","0","0"
"459","NCT00395135","BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management","Obesity",0,"Lorcaserin 10 mg BID","Drug","Arena Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","3182","November 2006","February 2009","Year 1: Co-Primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52","<0.0001","0","ANCOVA","3.6","Odds Ratio (OR)","95","2-Sided","3.0","4.2"
"460","NCT00395512","Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus","Diabetes Mellitus",0,"Alogliptin","Drug","Takeda","Industry",0,0,"All","18 Years","80 Years","655","November 2006","February 2008","Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)","<0.001","ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.","ANCOVA","-0.56","LS Mean Difference","95","2-Sided","-0.78","-0.33"
"461","NCT00396097","Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature","Idiopathic Short Stature",0,"Genotropin","Drug","Pfizer","Industry",0,0,"All","3 Years","10 Years","316","December 2006","August 2012","Absolute On-target Difference (AOTD) at 24 Months","0.5762","0","ANCOVA","-0.006","Mean Difference (Final Values)","97.5","1-Sided","-0.071","0"
"462","NCT00396214","Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients","Schizophrenia",0,"Bifeprunox","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","83","April 2007","January 2008","Weight","0","0","0","0","0","0","0","0","0"
"463","NCT00396448","Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.","Obesity",0,"CP-945,598 Treatment B","Drug","Pfizer","Industry",0,0,"All","18 Years","70 Years","1253","February 2007","February 2009","Change in body weight and proportion of subjects with 5% weight loss","0","0","0","0","0","0","0","0","0"
"464","NCT00396877","Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation","Heart Defects, Congenital",0,"Clopidogrel (SR25990)","Drug","Sanofi","Industry",0,0,"All","N/A","92 Days","906","November 2006","February 2010","Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)","0.4340","The a-priori threshold for statistical significance was < 0.035 reflecting the adjustment for interim analyses. No other adjustment for multiplicity was made.","Log Rank","11.1","Relative Risk Reduction (%)","95","2-Sided","-19.2","33.6"
"465","NCT00397033","Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.","Schizoaffective Disorder",0,"Paliperidone ER","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","65 Years","316","November 2006","February 2008","Baseline Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score","0","0","0","0","0","0","0","0","0"
"466","NCT00397345","TroVax Renal Immunotherapy Survival Trial","Clear Cell Renal Carcinoma",0,"Trovax","Biological","Oxford BioMedica","Industry",0,0,"All","18 Years","N/A","700","September 2006","December 2009","overall survival","0","0","0","0","0","0","0","0","0"
"467","NCT00399919","Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)","Peripheral Vascular Diseases",0,"Propionyl-L-Carnitine","Drug","Sigma-Tau Research, Inc.","Industry",0,0,"All","40 Years","80 Years","69","April 2006","March 2008","Peak walking time","0","0","0","0","0","0","0","0","0"
"468","NCT00400179","A Safety and Efficacy Study in Patients With Gastric Cancer","Gastric Cancer",0,"S-1/Cisplatin","Drug","Taiho Oncology, Inc.","Industry",0,0,"All","18 Years","N/A","1053","May 2005","March 2008","Median Survival","0.3952","0","Fisher Exact","0","0","0","0","0","0"
"469","NCT00400842","A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency","Exocrine Pancreatic Insufficiency, Chronic Pancreatitis",0,"SA-001","Drug","Abbott","Industry",0,0,"All","20 Years","N/A","274","May 2007","August 2009","Change in CFA from baseline to the end of double-blind treatment","0","0","0","0","0","0","0","0","0"
"470","NCT00401076","A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency","Pancreatic Exocrine Insufficiency, Chronic Pancreatitis, Pancreatectomy",0,"SA-001","Drug","Abbott","Industry",0,0,"All","20 Years","N/A","80","July 2008","September 2010","Safety of long-term use of 3.0 g/day SA 001 (12 capsules/day), flexibly increased or decreased within the range of 1.5 g/day SA 001 (6 capsules/day) to 6.0 g/day SA-001 (24 capsules/day)","0","0","0","0","0","0","0","0","0"
"471","NCT00401193","Efficacy and Safety of XP12B in Women With Menorrhagia","Menorrhagia",0,"Tranexamic acid tablets","Drug","Ferring Pharmaceuticals","Industry",0,0,"Female","18 Years","49 Years","304","November 2006","May 2008","Mean Reduction From Baseline in Menstrual Blood Loss (MBL)","0","0","0","0","0","0","0","0","0"
"472","NCT00401245","The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms","Vasomotor Symptoms",0,"desvenlafaxine succinate sustained release","Drug","Pfizer","Industry",0,0,"Female","18 Years","N/A","500","December 2006","January 2008","Number of Participants With Nausea During the First 2 Weeks of Treatment","0.024","The analysis was done at a significance level of alpha = 0.05, 2-sided, without any adjustments for multiple comparisons.","Chi-squared","0","0","0","0","0","0"
"473","NCT00402363","Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation","Fibrillation, Atrial",0,"omega-3-acid ethyl esters","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","663","November 2006","January 2010","Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter","0.263","0","Regression, Cox","1.15","Hazard Ratio (HR)","95","2-Sided","0.90","1.46"
"474","NCT00402688","An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis","Prostatitis",0,"levofloxacin","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"Male","40 Years","N/A","242","November 2006","March 2008","Clinical Success","0","0","0","0.063","Risk Difference (RD)","95","0","-0.089","0.215"
"475","NCT00402727","Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection","Abscess",0,"Moxifloxacin (Avelox, BAY12-8039)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","813","September 2006","June 2008","Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population","0","0","0","-1.0","Difference of cure rates (in percent)","95","0","-5.3","3.9"
"476","NCT00402831","ProQuad® Intramuscular vs Subcutaneous","Measles",0,"ProQuad® (prevention of measles, mumps, rubella and varicella)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Months","18 Months","405","October 2006","January 2008",NA,"0","0","0","0","0","0","0","0","0"
"477","NCT00403767","An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation","Atrial Fibrillation",0,"Rivaroxaban","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","14269","December 2006","September 2010","The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority)","<0.001","The p-value is not adjusted for multiple comparisons. The alpha threshold for statistical significance is 0.025 (1-sided).","Cox Proportional Hazards model","0.79","Hazard Ratio (HR)","95","2-Sided","0.66","0.96"
"478","NCT00404352","REbif FLEXible Dosing in Early Multiple Sclerosis (MS)","Multiple Sclerosis",0,"RNF","Drug","Merck KGaA","Industry",0,0,"All","18 Years","50 Years","517","November 2006","August 2010","Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)","<0.001","0","Log Rank","0","0","0","0","0","0"
"479","NCT00404612","A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis","Uveitis, Posterior",0,"Placebo","Drug","Lux Biosciences, Inc.","Industry",0,0,"All","13 Years","N/A","218","January 2007","November 2008","vitreous haze","0","0","0","0","0","0","0","0","0"
"480","NCT00404651","Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants","Diphtheria",0,"DTaP-IPV-HB-PRP~T vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","2 Months","N/A","1189","November 2006","April 2008","Equivalence of Seroprotection Against Vaccine Antigens in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine","0","0","0","0","0","0","0","0","0"
"481","NCT00404742","A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis","Uveitis, Posterior",0,"Placebo","Drug","Lux Biosciences, Inc.","Industry",0,0,"All","13 Years","N/A","232","January 2007","November 2008","recurrence of ocular inflammation","0","0","0","0","0","0","0","0","0"
"482","NCT00404885","A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis","Uveitis, Anterior",0,"Placebo","Drug","Lux Biosciences, Inc.","Industry",0,0,"All","13 Years","N/A","108","January 2007","November 2008","anterior chamber cells","0","0","0","0","0","0","0","0","0"
"483","NCT00405184","Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)","Primary Immune Deficiency (PID)",0,"IntragamP","Drug","CSL Limited","Industry",0,0,"All","18 Years","N/A","19","May 2007","July 2008","IgG Trough Pharmacokinetics","0","0","0","0","0","0","0","0","0"
"484","NCT00405756","A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.","Newly Diagnosed Multiple Myeloma",0,"Lenalidomide: Double-blind Induction","Drug","Celgene Corporation","Industry",0,0,"All","65 Years","N/A","459","January 2007","November 2009","Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)","<0.001","The p-value is based on unstratified log rank test of Kaplan-Meier curve differences between the treatment groups.","Log Rank","0.395","Hazard Ratio (HR)","95","2-Sided","0.278","0.560"
"485","NCT00405964","Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)","Allergic Rhinitis",0,"5-mg Desloratadine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","716","September 2006","April 2008","Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment","<.001","Determined for site. P-value of <.001 for treatment as well.","ANOVA","0","0","0","0","0","0"
"486","NCT00406068","Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer","Bladder Neoplasms",0,"Mycobacterial cell wall-DNA complex","Drug","Bioniche Life Sciences Inc.","Industry",0,0,"All","18 Years","N/A","129","November 2006","July 2011","One year disease-free survival rate","0","0","0","0","0","0","0","0","0"
"487","NCT00406588","SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations","Advanced Stage Parkinson's Disease",0,"Levodopa (Pardoprunox)","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","30 Years","N/A","295","March 2007","April 2008","Change from baseline to end of the maintenance period or at the early termination visit in 'off'-time as recorded in patients' home diaries.","0","0","0","0","0","0","0","0","0"
"488","NCT00406653","A Study of Abatacept in Patients With Active Crohn's Disease","Crohn's Disease",0,"abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","451","December 2006","November 2009","Induction Period (IP); Number of Participants With Crohn's Disease Activity Index (CDAI)-Defined Clinical Response at Both Day IP-57 and Day IP-85","0.611","Due to randomization misspecification, 2:2:2:1 ratio applied instead of planned 2:1:2:2 (placebo, ABA 3mg/kg, ~10mg/kg, 30/~10mg/kg). Only ~half intended number assigned to ABA 30/~10 mg/kg arm and ~double intended number assigned to ABA 3 mg/kg arm","Cochran-Mantel-Haenszel","1.2","Risk Ratio (RR)","95","2-Sided","0.6","2.4"
"489","NCT00407030","IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia","Cervical Dystonia",0,"incobotulinumtoxinA (Xeomin) (240 Units)","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","75 Years","233","July 2006","January 2008","Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Placebo","<0.001","Due to the hierarchical testing no adjustment of type I error was necessary.","ANCOVA","-9.0","Mean Difference (Final Values)","95","2-Sided","-12.0","-5.9"
"490","NCT00407095","An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.","Advanced Stage Parkinson's Disease",0,"Pardoprunox","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","30 Years","N/A","140","August 2007","May 2009","Safety: laboratory data, adverse events, vital signs, ECG","0","0","0","0","0","0","0","0","0"
"491","NCT00407745","A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury","Neuralgia",0,"placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","220","January 2007","February 2011","Duration Adjusted Average Change (DAAC) of Mean Pain Score","0.0032","Significance was declared if the 2-tailed test for the difference between treatment groups was significant at the 0.05 level.","ANCOVA","-0.59","LS Mean Difference","95","2-Sided","-0.98","-0.20"
"492","NCT00408083","Crossover Study With MultiHance vs a Comparator for Peripheral MRA","Peripheral Vascular Disease",0,"MultiHance","Drug","Bracco Diagnostics, Inc","Industry",0,0,"All","18 Years","N/A","100","December 2006","November 2008","Assessment of global paired diagnostic preference of the two MRA exams","0","0","0","0","0","0","0","0","0"
"493","NCT00408187","Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients","Psoriasis",0,"voclosporin","Drug","Aurinia Pharmaceuticals Inc.","Industry",0,0,"All","18 Years","N/A","642","December 2006","December 2008","Superiority in the proportion of subjects achieving a score of ""clear"" or ""almost clear"" in the Static Physician's Global Assessment (SPGA) score","0","0","0","0","0","0","0","0","0"
"494","NCT00408629","Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis","Ulcerative Colitis",0,"adalimumab","Biological","Abbott","Industry",0,0,"All","18 Years","N/A","518","November 2006","March 2010","Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8","0.019","Testing for ranked co-primary endpoints occurred in hierarchical order to control for multiple testing. Week 8 remission rate was tested first. If a significant difference in group rates was found at alpha=0.05, Week 52 rate was tested at alpha=0.05.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"495","NCT00409175","Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis","Familial Amyloid Polyneuropathy",0,"Fx-1006A","Drug","Pfizer","Industry",0,0,"All","18 Years","75 Years","128","January 2007","May 2009","Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18","0","0","0","0","0","0","0","0","0"
"496","NCT00409188","Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)","Non-small Cell Lung Cancer",0,"Tecemotide (L-BLP25)","Biological","EMD Serono","Industry",0,0,"All","18 Years","N/A","1513","January 2007","April 2012","Overall Survival","0.1566","0","Regression, Cox","0.893","Hazard Ratio (HR)","95","2-Sided","0.763","1.044"
"497","NCT00409617","Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease","Crohn's Disease",0,"adalimumab","Biological","Abbott","Industry",0,0,"All","18 Years","75 Years","945","December 2006","July 2008","Number of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) Score Less Than 5.","0","0","0","0","0","0","0","0","0"
"498","NCT00409682","Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease","Crohn's Disease",0,"Adalimumab","Biological","Abbott","Industry",0,0,"All","6 Years","17 Years","192","April 2007","May 2010","Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 26","0.075","There is no adjustment for multiple comparison on the primary outcome measure.","Cochran-Mantel-Haenszel","10.29","Mean Difference (Net)","95","2-Sided","-3.14","23.71"
"499","NCT00409838","A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","Rheumatoid Arthritis",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","113","April 2007","July 2008","Percentage of Participants Meeting the Criteria of the American College of Rheumatology for 20% Improvement (ACR20)","0","0","0","0","0","0","0","0","0"
"500","NCT00410072","Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B","Hepatitis B, Chronic",0,"Entecavir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","16 Years","N/A","669","April 2007","October 2010","Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96","0.0882","0","Cochran-Mantel-Haenszel","6.9","Mean Difference (Final Values)","95","2-Sided","-1.0","14.9"
"501","NCT00410202","Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus","Hepatitis B, Chronic",0,"Entecavir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","16 Years","N/A","629","March 2008","January 2011","Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48","0.1336","0","Hochberg procedure","8.9","Difference Estimate","95","2-Sided","-2.0","19.9"
"502","NCT00410384","A Study of Belimumab in Subjects With Systemic Lupus Erythematosus","Systemic Lupus Erythematosus",0,"Placebo","Drug","Human Genome Sciences Inc.","Industry",0,0,"All","18 Years","N/A","819","December 2006","September 2009","SLE Responder Index (SRI) Response Rate at Week 52","0.0167","For the primary analysis of the primary efficacy endpoint, a step-down sequential testing procedure was used to control the type 1 error.","Regression, Logistic","1.54","Odds Ratio (OR)","95","2-Sided","1.08","2.19"
"503","NCT00410410","A Study of Abatacept in Patients With Active Ulcerative Colitis","Ulcerative Colitis",0,"abatacept (ABA)","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","591","December 2006","June 2009","Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)","0.124","Cochran-Mantel-Haenszel Chi square p-value and RR along with 95% confidence interval provided, adjusting for randomization strata (whether a participant had an inadequate response and/or intolerance to anti-TNF therapy).","Cochran-Mantel-Haenszel","0.73","Risk Ratio (RR)","95","2-Sided","0.48","1.09"
"504","NCT00411645","Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients","Cytomegalovirus Infections",0,"maribavir","Drug","Shire","Industry",0,0,"All","18 Years","N/A","681","December 2006","November 2008","Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation","0.789","The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).","Cochran-Mantel-Haenszel","0.902","Odds Ratio (OR)","95","2-Sided","0.424","1.920"
"505","NCT00411801","Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)","Thrombotic Thrombocytopenic Purpura (TTP)",0,"Uniplas","Biological","Octapharma","Industry",0,0,"All","18 Years","N/A","8","May 2007","February 2008","Change from baseline in (log) platelet count 1 month after treatment initiation","0","0","0","0","0","0","0","0","0"
"506","NCT00411892","Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes","Diabetes",0,"pioglitazone","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","196","November 29, 2006","March 18, 2008","HbA1c change from baseline","0","0","0","0","0","0","0","0","0"
"507","NCT00412152","Oxycodone-naloxone in Relieving Opioid-related Constipation","Pain",0,"Oxycodone nalaxone prolonged release tablets (OXN)","Drug","Mundipharma Research GmbH & Co KG","Industry",0,0,"All","18 Years","N/A",NA,"January 2006","April 2008","To demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets.","0","0","0","0","0","0","0","0","0"
"508","NCT00412373","Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.","Schizoaffective Disorder",0,"Placebo","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","65 Years","307","December 2006","June 2008","Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score at Baseline.","0.774","0","ANOVA","0.5","LS Mean Difference","95","0","-2.7","3.7"
"509","NCT00412776","Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer","Carcinoma, Squamous Cell of Head and Neck",0,"Proxinium","Drug","Viventia Bio","Industry",0,0,"All","18 Years","N/A","165","December 2005","April 2008","Survival","0","0","0","0","0","0","0","0","0"
"510","NCT00412984","Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation","Atrial Fibrillation",0,"warfarin","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","18201","December 2006","June 2011","Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period","0","0","0","0","0","0","0","0","0"
"511","NCT00413010","Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).","Generalized Anxiety Disorder",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","356","December 2006","February 2008","Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores","0","0","0","-1.2","Mean Difference (Final Values)","95","0","-2.16","-0.26"
"512","NCT00413062","Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)","Contraception",0,"NOMAC-E2","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","50 Years","2281","June 2006","August 2008","Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)","0","0","0","0","0","0","0","0","0"
"513","NCT00414609","Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)","Myocardial Infarction",0,"Aliskiren","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","820","December 2006","September 2009","Core Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) as Measured by Echocardiography at End of Study.","0","0","0","0","0","0","0","0","0"
"514","NCT00414973","A Study for Patients With Osteoporosis","Osteoporosis",0,"Teriparatide","Drug","Eli Lilly and Company","Industry",0,0,"All","40 Years","85 Years","364","December 2006","July 2008","Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Postmenopausal Women","<0.0001","There were no adjustments for multiple comparisons.","ANCOVA","4.39","Mean Difference (Net)","95","0","2.89","5.89"
"515","NCT00415142","An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder","Depressive Disorder",0,"saredutant (SR48968)","Drug","Sanofi","Industry",0,0,"All","60 Years","64 Years","393","December 2006","February 2008","Change from baseline to Day 56 in the 17-item Hamilton Depression Rating Scale (HAM-D) total score.","0","0","0","0","0","0","0","0","0"
"516","NCT00415194","A Study for Patients With Head and Neck Cancer","Head and Neck Neoplasms",0,"pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","795","December 2006","March 2010","Overall Survival (OS)","0.082","0","Stratified Log Rank","0.87","Hazard Ratio (HR)","95","2-Sided","0.75","1.02"
"517","NCT00415519","Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III","Amyotrophic Lateral Sclerosis (ALS)",0,"MCI-186","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","75 Years","25","December 2006","July 2008","Revised ALS functional rating scale (ALSFRS-R) scores","0","0","0","0","0","0","0","0","0"
"518","NCT00415805","Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent","Steno-Occlusive Disease",0,"Multihance","Drug","Bracco Diagnostics, Inc","Industry",0,0,"All","18 Years","N/A","39","December 2006","December 2008","Sensitivity and specificity compared to DSA","0","0","0","0","0","0","0","0","0"
"519","NCT00416520","A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia","Chronic Kidney Disease",0,"MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","18 Years","N/A","336","June 2007","November 2009","Change in Serum Phosphorus Levels From Week 12 to Week 16 (LOCF) (ITT2)","0","0","0","0","0","0","0","0","0"
"520","NCT00417118","An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder","Generalized Anxiety",0,"Saredutant","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","365","December 2006","April 2008","Change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.","0","0","0","0","0","0","0","0","0"
"521","NCT00417209","Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen","Pancreatic Neoplasms",0,"Larotaxel (XRP9881)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","408","December 2006","July 2009","overall survival (OS) defined as the time interval from the date of randomization to the date of death due to any cause","0","0","0","0","0","0","0","0","0"
"522","NCT00417963","ViVEXX Carotid Revascularization Trial (VIVA)","Carotid Artery Stenosis",0,"Carotid Artery Stenting","Device","C. R. Bard","Industry",0,0,"All","18 Years","85 Years","407","October 2005","January 2009","Percentage of Patients Experiencing Major Adverse Events (MAE)","0","0","0","0","0","0","0","0","0"
"523","NCT00418379","Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets","Allergy",0,"300 IR (4M)","Drug","Stallergenes","Industry",0,0,"All","18 Years","50 Years","633","December 2006","August 2010","Average Adjusted Symptom Score (AAdSS)","< 0.0001","0","ANCOVA","0","0","0","0","0","0"
"524","NCT00418574","Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients","Ovarian Cancer",0,"Abagovomab","Biological","Menarini Group","Industry",0,0,"Female","18 Years","N/A","888","December 2006","December 2010","Recurrence Free Survival Evaluated by Clinical Event Adjudication Committee (CEAC)","0.301","0","Regression, Cox","1.099","Hazard Ratio (HR)","95","2-Sided","0.919","1.315"
"525","NCT00419094","Conversion to Monotherapy Study With Keppra XR for Partial Seizures","Epilepsy",0,"Keppra XR","Drug","UCB Pharma","Industry",0,0,"All","12 Years","75 Years","228","August 2007","September 2009","The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase","0","0","0","0","0","0","0","0","0"
"526","NCT00419393","Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures","Epilepsy",0,"Keppra XR (Levetiracetam XR)","Drug","UCB Pharma","Industry",0,0,"All","12 Years","75 Years","190","December 2007","March 2010","Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)","0","0","0","0","0","0","0","0","0"
"527","NCT00419705","Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)","Ischemic Stroke",0,"NeuroThera® Laser System","Device","PhotoThera, Inc","Industry",0,0,"All","40 Years","90 Years","660","December 2006","July 2008","Disability scale (mRS)score at 90 days; safety of the treatment procedure","0","0","0","0","0","0","0","0","0"
"528","NCT00420199","A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","Active Rheumatoid Arthritis",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","50","May 2007","August 2009","Double-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)","0","0","0","0","0","0","0","0","0"
"529","NCT00420212","Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis","Relapsing-Remitting Multiple Sclerosis",0,"BG00012","Drug","Biogen","Industry",0,0,"All","18 Years","55 Years","1234","January 2007","February 2011","Proportion of Subjects Relapsed","0","0","0","0","0","0","0","0","0"
"530","NCT00420277","Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty","Hypotension",0,"Hemospan (MP4OX)","Drug","Sangart","Industry",0,0,"All","50 Years","N/A","462","February 2007","March 2008","Total duration of all hypotensive episodes occurring during anesthesia/surgery and throughout the postoperative period (defined as the first 6 hours following skin closure)","0","0","0","0","0","0","0","0","0"
"531","NCT00421200","Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty","Hypotension",0,"Hemospan (MP4OX)","Drug","Sangart","Industry",0,0,"All","50 Years","N/A","375","February 2007","May 2008","Proportion of patients who develop at least one hypotensive episode during anesthesia/surgery and throughout the postoperative period (the first 6 hours following skin closure)","0","0","0","0","0","0","0","0","0"
"532","NCT00421434","Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C","Chronic Hepatitis C",0,"Nitazoxanide","Drug","Romark Laboratories L.C.","Industry",0,0,"All","18 Years","N/A","121","June 2006","September 2008","Sustained virologic response","0","0","0","0","0","0","0","0","0"
"533","NCT00421928","Tapentadol (CG5503)","Osteoarthritis, Knee",0,"oxycodone","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","40 Years","N/A","1030","January 2007","July 2008","Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12.","<0.05","0","ANCOVA","-0.7","Mean Difference (Final Values)","95","0","-1.04","-0.33"
"534","NCT00422292","Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers","Meningococcal Meningitis",0,"Meningococcal Polysaccharide Diphtheria Conjugate Vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","9 Months","12 Months","1664","December 2006","January 2009","Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only)","0","0","0","0","0","0","0","0","0"
"535","NCT00422734","Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life","Impotence",0,"tadalafil","Drug","Eli Lilly and Company","Industry",0,0,"Male","18 Years","N/A","342","November 2006","January 2008","Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF)- Erectile Function Domain Score (Sum of IIEF Questions 1-5 and 15)","<0.001","Hypotheses were tested in a sequential fashion using a gatekeeping strategy and adjusted for multiplicity. Statistical significance at 0.05 level was required for this variable","ANCOVA","0","0","0","0","0","0"
"536","NCT00423176","The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)","Sinusitis",0,"MFNS and antibiotic","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","237","December 2006","June 2008","Baseline Change in AM/PM PRIOR Major Symptoms Score (Mss) Minus Sinus Headache Averaged Over Days 1 to 29.","0","0","0","-0.44","Mean Difference (Net)","95","0","-1.14","0.25"
"537","NCT00423267","POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)","Coccidioidomycosis",0,"Posaconazole","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","13 Years","N/A","16","May 2007","May 2009","Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) or Fluconazole (FLU) in Period A","0","0","0","0","0","0","0","0","0"
"538","NCT00423319","Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)","Deep Vein Thrombosis",0,"Enoxaparin","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","5407","March 2007","September 2009","Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period","<0.0001","Statistically significant at the 1-sided 0.025 level","Farrington-Manning test","0.36","Risk Ratio (RR)","95","2-Sided","0.22","0.54"
"539","NCT00423605","Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.","Fibromyalgia",0,"Xyrem®","Drug","Jazz Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","560","December 2006","January 2010","Number of Subjects Reporting Adverse Events","0","0","0","0","0","0","0","0","0"
"540","NCT00423800","Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)","Hepatitis C, Chronic",0,"Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","56","December 2006","October 2009","Number of Participants With a Sustained Virologic Response","0","0","0","0","0","0","0","0","0"
"541","NCT00423813","A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.","Fibromyalgia",0,"placebo","Drug","Jazz Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","573","December 2006","April 2009","Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF).","0.001","0","Chi-squared","0","0","0","0","0","0"
"542","NCT00424008","Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","Asthma",0,"Mometasone furoate/formoterol (MF/F) MDI","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","722","April 2007","November 2008","The Area Under the Curve From 0 to 12 Hours [AUC](0-12 hr) of the Change From Baseline to the Week 12 Endpoint in Forced Expiratory Volume in One Second (FEV1)","0","0","0","0","0","0","0","0","0"
"543","NCT00424268","Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)","Chronic Obstructive Pulmonary Disease",0,"Roflumilast","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","743","January 2007","January 2008","Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)","<0.0001","No adjustment of the significance level (0.05) was done as a hierarchical approach for hypotheses testing was used.","ANCOVA","80","Mean Difference (Net)","95","2-Sided","51","110"
"544","NCT00424372","A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia","Neuralgia, Postherpetic",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","126","January 2007","August 2008","Summary of Adverse Events","0","0","0","0","0","0","0","0","0"
"545","NCT00424463","Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)","Amyotrophic Lateral Sclerosis (ALS)",0,"MCI-186","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","N/A","181","January 2007","May 2009","Revised ALS functional rating scale (ALSFRS-R) scores","0","0","0","0","0","0","0","0","0"
"546","NCT00424476","A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)","Systemic Lupus Erythematosus",0,"Placebo","Drug","Human Genome Sciences Inc.","Industry",0,0,"All","18 Years","N/A","865","May 2007","May 2009","SLE Responder Index (SRI) Response Rate at Week 52","0.0006","For the primary analysis of the primary efficacy endpoint, a step-down sequential testing procedure was used to control the type 1 error.","Regression, Logistic","1.83","Odds Ratio (OR)","95","0","1.30","2.59"
"547","NCT00426270","Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults","Immune Thrombocytopenic Purpura",0,"Octagam 10%","Drug","Octapharma","Industry",0,0,"All","18 Years","N/A","116","June 2006","September 2008","Percentage of Participants With a Clinical Response","0","0","0","0","0","0","0","0","0"
"548","NCT00426660","Expanded Access Program for Maraviroc At Multiple Centers","HIV Infections",0,"maraviroc","Drug","ViiV Healthcare","Industry",0,0,"All","16 Years","N/A","1047","February 2007","June 2010","Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)","0","0","0","0","0","0","0","0","0"
"549","NCT00426972","Trial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor Sites","Burn",0,"estradiol (Zesteem)","Drug","Renovo","Industry",0,0,"All","18 Years","85 Years","148","January 2007","July 2008","Complete wound closure of skin graft donor site.","0","0","0","0","0","0","0","0","0"
"550","NCT00427154","Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes","Diabetes",0,"rosiglitazone","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","227","January 10, 2007","March 11, 2008","Change in HbA1c","0","0","0","0","0","0","0","0","0"
"551","NCT00427895","Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults","Pneumococcal Infections",0,"13-valent pneumococcal conjugate vaccine (13vPnC)","Biological","Pfizer","Industry",0,0,"All","18 Years","64 Years","2141","March 2007","August 2011","Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1","0","0","0","1.4","GMT Ratio","95","2-Sided","1.10","1.78"
"552","NCT00427921","Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)","Crohn's Disease",0,"adalimumab","Biological","Abbott","Industry",0,0,"All","18 Years","N/A","304","January 2007","January 2008","Mean Extent of Exposure - Duration in Days","0","0","0","0","0","0","0","0","0"
"553","NCT00428090","Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease","Alzheimer's Disease",0,"Rosiglitazone","Drug","GlaxoSmithKline","Industry",0,0,"All","50 Years","90 Years","862","February 27, 2007","September 1, 2008","Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Apolipoprotein epsilon4 (APOE e4) Negative Cohort","0.074","Comparison between Placebo and RSG XR 2 mg in APOE e4 neg cohort","Mixed model for repeated measures","-1.8","Mean Difference (Final Values)","95","2-Sided","-3.8","0.2"
"554","NCT00428597","A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors","Carcinoma, Islet Cell",0,"sunitinib malate","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","171","June 2007","April 2009","Progression Free Survival (PFS)","0.000118","Log-rank test statistic and 2-sided p-value from the unstratified log-rank test","Log Rank","0.418","Hazard Ratio (HR)","95","2-Sided","0.263","0.662"
"555","NCT00428948","Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD","Polycystic Kidney Disease, Autosomal Dominant",0,"tolvaptan","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","50 Years","1445","January 2007","January 2012","Rate of total kidney volume change(%)","0","0","0","0","0","0","0","0","0"
"556","NCT00430248","Efficacy and Safety of Oral Febuxostat in Participants With Gout","Gout",0,"Febuxostat","Drug","Takeda","Industry",0,0,"All","18 Years","85 Years","2269","February 2007","March 2008","Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.","0","0","0","3.1","Difference in percentage","95","0","-1.9","8.1"
"557","NCT00430508","Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension","Essential Hypertension",0,"olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","N/A","972","February 2007","March 2008","Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16","<0.0001","0","ANCOVA","-5.3","Mean Difference (Net)","95","0","-6.97","-3.6"
"558","NCT00430625","A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease","Gaucher Disease, Type 1",0,"VPRIV ®,","Biological","Shire","Industry",0,0,"All","2 Years","N/A","25","January 2007","April 2009","Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group.","<0.0001","0","paired t-test","2.429","Mean Difference (Final Values)","95","2-Sided","1.717","3.141"
"559","NCT00430677","Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis","Systemic Lupus Erythematosus",0,"Corticosteroids (prednisone or prednisolone)","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","423","June 2007","September 2010","Time to First Confirmed Complete Renal Response (CRR) During the Short-term (Double-blind) Period","0.746","The median time to confirmed CRR was not estimable due to the low number of events. However, the time to confirmed CRR was compared between the abatacept and placebo treatment regimens using a score test.","Regression, Cox","1.1","Cox Proportional Hazard","95","2-Sided","0.60","2.03"
"560","NCT00431132","Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis","Menopause",0,"estradiol, 10 mcg","Drug","Novo Nordisk A/S","Industry",0,0,"Female","45 Years","N/A","336","January 2007","November 2008","Endometrial Hyperplasia Based on Histological Assessment of Endometrial Biopsies","0","0","0","0","0","0","0","0","0"
"561","NCT00431834","Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study","Atrial Fibrillation",0,"Cardioblate System Surgical Ablation System","Device","Medtronic Cardiovascular","Industry",0,0,"All","18 Years","N/A","75","May 2007","August 2010","Efficacy Endpoint: The Percent of Patients Off Class I and/or III Antiarrhythmic Drugs and Out of Atrial Fibrillation as Determined by 24 Hour Holter Recording Conducted at 6 Months Postoperatively.","<0.0041","The percent of patients off Class I and III AADs and successfully converted out of AF following treatment (ptest) will exceed the percenter of patients off Class I and III AADs and convereted out of AF, as reported in literature (pcontrol=22.1%)","Fisher Exact","37.7","binomial proportions","97.5","1-Sided","25.6","0"
"562","NCT00432276","Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","Diabetes Mellitus",0,"Alogliptin","Drug","Takeda","Industry",0,0,"All","18 Years","80 Years","803","January 2007","May 2009","Change From Baseline in Glycosylated Hemoglobin (HbA1c)","0","0","0","-0.47","LS mean difference","97.5","1-Sided","0","-0.35"
"563","NCT00432913","Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa","Adenomatous Polyps",0,"Eicosapentaenoic Acid (EPA)","Drug","S.L.A. Pharma AG","Industry",0,0,"All","18 Years","N/A","120","October 2006","June 2008","To measure levels of apoptosis in the normal colonic mucosa in subjects with a history of colonic adenomas, before and after treatment with EPA 99%.","0","0","0","0","0","0","0","0","0"
"564","NCT00433290","Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain","Osteoarthritis Knee Pain",0,"Duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","40 Years","N/A","256","February 2007","May 2008","Change in Brief Pain Inventory (BPI) 24-hour Average Rating","<0.001","P-value for Week 4 Change from Baseline. Treatment effects and interaction effects were evaluated based on two-sided significance level of 0.05. No adjustments for multiple comparisons were made.","Mixed Models Analysis","0","0","0","0","0","0"
"565","NCT00433615","Clinical Study of R744 to Predialysis Patients","Anemia in Pre-Dialysis Patients",0,"R744","Drug","Chugai Pharmaceutical","Industry",0,0,"All","20 Years","N/A","124","February 2007","November 2008","Ratio of Maintenance of target Hb concentration","0","0","0","0","0","0","0","0","0"
"566","NCT00433693","Correction Study of R744 in Renal Anemia Patients on Hemodialysis","Hemodialysis Patients",0,"R744","Drug","Chugai Pharmaceutical","Industry",0,0,"All","20 Years","N/A","50","February 2007","March 2008","The ratio of patients whose Hb concentration reach ≥ 10.0g/dL and increasing amount of Hb concentration reach ≥ 1.0g/dL","0","0","0","0","0","0","0","0","0"
"567","NCT00433771","A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction","Cholestasis, Extrahepatic",0,"WallFlex™ Biliary Fully Covered Metal Stent placement","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","74","March 2007","May 2008","Adequate Clinical Palliation of the Biliary Obstruction","0","0","0","0","0","0","0","0","0"
"568","NCT00433849","Clinical Study of R744 to Peritoneal Dialysis Patients","Peritoneal Dialysis Patients",0,"R744","Drug","Chugai Pharmaceutical","Industry",0,0,"All","20 Years","N/A","72","February 2007","October 2008","Rate of patients who maintain Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dL","0","0","0","0","0","0","0","0","0"
"569","NCT00433888","Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)","Hemodialysis Patients",0,"R744","Drug","Chugai Pharmaceutical","Industry",0,0,"All","20 Years","N/A","179","January 2007","July 2008","Rate of patients who maintain Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dL","0","0","0","0","0","0","0","0","0"
"570","NCT00434057","Evaluation of Pigmented Skin Lesions With MelaFind(R) System","Melanoma",0,"MelaFind(R)","Device","MELA Sciences, Inc.","Industry",0,0,"All","N/A","N/A","1383","January 2007","July 2008","Sensitivity and Specificity","0.05","0","exact mid-P","98","Sensitivity to melanoma","95","0","95.1","100"
"571","NCT00434148","Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","Cushing's Disease",0,"Pasireotide","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","162","December 2006","March 2010","Number of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group","0","0","0","0","0","0","0","0","0"
"572","NCT00434161","A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","Multiple Myeloma",0,"Palifermin before only","Drug","Swedish Orphan Biovitrum","Industry",0,0,"All","18 Years","70 Years","281","December 2006","March 2009","Maximum Severity of Oral Mucositis (World Health Organization (WHO) Grades 0/1, 2, 3, or 4)","0.188","A 2.5% type I error rate for each comparison gives an overall type I error rate of 5%.","Proportional odds model","0.679","Odds Ratio (OR)","97.5","2-Sided","0.351","1.313"
"573","NCT00434538","BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers","Diabetic Foot Ulcer",0,"BST-DermOn","Device","BioSyntech Canada Inc.","Industry",0,0,"All","18 Years","80 Years","40","February 2007","November 2008","Percentage of subjects with closed ulcers at week 12","0","0","0","0","0","0","0","0","0"
"574","NCT00434954","Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"exenatide twice daily (BID)","Drug","AstraZeneca","Industry",0,0,"All","18 Years","90 Years","494","February 2007","June 2009","Change in Glycosylated Hemoglobin (HbA1c)","0.055","Non-inferiority: upper limit of 95% Confidence Interval (CI) to be < 0.4%.","Mixed effect model repeat measures(MMRM)","0.14","Mean Difference (Net)","95","2-Sided","-0.003","0.291"
"575","NCT00435019","Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes","Diabetes",0,"insulin detemir","Drug","Novo Nordisk A/S","Industry",0,0,"All","2 Years","16 Years","348","February 2007","September 2008","Glycosylated Haemoglobin A1c (HbA1c)","0","0","0","0.12","Mean Difference (Final Values)","95","0","-0.12","0.36"
"576","NCT00435279","A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia","Major Depressive Disorder",0,"Eszopiclone","Drug","Sunovion","Industry",0,0,"All","18 Years","64 Years","678","June 2007","July 2009","The primary endpoint is the change from baseline in HAM-D-17 total score at Week 8.","0","0","0","0","0","0","0","0","0"
"577","NCT00435409","A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer","Breast Neoplasms",0,"Sunitinib + Capecitabine","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","442","February 2007","December 2009","Progression Free Survival (PFS)","0.9409","Stratification factors included metastatic organ sites (2 or less versus [vs] more than [>] 2 sites), hormone receptor status (HER2-/ER-/PR-) vs all others), and prior chemotherapy regimens (1 vs >1), from interactive voice response system (IVRS).","Log Rank","1.2239","Hazard Ratio (HR)","95","2-Sided","0.9487","1.5789"
"578","NCT00435812","Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine","Hepatitis B",0,"1018 ISS with HBsAg and Placebo","Biological","Dynavax Technologies Corporation","Industry",0,0,"All","11 Years","55 Years","2428","December 2006","February 2008","Proportion of subjects who have a seroprotective immune response (anti-HBsAg ≥ 10 milli-international unit (mIU)/ml after the final active injection in each treatment group (Week 12 for HEPLISAV™ and Week 28 for Engerix-B®)","0","0","0","0","0","0","0","0","0"
"579","NCT00436969","ORTHOVISC Shoulder Osteoarthritis Study","Glenohumeral Osteoarthritis",0,"Orthovisc","Device","DePuy Mitek","Industry",0,0,"All","25 Years","75 Years","274","December 2006","February 2010","Visual Analog Scale (VAS) Pain Score (Per Protocol)","0.696","The a priori threshold for significance was a two-sided p <0.05.","Mixed Models Repeated Measures ANCOVA","-1.472","Adjusted Mean Difference","95","2-Sided","-8.888","5.943"
"580","NCT00438399","Subject Preference for Scalp Psoriasis Treatment","Scalp Psoriasis",0,"C. propionate - Corticosteroid 1","Drug","Galderma","Industry",0,0,"All","18 Years","N/A","219","February 2007","January 2008","Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator","0.0003","0","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"581","NCT00438867","Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization","Angina Pectoris",0,"Ad5FGF-4","Genetic","Cardium Therapeutics","Industry",0,0,"Female","18 Years","75 Years","300","May 2007","November 2009","Change in time to onset of ECG changes diagnostic of myocardial ischemia during ETT","0","0","0","0","0","0","0","0","0"
"582","NCT00439140","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","Overactive Bladder",0,"botulinum toxin Type A","Biological","Allergan","Industry",0,0,"All","18 Years","80 Years","41","June 2007","December 2012","Change From Baseline in Forced Vital Capacity (FVC)","0","0","0","0","0","0","0","0","0"
"583","NCT00439725","Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study","Venous Thromboembolism",0,"Rivaroxaban (Xarelto, BAY59-7939)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","1197","February 2007","August 2009","Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment","< 0.0001","1st test in a hierarchy, a p-value of less than 0.05 would be considered significant.","Regression, Cox","0.185","Hazard Ratio (HR)","95","0","0.087","0.393"
"584","NCT00439777","Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study","Pulmonary Embolism",0,"Rivaroxaban (Xarelto, BAY59-7939)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","4833","March 2007","September 2011","Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment","0.0026","0","Regression, Cox","1.12","Hazard Ratio (HR)","95","2-Sided","0.75","1.68"
"585","NCT00440037","Open Label Extension Study of AMG 531 in Japanese Subjects With ITP","Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",0,"AMG 531","Biological","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","20 Years","N/A","44","November 2006","July 2011","The primary endpoint is the incidence of all adverse events including clinically significant changes in laboratory values.","0","0","0","0","0","0","0","0","0"
"586","NCT00440193","Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study","Venous Thrombosis",0,"Rivaroxaban (Xarelto, BAY59-7939)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","3449","March 2007","April 2010","Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment","< 0.0001","0","Regression, Cox","0.68","Hazard Ratio (HR)","95","0","0.44","1.04"
"587","NCT00440310","Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases","Liver Metastases",0,"Talaporfin sodium","Drug","Light Sciences Oncology","Industry",0,0,"All","18 Years","N/A","483","February 2007","May 2011","Overall Survival","0","0","0","0","0","0","0","0","0"
"588","NCT00440466","PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients","Anemia",0,"epoetin alfa","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","430","July 2007","March 2009","Change in Hemoglobin Concentration in Grams Per Deciliter (g/dL) From Baseline to the Average of the Last 12 Weeks of Treatment","0","0","0","-0.03","Difference of Least Squares Means","95","2-Sided","-0.208","0.153"
"589","NCT00440557","An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease","Anemia",0,"Epoetin alfa 3 times weekly /once weekly","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","375","September 2006","February 2008","Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22","0","0","0","-0.17","Difference of Least Squares Means","95","0","-0.380","0.037"
"590","NCT00440947","Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection","Infection, Human Immunodeficiency Virus I",0,"Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)","Drug","ViiV Healthcare","Industry",0,0,"All","18 Years","N/A","515","March 2007","July 2010","Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c) /Milliliter (ml) at the Week 84 Visit","0.140","0","Cochran-Mantel-Haenszel","5.4","Risk Difference (RD)","95","2-Sided","-1.8","12.5"
"591","NCT00441350","Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension","Hypertension",0,"OM 40","Drug","Menarini Group","Industry",0,0,"All","18 Years","N/A","1004","July 2007","May 2008","Change in diastolic blood pressure.","0","0","0","0","0","0","0","0","0"
"592","NCT00441441","A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma","Asthma",0,"fluticasone propionate","Drug","GlaxoSmithKline","Industry",0,0,"All","4 Years","11 Years","351","February 2007","January 2008","Possible Drug-Related Adverse Events","0","0","0","0","0","0","0","0","0"
"593","NCT00441558","A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).","Sexual Dysfunctions, Psychological",0,"Flibanserin","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","18 Years","55 Years","1723","February 2007","August 2009","The Frequency of Adverse Events (Side Effects).","0","0","0","0","0","0","0","0","0"
"594","NCT00441584","The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)","Hepatitis C, Chronic",0,"PegIntron (peginterferon alfa-2b)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","70 Years","117","July 2005","June 2008","Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment","0","0","0","0","0","0","0","0","0"
"595","NCT00442065","ARBITER-II: Aorfix™ Bifurcated Safety and Performance Trial: Phase II, Angulated Vessels","Abdominal Aortic Aneurysm",0,"Aorfix™ Stent Grafts (AAA endovascular procedure)","Device","Lombard Medical","Industry",0,0,"All","19 Years","N/A","30","October 2006","April 2009","The primary endpoints are acute technical success, initial performance and safety at 1-month follow up.","0","0","0","0","0","0","0","0","0"
"596","NCT00442117","A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)","Asthma",0,"mometasone furoate dry powder inhaler","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","180","June 2007","July 2009","Mean Percent Change of Forced Expiratory Volume in One Second (FEV1) From Baseline to Week 12.","0.4982","0","ANOVA","-1.074","Mean Difference (Final Values)","95","2-Sided","-4.196","2.049"
"597","NCT00442546","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement","Osteoarthritis",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","80 Years","307","May 2007","December 2008","Subject Reported Worst Pain Score in Daily Diaries Using the Worst Pain Item of the Modified Brief Pain Inventory - Short Form (m-BPI-sf)","0.9185","A step-down procedure was used for multiple comparisons adjustment. If the difference between the high dose and placebo groups was statistically significant (p<0.05), then the next step conducted where the low dose group was compared to placebo.","ANOVA","-0.038","Mean Difference (Final Values)","95","0","-0.766","0.691"
"598","NCT00443209","Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)","Migraine",0,"Telcagepant 300 mg soft gel capsules","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1068","February 21, 2007","January 22, 2009","Percentage of Participants With At Least One Triptan-Related Adverse Experience (AE)","<0.001","0","Miettenen and Nurminen method","-6.2","Treatment Difference","95","2-Sided","-10.4","-2.6"
"599","NCT00443456","Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is Insufficient","Hypertension",0,"Amlodipine","Drug","Pfizer","Industry",0,0,"All","20 Years","79 Years","134","May 2007","June 2008","Change in Systolic Blood Pressure From Baseline of the Preceding Study","0","0","0","0","0","0","0","0","0"
"600","NCT00443690","Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy","Heart Failure, Congestive",0,"rolofylline","Drug","NovaCardia, Inc.","Industry",0,0,"All","18 Years","N/A","480","August 2007","January 2009","Effect on heart failure signs and symptoms","0","0","0","0","0","0","0","0","0"
"601","NCT00443820","Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail","Onychomycosis",0,"terbinafine","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","12 Years","75 Years","526","December 2006","June 2008","Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks","0","0","0","0","0","0","0","0","0"
"602","NCT00443898","Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail","Onychomycosis",0,"terbinafine","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","12 Years","75 Years","518","December 2006","June 2008","Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.","0","0","0","0","0","0","0","0","0"
"603","NCT00444626","A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)","Facial Wrinkles at the Nasolabial Folds",0,"Dermal Gel Extra (DGE)","Device","Genzyme, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","140","May 2007","February 2008","Change From Baseline in the Blinded Evaluator's Assessment of Nasolabial Fold (NLF) Wrinkle Severity at Week 24","0","0","0","0","0","0","0","0","0"
"604","NCT00444873","Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly","Acromegaly",0,"lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval","Drug","Ipsen","Industry",0,0,"All","25 Years","N/A","38","January 2005","January 2008","Mean Insulin like Growth Factor 1 (IGF-1) and Growth Hormone (GH) levels at the beginning and end of the study and as proportion of patients conforming to internationally accepted levels.","0","0","0","0","0","0","0","0","0"
"605","NCT00444925","Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)","Overactive Bladder",0,"fesoterodine fumarate","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","1712","April 2007","July 2008","Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment).","<0.0001","Comparison fesoterodine vs tolterodine ER performed only if statistical significance favoring fesoterodine achieved for fesoterodine vs placebo to preserve overall alpha level at 5%; pairwise comparison also performed for tolterodine ER vs placebo.","Van Elteren's Test","0","0","0","0","0","0"
"606","NCT00444951","Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia","Neisseria Meningitidis",0,"Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","16 Years","19 Years","450","February 2007","February 2008","Geometric Mean Titers (GMTs) of Vaccine Serogroups Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination","0","0","0","0","0","0","0","0","0"
"607","NCT00445185","Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™","Hepatitis B",0,"Henogen HB vaccine","Biological","Henogen","Industry",0,0,"All","16 Years","N/A","102","March 2007","July 2009","Anti-HBs antibody concentrations","0","0","0","0","0","0","0","0","0"
"608","NCT00445770","Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis","Arthritis, Rheumatoid",0,"Etanercept","Drug","Pfizer","Industry",0,0,"All","20 Years","75 Years","550","July 2006","July 2010","Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52","<0.0001","Based on rank transformed data: rank of change = rank baseline+treatment +pooled study center+prior methotrexate use. If overall treatment effect statistically significant, 3 pairwise comparisons conducted, otherwise no further testing was made.","ANCOVA","0","0","0","0","0","0"
"609","NCT00446199","Low-dose Hormone Therapy for Relief of Vasomotor Symptoms","Vasomotor Symptoms",0,"0.5mg DRSP / 0.5mg E2 (BAY86-4891)","Drug","Bayer","Industry",0,0,"Female","40 Years","N/A","735","March 2007","October 2008","Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)","<0.0001","significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.","Wilcoxon/van Elteren","0","0","0","0","0","0"
"610","NCT00446511","Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension","Hypertension",0,"Valsartan","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","6 Years","17 Years","250","June 2007","June 2009","Number of Patients With Adverse Events","0","0","0","0","0","0","0","0","0"
"611","NCT00446524","Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)","Hypertension",0,"Valsartan + Amlodipine besilate","Drug","Novartis","Industry",0,0,"All","20 Years","N/A","403","February 2007","October 2008","Safety assessed by serious and non-serious adverse events","0","0","0","0","0","0","0","0","0"
"612","NCT00446563","Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy","Hypertension; Hypertrophy, Left Ventricular",0,"Valsartan","Drug","Novartis","Industry",0,0,"All","18 Years","80 Years","90","March 2007","March 2010","Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)","0","0","0","0","0","0","0","0","0"
"613","NCT00446680","Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study","Cystic Fibrosis",0,"Mannitol","Drug","Pharmaxis","Industry",0,0,"All","6 Years","N/A","340","March 2007","May 2010","To determine the effects of 400 mg twice-daily administration of IDPM on FEV1 in patients with CF compared to control","0","0","0","0","0","0","0","0","0"
"614","NCT00446732","The Use of the UroShield Device in Patients With Indwelling Urinary Catheters","Urinary Tract Infection",0,"UroSshield","Device","Nanovibronix","Industry",0,0,"All","18 Years","N/A","200","March 2007","April 2009","primary end points","0","0","0","0","0","0","0","0","0"
"615","NCT00447187","Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk","Corneal Diseases",0,"LX201","Drug","Lux Biosciences, Inc.","Industry",0,0,"All","18 Years","N/A","368","April 2007","March 2009","graft rejection or graft failure","0","0","0","0","0","0","0","0","0"
"616","NCT00447291","Safety & Efficacy of Omega-3 Fish Oil in Overweight Children & Adolescents","Overweight",0,"Supplement: Omega-3 Fish Oil","Drug","Children's Heart Center","Industry",0,0,"All","8 Years","18 Years","60","December 2006","March 2010","To compare effects between Omega 3 fish oil and placebo","0","0","0","0","0","0","0","0","0"
"617","NCT00447382","Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes","Diabetes",0,"insulin detemir","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","330","March 2007","July 2008","Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies","0.649","0","ANOVA","1.04","Treatment Ratio","95","0","0.86","1.26"
"618","NCT00447564","Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence","Opioid Dependence",0,"Probuphine","Drug","Braeburn Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","163","October 2006","July 2008","The cumulative distribution function (CDF) of the percent of urine samples negative for illicit opioids","0","0","0","0","0","0","0","0","0"
"619","NCT00447642","Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty","Corneal Transplantation",0,"LX201","Drug","Lux Biosciences, Inc.","Industry",0,0,"All","18 Years","N/A","122","April 2007","August 2008","prevention of corneal allograft rejection or graft failure","0","0","0","0","0","0","0","0","0"
"620","NCT00447772","Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia","Cervical Dystonia",0,"Botulinum type A toxin (Dysport®)","Drug","Ipsen","Industry",0,0,"All","18 Years","N/A","516","October 2004","February 2008","Change in Tsui score","0","0","0","0","0","0","0","0","0"
"621","NCT00447876","Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis","Chronic Plantar Fasciitis",0,"Botulinum type A toxin (Dysport®)","Drug","Ipsen","Industry",0,0,"All","18 Years","N/A","40","July 2005","January 2009","Improvement of score value on the visual analogue scale for pain during weight-bearing in the last 48 hours in week 6. ""Responder"" is defined as a reduction in score value of ≥ 50%","0","0","0","0","0","0","0","0","0"
"622","NCT00447915","Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis","Primary Osteoporosis",0,"ibandronic acid 0.5mg","Drug","Chugai Pharmaceutical","Industry",0,0,"All","60 Years","N/A","1265","March 2007","August 2011","Incidence of vertebral fracture","0","0","0","0","0","0","0","0","0"
"623","NCT00448422","Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers","Acute Bacterial Gastroenteritis",0,"prulifloxacin","Drug","Optimer Pharmaceuticals LLC","Industry",0,0,"All","18 Years","N/A","268","December 2006","August 2008","Time to Last Unformed Stool (TLUS)","0","0","0","0","0","0","0","0","0"
"624","NCT00448539","Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures","Refractory Partial Onset Seizures",0,"Rufinamide","Drug","Eisai Inc.","Industry",0,0,"All","12 Years","80 Years","286","March 2007","May 2010","Percentage Change in Total Partial Seizure Frequency Per 28 Days Relative to the Baseline Phase","0","0","0","0","0","0","0","0","0"
"625","NCT00448747","Investigation of a New, Oral Growth Hormone Secretagogue, Macimorelin (AEZS-130) as a Growth Hormone Stimulation Test.","Diagnosis of Adult Growth Hormone Deficiency (AGDH)",0,"diagnostic","Drug","AEterna Zentaris","Industry",0,0,"All","18 Years","N/A","98","June 2007","July 2011","Diagnostic efficacy","0","0","0","0","0","0","0","0","0"
"626","NCT00448903","Clinical Trial to Evaluate the Efficacy and Safety of Sodium Bemiparin for Treatment of Diabetic Foot Ulcers","Foot Ulcer, Diabetic",0,"Bemiparin","Drug","Rovi Pharmaceuticals Laboratories","Industry",0,0,"All","18 Years","N/A","329","March 2007","December 2009","total healing with intact skin or a significant improvement defined as a reduction of ulcer area > or = 50% or one degree reduction on Wagner Classification.","0","0","0","0","0","0","0","0","0"
"627","NCT00449033","A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)","Carcinoma, Non-Small-Cell Lung",0,"Sorafenib (Nexavar, BAY43-9006)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","904","February 2007","April 2010","Overall Survival (OS) in the ITT (Non-squamous) Population","0.401","0","Log Rank","0.98","Hazard Ratio (HR)","95","0","0.83","1.16"
"628","NCT00449150","Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)","Benign Prostatic Hypertrophy",0,"Cetrorelix","Drug","AEterna Zentaris","Industry",0,0,"Male","50 Years","N/A","667","March 2007","June 2009","International Prostate Symptoms Score (IPSS)","0.7424","0","ANOVA","-0.198","LS means estimate","95","2-Sided","-1.38","0.98"
"629","NCT00449176","A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain","Low Back Pain",0,"tapentadol (CG5503) ER","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","981","February 2007","May 2008","Change From Baseline of the Average Pain Intensity Based on a 11-point Numerical Rating Scale (NRS) Over the Last Week of the Maintenance Period at Week 12.","<0.001","0","ANCOVA","-0.8","Mean Difference (Final Values)","95","0","-1.22","-0.47"
"630","NCT00449540","Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura","Migraine With Aura",0,"Active Transcranial Magnetic Stimulation (TMS) Device","Device","Neuralieve","Industry",0,0,"All","18 Years","65 Years","201","August 2006","January 2008","Percentage of Participants Experiencing no Pain at Two Hours Post-treatment","0","0","0","0","0","0","0","0","0"
"631","NCT00449605","A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","508","March 2007","November 2008","Change from baseline in glycemic measure HbA1c","0","0","0","0","0","0","0","0","0"
"632","NCT00449878","Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency","Cystic Fibrosis",0,"Liprotamase","Drug","Anthera Pharmaceuticals","Industry",0,0,"All","7 Years","N/A","163","May 2007","June 2008","Change from open label baseline to end of 6 day double blind treatment period in Coefficient of Fat Absorption (CFA)","0","0","0","0","0","0","0","0","0"
"633","NCT00449904","Open-Label Phase III Long-Term Safety Trial of Liprotamase","Cystic Fibrosis",0,"Liprotamase","Drug","Anthera Pharmaceuticals","Industry",0,0,"All","7 Years","N/A","214","June 2007","April 2009","Number of participants with an adverse event","0","0","0","0","0","0","0","0","0"
"634","NCT00449930","Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)","Type 2 Diabetes Mellitus",0,"sitagliptin phosphate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","78 Years","1050","March 1, 2007","July 25, 2008","Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24","0","0","0","0.14","Mean Difference (Net)","95","0","0.06","0.21"
"635","NCT00450086","Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis","Collagenous Colitis",0,"Budesonide","Drug","Dr. Falk Pharma GmbH","Industry",0,0,"All","18 Years","80 Years","92","March 2007","June 2011","Rate of clinical remission (<= 3 stools per day) after 8 weeks","0","0","0","0","0","0","0","0","0"
"636","NCT00450112","Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee","Osteoarthritis of the Knee",0,"Gel-200","Device","Seikagaku Corporation","Industry",0,0,"All","40 Years","80 Years","202","March 2007","June 2009","Occurrence of Systemic and Local Adverse Events Following a Single or Repeat Intra-articular Injection of Gel-200",">0.1","0","Fisher Exact","0","0","0","0","0","0"
"637","NCT00450216","Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment","Ulcer",0,"Ibuprofen/famotidine","Drug","Horizon Pharma Ireland, Ltd., Dublin Ireland","Industry",0,0,"All","40 Years","80 Years","906","March 2007","August 2008","Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers","<0.0001","CMH test stratified by use of low-dose aspirin (yes/no) and prior upper gastrointestinal (UGI) ulcer history (yes/no) at randomization.","Cochran-Mantel-Haenszel","9.8","Risk Difference (RD)","95","2-Sided","4.4","15.3"
"638","NCT00450333","Dynepo Infrequent Dosing Study","Anemia",0,"Dynepo (Epoetin delta)","Drug","Shire","Industry",0,0,"All","18 Years","N/A","407","October 2006","July 2008","Change From Baseline in Hemoglobin (Hb) Concentration at 24 Weeks","0","0","0","0","0","0","0","0","0"
"639","NCT00450658","Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers","Peptic Ulcer",0,"HZT-501","Drug","Horizon Pharma Ireland, Ltd., Dublin Ireland","Industry",0,0,"All","40 Years","80 Years","627","March 2007","September 2008","Number of Subjects Who Develop Endoscopically-diagnosed Upper Gastrointestinal Ulcers Confirmed by Endoscopy.","0.0018","0","Cochran-Mantel-Haenszel","9.5","Risk Difference (RD)","95","2-Sided","3.0","15.9"
"640","NCT00450970","Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)","Prostate Cancer",0,"Oral Satraplatin","Drug","Agennix","Industry",0,0,"Male","18 Years","N/A","344","February 2007","March 2009","The SPERA trial is designed to provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited prior cytotoxic chemotherapy regimens for metastatic disease.","0","0","0","0","0","0","0","0","0"
"641","NCT00451295","A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia","Chronic Kidney Disease",0,"MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","18 Years","80 Years","6","May 2007","January 2011","Serum phosphorus change compared to placebo from baseline to week 12.","0","0","0","0","0","0","0","0","0"
"642","NCT00451412","A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients","Thromboembolism",0,"Certoparin","Drug","Novartis","Industry",0,0,"All","70 Years","N/A","3254","January 2007","June 2009","Incidence of venous thromboembolism during treatment (proximal deep vein thrombosis, pulmonary embolism, death related to venous thromboembolism)","0","0","0","0","0","0","0","0","0"
"643","NCT00451451","Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis","Relapsing-Remitting Multiple Sclerosis",0,"BG00012","Drug","Biogen","Industry",0,0,"All","18 Years","55 Years","1417","June 2007","August 2011","Annualized Relapse Rate","0","0","0","0","0","0","0","0","0"
"644","NCT00451958","A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy","Prostate Cancer",0,"Degarelix 80 mg / Degarelix 80 mg","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","386","March 2007","October 2011","Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight","0","0","0","0","0","0","0","0","0"
"645","NCT00452491","MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children","Fetal Growth Retardation",0,"somatropin","Drug","Sanofi","Industry",0,0,"All","3 Years","11 Years","306","May 1993","April 2010","Efficacy data : measurement of height","0","0","0","0","0","0","0","0","0"
"646","NCT00452530","Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery","Deep Vein Thrombosis",0,"Enoxaparin","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","3221","June 2007","January 2009","Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period","0.0003","1-sided P-value","Yanagawa, Tango, and Hiejima test",".50","Risk Ratio (RR)","0","0","0","0"
"647","NCT00452569","Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma","Multiple Myeloma",0,"Thalidomide","Drug","Celgene Corporation","Industry",0,0,"All","18 Years","N/A","499","February 2006","December 2008","The evaluation of Independent Review Committee-documented time to progression (TTP).","0","0","0","0","0","0","0","0","0"
"648","NCT00452725","Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome","Noonan Syndrome",0,"MAXOMAT ®, biosynthetic growth hormone","Drug","Sanofi","Industry",0,0,"All","3 Years","15 Years","36","October 1997","July 2010","Evaluation of height : gain in height and rate of growth","0","0","0","0","0","0","0","0","0"
"649","NCT00453349","A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease","Pelvic Inflammatory Disease",0,"Moxifloxacin (Avelox, BAY12-8039)","Drug","Bayer","Industry",0,0,"Female","18 Years","N/A","460","January 2007","May 2008","Clinical Response 7 to 14 Days After Completion of Study Drug Therapy in Per Protocol (PP) Population","0","0","0","-3.2","Mean Difference (Final Values)","95","0","-10.7","4.9"
"650","NCT00453570","Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months","Diphtheria",0,"Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib","Biological","Sanofi","Industry",0,0,"All","60 Days","74 Days","792","March 2007","December 2008","To provide information concerning the immunogenicity of DTacP-IPV//PRP~T combined vaccine","0","0","0","0","0","0","0","0","0"
"651","NCT00454207","Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension","Pulmonary Hypertension",0,"sildenafil citrate (UK-92,480)","Drug","Pfizer","Industry",0,0,"All","16 Years","N/A","44","April 2007","February 2009","Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I","0","0","0","0","0","0","0","0","0"
"652","NCT00454389","A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration","Macular Degeneration",0,"Epi-Rad90™ Ophthalmic System","Device","NeoVista","Industry",0,0,"All","50 Years","N/A","494","April 2007","September 2011","Percentage of subjects losing fewer than 15 letters of best corrected visual acuity score at 12 months compared to baseline. Gain of 15 more letters of best correct visual acuity score compared to baseline","0","0","0","0","0","0","0","0","0"
"653","NCT00454584","An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis","Psoriasis",0,"CNTO 1275 45 mg","Drug","Centocor, Inc.","Industry",0,0,"All","18 Years","N/A","903","March 2007","January 2008","Number of Participants Achieving a Greater Than or Equal to 75 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 12","<0.001","0","Cochran-Mantel-Haenszel (CMH) chi square","0","0","0","0","0","0"
"654","NCT00455520","A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy","Diabetic Neuropathy",0,"CG5503","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","395","April 2007","August 2008","Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12","<0.001","0","ANCOVA","-1.3","Mean Difference (Final Values)","95","0","-1.7","-0.92"
"655","NCT00456508","Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)","Hereditary Angioedema",0,"ecallantide","Drug","Shire","Industry",0,0,"All","10 Years","N/A","147","April 2007","June 2010","Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hrs Post Dosing","0","0","0","0","0","0","0","0","0"
"656","NCT00456521","A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program","Obesity",0,"Naltrexone SR 32 mg/ bupropion SR 360 mg/ day","Drug","Orexigen Therapeutics, Inc","Industry",0,0,"All","18 Years","65 Years","793","March 2007","December 2008","Co-primary: Body Weight- Mean Percent Change","<0.001","0","ANCOVA","-4.21","Mean Difference (Net)","95","0","-5.56","-2.86"
"657","NCT00457002","Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness","Venous Thrombosis",0,"Apixaban","Drug","Bristol-Myers Squibb","Industry",0,0,"All","40 Years","N/A","6758","June 2007","May 2011","Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population","0.4364","0","Mantel Haenszel","0.87","Risk Ratio (RR)","95","2-Sided","0.62","1.23"
"658","NCT00457015","Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)","Hereditary Angioedema",0,"ecallantide","Drug","Shire","Industry",0,0,"All","10 Years","N/A","96","April 2007","June 2008","Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose","0.010","No adjustment was made for multiple comparisons. Treatment effect will be deemed statistically significant if the coefficient for the treatment group within the statistical model is significant at level 0.05.","Blocked Wilcoxon rank sum test","0","0","0","0","0","0"
"659","NCT00457392","A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone","Carcinoma, Non-Small Cell Lung",0,"erlotinib","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","960","July 2007","July 2010","Overall Survival (OS)","0.1933","p-value was not adjusted for multiple comparisons.","Log Rank","0.942","Hazard Ratio (HR)","95","2-Sided","0.822","1.079"
"660","NCT00457626","An Open Label Extension Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension","Hypertension",0,"Valsartan","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","6 Months","5 Years","66","April 2007","May 2009","Safety and tolerability of valsartan in children 6 months - 5 years old with hypertension.","0","0","0","0","0","0","0","0","0"
"661","NCT00457691","Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer","Metastatic Colorectal Cancer",0,"5 fluorouracil","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","768","June 2007","March 2010","Progression-free Survival (PFS)","0.8072","p-value from 1-sided log-rank test, stratified by Eastern Cooperative Oncology Group (ECOG) performance status, organ sites with disease, primary tumor site, prior adjuvant treatment","Log Rank","1.095","Hazard Ratio (HR)","95","2-Sided","0.892","1.344"
"662","NCT00458081","Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors","Obesity",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","30 Years","75 Years","174","March 2007","January 2009","Relative change in the microalbuminuria level.","0","0","0","0","0","0","0","0","0"
"663","NCT00458276","Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery","Heart Diseases",0,"tezosentan","Drug","Actelion","Industry",0,0,"All","18 Years","N/A","274","April 2007","February 2008","The primary objective of this trial is to demonstrate that tezosentan, a dual ERA, reduces the incidence of clinically relevant right ventricular failure in patients with pre-operative pulmonary hypertension, due to left heart disease, undergoing CPB.","0","0","0","0","0","0","0","0","0"
"664","NCT00458302","Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir","HIV Infections",0,"darunavir (DRV, TMC114)","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","N/A","256","June 2007","February 2009","Virological Response [Per Protocol (PP) - Time to Loss of Virologic Response (TLOVR), < 50 Copies/ml, Week 48]","0","0","0","-1.6","Difference in proportion of response","95","2-Sided","-10.1","6.8"
"665","NCT00458510","Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain","Cancers, Pain",0,"Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)","Drug","Archimedes Development Ltd","Industry",0,0,"All","18 Years","N/A","403","January 2007","October 2011","Long term Safety, tolerability and acceptability","0","0","0","0","0","0","0","0","0"
"666","NCT00459277","Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids","Cancer Pain",0,"Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)","Drug","Archimedes Development Ltd","Industry",0,0,"All","18 Years","N/A","73","December 2006","July 2008","Summed pain intensity difference at 30 min","0","0","0","0","0","0","0","0","0"
"667","NCT00459667","BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose","Multiple Sclerosis, Relapsing-Remitting",0,"Interferon beta-1b (Betaseron, BAY86-5046)","Drug","Bayer","Industry",0,0,"All","18 Years","55 Years","1420","May 2007","March 2008","Flu-like-syndrome","0","0","0","17.4","Number of patients w/ Flu-Like-Syndrome","95","0","14.4","20.7"
"668","NCT00459719","A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Liver Transplantation","Liver Transplantation",0,"Tacrolimus modified-release","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","70 Years","42","March 2007","March 2009","Event rate of patients with acute rejections","0","0","0","0","0","0","0","0","0"
"669","NCT00460265","Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer","Recurrent and/or Metastatic Head and Neck Cancer",0,"ARM 2","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","658","May 2007","May 2010","Overall Survival","0.1403","0","Log Rank","0.873","Hazard Ratio (HR)","95","0","0.729","1.046"
"670","NCT00460317","MONET1-MOtesanib NSCLC Efficacy and Tolerability Study","Non-Small Cell Lung Cancer",0,"AMG 706","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","1450","July 2007","March 2011","Overall survival time. Time from randomization to death. Subjects who have not died while on study or are lost to follow up will be censored at their last contact date.","0","0","0","0","0","0","0","0","0"
"671","NCT00460512","An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia","Schizophrenia",0,"Paliperidone ER","Drug","Janssen-Cilag International NV","Industry",1,0,"All","18 Years","N/A","1815","April 25, 2007","January 22, 2009","Percentage of Participants With at Least 20 Percent Improvement in Total Positive and Negative Syndrome Scale (PANSS) Score in Those Participants who Transitioned due to Lack of Efficacy","0","0","0","0","0","0","0","0","0"
"672","NCT00460564","Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity","Post-Stroke Spasticity",0,"GSK1358820","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","80 Years","109","May 2007","December 2008","Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Wrist Score to the End of the DB Phase (Week 12) in the High-dose Groups","<0.001","0","t-test, 2 sided","-6.830","Mean Difference (Net)","95","0","-10.567","-3.093"
"673","NCT00460655","Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity","Post-Stroke Spasticity",0,"GSK1358820","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","80 Years","120","May 2007","December 2008","Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Ankle Score to the End of the DB Phase (Week 12)","0.006","0","t-test, 2 sided","-3.428","Mean Difference (Net)","95","0","-5.841","-1.016"
"674","NCT00460746","Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.","HIV",0,"TMC125, Darunavir; Ritonavir","Drug","Tibotec, Inc","Industry",0,0,"All","18 Years","N/A","10","May 2007","October 2008","Proportion of Patients Who Maintain Plasma HIV Viral Load Measurements < 400 Copies/ml at 2, 4, 8, 12, 16, 24, 36 and 48 Weeks After Switching to DRV/r and ETR, Missing Equals Failure.","0","0","0","0","0","0","0","0","0"
"675","NCT00461305","Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea","Dysmenorrhea",0,"DRSP 3 mg/EE 20 µg (13 cycles)","Drug","Bayer","Industry",0,0,"Female","20 Years","N/A","420","February 2007","January 2009","Number of Participants With Intracyclic Bleeding at Cycle 6","0","0","0","13.4","Incidence on one treatment arm","95","2-Sided","9.73","17.77"
"676","NCT00461591","Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing TUR-BT","Bladder Cancer",0,"EOquin®","Drug","Spectrum Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","802","April 2007","December 2009","Recurrence Rate at 2 years","0","0","0","0","0","0","0","0","0"
"677","NCT00462202","Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong","Diabetic Nephropathy",0,"sulodexide","Drug","Keryx Biopharmaceuticals","Industry",0,0,"All","18 Years","N/A","200","April 2007","March 2008","Observed ACR level from the first visit to the end of study","0","0","0","0","0","0","0","0","0"
"678","NCT00462670","A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","Edema, Cardiac",0,"OPC-41061(Tolvaptan)","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","85 Years","110","April 2007","October 2008","Body Weight (Amount of Change)","<0.0001","0","t-test, 2 sided","-1.09","Mean Difference (Final Values)","95","2-Sided","-1.58","-0.60"
"679","NCT00463606","A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia","Hypercholesterolemia",0,"ABT-335 and rosuvastatin calcium","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","760","April 2007","February 2008","Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set)","0","0","0","0","0","0","0","0","0"
"680","NCT00464204","Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis","Sepsis",0,"6 % Hydroxyethylstarch 130/0.4 = ""Voluven®""","Drug","Fresenius Kabi","Industry",0,0,"All","18 Years","N/A","196","July 2007","May 2010","Amount of Study Drug Required to Achieve Initial Hemodynamic Stabilization","0.0185","One-sided t-test assuming unequal variances (as variances were significantly different between treatment groups).No multiple comparisons were made. A priori threshold for statistical significance for the confirmatory analysis on FAS: 0.025 one-sided.","t-test, 1 sided","-331","Mean Difference (Final Values)","95","2-Sided","-640","-21"
"681","NCT00464269","Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","Epilepsy",0,"Placebo","Other","UCB Pharma","Industry",0,0,"All","16 Years","70 Years","400","September 2007","December 2008","Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period","=0.025","0","ANCOVA","12.8","% reduction over Placebo","95","2-Sided","1.7","22.6"
"682","NCT00465491","Study of Picoplatin Efficacy After Relapse","Small Cell Lung Cancer",0,"picoplatin","Drug","Poniard Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","399","April 2007","May 2009","overall survival","0","0","0","0","0","0","0","0","0"
"683","NCT00465738","IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity","Upper Limb Spasticity",0,"incobotulinumtoxinA (Xeomin, also known as ""NT 201"" or ""Botulinum toxin type A (150 kD), free from complexing proteins"")","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","N/A","216","February 2007","January 2008","Responder in Disability Assessment Scale (DAS) at Week 4 - Per Protocol Set","0","0","0","10.6","difference in response rates","95","2-Sided","-4.4","24.9"
"684","NCT00465803","A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension","Open-angle Glaucoma",0,"Travoprost 0.004%/timolol 0.5% ophthalmic solution","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","81","March 2007","January 2009","Patient compliance","0","0","0","0","0","0","0","0","0"
"685","NCT00467259","Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women","Hypoactive Sexual Desire Disorder",0,"Testosterone Transdermal System","Drug","Warner Chilcott","Industry",0,0,"Female","45 Years","70 Years","1271","April 2007","January 2009","Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1","1.0000","0","Fisher Exact","0","0","0","0","0","0"
"686","NCT00467376","Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus","Diabetes Mellitus",0,"Insulin Glulisine","Drug","Sanofi","Industry",0,0,"All","18 Years","70 Years","485","January 2007","June 2008","Hypoglycemic episodes","0","0","0","0","0","0","0","0","0"
"687","NCT00467519","Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age","Tetanus",0,"Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","4 Years","6 Years","1045","April 2007","November 2009","Percentage of Participants Who Achieved Seroprotection at Baseline and 30 Days Post-vaccination for Diphtheria and Tetanus at ≥ 0.1 IU/mL Level","0","0","0","0","0","0","0","0","0"
"688","NCT00467870","Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men","Hypogonadism",0,"Testosterone Undecanoate 750 mg","Drug","Endo Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","531","March 2006","July 2009","Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval in Part C","0","0","0","0","0","0","0","0","0"
"689","NCT00468273","A Clinical Study of Intravenous Immunoglobulin","Immunologic Deficiency Syndromes",0,"Immune Globulin Intravenous (Human) Omr-IgG-am IGIV","Drug","FFF Enterprises","Industry",0,0,"All","3 Years","75 Years","57","November 2006","May 2009","Incidence of acute serious bacterial infections","0","0","0","0","0","0","0","0","0"
"690","NCT00468481","Efficacy and Safety Study for an Oral Contraceptive Containing Folate","Neural Tube Defects",0,"Drospirenone/Ethinylestradiol/Methyltetrahydrofolate","Drug","Bayer","Industry",0,0,"Female","18 Years","40 Years","385","April 2007","August 2008","Red Blood Cell (RBC) Folate Level at 24 Weeks","<0.0001","0","ANCOVA","384.70","Mean Difference (Final Values)","95","0","282.42","486.98"
"691","NCT00468611","Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis","Multiple Sclerosis, Secondary Progressive",0,"MBP8298","Drug","BioMS Technology Corp.","Industry",0,0,"All","18 Years","65 Years","510","June 2007","July 2009","Time to progression of disease in subjects with SPMS as measured by the EDSS after 24 months of treatment","0","0","0","0","0","0","0","0","0"
"692","NCT00468728","PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","Clostridium Infections",0,"PAR-101/OPT-80","Drug","Optimer Pharmaceuticals LLC","Industry",0,0,"All","16 Years","N/A","535","October 4, 2006","December 11, 2009","Cure Rate at End of Therapy","0","0","0","1.0","Risk Difference (RD)","95","2-Sided","-4.8","6.8"
"693","NCT00468845","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy","Pain, Postoperative",0,"pregabalin (Lyrica)","Drug","Pfizer","Industry",0,0,"Female","25 Years","70 Years","501","June 2007","May 2010","Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)","0.1378","Weighted Z-score test method of Fisher (1998) and Cui et al (1999)applied to maintain alpha level. A step down procedure for multiple comparisons to control the maximum experiment wise type I error rate at 0.05 level. 300mg tested prior to 150mg.","ANOVA","0","0","0","0","0","0"
"694","NCT00469586","Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes","Diabetes",0,"inhaled human insulin","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","174","April 26, 2007","April 24, 2008","HbA1c change from baseline","0","0","0","0","0","0","0","0","0"
"695","NCT00470600","Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients","Pain",0,"Caldolor","Drug","Cumberland Pharmaceuticals","Industry",0,0,"All","18 Years","80 Years","185","May 2007","September 2008","AUC-VAS With Movement (Post-operative Period, Hour-6-28)","0","0","0","0","0","0","0","0","0"
"696","NCT00471146","Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.","Carcinoma, Pancreatic Ductal",0,"AG-013736","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","630","July 2007","January 2009","Overall Survival (OS)","0.5436","One-sided log-rank test at alpha = 0.025 significance level was used.","Log Rank","1.014","Hazard Ratio (HR)","95","2-Sided","0.786","1.309"
"697","NCT00471328","Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib","Gastrointestinal Stromal Tumors",0,"Nilotinib","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","248","March 2007","August 2008","Progression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)","0","0","0","0","0","0","0","0","0"
"698","NCT00471965","Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients","Carcinoma, Hepatocellular",0,"Oxaliplatin + 5-Fluorouracil/Leucovorin","Drug","Sanofi","Industry",0,0,"All","18 Years","75 Years","371","March 2007","March 2010","Overall survival","0","0","0","0","0","0","0","0","0"
"699","NCT00472303","A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine","Tumor",0,"Tapentadol Extended Release","Drug","Grünenthal GmbH","Industry",0,0,"All","18 Years","N/A","622","July 2007","June 2012","Number of Participants Scored as Responder in Maintenance Phase.","0","0","0","0","0","0","0","0","0"
"700","NCT00472810","Ologen (OculusGen)-Glaucoma MMC Control in Pakistan","Glaucoma",0,"ologen collagen matrix in glaucoma filtering surgery","Device","Pro Top & Mediking Company Limited","Industry",0,0,"All","18 Years","N/A","40","March 2007","May 2008","the effectiveness via the reduction of IOP","0","0","0","0","0","0","0","0","0"
"701","NCT00472862","Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usual","Schizophrenia",0,"Cognitive training","Behavioral","Neurocom","Industry",0,0,"All","18 Years","35 Years","117","January 2007","April 2010","USCD Performance-Based Skills Assessment","0","0","0","0","0","0","0","0","0"
"702","NCT00472901","Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)","Polymorphic Light Eruption (PLE)",0,"Afamelanotide (CUV1647)","Drug","Clinuvel Pharmaceuticals Limited","Industry",0,0,"All","18 Years","70 Years","18","May 2007","December 2009","To evaluate whether afamelanotide (CUV1647) prevents episodes or reduces the severity of PLE symptoms in patients with a well documented history of PLE","0","0","0","0","0","0","0","0","0"
"703","NCT00472953","Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)","Diabetes",0,"inhaled human insulin","Drug","Novo Nordisk A/S","Industry",0,0,"All","30 Years","N/A","38","May 15, 2007","March 5, 2008","To evaluate pulmonary safety comparing inhaled insulin to subcutaneous injections","0","0","0","0","0","0","0","0","0"
"704","NCT00473434","An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia","Schizophrenia",0,"Paliperidone","Drug","Janssen-Cilag Pty Ltd","Industry",0,0,"All","18 Years","65 Years","64","April 2007","August 2009","The Mean Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 1 to Day 84","0","0","0","0","0","0","0","0","0"
"705","NCT00473889","A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)","Stage IIIB or IV Non-Small Cell Lung Cancer",0,"vorinostat","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","253","May 2007","December 2008","Overall Survival","0.992","This is a one sided p-value, which corresponds to the null hypothesis.","Stratified Log Rank","0","0","0","0","0","0"
"706","NCT00474045","Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes","Diabetes",0,"insulin detemir","Drug","Novo Nordisk A/S","Industry",0,0,"Female","18 Years","N/A","470","May 2007","August 2010","Glycosylated Haemoglobin (HbA1c) for Full Analysis Set (Pregnant Subjects) at GW 36","0.400","P-value for superiority was calculated.","Regression, Linear","-0.06","Mean Difference (Final Values)","95","0","-0.21","0.08"
"707","NCT00474058","Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine","Parkinson's Disease",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","18 Years","N/A","287","May 2007","March 2009","Change in Early Morning UPDRS Part III Score","0.0002","No p-value adjustment was necessary, since a multiple test procedure in a hierarchical sequentially rejective manner for the primary variable was applied.","ANCOVA","-3.55","Mean Difference (Final Values)","95","0","-5.37","-1.73"
"708","NCT00474370","Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)","HIV Infections",0,"Vicriviroc","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","16 Years","N/A","400","May 2007","August 2009","Proportion of subjects with undetectable plasma HIV-1 RNA (<50 copies/mL)","0","0","0","0","0","0","0","0","0"
"709","NCT00474630","A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes","Obesity",0,"Naltrexone SR 32 mg/bupropion SR 360 mg/ day","Drug","Orexigen Therapeutics, Inc","Industry",0,0,"All","18 Years","70 Years","505","May 2007","June 2009","Co-primary: Body Weight- Mean Percent Change","<0.001","0","ANCOVA","-3.28","Mean Difference (Net)","95","0","-4.34","-2.22"
"710","NCT00474786","Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib","Renal Cell Carcinoma",0,"Sorafenib","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","512","September 2007","January 2012","Progression-Free Survival (PFS)","0.1933","Stratified for nephrectomy status, duration of response to sunitinib therapy, tumor histology, and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic group.","Log Rank","0.87","Cox Proportional Hazard","95","2-Sided","0.71","1.07"
"711","NCT00475033","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants","Vaccines, Pneumococcal Conjugate Vaccine",0,"13-valent Pneumococcal Conjugate Vaccine","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","42 Days","98 Days","603","June 2007","May 2009","Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C Serum Bactericidal Assay (SBA) in the 13vPnC Group Relative to 7vPnC Group After 2 Doses of NeisVac-C® in the Infant Series","0","0","0","-2.4","Difference","95","2-Sided","-5.3","-0.1"
"712","NCT00475410","Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease","Anal Fistula",0,"ASCs (Cx401, company code)","Drug","Cellerix","Industry",0,0,"All","18 Years","N/A","214","February 2007","August 2009","Closure of fistulas defined as absence of suppuration and re-epithelization of the external opening and absence of collections>2 cm directly related to the fistula tract treated, as measured by MRI (healing)","0","0","0","0","0","0","0","0","0"
"713","NCT00475813","Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma","Asthma",0,"FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)","Drug","Mundipharma Research Limited","Industry",0,0,"All","4 Years","12 Years","211","March 2007","February 2008","FEV1, recorded at visits to investigator at 2 wks, 6wks & 12 wks.","0","0","0","0","0","0","0","0","0"
"714","NCT00475852","A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure","Heart Decompensation",0,"Nesiritide","Drug","Scios, Inc.","Industry",0,0,"All","18 Years","N/A","7141","May 2007","March 2011","Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality","0.313","0","Cochran-Mantel-Haenszel","-0.7","Risk Difference (RD)","95","2-Sided","-2.1","0.7"
"715","NCT00476073","Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma","Asthma Bronchiale",0,"FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)","Drug","Mundipharma Research Limited","Industry",0,0,"All","18 Years","N/A","228","April 2007","January 2008","FEV1, (Forced expiratory volume in the 1st second).","0","0","0","0","0","0","0","0","0"
"716","NCT00476099","Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD","Chronic Obstructive Pulmonary Disease",0,"Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","40 Years","N/A","828","December 2006","August 2008","Number of COPD exacerbations and pre-dose morning FEV1","0","0","0","0","0","0","0","0","0"
"717","NCT00477230","Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs","Atrial Fibrillation",0,"Endoscopic Ablation System","Device","CardioFocus","Industry",0,0,"All","18 Years","80 Years","64","March 2007","May 2009","Freedom for Symptomatic Episode of Atrial Fibrillation at One Year","0","0","0","0","0","0","0","0","0"
"718","NCT00477490","Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia","Nocturia",0,"desmopressin acetate","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","799","May 2007","February 2008","Part I: Change From Baseline in Mean Number of Nocturnal Voids at Week 4","0.9303","The a priori statistically significant difference versus placebo is p≤0.05.","ANCOVA","0.010","Mean Difference (Final Values)","95","2-Sided","-0.221","0.242"
"719","NCT00477633","Study of Safety and Efficacy of an Oral Contraceptive","Contraception",0,"Norethindrone/ethinyl estradiol","Drug","Warner Chilcott","Industry",0,0,"Female","18 Years","45 Years","1700","June 2007","January 2009","Pearl Index, 18-35 Years, MITT Population","0","0","0","0","0","0","0","0","0"
"720","NCT00477672","A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","Parkinson's Disease Psychosis",0,"Pimavanserin tartrate (ACP-103)","Drug","ACADIA Pharmaceuticals Inc.","Industry",1,0,"All","40 Years","N/A","298","June 2007","June 2009","Antipsychotic Efficacy","0","0","0","0","0","0","0","0","0"
"721","NCT00478023","A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy","Hysterectomy",0,"Morphine","Drug","Grünenthal GmbH","Industry",0,0,"Female","18 Years","80 Years","854","May 2007","February 2008","Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.","<0.0001","Adjusted. The Hochberg procedure used for multiplicity comparisons","ANCOVA","18.1","Least square mean difference","95","0","10.9","25.3"
"722","NCT00478192","Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia","Hyponatremia",0,"Conivaptan","Drug","Cumberland Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","50","April 2007","August 2008","Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation.","0.028","P-Values are not adjusted on the basis of multiple comparrisons","ANCOVA","0","0","0","0","0","0"
"723","NCT00478231","Multicenter, Safety Study Of Maraviroc","Acquired Immunodeficiency Syndrome",0,"Maraviroc","Drug","ViiV Healthcare","Industry",0,0,"All","18 Years","N/A","209","July 2007","August 2010","Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"724","NCT00478647","Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase","Gaucher Disease, Type 1",0,"GA-GCB (velaglucerase alfa)","Biological","Shire","Industry",0,0,"All","2 Years","N/A","40","July 2007","July 2009","Participants Who Experienced at Least One Adverse Event","0","0","0","0","0","0","0","0","0"
"725","NCT00478790","Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's Hospital","Glaucomas",0,"ologen™ Collagen matrix implantation in glaucoma filtering surgery","Device","Pro Top & Mediking Company Limited","Industry",0,0,"All","18 Years","N/A","60","February 2007","October 2011","the effectiveness via the reduction of IOP and the incidence of pterygium recurrence","0","0","0","0","0","0","0","0","0"
"726","NCT00478972","Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise","Obesity",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","20 Years","N/A","321","April 2007","January 2009","Absolute change from baseline in HbA1C","0","0","0","0","0","0","0","0","0"
"727","NCT00479661","Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU)","Continuous Sedation in Initially Sedated Adults in ICU",0,"Dexmedetomidine","Drug","Orion Corporation, Orion Pharma","Industry",0,0,"All","18 Years","N/A","500","May 2007","March 2010","Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required.","0","0","0","0","0","0","0","0","0"
"728","NCT00479687","SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder","Osteoarthritis of the Shoulder",0,"SUPARTZ","Device","Bioventus LLC","Industry",0,0,"All","35 Years","N/A","256","May 2007","October 2009","Improvement in shoulder pain compared to subjects treated with placebo","0","0","0","0","0","0","0","0","0"
"729","NCT00479882","MK-0524B Lipid Study (MK-0524B-063)","Primary Hypercholesterolemia",0,"Comparator: simvastatin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","85 Years","2414","June 2007","June 2008","Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)","0","0","0","2.4","Difference in Least squares mean","95","2-Sided","1.3","3.4"
"730","NCT00480116","Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule","Hepatitis B",0,"Adjuvanted Hepatitis B vaccine Lot 1","Biological","Henogen","Industry",0,0,"All","18 Years","40 Years","450","January 2008","April 2008","Anti-HBs seroprotection rates at Month 2.","0","0","0","0","0","0","0","0","0"
"731","NCT00481247","A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia","Myeloid Leukemia, Chronic",0,"Dasatinib","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","547","September 2007","December 2009","Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months","0.0056","A priori threshold for statistical significance=0.05.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"732","NCT00481312","Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)","Continuous Sedation in Initially Sedated Adults in ICU",0,"Dexmedetomidine","Drug","Orion Corporation, Orion Pharma","Industry",0,0,"All","18 Years","N/A","501","June 2007","August 2009","Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required","0","0","0","0","0","0","0","0","0"
"733","NCT00481325","Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder","Generalized Anxiety Disorder",0,"pexacerfont","Drug","Bristol-Myers Squibb","Industry",0,0,"Female","18 Years","65 Years","260","July 2007","March 2008","Mean change from baseline to Week 8 on the Site-Rated Hamilton Anxiety Rating Scale (total score)","0","0","0","0","0","0","0","0","0"
"734","NCT00481481","Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects","Transplantation",0,"tacrolimus","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","346","April 2007","April 2009","Change in creatinine clearance, calculated according to Cockcroft and Gault formula.","0","0","0","0","0","0","0","0","0"
"735","NCT00481819","A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation","Kidney Transplantation",0,"FK506MR","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","70 Years","240","July 2007","March 2009","Event rate of patients with acute rejections","0","0","0","0","0","0","0","0","0"
"736","NCT00482612","Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)","Insomnia",0,"Esmirtazapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","526","December 2006","August 2008","Average Total Sleep Time (TST) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period","<0.0001","0","ANCOVA","0","0","0","0","0","0"
"737","NCT00483171","A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients","Obesity",0,"CP-945,598","Drug","Pfizer","Industry",0,0,"All","18 Years","70 Years","699","January 2008","January 2009","Percent weight regained during the 12 month treatment period after a prior weight loss on the low calorie diet (8 weeks).","0","0","0","0","0","0","0","0","0"
"738","NCT00483548","Adjunctive Ziprasidone in the Treatment of Bipolar I Depression","Bipolar Disorder",0,"Ziprasidone","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","298","October 2007","December 2008","Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","0.7921","Due to planned interim analysis of primary endpoint, to control type I error at 2-sided alpha=0.05, a nominal 2-sided p-value ≤0.0476 needed at final analysis to reject the null hypothesis of no treatment effect.","ANCOVA Mixed-effects repeated-measures","-0.36","Least squares mean","95","0","-3.07","2.34"
"739","NCT00483574","Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers","Meningococcal Meningitis",0,"Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","9 Months","12 Months","1378","May 2007","January 2009","Percentage of Participants With at Least One Solicited Injection Site Reaction or Systemic Reaction Following Vaccination.","0","0","0","0","0","0","0","0","0"
"740","NCT00483652","Study of Fampridine-SR Tablets in Multiple Sclerosis Patients","Multiple Sclerosis",0,"Fampridine-SR","Drug","Acorda Therapeutics","Industry",0,0,"All","18 Years","70 Years","240","May 2007","February 2008","Responders Based Upon the Timed 25-Foot Walk [T25FW]","0","0","0","0","0","0","0","0","0"
"741","NCT00483704","Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)","Migraines",0,"Telcagepant 140 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1935","August 14, 2008","March 25, 2009","Percentage of Participants Reporting Pain Freedom at 2 Hours Post-dose (First Migraine Attack)","<0.001","0","Regression, Logistic","2.54","Odds Ratio (OR)","95","2-Sided","1.80","3.58"
"742","NCT00483730","Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)","Symptomatic Diabetic Peripheral Polyneuropathy",0,"Deproteinised hemoderivative of calf blood (Actovegin)","Drug","Nycomed","Industry",0,0,"All","18 Years","65 Years","569","December 2006","May 2008","TSSaverage: Average of the TSS over the treatment period (AUC / exposure time) VPTaverage: Average of the VPT measurement over the treatment period (AUC / exposure time)","0","0","0","0","0","0","0","0","0"
"743","NCT00484198","Randomized, Double-Blind Active Comparator-Controlled Study of Rivoglitazone in Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"pioglitazone","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","N/A","1820","April 2007","February 2009","Glycemic control - HbA1c","0","0","0","0","0","0","0","0","0"
"744","NCT00484289","A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","20 Years","N/A","217","December 2006","December 2010","Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to AEs","0","0","0","0","0","0","0","0","0"
"745","NCT00484315","TAXUS PERSEUS Workhorse","Coronary Artery Disease",0,"Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","1264","July 2007","September 2009","Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.","0.9996","The p-value is the posterior probability that the difference in 12-month TLF between TAXUS Element and TAXUS Express was < 4.1%, given the data observed.","Bayesian modeling","-0.570","Median Difference (Final Values)","95","1-Sided","0","1.85"
"746","NCT00486031","Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study","Inflammatory Bowel Disease",0,"Balsalazide Disodium","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","500","October 2006","April 2008","Incidence of adverse events and serious adverse events,relationship to study medication, and severity","0","0","0","0","0","0","0","0","0"
"747","NCT00486473","Multihance Versus Magnevist in Breast MRI","Breast Cancer",0,"Multihance","Drug","Bracco Diagnostics, Inc","Industry",0,0,"Female","18 Years","N/A","130","July 2007","December 2009","Sensitivity in diagnosing breast lesions compared to histopathology results","0","0","0","0","0","0","0","0","0"
"748","NCT00486512","Chemoprevention of Colorectal Adenomas","Adenomatous Polyps",0,"aspirin, 1,25-dihydroxycholecalciferol, calcium","Drug","Colotech A/S","Industry",0,0,"All","40 Years","75 Years","1000","June 2007","June 2012","cumulative frequency of recurrence of colorectal adenomas","0","0","0","0","0","0","0","0","0"
"749","NCT00486811","A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee","Pain",0,"Tapentadol ER (100 to 250 mg twice daily)","Drug","Grünenthal GmbH","Industry",0,0,"All","40 Years","N/A","990","June 2007","July 2008","Change From Baseline of the Average Pain Intensity Overall in the 12-week Maintenance Period of the Daily Pain Intensity on an 11-point Numeric Rating Scale (NRS).","0","0","0","0","0","0","0","0","0"
"750","NCT00486954","Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer","Neoplasms, Gastrointestinal Tract",0,"Lapatinib","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","N/A","273","July 2007","January 2012","Number of Participants With Dose Limiting Toxicities (DLTs) in the Pilot Part of the Study","0","0","0","0","0","0","0","0","0"
"751","NCT00487240","Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes","Diabetes Mellitus, Type 1",0,"Insulin Lispro Protamine Suspension","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","387","June 2007","August 2008","Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint","0.332","0","ANCOVA","-0.10","Mean Difference (Net)","95","0","-0.29","0.10"
"752","NCT00487435","An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain","Pain",0,"Tapentadol (CG5503) Extended Release (ER)","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","1166","June 2007","June 2009","Number of Subjects With Treatment-emergent Adverse Events (TEAE)","0","0","0","0","0","0","0","0","0"
"753","NCT00487539","An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","Colitis, Ulcerative",0,"Placebo","Biological","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","N/A","1065","August 2007","October 2010","Number of Participants With Clinical Response at Week 6","<0.0001","0","Chi-squared","0","0","0","0","0","0"
"754","NCT00488267","Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee","Osteoarthritis",0,"ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)","Drug","ZARS Pharma Inc.","Industry",0,0,"All","18 Years","75 Years","679","June 2007","June 2008","The primary outcome measure is the change from baseline in the Visual Analog Scale score for the average pain during the previous 24 hours.","0","0","0","0","0","0","0","0","0"
"755","NCT00488319","Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.","Schizophrenia",0,"Paliperidone ER","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","12 Years","17 Years","400","June 2007","July 2012","The Number of Participants Who Experienced Adverse Events as a Measure of Safety and Tolerability","0","0","0","0","0","0","0","0","0"
"756","NCT00488514","Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents","Migraine Disorders",0,"Combination Tablet of Treximet (sumatriptan/naproxen sodium)","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","17 Years","656","July 13, 2007","August 1, 2009","Number of Participants With the Indicated Drug-related Adverse Events","0","0","0","0","0","0","0","0","0"
"757","NCT00488631","An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","Colitis, Ulcerative",0,"Placebo","Biological","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","N/A","1228","September 2007","October 2011","Number of Participants in Clinical Response Through Week 54","0.010","A fixed sequence testing procedure was employed to control the overall Type I error rate at the 0.05 level (i.e., testing golimumab 100 mg vs. placebo first, then, if positive, testing 50 mg vs. placebo).","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"758","NCT00488774","An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis","Colitis, Ulcerative",0,"Placebo","Other","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","N/A","291","August 2007","May 2009","Number of Participants With Clinical Response","0.467","0","Chi-squared","0","0","0","0","0","0"
"759","NCT00488839","IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis","Multiple Sclerosis",0,"IPX056 20 mg","Drug","IMPAX Laboratories, Inc.","Industry",0,0,"All","18 Years","N/A","173","June 2007","May 2008","Overall mean changes from predose (baseline) in total Ashworth scores of the four lower extremity muscle groups (hip adductors, knee flexors, knee extensors, and plantar flexors) of both lower limbs over 12 hours assessed hourly after dosing","0","0","0","0","0","0","0","0","0"
"760","NCT00489541","TAXUS PERSEUS Small Vessel","Coronary Artery Disease",0,"Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","224","July 2007","June 2009","In-stent Late Loss Measured by Quantitative Coronary Angiography (QCA)","<0.0001","0","t-test, 2 sided","-0.42","Mean Difference (Final Values)","95","2-Sided","-0.54","-0.30"
"761","NCT00489736","Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation","Atrial Fibrillation",0,"dronedarone (SR33589)","Drug","Sanofi","Industry",0,0,"All","21 Years","N/A","504","June 2007","October 2008","Treatment Failure","<0.0001","Cumulative incidence functions in each treatment group were calculated using time-to-event non-parametric Kaplan-Meier estimate. The primary comparison was performed at the 5% level using a 2-sided Log rank test.","Log Rank","1.59","Hazard Ratio (HR)","95","0","1.28","1.98"
"762","NCT00490035","Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","Epilepsy",0,"Placebo","Other","UCB Pharma SA","Industry",0,0,"All","16 Years","70 Years","399","September 2007","February 2009","Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period","=0.261","0","ANCOVA","6.5","Percentage Reduction over Placebo","95","2-Sided","-5.2","16.9"
"763","NCT00490854","A Study for Patients With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2",0,"Human Insulin Inhalation Powder","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","N/A","129","July 2007","May 2008","Mean change in Hemoglobin A1c (HbA1c) from baseline to the end of each treatment period of Primary Phase","0","0","0","0","0","0","0","0","0"
"764","NCT00490919","Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain","Low Back Pain",0,"Buprenorphine transdermal system","Drug","Purdue Pharma LP","Industry",0,0,"All","18 Years","N/A","539","June 2007","July 2008","Average Pain Over the Last 24 Hours Scores at Week 12 of the Double-blind Phase.",".0104","0","Mixed Models Analysis","-0.58","Mean Difference (Final Values)","95","2-Sided","-1.02","-0.14"
"765","NCT00490971","A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder","Bipolar Disorder",0,"Olanzapine","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","65 Years","768","May 2006","April 2010","Time to Recurrence of Any Mood Symptoms (Manic or Depressive) Associated With Bipolar I Disorder","0.017","The two treatment groups were compared using a weighted z-statistic based on rho-family of alpha spending function at information fraction of 85.0% at interim analysis analysis (rho=2.5) at 0.025 (1-sided) level. One-sided alpha at final was 0.0195.","Weighted Z- test","0","0","0","0","0","0"
"766","NCT00491530","A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia","Mixed Dyslipidemia",0,"ABT-335","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","310","June 2007","November 2008","Percentage of Subjects Reporting Adverse Events During Combination Therapy in the Preceding Double-Blind Studies or in the Preceding Open-Label Year 1 Study or in This Open-Label Year 2 Study","0","0","0","0","0","0","0","0","0"
"767","NCT00491608","Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis","Spinal Surgery",0,"rThrombin","Biological","ZymoGenetics","Industry",0,0,"All","18 Years","N/A","234","June 2007","July 2008","Number of Participants With Anti-recombinant Thrombin (rThrombin) Product Antibodies at Day 29 in Participants With and Without Anti-bovine Thrombin Product Antibodies at Baseline","0","0","0","0","0","0","0","0","0"
"768","NCT00491829","Flibanserin Versus Placebo in Premenopausal Women With HSDD","Sexual Dysfunctions, Psychological",0,"50 mg qhs","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","18 Years","N/A","945","June 2007","March 2009","Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary.","0","0","0","0","0","0","0","0","0"
"769","NCT00491868","Clinical Study of R744 to Hemodialysis Patients","Hemodialysis Patients",0,"R744","Drug","Chugai Pharmaceutical","Industry",0,0,"All","20 Years","N/A","134","June 2007","May 2008","Variation of Hb concentration from baseline Hb concentration in evaluation period","0","0","0","0","0","0","0","0","0"
"770","NCT00491894","Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions","Cerebral Palsy",0,"Oral Glycopyrrolate Liquid","Drug","Shionogi","Industry",0,0,"All","3 Years","18 Years","137","March 2007","May 2008","Proportion of Responders According to the Modified Teacher's Drooling Scale (mTDS)","0","0","0","0","0","0","0","0","0"
"771","NCT00492024","BAY12-8039: 5 Days for Sinusitis vs Placebo","Sinusitis",0,"Moxifloxacin (Avelox, BAY12-8039)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","374","January 2005","March 2008","Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT))","0.189","P-value is adjusted for study center; p-value applies to percentage of subjects with success (clinical cure)","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"772","NCT00492388","Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients","Pain",0,"PMI-150 (intranasal ketamine)","Drug","Hospira, now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","N/A","2","June 2007","August 2011","pain intensity difference","0","0","0","0","0","0","0","0","0"
"773","NCT00492427","Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)","Predialysis Patients",0,"R744","Drug","Chugai Pharmaceutical","Industry",0,0,"All","20 Years","N/A","187","June 2007","January 2008","Rate of patients who maintain mean Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dL","0","0","0","0","0","0","0","0","0"
"774","NCT00492557","Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults","Pneumococcal Infections",0,"13-valent pneumococcal conjugate vaccine","Biological","Pfizer","Industry",0,0,"All","65 Years","N/A","1185","September 2007","February 2008","TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)","0","0","0","1.7","Percent Difference","95","2-Sided","-3.1","6.5"
"775","NCT00492596","The AttenueX IntraVesical System for the Treatment of Female Stress Urinary Incontinence","Urinary Incontinence, Stress",0,"AttenueX IntraVesical System","Device","Solace Therapeutics, Inc.","Industry",0,0,"Female","18 Years","N/A","166","June 2006","April 2011","Stamey Grade","0","0","0","0","0","0","0","0","0"
"776","NCT00492726","Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem","Infection",0,"Moxifloxacin (Avelox, BAY12-8039)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","804","July 2006","February 2009","Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population","0","0","0","-3.8","Difference of cure rates (in percent)","95","0","-7.9","0.4"
"777","NCT00492986","An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma","Carcinoma, Renal Cell",0,"Nexavar (Sorafenib, BAY43-9006)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","1150","October 2005","November 2008","Safety Parameters","0","0","0","0","0","0","0","0","0"
"778","NCT00494013","Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)","Diabetes Mellitus Type 2",0,"Insulin Lispro Protamine Suspension","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","442","August 2007","September 2008","Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c)","0.026","0","ANCOVA","-0.21","Mean Difference (Net)","95","0","-0.39","-0.03"
"779","NCT00494299","Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)","Carcinoma, Hepatocellular",0,"Sorafenib (Nexavar, BAY43-9006)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","458","April 2006","July 2009","Time to Progression (TTP)","0","0","0","0.25204620","Log Rank","0","0","0","0"
"780","NCT00494871","Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation","Atrial Fibrillation",0,"Rivaroxaban (Xarelto, BAY59-7939)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","1280","June 2007","December 2009","Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding","0.025","0","Regression, Cox","1.11","Hazard Ratio (HR)","95","2-Sided","0.87","1.42"
"781","NCT00495885","Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus","Sleep Initiation and Maintenance Disorders",0,"volinanserin (M100907)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","848","June 2007","October 2008","change from baseline to 12 weeks for Sleep Maintenance Insomnia using patient reported Wake After Sleep Onset (pr-WASO)","0","0","0","0","0","0","0","0","0"
"782","NCT00496392","Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)","Pain",0,"Nasal fentanyl","Drug","Nycomed","Industry",0,0,"All","18 Years","N/A","115","January 2007","August 2008","Primary endpoint: Time to onset of meaningful pain relief recorded by stopwatch","0","0","0","0","0","0","0","0","0"
"783","NCT00496769","A Phase III Study of Apixaban in Patients With Atrial Fibrillation","Atrial Fibrillation",0,"Apixaban","Drug","Bristol-Myers Squibb","Industry",0,0,"All","50 Years","N/A","6421","August 2007","November 2010","Event Rate of Stroke/Systemic Embolism During the Intended-treatment Period","<0.00001","0","Log Rank","0.45","Hazard Ratio (HR)","95","2-Sided","0.32","0.62"
"784","NCT00496847","Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect","Intrabony Periodontal Defect",0,"PERIOGEN","Drug","Virchow Group","Industry",0,0,"All","25 Years","75 Years","60","August 2007","August 2008","1.Area under curve (AUC) of clinical attachment level (CAL) gain (0-24 weeks) 2.Extent of linear bone growth (LBG) and percentage of bone fill (%BF) at 6 months.","0","0","0","0","0","0","0","0","0"
"785","NCT00497146","The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4","Chronic Kidney Disease",0,"paricalcitol","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","227","February 2008","September 2010","Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI)","0.145","0","Mixed Models Analysis","0","0","0","0","0","0"
"786","NCT00497237","Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma","Asthma",0,"Beclomethasone plus formoterol fixed combination","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","18 Years","65 Years","382","April 2007","March 2010","Morning pre-dose PEF measured daily by patients (mean of the last 2 weeks of treatment period).","0","0","0","0","0","0","0","0","0"
"787","NCT00497796","Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients","Cytomegalovirus Infections",0,"maribavir","Drug","Shire","Industry",0,0,"All","18 Years","N/A","307","July 2007","May 2009","Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation","0","0","0","0.041","Rate difference","95","2-Sided","-0.038","0.119"
"788","NCT00498225","Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer","Pancreatic Cancer",0,"Gemcitabine plus TS-1","Drug","Taiho Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","79 Years","834","July 2007","July 2011","Over all survival(OS)","0","0","0","0","0","0","0","0","0"
"789","NCT00499590","Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD","Macular Degeneration",0,"bevasiranib","Drug","OPKO Health, Inc.","Industry",0,0,"All","50 Years","N/A","338","August 2007","March 2009","Visual Acuity","0","0","0","0","0","0","0","0","0"
"790","NCT00499863","Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD","ADHD",0,"methylphenidate transdermal system","Drug","Noven Therapeutics","Industry",0,0,"All","13 Years","17 Years","217","July 2007","May 2008","Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Endpoint","< 0.001","0","ANCOVA","0","0","0","0","0","0"
"791","NCT00500084","Phase III ALTU-135 CP Safety Trial","Exocrine Pancreatic Insufficiency",0,"Liprotamase","Drug","Anthera Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","39","December 2007","March 2009","Number of participants with an adverse event","0","0","0","0","0","0","0","0","0"
"792","NCT00500266","Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects","Pneumococcal Infections",0,"13-valent Pneumococcal Conjugate Vaccine (13vPnC)","Biological","Pfizer","Industry",0,0,"All","68 Years","N/A","1053","May 2008","April 2009","Percentage of Participants With Pre-specified Local Reactions","0","0","0","0","0","0","0","0","0"
"793","NCT00500357","Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects","Vaccines, Pneumococcal Conjugate Vaccine",0,"13-valent Pneumococcal Conjugate Vaccine","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","65 Years","N/A","105","November 2007","January 2010","Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)","0","0","0","0.4","geometric mean fold rise","95","2-Sided","0.28","0.56"
"794","NCT00500656","Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)","Hereditary Angioedema",0,"Icatibant","Drug","Shire","Industry",0,0,"All","18 Years","N/A","85","March 2005","March 2008","Time to Onset of Symptom Relief.","< 0.001","0","The Wilcoxon version of the log rank","3.475","Hazard Ratio (HR)","95","2-Sided","1.901","6.355"
"795","NCT00500682","A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)","Chronic Kidney Disease",0,"Placebo","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","18 Years","N/A","1020","July 2007","October 2011","Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported.","0","0","0","0","0","0","0","0","0"
"796","NCT00501046","A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)","Chronic Kidney Disease",0,"Placebo","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","18 Years","N/A","1015","July 2007","October 2011","Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported.","0","0","0","0","0","0","0","0","0"
"797","NCT00501293","Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD","ADHD",0,"Methylphenidate Transdermal System","Drug","Noven Therapeutics","Industry",0,0,"All","13 Years","17 Years","163","August 2007","February 2009","Systolic Blood Pressure","0.028","0","t-test, 2 sided","0","0","0","0","0","0"
"798","NCT00501371","MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia","Benign Prostatic Hyperplasia",0,"MCS","Drug","Health Ever Bio-Tech Co., Ltd.","Industry",0,0,"Male","40 Years","N/A","85","July 2007","October 2009","MCS-2: To compare changes in I-PSS points after 12 weeks of MCS or placebo supplementation.","0","0","0","0","0","0","0","0","0"
"799","NCT00501631","ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence","Alcohol Dependence",0,"VIVITROL 380 mg","Drug","Alkermes, Inc.","Industry",0,0,"All","18 Years","65 Years","300","July 2007","January 2011","Cumulative Percentage of Participants by Heavy Drinking Rate","0.336","0","Van der Waerden test","0","0","0","0","0","0"
"800","NCT00501969","An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease","Advanced Stage Parkinson's Disease",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","31 Years","N/A","395","August 2004","December 2008","Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","0","0","0","0","0","0","0","0","0"
"801","NCT00502086","Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.","Cirrhosis",0,"Viusid (nutritional supplement)","Dietary Supplement","Catalysis SL","Industry",0,0,"All","18 Years","70 Years","100","May 2005","July 2009","The mortality secondary to liver failure at 96 weeks.","0","0","0","0","0","0","0","0","0"
"802","NCT00503399","Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis","Osteoporosis",0,"Teriparatide","Drug","Eli Lilly and Company","Industry",0,0,"Male","25 Years","N/A","92","July 2007","October 2010","Change From Baseline in Lumbar Spine Volumetric Trabecular Bone Mineral Density (BMD) by Quantitative Computerized Tomography (QCT) at 18 Months","0","0","0","0","0","0","0","0","0"
"803","NCT00503516","Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients","Dementia",0,"Megestrol acetate","Drug","Rottapharm Spain","Industry",0,0,"All","65 Years","95 Years","39","June 2007","December 2009","To evaluate the change in the body weight","0","0","0","0","0","0","0","0","0"
"804","NCT00503698","The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis","Chronic Kidney Disease",0,"somatropin","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","712","July 2007","December 2008","Mortality - Time to All-cause Death","0.91","0","Regression, Cox","0.97","Cox Proportional Hazard","95","2-Sided","0.60","1.57"
"805","NCT00504127","Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee","Osteoarthritis",0,"Naproxcinod 375 mg bid","Drug","NicOx","Industry",0,0,"All","40 Years","N/A","1020","April 2007","December 2008","To show that both doses of Naproxcinod (375 mg twice daily [bid] and 750 mg bid) were superior to placebo in relieving osteoarthritis (OA) signs and symptoms in subjects with OA of the knee at Week 13.","0","0","0","0","0","0","0","0","0"
"806","NCT00504881","Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy","Epilepsy",0,"Placebo","Drug","UCB Pharma SA","Industry",0,0,"All","16 Years","70 Years","480","October 2007","November 2008","Percentage of Subjects With at Least One Adverse Event During the 16-week Treatment Period","0","0","0","0","0","0","0","0","0"
"807","NCT00505284","An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy","Diabetic Neuropathy",0,"Placebo","Drug","Eisai Inc.","Industry",0,0,"All","18 Years","N/A","352","June 2007","July 2008","Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT)","0","0","0","0","0","0","0","0","0"
"808","NCT00505414","A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine","Pain",0,"Tapentadol in the Titration Phase","Drug","Grünenthal GmbH","Industry",0,0,"All","18 Years","N/A","136","June 2007","February 2009","Responder Rates in Maintenance Period","0","0","0","0","0","0","0","0","0"
"809","NCT00505687","An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease","Idiopathic Parkinson's Disease",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","31 Years","N/A","186","February 2005","December 2008","Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","0","0","0","0","0","0","0","0","0"
"810","NCT00505778","A Comparison of Once a Day Dose Compared to 2 Doses/Day","Ulcerative Colitis",0,"Mesalamine Once-Daily","Drug","Warner Chilcott","Industry",0,0,"All","18 Years","N/A","1027","July 2007","July 2009","Percentage of Patients Remaining in Remission at Month 6, ITT Population, Determined by the Simple Clinical Colitis Activity Index (SCCAI)","0.5016","0","Cochran-Mantel-Haenszel","1.3","BID-QD Difference in Remission Rates","95","2-Sided","-2.3","4.9"
"811","NCT00506389","A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)","Insomnia",0,"Esmirtazapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","419","June 2007","February 2008","Average Wake Time After Sleep Onset (WASO) During the In-Treatment Period","0","0","0","0","0","0","0","0","0"
"812","NCT00506441","A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia","Chronic Kidney Disease",0,"MCI-196","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","18 Years","N/A","245","September 2007","September 2009","The Change in Serum Phosphorus From Week 12 to Week 16","0","0","0","0","0","0","0","0","0"
"813","NCT00506493","Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent","Atrial Fibrillation",0,"Cardioblate Surgical Ablation System","Device","Medtronic Cardiovascular","Industry",0,0,"All","18 Years","N/A","75","September 2007","July 2011","Efficacy Endpoint: The Percent of Patients Off Class I or III Antiarrhythmic Drugs and Out of AF as Determined by 24 Hour Holter Recording at 9 Months","<0.01","The percent of patients off Class I and III AADs and successfully converted out of AF following treatment (ptest) will exceed the percent of patients off Class I and III AADs and convereted out of AF, as reported in literature (pcontrol=22.1%)","Fisher Exact","42.6","Binomial Proportions","97.5","1-Sided","30.0","0"
"814","NCT00507026","Efficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery","Postoperative Pain",0,"IV Diclofenac","Drug","Javelin Pharmaceuticals","Industry",0,0,"All","18 Years","85 Years","277","July 2007","December 2008","Sum of the pain intensity differences (SPID) over 0-24, 0-48, 0-72, 0-96 and 0-120 hour time intervals.","0","0","0","0","0","0","0","0","0"
"815","NCT00507429","Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer","Anaplastic Thyroid Cancer",0,"CA4P","Drug","Mateon Therapeutics","Industry",0,0,"All","18 Years","N/A","80","August 2007","October 2011","Overall Survival","0.223","0","Log Rank","0","0","0","0","0","0"
"816","NCT00508495","Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-Containing Solutions in Post-Surgical Hip Replacement Pain","Pain, Postoperative",0,"Paracetamol (acetaminophen)","Drug","Baxter Healthcare Corporation","Industry",0,0,"All","18 Years","75 Years","148","August 2007","March 2008","Amount of PCA-administered morphine consumed during first six hours of study drug treatment","0","0","0","0","0","0","0","0","0"
"817","NCT00508742","Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization","Pneumococcal Infections",0,"13-valent Pneumococcal Conjugate Vaccine","Biological","Pfizer","Industry",0,0,"All","42 Days","98 Days","1866","December 2007","August 2011","Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age","0","0","0","0.56","Rate Ratio","95","2-Sided","0.47","0.65"
"818","NCT00509028","Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma","Asthma",0,"Budesonide","Drug","AstraZeneca","Industry",0,0,"All","5 Years","15 Years","241","December 2006","October 2008","Number of Patients With Adverse Events (AEs).","0","0","0","0","0","0","0","0","0"
"819","NCT00509106","Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia","Bacterial Pneumonia",0,"Ceftaroline fosamil for Injection","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","622","July 2007","August 2008","Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at the Test of Cure (TOC) in the Modified Intent to Treat Efficacy (MITTE) Population","0","0","0","5.9","Risk Difference (RD)","95","2-Sided","-1.0","12.7"
"820","NCT00509145","Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)","Multiple Sclerosis",0,"Laquinimod","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","18 Years","55 Years","1106","December 2007","November 2010","Relapse Rate: Number of confirmed relapses during the double blind study period.","0","0","0","0","0","0","0","0","0"
"821","NCT00509236","Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)","Diabetes Mellitus, Type 2",0,"Sitagliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","30 Years","N/A","129","October 19, 2007","March 14, 2011","Change From Baseline in Hemoglobin A1c After Sitagliptin Treatment","<0.001","0","ANCOVA","0","0","0","0","0","0"
"822","NCT00509262","Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)","Diabetes Mellitus, Type 2",0,"Sitagliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","30 Years","N/A","426","October 9, 2007","March 16, 2011","Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 54","0","0","0","-0.11","Difference in least squares mean","95","2-Sided","-0.29","0.06"
"823","NCT00509639","Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease","Crohn's Disease",0,"10% Metronidazole Ointment","Drug","S.L.A. Pharma AG","Industry",0,0,"All","18 Years","N/A","74","May 2005","February 2008","To evaluate the effect of 10% metronidazole ointment, applied topically three times a day, in and around the anus, on the change in perianal Crohn's disease activity.","0","0","0","0","0","0","0","0","0"
"824","NCT00509795","Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","Macular Degeneration",0,"ranibizumab","Biological","Regeneron Pharmaceuticals","Industry",0,0,"All","50 Years","N/A","1217","August 2007","September 2010","Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)","0","0","0","-0.7","Risk Difference (RD)","95.1","2-Sided","-4.4","3.1"
"825","NCT00510068","Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors","Advanced Neuroendocrine Tumors of Pancreatic Origin",0,"Everolimus","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","410","July 2007","February 2010","Time to Progression Free Survival (PFS) Based as Per Investigator Using Kaplan-Meier Methodology","0","0","0","0","0","0","0","0","0"
"826","NCT00510146","Olanzapine Treatment of Patients With Bipolar I Disorder","Depression, Bipolar",0,"Olanzapine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","64 Years","514","August 2007","March 2010","Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase)","0.018","p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in MADRS total score from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.","ANCOVA","-2.15","Mean Difference (Final Values)","95","2-Sided","-3.93","-0.36"
"827","NCT00510484","Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis","Cystic Fibrosis",0,"Pancrelipase Delayed Release","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","35","November 2007","March 2008","Coefficient of Fat Absorption (%)","<0.001","0","ANOVA","0","0","0","0","0","0"
"828","NCT00510692","Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA","Familial Adenomatous Polyposis Coli",0,"Eicosapentanoic Acid (EPA)","Drug","S.L.A. Pharma AG","Industry",0,0,"All","18 Years","N/A","58","November 2006","April 2008","Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum.","0.005","0","ANCOVA","-1.06","Mean Difference (Net)","95","2-Sided","-1.78","-0.35"
"829","NCT00510952","Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)","Diabetes Mellitus, Type 2",0,"Insulin Lispro Protamine Suspension","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","471","August 2007","October 2008","Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c)","0.551","P-value for Change from Baseline.","ANCOVA","-0.05","Mean Difference (Net)","95","0","-0.21","0.11"
"830","NCT00511199","Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)","Contraception",0,"NOMAC-E2","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","50 Years","2152","May 2006","April 2008","Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)","0","0","0","0","0","0","0","0","0"
"831","NCT00511342","Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)","Contraception",0,"NOMAC-E2","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","20 Years","35 Years","110","September 2006","June 2009","Mean Change From Baseline in Z-scores of the Lumbar Spine (L2-L4) and Femoral Neck","0","0","0","0","0","0","0","0","0"
"832","NCT00511355","Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)","Contraception",0,"NOMAC-E2","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","50 Years","121","October 2006","January 2008","Serum Concentration of Prothrombin Fragments 1 + 2","0.0849","No correction for multiple testing was made.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"833","NCT00511433","Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)","Contraception",0,"NOMAC-E2","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","35 Years","48","October 2006","January 2008","Effect on Ovarian Function as Determined by the Number of Participants With an Occurrence of Ovulation","0","0","0","0","0","0","0","0","0"
"834","NCT00511797","SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study","Dysmenorrhea",0,"SH T04740B","Drug","Bayer","Industry",0,0,"Female","20 Years","N/A","249","July 2007","January 2009","Change From Baseline in Total Dysmenorrheal Score at Final Evaluation","<0.001","Pre-defined sequential tests were applied to protect alpha inflation by multiplicity.","t-test, 1 sided","-0.92","Median Difference (Final Values)","95","2-Sided","-1.49","-0.34"
"835","NCT00512135","Safety and Efficacy of IncobotulinumtoxinA (Xeomin) in the Treatment of Glabellar Frown Lines","Glabellar Lines",0,"IncobotulinumtoxinA (Xeomin) (20 units)","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","N/A","796","June 2007","December 2009","- Safety endpoints - Investigator's assessment - Patient's assessment","0","0","0","0","0","0","0","0","0"
"836","NCT00513370","A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis","Psoriasis",0,"Humira (adalimumab)","Biological","Abbott","Industry",0,0,"All","18 Years","N/A","203","September 2007","September 2008","Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks","0","0","0","0","0","0","0","0","0"
"837","NCT00513682","Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)","Cystic Fibrosis",0,"Ultrase® MT20","Drug","Forest Laboratories","Industry",0,0,"All","7 Years","11 Years","9","July 2007","March 2008","Percent Coefficient of Fat Absorption (CFA)","0.0013","0","t-test, 1 sided","0","0","0","0","0","0"
"838","NCT00514709","Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants","Diphtheria",0,"DTaP-HB PRP~T Combined Vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","12 Months","18 Months","1843","September 2007","December 2008","Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV)","0","0","0","0","0","0","0","0","0"
"839","NCT00514735","Tailored Treatment of Permanent Atrial Fibrillation","Atrial Fibrillation",0,"Medtronic Cardiac Ablation System","Procedure","Medtronic Atrial Fibrillation Solutions","Industry",0,0,"All","18 Years","70 Years","210","May 2007","November 2010","Chronic Effectiveness","<0.0001","In order to maintain the overall level of significance at the α=0.025 level after a planned interim analysis using α=0.003, this test will actually be performed using an adjusted α=0.0245 at the completion of the study.","Chi-squared","0","0","0","0","0","0"
"840","NCT00514917","A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)","Prostatic Neoplasms",0,"Docetaxel","Drug","Sanofi","Industry",0,0,"Male","18 Years","N/A","413","July 2007","September 2012","Median Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population","0.0501","A priori threshold for statistical significance = 0.05","Log Rank","1.29","Hazard Ratio (HR)","95","2-Sided","1.00","1.65"
"841","NCT00515320","Study of Fluoxetine in Autism","Autistic Disorder",0,"Fluoxetine","Drug","Neuropharm","Industry",0,0,"All","5 Years","17 Years","158","August 2007","January 2009","The percentage change from baseline to the endpoint visit for the CYBOCS-PDD score.","0","0","0","0","0","0","0","0","0"
"842","NCT00515450","Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis","Generalized Myasthenia Gravis",0,"GB-0998 (Intravenous immunoglobulin)","Biological","Benesis Corporation","Industry",0,0,"All","16 Years","N/A","46","July 2007","May 2010","Changes in QMG score","0","0","0","0","0","0","0","0","0"
"843","NCT00515619","Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures","Epilepsy",0,"Lacosamide","Drug","UCB Pharma","Industry",0,0,"All","16 Years","70 Years","376","December 2004","August 2010","Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) During the Treatment Period (up to 5.5 Years)","0","0","0","0","0","0","0","0","0"
"844","NCT00516048","An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","20 Years","N/A","58","August 2007","April 2008","Treatment-emergent Antibody Status (Maximum Titer Level Experienced)","0","0","0","0","0","0","0","0","0"
"845","NCT00516074","A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","18 Years","75 Years","54","September 2007","April 2008","Change in Mean 24-hour Heart Rate From Baseline to Endpoint","0.1585","0","ANCOVA","0","0","0","0","0","0"
"846","NCT00516139","Lamotrigine Extended-Release In Elderly Patients With Epilepsy","Epilepsy",0,"Lamotrigine","Drug","GlaxoSmithKline","Industry",0,0,"All","65 Years","N/A","122","August 2007","July 2010","Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event","0","0","0","0","0","0","0","0","0"
"847","NCT00516321","Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease","Hepatitis C, Chronic",0,"eltrombopag","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","687","October 2007","April 2011","Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase","0.0064","Stratified Cochran-Mantel-Haenszel (CMH) chi-square test adjusted for the randomization strata","Cochran-Mantel-Haenszel","7.9","Percentage difference in SVR","95","2-Sided","2.4","13.4"
"848","NCT00517881","Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia","Anemia",0,"Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)","Drug","Hoffmann-La Roche","Industry",0,0,"All","18 Years","N/A","29","June 2007","November 2009","Percentage of Participants Maintaining Mean Hemoglobin Concentration Within Plus or Minus (+/-) 1 Gram Per Deciliter (g/dL) of Their Reference Hemoglobin and Within the Target Range","0","0","0","0","0","0","0","0","0"
"849","NCT00518180","A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents","Meningococcal Meningitis",0,"Novartis Meningococcal ACWY Conjugate Vaccine","Biological","Novartis Vaccines","Industry",0,0,"All","11 Years","18 Years","1620","July 2007","April 2008","Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Seroresponse","0","0","0","-2","Vaccine Group differences (%)","95","2-Sided","-6","3"
"850","NCT00518687","Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)","Staphylococcus Aureus",0,"V710","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","8031","December 2007","August 2011","Number of Participants With Staphylococcus Aureus Bacteremia and/or Deep Sternal Wound Infection","0.584","A 1-sided p-value <0.025 implies that the V710 vaccine efficacy is statistically significantly greater than 20%","Exact 1-sided binomial test","18.5","Vaccine Efficacy (VE)","95","2-Sided","-48.6","55.8"
"851","NCT00518713","Clobazam in Patients With Lennox-Gastaut Syndrome","Epilepsy",0,"Clobazam Low Dose","Drug","Lundbeck LLC","Industry",0,0,"All","2 Years","60 Years","238","August 2007","December 2009","Percent Reduction in Number of Drop Seizures (12-week Maintenance Period).","0.0120","0","ANCOVA","0","0","0","0","0","0"
"852","NCT00518869","Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue","Quality of Life",0,"PG2","Drug","PhytoHealth Corporation","Industry",0,0,"All","17 Years","75 Years","210","September 2007","June 2008","Clinical Benefit Response","0","0","0","0","0","0","0","0","0"
"853","NCT00518882","Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes","Diabetes",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","80 Years","467","August 2007","April 2008","Change in Glycosylated A1c (HbA1c) at Week 26","<.0001","No multiplicity concerns","ANCOVA","-0.33","Estimated treatment difference, LS Mean","95","0","-0.47","-0.18"
"854","NCT00518895","Trial of Dacarbazine With or Without Genasense in Advanced Melanoma","Melanoma",0,"dacarbazine plus Genasense","Drug","Genta Incorporated","Industry",0,0,"All","18 Years","N/A","300","July 2007","May 2011","Progression-free survival and overall survival","0","0","0","0","0","0","0","0","0"
"855","NCT00519090","Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","Myelogenous Leukemia",0,"Imatinib","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","6","October 2007","October 2008","Complete Cytogenetic Response Rate(CCyR) in Patients Who Had a Suboptimal Cytogenetic Response on Imatinib","0","0","0","0","0","0","0","0","0"
"856","NCT00519142","Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2",0,"placebo for mitiglinide","Drug","Elixir Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","367","August 2007","October 2008","change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"857","NCT00519285","Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer","Prostatic Neoplasms",0,"Aflibercept","Drug","Sanofi","Industry",0,0,"Male","18 Years","N/A","1224","August 2007","April 2012","Overall Survival Time","0.3802","A priori threshold for statistical significance was set to 0.044 using the O'Brien-Fleming alpha spending function to account for two interim analyses.","Log Rank","0.942","Hazard Ratio (HR)","95.6","2-Sided","0.822","1.08"
"858","NCT00519532","Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease","Parkinson's Disease",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","18 Years","N/A","84","July 2007","May 2009","Change From Baseline in UPDRS III Score at Week 13 (End of Maintenance)","0","0","0","0","0","0","0","0","0"
"859","NCT00520676","Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer",0,"pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","260","October 2007","July 2010","Survival Without Grade 3 or 4 Toxicity","<0.001","The comparison was conducted at a 1-sided significance level of 0.05.","Log Rank","0.45","Hazard Ratio (HR)","95","2-Sided","0.34","0.60"
"860","NCT00520741","Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures","Epilepsy",0,"Lacosamide","Drug","UCB BIOSCIENCES, Inc.","Industry",0,0,"All","16 Years","70 Years","426","August 2007","December 2012","Percentage of Subjects (Using Kaplan-Meier) Who Are Identified As Meeting At Least 1 Pre-defined Exit Criteria By Day 112 Relative To The Start of Withdrawal of Background Antiepileptic Drug(s)","0","0","0","0.300","Predicted exit rate at 112 days","95","2-Sided","0.246","0.355"
"861","NCT00520780","Ferinject® Assessment in Patients With IRon Deficiency and Chronic Heart Failure (FAIR-HF)","Chronic Heart Failure",0,"Ferinject ® (Ferric carboxymaltose)","Drug","Vifor Inc.","Industry",0,0,"All","18 Years","N/A","456","April 2007","July 2009","Self-reported patient global assessment (PGA) and NYHA functional status 24 weeks after initiation of therapy","0","0","0","0","0","0","0","0","0"
"862","NCT00520806","Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure","Heart Failure, Congestive",0,"Relaxin","Drug","Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies","Industry",0,0,"All","18 Years","N/A","1161","October 2007","September 2012","Relief of dyspnea in acute heart failure","0","0","0","0","0","0","0","0","0"
"863","NCT00521924","Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)","Rheumatoid Arthritis",0,"infliximab","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","19 Years","65 Years","8","June 2007","April 2008","Number of Patients in Remission According to Disease Activity Score (DAS) 28 (< 2.6)","0","0","0","0","0","0","0","0","0"
"864","NCT00521937","Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer","Diabetes",0,"Dermagen®","Other","Laboratoires Genévrier","Industry",0,0,"All","18 Years","N/A","388","January 2009","June 2010","Complete wound closure at week 12","0","0","0","0","0","0","0","0","0"
"865","NCT00522041","A Study to Determine the Effect of Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With Chronic Anal Fissures","Fissure in Ano",0,"Cellegesic","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","75 Years","248","August 2007","July 2008","Change From Baseline in Pain Intensity at Days 14-18","0","0","0","0","0","0","0","0","0"
"866","NCT00522275","Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures","Partial Epilepsies",0,"lacosamide","Drug","UCB BIOSCIENCES, Inc.","Industry",0,0,"All","16 Years","70 Years","308","October 2004","October 2009","Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (Maximum 6 Years)","0","0","0","0","0","0","0","0","0"
"867","NCT00522379","Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch","Parkinson's Disease",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","30 Years","N/A","514","July 2007","July 2011","The Change in the Absolute Time Spent ""Off"" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary","0","0","0","0","0","0","0","0","0"
"868","NCT00522834","Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma","Melanoma",0,"Elesclomol (STA-4783)","Drug","Synta Pharmaceuticals Corp.","Industry",0,0,"All","18 Years","N/A","630","August 2007","June 2009","Progression free survival","0","0","0","0","0","0","0","0","0"
"869","NCT00522873","Endometrial Safety Study","Postmenopause",0,"0.25mg DRSP / 0.5mg E2 (BAY86-4891)","Drug","Bayer","Industry",0,0,"Female","40 Years","65 Years","662","August 2007","August 2009","Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment)","0","0","0","0.0000","proportion","95","2-Sided","0.0000","0.0119"
"870","NCT00522951","SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study","Brain Metastases",0,"Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","165","August 2007","August 2008","Number of Lesions Detected by Blinded Readers (BR) and Investigator","0","0","0","-0.58","Mean Difference (Final Values)","95","0","-0.87","-0.29"
"871","NCT00523042","Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma","Diabetes",0,"insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","10","August 30, 2007","February 28, 2008","Changes in lung function, chest X-rays, or asthma exacerbation frequency","0","0","0","0","0","0","0","0","0"
"872","NCT00523107","PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care","Fatigue",0,"PG2","Drug","PhytoHealth Corporation","Industry",0,0,"All","N/A","N/A","91","August 2007","January 2008","The fatigue improvement response rate among patients between two study arms will be compared as the basis for efficacy evaluation at the end of the first treatment cycle.","0","0","0","0","0","0","0","0","0"
"873","NCT00523211","Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)","HIV Infections",0,"Vicriviroc","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","16 Years","N/A","506","July 2007","June 2009","Proportion of subjects with undetectable plasma HIV-1 RNA (<50 copies/mL)","0","0","0","0","0","0","0","0","0"
"874","NCT00523978","A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation","Paroxysmal Atrial Fibrillation",0,"Arctic Front® Cryoablation Catheter","Device","Medtronic Atrial Fibrillation Solutions","Industry",0,0,"All","18 Years","75 Years","245","October 2006","August 2010","Acute Procedural Success (APS)","0","0","0","0","0","0","0","0","0"
"875","NCT00524030","Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures","Epilepsies, Partial",0,"pregabalin 600 mg/day","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","161","September 2007","April 2011","Percentage of Participants in the Pregabalin 600 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria","<0.001","0","Wald Test","0","0","0","0","0","0"
"876","NCT00524368","A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)","Human Immunodeficiency Virus - Type 1",0,"Darunavir (DRV)","Drug","Tibotec Pharmaceuticals, Ireland","Industry",0,0,"All","18 Years","N/A","590","October 2007","August 2009","Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm","<0.001","0","Regression, Logistic","0.0019","Difference in proportion of response","95","2-Sided","-0.054","0.092"
"877","NCT00524758","Oculusgen (Ologen) Glaucoma MMC Control in Estonia","Open Angle Glaucoma",0,"ologen (oculusgen) collagen matrix","Device","Pro Top & Mediking Company Limited","Industry",0,0,"All","19 Years","N/A","20","July 2007","October 2011","IOP <21mmHg without anti glaucoma medication","0","0","0","0","0","0","0","0","0"
"878","NCT00525265","A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","Cardiac Edema",0,"OPC-41061(Tolvaptan)","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","85 Years","20","September 2007","January 2009","Body Weight","0","0","0","0","0","0","0","0","0"
"879","NCT00525577","ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study","Diabetes",0,"Placebo","Drug","AtheroGenics","Industry",0,0,"All","18 Years","75 Years","1012","August 2007","June 2008","Change from baseline in HbA1c to the 6-month time point is identical in the study groups (placebo and AGI-1067 treatment groups)","0","0","0","0","0","0","0","0","0"
"880","NCT00525798","A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D","Osteoporosis",0,"SMC021 Oral calcitonin","Drug","Nordic Bioscience A/S","Industry",0,0,"Female","55 Years","85 Years","4665","March 2007","August 2011","Number of Patients With New Vertebral Fractures","0","0","0","0","0","0","0","0","0"
"881","NCT00525941","An Exploratory Study of NBI-34060 Capsules and Next Day Functioning","Insomnia",0,"NBI-34060","Drug","Neurocrine Biosciences","Industry",0,0,"All","18 Years","64 Years","0","September 2007","January 2008","Assessments of Next-Day Function","0","0","0","0","0","0","0","0","0"
"882","NCT00526188","Efficacy and Safety of Primovist in Chinese Patients","Known or Suspected Focal Liver Lesions",0,"Gadoxetic Acid Disodium (Primovist, BAY86-4873)","Drug","Bayer","Industry",0,0,"All","18 Years","75 Years","234","August 2007","August 2008","Difference in Sensitivity of Lesion Detection in MRI Images (Post-contrast MRI Minus Pre-contrast MRI) Measured as Percentage Points","0","0","0","9.46","Mean Difference (Final Values)","95","0","6.00","12.93"
"883","NCT00526474","Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)","Atherosclerosis",0,"Vorapaxar","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","26449","September 1, 2007","December 1, 2011","Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, or Urgent Coronary Revascularization (UCR) Within 3 Years From Randomization","0.001","0","Cox Proportional Hazards Regression","0.88","Cox Proportional Hazard","95","2-Sided","0.82","0.95"
"884","NCT00526760","Long-term Clinical Study Evaluating the Safety and Efficacy of Dexmedetomidine in ICU Subjects","Sedation",0,"Dexmedetomidine","Drug","Hospira, now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","20 Years","N/A","80","October 2007","June 2008","Incidence rate of adverse drug reactions of hypotension, hypertension and bradycardia which correspond to the protocol definitions","0","0","0","0","0","0","0","0","0"
"885","NCT00527072","PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept","Psoriasis",0,"infliximab","Biological","Centocor Ortho Biotech Services, L.L.C.","Industry",0,0,"All","18 Years","75 Years","217","July 2007","May 2009","Number of Patients Who Achieve a Physician Global Assessment (PGA) Score of Minimal (1) or Clear (0)","0.05","0","exact binomial distribution","0.654","Proportion","95","2-Sided","0.586","0.718"
"886","NCT00527397","Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes","Diabetes Mellitus, Type 2",0,"CP-464,005","Drug","Pfizer","Industry",0,0,"All","16 Years","75 Years","24","August 2007","July 2008","Self-Monitoring Blood Glucose Levels: Change From Baseline","0","0","0","0","0","0","0","0","0"
"887","NCT00527514","Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension","Hypertension",0,"Amlodipine","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","N/A","185","September 2007","April 2008","Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring","<0.0001","No multiplicity adjustments","one-sample t-test","0","0","0","0","0","0"
"888","NCT00527605","Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Hyperplasia",0,"Dutasteride 0.5mg capsule","Drug","GlaxoSmithKline","Industry",0,0,"Male","50 Years","N/A","253","October 2007","March 2009","Percent Change From Baseline in the Prostate Volume at Month 6","<0.0001","0","t-test, 2 sided","-14.23","Median Difference (Final Values)","95","0","-20.23","-8.22"
"889","NCT00527787","Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","Gastric Ulcer",0,"PN400 (VIMOVO)","Drug","POZEN","Industry",0,0,"All","18 Years","N/A","434","September 2007","October 2008","Number of Participants With Gastric Ulcer Confirmed by Endoscopy","0.001","0","Cochran-Mantel-Haenszel","4.1","proportions","95","2-Sided","1.9","7.7"
"890","NCT00527904","A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)","Gastric Ulcer",0,"PN400 (VIMOVO)","Drug","POZEN","Industry",0,0,"All","18 Years","N/A","239","March 2007","March 2009","Number of Subjects Monitored for Long-term Safety of PN 400","0","0","0","0","0","0","0","0","0"
"891","NCT00527943","Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)","Atherosclerosis",0,"Vorapaxar","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","12944","December 1, 2007","July 1, 2011","Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular Death, Myocardial Infarction, Stroke, Recurrent Ischemia With Re-hospitalization, and/or Urgent Coronary Revascularization Within 2 Years From Randomization","0.072","0","Cox Proportional Hazards Regression","0.92","Cox Proportional Hazard","95","2-Sided","0.85","1.01"
"892","NCT00528112","Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study","Contraception",0,"LCS12","Drug","Bayer","Industry",0,0,"Female","18 Years","35 Years","2885","August 2007","July 2011","Pearl Index up to 3 Years","0","0","0","0.009","failure rate","95","2-Sided","0.005","0.017"
"893","NCT00528372","A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","77 Years","1067","September 2007","February 2009","Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1C (HbA1c) (Last Observation Carried Forward [LOCF]): Group 1","0.0207","Tested at alpha=0.019, applying the Dunnett adjustment","ANCOVA","-0.35","Mean Difference (Final Values)","0","0","0","0"
"894","NCT00528424","AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease","Advanced Dupuytren's Disease",0,"AA4500","Biological","Endo Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","286","December 2007","November 2008","Reduction in Contracture to 5° or Less","0","0","0","0","0","0","0","0","0"
"895","NCT00528606","AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture","Dupuytren's Contracture",0,"collagenase clostridium histolyticum","Biological","Endo Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","308","August 2007","April 2008","Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"896","NCT00528723","Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma","Bronchial Asthma",0,"salbutamol 100 mcg","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","18 Years","64 Years","180","November 2007","January 2009","Mean value of morning PEF (daily measured by the patient)","0","0","0","0","0","0","0","0","0"
"897","NCT00528840","Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease","Advanced Dupuytren's Disease",0,"collagenase clostridium histolyticum","Biological","Endo Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","201","October 2007","October 2008","Reduction in Contracture to 5° or Less","0","0","0","0","0","0","0","0","0"
"898","NCT00528879","A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","77 Years","915","September 2007","November 2008","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])","0.0002","Tested at alpha=0.019, applying the Dunnett adjustment","ANCOVA","-0.38","Mean Difference (Final Values)","0","0","0","0"
"899","NCT00528957","Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children","HIV Infections",0,"Tenofovir DF","Drug","Gilead Sciences","Industry",0,0,"All","2 Years","11 Years","97","December 2006","April 2009","Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48","0","0","0","-8.5","Difference in percentages between groups","95","2-Sided","-21.5","4.5"
"900","NCT00529152","Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients","Iron Overload",0,"Deferiprone","Drug","ApoPharma","Industry",0,0,"All","N/A","10 Years","100","August 2007","July 2008","Occurrence of Adverse Events","0","0","0","0","0","0","0","0","0"
"901","NCT00529282","A Study of Ceftobiprole in Patients With Fever and Neutropenia.","Fever",0,"Ceftobiprole Medocaril","Drug","Basilea Pharmaceutica","Industry",0,0,"All","18 Years","N/A","2","October 2007","January 2008","Clinical Cure Rate of Ceftobiprole vs Comparator in Patients With Fever and Neutropenia.","0","0","0","0","0","0","0","0","0"
"902","NCT00529373","A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)","Postmenopausal Osteoporosis",0,"Odanacatib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","65 Years","N/A","16713","September 2007","November 2012","(Base Study) Time From Baseline to First Morphometrically-Assessed Vertebral Fracture","0","0","0","0","0","0","0","0","0"
"903","NCT00529451","Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg","Hypertension",0,"Aliskiren","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","1613","September 2007","July 2008","Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)","0","0","0","0","0","0","0","0","0"
"904","NCT00529555","Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis","Adult Periodontitis",0,"minocycline HCl 2.1%","Drug","Sunstar Americas","Industry",0,0,"All","18 Years","N/A","602","January 2006","December 2008","Change in Pocket Depth.","0","0","0","0","0","0","0","0","0"
"905","NCT00529568","Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease","Hepatitis C, Chronic",0,"eltrombopag","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","759","October 2007","August 2011","Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase","0.0202","Stratified Cochran-Mantel-Haenszel (CMH) chi-square test adjusted for the randomization strata","Cochran-Mantel-Haenszel","6.0","Percentage difference in SVR","95","2-Sided","1.2","10.9"
"906","NCT00530348","Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Multiple Sclerosis, Relapsing-Remitting",0,"Alemtuzumab","Biological","Genzyme, a Sanofi Company","Industry",0,0,"All","18 Years","50 Years","581","August 2007","April 2011","Percentage of Participants With Sustained Accumulation of Disability (SAD)","0.2173","Hochberg method was used to adjust for the two co-primary outcomes.","Cox Proportional Hazards Regression","0.70","Hazard Ratio (HR)","95","2-Sided","0.40","1.23"
"907","NCT00530712","Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis","Peripheral Vascular Diseases",0,"PROTÉGÉ® EverFlex™ Self-Expanding Stent System","Device","Medtronic Endovascular","Industry",0,0,"All","18 Years","N/A","287","August 2007","March 2012","Primary Patency","0","0","0","0","0","0","0","0","0"
"908","NCT00530946","A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin","Hypertension",0,"Amlodipine 2.5mg/Atorvastatin 5mg","Drug","Pfizer","Industry",0,0,"All","20 Years","79 Years","165","September 2007","April 2008","Change in Systolic Blood Pressure","0","0","0","0","0","0","0","0","0"
"909","NCT00531427","Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee","Chronic Pain",0,"Buprenorphine","Drug","Purdue Pharma LP","Industry",0,0,"All","40 Years","N/A","567","September 2007","April 2009","""Average Pain Over the Last 24 Hours"" Score of the Study Knee at Week 12 of the Double Blind Phase.","0.0853","0","Mixed Models Analysis","-0.37","Mean Difference (Final Values)","95","2-Sided","-0.80","0.05"
"910","NCT00531479","Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis","Aspergillosis",0,"voriconazole","Drug","Pfizer","Industry",0,0,"All","16 Years","N/A","459","July 2008","April 2011","All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive Aspergillosis","0.0434","P-value based on a 1-sided test and tested against a 1-sided alpha of 0.025 to determine statistical significance.","Z test for difference in proportions","-8.74","Mean Difference (Final Values)","95","2-Sided","-18.99","1.51"
"911","NCT00531622","An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder","Major Depressive Disorder",0,"saredutant (SR48968)","Drug","Sanofi","Industry",0,0,"All","18 Years","65 Years","643","September 2007","January 2009","Change from baseline to Day 56 in Hamilton depression rating scale (HAM-D) total score","0","0","0","0","0","0","0","0","0"
"912","NCT00532038","A Phase 3 Study to Evaluate the Long-Term Safety of ThermoProfen™ in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee.","Osteoarthritis",0,"ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)","Drug","ZARS Pharma Inc.","Industry",0,0,"All","18 Years","75 Years","179","September 2007","November 2008","To evaluate the safety of long-term administration of ThermoProfen™","0","0","0","0","0","0","0","0","0"
"913","NCT00532155","A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","Carcinoma",0,"Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","913","September 2007","January 2011","Overall Survival (OS)","0.8985","0","Stratified log-rank test","1.01","Hazard Ratio (HR)","95","2-Sided","0.868","1.174"
"914","NCT00532311","Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia","Hypercholesterolemia",0,"Lapaquistat acetate and stable statin therapy","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","411","July 2007","April 2008","Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol","0","0","0","0","0","0","0","0","0"
"915","NCT00532558","Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia","Hypercholesterolemia",0,"Lapaquistat acetate","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","657","October 2007","May 2008","Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol","0","0","0","0","0","0","0","0","0"
"916","NCT00532779","A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects","Obesity",0,"Naltrexone SR 16 mg/Bupropion SR 360 mg /day","Drug","Orexigen Therapeutics, Inc","Industry",0,0,"All","18 Years","65 Years","1742","October 2007","May 2009","Co-primary: Body Weight- Mean Percent Change","<0.001","0","ANCOVA","-3.67","Mean Difference (Net)","95","0","-4.50","-2.85"
"917","NCT00533273","Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease","Advanced Dupuytren's Disease",0,"collagenase clostridium histolyticum","Biological","Endo Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","66","August 2007","September 2008","Reduction in Contracture to 5° or Less of the Primary Joint","0","0","0","0","0","0","0","0","0"
"918","NCT00533897","Phase IIIB Subcutaneous Missed Dose Study","Rheumatoid Arthritis",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","270","November 2007","December 2008","Double-blind Withdrawal (DBW) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibody Responses by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 169","0.119","There was no adjustment made for multiple comparisons.","Chi-squared, Corrected","9.59","estimate of difference","95","2-Sided","0.83","18.34"
"919","NCT00534833","Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™","Diphtheria",0,"DTaP-HB-PRP~T vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","15 Months","18 Months","362","September 2007","September 2008","Summary of Antibody Persistence and Immunogenicity Booster Response in Participants Who Were Vaccinated With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV","0","0","0","0","0","0","0","0","0"
"920","NCT00535496","Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)","Neuromuscular Blockade",0,"sugammadex","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","64 Years","91","September 2007","January 2008","Time From Start of Administration of 4.0 mg/kg Sugammadex to Recovery of the T4/T1 Ratio to 0.9 Measured by a TOF-Watch® SX","0","0","0","0","0","0","0","0","0"
"921","NCT00536263","PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)","Hepatitis B, Chronic",0,"pegylated interferon alpha-2b","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","671","September 2007","November 2009","Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss","0.860","P-values are unadjusted; Hochberg’s adjustment for multiple comparisons was used to maintain the overall 0.05 significance level in test of superiority using the Cochran-Mantel-Haenszel test.","Cochran-Mantel-Haenszel","0.008","Pairwise rate difference","95","2-Sided","-0.063","0.079"
"922","NCT00536302","A Placebo-Controlled Study of Collagen Hydrolysate in Subjects With Knee Osteoarthritis (OA)","Knee Osteoarthritis (OA)",0,"Collagen Hydrolysate","Dietary Supplement","GELITA","Industry",0,0,"All","49 Years","90 Years","30","March 2007","November 2008","To measure the effect of collagen hydrolysate on knee cartilage as measured by MRI.","0","0","0","0","0","0","0","0","0"
"923","NCT00536484","Fesoterodine Flexible Dose Study","Overactive Bladder",0,"Fesoterodine","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","896","August 2007","March 2008","Change in Mean Number of Micturition Episodes Per 24 Hours at Week 12 Relative to Baseline.","0.0002","Significance level p <0.05","ANCOVA","-0.7","Mean Difference (Final Values)","95","0","-1.1","-0.4"
"924","NCT00536666","A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients","Chronic Kidney Disease",0,"Iron oligosaccharide","Drug","Pharmacosmos A/S","Industry",0,0,"All","18 Years","N/A","182","May 2007","August 2008","Adverse events (AE) (Number and type of AE)","0","0","0","0","0","0","0","0","0"
"925","NCT00536731","Symbicort Rapihaler Therapeutic Equivalence Study","Bronchial Asthma",0,"Symbicort Turbuhaler","Drug","AstraZeneca","Industry",0,0,"All","12 Years","N/A","742","September 2007","April 2008","Morning Peak Expiratory Flow (PEF)","0","0","0","0","0","0","0","0","0"
"926","NCT00536744","Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers","Diabetic Foot Ulcers",0,"acoustical pulse energy (extracorporeal shockwave)","Device","SANUWAVE, Inc.","Industry",0,0,"All","18 Years","N/A","206","October 2007","June 2010","The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups 12 Weeks Post Initial Application.","0","0","0","0","0","0","0","0","0"
"927","NCT00536913","Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma","Asthma",0,"Budesonide/formoterol pMDI 40/2.25ug + spacer","Drug","AstraZeneca","Industry",0,0,"All","6 Years","11 Years","107","September 2007","February 2008","Urinary Free Cortisol (UFC)","0","0","0","0","0","0","0","0","0"
"928","NCT00537186","A Study of Iron Oligosaccharide in CHF Patients","Heart Failure, Congestive",0,"Iron oligosaccharide","Drug","Pharmacosmos A/S","Industry",0,0,"All","18 Years","N/A","20","June 2007","July 2008","Adverse events (AE) (Number and type of AE)","0","0","0","0","0","0","0","0","0"
"929","NCT00537238","Pregabalin Versus Levetiracetam In Partial Seizures","Partial Seizures",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","509","October 2007","May 2012","Proportion of Participants With Response to Treatment","0","0","0","0.00","Difference in Proportion","90","2-Sided","-0.08","0.09"
"930","NCT00537316","Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)","Ulcerative Colitis",0,"Infliximab (IFX)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","21 Years","N/A","242","July 2007","February 2010","Proportion of Participants in Steroid-free Remission at Week 16","0.032","0","Chi-squared","0","0","0","0","0","0"
"931","NCT00537329","Anidulafungin In Treatment Of Candidemia In Asian Subjects","Candidemia",0,"Anidulafungin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","43","January 2008","March 2009","Number of Subjects With Global Response of Success at End of Treatment","0","0","0","86.1","2-sided exact Clopper-Pearson (percent)","95","0","70.5","95.3"
"932","NCT00537342","Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)","Allergy",0,"Immunotherapy with modified extract of O. europaea pollen","Biological","Laboratorios Leti, S.L.","Industry",0,0,"All","18 Years","55 Years","83","October 2007","September 2009","Symptom score","0","0","0","0","0","0","0","0","0"
"933","NCT00537485","A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients","Early Parkinson's Disease",0,"SPM 962","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","30 Years","79 Years","180","September 2007","December 2009","Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3","0.002","0","t-test, 2 sided","-1.3","Mean Difference (Final Values)","95","2-Sided","-3.7","1.1"
"934","NCT00537680","Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia","Friedreich's Ataxia",0,"Idebenone","Drug","Santhera Pharmaceuticals","Industry",0,0,"All","8 Years","17 Years","70","December 2007","April 2009","ICARS","0","0","0","0","0","0","0","0","0"
"935","NCT00538239","Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)","Metastatic Soft-Tissue Sarcomas",0,"ridaforolimus","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","13 Years","N/A","711","October 2007","October 2010","Progression-free Survival","0","0","0","0","0","0","0","0","0"
"936","NCT00538434","Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years","Eosinophilic Esophagitis",0,"Reslizumab","Biological","Ception Therapeutics","Industry",0,0,"All","5 Years","18 Years","227","March 2008","October 2009","Mean Percent Change From Baseline to End of Treatment in Peak Esophageal Eosinophil (EE) Levels","< 0.0001","0","ANCOVA","-52.78","Adjusted mean difference","95","2-Sided","-75.24","-30.32"
"937","NCT00538863","Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain","Cancer",0,"Fentanyl sublingual spray","Drug","INSYS Therapeutics Inc","Industry",0,0,"All","18 Years","N/A","319","December 2007","October 2010","Percentage of Patients That Experienced 1 or More Adverse Events","0","0","0","0","0","0","0","0","0"
"938","NCT00538902","Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate","Rheumatoid Arthritis",0,"Placebo","Biological","Abbott","Industry",0,0,"All","18 Years","N/A","302","August 2007","July 2008","Number of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period","0.026","Each comparison was tested at the 2-sided alpha level of 0.05. Subjects with missing data were imputed to be non-responders. The overall type I error rate was preserved by a hierarchical stepwise closed testing procedure.","Cochran-Mantel-Haenszel","2.19","Odds Ratio (OR)","95","0","1.09","4.39"
"939","NCT00538915","Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)","Primary Immune Deficiency Disorders (PIDD)",0,"Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]","Biological","Biotest Pharmaceuticals Corporation","Industry",0,0,"All","6 Years","75 Years","63","September 2007","July 2009","Serious Bacterial Infections (SBIs) Compared to Historical Control Data.","0","0","0","0","0","0","0","0","0"
"940","NCT00539864","Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV","Influenza",0,"FluBlok Influenza Vaccination","Biological","Protein Sciences Corporation","Industry",0,0,"All","50 Years","64 Years","602","September 2007","April 2008","Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"941","NCT00539981","Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","Influenza",0,"Influenza Vaccine, recombinant hemagglutinin, FluBlok","Biological","Protein Sciences Corporation","Industry",0,0,"All","18 Years","49 Years","4648","September 2007","May 2008","Evaluation of safety and reactogenicity of trivalent recombinant hemagglutinin influenza vaccine in healthy adults aged 18-49 years","0","0","0","0","0","0","0","0","0"
"942","NCT00540423","Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)","Chronic Idiopathic Thrombocytopenic Purpura",0,"SB-497115-GR 12.5mg","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","N/A","23","September 2007","December 2008","Number of Responders at Week 6","0","0","0","60","Risk Difference (RD)","95","0","35.21","84.79"
"943","NCT00540449","TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.","HIV Infections",0,"TMC278","Drug","Tibotec Pharmaceuticals, Ireland","Industry",0,0,"All","18 Years","99 Years","694","May 2008","February 2010","Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48","<0.0001","Significance level was set at 2.5% (one-sided). No adjustment of p-value for multiple comparisons, since there was only single comparison for the primary endpoint.","Regression, Logistic","-0.4","Difference in proportion of response","95","0","-5.9","5.2"
"944","NCT00540514","Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer","Non-Small Cell Lung Carcinoma",0,"Albumin-bound paclitaxel","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","1052","November 2007","October 2009","Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment","0.005","Statistical significance defined as P-value < 0.049.","Chi-squared","1.313","Response Rate Ratio","95.1","2-Sided","1.082","1.593"
"945","NCT00540631","Multicenter Trial of Immunotherapy With House Dust Mite Allergoid","Rhinoconjunctivitis",0,"specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)","Biological","Allergopharma GmbH & Co. KG","Industry",0,0,"All","18 Years","60 Years","108","October 2007","August 2010","The primary endpoint is the change of the area under the curve (AUC)of the Symptom-Medication-Score (SMS)after 2 years of double-blind treatment to baseline","0","0","0","0","0","0","0","0","0"
"946","NCT00540839","A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)","Asthma, Bronchial",0,"Montelukast sodium","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","6 Months","5 Years","0","November 2007","March 2008","Percentage of days without asthma","0","0","0","0","0","0","0","0","0"
"947","NCT00541489","Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip","Osteoarthritis",0,"Naproxcinod","Drug","NicOx","Industry",0,0,"All","40 Years","N/A","800","June 2007","September 2008","The primary objective of this study is to show that Naproxcinod is superior to placebo in relieving OA signs and symptoms in subjects with OA of the hip","0","0","0","0","0","0","0","0","0"
"948","NCT00541658","A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis","Postmenopausal Osteoporosis",0,"risedronate","Drug","Warner Chilcott","Industry",0,0,"Female","50 Years","N/A","923","October 2007","April 2010","Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Week 52 / Endpoint, ITT Population","0","0","0","-0.233","Least Squares Mean Difference","95","2-Sided","-0.812","0.345"
"949","NCT00541723","Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles","Lateral Periorbital Wrinkles",0,"IncobotulinumtoxinA (Xeomin)","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","60 Years","111","September 2007","February 2008","Response assessed by an independent rater at maximum smile at week 4 for either eye area compared to baseline.","0","0","0","0","0","0","0","0","0"
"950","NCT00542386","A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia","Chronic Kidney Disease",0,"MCI-196","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","18 Years","N/A","642","December 2007","November 2009","The Change in Serum Phosphorus","0","0","0","0","0","0","0","0","0"
"951","NCT00542633","An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"VIAject™","Drug","Biodel","Industry",0,0,"All","30 Years","70 Years","472","December 2006","August 2008","change in HbA1c","0","0","0","0","0","0","0","0","0"
"952","NCT00542685","A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder","Generalized Anxiety Disorder",0,"PD 0332334","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","551","October 2007","December 2008","The efficacy of PD 0332334 in the treatment of GAD will be measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) total scores from baseline observed following 8 weeks of double-blind treatment.","0","0","0","0","0","0","0","0","0"
"953","NCT00542724","An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus","Type 1 Diabetes Mellitus",0,"VIAject™","Drug","Biodel","Industry",0,0,"All","18 Years","70 Years","462","September 2006","July 2008","Change in HbA1c","0","0","0","0","0","0","0","0","0"
"954","NCT00542815","A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia","Chronic Kidney Disease",0,"MCI-196","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","N/A","N/A","632","November 2007","August 2010","The Change in Serum Phosphorus for MCI-196 and Sevelamer","0","0","0","0","0","0","0","0","0"
"955","NCT00542997","Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy","Common Variable Immunodeficiency",0,"Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)","Biological","CSL Behring","Industry",0,0,"All","2 Years","65 Years","51","September 2007","August 2009","Total Serum IgG Trough Levels","0","0","0","0","0","0","0","0","0"
"956","NCT00543270","Powerlink Bifurcated Stent Graft Long-Term Follow-up Study","Abdominal Aortic Aneurysm",0,"Powerlink infrarenal bifurcated stent graft delivery system","Device","Endologix","Industry",0,0,"All","18 Years","N/A","231","October 2005","November 2009","Safety: Major adverse events. Effectiveness: Stent graft patency, aneurysm exclusion, aneurysm related mortality, and all-cause mortality.","0","0","0","0","0","0","0","0","0"
"957","NCT00543374","Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease","Crohn's Disease",0,"Placebo","Drug","Mesoblast International Sàrl","Industry",0,0,"All","18 Years","70 Years","98","October 2007","July 2009","Duration of clinical benefit (Crohn's disease activity index)","0","0","0","0","0","0","0","0","0"
"958","NCT00543673","Tolerance of Healthy, Term Infants to Infant Formulas","Healthy",0,"Milk based formula A","Other","Abbott Nutrition","Industry",0,0,"All","N/A","8 Days","180","September 2007","May 2008","Mean rank stool consistency (MRSC)","0","0","0","0","0","0","0","0","0"
"959","NCT00543725","TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors","HIV Infections",0,"TMC278","Drug","Tibotec Pharmaceuticals, Ireland","Industry",0,0,"All","18 Years","99 Years","680","June 2008","January 2010","Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48","<0.0001","Significance level was set at 2.5% (one-sided). No adjustment of p-value for multiple comparisons, since there was only single comparison for the primary endpoint.","Regression, Logistic","3.7","Difference in proportion of response","95","0","-1.6","9.0"
"960","NCT00544869","A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)","Cardiac Edema",0,"OPC-41061 （Tolvaptan)","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","85 Years","52","October 2007","February 2009","Body Weight","0","0","0","0","0","0","0","0","0"
"961","NCT00544882","A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021","Healthy",0,"DR-1021","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"Female","18 Years","35 Years","61","October 2007","March 2008","Serum Estradiol Levels by Cycle Day","0.6346","0","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"962","NCT00545103","Prevention of Recurrence of Diverticulitis","Diverticulitis",0,"SPD476, MMX™ mesalazine, 1.2g extended release tablet","Drug","Shire","Industry",0,0,"All","18 Years","N/A","592","December 2007","November 2011","Percent of Subjects Without Recurrence of Diverticulitis","0.778","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"963","NCT00545168","Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice","Pediculus Capitis Infestation",0,"Spinosad","Drug","ParaPRO LLC","Industry",0,0,"All","6 Months","N/A","480","September 2007","March 2008","Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice","0","0","0","0","0","0","0","0","0"
"964","NCT00545584","Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)","Diabetes Mellitus, Non-Insulin-Dependent",0,"sitagliptin phosphate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1512","April 1, 2007","November 19, 2009","Hemoglobin A1c Measurement","0","0","0","0","0","0","0","0","0"
"965","NCT00545740","Prevention of Recurrence of Diverticulitis","Diverticulitis",0,"SPD476 (1.2g)","Drug","Shire","Industry",0,0,"All","18 Years","N/A","590","November 2007","February 2012","Percent of Subjects Without Recurrence of Diverticulitis","0.063","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"966","NCT00545753","Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice","Pediculosis",0,"Spinosad","Drug","ParaPRO LLC","Industry",0,0,"All","6 Months","N/A","558","September 2007","March 2008","Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice","0","0","0","0","0","0","0","0","0"
"967","NCT00546351","Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.","Painful Diabetic Neuropathy",0,"Lacosamide","Drug","UCB Pharma","Industry",0,0,"All","18 Years","N/A","621","May 2004","January 2011","Number of Participants Experiencing the Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).","0","0","0","0","0","0","0","0","0"
"968","NCT00546507","Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I","Osteoarthritis",0,"TDS-943 (topical diclofenac sodium 4% spray)","Drug","Mika Pharma GmbH","Industry",0,0,"All","40 Years","N/A","650","October 2007","October 2008","Change from baseline in the WOMAC Composite Pain Score","0","0","0","0","0","0","0","0","0"
"969","NCT00546572","Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)","Pneumococcal Infections",0,"13 valent Pneumococcal Conjugate Vaccine","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","70 Years","N/A","938","November 2007","July 2010","Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)","0","0","0","1.5","ratio of geometric mean titer","95","2-Sided","1.17","1.88"
"970","NCT00546780","A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse","Multiple Myeloma",0,"Tanespimycin","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","31","February 2008","March 2010","Progression-free survival","0","0","0","0","0","0","0","0","0"
"971","NCT00546832","Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II","Osteoarthritis",0,"TDS-943 (topical diclofenac sodium 4% spray)","Drug","Mika Pharma GmbH","Industry",0,0,"All","40 Years","N/A","650","October 2007","October 2008","Change from baseline in the WOMAC Composite Pain Score","0","0","0","0","0","0","0","0","0"
"972","NCT00546871","Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects","Primary Immunodeficiency (PID)",0,"Immune Globulin Intravenous (Human), 10%","Drug","Baxalta US Inc.","Industry",0,0,"All","24 Months","N/A","49","October 2007","July 2009","Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part 3b), Expressed as a Percentage","0","0","0","0","0","0","0","0","0"
"973","NCT00547521","Phase IIIB Subcutaneous Abatacept Monotherapy Study","Rheumatoid Arthritis (RA)",0,"abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","119","December 2007","December 2008","Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study","0","0","0","0","0","0","0","0","0"
"974","NCT00547651","AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy","Small Cell Lung Cancer",0,"Amrubicin","Drug","Celgene Corporation","Industry",0,0,"All","18 Years","N/A","637","September 2007","May 2011","The primary objective is to demonstrate superiority in overall survival of amrubicin compared with topotecan hydrochloride in patients with small cell lung cancer (SCLC) after failure of first-line chemotherapy.","0","0","0","0","0","0","0","0","0"
"975","NCT00548405","Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","Multiple Sclerosis, Relapsing-Remitting",0,"Alemtuzumab 12 mg","Biological","Genzyme, a Sanofi Company","Industry",0,0,"All","18 Years","55 Years","840","October 2007","September 2011","Percentage of Participants With Sustained Accumulation of Disability (SAD)","0.0084","Hochberg method was used to adjust for the two co-primary outcomes.","Cox Proportional Hazards Regression","0.58","Hazard Ratio (HR)","95","2-Sided","0.38","0.87"
"976","NCT00548691","Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients","Anemia",0,"Ferric Carboxymaltose","Drug","Luitpold Pharmaceuticals","Industry",0,0,"All","18 Years","85 Years","513","October 2007","January 2009","Incidence of Treatment-emergent Serious Adverse Events (SAE's)","0","0","0","0","0","0","0","0","0"
"977","NCT00548860","Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients","Anemia",0,"Ferric Carboxymaltose","Drug","Luitpold Pharmaceuticals","Industry",0,0,"Female","N/A","N/A","2018","October 2007","March 2009","Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.","0","0","0","0","0","0","0","0","0"
"978","NCT00549302","Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs","Hypertension, Pulmonary",0,"tadalafil","Drug","Eli Lilly and Company","Industry",0,0,"All","12 Years","N/A","357","December 2005","February 2012","Number of Participants With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"979","NCT00549549","Celebrex In Acute Gouty Arthritis Study","Arthritis, Gouty",0,"Indomethacin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","402","February 2008","December 2009","Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity","0","0","0","-0.46","Median Difference (Final Values)","95","2-Sided","-0.74","-0.18"
"980","NCT00549692","Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy","IgA Nephropathy",0,"Omega-3 fatty acid ethylester90","Drug","Kuhnil Pharmaceutical Co., Ltd.","Industry",0,0,"All","18 Years","N/A","152","November 2007","August 2012","The rate of number of patients that 50% or more increase in SCr after 42 months","0","0","0","0","0","0","0","0","0"
"981","NCT00549718","Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia","Schizophrenia",0,"Lurasidone HCl","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","489","October 2007","October 2010","Change in Total PANSS Score From Baseline to the End of the Double Blind Phase","<0.05","0","Mixed Models Analysis","0","0","0","0","0","0"
"982","NCT00549939","Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction","Neurogenic Urinary Bladder",0,"Alfuzosin","Drug","Sanofi","Industry",0,0,"All","2 Years","16 Years","172","October 2007","March 2009","Number of Patients With Detrusor Leak Point Pressure (LPP) < 40 cm H2O","1.00","P-value was adjusted for multiplicity using the Hochberg procedure. The a priori threshold for statistical significance was 0.05.","Fisher Exact","0","0","0","0","0","0"
"983","NCT00550407","An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients","Bipolar Disorder",0,"lamotrigine","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","N/A","215","November 2007","October 2009","Time to Withdrawal From Study","0.010","0","Log Rank","0","0","0","0","0","0"
"984","NCT00550459","Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients","Hyponatremia",0,"Tolvaptan","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","50 Years","N/A","57","August 2007","February 2009","Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)","0.08","Secondary endpoints were ordered in 5 tiers to be analyzed only when >=1 of the endpoints in the prior tier were significant. Since primary endpoint not stat significant, analyses of secondary endpoint tiers presented for exploratory purposes only","ANCOVA","0.23","Mean Difference (Net)","95","2-Sided","-0.03","0.50"
"985","NCT00550550","Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)","Rhinoconjunctivitis",0,"Placebo","Drug","ALK-Abelló A/S","Industry",0,0,"All","5 Years","17 Years","345","November 2007","September 2009","Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)","=0.001","0","ANOVA","-1.63","Mean Difference (Final Values)","95","2-Sided","-2.60","-0.66"
"986","NCT00551135","Surgical Pain After Inguinal Hernia Repair (SPAIHR)","Pain, Postoperative",0,"Pregabalin","Drug","Pfizer","Industry",0,0,"Male","17 Years","75 Years","425","January 2008","June 2009","Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery","0.0668","Hochberg's adjustment applied to p-value; Hochberg's adjusted p-value was the primary analysis.","ANOVA","0","0","0","0","0","0"
"987","NCT00551616","Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception","Contraception",0,"CDB-2914","Drug","HRA Pharma","Industry",0,0,"Female","16 Years","N/A","2321","April 2007","April 2009","Pregnancy rate","0","0","0","0","0","0","0","0","0"
"988","NCT00551642","Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies","Lung Disease",0,"Nitric Oxide for inhalation","Drug","Mallinckrodt","Industry",0,0,"All","N/A","26 Hours","800","May 2005","February 2008","Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress","0","0","0","0","0","0","0","0","0"
"989","NCT00552032","Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (P05155)","Adenoids Hypertrophy",0,"Mometasone Furoate nasal spray","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","2 Years","11 Years","132","August 1, 2007","January 1, 2010","Change From Baseline in Adenoid/Choana (A/C) Index Grade","0","0","0","0","0","0","0","0","0"
"990","NCT00552058","Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease","Crohn Disease",0,"certolizumab pegol (CDP870, CZP)","Biological","UCB Pharma","Industry",0,0,"All","18 Years","75 Years","439","March 2008","October 2009","Percentage of Subjects in Clinical Remission at Week 6","0","0","0","0","0","0","0","0","0"
"991","NCT00552175","A Study for the Treatment of Diabetic Peripheral Neuropathic Pain","Diabetic Neuropathies",0,"Duloxetine hydrochloride - 40 mg","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","79 Years","339","November 2007","March 2009","Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg)","<0.0001","0","Mixed Models Analysis","-0.87","Least Squares Mean Difference","95","2-Sided","-1.17","-0.56"
"992","NCT00553280","A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy","Diabetic Neuropathy, Painful",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","123","February 2008","January 2010","Summary of Adverse Events","0","0","0","0","0","0","0","0","0"
"993","NCT00553358","Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study","Neoplasms, Breast",0,"Lapatinib","Drug","Novartis Pharmaceuticals","Industry",0,0,"Female","18 Years","N/A","455","January 2008","May 2010","Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery","0.3416","0","Binomial","-4.85","Percentage of participants with pCR","97.5","2-Sided","-17.6","8.16"
"994","NCT00553475","Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy","Diabetic Neuropathy, Painful",0,"placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","314","October 2007","March 2009","Change From Baseline to Study Endpoint in Mean Weekly Pain Scores","0.0075","0","ANCOVA","-0.63","Mean Difference (Final Values)","95","0","-1.09","-0.17"
"995","NCT00553631","Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease","Gaucher Disease, Type 1",0,"velaglucerase alfa","Biological","Shire","Industry",0,0,"All","2 Years","N/A","34","January 2008","May 2009","Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group.","0","0","0","0","0","0","0","0","0"
"996","NCT00553787","Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions","Obesity",0,"VI-0521","Drug","VIVUS, Inc.","Industry",0,0,"All","18 Years","70 Years","2487","November 2007","June 2009","Percent Weight Loss From Baseline to Week 56","<0.0001","Intersection-union method applied in a step-down testing approach","ANCOVA","8.6","Mean Difference (Final Values)","95","2-Sided","7.96","9.25"
"997","NCT00554216","Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults","Obesity",0,"VI-0521","Drug","VIVUS, Inc.","Industry",0,0,"All","18 Years","70 Years","1267","November 2007","May 2009","Percent Weight Loss From Baseline to Week 56","<0.0001","Intersection-union method applied in a step-down testing approach","ANCOVA","9.36","Mean Difference (Final Values)","95","2-Sided","8.43","10.30"
"998","NCT00554229","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases","Prostate Cancer",0,"ZD4054","Drug","AstraZeneca","Industry",0,0,"Male","18 Years","N/A","896","November 2007","July 2010","Overall Survival","0","0","0","0","0","0","0","0","0"
"999","NCT00554983","Efficacy and Safety From a Recombinant Folding Variant of Bet v 1","Allergy",0,"recombinant birch pollen allergen","Biological","Allergopharma GmbH & Co. KG","Industry",0,0,"All","18 Years","60 Years","255","September 2007","June 2010","Symptom-Medication-Score","0","0","0","0","0","0","0","0","0"
"1000","NCT00556478","Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation","Premature Ejaculation",0,"PSD502, contains a mixture of lidocaine and prilocaine","Drug","Plethora Solutions Ltd","Industry",0,0,"Male","18 Years","N/A","256","October 2007","October 2009","Mean Intravaginal Ejaculatory Latency Time (IELT): Change From Baseline to During 3 Month Double Blind-treatment","<0.0001","0","ANCOVA","3.05","Ratio (over 3 months/Baseline)","95","2-Sided","2.29","4.06"
"1001","NCT00556959","Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)","Attention Deficit Disorder With Hyperactivity",0,"high dose clonidine HCl sustained release","Drug","Addrenex Pharmaceuticals, Inc.","Industry",0,0,"All","6 Years","17 Years","236","October 2007","August 2008","ADHDRS-IV","0","0","0","0","0","0","0","0","0"
"1002","NCT00557791","Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)","Age Related Macular Degeneration",0,"Bevasiranib","Drug","OPKO Health, Inc.","Industry",0,0,"All","50 Years","N/A","0","November 2009","July 2011","Primary efficacy measure: The proportion of patients at week 60 in each group with a successful visual acuity outcome (as defined as avoidance of a 3, or more, line loss in vision).","0","0","0","0","0","0","0","0","0"
"1003","NCT00557921","Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)","Acute Coronary Syndrome",0,"CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin","Drug","Cogentus Pharmaceuticals","Industry",0,0,"All","21 Years","N/A","5000","December 2007","November 2009","Composite of upper gastrointestinal clinical events, including gastroduodenal bleeding, symptomatic gastroduodenal ulcer, persistent pain with multiple gastric erosions, obstruction or perforation","0","0","0","0","0","0","0","0","0"
"1004","NCT00558311","Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping","Aneurysmal Subarachnoid Hemorrhage",0,"clazosentan","Drug","Actelion","Industry",0,0,"All","18 Years","75 Years","1157","November 2007","July 2010","Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol","0","0","0","0","0","0","0","0","0"
"1005","NCT00558636","A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)","Carcinoma, Non-Small-Cell Lung",0,"Sorafenib + Paclitaxel + Carboplatin","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","91","September 2007","May 2008","Progression Free Survival","0","0","0","0","0","0","0","0","0"
"1006","NCT00559364","Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea","Exocrine Pancreatic Insufficiency",0,"Viokase® 16","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","80 Years","50","November 2007","July 2009","Percent Coefficient of Fat Absorption (CFA)","<0.0001","0","ANCOVA","0","0","0","0","0","0"
"1007","NCT00559585","Methotrexate-Inadequate Response Study","Rheumatoid Arthritis (RA)",0,"Subcutaneous (SC) Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","2492","January 2008","November 2009","Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169","0","0","0","0","0","0","0","0","0"
"1008","NCT00560183","Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain","Postoperative Pain",0,"Q8003 (morphine sulfate and oxycodone hydrochloride)","Drug","QRxPharma Inc.","Industry",0,0,"All","18 Years","N/A","256","November 2007","April 2008","Difference in pain intensity scores from baseline","0","0","0","0","0","0","0","0","0"
"1009","NCT00560417","Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide","Diabetes Mellitus, Type 2",0,"Insulin Lispro Protamine Suspension","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","74 Years","339","November 2007","December 2009","Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])","0","0","0","0.22","Mean Difference (Final Values)","95","2-Sided","0.06","0.38"
"1010","NCT00560755","ProQuad® rHA Safety","Measles",0,"ProQuad® manufactured with rHA","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Months","22 Months","3340","October 2007","November 2008","Solicited injection-site adverse reactions (erythema, swelling, pain)","0","0","0","0","0","0","0","0","0"
"1011","NCT00560885","AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation","Atrial Fibrillation",0,"AtriCure Bipolar System","Device","AtriCure, Inc.","Industry",0,0,"All","18 Years","N/A","55","November 2007","December 2009","Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months.","0","0","0","0","0","0","0","0","0"
"1012","NCT00561470","Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen","Colorectal Neoplasms",0,"Placebo","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","1226","November 2007","February 2011","Overall Survival (OS)","0.0032","Stratified Log-Rank test p-value. Stratified on ECOG Performance Status and prior Bevacizumab according to IVRS using the Cox Proportional Hazard Model. Significance threshold was set to 0.0466 using the O'Brien-Fleming alpha spending function.","Stratified Log-Rank test","0.817","Stratified Hazard Ratio","95.34","2-Sided","0.713","0.937"
"1013","NCT00561574","A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)","Sleep Initiation and Maintenance Disorder; Elderly",0,"Esmirtazapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","65 Years","N/A","259","January 2008","February 2010","Number of Participants Who Experience at Least One Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"1014","NCT00561821","Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)","Insomnia",0,"Esmirtazapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","65 Years","N/A","538","November 2007","December 2009","Average Wake Time After Sleep Onset Measured by Polysomnography","<0.0001","Pairwise comparisons on rank transformed data with effects for treatment and center, and baseline of variable as a covariate","ANCOVA","0","0","0","0","0","0"
"1015","NCT00562016","Protect II, A Prospective, Multicenter Randomized Controlled Trial","Coronary Artery Disease",0,"IMPLELLA LP 2.5","Device","Abiomed Inc.","Industry",0,0,"All","18 Years","90 Years","452","October 2007","April 2011","Composite rate of 10 major adverse events including death; MI;Stroke or TIA; and repeat revascularization.","0","0","0","0","0","0","0","0","0"
"1016","NCT00562159","Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)","Rhinoconjunctivitis",0,"Placebo","Drug","ALK-Abelló A/S","Industry",0,0,"All","18 Years","65 Years","439","November 2007","September 2009","Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)","=0.005","0","ANOVA","-1.31","Mean Difference (Final Values)","95","2-Sided","-2.22","-0.40"
"1017","NCT00562302","Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure","Pneumothorax",0,"Bio-Seal Plug","Device","Angiotech Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","339","April 2005","June 2008","Incidence Rate of Treatment Success","0","0","0","0","0","0","0","0","0"
"1018","NCT00562497","Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD","Graft Versus Host Disease",0,"Prochymal","Drug","Mesoblast International Sàrl","Industry",0,0,"All","18 Years","70 Years","184","September 2007","August 2009","Achieved an induction of a complete response, Followed by 28 days of maintenance of a clinically meaningful response that does not did not require an increase in corticosteroid dose , did not require second line therapy and survived 90 days.","0","0","0","0","0","0","0","0","0"
"1019","NCT00562965","Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)","Lymphoma, Follicular",0,"inotuzumab ozogamicin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","29","November 2007","April 2011","To assess efficacy as measured by progression free survival (PFS), with a goal of demonstrating the superiority of inotuzumab ozogamicin when administered in combination with rituximab, compared with an active comparator arm.","0","0","0","0","0","0","0","0","0"
"1020","NCT00563368","A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults","Obesity",0,"VI-0521","Drug","VIVUS, Inc.","Industry",0,0,"All","18 Years","70 Years","756","December 2007","September 2008","Percent Weight Loss From Baseline to Week 28","0.0009","Intersection-union method applied in a step-down testing approach","ANCOVA","2.76","Mean Difference (Final Values)","95","2-Sided","1.13","4.39"
"1021","NCT00563459","Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.","Epilepsy",0,"carisbamate","Drug","SK Life Science","Industry",0,0,"All","16 Years","N/A","89","November 2007","April 2010","The primary efficacy endpoint is time from the first intake of study medication to discontinuation (all causes) of study medication during the 6 month core double-blind phase.","0","0","0","0","0","0","0","0","0"
"1022","NCT00564486","Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain","Pain",0,"IV Placebo","Drug","Mallinckrodt","Industry",0,0,"All","18 Years","80 Years","244","November 2007","September 2008","Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 1 g IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, and 24 Hours.)","0","0","0","0","0","0","0","0","0"
"1023","NCT00564850","Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty","Precocious Puberty",0,"Triptorelin pamoate 11.25mg (Decapeptyl® SR)","Drug","Ipsen","Industry",0,0,"All","N/A","N/A","37","October 2007","October 2010","Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L","0","0","0","0","0","0","0","0","0"
"1024","NCT00565279","Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis","Seborrheic Dermatitis",0,"ASF1057","Drug","Astion Pharma A/S","Industry",0,0,"All","18 Years","N/A","300","December 2007","May 2008","Proportion of responders, defined as patients with OSS ≤ 1 score units.","0","0","0","0","0","0","0","0","0"
"1025","NCT00565747","Efficacy Study of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for Use in Human IVF","Infertility",0,"Test culture","Device","Origio A/S","Industry",0,0,"Female","25 Years","39 Years","1332","November 2007","November 2010","Ongoing Implantation Rate Week 7","0","0","0","0","0","0","0","0","0"
"1026","NCT00565760","Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain","Acute Moderate to Severe Pain",0,"Q8003","Drug","QRxPharma Inc.","Industry",0,0,"All","18 Years","N/A","16","November 2007","March 2008","Safety: adverse events","0","0","0","0","0","0","0","0","0"
"1027","NCT00566254","Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)","Epilepsy; Paediatric Partial Onset Seizures",0,"Zonisamide","Drug","Eisai Inc.","Industry",0,0,"All","6 Years","17 Years","207","December 2008","March 2011","Percentage of Participants With a Decrease From Baseline in 28-day Seizure Frequency of =50%(Responder) in the Maintenance Period(LOCF)","0","0","0","0","0","0","0","0","0"
"1028","NCT00566345","Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)","Influenza",0,"Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)","Biological","Baxter Healthcare Corporation","Industry",0,0,"All","18 Years","49 Years","3670","November 2007","June 2008","Number of subjects developing influenza infection, as confirmed by viral culture and typing of naso-pharyngeal specimens","0","0","0","0","0","0","0","0","0"
"1029","NCT00566527","Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA","Measles",0,"ProQuad® manufactured with recombinant Human Albumine","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","9 Months","N/A","1260","November 2007","December 2008","antibody response rates to measles, mumps, rubella and varicella measured at Day 42 following Dose 2","0","0","0","0","0","0","0","0","0"
"1030","NCT00566631","An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia","Schizophrenia",0,"Paliperidone","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","N/A","294","July 2007","May 2008","Number of Participants With Treatment Response Based on Total PANSS Scale Score","0","0","0","0","0","0","0","0","0"
"1031","NCT00566657","Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions","Peripheral Vascular Diseases",0,"riferminogene pecaplasmid","Biological","Sanofi","Industry",0,0,"All","50 Years","N/A","525","November 2007","August 2010","Time to major amputation of the treated leg or death from any cause, whichever comes first","0","0","0","0","0","0","0","0","0"
"1032","NCT00566722","Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy","Psoriasis",0,"adalimumab","Biological","Abbott","Industry",0,0,"All","18 Years","N/A","152","January 2008","April 2009","Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16","0","0","0","0","0","0","0","0","0"
"1033","NCT00567164","Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ","Contraception",0,"EE20/DRSP (BAY86-5300)","Drug","Bayer","Industry",0,0,"Female","18 Years","45 Years","1887","October 2007","November 2009","Pearl Index","0","0","0","0","0","0","0","0","0"
"1034","NCT00567255","A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects","Obesity",0,"Naltrexone SR 32 mg/bupropion SR 360 mg/day","Drug","Orexigen Therapeutics, Inc","Industry",0,0,"All","18 Years","65 Years","1496","December 2007","June 2009","Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28","<0.001","0","ANCOVA","-4.56","Mean Difference (Net)","95","0","-5.19","-3.93"
"1035","NCT00567398","IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients","ESRD",0,"Dianeal","Drug","Baxter Healthcare Corporation","Industry",0,0,"All","18 Years","N/A","43","April 2008","July 2011","Change from the baseline value in HbA1c between the PEN group compared to the Dianeal only group","0","0","0","0","0","0","0","0","0"
"1036","NCT00567918","Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis","Keratoconjunctivitis",0,"FK506","Drug","Astellas Pharma Inc","Industry",0,0,"All","6 Years","N/A","52","May 2004","January 2008","Safety","0","0","0","0","0","0","0","0","0"
"1037","NCT00568178","An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))","Proteinuria",0,"Losartan Potassium","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Months","17 Years","306","June 2007","September 2008","Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12","0.001","0","Mixed Models Analysis","0.63","Ratio in Geometric Mean","95","2-Sided","0.54","0.74"
"1038","NCT00568308","Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma","Cancer",0,"PI-88","Drug","Progen Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","600","December 2007","July 2008","Disease-free Survival","0","0","0","0","0","0","0","0","0"
"1039","NCT00568685","Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder",0,"Atomoxetine Hydrochloride","Drug","Eli Lilly and Company","Industry",0,0,"All","6 Years","18 Years","153","November 2007","November 2008","Change From Baseline to Day 42 Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score","0.0048","This is the p value for CGI-ADHD-S score change at endpoint","Mixed Models Analysis","0","0","0","0","0","0"
"1040","NCT00569192","A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children","Asthma",0,"0.135mg MAP0010","Drug","Allergan","Industry",0,0,"All","12 Months","8 Years","360","December 2007","September 2008","Change From Baseline in Daytime Composite Symptom Score","0","0","0","0","0","0","0","0","0"
"1041","NCT00569244","SH T00186 in the Treatment of Primary Dysmenorrhea","Primary Dysmenorrhea",0,"Drug: YAZ flex (SH T00186D)","Drug","Bayer","Industry",0,0,"Female","18 Years","40 Years","223","December 2007","December 2009","Number of days with dysmenorrheic pain","0","0","0","0","0","0","0","0","0"
"1042","NCT00569582","A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome","Cushing's Syndrome",0,"mifepristone","Drug","Corcept Therapeutics","Industry",0,0,"All","18 Years","N/A","50","December 2007","January 2011","Improvement in Diabetes and/or Glucose Intolerance.","0","0","0","0","0","0","0","0","0"
"1043","NCT00570739","Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.","Type 2 Diabetes Mellitus",0,"Metformin HCl and Colesevelam Placebo","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","79 Years","502","November 2007","April 2009","Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-naïve, Diabetic Subjects.","0.0123","P-Value is for the LS mean difference between treatment groups","ANCOVA","-0.15","Mean Difference (Final Values)","95","2-Sided","-0.27","-0.03"
"1044","NCT00570986","A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","Plaque Psoriasis",0,"Placebo","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","1465","November 2007","June 2009","PGA","0","0","0","0","0","0","0","0","0"
"1045","NCT00571519","Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"Rivoglitazone HCl","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","N/A","94","November 2007","May 2008","HbA1c","0","0","0","0","0","0","0","0","0"
"1046","NCT00571649","Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients","Venous Thromboembolism",0,"Rivaroxaban (Xarelto, BAY59-7939)","Drug","Bayer","Industry",0,0,"All","40 Years","N/A","8101","December 2007","August 2010","Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days","0.0211","Hochberg procedure: A 2-sided p-value of less than 0.05 would be considered significant, if the 1-sided p-value of the other primary efficacy outcome measure was less than 0.025, elsewise a p-value of less than 0.025 would be considered significant.","Cochran-Mantel-Haenszel","0.771","Risk Ratio (RR)","95","0","0.618","0.962"
"1047","NCT00573157","The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis","Lupus Nephritis",0,"Atacicept","Drug","EMD Serono","Industry",0,0,"All","16 Years","N/A","6","December 2007","April 2009","Percentage of Participants With Confirmed Complete Renal Response (CRR), Partial Response, and Non-response","0","0","0","0","0","0","0","0","0"
"1048","NCT00573170","TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults","Migraine Disorders",0,"TREXIMET®","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","65 Years","375","February 2008","August 2009","Number of Participants With a Sustained Pain-free (SPF) Response From 2 to 24 Hours Post-dose","0.378","Compares odds ratio.","Generalized Estimating Equations","1.3","Odds Ratio (OR)","95","2-Sided","0.7","2.5"
"1049","NCT00573443","Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS","Pseudobulbar Affect (PBA)",0,"dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg","Drug","Avanir Pharmaceuticals","Industry",0,0,"All","18 Years","80 Years","326","December 2007","June 2009","PBA Episode Rate Ratio (Post/Pre), Regression Adjusted","<0.0001","0","Regression, Longitudinal neg. binomial","0.5312","Ratio of episode-rate reduction ratios","95","2-Sided","0.4939","0.5714"
"1050","NCT00574249","Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment","Chronic Plaque Psoriasis",0,"adalimumab","Biological","Abbott","Industry",0,0,"All","18 Years","N/A","730","November 2007","October 2008","Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)","0.086","Level of significance 5%; no adjustment for multiple comparisons necessary.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1051","NCT00574275","Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer","Pancreatic Neoplasm",0,"Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","546","December 2007","October 2009","Overall Survival (OS)","0","0","0","0","0","0","0","0","0"
"1052","NCT00574548","Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS","Pneumococcal Vaccines",0,"13 valent Pneumococcal Conjugate Vaccine","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","60 Years","64 Years","720","November 2007","February 2010","Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0)","0","0","0","1.0","ratio of geometric mean titer","95","2-Sided","0.75","1.33"
"1053","NCT00574795","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants","Vaccines, Pneumococcal Conjugate Vaccine",0,"13vPnC","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","2 Months","6 Months","193","September 2007","August 2008","Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series","0","0","0","0","0","0","0","0","0"
"1054","NCT00574860","EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer","Oral Mucositis",0,"EN3285","Drug","Endo Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","240","December 2007","June 2009","NCI v3 to measure severity of OM","0","0","0","0","0","0","0","0","0"
"1055","NCT00574873","Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML","Chronic Myeloid Leukemia",0,"Bosutinib","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","502","February 2008","August 2010","Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1","0.667","p-value was based on a Cochran Mantel Haenszel test for general association between treatment and responder stratification by Sokal risk group (low, intermediate, high) and region (1 to 3) as determined at time of randomization.","Stratified Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1056","NCT00575588","52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period","Type 2 Diabetes",0,"Metformin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","891","December 2007","August 2009","Hemoglobin A1c (HbA1c) Change From Baseline to Week 52","0","0","0","0.06","Mean Difference (Net)","95","2-Sided","-0.05","0.16"
"1057","NCT00576251","TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension","Ocular Inflammation Associated With Blepharaconjunctivitis",0,"Tobramycin 0.3%/Dexamethasone 0.05%","Drug","Alcon Research","Industry",0,0,"All","2 Years","N/A","221","October 2007","February 2008","Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4)","0","0","0","0","0","0","0","0","0"
"1058","NCT00576342","Patient Preference Study","Glaucoma",0,"AL-3862+timolol ophthalmic suspension","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","129","December 2007","January 2008","Percentage of patients with a stated preference for either study medication","0","0","0","0","0","0","0","0","0"
"1059","NCT00576667","An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes","Fatty Liver",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","165","January 2008","February 2009","Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS)","0","0","0","0","0","0","0","0","0"
"1060","NCT00576823","Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology","Hydronephrosis",0,"Alfuzosin","Drug","Sanofi","Industry",0,0,"All","2 Years","16 Years","25","December 2007","January 2009","Number of Participants With a Decrease From Baseline ≥ 1 in the Society of Fetal Urology (SFU) Grade of Hydronephrosis","0","0","0","0","0","0","0","0","0"
"1061","NCT00577148","An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes","Fatty Liver",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","89","February 2008","February 2009","Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS)","0","0","0","0","0","0","0","0","0"
"1062","NCT00577161","Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL","Non-Hodgkin's Lymphoma",0,"fludarabine and rituximab","Drug","CTI BioPharma","Industry",0,0,"All","18 Years","N/A","300","September 2007","July 2012","progression-free survival","0","0","0","0","0","0","0","0","0"
"1063","NCT00577304","A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon","Raynaud's Disease",0,"Nitroglycerin","Drug","MediQuest Therapeutics","Industry",0,0,"All","15 Years","70 Years","200","December 2007","March 2008","Reduction in Raynaud's Condition Score","0","0","0","0","0","0","0","0","0"
"1064","NCT00577655","Albuterol HFA MDI in Pediatric Participants With Asthma","Asthma",0,"Albuterol","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","4 Years","11 Years","103","August 2007","July 2008","Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Observed up to Two Hours Post Dose (FEV1max%0-2) on Day 22","0.0138","In order to control the overall alpha level at the 0.05 value, each of the primary endpoints were tested separately at the 0.025 level of significance.","ANCOVA","3.496","Mean Difference (Final Values)","95","2-Sided","0.729","6.262"
"1065","NCT00577824","Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)","Type 2 Diabetes",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","20 Years","75 Years","181","January 2008","November 2008","Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24","<0.001","Bonferroni's method was used to adjustment for multiplicity, and significant level was set to 2.5%(two-sided).","ANCOVA","0","0","0","0","0","0"
"1066","NCT00577863","Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy","Osteoporosis",0,"teriparatide","Drug","Eli Lilly and Company","Industry",0,0,"All","N/A","N/A","200","January 2008","May 2008","Summary of Forteo B Pen Complaints at 8 Weeks","0","0","0","0","0","0","0","0","0"
"1067","NCT00578331","Safety Study of Olopatadine Nasal Spray","Perennial Allergic Rhinitis",0,"Olopatadine 0.6% nasal spray","Drug","Alcon Research","Industry",0,0,"All","12 Years","N/A","890","December 2006","March 2008","Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire","0","0","0","0","0","0","0","0","0"
"1068","NCT00578474","A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes","Acute Otitis Media",0,"Moxidex otic solution","Drug","Alcon Research","Industry",0,0,"All","6 Months","12 Years","911","December 2005","August 2008","Clinical cure rate at the test of cure visit as determined by the investigator","0","0","0","0","0","0","0","0","0"
"1069","NCT00578695","THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation","Hyponatremia",0,"lixivaptan","Drug","CardioKine Inc.","Industry",0,0,"All","18 Years","N/A","652","January 2007","June 2010","To determine whether lixivaptan can effectively and safely produce an increase in serum sodium from Baseline in heart failure subjects with hyponatremia and volume overload. Effects on body weight and other clinical measures will be evaluated.","0","0","0","0","0","0","0","0","0"
"1070","NCT00578786","A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)","Pulmonary Arterial Hypertension",0,"ambrisentan","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","383","February 2004","March 2010","Frequently Reported (15% or More Overall) Adverse Events by Severity","0","0","0","0","0","0","0","0","0"
"1071","NCT00578812","PCM Cervical Disc System","Radiculopathy",0,"Anterior Cervical Discectomy and Fusion (ACDF)","Device","NuVasive","Industry",0,0,"All","18 Years","65 Years","494","January 2005","March 2010","Individual Patient Overall Success","0","0","0","0","0","0","0","0","0"
"1072","NCT00578929","Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients","Seasonal Allergic Rhinitis",0,"Olopatadine Hydrochloride Nasal Spray 0.6%","Drug","Alcon Research","Industry",0,0,"All","6 Years","11 Years","2388","September 2007","November 2008","Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)","0","0","0","0","0","0","0","0","0"
"1073","NCT00578955","Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis","Blepharoconjunctivitis",0,"1% Azithromycin and 0.1% Dexamethasone","Drug","InSite Vision","Industry",0,0,"All","1 Year","N/A","417","December 2007","October 2008","The resolution of the clinical signs and symptoms.","0","0","0","0","0","0","0","0","0"
"1074","NCT00579189","Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes","Acute Otitis Media",0,"Moxidex otic solution","Drug","Alcon Research","Industry",0,0,"All","6 Months","12 Years","776","January 2006","January 2009","Time to cessation of otorrhea as recorded by the parent or guardian via a patient diary","0","0","0","0","0","0","0","0","0"
"1075","NCT00579345","Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup","Influenza",0,"Cell culture derived seasonal trivalent influenza vaccine (cTIV)","Biological","Novartis","Industry",0,0,"All","18 Years","N/A","1522","October 2007","June 2008","Number of Randomized Participants Reporting Local and Systemic Reactions.","0","0","0","0","0","0","0","0","0"
"1076","NCT00580216","Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation","Atrial Fibrillation",0,"Idrabiotaparinux sodium","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","3773","December 2007","October 2010","Composite of all fatal or non-fatal strokes or non central nervous system (CNS) systemic embolic events (SE)","0","0","0","0","0","0","0","0","0"
"1077","NCT00584896","Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease","Coronary Artery Disease",0,"PB127 for Injectable Suspension","Drug","Point Biomedical","Industry",0,0,"All","18 Years","N/A","1000","October 2007","July 2008","To evaluate the diagnostic performance of PB127 MPE for the detection and/or exclusion of significant obstructive coronary artery disease as defined by qualitative coronary angiography or qualifying clinical outcome","0","0","0","0","0","0","0","0","0"
"1078","NCT00586105","Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)","Carcinoma, Renal Cell",0,"Sorafenib (Nexavar, BAY43-9006)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","39","December 2005","May 2008","Pharmacokinetics Measured as Area Under Curve (AUC[0-12h])","0","0","0","0","0","0","0","0","0"
"1079","NCT00586378","Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study","Sudden Cardiac Death",0,"Ovatio DR and Ovatio VR","Device","ELA Medical, Inc.","Industry",0,0,"All","18 Years","N/A","85","April 2006","December 2009","The percentage of patients free from complications","0","0","0","0","0","0","0","0","0"
"1080","NCT00586625","Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers","Allergic Conjunctivitis",0,"Bepreve","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","3 Years","N/A","861","October 2007","May 2008","Ocular Comfort","0","0","0","0","0","0","0","0","0"
"1081","NCT00586664","Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis","Allergic Conjunctivitis",0,"Bepreve (bepotastine besilate ophthalmic solution) 1.5%","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","10 Years","N/A","130","October 2007","June 2008","Ocular Itching","0","0","0","0","0","0","0","0","0"
"1082","NCT00587223","Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)","Epidermolysis Bullosa, Junctional",0,"Apligraf","Device","Organogenesis","Industry",0,0,"All","2 Years","65 Years","1","December 2007","December 2008","Proportion of Wounds First Achieving 100% Epithelialization of Tissue With the Absence of Drainage (i.e. Complete Wound Closure) Through Study Week 12","0","0","0","0","0","0","0","0","0"
"1083","NCT00587834","Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration","Gingival Recession",0,"Gintuit","Device","Organogenesis","Industry",0,0,"All","18 Years","70 Years","96","October 2007","December 2008","Percentage of Subjects With at Least 2 mm Keratinized Tissue (KT) at 6 Months at the Gintuit Treated Site.","<0.0001","0","Exact Bionomial Test","0","0","0","0","0","0"
"1084","NCT00589693","To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia","Ventilator-Associated Pneumonia",0,"Doripenem","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","274","April 2008","June 2011","Clinical Cure Rate at the End-of-treatment (EOT) Visit","0","0","0","-11.2","Difference of 2 binomial proportions","95","2-Sided","-26.3","3.8"
"1085","NCT00589797","Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease","Degenerative Disc Disease",0,"Activ-L Artificial Disc","Device","Aesculap Implant Systems","Industry",0,0,"All","18 Years","60 Years","414","January 2007","December 2012","Overall success relative to baseline","0","0","0","0","0","0","0","0","0"
"1086","NCT00589823","Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids","Cancers, Pain",0,"Fentanyl citrate","Drug","Archimedes Development Ltd","Industry",0,0,"All","18 Years","N/A","135","June 2007","March 2009","Pain Relief","0","0","0","0","0","0","0","0","0"
"1087","NCT00589914","Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia","Schizophrenia",0,"RISPERDAL CONSTA","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","1221","March 2007","June 2009","Change in the Positive and Negative Syndrome Scale (PANSS) Total Score for Schizophrenia","0","0","0","0.4","Mean Difference (Final Values)","95","2-Sided","-1.62","2.38"
"1088","NCT00591253","Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension","Hypertension",0,"Azilsartan medoxomil","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","413","October 2007","April 2009","Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","0.001","Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.","ANCOVA","-5.00","Mean Difference (Final Values)","95","2-Sided","-7.97","-2.04"
"1089","NCT00591266","Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension","Hypertension",0,"Azilsartan Medoxomil and amlodipine","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","566","October 2007","March 2009","Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","<0.001","Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.","ANCOVA","-11.19","Mean Difference (Final Values)","95","2-Sided","-13.29","-9.09"
"1090","NCT00591578","Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension","Hypertension",0,"Azilsartan Medoxomil","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","984","December 2007","September 2009","Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","<0.001","Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.","ANCOVA","-3.64","Mean Difference (Final Values)","95","2-Sided","-5.59","-1.69"
"1091","NCT00591591","Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers","Obstructive Sleep Apnea Syndrome",0,"OxiplexTS","Device","ISS, Inc.","Industry",0,0,"All","21 Years","55 Years","309","August 2007","June 2010","Percentage of Oxygen Saturation in the Brain During Sleep","0","0","0","0","0","0","0","0","0"
"1092","NCT00591773","Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension","Hypertension",0,"Azilsartan medoxomil and chlorthalidone","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","551","September 2007","March 2009","Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","<0.001","Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.","ANCOVA","-15.86","Mean Difference (Final Values)","95","2-Sided","-18.54","-13.19"
"1093","NCT00591799","Jarvik 2000 Heart as a Bridge to Cardiac Transplantation - Pivotal Trial","Heart Failure",0,"The Jarvik 2000 Ventricular Assist System","Device","Jarvik Heart, Inc.","Industry",0,0,"All","18 Years","N/A","150","April 2005","May 2012","Survival to cardiac transplantation or survival and transplant listed at 180 days following implant of the Jarvik 2000 Heart.","0","0","0","0","0","0","0","0","0"
"1094","NCT00592553","Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (DMD/BMD)","Duchenne Muscular Dystrophy",0,"PTC124","Drug","PTC Therapeutics","Industry",0,0,"Male","5 Years","N/A","174","February 2008","December 2009","To determine the effect of PTC124 on ambulation in subjects with nonsense-mutation-mediated DMD/BMD (as assessed by changes in the distance walked during a 6-minute walk test)","0","0","0","0","0","0","0","0","0"
"1095","NCT00594100","GORE Embolic Protection With Reverse Flow","Carotid Artery Stenosis",0,"GORE Flow Reversal System (GFRS)","Device","W.L.Gore & Associates","Industry",0,0,"All","18 Years","N/A","245","July 2006","September 2008","Composite Major Adverse Event (MAE) Rate","0.002","0","One-Sample Binomial","0.054","Binomial Proportion","95","2-Sided","0.027","0.095"
"1096","NCT00594165","An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.","Early-Stage Parkinson's Disease",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","31 Years","N/A","217","June 2002","November 2008","Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","0","0","0","0","0","0","0","0","0"
"1097","NCT00594347","Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar","Streptococcus Pneumoniae",0,"Pneumo 23","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","12 Months","18 Months","339","November 2007","March 2008","To provide information concerning the safety after booster administration of 23-valent polysaccharidic pneumococcal vaccine","0","0","0","0","0","0","0","0","0"
"1098","NCT00594386","An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease","Parkinson's Disease",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","31 Years","N/A","258","August 2002","December 2008","Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","0","0","0","0","0","0","0","0","0"
"1099","NCT00594568","Effect of LY450139 on the Long Term Progression of Alzheimer's Disease","Alzheimer's Disease",0,"LY450139","Drug","Eli Lilly and Company","Industry",0,0,"All","55 Years","N/A","1537","March 2008","May 2011","Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks","0.134","0","Mixed Models Analysis","0","0","0","0","0","0"
"1100","NCT00594854","Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec","Gastric Ulcer",0,"PN400 (VIMOVO)","Drug","POZEN","Industry",0,0,"All","18 Years","N/A","20","September 2007","September 2008","Number of Participants With Gastric Ulcer Confirmed by Endoscopy","0","0","0","0","0","0","0","0","0"
"1101","NCT00595309","Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51","Japanese Encephalitis",0,"IC51","Biological","Valneva Austria GmbH","Industry",0,0,"All","18 Years","N/A","198","December 2007","October 2009","Seroconversion Rate","0","0","0","0","0","0","0","0","0"
"1102","NCT00595465","Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51","Japanese Encephalitis",0,"Japanese Encephalitis purified inactivated vaccine","Biological","Valneva Austria GmbH","Industry",0,0,"All","18 Years","N/A","389","December 2007","February 2008","Geometric Mean Titer (GMT) for Anti-JEV Neutralizing Antibody","0","0","0","0","0","0","0","0","0"
"1103","NCT00595517","Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer","Gastric Ulcer",0,"Esomeprazole 20 mg","Drug","AstraZeneca","Industry",0,0,"All","20 Years","N/A","395","October 2007","September 2009","Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period","0","0","0","0","0","0","0","0","0"
"1104","NCT00595946","Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone","Opioid-Induced Bowel Dysfunction",0,"Lubiprostone","Drug","Sucampo Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","439","August 2007","March 2009","Change From Baseline in Mean Weekly Spontaneous Bowel Movement Frequency","0","0","0","0","0","0","0","0","0"
"1105","NCT00596037","Treatment of Adults With Growth Hormone Deficiency","Pituitary Disorders",0,"Growth hormone - LB03002","Drug","LG Life Sciences","Industry",0,0,"All","23 Years","70 Years","136","August 2006","September 2008","Incidence of adverse events, antibody formation and local tolerability assessment after 1 year treatment from baseline of BPLG-005","0","0","0","0","0","0","0","0","0"
"1106","NCT00596466","Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures","Epilepsy",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","75","April 2008","December 2011","Seizure Frequency","0","0","0","0","0","0","0","0","0"
"1107","NCT00596492","DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery","Mature Cataracts",0,"DYME","Drug","Aqumen Biopharmaceuticals, N.A.","Industry",0,0,"All","18 Years","N/A","200","May 2008","September 2008","Optimal curvilinear capsulorrhexis with a single dose, as assessed by the surgeon based on the tissue dyed and subsequently removed.","0","0","0","0","0","0","0","0","0"
"1108","NCT00596583","DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery","Mature Cataracts",0,"DYME","Drug","Aqumen Biopharmaceuticals, N.A.","Industry",0,0,"All","18 Years","N/A","300","April 2007","May 2008","Optimal curvilinear capsulorrhexis with a single dose, as assessed by the surgeon based on the tissue dyed and subsequently removed.","0","0","0","0","0","0","0","0","0"
"1109","NCT00596791","Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops","Ocular Hypertension",0,"tafluprost","Drug","Santen Oy","Industry",0,0,"All","18 Years","N/A","150","January 2008","July 2008","Change from screening in ocular symptoms and signs","0","0","0","0","0","0","0","0","0"
"1110","NCT00596817","Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes","Major Depressive Disorder",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","75 Years","639","December 2007","September 2009","Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator","0.0035","0","Cox-model","2.01","Hazard Ratio (HR)","95","2-Sided","1.26","3.21"
"1111","NCT00596830","Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology","Carcinoma, Squamous Cell",0,"CP-751,871 (Figitumumab)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","681","April 2008","March 2011","Overall Survival (OS)","0.064","The p-value stated is the 2-sided p-value from the log rank test stratified by gender, prior adjuvant chemotherapy, and histology.","Log Rank","1.179","Hazard Ratio (HR)","95","2-Sided","0.990","1.404"
"1112","NCT00597428","Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone","Opioid-Induced Bowel Dysfunction",0,"Lubiprostone","Drug","Sucampo Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","437","August 2007","March 2009","Change From Baseline in Mean Weekly Spontaneous Bowel Movement (SBM) Frequency in Subjects Without Dose Reduction Prior to Week 8","0","0","0","0","0","0","0","0","0"
"1113","NCT00597584","Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","Chronic Renal Failure",0,"peginesatide","Drug","Affymax","Industry",0,0,"All","18 Years","N/A","823","October 2007","July 2009","Mean Change in Hemoglobin Between Baseline and the Evaluation Period","0","0","0","0.10","Least Squares Mean Difference","95","2-Sided","-0.05","0.26"
"1114","NCT00597753","Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","Chronic Renal Failure",0,"peginesatide","Drug","Affymax","Industry",0,0,"All","18 Years","N/A","803","September 2007","July 2009","Mean Change in Hemoglobin Between Baseline and the Evaluation Period","0","0","0","-0.15","Least Squares Mean Difference","95","2-Sided","-0.30","-0.01"
"1115","NCT00598273","Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis","Chronic Renal Failure",0,"peginesatide","Drug","Affymax","Industry",0,0,"All","18 Years","N/A","490","October 2007","March 2009","Mean Change in Hemoglobin Between Baseline and the Evaluation Period","0","0","0","0.03","Least Squares Mean Difference","97.5","2-Sided","-0.19","0.26"
"1116","NCT00598312","Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer","Prostate Cancer",0,"Leuprolide Acetate for Injectable Suspension","Drug","Oakwood Laboratories, LLC","Industry",0,0,"Male","45 Years","N/A","201","April 2007","August 2008","The percentage of responders who attain and maintain castrate levels of serum testosterone","0","0","0","0","0","0","0","0","0"
"1117","NCT00598403","Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis","Urinary Tract Infections",0,"cefditoren pivoxil","Drug","Tedec-Meiji Farma, S.A.","Industry",0,0,"Female","18 Years","N/A","611","November 2007","December 2009","Microbiological efficacy","0","0","0","0","0","0","0","0","0"
"1118","NCT00598442","Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis","Chronic Renal Failure",0,"peginesatide","Drug","Affymax","Industry",0,0,"All","18 Years","N/A","493","November 2007","July 2009","Mean Change in Hemoglobin Between Baseline and the Evaluation Period","0","0","0","0.14","Least Squares Mean Difference","97.5","2-Sided","-0.09","0.36"
"1119","NCT00598559","Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients","Acute Pain",0,"IV Acetaminophen","Drug","Mallinckrodt","Industry",0,0,"All","18 Years","85 Years","213","January 2008","November 2008","Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE).","0","0","0","0","0","0","0","0","0"
"1120","NCT00598702","Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients","Pain",0,"IV Acetaminophen","Drug","Mallinckrodt","Industry",0,0,"All","37 Weeks","16 Years","100","January 2008","December 2008","Number of Subjects Reporting at Least One Treatment Emergent Adverse Event (TEAE)","0","0","0","0","0","0","0","0","0"
"1121","NCT00598806","Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant for Noninvasive Bladder Cancer","Bladder Cancer",0,"EOquin® (Apaziquone)","Drug","Spectrum Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","813","September 2007","December 2009","To evaluate the recurrence rate at 2 years in randomized patients with tumor histology Ta, G1-G2 who receive TUR-BT plus EOquin® versus those who receive TUR-BT plus placebo.","0","0","0","0","0","0","0","0","0"
"1122","NCT00598832","Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%","Acne Vulgaris",0,"Adapalene lotion 0.1%","Drug","Galderma","Industry",0,0,"All","12 Years","N/A","1075","November 2007","October 2008","Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12","0","0","0","0","0","0","0","0","0"
"1123","NCT00599027","An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma","Allergic Rhinitis",0,"Mometasone furoate nasal spray (MFNS)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","75 Years","51","May 2008","May 2009","The Change of the Rhinasthma Global Summary Score From Baseline to Endpoint After 28 Days of Treatment.","0.001","Endpoint after 28 days of treatment","ANCOVA","0","0","0","0","0","0"
"1124","NCT00599196","An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease","Early Stage Parkinson's Disease",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","30 Years","N/A","381","August 2002","December 2008","Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","0","0","0","0","0","0","0","0","0"
"1125","NCT00599521","Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%","Acne Vulgaris",0,"Adapalene lotion 0.1%","Drug","Galderma","Industry",0,0,"All","12 Years","N/A","1067","November 2007","November 2008","Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12","0","0","0","0","0","0","0","0","0"
"1126","NCT00599716","Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome","Dry Eye Disease",0,"sodium hyaluronate","Drug","Lantibio","Industry",0,0,"All","18 Years","N/A","300","December 2006","April 2008","staining of the cornea and conjunctiva","0","0","0","0","0","0","0","0","0"
"1127","NCT00599872","Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies","Allergic Rhinitis",0,"Standardized Ragweed Allergenic Extract","Biological","Greer Laboratories","Industry",0,0,"All","18 Years","50 Years","430","March 2008","November 2008","Scores on a Scale (Average of Daily Rhinoconjunctivitis Symptom Score (RSS) Recorded During the Ragweed Season","<0.05","0","ANCOVA","-0.418","Mean Difference (Net)","95","2-Sided","-1.15","0.48"
"1128","NCT00600483","Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection","Cardiac Surgery",0,"gentamicin-collagen sponge dipped in saline","Drug","Innocoll","Industry",0,0,"All","18 Years","N/A","1502","December 2007","September 2010","Efficacy will be evaluated by a comparison between the 2 study groups of the incidence of surgical wound infections that occur within the period from surgery through postop day 90.","0","0","0","0","0","0","0","0","0"
"1129","NCT00600925","A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection","Colorectal Surgery",0,"gentamicin-collagen sponge dipped in saline","Drug","Innocoll","Industry",0,0,"All","18 Years","N/A","600","January 2008","March 2009","Primarily, efficacy will be evaluated by a comparison between the 2 study groups of the incidence of surgical wound infections (involving the laparotomy incision) that occur within the period from surgery through postop day 60.","0","0","0","0","0","0","0","0","0"
"1130","NCT00601172","A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.","Nausea and Vomiting",0,"Casopitant","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","710","March 2008","April 2009","Complete response (no vomiting and no use of rescue medication) assessed via subject diary completed during cycle 1, that records vomiting and the use of rescue medication.","0","0","0","0","0","0","0","0","0"
"1131","NCT00601367","Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder","Sexual Dysfunctions, Psychological",0,"flibanserin flexible dose","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","18 Years","N/A","480","January 2008","October 2009","Frequency of Adverse Events","0","0","0","0","0","0","0","0","0"
"1132","NCT00602745","S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen","Pancreatic Neoplasm",0,"S-1","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","61","February 2008","March 2010","Overall Survival","0","0","0","0","0","0","0","0","0"
"1133","NCT00603239","Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin","Type 2 Diabetes Mellitus",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","165","January 2008","July 2009","Change in Glycosylated Hemoglobin (HbA1c)","<0.001","No adjustments were made (alpha = 0.05).","ANCOVA","0","0","0","0","0","0"
"1134","NCT00603291","BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus","Obesity",0,"Lorcaserin 10 mg QD","Drug","Arena Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","604","December 2007","June 2010","Co-primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52","<0.0001","0","Regression, Logistic","3.14","Odds Ratio (OR)","95","2-Sided","2.05","4.80"
"1135","NCT00603473","A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures","Epilepsies, Partial",0,"gabapentin","Drug","Pfizer","Industry",0,0,"All","3 Years","15 Years","92","January 2008","December 2009","Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures","0","0","0","0","0","0","0","0","0"
"1136","NCT00603525","Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy","Arthritis, Rheumatoid",0,"Ofatumumab","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","169","January 2008","March 2011","Number of Participants With a 20% Improvement From Baseline in Their American College of Rheumatology (ACR) Score (ACR20) at Week 24","0","0","0","0","0","0","0","0","0"
"1137","NCT00603577","Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens","Colorectal Neoplasms",0,"Placebo","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","102","January 2008","November 2009","Neurological sensory assessment using the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE, Version 3.0)","0","0","0","0","0","0","0","0","0"
"1138","NCT00603707","Assessment of Whole Gut Transit Time Using the SmartPill Capsule","Constipation",0,NA,NA,"The SmartPill Corporation","Industry",0,0,"All","18 Years","80 Years","178","October 2006","June 2008","whole gut transit time","0","0","0","0","0","0","0","0","0"
"1139","NCT00603733","Canadian Active & Maintenance Modified Pentasa Study","Active Ulcerative Colitis",0,"5-ASA (5-Aminosalicylate)","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","288","October 2007","May 2011","Active Phase: Proportion of Active Subjects Achieving Overall Improvement","0","0","0","0","0","0","0","0","0"
"1140","NCT00603798","Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)","Actinic Keratosis",0,"Imiquimod cream","Drug","Graceway Pharmaceuticals, LLC","Industry",0,0,"All","18 Years","N/A","490","January 2008","July 2008","Number of Participants With Complete Clearance of AK Lesions","0","0","0","0","0","0","0","0","0"
"1141","NCT00603902","BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management","Obesity",0,"Lorcaserin 10 mg QD","Drug","Arena Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","4008","January 2008","July 2009","Co-primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52","<0.0001","0","Regression, Logistic","2.69","Odds Ratio, log","95","2-Sided","2.31","3.13"
"1142","NCT00604214","Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock","Sepsis",0,"Drotrecogin alfa (activated)","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1696","March 2008","September 2011","28-Day All-Cause Mortality","0.313","No adjustment for multiple comparisons.","Chi-squared","1.088","Risk Ratio (RR)","95","2-Sided","0.923","1.283"
"1143","NCT00604279","A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia","Schizophrenia",0,"Paliperidone palmitate (R092670)","Drug","Xian-Janssen Pharmaceutical Ltd.","Industry",0,0,"All","18 Years","N/A","452","January 2008","January 2009","Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 92 or Early Withdrawal","0","0","0","-2.3","Least Square Mean Difference","95","0","-5.20","0.63"
"1144","NCT00604500","A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)","Asthma",0,"SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","272","March 2008","November 2008","Overall Discrepancy Rate","0","0","0","0","0","0","0","0","0"
"1145","NCT00604539","Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee","Synovitis",0,"Chondroitin sulphate (Condrosan)","Drug","Bioiberica","Industry",0,0,"All","40 Years","N/A","70","February 2008","November 2009","Evaluation of the change in the severity of synovitis measured by MRI according to the modified methods of Loeuille et al. after chondroitin sulphate treatment in patients with knee OA and clinical signs of synovitis","0","0","0","0","0","0","0","0","0"
"1146","NCT00605176","Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)","Actinic Keratoses",0,"imiquimod cream","Drug","Graceway Pharmaceuticals, LLC","Industry",0,0,"All","18 Years","N/A","479","January 2008","July 2008","Number of Participants With Complete Clearance of AK Lesions","0","0","0","0","0","0","0","0","0"
"1147","NCT00605215","BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)","Multiple Sclerosis",0,"laquinimod","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","18 Years","55 Years","1331","April 2008","November 2011","Assess efficacy, as measured by number of confirmed relapses","0","0","0","0","0","0","0","0","0"
"1148","NCT00605280","A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.","Macular Edema Associated With Diabetes Mellitus",0,"Standard of Care","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","317","September 2005","November 2009","Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 Year","0.0047","Adjusted for glycolated hemoglobin (HbA1c), systolic blood pressure (BP), diastolic BP, and baseline VA. Baseline values not carried forward for missing post-baseline data.","Cochran-Mantel-Haenszel","2.38","Odds Ratio (OR)","95","2-Sided","1.32","4.30"
"1149","NCT00605384","A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection","Chronic Hepatitis B",0,"Entecavir + Tenofovir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","4","August 2008","February 2009","Number of Participants Who Achieved an Hepatitis B Virus DNA (HBV DNA) Level < 50 IU/mL at Week 48","0","0","0","0","0","0","0","0","0"
"1150","NCT00606177","A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode","Bipolar I Disorder",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","18 Years","65 Years","99","January 2008","November 2010","Young Mania Rating Scale (YMRS)","0","0","0","0","0","0","0","0","0"
"1151","NCT00606229","A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode","Bipolar I Disorder",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","18 Years","65 Years","41","January 2008","November 2010","Young Mania Rating Scale (YMRS)","0","0","0","0","0","0","0","0","0"
"1152","NCT00606281","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode","Bipolar I Disorder",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","18 Years","65 Years","258","January 2008","November 2010","Young Mania Rating Scale (YMRS)","<0.001","0","ANCOVA","-6.0","Mean Difference (Final Values)","95","2-Sided","-9.4","-2.7"
"1153","NCT00606320","A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode","Bipolar I Disorder",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","18 Years","65 Years","59","January 2008","November 2010","Young Mania Rating Scale (YMRS)","0","0","0","0","0","0","0","0","0"
"1154","NCT00606489","Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients","Burns",0,"Caldolor","Drug","Cumberland Pharmaceuticals","Industry",0,0,"All","N/A","N/A","61","November 2007","May 2009","Temperature","0","0","0","0","0","0","0","0","0"
"1155","NCT00606632","Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody","Renal Cell Carcinoma",0,"124-Iodine-cG250 (124I-cG250)","Drug","Wilex","Industry",0,0,"All","18 Years","N/A","226","March 2008","November 2009","Sensitivity - Proportion of Participant Determinded to Have Clear Cell Renal Carcinoma (ccRCC) by PET/CT.","0","0","0","0","0","0","0","0","0"
"1156","NCT00607152","Rasburicase (Fasturtec) Registration Trial","Hyperuricemia",0,"Rasburicase","Drug","Sanofi","Industry",0,0,"All","18 Years","50 Years","10","October 2007","January 2009","Mean plasma uric acid AUC0-96","0","0","0","0","0","0","0","0","0"
"1157","NCT00607256","Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia","Fibromyalgia",0,"[S,S]-reboxetine","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","500","October 2007","May 2009","12-lead ECG","0","0","0","0","0","0","0","0","0"
"1158","NCT00607373","Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia","Lipid Metabolism, Inborn Errors",0,"mipomersen","Drug","Kastle Therapeutics, LLC","Industry",0,0,"All","12 Years","N/A","51","July 2007","March 2009","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point","<0.001","Statistical significance was concluded if p≤0.05","t-test, 2 sided","0","0","0","0","0","0"
"1159","NCT00607971","Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)","Constipation-Predominant Irritable Bowel Syndrome",0,"Renzapride","Drug","Alizyme","Industry",0,0,"Female","18 Years","N/A","939","April 2006","June 2008","Adverse events","0","0","0","0","0","0","0","0","0"
"1160","NCT00608959","Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects","Infection",0,"omiganan 1% gel","Drug","Mallinckrodt","Industry",0,0,"All","18 Years","70 Years","30","May 2008","June 2008","Change in Mean Number of Skin Bacterial Counts From Baseline to 72 Hours","<0.001","0","t-test, 2 sided","-1.91","Mean Difference (Final Values)","95","0","-2.55","-1.26"
"1161","NCT00608985","Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia","Primary Insomnia",0,"almorexant","Drug","Midnight Pharma, LLC","Industry",0,0,"All","18 Years","64 Years","709","March 2008","September 2009","Change From Baseline to Day 1&2 in Wake After Sleep Onset (WASO)","<0.0001","0","Wilcoxon rank-sum","-15.0","Median Difference (Net)","95","2-Sided","-21.8","-8.8"
"1162","NCT00609466","A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy","Bunionectomy",0,"CG5503 IR","Drug","Grünenthal GmbH","Industry",0,0,"All","18 Years","80 Years","291","September 2007","February 2008","Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.","<0.0001","No multiplicity adjustment used.","ANCOVA","70.8","Least square mean","95","0","35.9","105.6"
"1163","NCT00610675","Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)","Insomnia",0,"Org 50081","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","346","December 2006","August 2009","Number of Participants With an Adverse Event","0","0","0","0","0","0","0","0","0"
"1164","NCT00610935","Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza","Influenza",0,"Peramivir","Drug","BioCryst Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","82","January 2007","June 2008","The time to alleviation of clinical signs and symptoms of influenza","0","0","0","0","0","0","0","0","0"
"1165","NCT00611026","Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.","Overactive Bladder",0,"Tolterodine ER","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","2417","February 2008","October 2009","Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12","<0.0001","Comparison fesoterodine vs tolterodine ER performed only if statistical significance favoring fesoterodine achieved for fesoterodine vs placebo to preserve overall alpha level at 5%; pairwise comparison also performed for tolterodine ER vs placebo.","Van Elteren's Test","0","0","0","0","0","0"
"1166","NCT00611455","Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy","Arthritis, Rheumatoid",0,"ofatumumab","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","265","January 1, 2008","June 8, 2009","Number of Participants With a 20% Improvement From Baseline in Their American College of Rheumatology (ACR) Score (ACR20) at Week 24","<0.001","0","Cochran-Mantel-Haenszel","2.86","Odds Ratio (OR)","95","2-Sided","1.67","4.91"
"1167","NCT00612170","A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.","Fibromyalgia",0,"[S,S]-Reboxetine","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","1129","December 2007","May 2009","Change from baseline in the endpoint mean pain score","0","0","0","0","0","0","0","0","0"
"1168","NCT00612742","Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women","Hypoactive Sexual Desire Disorder",0,"testosterone gel","Drug","BioSante Pharmaceuticals","Industry",0,0,"Female","50 Years","N/A","3656","January 2008","October 2012","The rate of adjudicated, predefined cardiovascular events in LibiGel-treated subjects compared to that of placebo-treated subjects.","0","0","0","0","0","0","0","0","0"
"1169","NCT00612898","Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection","HIV Infections",0,"apricitabine","Drug","Avexa","Industry",0,0,"All","18 Years","N/A","239","February 2008","January 2010","Proportion of patients with plasma HIV-1 RNA <50 copies/mL at W24","0","0","0","0","0","0","0","0","0"
"1170","NCT00613002","Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women","Hypoactive Sexual Desire Disorder",0,"testosterone gel","Drug","BioSante Pharmaceuticals","Industry",0,0,"Female","30 Years","65 Years","597","December 2006","September 2011","Co-primary endpoints are the change in the 4-week total number of satisfying sexual events from the Baseline period to Weeks 21-24, and the change from Baseline to Weeks 21-24 in the mean ISED desire score.","0","0","0","0","0","0","0","0","0"
"1171","NCT00613106","Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)","Osteoarthritis",0,"HZT-501","Drug","Horizon Pharma Ireland, Ltd., Dublin Ireland","Industry",0,0,"All","40 Years","81 Years","179","September 2007","October 2008","Number of Participants With Treatment Emergent Adverse Events","0.4228","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1172","NCT00613938","A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.","Arthralgia",0,"Tapentadol (CG5503)","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","80 Years","901","February 2008","October 2008","Sum of Pain Intensity Difference Over 48 Hours (SPID48)","<0.001","Comparisons of tapentadol dose groups and placebo was performed with Hochberg procedure for adjustment for the multiple tests.","ANCOVA","62.4","Mean Difference (Final Values)","95","0","39.01","85.73"
"1173","NCT00614120","Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes","Diabetes",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","80 Years","929","January 2008","February 2009","Change in Glycosylated Haemoglobin A1c (HbA1c)","<0.0001","Non-inferiority; <.0001. In order to protect the overall Type I error rate when testing for non-inferiority of the three doses of lira + met to glim + met, the comparisons will be invoked sequentially for descending doses of liraglutide.","ANCOVA","-0.06","Estimated treatment difference, LS Mean","95","0","-0.23","0.11"
"1174","NCT00614445","The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy","Nausea and Vomiting of Pregnancy",0,"doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg","Drug","Duchesnay Inc.","Industry",0,0,"Female","18 Years","N/A","280","January 2008","July 2009","Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall Score of Symptoms From Baseline (Day 1) to End of Study Visit (Day 15).","0","0","0","0","0","0","0","0","0"
"1175","NCT00614939","Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment","Type 2 Diabetes",0,"Saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","572","January 2008","June 2009","Absolute Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) Level to Week 12 Last Observation Carried Forward (LOCF)","0.007","0","ANCOVA","-0.42","Mean Difference (Net)","95","2-Sided","-0.71","-0.12"
"1176","NCT00615030","Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease (COPD)",0,"Indacaterol","Drug","Novartis","Industry",0,0,"All","40 Years","N/A","96","January 2008","July 2008","Trough Forced Expiratory Volume in 1 Second (FEV1) Following 14 Days of Evening Dosing of Indacaterol Versus Placebo","0","0","0","0","0","0","0","0","0"
"1177","NCT00615251","A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization","Infertility",0,"DR-2011","Drug","Duramed Research","Industry",0,0,"Female","18 Years","42 Years","1297","February 2008","August 2009","Clinical pregnancy rate at 8 weeks and 12 weeks of pregnancy","0","0","0","0","0","0","0","0","0"
"1178","NCT00615264","Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients","Type 1 Diabetes",0,"DiaPep277","Drug","Andromeda Biotech Ltd.","Industry",0,0,"All","16 Years","45 Years","457","September 2005","September 2011","Change From Baseline in Glucagon-stimulated C-peptide AUC at 24 Months","0.2851","0","Mixed Models Analysis","0","0","0","0","0","0"
"1179","NCT00615433","Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia","Schizophrenia",0,"Lurasidone","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","478","January 2008","December 2009","Change in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period.","<0.05","0","Mixed Models Analysis","0","0","0","0","0","0"
"1180","NCT00615459","A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control","Chronic Obstructive Pulmonary Disease (COPD)",0,"Indacaterol","Drug","Novartis","Industry",0,0,"All","40 Years","N/A","169","February 2008","December 2008","24-hour Post-dose Trough Forced Expiratory Volume in 1 Second (FEV1) After 14 Days of Treatment","0","0","0","0","0","0","0","0","0"
"1181","NCT00615550","PREGNANT Short Cervix Trial","Preterm Delivery",0,"progesterone","Drug","Juniper Pharmaceuticals, Inc.","Industry",0,0,"Female","15 Years","45 Years","465","March 2008","November 2010","Number of Participants With Birth <=32 6/7 Weeks Gestation.","0.020","0","Cochran-Mantel-Haenszel","0.55","Risk Ratio (RR)","95","2-Sided","0.33","0.92"
"1182","NCT00615836","An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (""Melt"") Formulation of Desmopressin for the Treatment of Nocturia in Adults","Nocturia",0,"Desmopressin Melt","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","554","December 2007","May 2010","Change From Baseline in Mean Number of Nocturnal Voids","0","0","0","0","0","0","0","0","0"
"1183","NCT00616421","Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children","Meningococcal Infections",0,"MenACWY-CRM","Biological","Novartis Vaccines","Industry",0,0,"All","2 Years","10 Years","2907","March 2008","April 2009","Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age","0","0","0","0","0","0","0","0","0"
"1184","NCT00616551","Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients","Acromegaly",0,"C2L-OCT-01 PR, 30 mg","Drug","Ambrilia Biopharma, Inc.","Industry",0,0,"All","18 Years","65 Years","65","April 2007","February 2008","Compare the mean serum concentrations of insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in patients treated with C2L-OCT-01 PR, 30 mg or Sandostatin LAR 30 mg","0","0","0","0","0","0","0","0","0"
"1185","NCT00616772","Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood","Coronary Artery Disease",0,"ABT-335","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","45 Years","N/A","682","February 2008","September 2012","Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT)","0.220","0","Repeated measures linear mixed model","-0.006","Mean Difference (Final Values)","95","2-Sided","-0.016","0.004"
"1186","NCT00616902","The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5","Chronic Kidney Disease (CKD) Stage 5",0,"paricalcitol injection 4 mcg/mL","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","12","January 2009","May 2009","Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI)","0","0","0","0","0","0","0","0","0"
"1187","NCT00617123","Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)","Atherosclerosis",0,"Vorapaxar 2.5 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","258","July 1, 2008","October 1, 2010","Number of Participants Who Develop Vacuolization in the Inner Nuclear Layer (INL) of the Retina as Measured by Ocular Coherence Tomography (OCT)","0","0","0","0","0","0","0","0","0"
"1188","NCT00617669","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer","Prostate Cancer",0,"Docetaxel","Drug","AstraZeneca","Industry",0,0,"Male","18 Years","N/A","1494","January 2008","May 2011","Overall Survival","0","0","0","0","0","0","0","0","0"
"1189","NCT00617760","Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)","Neisseria Meningitidis (Bacterial Meningitis)",0,"Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)","Biological","Pfizer","Industry",0,0,"All","12 Months","18 Months","330","March 2008","August 2009","Number of subjects achieving PCV7-specific (elicited by each vaccine pneumococcal serotype) antibody concentrations of at least 0.2 mg/mL 1 month after a booster vaccination with PCV7","0","0","0","0","0","0","0","0","0"
"1190","NCT00618098","Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures","Reversal of Anticoagulant Treatment",0,"Octaplex (human prothrombin complex concentrate)","Biological","Octapharma","Industry",0,0,"All","18 Years","N/A","200","May 2008","March 2012","There will be two primary end points in this study. The first primary efficacy endpoint is the correction of INR to < 1.5.","0","0","0","0","0","0","0","0","0"
"1191","NCT00618748","Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed","Bipolar I Disorder",0,"Olanzapine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","75 Years","101","February 2008","September 2010","Percentage of Participants With Adverse Events Leading to Discontinuation","0","0","0","0","0","0","0","0","0"
"1192","NCT00618956","A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring","Fibromyalgia",0,"Milnacipran hydrochloride","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","70 Years","321","October 2007","July 2008","Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 4","0","0","0","0","0","0","0","0","0"
"1193","NCT00619229","Alprostadil in Maculopathy Study (AIMS)","Macular Degeneration",0,"Alprostadil (prostaglandin E1)","Drug","UCB Pharma","Industry",0,0,"All","50 Years","N/A","37","July 2006","February 2010","Difference in Visual Acuity Between Measurements at 3 Months After Drug Intervention and Measurements at Baseline (Assessed Within Early Treatment Diabetic Retinopathy Study (ETDRS) Chart)","0.1220","The criterion for significance (α) was set at one-sided α = 0.025, which means that only an effect in the expected direction was interpreted.","ANCOVA","0.94","Mean Difference (Final Values)","95","2-Sided","-0.674","2.55"
"1194","NCT00619398","A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients","Liver Transplantation",0,"Prograf","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","70 Years","172","January 2008","March 2009","Event rate of patients with acute rejections","0","0","0","0","0","0","0","0","0"
"1195","NCT00619502","Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants","Diphtheria",0,"DTaP-IPV-HB-PRP~T vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","15 Months","18 Months","254","December 2007","July 2008","Percentage of Participants With Pre-booster Antibody Persistence and Booster Response to DTaP-IPV-Hep B-PRP~T After Primary Vaccination With Either DTaP-IPV-Hep B-PRP~T or Pentaxim™ + Engerix B Vaccine™","0","0","0","0","0","0","0","0","0"
"1196","NCT00620022","The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","Chronic Obstructive Pulmonary Disease",0,"Indacaterol 300 μg","Drug","Novartis","Industry",0,0,"All","40 Years","N/A","90","April 2008","January 2009","Exercise Duration Time Assessed by Constant-load Cycle Ergometry at the End of Each Treatment Period","0","0","0","0","0","0","0","0","0"
"1197","NCT00620035","A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)","Contraception",0,"Radiopaque Etonogestrel Implant","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","40 Years","301","March 2007","October 2010","Percentage of Applicator Users Who Were Very Satisfied and Satisfied- User Satisfaction Questionnaire for Domain: Design & Technical Aspects","0","0","0","0","0","0","0","0","0"
"1198","NCT00620282","The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus","Diabetes",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","40 Years","70 Years","49","February 2008","May 2010","Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)","0.0549","2-sided significance level of 5%.","ANCOVA","7.43","Least squares mean","95","0","-0.164","15.025"
"1199","NCT00620464","A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)","Contraception",0,"Radiopaque Implanon","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","40 Years","108","May 2005","February 2009","Bioequivalence of Implanon® and Radiopaque Implanon.","0.05","Applies to all parameters.","Bioequivalence Testing","0","0","0","0","0","0"
"1200","NCT00620555","A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures","Epilepsies, Partial",0,"gabapentin","Drug","Pfizer","Industry",0,0,"All","3 Years","N/A","65","May 2008","December 2010","Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)","0","0","0","0","0","0","0","0","0"
"1201","NCT00621504","Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia","Bacterial Pneumonia",0,"Ceftaroline fosamil for Injection","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","606","January 2008","December 2008","Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) Populations","0","0","0","6.2","Risk Difference (RD)","95","2-Sided","-0.2","12.6"
"1202","NCT00622089","Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients","Type 2 Diabetes",0,"DIO-902","Drug","DiObex","Industry",0,0,"All","18 Years","75 Years","150","January 2008","December 2008","The following parameters will be evaluated at Week 12 and Week 24: • Proportion of subjects who reach the lipid goal as defined in the protocol from baseline • Proportion of subjects who meet the HbA1c goal as defined in the protocol from baseline","0","0","0","0","0","0","0","0","0"
"1203","NCT00622700","Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis","Multiple Sclerosis",0,"Teriflunomide","Drug","Sanofi","Industry",0,0,"All","18 Years","55 Years","618","February 2008","December 2012","Core Treatment Period: Time to Conversion to Clinically Deﬁnite Multiple Sclerosis (CDMS)","0.0087","P value was derived using Wald chi-squared test in the Cox proportional hazard model.","Wald chi-squared","0.574","Hazard Ratio (HR)","95","2-Sided","0.379","0.869"
"1204","NCT00623025","Creon in HIV Patients With Steatorrhea","Steatorrhea",0,"Creon 25000","Drug","Abbott","Industry",0,0,"All","18 Years","80 Years","34","January 2009","August 2009","Coefficient of fat absorption (CFA)","0","0","0","0","0","0","0","0","0"
"1205","NCT00623194","Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689","Diabetes",0,"insulin detemir","Drug","Novo Nordisk A/S","Industry",0,0,"All","3 Years","17 Years","146","February 2008","September 2009","Insulin Detemir-insulin Aspart Cross-reacting Antibodies","0","0","0","0","0","0","0","0","0"
"1206","NCT00623467","Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging","Central Nervous System Diseases",0,"Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","343","December 2007","December 2008","Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 1 (BR1)","< 0.0001","for contrast enhancement","paired t-test","2.03","Mean Difference (Final Values)","0","0","0","0"
"1207","NCT00623480","Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment","Hemophilia A",0,"Recombinant Factor VIII (Kogenate FS, BAY14-2222)","Biological","Bayer","Industry",0,0,"Male","12 Years","50 Years","84","March 2008","September 2011","Bleeding Frequency (Number of Total Bleeds)","<0.0001","0","Negative Binomial Regression Model","14.7","Ratio (On-Demand vs. Prophylaxis)","95","2-Sided","8.1","26.5"
"1208","NCT00623636","Phase 3 Study of MAP0004 in Adult Migraineurs","Migraine Disorders",0,"MAP0004","Drug","Allergan","Industry",0,0,"All","18 Years","65 Years","902","July 2008","December 2010","Number of Subjects With Pain Relief at 2 Hours From Time of First Dose","0","0","0","0","0","0","0","0","0"
"1209","NCT00623701","Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation","Allergy",0,"Allerslit forte","Biological","Allergopharma GmbH & Co. KG","Industry",0,0,"All","18 Years","65 Years","126","March 2008","October 2011","Symptom and Medication Score","0","0","0","0","0","0","0","0","0"
"1210","NCT00624026","Memantine - Communication Study","Alzheimer's Disease",0,"Memantine-HCl","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","50 Years","90 Years","107","November 2007","December 2008","To assess the efficacy of the memantine OD IR treatment using the Consortium to establish a registry for Alzheimer's Disease (CERAD-NP) total score","0","0","0","0","0","0","0","0","0"
"1211","NCT00624078","Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation","Scorpion Sting Envenomation",0,"Antivenin Centruroides (scorpion) F(ab)2 Anascorp™","Drug","Instituto Bioclon S.A. de C.V.","Industry",0,0,"All","N/A","N/A","1426","May 2005","September 2010","Evaluate the adverse events profile of each patient","0","0","0","0","0","0","0","0","0"
"1212","NCT00624286","Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease",0,"Indacaterol 150 μg","Drug","Novartis","Industry",0,0,"All","40 Years","N/A","416","February 2008","July 2008","Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85)","0","0","0","0","0","0","0","0","0"
"1213","NCT00624845","Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy","Postoperative Pain",0,"OMS103HP","Drug","Omeros Corporation","Industry",0,0,"All","18 Years","75 Years","200","December 2007","May 2009","The primary efficacy endpoint is the mean VAS at 24 hours postoperatively.","0","0","0","0","0","0","0","0","0"
"1214","NCT00625612","Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease","Cystic Fibrosis",0,"Denufosol Tetrasodium (INS37217) Inhalation Solution","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","5 Years","N/A","466","February 2008","October 2010","Change in lung function","0","0","0","0","0","0","0","0","0"
"1215","NCT00625872","Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy","Growth Hormone Therapy",0,"Somatropin","Drug","Pfizer","Industry",0,0,"All","6 Years","10 Years","23","July 2008","March 2011","Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6","0.7232","The statistical test was 2-sided and performed at the 5 percent significance level.","ANCOVA","-0.43","Least squares (LS) mean difference","95","2-Sided","-3.93","3.08"
"1216","NCT00626002","Open Label Continuation Study in Moderate to Severe Psoriasis","Moderate to Severe Plaque Psoriasis",0,"ABT-874","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","2301","February 2008","October 2011","Proportion of subjects achieving PGA ""clear"" (0) or ""minimal"" (1) scores by visit.","0","0","0","0","0","0","0","0","0"
"1217","NCT00626028","Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing","Idiopathic Pulmonary Arterial Hypertension",0,"Nitric Oxide for inhalation","Drug","Mallinckrodt","Industry",0,0,"All","N/A","18 Years","136","September 2004","February 2010","Reversible Pulmonary Hypertension (Vasoreactivity)as Defined by Hemodynamic Measurements","0","0","0","0","0","0","0","0","0"
"1218","NCT00626288","Mesalazine Therapy in Patients With Irritable Bowel Syndrome","Irritable Bowel Syndrome",0,"Mesalazine","Drug","SOFAR S.p.A.","Industry",0,0,"All","18 Years","65 Years","187","December 2007","March 2012","""Responder"" is the patient who affirmatively answers on at least 50% of the weekly question:""Did you have satisfactory relief of your abdominal discomfort or pain during the last week?"".","0","0","0","0","0","0","0","0","0"
"1219","NCT00626392","Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia","Dyslipidemia",0,"niacin extended-release (NER)","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","277","February 2008","April 2008","Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment","0.010","No adjustments were made for multiple comparisons. P-values <= 0.05 were reported as statistically significant.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1220","NCT00626431","A Study of Leuprolide to Treat Prostate Cancer","Prostate Cancer",0,"Leuprolide acetate - Formulation A","Drug","Abbott","Industry",0,0,"Male","18 Years","N/A","310","February 2008","August 2009","Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint.","0","0","0","0","0","0","0","0","0"
"1221","NCT00626548","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer","Prostate Cancer",0,"ZD4054","Drug","AstraZeneca","Industry",0,0,"Male","18 Years","N/A","2577","January 2008","January 2011","Overall Survival","0","0","0","0","0","0","0","0","0"
"1222","NCT00627016","A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn","Gastroesophageal Reflux",0,"Dexlansoprazole","Drug","Takeda","Industry",0,0,"All","18 Years","65 Years","305","March 2008","March 2009","Median Percentage of Nights Without Heartburn Over 4 Weeks as Assessed by Daily Diary.","<0.001","Statistical significance for the comparison of the primary endpoint was determined at 0.05 level.","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"1223","NCT00627094","Biatain Ibu vs. Biatain in Painful Chronic Venous Leg Ulcers","Leg Ulcers",0,"Biatain","Device","Coloplast A/S","Industry",0,0,"All","18 Years","N/A","120","March 2008","April 2009","Pain Relief","0.0438","In order to obtain 90% power to show superiority of Biatain Ibu compared to Biatain, a sample size of 60 pts per group (assuming a 15% drop-out rate) was found by simulating data from multi-nomial distributions over time.","Chi-squared","1.73","Odds Ratio (OR)","95","2-Sided","1.02","2.96"
"1224","NCT00627445","Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes","Diabetes",0,"biphasic insulin aspart 30","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","441","February 2008","January 2009","Change in Glycosylated Haemoglobin A1c (HbA1c)","0","0","0","0","0","0","0","0","0"
"1225","NCT00627497","DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral Fusion","Degenerative Lumbar Spinal Stenosis",0,"Single-Level Posterior Decompression","Procedure","Medtronic Spinal and Biologics","Industry",0,0,"All","35 Years","N/A","32","February 2008","December 2010","Rate of Overall Success","0","0","0","0","0","0","0","0","0"
"1226","NCT00627926","A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","Hepatitis C",0,"Pegylated Interferon Alfa 2a","Biological","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","18 Years","70 Years","1095","March 2008","May 2010","Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study Treatment","0","0","0","23.0","Difference in percentage","95","2-Sided","15.9","30.0"
"1227","NCT00628095","Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate","Arthritis, Rheumatoid",0,"CE-224,535","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","100","March 2008","February 2009","ACR 20","0","0","0","0","0","0","0","0","0"
"1228","NCT00628108","Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months","Allergic Rhinitis",0,"Levocetirizine 1.25 mg","Drug","UCB Pharma","Industry",0,0,"All","6 Months","11 Months","69","March 2008","September 2008","Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Ventricular Rate (VR)","0","0","0","0","0","0","0","0","0"
"1229","NCT00628589","Staccato® Loxapine Treatment of Schizophrenic Patients With Agitation","Schizophrenic Patients With Acute Agitation",0,"loxapine","Drug","Alexza Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","65 Years","300","February 2008","May 2008","Change in PANSS Excited Component (PEC) score from baseline following Dose #1 of Staccato Loxapine, compared with placebo","0","0","0","0","0","0","0","0","0"
"1230","NCT00628680","A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis","End Stage Renal Disease",0,"AAT-023 solution (Zuragen)","Device","Ash Access Technology","Industry",0,0,"All","18 Years","N/A","415","July 2006","July 2008","To show that AAT-023 (Zuragen) solution is superior to Heparin in preventing CRBSI when used as a catheter lock solution in CVCD's between hemodialysis treatments.","0","0","0","0","0","0","0","0","0"
"1231","NCT00628758","A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma","Asthma",0,"Symbicort TBH - Turbuhaler","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","430","December 2005","September 2008","Time to First Severe Asthma Exacerbation","0","0","0","0","0","0","0","0","0"
"1232","NCT00628862","Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU","Chronic Obstructive Pulmonary Disease",0,"Formoterol Turbuhaler® 4.5mg","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","613","December 2007","April 2009","Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose","0","0","0","0","0","0","0","0","0"
"1233","NCT00629551","An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder","Depressive Disorder, Major",0,"saredutant (SR48968)","Drug","Sanofi","Industry",0,0,"All","18 Years","65 Years","825","February 2008","February 2009","Change from baseline in the Hamilton Depression Rating Scale (HAM-D) total score","0","0","0","0","0","0","0","0","0"
"1234","NCT00630201","Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence","Opioid Dependence",0,"Probuphine (buprenorphine implant)","Drug","Braeburn Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","62","October 2007","February 2009","Number of subjects with adverse events as a measure of safety","0","0","0","0","0","0","0","0","0"
"1235","NCT00630487","Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency","Growth Hormone Deficiency",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","9","May 2008","October 2008","Change of Visceral Fat Mass Assessed by Magnetic Resonance Imaging Scanning (MRI)","0","0","0","0","0","0","0","0","0"
"1236","NCT00630747","Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase","Hunter Syndrome",0,"Idursulfase","Biological","Shire","Industry",0,0,"Male","5 Years","N/A","94","September 2004","January 2008","Change From Baseline in Mean Percent Predicted Forced Vital Capacity (FVC) at Week 105","0","0","0","0","0","0","0","0","0"
"1237","NCT00630799","Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients","Prostate Cancer",0,"leuprolide acetate","Drug","GP-Pharm","Industry",0,0,"Male","18 Years","N/A","20","May 2008","April 2009","Percent of successful patients achieving chemical castration","0","0","0","0","0","0","0","0","0"
"1238","NCT00630812","Long Term Administration of Inhaled Mannitol in Cystic Fibrosis","Cystic Fibrosis",0,"inhaled mannitol","Drug","Pharmaxis","Industry",0,0,"All","6 Years","N/A","318","September 2008","April 2010","Change in absolute FEV1","0","0","0","0","0","0","0","0","0"
"1239","NCT00630877","Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin","Dyslipidemia",0,"Niacin extended-release (NER)","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","276","February 2008","June 2008","Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score","0","0","0","0","0","0","0","0","0"
"1240","NCT00631111","Study Evaluating the Efficacy of an Ibuprofen Effervescent Tablet in the Treatment of Post-Surgical Dental Pain","Pain",0,"effervescent ibuprofen tablets","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","16 Years","40 Years","270","November 2007","April 2008","Sum of pain relief and pain intensity difference scores","0","0","0","0","0","0","0","0","0"
"1241","NCT00631319","A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic OA Pain","Chronic Pain",0,"OROS HYDROMORPHONE","Drug","Mallinckrodt","Industry",0,0,"All","30 Years","80 Years","200","February 2008","April 2009","Mean change from baseline to week 12 (or last visit) of the average PI of the DB treatment based on weekly avrg. PI scores from the patient diary.","0","0","0","0","0","0","0","0","0"
"1242","NCT00631371","Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects","Renal Cell Carcinoma",0,"Bevacizumab","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","791","April 2008","April 2012","Progression-Free Survival (PFS): Independent-Assessment","0.8","0","Log Rank","1.1","Hazard Ratio (HR)","95","2-Sided","0.9","1.3"
"1243","NCT00631475","Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443","Idiopathic Pulmonary Fibrosis",0,"Bosentan","Drug","Actelion","Industry",0,0,"All","18 Years","N/A","128","April 2008","April 2010","Extent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF)","0","0","0","0","0","0","0","0","0"
"1244","NCT00631657","A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)","Sleep Initiation and Maintenance Disorders",0,"Esmirtazapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","460","March 2008","November 2009","Change From Baseline in Total Sleep Time (TST) - 6-Month Treatment Period","<0.0001","0","ANCOVA","48.7","Difference in Least Squares (LS) Means","95","2-Sided","35.0","62.5"
"1245","NCT00631969","Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction","Erectile Dysfunction",0,"Vardenafil ODT (STAXYN, BAY38-9456)","Drug","Bayer","Industry",0,0,"Male","18 Years","N/A","362","April 2008","January 2009","Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or LOCF","< 0.0001","0","ANCOVA","-7.109","Mean Difference (Final Values)","95","0","-8.562","-5.6561"
"1246","NCT00632008","Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers","Chronic Diabetic Foot Ulcers",0,"Soluble beta-glucan (SBG)","Drug","Biotec Pharmacon ASA","Industry",0,0,"All","18 Years","N/A","122","March 2007","August 2009",NA,"0","0","0","0","0","0","0","0","0"
"1247","NCT00632736","An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease","Parkinson Disease",0,"Ropinirole XL (formerly CR)","Drug","GlaxoSmithKline","Industry",0,0,"All","30 Years","N/A","419","February 2004","March 2010","Number of Participants With the Indicated Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"1248","NCT00633477","Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure","Sepsis",0,"Resatorvid","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","18","February 2008","February 2009","All-cause Mortality","0","0","0","0","0","0","0","0","0"
"1249","NCT00633880","Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)","Symptomatic Neurogenic Orthostatic Hypotension (NOH)",0,"Placebo","Drug","Chelsea Therapeutics","Industry",0,0,"All","18 Years","N/A","181","January 2008","August 2009","Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)","0.509","Statistical analysis plan involved a hierarchical assessment of secondary endpoints to prevent inflation of type I errors. As the primary endpoint was not positive, statistical analysis was not performed on secondary endpoints.","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"1250","NCT00633893","Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism","Venous Thrombosis",0,"Apixaban","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","2711","May 2008","August 2012","Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation","<0.0001","Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.","Cochran-Mantel-Haenszel","0.3283","Risk Ratio (RR)","95","2-Sided","0.2225","0.4844"
"1251","NCT00633919","Efficacy of SLITone in House Dust Mite Allergic Patients","Allergy",0,"SLITone(TM) Dermatophagoides mix","Biological","ALK-Abelló A/S","Industry",0,0,"All","18 Years","65 Years","124","July 2006","December 2008","Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2008","0.85","0","Linear mixed effect (LME) model","0","0","0","0","0","0"
"1252","NCT00634517","4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma","Asthma",0,"Armstrong Albuterol Sulfate Inhalation Aerosol","Drug","Amphastar Pharmaceuticals, Inc.","Industry",0,0,"All","4 Years","11 Years","48","March 2008","December 2008","The primary endpoint for efficacy evaluation is to obtain the ratio of the geometric mean of area under the curve of change in FEV1%versus time for pediatric patients using the study drug to the active reference drug.","0","0","0","0","0","0","0","0","0"
"1253","NCT00634829","Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction","Asthma",0,"albuterol (Armstrong Albuterol HFA)","Drug","Amphastar Pharmaceuticals, Inc.","Industry",0,0,"All","12 Years","50 Years","24","February 2008","October 2008","The maximum percentage fall in FEV1, from the Pre-Exercise FEV1, between Albuterol-HFA and Placebo-HFA.","0","0","0","0","0","0","0","0","0"
"1254","NCT00635089","Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis","Eosinophilic Esophagitis",0,"reslizumab","Drug","Ception Therapeutics","Industry",0,0,"All","5 Years","N/A","190","July 2008","January 2012","Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs, or Discontinuation Due to AEs","0","0","0","0","0","0","0","0","0"
"1255","NCT00635206","Investigation of a Novel Positive Pressure Therapy to Rescue Patients Failing to Tolerate CPAP During an Initial Encounter","Obstructive Sleep Apnea",0,"BiPap auto with Fi Flex","Device","Clayton Sleep Insititute","Industry",0,0,"All","21 Years","75 Years","51","September 2007","May 2009","proportion of participants compliant (at least four hours of use per night for all nights) in the Auto Bilevel group compared to the CPAP group after 90 days of treatment during the investigation.","0","0","0","0","0","0","0","0","0"
"1256","NCT00635219","Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder","Major Depressive Disorder",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","75 Years","766","February 2008","April 2009","Change From Baseline in MADRS Total Score After 8 Weeks of Treatment","0.1321","Since p-value >0.025, hierarchically testing stopped here.","ANCOVA","-1.70","Mean Difference (Final Values)","95","2-Sided","-3.92","0.51"
"1257","NCT00635427","An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease","Gaucher Disease, Type 1",0,"VPRIV®","Biological","Shire","Industry",0,0,"All","2 Years","N/A","95","May 2008","December 2012","Overall Summary of Treatment Emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"1258","NCT00635505","Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients","Asthma",0,"albuterol HFA (Armstrong's)","Drug","Amphastar Pharmaceuticals, Inc.","Industry",0,0,"All","12 Years","75 Years","300","September 2007","August 2008","The primary endpoint is the bronchodilator effect expressed as the mean area under the curve (AUC) of FEV1 (% change from Same-Day Baseline FEV1) versus time.","0","0","0","0","0","0","0","0","0"
"1259","NCT00635765","Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients","Acromegaly",0,"C2L-OCT-01 PR 30 mg","Drug","Ambrilia Biopharma, Inc.","Industry",0,0,"All","18 Years","65 Years","63","October 2007","June 2009","Assess, for up to an additional 96 weeks, the safety profile of C2L-OCT-01 PR administered intra muscularly every 6, 5 or 4 weeks in patients who have completed the C2L-OCT-01 PR-301 study.","0","0","0","0","0","0","0","0","0"
"1260","NCT00635817","A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty","Puberty, Precocious",0,"Leuprolide acetate 11.25 mg","Drug","Abbott","Industry",0,0,"All","2 Years","11 Years","84","June 2008","January 2010","Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6","0","0","0","0","0","0","0","0","0"
"1261","NCT00636116","Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.","Snake Bite",0,"Crotalinae (pit viper) equine immune F(ab)2","Biological","Instituto Bioclon S.A. de C.V.","Industry",0,0,"All","2 Years","80 Years","121","May 2008","November 2011","Incidence rate of patients experiencing coagulopathy during the follow-up phase of the study. Absolute Platelet levels < 150,000/mm3. Absolute Fibrinogen levels < 150 mg/dL. Clinical coagulopathy requiring additional antivenom.","0","0","0","0","0","0","0","0","0"
"1262","NCT00636480","Preoperative Skin Preparation Evaluation","Topical Antisepsis",0,"Chlorhexidine gluconate","Drug","CareFusion","Industry",0,0,"All","16 Years","N/A","60","October 2007","March 2008","3.0 log10 reduction in CFU/cm2 on inguinal sites, and 2.0 log10 reduction in CFU/cm2 on abdominal sites","0","0","0","0","0","0","0","0","0"
"1263","NCT00636636","Safety and Efficacy of Gabapentin in Postherpetic Neuralgia","Neuralgia,Postherpetic",0,"Gabapentin Extended Release tablets","Drug","Depomed","Industry",0,0,"All","18 Years","N/A","452","March 2008","August 2009","Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score","0.0125","0","ANCOVA","-0.49","Least squares mean difference","95","2-Sided","-0.88","-0.11"
"1264","NCT00637104","European Multicenter, Randomized, Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent","Coronary Artery Disease",0,"Mar-Tyn TiN coated Co-Cr Numen stent implant","Device","International Biomedical Systems S.p.A.","Industry",0,0,"All","18 Years","N/A","160","July 2008","December 2010","in-stent minimum lumen diameter (MLD)","0","0","0","0","0","0","0","0","0"
"1265","NCT00637156","Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels","Cervical Degenerative Disc Disease",0,"PRESTIGE LP device at two adjacent levels","Device","Medtronic Spinal and Biologics","Industry",0,0,"All","18 Years","N/A","397","June 2006","January 2011","Rate of Overall Success","1.000","The posterior probability of non-inferiority was calculated and presented instead of the p-value.","Bayesian model","0.113","Risk Difference (RD)","95","2-Sided","0.022","0.201"
"1266","NCT00637273","A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)","Type 2 Diabetes Mellitus",0,"exenatide once weekly","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","514","January 2008","February 2009","Change in HbA1c From Baseline to Week 26","<.0001","Adjusted p-value was derived using Hochberg's procedure for multiple treatment comparisons.","ANOVA","0.63","Least Squares Mean Difference","95","2-Sided","0.37","0.89"
"1267","NCT00637377","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","Macular Degeneration",0,"Ranibizumab","Drug","Bayer","Industry",0,0,"All","50 Years","N/A","1240","April 2008","September 2010","Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)","0","0","0","-1.20","Risk Difference (RD)","95","2-Sided","-4.86","2.46"
"1268","NCT00638690","Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy","Prostatic Neoplasms",0,"Placebo","Drug","Cougar Biotechnology, Inc.","Industry",0,0,"Male","18 Years","N/A","1195","May 2008","August 2010","Overall Survival","<0.0001","Nominal P-value is 0.0142 at interim analysis based on group sequential design.","Log Rank","0.646","Hazard Ratio (HR)","95","2-Sided","0.543","0.768"
"1269","NCT00638703","Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients","Primary Hyperoxaluria",0,"Oxalobacter formigenes","Biological","OxThera","Industry",0,0,"All","5 Years","N/A","43","October 2007","September 2008","Reduction in urinary oxalate Percentage change in urinary oxalate (expressed as mmole/1.73m2 /day) from Baseline to Week 24","0","0","0","0","0","0","0","0","0"
"1270","NCT00639158","Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood","Dyslipidemias",0,"ABT-335","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","543","February 2008","October 2008","Median Percent Change in Triglycerides From Baseline to Final Visit","< 0.001","The treatment group comparisons for both primary efficacy variables must have demonstrated superiority of ABT-335 + atorvastatin + ezetimibe to declare this arm successful. Thus, no adjustments were made for multiple comparisons.","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"1271","NCT00639678","A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects","Healthy",0,"placebo","Drug","Human Genome Sciences Inc., a GSK Company","Industry",0,0,"All","18 Years","N/A","322","March 2008","July 2008","Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period","0","0","0","0","0","0","0","0","0"
"1272","NCT00640406","Comparison of Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting","Renal Artery Stenosis",0,"Dynamic Renal Stent plus Best Medical Treatment","Device","Biotronik AG","Industry",0,0,"All","18 Years","N/A","86","April 2008","December 2011","Difference between treatments in change of estimated glomerular filtration rate (eGFR)","0","0","0","0","0","0","0","0","0"
"1273","NCT00640510","A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia","Schizophrenia",0,"Rapid Acting Intramuscular Olanzapine","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","64 Years","34","March 2008","July 2008","Change From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC)","0.940","0","t-test, 2 sided","0","0","0","0","0","0"
"1274","NCT00640562","Quetiapine Extended Release Depression Symptoms","Schizophrenia",0,"Quetiapine Extended Release","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","216","February 2008","February 2010","Change From Baseline to Week 12 of Calgary Depression Scale for Schizophrenia (CDSS) Score.","0","0","0","0","0","0","0","0","0"
"1275","NCT00640601","Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia","Schizophrenia",0,"Quetiapine Fumarate Extended- Release","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","331","March 2008","July 2010","Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study","0","0","0","0","0","0","0","0","0"
"1276","NCT00640614","Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy","Contact Dermatitis",0,"T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens","Biological","Allerderm","Industry",0,0,"All","18 Years","N/A","235","April 2008","August 2009","Diagnostic Performance: Concordance","0","0","0","0","0","0","0","0","0"
"1277","NCT00640705","Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain","Ankle Sprain",0,"diclofenac sodium","Drug","Cerimon Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","170","January 2008","July 2008","Assess the efficacy of diclofenac in subjects with mild to moderate ankle sprain.","0","0","0","0","0","0","0","0","0"
"1278","NCT00640822","Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds","Psoriasis Vulgaris",0,"Calcipotriol plus hydrocortisone ointment vehicle","Drug","LEO Pharma","Industry",0,0,"All","18 Years","N/A","782","February 2008","June 2009","Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8","0","0","0","0","0","0","0","0","0"
"1279","NCT00640939","Diclofenac Patch for Treatment of Mild to Moderate Tendonitis or Bursitis","Rotator Cuff Tendonitis",0,"diclofenac sodium","Drug","Cerimon Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","308","December 2007","April 2008","Assess the efficacy of diclofenac in subjects with tendonitis or bursitis of the shoulder, elbow, or wrist.","0","0","0","0","0","0","0","0","0"
"1280","NCT00641056","Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)","Type 2 Diabetes Mellitus",0,"Exenatide Once Weekly","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","467","April 2008","May 2009","Change in HbA1c From Baseline to Week 26","0.017","No adjustments for multiplicity were performed","Mixed Models Analysis","-0.16","Least Squares Mean Difference","95","2-Sided","-0.29","-0.03"
"1281","NCT00641329","CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD","ADHD",0,"CLONICEL (clonidine HCl sustained release)","Drug","Addrenex Pharmaceuticals, Inc.","Industry",0,0,"All","6 Years","17 Years","198","February 2008","February 2009","ADHDRS-IV Total Score","0","0","0","0","0","0","0","0","0"
"1282","NCT00641667","An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain","Pain",0,"Fentanyl","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","66","January 2008","June 2008","Percentage of Participants Achieving Pain Control","0","0","0","0","0","0","0","0","0"
"1283","NCT00641719","A Long-term Study for the Treatment of Painful Diabetic Neuropathy","Diabetic Neuropathies",0,"Duloxetine hydrochloride","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","80 Years","258","March 2008","March 2010","Number of Participants Who Experienced an Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"1284","NCT00641745","Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia","Schizophrenia",0,"Lurasidone HCl","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","629","March 2008","July 2010","Number of Participants With Adverse Events.","0","0","0","0","0","0","0","0","0"
"1285","NCT00642382","Safety and Effectiveness of Agilus (Hyaluronic Acid) for Ankle Osteoarthritis","OSTEOARTHRITIS",0,"Agilus","Device","Cartiva, Inc.","Industry",0,0,"All","18 Years","95 Years","17","April 2008","October 2008","The comparison between the Agilus injection and the saline control injection groups in the proportion of subjects experiencing a reduction in the assessment of pain determined by the AOS subscale for pain.","0","0","0","0","0","0","0","0","0"
"1286","NCT00642421","Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients","Acromegaly",0,"C2L-OCT-01 PR, 10 or 20 mg","Drug","Ambrilia Biopharma, Inc.","Industry",0,0,"All","18 Years","N/A","40","February 2008","August 2009","To assess the safety profile of a new prolonged release formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or 6 weeks in acromegalic patients.","0","0","0","0","0","0","0","0","0"
"1287","NCT00642642","Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring","Acne Scarring of the Face",0,"Autologous Human Fibroblasts (azficel-T)","Biological","Fibrocell Technologies, Inc.","Industry",0,0,"All","18 Years","65 Years","122","November 2007","March 2009","Evaluator Live Acne Scarring Assessment Responders","0.0109","a priori threshold for statistical significance was 0.05","McNemar","0","0","0","0","0","0"
"1288","NCT00643071","Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients","Ulcerative Colitis",0,"Tacrolimus","Drug","Astellas Pharma Inc","Industry",0,0,"All","16 Years","64 Years","32","September 2006","May 2008","Improvement of Disease Activity Index score (DAI score)","0","0","0","0","0","0","0","0","0"
"1289","NCT00643357","Study of the Efficacy and Safety of Kalinox® 170 Bar for the Performance of Care Procedures in Children With Burns","Burns",0,"50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)","Drug","Air Liquide Santé International","Industry",0,0,"All","4 Years","15 Years","0","March 2008","January 2009","The intensity of the pain was assessed using the ""Faces Pain Scale Revised""","0","0","0","0","0","0","0","0","0"
"1290","NCT00643838","Use of 50% Nitrous Oxide / 50% Oxygen Premix in Primary Care Dental Centers","Dental Cares",0,"Kalinox 170 bar","Drug","Air Liquide Santé International","Industry",0,0,"All","1 Year","N/A","480","December 2007","July 2008","Pain measurement by using Visual Analog Scale (VAS) and Face Pain Scale (FPS)","0","0","0","0","0","0","0","0","0"
"1291","NCT00643851","An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","77 Years","994","June 2008","August 2009","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])","<0.0001","Primary endpoint was tested at alpha=0.05; significance was claimed only if DAPA 5MG + MET was superior to both controls.","ANCOVA","-0.86","Mean Difference (Final Values)","95","2-Sided","-1.11","-0.62"
"1292","NCT00644007","Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction and Hypertension","Erectile Dysfunction",0,"Placebo","Drug","SK Chemicals Co.,Ltd.","Industry",0,0,"Male","19 Years","N/A","109","December 2007","September 2008","Erectile Function domain score (sum of Question 1,2,3,4,5 and 15) of the International Index of Erectile Function (IIEF) Questionnaire","0","0","0","0","0","0","0","0","0"
"1293","NCT00644059","Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines","Influenza, Human",0,"Adjuvanted trivalent inactivated subunit influenza vaccine","Biological","Novartis","Industry",0,0,"All","6 Months","71 Months","4902","November 2007","April 2010","Number of Subjects (Unprimed) 6 to <36 Months Age With Local and Systemic Reactions After Any Vaccination for All Seasons, Comparison of Adjuvanted Trivalent Influenza Vaccine (aTIV) and Flu Vaccine Control.","0","0","0","0","0","0","0","0","0"
"1294","NCT00644358","A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)","Major Depressive Disorder",0,"vilazodone","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","70 Years","616","December 2007","May 2009","adverse events (AEs), laboratory parameters, physical examinations, vital signs, weight, ECGs, the CSFQ, ophthalmologic exams, the Columbia-Suicide Severity Rating Scale (C-SSRS).","0","0","0","0","0","0","0","0","0"
"1295","NCT00644787","A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain","Pain",0,"Fentanyl 1-day transdermal patch (Titration Phase)","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","156","December 2007","October 2008","Percentage of Participants Achieving Dose Titration Success","0","0","0","0","0","0","0","0","0"
"1296","NCT00644969","Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder","Smoking Cessation",0,"placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","75 Years","128","May 2008","April 2010","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"1297","NCT00645099","A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia","Schizophrenia",0,"olanzapine","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","65 Years","462","October 2007","April 2009","Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio)","< 0.0001","0","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"1298","NCT00645411","Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents","Influenza",0,"Cell culture-derived influenza subunit vaccine (cTIV)","Biological","Novartis","Industry",0,0,"All","3 Years","17 Years","3604","October 2007","February 2008","Geometric Mean Titers of the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children","0","0","0","0.85","Ratio of GMTs","95","2-Sided","0.72","1.01"
"1299","NCT00645671","Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery","Ocular Inflammation",0,"0.5% Loteprednol Etabonate Ophthalmic Ointment","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","400","March 2008","March 2009","Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.","0","0","0","0","0","0","0","0","0"
"1300","NCT00646399","Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis","Staphylococcal Sepsis",0,"Placebo","Drug","Biosynexus Incorporated","Industry",0,0,"All","N/A","48 Hours","1579","March 2009","May 2011","The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35.","0","0","0","0","0","0","0","0","0"
"1301","NCT00646477","ISIS 1 Therapeutic Effectiveness","OSAS (Obstructive Sleep Apneas Syndrome)",0,"titration night","Device","Tyco Healthcare Group","Industry",0,0,"All","18 Years","75 Years","24","October 2007","May 2008","To determine the sensitivity and specificity of the CPAP/autoCPAP Sandman in adequately detecting respiratory events and to evaluate the therapeutic effectiveness of the device in improving sleep quality and normalizing respiratory events","0","0","0","0","0","0","0","0","0"
"1302","NCT00646542","Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency","Diabetes Mellitus, Type 2",0,"Vildagliptin","Drug","Novartis","Industry",0,0,"All","18 Years","85 Years","525","March 2005","October 2010","To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatment","0","0","0","0","0","0","0","0","0"
"1303","NCT00647270","Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing","Rheumatoid Arthritis",0,"adalimumab","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","420","December 2007","April 2009","The Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly Dose Versus Placebo and Adalimumab 40 mg Every Other Week (Eow)","0.074","0","Chi-squared","-3.0","Mean Difference (Final Values)","95","2-Sided","-13.3","7.4"
"1304","NCT00647556","Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage","Photoaging",0,"adapalene gel, 0.3%","Drug","Galderma Laboratories, L.P.","Industry",0,0,"All","40 Years","N/A","30","April 2008","January 2010","Change From Baseline in Overall Integrated Assessment of Photodamage at Week 24","0","0","0","0","0","0","0","0","0"
"1305","NCT00647699","Corneal Collagen Cross-linking for Progressive Keratoconus","Progressive Keratoconus",0,"riboflavin ophthalmic solution","Drug","Avedro, Inc.","Industry",0,0,"All","14 Years","N/A","147","December 2007","April 2011","Mean Change From Baseline in Maximum Keratometry (Kmax)","0","0","0","0","0","0","0","0","0"
"1306","NCT00648895","A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients","Hypertension",0,"Nebivolol","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","79 Years","12","November 2007","July 2009","Percentage Change From Baseline to End of Treatment for the Difference Between the Post-ischemia and Pre-ischemia Forearm Vascular Resistance (FVR).","0","0","0","0","0","0","0","0","0"
"1307","NCT00648908","Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial","Multiple Sclerosis",0,"Fampridine-SR","Drug","Acorda Therapeutics","Industry",0,0,"All","18 Years","70 Years","269","June 2006","January 2011","Summary of Treatment Emergent Adverse Events (TEAE).","0","0","0","0","0","0","0","0","0"
"1308","NCT00649025","A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults","Asthma",0,"FlutiForm 250/10","Drug","SkyePharma AG","Industry",0,0,"All","12 Years","N/A","438","March 2008","October 2008","To demonstrate the efficacy in terms of the Formoterol fumarate component of SKP FlutiForm HFA pMDI (250/10ug) compared to SKP Fluticasone HFA pMDI (250ug), on the change in FEV1 from morning pre-dose at Baseline (Week 0) to 2 hours post-dose at Week 12.","0","0","0","0","0","0","0","0","0"
"1309","NCT00649389","Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension","Hypertension",0,"Olmesartan medoxomil","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","80 Years","2500","May 2008","April 2009","Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).","<0.0001","0","ANCOVA","0","0","0","0","0","0"
"1310","NCT00649428","Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles","Bilateral Nasolabial Fold Wrinkles",0,"Autologous Human Fibroblast (azficel-T)","Biological","Fibrocell Technologies, Inc.","Industry",0,0,"All","18 Years","N/A","203","October 2006","July 2008","Subject Wrinkle Assessment Responders",".00001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1311","NCT00649792","Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial","Multiple Sclerosis",0,"Fampridine-SR","Drug","Acorda Therapeutics","Industry",0,0,"All","18 Years","70 Years","214","August 2007","January 2011","Summary of Treatment Emergent Adverse Events (TEAE).","0","0","0","0","0","0","0","0","0"
"1312","NCT00650078","Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis","Rheumatoid Arthritis",0,"MR prednisone","Drug","Horizon Pharma Ireland, Ltd., Dublin Ireland","Industry",0,0,"All","18 Years","80 Years","350","March 2008","May 2009","ACR 20 Response Rate at Visit 4","0.0010","The p-value was based on logistic regression with treatment, geographic region, gender, and median age class as factors.","Regression, Logistic","2.25","Odds Ratio (OR)","95","2-Sided","1.39","3.64"
"1313","NCT00650104","Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164","Parkinson Disease",0,"Ropinirole XL (formerly CR)","Drug","GlaxoSmithKline","Industry",0,0,"All","30 Years","N/A","76","May 2002","March 2009","Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population)","0","0","0","0","0","0","0","0","0"
"1314","NCT00651105","Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects","Type-2 Diabetes",0,"Vildagliptin","Drug","Novartis","Industry",0,0,"All","30 Years","75 Years","63","February 2008","May 2009","GLP-1 and non GLP-1 effects of LAF237 on glucagon secretion in patients with Type-2 diabetes and matching healthy subjects","0","0","0","0","0","0","0","0","0"
"1315","NCT00651118","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis",0,"Placebo","Drug","Meda Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","832","March 2008","June 2008","Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (rTNSS)","0","0","0","0","0","0","0","0","0"
"1316","NCT00653523","Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)","Hypercholesterolemia",0,"Ezetimibe","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","N/A","151","December 1, 2007","June 1, 2009","Number of Participants With Adverse Events and Adverse Reactions","0","0","0","0","0","0","0","0","0"
"1317","NCT00654069","Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy","Pain",0,"Oxycodone HCl/Niacin Tablets 5/30 mg","Drug","Acura Pharmaceuticals Inc.","Industry",0,0,"All","18 Years","N/A","405","September 2007","February 2008","Reduction in pain intensity","0","0","0","0","0","0","0","0","0"
"1318","NCT00654095","Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)","Hypercholesterolemia",0,"Ezetimibe","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","N/A","146","December 1, 2007","June 1, 2009","Number of Participants With Adverse Events and Adverse Reactions","0","0","0","0","0","0","0","0","0"
"1319","NCT00654433","ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases","Inherited Metabolic Diseases",0,"ALD-101","Biological","Aldagen","Industry",0,0,"All","N/A","16 Years","40","March 2008","July 2011","To assess the efficacy of adjuvant therapy of ALD-101 in accelerating platelet engraftment in patients also receiving a standard unrelated UCBT for treatment of inherited metabolic diseases","0","0","0","0","0","0","0","0","0"
"1320","NCT00654706","Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia","Schizophrenia",0,"Sertindole","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","55 Years","264","March 2008","January 2010","Neurocognitive effect of treatment based on the overall composite score on the MCCB","0","0","0","0","0","0","0","0","0"
"1321","NCT00654901","Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™","Diphtheria",0,"DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","15 Months","18 Months","881","March 2008","May 2009","Geometric Mean Titers of Antibodies Before and After Booster Vaccination With DTaP-IPV-Hep B-PRP~T","0","0","0","0","0","0","0","0","0"
"1322","NCT00654927","Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis","Multiple Sclerosis",0,"Fampridine-SR b.i.d. (Twice Daily)","Drug","Acorda Therapeutics","Industry",0,0,"All","18 Years","70 Years","177","November 2003","January 2011","Summary of Treatment Emergent Adverse Events (TEAE).","0","0","0","0","0","0","0","0","0"
"1323","NCT00655291","Efficacy of XP20B Following Bunionectomy Surgery","Acute Pain",0,"XP20B","Drug","Xanodyne Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","190","April 2008","August 2008","Average pain over a fixed dosing period","0","0","0","0","0","0","0","0","0"
"1324","NCT00655356","Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles","Bilateral Nasolabial Fold Wrinkles",0,"Autologous Human Fibroblasts (azficel-T)","Biological","Fibrocell Technologies, Inc.","Industry",0,0,"All","18 Years","N/A","218","November 2006","July 2008","Subject Wrinkle Assessment Responders","<.00001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1325","NCT00655486","Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures","Partial Epilepsies",0,"lacosamide","Drug","UCB BIOSCIENCES, Inc.","Industry",0,0,"All","16 Years","60 Years","97","April 2008","June 2010","Number of Subjects With at Least One Adverse Event During This Open-label Extension Study (Maximum Study Duration 2 Years)","0","0","0","0","0","0","0","0","0"
"1326","NCT00655551","Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures","Partial Epilepsies",0,"lacosamide","Drug","UCB BIOSCIENCES, Inc.","Industry",0,0,"All","16 Years","60 Years","100","April 2008","September 2009","Number of Subjects With at Least One Adverse Event During the Treatment Period (up to 7 Days)","0","0","0","0","0","0","0","0","0"
"1327","NCT00655629","Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.","Erectile Dysfunction",0,"Vardenafil ODT (STAXYN, BAY38-9456)","Drug","Bayer","Industry",0,0,"Male","18 Years","N/A","339","April 2008","February 2009","Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or Last Observation Carried Forward (LOCF)","<0.0001","0","ANCOVA","-6.92","Mean Difference (Final Values)","95","0","-8.45","-5.38"
"1328","NCT00655863","Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.","Diabetes Mellitus",0,"Alogliptin and Pioglitazone","Drug","Takeda","Industry",0,0,"All","18 Years","70 Years","71","July 2007","December 2009","Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.","<0.001","p-value and confidence interval presented without multiplicity adjustment.","ANCOVA","-307.229","Mean Difference (Final Values)","95","2-Sided","-443.168","-171.290"
"1329","NCT00656578","Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy","Pain",0,"4975","Drug","Anesiva, Inc.","Industry",0,0,"All","18 Years","N/A","300","March 2008","August 2008","Evaluate efficacy of a single intraoperative administration of 4975 in the management of acute postoperative pain in patients undergoing bunionectomy","0","0","0","0","0","0","0","0","0"
"1330","NCT00656799","Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)","Neuromuscular Blockade",0,"sugammadex","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","6","April 2008","July 2009","Clearance of Sugammadex by Dialysis as Measured by the Reduction Ratio (RR)","0","0","0","0","0","0","0","0","0"
"1331","NCT00657501","Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women","Hypoactive Sexual Desire Disorder",0,"testosterone gel","Drug","BioSante Pharmaceuticals","Industry",0,0,"Female","30 Years","65 Years","575","March 2008","September 2011","Co-primary endpoints are the change in the 4-week total number of satisfying sexual events from the Baseline period to Weeks 21-24, and the change from Baseline to Weeks 21-24 in the mean ISED desire score.","0","0","0","0","0","0","0","0","0"
"1332","NCT00657709","Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","Serogroup B Meningococcal Meningitis",0,"Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)","Biological","Novartis Vaccines","Industry",0,0,"All","55 Days","89 Days","3630","March 2008","January 2010","The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination","0","0","0","0.9","hSBA GMT ratios","95","2-Sided","0.81","0.99"
"1333","NCT00657904","Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer","Non-metastatic Prostate Cancer",0,"Bicalutamide","Drug","AstraZeneca","Industry",0,0,"Male","18 Years","N/A","3618","August 1995","July 2008","Time to clinical progression","0","0","0","0","0","0","0","0","0"
"1334","NCT00658008","A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)","Generalized Anxiety Disorder",0,"PD 0332334","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","501","April 2008","March 2009","The efficacy of PD 0332334 in the treatment of GAD will be measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) total scores from baseline observed following 8 weeks of double-blind treatment.","0","0","0","0","0","0","0","0","0"
"1335","NCT00658372","A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)","Generalized Anxiety Disorder",0,"PD 0332334","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","360","May 2008","March 2009","The efficacy of PD 0332334 in the treatment of GAD will be measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) total scores from baseline observed following 8 weeks of double-blind treatment.","0","0","0","0","0","0","0","0","0"
"1336","NCT00658567","A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","Parkinson's Disease Psychosis",0,"Pimavanserin tartrate (ACP-103)","Drug","ACADIA Pharmaceuticals Inc.","Industry",1,0,"All","40 Years","N/A","123","March 2008","December 2009","Antipsychotic Efficacy","0","0","0","0","0","0","0","0","0"
"1337","NCT00658645","Efficacy of Bifeprunox in Patients With Schizophrenia","Schizophrenia",0,"Bifeprunox","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","227","March 2008","August 2009","The difference in change from baseline to the 12-week time point between bifeprunox and placebo using the Positive and Negative Syndrome Scale (PANSS).","0","0","0","0","0","0","0","0","0"
"1338","NCT00658684","Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.","Overactive Bladder",0,"fesoterodine fumarate","Drug","Pfizer","Industry",0,0,"All","20 Years","N/A","153","February 2008","August 2009","Safety Measurement Based on Adverse Events (AEs), Vital Signs, Clinical Laboratory Test, 12-lead ECG and Residual Urine Volume","0","0","0","0","0","0","0","0","0"
"1339","NCT00658762","A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)","Generalized Anxiety Disorder",0,"PD 0332334","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","286","May 2008","April 2009","Change from Baseline in HAM-A total score at Week 8","0","0","0","0","0","0","0","0","0"
"1340","NCT00658788","Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis","Psoriasis",0,"clobetasol propionate spray 0.05%","Drug","Galderma Laboratories, L.P.","Industry",0,0,"All","18 Years","80 Years","305","March 2008","January 2009","Overall Disease Severity Success (ODS)","0","0","0","0","0","0","0","0","0"
"1341","NCT00660010","Study of Lupron Depot In The Treatment of Central Precocious Puberty","Puberty, Precocious",0,"Lupron (leuprolide acetate)","Drug","Abbott","Industry",0,0,"All","N/A","10 Years","55","January 1991","April 2009","Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)","0","0","0","0","0","0","0","0","0"
"1342","NCT00660179","Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension",0,"macitentan (ACT-064992)","Drug","Actelion","Industry",0,0,"All","12 Years","N/A","742","May 2008","March 2012","Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event)","0.0108","0","Log Rank","0.704","Hazard Ratio (HR)","97.5","2-Sided","0.516","0.960"
"1343","NCT00660335","Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas","Pancreatitis",0,"RG1068 (synthetic human secretin)","Drug","Repligen Corporation","Industry",0,0,"All","18 Years","N/A","258","March 2008","October 2009","The primary outcome measure will be assessed by comparing baseline MRCP images and RG1068-enhanced MRCP images for the presence or absence of pancreatic abnormalities.","0","0","0","0","0","0","0","0","0"
"1344","NCT00660387","Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","Advanced Parkinson's Disease",0,"Levodopa carbidopa intestinal gel (LCIG)","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","30 Years","N/A","35","December 2009","October 2011","Change From Baseline to Week 12 in Average Daily Normalized ""Off"" Time","0.0015","Treatment comparisons are based on an ANCOVA model including effects for treatment, country, and with the corresponding baseline and the natural logarithm of the mean daily dose of rescue medication on valid symptom diary days as covariates.","ANCOVA","-1.91","Treatment Difference (LS Mean)","95","2-Sided","-3.05","-0.76"
"1345","NCT00660452","A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites","Allergy",0,"Staloral","Drug","Stallergenes","Industry",0,0,"All","16 Years","50 Years","484","October 2007","July 2009","determine the proportion of patients who achieve well-controlled asthma with SLIT compared to placebo","0","0","0","0","0","0","0","0","0"
"1346","NCT00660504","Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer","Lung Cancer",0,"Amrubicin Hydrochloride","Drug","Sumitomo Pharmaceutical (Suzhou) Co., Ltd.","Industry",0,0,"All","18 Years","N/A","300","April 2008","February 2012","Overall Survival","0","0","0","0","0","0","0","0","0"
"1347","NCT00660517","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis",0,"MP29-02","Drug","Meda Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","607","December 2007","February 2008","Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)","0","0","0","0","0","0","0","0","0"
"1348","NCT00660595","Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose","Schizophrenic Disorders",0,"Quetiapine","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","29","September 2008","December 2008","Change From Baseline in Positive and Negative Symptoms Scale, Excitatory Subscale (PANSS-EC) Score (Time Frame: 3 Weeks)","0","0","0","0","0","0","0","0","0"
"1349","NCT00660829","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis",0,"Placebo","Drug","Meda Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","536","December 2007","February 2008","Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) (AM and PM Combined)at 14 Days","<0.001","0","ANCOVA","-1.5633","Mean Difference (Final Values)","95","0","-2.22","-0.91"
"1350","NCT00660907","Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients","Type 2 Diabetes",0,"dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","1217","March 2008","December 2009","Adjusted Mean Change in HbA1c Levels","<0.0001","Significant at alpha=0.025 (1-sided). A hierarchical closed testing procedure was used to control Type I error across the primary & key secondary objectives","ANCOVA","0.00","Mean Difference (Final Values)","95","2-Sided","-0.11","0.11"
"1351","NCT00660959","Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia","Hyponatremia With Normal Extracellular Fluid Volume",0,"lixivaptan","Drug","CardioKine Inc.","Industry",0,0,"All","18 Years","N/A","106","April 2008","June 2010","Average daily area under the curve (AUC) of change from baseline in serum sodium concentrations up to 72 hrs in lixivaptan treated subjects compared to placebo","0","0","0","0","0","0","0","0","0"
"1352","NCT00661245","Transoral Gastroplasty for the Treatment of Morbid Obesity","Obesity",0,"TOGA","Device","Satiety, Inc.","Industry",0,0,"All","18 Years","60 Years","275","July 2008","October 2010","Effectiveness: The proportion of subjects with ≥ 25% EWL (excess weight loss); Safety: Pre-defined objective performance criteria (OPC)","0","0","0","0","0","0","0","0","0"
"1353","NCT00661362","Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes","Type 2 Diabetes",0,"Saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","570","June 2008","September 2009","Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)","<0.0001","0","ANCOVA","-0.42","Mean Difference (Net)","95","2-Sided","-0.55","-0.29"
"1354","NCT00661687","Comparative Performance of PureVision Lens Designs","Myopia",0,"Currently Marketed PureVision Contact Lens.","Device","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","206","December 2007","February 2008","Subjective Responses to Symptoms/Complaints","0","0","0","0","0","0","0","0","0"
"1355","NCT00662532","Antibiotic Study for Dental Implants","Periodontitis",0,"Minocycline HCl","Drug","OraPharma","Industry",0,0,"All","21 Years","N/A","44","April 2008","April 2009","Overall PD Reduction","0","0","0","0","0","0","0","0","0"
"1356","NCT00662558","A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain","Low Back Pain",0,"celecoxib","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","802","January 2008","September 2008","Treatment Responders Based on the Numerical Rating Scale-Pain (NRS-Pain)","0","0","0","0.0910","Risk Difference (RD)","95","0","0.0255","0.1565"
"1357","NCT00662818","Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)","Migraine Disorders",0,"Telcagepant","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","165","March 17, 2008","September 2, 2009","Percentage of Participants With Pain Freedom at 2 Hours Post-dose (Period 1, Migraine Attack 1)","0.329","0","Regression, Logistic","1.62","Odds Ratio (OR)","95","2-Sided","0.62","4.25"
"1358","NCT00662831","Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients","Diabetic Foot Ulcer",0,"Fragmin/ Dalteparin Sodium","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","276","April 2008","October 2010","Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing","0","0","0","0","0","0","0","0","0"
"1359","NCT00662909","Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","Urinary Bladder, Overactive",0,"Mirabegron","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","2149","April 2008","April 2009","Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours","0.026","The response variable for the stratified rank ANCOVA was standardized ranks on change from baseline to Final Visit value with baseline standardized ranks and gender as covariates and geographic region as a stratum.","Stratified rank ANCOVA","-0.34","LS Mean Difference","95","2-Sided","-0.66","-0.03"
"1360","NCT00663260","Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment","Diabetes Mellitus, Type 2",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","631","June 2008","December 2009","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]","0.561","Primary endpoints were tested at alpha=0.027 applying Dunnett’s adjustment","ANCOVA","-0.08","Mean Difference (Final Values)","95","2-Sided","-0.37","0.20"
"1361","NCT00663273","Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower","Hygiene",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","10 Years","20 Years","30","December 2007","January 2008","Adverse events and their intensity and their association with the treatment.","0","0","0","0","0","0","0","0","0"
"1362","NCT00663325","Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower","Hygiene",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","10 Years","20 Years","30","December 2007","January 2008","Adverse events and their intensity and their association with the treatment","0","0","0","0","0","0","0","0","0"
"1363","NCT00663390","Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata Pocket BR","Hygiene",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","30","December 2007","January 2008","Adverse events and their intensity and their association with the treatment.","0","0","0","0","0","0","0","0","0"
"1364","NCT00663702","Phase IIIB Switching From Intravenous to Subcutaneous Study","Arthritis, Rheumatoid",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","123","May 2008","December 2009","Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Treatment-related Adverse Events (AEs), AEs Leading to Discontinuation, and AEs of Interest (AEIs) at Day 85","0","0","0","0","0","0","0","0","0"
"1365","NCT00663858","Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)","Benign Prostatic Hypertrophy",0,"Cetrorelix 78+78","Drug","AEterna Zentaris","Industry",0,0,"Male","50 Years","N/A","420","March 2008","September 2009","International Prostate Symptom Score (IPSS)","0.371","0","ANOVA","-0.592","Mean Difference (Final Values)","95","2-Sided","-1.894","0.709"
"1366","NCT00664183","A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects","Diabetic Retinopathy",0,"Vitreosolve","Drug","Vitreoretinal Technologies, Inc.","Industry",0,0,"All","30 Years","N/A","400","March 2008","December 2009","Ultrasound","0","0","0","0","0","0","0","0","0"
"1367","NCT00664391","Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Breeze","Hygiene",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","32","January 2008","February 2008","Adverse events and their intensity and their association with the treatment.","0","0","0","0","0","0","0","0","0"
"1368","NCT00664560","Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis","Osteoarthritis",0,"PN 400 (VIMOVO)","Drug","POZEN","Industry",0,0,"All","50 Years","N/A","614","April 2008","December 2008","Change in Western Ontario and McMaster Universities (WOMAC) Pain Questionnaire Subscore From Baseline","0","0","0","-0.22","Mean Difference (Final Values)","95","2-Sided","-4.76","4.32"
"1369","NCT00664859","12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia","Dyslipidemia",0,"LCP-AtorFen","Drug","Veloxis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","220","October 2007","February 2009","The primary endpoints are the mean percent changes in non-HDL cholesterol, HDL cholesterol, TG levels from the double-blind baseline (Week 0) to end-of-treatment (Week 52), and from the open-label baseline (Visit 1) to Week 52 (Visit 8).","0","0","0","0","0","0","0","0","0"
"1370","NCT00665223","A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease","Huntington's Disease",0,"ACR16","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","30 Years","N/A","437","April 2008","June 2011","The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score mMS) at 26 weeks of treatment.","0","0","0","0","0","0","0","0","0"
"1371","NCT00665366","Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder","Bipolar Disorder Mania",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","N/A","493","June 2008","October 2011","Change From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set)","0.058","0","ANCOVA","-2.04","Mean Difference (Final Values)","95","2-Sided","-4.14","0.07"
"1372","NCT00665431","Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis","Osteoarthritis",0,"PN 400 (VIMOVO)","Drug","POZEN","Industry",0,0,"All","50 Years","N/A","610","April 2008","December 2008","Change in Western Ontario and McMaster Universities (WOMAC) Pain Questionnaire Subscore From Baseline","0","0","0","-1.3","Mean Difference (Final Values)","95","2-Sided","-5.94","3.34"
"1373","NCT00665509","Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.","Influenza",0,"Trivalent influenza subunit vaccine Influvac","Biological","Solvay Biologicals","Industry",0,0,"All","18 Years","N/A","120","June 2008","July 2008","Immunogenicity (HI-titers after 2 and 3 weeks), reactogenicity and inconvenience of Influvac® 2008/2009","0","0","0","0","0","0","0","0","0"
"1374","NCT00665977","Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure","Obstructive Sleep Apnea",0,"Thermosmart & placebo","Drug","Clayton Sleep Insititute","Industry",0,0,"All","16 Years","65 Years","44","September 2007","July 2010","Although an exact & universal definition of CPAP compliance has not been determined. Compliance will be tracked by the CPAP unit and downloaded into an analysis program for review at each visit.","0","0","0","0","0","0","0","0","0"
"1375","NCT00666263","Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy","Multifocal Motor Neuropathy",0,"Immune Globulin Intravenous (human), 10%","Biological","Baxalta US Inc.","Industry",0,0,"All","18 Years","N/A","50","August 2008","August 2011","Grip Strength in the More Affected Hand","0","0","0","0","0","0","0","0","0"
"1376","NCT00666328","Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)","Hypertension",0,"clevidipine","Drug","The Medicines Company","Industry",0,0,"All","18 Years","N/A","37","June 2008","April 2010","Median Time to Achieve Target SBP Range (≤160 mmHg to ≥140 mmHg) Within 30 Minutes of Initiation of Clevidipine","0","0","0","0","0","0","0","0","0"
"1377","NCT00666393","An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients","Pain, Postoperative",0,"fentanyl iontophoretic transdermal system (40mcg) No placebo","Drug","Alza Corporation, DE, USA","Industry",0,0,"All","6 Years","17 Years","0","October 2008","December 2010","Any adverse events will be recorded. Oxygen saturation will be monitored continuously. Vital signs (BP, HR, RR, T), oxygen saturation, and concomitant medications will be recorded at Hours 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and every 4 hours thereafter.","0","0","0","0","0","0","0","0","0"
"1378","NCT00666458","18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)","Type 2 Diabetes",0,"saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","822","April 2008","March 2009","Hemoglobin A1c (HbA1c) Change From Baseline to Week 18","0","0","0","0.09","Mean Difference (Net)","95","2-Sided","-0.01","0.20"
"1379","NCT00666718","A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients","Diabetes Mellitus, Type 2",0,"Insulin Glargine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","374","April 2008","February 2010","Change From Baseline in Hemoglobin A1c (HbA1c) to Week 24","0","0","0","0.10","Mean Difference (Final Values)","95","2-Sided","-0.11","0.31"
"1380","NCT00667251","Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer","Breast Cancer",0,"trastuzumab","Biological","Novartis Pharmaceuticals","Industry",1,0,"Female","18 Years","N/A","649","October 7, 2008","August 1, 2012","Progression-free Survival","0","0","0","0","0","0","0","0","0"
"1381","NCT00667355","A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis","Ankylosing Spondylitis",0,"adalimumab","Biological","Abbott","Industry",0,0,"All","15 Years","N/A","41","February 2008","May 2009","Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12","0","0","0","0","0","0","0","0","0"
"1382","NCT00667446","Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty","Precocious",0,"Leuprolide Acetate 3 Month Depot","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","N/A","N/A","72","December 2008","October 2012","Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone","0","0","0","0","0","0","0","0","0"
"1383","NCT00667459","Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD","Cervical Degenerative Disc Disease",0,"PRESTIGE® LP Cervical Disc","Device","Medtronic Spinal and Biologics","Industry",0,0,"All","18 Years","N/A","280","January 2005","January 2008","Rate of Overall Success","0.995","The posterior probably of non-inferiority was calculated and presented instead of the p-value.","Bayesian logistic model","0.032","Risk Difference (RD)","95","2-Sided","-0.070","0.134"
"1384","NCT00667719","A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension","Essential Hypertension",0,"aliskiren /amlodipine/hydrochlorothiazide","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","564","June 2008","October 2009","To assess the long term safety of the combination of aliskiren /amlodipine / hydrochlorothiazide in patients with essential hypertension over 28 weeks to 54 weeks of treatment.","0","0","0","0","0","0","0","0","0"
"1385","NCT00667810","Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients","Alzheimer Disease",0,"bapineuzumab","Drug","Pfizer","Industry",0,0,"All","50 Years","89 Years","901","June 2008","October 2012","The Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)/11 Total Score at Week 78","0.057","The p-value is not adjusted for multiple comparison. The Hochberg approach is used to control for multiplicity between the two dose levels (0.5 mg/kg and 1.0 mg/kg) of bapineuzumab.","Mixed Models Analysis","-1.83","Mean Difference (Final Values)","95","2-Sided","-3.71","0.05"
"1386","NCT00667992","Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma","Asthma",0,"Budesonide HFA","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","99","April 2008","May 2009","PC 20 Methacholine (Provocative Concentration of Methacholine Causing 20 % Fall in FEV1(Forced Expiratory Volume)","0","0","0","0","0","0","0","0","0"
"1387","NCT00668226","Dermacyd Delicata Pocket BR - Photo Evaluation","Healthy",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","25","December 2007","January 2008","The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. The sensibility will be evaluated according to the skin type.","0","0","0","0","0","0","0","0","0"
"1388","NCT00668460","Dermatological Evaluation of Topic Compatibility-Dermacyd Delicata Pocket BR","Healthy",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","52","November 2007","January 2008","The absence of primary and accumulated dermal irritability and dermical sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.","0","0","0","0","0","0","0","0","0"
"1389","NCT00668486","Dermacyd Delicata Breeze - Photo Evaluation","Healthy",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","28","January 2008","February 2008","The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. The sensibility will be evaluated according to the skin type.","0","0","0","0","0","0","0","0","0"
"1390","NCT00668525","Escitalopram in Adult Patients With Major Depressive Disorder","Major Depressive Disorder",0,"Escitalopram","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","65 Years","877","April 2008","February 2009","Change From Baseline in Total Montgomery Asberg Depression Rating Scale (MADRS) at 8 Weeks.","0","0","0","0","0","0","0","0","0"
"1391","NCT00668577","Dermatological Evaluation of Topic Compatibility - Dermacyd Breeze","Healthy",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","52","December 2007","February 2008","The absence of primary and accumulated dermal irritability and dermal sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.","0","0","0","0","0","0","0","0","0"
"1392","NCT00668629","Dermacyd Tina Gel Sweet Flower - Photo Evaluation","Healthy",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","25","November 2007","January 2008","The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. The sensibility will be evaluated according to the skin type.","0","0","0","0","0","0","0","0","0"
"1393","NCT00668668","Dermatological Evaluation of Topic Compatibility-Dermacyd Tina Gel Sweet Flower","Hygiene",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","52","December 2007","January 2008","The absence of primary and accumulated dermal irritability and dermal sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.","0","0","0","0","0","0","0","0","0"
"1394","NCT00668759","A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation","Atrial Fibrillation",0,"Vernakalant Injection","Drug","Cardiome Pharma","Industry",0,0,"All","18 Years","85 Years","254","April 2008","October 2009","Proportion of subjects with conversion of atrial fibrillation to sinus rhythm within 90 minutes after the start of infusion.","0","0","0","0","0","0","0","0","0"
"1395","NCT00668850","Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin","Diabetes Mellitus",0,"Generex Oral-lyn™","Drug","Generex Biotechnology Corp.","Industry",0,0,"All","18 Years","75 Years","500","April 2008","August 2011","To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy","0","0","0","0","0","0","0","0","0"
"1396","NCT00668889","Dermacyd Tina Gel Tangerina Mix - Photo Evaluation","Healthy",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","25","November 2007","January 2008","The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. The sensibility will be evaluated according to the skin type.","0","0","0","0","0","0","0","0","0"
"1397","NCT00669058","Dermatological Evaluation of Topic Compatibility-Dermacyd Tina Gel Tangerina Mix","Healthy",0,"Lactic acid (Dermacid)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","52","December 2007","January 2008","The absence of primary and accumulated dermal irritability and dermal sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.","0","0","0","0","0","0","0","0","0"
"1398","NCT00669617","Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease",0,"Indacaterol","Drug","Novartis","Industry",0,0,"All","40 Years","N/A","89","April 2008","August 2008","Forced Expiratory Volume in 1 Second (FEV1) at 5 Minutes Post-dose","0","0","0","0","0","0","0","0","0"
"1399","NCT00669955","Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy","Helicobacter Infections",0,"Omeprazole, amoxicillin, clarithromycin","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","440","June 2008","July 2009","Helicobacter Pylori Eradication Confirmed by Urea Breath Test","0","0","0","0","0","0","0","0","0"
"1400","NCT00670228","Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction","AMI",0,"Insulin Glargine (LANTUS)","Drug","Sanofi","Industry",0,0,"All","35 Years","80 Years","34","April 2008","November 2009","Infarct Size Absolute Change From Baseline at Day 60","0","0","0","0","0","0","0","0","0"
"1401","NCT00670241","Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris","Psoriasis Vulgaris",0,"calcipotriol and betamethasone (LEO 80185 gel)","Drug","LEO Pharma","Industry",0,0,"All","18 Years","N/A","458","April 2008","February 2009","Subjects With ""Controlled Disease"" (""Clear"" or ""Almost Clear"" Disease) According to Investigator's Global Assessment of Disease Severity at Week 8","< 0.001","0","Cochran-Mantel-Haenszel","3.42","Odds Ratio (OR)","95","2-Sided","2.05","5.70"
"1402","NCT00670306","Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Hypertrophy",0,"Cetrorelix Pamoate","Drug","AEterna Zentaris","Industry",0,0,"Male","50 Years","N/A","528","March 2008","August 2009","IPSS Change From Baseline","<0.001","0","t-test, 2 sided","-5.6","Mean Difference (Net)","0","0","0","0"
"1403","NCT00671203","Prevention of Colon Ischemia During Aortic Aneurysm (AAA) Repair","Colon Ischemia",0,"Reestablish colon blood flow","Procedure","Spectros Corporation","Industry",0,0,"All","N/A","N/A","500","June 2007","September 2010","Detect colon ischemia early","0","0","0","0","0","0","0","0","0"
"1404","NCT00671268","Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma","Rhinoconjunctivitis",0,"AL0704rP","Biological","Allergopharma GmbH & Co. KG","Industry",0,0,"All","18 Years","60 Years","256","March 2008","March 2012","Change of Symptom and Medication score","0","0","0","0","0","0","0","0","0"
"1405","NCT00671502","A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back","Lower Back Pain",0,"Carisoprodol SR","Drug","Meda Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","840","April 2008","February 2009","Subject Rating of Pain on a 100-point Visual Analog Scale (VAS)","0","0","0","0","0","0","0","0","0"
"1406","NCT00671879","Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back","Lower Back Pain",0,"Carisoprodol SR 700 mg","Drug","Meda Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","830","April 2008","March 2009","Subject Rated Change Relief From Starting Backache of Pain on a 100-point Visual Analog Scale","0","0","0","0","0","0","0","0","0"
"1407","NCT00671918","Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma","Breast Cancer",0,"Lymphoseek","Drug","Navidea Biopharmaceuticals","Industry",0,0,"All","18 Years","N/A","186","April 2008","June 2009","Concordance of Blue Dye and Lymphoseek","0","0","0","0","0","0","0","0","0"
"1408","NCT00672620","Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder","Major Depressive Disorder",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","75 Years","611","April 2008","November 2008","Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8","0.577","Pre-specified sequential statistical testing procedure indicates that when p-value >0.05, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.","ANCOVA","-0.58","LS Mean Difference","95","2-Sided","-2.61","1.46"
"1409","NCT00672958","Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder","Major Depressive Disorder",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","75 Years","600","April 2008","November 2008","Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6","0.407","Pre-specified sequential statistical testing procedure indicates that when p-value for change from baseline in HAMD-24 at Week 6 >0.05, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.","ANCOVA","-0.74","LS Mean Difference","95","2-Sided","-2.48","1.01"
"1410","NCT00672997","A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension","Open-Angle Glaucoma",0,"Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution","Drug","Alcon Research","Industry",0,0,"All","20 Years","N/A","301","May 2008","December 2008","Mean Intraocular Pressure (IOP) combined across all visits and timepoints","0","0","0","0","0","0","0","0","0"
"1411","NCT00673049","Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer","Carcinoma, Large Cell",0,"CP 751,871 (Figitumumab)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","583","May 2008","March 2011","Overall Survival","0.35","One-sided significance level at alpha=0.024 was used. Two-sided p-value was reported.","Log Rank","1.091","Hazard Ratio (HR)","95","2-Sided","0.909","1.310"
"1412","NCT00673205","(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer","Non-Metastatic Prostate Cancer",0,"Bicalutamide","Drug","AstraZeneca","Industry",0,0,"Male","18 Years","N/A","3588","September 1995","August 2008","Time to clinical progression","0","0","0","0","0","0","0","0","0"
"1413","NCT00673231","Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","80 Years","1240","April 2008","May 2009","Adjusted Mean Change in HbA1c Levels","<0.0001","significant at alpha=0.019 (2-sided) applying Dunnett's adjustment. A hierarchical closed testing procedure was used to control the Type I error rate across the primary and key secondary endpoints.","ANCOVA","-0.45","Mean Difference (Final Values)","95","2-Sided","-0.59","-0.31"
"1414","NCT00673426","Safety Evaluation of Use Sodic Enoxaparin","Kidney Disease",0,"Enoxaparin sodic","Biological","Azidus Brasil","Industry",0,0,"Female","18 Years","80 Years","60","January 2008","March 2008",NA,"0","0","0","0","0","0","0","0","0"
"1415","NCT00674115","A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)","Gastric Acid",0,"Omeprazole/sodium bicarbonate","Drug","Bayer","Industry",0,0,"All","18 Years","65 Years","60","April 2008","June 2008","Change From Baseline in Median 24-hour Intragastric pH on the 7th Day of Drug Administration","0","0","0","0","0","0","0","0","0"
"1416","NCT00674362","Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study","Rheumatoid Arthritis",0,"Certolizumab pegol","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","194","June 2008","May 2010","Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24","0","0","0","0","0","0","0","0","0"
"1417","NCT00674661","Corneal Collagen Cross-Linking for Ectasia (CXL)","Ectasia",0,"riboflavin ophthalmic solution","Drug","Avedro, Inc.","Industry",0,0,"All","14 Years","N/A","130","December 2007","November 2011","Mean Change From Baseline in Maximum Keratometry (Kmax)","0","0","0","0","0","0","0","0","0"
"1418","NCT00674700","Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis","Allergic Rhinitis",0,"300 IR house dust mites allergen extract tablet","Drug","Stallergenes","Industry",0,0,"All","18 Years","50 Years","509","October 2007","February 2009","Average Adjusted Symptom Score (AAdSS) During the Year 1 Primary Period","0.0066","main effects = treatment and pools of study centers, Covariates = age, gender, asthma status, sensitization status and baseline ARTSS","ANCOVA","0","0","0","0","0","0"
"1419","NCT00674739","Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts","Genital Warts",0,"Imiquimod","Drug","Graceway Pharmaceuticals, LLC","Industry",0,0,"All","12 Years","N/A","470","May 2008","July 2009","Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study","0","0","0","0","0","0","0","0","0"
"1420","NCT00675103","Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients","Chronic Gout Refractory to Conventional Therapy",0,"pegloticase 8 mg i.v.","Drug","Savient Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","7","May 2008","January 2009","Adverse Event Profile","0","0","0","0","0","0","0","0","0"
"1421","NCT00675623","A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease","Alzheimer's Disease",0,"Dimebon","Drug","Medivation, Inc.","Industry",0,0,"All","50 Years","N/A","598","May 2008","December 2009","To determine the effect of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog).","0","0","0","0","0","0","0","0","0"
"1422","NCT00675792","Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)","Anesthesia",0,"Sugammadex","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","100","May 2008","September 2008","Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation","0","0","0","0","0","0","0","0","0"
"1423","NCT00676091","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil","Vaccines, Pneumococcal Conjugate Vaccine",0,"13-Valent Pneumococcal Conjugate Vaccine (13vPnC)","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","N/A","54 Days","354","April 2008","September 2009","Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Micrograms Per Milliliter (Mcg/mL) in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series","0","0","0","0","0","0","0","0","0"
"1424","NCT00676143","Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients","Alzheimer Disease",0,"bapineuzumab","Drug","Pfizer","Industry",0,0,"All","50 Years","88 Years","1100","January 2008","October 2012","Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78","0.979","Primary variable ADAS-Cog/11 total score had to reach statistical significance, p-values had to reach p <=0.05, in order to be declared effective.","Mixed Models Analysis","0.02","Mean Difference (Final Values)","95","2-Sided","-1.18","1.22"
"1425","NCT00676338","Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)","Type 2 Diabetes Mellitus",0,"exenatide once weekly","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","820","November 2008","July 2010","Change in HbA1c From Baseline to Week 26","0.620","Noninferiority was tested by Bonferroni (margin 0.3%, adjusted significance of 0.0167). Superiority was tested by Hommel (nominal significance level was between 0.0167 and 0.05 depended on the number of noninferiority hypotheses rejected).","Mixed Models Analysis","-0.05","Least Squares Mean Difference","98.3","2-Sided","-0.26","0.17"
"1426","NCT00676650","Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy","Prostatic Neoplasms",0,"Prednisone","Drug","Pfizer","Industry",0,0,"Male","18 Years","N/A","873","July 2008","December 2011","Overall Survival (OS)","0.1678","1-sided p-value from the stratified log-rank test","Log Rank","0.914","Hazard Ratio (HR)","95","2-Sided","0.762","1.097"
"1427","NCT00676845","Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection","Metabolic Syndrome",0,"olmesartan medoxomil","Drug","Daiichi Sankyo Europe, GmbH","Industry",0,0,"All","18 Years","75 Years","133","August 2008","May 2011","The change from baseline in carotid-femoral pulse wave velocity (PWV)","0","0","0","0","0","0","0","0","0"
"1428","NCT00677807","Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","COPD",0,"Indacaterol","Drug","Novartis","Industry",0,0,"All","40 Years","N/A","415","May 2008","March 2009","The Number of Participants With a Clinically Notable Pulse Rate During 52 Weeks of Treatment With Indacaterol 150 µg or 300 µg Compared to Placebo","0","0","0","0","0","0","0","0","0"
"1429","NCT00677833","Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa","Malaria, Falciparum",0,"Azithromycin plus Chloroquine","Drug","Pfizer","Industry",0,0,"All","6 Months","12 Years","361","June 2008","September 2010","Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28 in the Modified Intent-to-treat (mITT) Population","0","0","0","-9.10","ACPR percent difference","95","2-Sided","-16.02","-2.18"
"1430","NCT00678392","Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer","Kidney Neoplasms",0,"Axitinib (AG-013736)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","723","September 2008","August 2010","Progression-Free Survival (PFS)","<0.0001","P-value was obtained from 1-sided log rank test, stratified by eastern cooperative oncology group (ECOG) and prior treatment. One-sided log-rank test at 0.025 level of significance was used to compare PFS between the 2 treatment arms.","Log Rank","0.665","Hazard Ratio (HR)","95","2-Sided","0.544","0.812"
"1431","NCT00678418","ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence","Opiate Dependence",0,"VIVITROL® 380 mg","Drug","Alkermes, Inc.","Industry",0,0,"All","18 Years","N/A","250","June 2008","October 2009","Percentage (%) of Opioid-free Weeks Per Subject in Double-blind Period (Part A)","0.0002","0","Van der Waerden","0","0","0","0","0","0"
"1432","NCT00678483","Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients","Obesity",0,"rimonabant (SR141716)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","331","April 2008","November 2008","The primary endpoint is the change in weight from baseline to 12 months","0","0","0","0","0","0","0","0","0"
"1433","NCT00678535","Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer","Gastric Cancer",0,"Cetuximab","Drug","Merck KGaA","Industry",0,0,"All","18 Years","N/A","904","June 2008","March 2012","Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments","0.3158","0","Stratified log rank","1.091","Hazard Ratio (HR)","95","0","0.920","1.292"
"1434","NCT00678587","Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures","Non-alcoholic Steatohepatitis",0,"Eltrombopag","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","292","June 2008","October 2009","Number of Participants With Chronic Liver Disease and Thrombocytopenia (Platelets <50 Gi/L) Who do Not Require a Platelet Transfusion Prior to, During, and up to 7 Days Following Elective Invasive Procedures","<0.0001","0","Cochran-Mantel-Haenszel","52.8","Absolute difference in proportions","95","2-Sided","43.2","62.4"
"1435","NCT00678847","Chronic Venous ULcer TReatment Analyzing Bio-Electrical Stimulation Therapy","Chronic Venous Leg Ulcers",0,"KFH NOVO (inactive) + SCT","Device","Kingfisher Healthcare","Industry",0,0,"All","18 Years","N/A","50","March 2008","March 2009","To evaluate the efficacy of bio-electrical stimulation therapy in the healing of chronic venous leg ulcers","0","0","0","0","0","0","0","0","0"
"1436","NCT00678886","Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1","Diabetes Mellitus, Type 1",0,"otelixizumab infusion plus physician determined standard of care","Biological","GlaxoSmithKline","Industry",0,0,"All","12 Years","45 Years","272","July 2008","January 2012","Amount of C-peptide (a protein that shows how much insulin the body is producing) during a mixed meal stimulation test.","0","0","0","0","0","0","0","0","0"
"1437","NCT00679380","(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","Ulcerative Colitis",0,"Blood sampling, endoscopy","Procedure","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","75 Years","514","June 2008","February 2010","Clinical and Endoscopic Remission.","0.2876","P-Value was adjusted for multiple comparisons; two dosage strengths were compared with placebo.","Chi-squared","3.8","Difference in proportions","95","2-Sided","-3.0","10.5"
"1438","NCT00679432","(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","Ulcerative Colitis",0,"Blood sampling, endoscopy","Procedure","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","75 Years","510","June 2008","May 2010","Clinical and Endoscopic Remission.","0.1393","P-Value was adjusted for multiple comparisons; two budesonide dosage strengths were compared with placebo.","Chi-squared","5.8","Difference in proportions","95","2-Sided","-1.8","13.4"
"1439","NCT00679484","Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24","Chronic Heart Failure",0,"olmesartan medoxomil + candesartan cilexetil placebo","Drug","Daiichi Sankyo Europe, GmbH","Industry",0,0,"All","18 Years","85 Years","400","June 2008","November 2009","Absolute BNP change from week 0 to 24 of treatment","0","0","0","0","0","0","0","0","0"
"1440","NCT00679588","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery","Venous Thromboembolism",0,"Semuloparin Sodium","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","4413","April 2008","August 2010","Percentage of Participants Who Experience Venous Thromboembolism Event (VTE) or All-cause Death","0","0","0","0","0","0","0","0","0"
"1441","NCT00679731","A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis","Psoriasis",0,"ABT-874","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","317","April 2008","November 2009","Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 24","0","0","0","0","0","0","0","0","0"
"1442","NCT00679900","Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties","Sleep Initiation and Maintenance Disorders",0,"eplivanserin (SR46349)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","283","April 2008","March 2009","Sleepiness in the morning measured on a visual analog scale of the patient's sleep questionnaire","0","0","0","0","0","0","0","0","0"
"1443","NCT00680472","HKT-500 in Adult Patients With Shoulder Pain","Pain",0,"HKT-500 Ketoprofen Topical Patch","Drug","Hisamitsu Pharmaceutical Co., Inc.","Industry",0,0,"All","18 Years","N/A","368","April 2008","October 2008","Pain Assessment","0","0","0","0","0","0","0","0","0"
"1444","NCT00680745","Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","Type 2 Diabetes",0,"dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","597","April 2008","November 2009","Adjusted Mean Change in HbA1c Levels","<0.0001","significant at alpha=0.019 (2-sided) applying Dunnett's adjustment. A hierarchical closed testing procedure was used to control the Type I error rate across the primary and key secondary endpoints.","ANCOVA","-0.44","Mean Difference (Final Values)","95","2-Sided","-0.61","-0.27"
"1445","NCT00680784","HKT-500 in Adult Patients With Ankle Sprain","Ankle Sprain",0,"HKT-500 Ketoprofen Topical Patch","Drug","Hisamitsu Pharmaceutical Co., Inc.","Industry",0,0,"All","18 Years","N/A","260","April 2008","November 2008","Pain Assessment","0","0","0","0","0","0","0","0","0"
"1446","NCT00680901","LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","Neoplasms, Gastrointestinal Tract",0,"Lapatinib","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","545","June 2008","September 24, 2012","Overall Survival","0.3492","0","Log Rank","0.91","Hazard Ratio (HR)","95","2-Sided","0.73","1.12"
"1447","NCT00680953","Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis","Osteoporosis",0,"Denosumab","Drug","Daiichi Sankyo Co., Ltd.","Industry",0,0,"All","50 Years","N/A","1262","May 2008","June 2012","Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo","0.0001","0","Log Rank","0.343","Hazard Ratio (HR)","95","2-Sided","0.194","0.606"
"1448","NCT00681356","Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement","Total Knee Arthroplasty (Replacement)",0,"4975, 15 and 5 mg","Drug","Anesiva, Inc.","Industry",0,0,"All","18 Years","85 Years","214","September 2007","September 2008","Numerical Rating Scale (NRS) measures of pain at prespecified times","0","0","0","0","0","0","0","0","0"
"1449","NCT00681538","A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)","Spasticity",0,"Sativex®","Drug","GW Pharmaceuticals Ltd.","Industry",0,0,"All","18 Years","N/A","572","January 2008","January 2009","The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B).","0.0002","0","ANCOVA","-0.84","Treatment Difference","95","2-Sided","-1.29","-0.40"
"1450","NCT00683514","Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer","NSCLC",0,"Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)","Drug","Pierre Fabre Medicament","Industry",0,0,"All","18 Years","75 Years","201","April 2005","September 2011","Assessments of measurable and not measurable lesions been carried out at baseline and every 2 treatment cycles by using RECIST criteria","0","0","0","0","0","0","0","0","0"
"1451","NCT00683592","Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)","Major Depressive Disorder",0,"vilazodone","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","70 Years","481","March 2008","February 2009","Change From Baseline to Week 8 in the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score.","0.009","0","ANCOVA","-2.5","Difference in Least Squares Mean Change","95","2-Sided","-4.4","-0.6"
"1452","NCT00683618","Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia","Hypercholesterolemia",0,"Rosuvastatin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","934","May 2008","July 2009","Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg","0","0","0","0","0","0","0","0","0"
"1453","NCT00683657","Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone","Type 2 Diabetes",0,"Saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","77 Years","93","July 2008","February 2009","Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4","0.0001","Between-group comparisons significant at alpha = 0.05, significance testing based on hierarchical testing. Primary and secondary endpoints are presented in order of testing.","ANCOVA","-16.8","Mean Difference (Final Values)","95","2-Sided","-25.1","-8.5"
"1454","NCT00683800","Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women","Vasomotor Symptoms",0,"desvenlafaxine succinate (DVS) SR","Drug","Pfizer","Industry",0,0,"Female","45 Years","N/A","2186","June 2008","May 2010","Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4","<0.001","0","ANCOVA","-2.89","Adjusted Mean Difference","95","2-Sided","-3.80","-1.98"
"1455","NCT00683878","Add-on to Thiazolidinedione (TZD) Failures","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","972","July 2008","January 2010","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])","0.0007","Primary endpoints were tested at alpha=0.027 applying Dunnett’s adjustment","ANCOVA","-0.40","Mean Difference (Final Values)","95","2-Sided","-0.63","-0.17"
"1456","NCT00683995","A Phase III Clinical Study of KW-2246","Pain, Cancer",0,"KW-2246 (fentanyl citrate)","Drug","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","20 Years","80 Years","43","March 2008","July 2009",NA,"0","0","0","0","0","0","0","0","0"
"1457","NCT00684177","Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)","Skin Infections, Bacterial",0,"Retapamulin Ointment, 1%","Drug","GlaxoSmithKline","Industry",0,0,"All","2 Months","N/A","508","May 2008","October 2009","Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Primary Efficacy Population","0.098","0","Chi-squared","8.4","Risk Difference (RD)","95","2-Sided","-1.6","18.4"
"1458","NCT00684632","A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients","Pain, Cancer",0,"Placebo","Drug","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","20 Years","80 Years","51","March 2008","April 2009",NA,"0","0","0","0","0","0","0","0","0"
"1459","NCT00685113","A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder","Overactive Bladder",0,"DR-3001","Drug","Duramed Research","Industry",0,0,"Female","18 Years","N/A","1104","May 2008","March 2010","Change in total weekly number of incontinence (urge and stress)episodes","0","0","0","0","0","0","0","0","0"
"1460","NCT00685776","Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)","Coronary Heart Disease (CHD)",0,"anacetrapib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","80 Years","1500","March 2008","July 2009","Change from baseline in Low Density Lipoprotein Cholesterol","0","0","0","0","0","0","0","0","0"
"1461","NCT00686205","Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay","Healthy Donors",0,"collection of follow-up sample based on PRISM HIV O Plus result","Device","Abbott Diagnostics Division","Industry",0,0,"All","17 Years","N/A","24111","August 2007","August 2008","PRISM HIV O Plus Test Data for Specificity","0","0","0","99.94","Clinical Specificity","95","0","99.88","99.97"
"1462","NCT00686270","A Long Term Safety Study of Apricitabine in HIV-infected Patients","HIV Infections",0,"apricitabine","Drug","Avexa","Industry",0,0,"All","18 Years","N/A","0","May 2008","May 2012","The number, type and severity of SAEs occuring during the study","0","0","0","0","0","0","0","0","0"
"1463","NCT00686517","Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)","Hepatitis C",0,"Pegylated interferon alfa-2b","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","130","December 2003","December 2010","Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period","0","0","0","0","0","0","0","0","0"
"1464","NCT00686621","Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)(COMPLETED)","Mycoses",0,"Posaconazole","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","2 Years","N/A","1","January 2007","January 2010","Clinical efficacy and safety of use","0","0","0","0","0","0","0","0","0"
"1465","NCT00686686","Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)","Psoriasis",0,"Infliximab","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","70 Years","23","December 2007","February 2009","Number of Participants Who Achieve at Least 75% Improvement in Palmoplantar Psoriasis Activity Severity Index (PPPASI) After 3 Infusions.","0","0","0","0","0","0","0","0","0"
"1466","NCT00686790","Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)","Hepatitis D, Chronic",0,"Peginterferon alfa-2b (PegIntron, SCH 54031)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","68","December 2005","May 2009","Number of Participants With a Virological Response","0","0","0","0","0","0","0","0","0"
"1467","NCT00686881","Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)","Hepatitis C, Chronic",0,"Peginterferon alfa-2b (PegIFN-2b)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","N/A","261","December 2006","February 2011","Number of Participants With Change in Metavir Fibrosis Score","0","0","0","0","0","0","0","0","0"
"1468","NCT00686920","Safety Study for Patients With a History of Hepatic Encephalopathy","Hepatic Encephalopathy",0,"rifaximin","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","500","March 2007","December 2010","Incidence of treatment-emergent AEs and SAEs","0","0","0","0","0","0","0","0","0"
"1469","NCT00687037","Safety Oral Mucosa Evaluation - Acceptability With Odontological Follow up - Cepacol Canela Power","Healthy",0,"Cetylpyridinium chloride","Drug","Sanofi","Industry",0,0,"All","18 Years","60 Years","30","January 2008","February 2008","Patients will be evaluated according to the adverse reactions and the intensity of them. The volunteers will also answer a questionnaire about the physical attributes of the product.","0","0","0","0","0","0","0","0","0"
"1470","NCT00687219","Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)","Hepatitis C, Chronic",0,"Peginterferon alfa-2b","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","70 Years","102","June 2007","October 2010","Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)","0","0","0","0","0","0","0","0","0"
"1471","NCT00687401","A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)","Psoriasis",0,"Infliximab","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","75 Years","215","June 2006","May 2009","Number of Participants Who Achieve a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI) Score","0","0","0","0","0","0","0","0","0"
"1472","NCT00687791","Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study","Cataract",0,"ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery","Device","Pro Top & Mediking Company Limited","Industry",0,0,"All","18 Years","N/A","20","December 2007","December 2008","The primary endpoint is to prove the effectiveness via the reduction of IOP.","0","0","0","0","0","0","0","0","0"
"1473","NCT00687908","Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance","Acne",0,"Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel","Drug","Galderma","Industry",0,0,"All","12 Years","35 Years","243","November 2008","July 2009","Maintenance Success for Total Lesions at Week 24","0","0","0","0","0","0","0","0","0"
"1474","NCT00688064","Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris","Severe Acne Vulgaris",0,"Adapalene BPO Gel associated with Doxycyline Hyclate","Drug","Galderma","Industry",0,0,"All","12 Years","35 Years","459","August 2008","February 2009","Percent Change From Baseline in Total Lesion Counts at Week 12.","0","0","0","0","0","0","0","0","0"
"1475","NCT00688376","Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment","Attention Impairment",0,"Donepezil hydrochloride","Drug","Eisai Inc.","Industry",0,0,"All","6 Years","17 Years","300","August 2008","June 2009","Change in the TOVA-CPT (Test of Variables in Attention - Continuous Performance Test) reaction time variability measure (administered to subjects).","0","0","0","0","0","0","0","0","0"
"1476","NCT00688519","Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies","Psoriasis",0,"U0267","Drug","Stiefel, a GSK Company","Industry",0,0,"All","12 Years","N/A","336","March 2008","December 2008","Number of Subjects With Treatment Success, Assessed Per the Investigator's Static Global Assessment (ISGA)","0.058","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1477","NCT00688649","Nutritional Supplement Compliance Study","Undernutrition",0,"Standard Oral Nutritional Supplement (ONS)","Dietary Supplement","Nutricia UK Ltd","Industry",0,0,"All","18 Years","N/A","80","May 2008","January 2009","Nutrient intake (energy, protein and micronutrients)","0","0","0","0","0","0","0","0","0"
"1478","NCT00688688","Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","Urinary Bladder, Overactive",0,"Mirabegron","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","2792","April 2008","May 2010","Number of Participants With and Severity of Treatment-emergent Adverse Events (TEAEs)","0","0","0","0","0","0","0","0","0"
"1479","NCT00688701","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy","Diabetes Mellitus, Type 2",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","361","May 2008","December 2009","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12","<0.0001","Stepwise testing procedure applied to control type 1 error: Lixisenatide (2-step titration) was compared with Placebo (combined), if found statistically significant, then Lixisenatide (1-step titration) arm compared with Placebo (combined).","ANCOVA","-0.54","Least squares (LS) mean difference","95","2-Sided","-0.785","-0.300"
"1480","NCT00688740","Docetaxel in Node Positive Adjuvant Breast Cancer","Breast Cancer",0,"Docetaxel","Drug","Sanofi","Industry",0,0,"Female","18 Years","70 Years","1491","June 1997","January 2010","Number of Participants With Disease-Free Survival Events","0.0043","Pairwise stratified log-rank test on the number of positive axillary nodes as per randomization","Log Rank","0.795","Cox Proportional Hazard","95","2-Sided","0.679","0.932"
"1481","NCT00688766","Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib","Gastrointestinal Stromal Tumors",0,"retaspimycin hydrochloride (IPI-504)","Drug","Infinity Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","47","August 2008","May 2009","Compare the progression free survival (PFS) in both study arms","0","0","0","0","0","0","0","0","0"
"1482","NCT00688870","Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan","Vaccines",0,"13-valent pneumococcal conjugate vaccine (13vPnC)","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","42 Days","98 Days","168","June 2008","March 2009","Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (Mcg)/mL, 1 Month After the Infant Series.","0","0","0","-1.2","Difference","95","2-Sided","-6.8","3.3"
"1483","NCT00689104","Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","Urinary Bladder, Overactive",0,"Mirabegron","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","2336","April 2008","March 2009","Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours","0.003","The response variable for the stratified rank ANCOVA was standardized ranks on change from baseline to Final Visit value with baseline standardized ranks and gender as covariates and geographic region as a stratum.","Stratified rank ANCOVA","-0.41","LS Mean Difference","95","2-Sided","-0.72","-0.09"
"1484","NCT00689117","A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel","Acne Vulgaris",0,"CT Gel","Drug","Stiefel, a GSK Company","Industry",0,0,"All","12 Years","N/A","1649","April 2008","April 2009","Absolute Change From Baseline in Lesion Counts (Total, Inflammatory, and Non-inflammatory) at Week 12 (End of Study)","0.063","Inflammatory lesion count","Ranked ANCOVA","0","0","0","0","0","0"
"1485","NCT00689221","Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status","Glioblastoma",0,"Cilengitide","Drug","EMD Serono","Industry",0,0,"All","18 Years","N/A","545","September 2008","November 2012","Overall Survival (OS) Time","0.8623","P-value is not adjusted for multiple testing.","Log Rank","1.021","Hazard Ratio (HR)","95","2-Sided","0.808","1.291"
"1486","NCT00689338","Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study","Invasive Candidiasis",0,"Anidulafungin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","216","July 2008","May 2010","Percentage of Participants With Global Treatment Response Success at End of Treatment","0","0","0","0","0","0","0","0","0"
"1487","NCT00689481","Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies","Psoriasis",0,"U0267 Foam","Drug","Stiefel, a GSK Company","Industry",0,0,"All","12 Years","N/A","323","March 2008","October 2008","Number of Subjects With Treatment Success, Assessed Per the Investigator's Static Global Assessment","0.016","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1488","NCT00690430","Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease","Symptomatic Refractory Resistant Carcinoid Disease",0,"Pasireotide","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","186","April 2008","April 2012","Percentage of Patients Who Achieved Clinical Symptom Improvement by Randomization Stratum and Treatment.","0","0","0","0","0","0","0","0","0"
"1489","NCT00690456","Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","403","May 2008","February 2009","Change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"1490","NCT00690495","Use of a Modified Propofol Emulsion in Adults","Anesthesia",0,"Propofol","Drug","B. Braun Melsungen AG","Industry",0,0,"All","18 Years","80 Years","100","May 2008","September 2008","Incidence of Expression of Pain During Injection","0","0","0","0","0","0","0","0","0"
"1491","NCT00690573","Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis","Juvenile Rheumatoid Arthritis",0,"Adalimumab","Biological","Abbott","Industry",0,0,"All","4 Years","17 Years","25","May 2008","March 2010","Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16","0","0","0","0","0","0","0","0","0"
"1492","NCT00690612","Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)","Hypertension",0,"candesartan cilexetil","Drug","AstraZeneca","Industry",0,0,"All","1 Year","10 Years","35","September 2007","September 2009","Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP).","0","0","0","0","0","0","0","0","0"
"1493","NCT00690638","Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"PHX1149T","Drug","Phenomix","Industry",0,0,"All","18 Years","85 Years","480","July 2008","January 2010","To demonstrate changes in HbA1c","0","0","0","0","0","0","0","0","0"
"1494","NCT00690794","Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension","Open-angle Glaucoma",0,"Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","726","July 2008","May 2009","Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score","0","0","0","0","0","0","0","0","0"
"1495","NCT00690820","Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)","Cystic Fibrosis",0,"Pancrelipase Delayed Release","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","7 Years","11 Years","17","June 2008","December 2008","Coefficient of Fat Absorption (%)","<0.001","0","ANOVA","0","0","0","0","0","0"
"1496","NCT00690898","Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma","Acromegaly",0,"Lanreotide autogel 120 mg","Drug","Ipsen","Industry",0,0,"All","18 Years","75 Years","108","May 2008","February 2012","Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)","0","0","0","0","0","0","0","0","0"
"1497","NCT00691002","Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds","Psoriasis Vulgaris",0,"Calcipotriol plus hydrocortisone (LEO 80190)","Drug","LEO Pharma","Industry",0,0,"All","18 Years","N/A","1245","May 2008","January 2010","Overall disease severity of the face according to the investigator's global assessment","0","0","0","0","0","0","0","0","0"
"1498","NCT00691197","Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear","Ametropia",0,"Carboxymethylcellulose sodium and Glycerin","Device","Allergan","Industry",0,0,"All","18 Years","N/A","246","March 2008","October 2008","Best Corrected Visual Acuity","0","0","0","0","0","0","0","0","0"
"1499","NCT00691470","Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation","Atrial Fibrillation",0,"ATI-5923","Drug","ARYx Therapeutics","Industry",0,0,"All","18 Years","N/A","600","May 2008","June 2009","Percent of time INR is in therapeutic range after the exclusion of the first 4 weeks of treatment, using the linear interpolation method of Rosendaal(Rosendaal, 1993).","0","0","0","0","0","0","0","0","0"
"1500","NCT00691717","Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension","Open-angle Glaucoma",0,"Anecortave Acetate Sterile Suspension, 30 mg/mL","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","201","June 2008","September 2009","Mean Intraocular Pressure at 8 am","0","0","0","0","0","0","0","0","0"
"1501","NCT00691964","Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","Plaque Psoriasis",0,"ABT-874","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","347","May 2008","March 2009","Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12","0","0","0","0","0","0","0","0","0"
"1502","NCT00692484","Pilot Evaluation of the Application Procedure on the Antimicrobial Effects of 2 Antiseptics","Healthy",0,"Chlorhexidine gluconate","Drug","CareFusion","Industry",0,0,"All","18 Years","N/A","25","October 2007","February 2008","3.0 log10 reduction in CFU/cm2 on inguinal sites, and 2.0 log10 reduction in CFU/cm2 on abdominal sites","0","0","0","0","0","0","0","0","0"
"1503","NCT00693186","A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA","Hepatitis B",0,"HBVaxPRO® 5 µg / 0.5 mL","Biological","MCM Vaccines B.V.","Industry",0,0,"All","4 Years","7 Years","410","October 2008","December 2009","Percentage of subjects with anti-HBs antibody titres >=10 mIU/mL measured at 1 month post-booster dose","0","0","0","0","0","0","0","0","0"
"1504","NCT00694148","Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines","Healthy",0,"NT 201","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","65 Years","108","May 2008","January 2009","Investigator`s assessment","0","0","0","0","0","0","0","0","0"
"1505","NCT00694304","Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","Major Depressive Disorder",0,"Vortioxetine (Lu AA21004)","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","75 Years","535","May 2008","March 2010","Number of Patients With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"1506","NCT00694369","A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)","Postoperative Dental Pain",0,"Comparator: etoricoxib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","588","June 2008","December 2008","Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)","<0.001","0.05 critical level was used.","ANOVA","0","0","0","0","0","0"
"1507","NCT00694382","Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy","Venous Thromboembolism",0,"Semuloparin sodium","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","3212","June 2008","November 2010","Percentage of Participants Who Experienced Venous Thromboembolism Event [VTE] or VTE-related Death","0","0","0","0","0","0","0","0","0"
"1508","NCT00695396","A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion","Myelodysplastic Syndromes",0,"Placebo","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","25","June 2008","January 2010","Red Blood Cell (RBC) Transfusion","0","0","0","0","0","0","0","0","0"
"1509","NCT00695643","Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis","Diverticulitis",0,"Mesalazine","Drug","Dr. Falk Pharma GmbH","Industry",0,0,"All","40 Years","80 Years","345","January 2008","November 2011","Proportion of recurrence-free patients within 48 weeks","0","0","0","0","0","0","0","0","0"
"1510","NCT00695955","One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","Hypertension",0,"Azilsartan medoxomil with or without add-on chlorthalidone","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","669","June 2007","May 2010","Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.","0","0","0","0","0","0","0","0","0"
"1511","NCT00696137","Long-term Extension Study of BEMA™ Fentanyl","Cancer",0,"BEMA Fentanyl","Drug","BioDelivery Sciences International","Industry",0,0,"All","18 Years","N/A","5","June 2008","July 2009","Safety and tolerability of BEMA Fentanyl (any dose) as demonstrated by the occurrence of drug-related SAEs.","0","0","0","0","0","0","0","0","0"
"1512","NCT00696241","Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension","Hypertension",0,"Azilsartan medoxomil and olmesartan","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","1275","June 2007","October 2008","Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","<0.001","Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.","ANCOVA","-10.75","Mean Difference (Final Values)","95","0","-13.17","-8.34"
"1513","NCT00696384","A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","Hypertension",0,"Azilsartan medoxomil","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","418","June 2007","April 2009","Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32","<0.001","Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Includes participants with both a double-blind baseline and postbaseline value.","ANCOVA","-7.78","Mean Difference (Final Values)","95","2-Sided","-9.78","-5.78"
"1514","NCT00696436","An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.","Hypertension",0,"Azilsartan medoxomil","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","1291","April 2008","August 2009","Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","<0.001","Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.","ANCOVA","-14.27","Mean Difference (Final Values)","95","2-Sided","-16.54","-12.01"
"1515","NCT00696878","Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)","In Vitro Fertilization",0,"Corifollitropin alfa","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","39 Years","682","September 26, 2006","February 17, 2009","Percentage of Participants With Clinically Relevant Immunogenicity","0","0","0","0.0","Percentage with immunogenicity","95","1-Sided","0","0.4"
"1516","NCT00697073","Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients","Friedreich's Ataxia",0,"Idebenone","Drug","Santhera Pharmaceuticals","Industry",0,0,"All","8 Years","18 Years","68","July 2008","May 2010","Change in ICARS","0","0","0","0","0","0","0","0","0"
"1517","NCT00697099","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery","Venous Thromboembolism",0,"Semuloparin sodium","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","2326","June 2008","June 2009","Percentage of Participants Who Experienced Venous Thromboembolism Event [VTE] or Death From Any Cause","0","0","0","0","0","0","0","0","0"
"1518","NCT00697515","Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)","ADHD",0,"LDX","Drug","Shire","Industry",0,0,"All","18 Years","55 Years","142","July 2008","December 2008","Permanent Product Measure of Performance (PERMP) Total Score Over the Treatment Day in the Crossover Phase","<0.0001","0","ANOVA","0","0","0","0","0","0"
"1519","NCT00697697","A Study of 2 Doses of MAP0010 in Asthmatic Children","Asthma",0,"0.135mg MAP0010","Drug","Allergan","Industry",0,0,"All","12 Months","8 Years","192","April 2008","August 2009","Number of Patients With Treatment Emergent Adverse Events Related to Study Drug","0","0","0","0","0","0","0","0","0"
"1520","NCT00697762","Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures","Seizures",0,"RWJ-333369","Drug","SK Life Science","Industry",0,0,"All","16 Years","N/A","56","October 2007","May 2008","Percent reduction in partial seizure frequency (including simple partial motor seizures, complex partial seizures, and secondarily generalized seizures) for Double-Blind Treatment Phase from the baseline period","0","0","0","0","0","0","0","0","0"
"1521","NCT00697827","A Study of the In-Space Device for Treatment of Moderate Spinal Stenosis","Spinal Stenosis",0,"Interspinous Spacer device","Device","Synthes USA HQ, Inc.","Industry",0,0,"All","50 Years","N/A","44","June 2008","June 2011","Zurich Claudication Questionnaire(ZCQ)","0","0","0","0","0","0","0","0","0"
"1522","NCT00698581","A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures","Epilepsy",0,"Brivaracetam","Drug","UCB Pharma","Industry",0,0,"All","16 Years","75 Years","88","August 2008","January 2010","The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase","0","0","0","0","0","0","0","0","0"
"1523","NCT00698932","Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control","Type 2 Diabetes",0,"Saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","568","June 2008","October 2009","Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)","<0.0001","0","ANCOVA","-0.50","Mean Difference (Net)","95","0","-0.65","-0.34"
"1524","NCT00699153","Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery","Ocular Inflammation",0,"Loteprednol Etabonate","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","400","June 2008","May 2009","Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0","0","0","0","0","0","0","0","0","0"
"1525","NCT00699192","Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension","Hypertension",0,"Amlodipine 5 mg","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","65 Years","N/A","965","May 2008","May 2009","Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)","0","0","0","0","0","0","0","0","0"
"1526","NCT00699283","A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures","Epilepsy",0,"Brivaracetam","Drug","UCB Pharma","Industry",0,0,"All","16 Years","75 Years","62","August 2008","March 2010","The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase","0","0","0","0","0","0","0","0","0"
"1527","NCT00699374","Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer","Carcinoma, Hepatocellular",0,"sunitinib malate","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","1075","July 2008","December 2011","Overall Survival (OS)","0.9993","One-sided p-value based on stratified log-rank test controlling the effects of geographic region, prior transarterial chemoembolization (TACE) and tumor invasion condition.","Log Rank","1.31","Hazard Ratio (HR)","95","2-Sided","1.14","1.50"
"1528","NCT00699751","A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","Hormone Refractory Prostate Cancer",0,"Radium-223 dichloride (Xofigo, BAY88-8223)","Drug","Bayer","Industry",0,0,"Male","18 Years","N/A","921","June 2008","July 2011","Overall Survival","0.00005","0","Log Rank","0.691","Hazard Ratio (HR)","95","2-Sided","0.578","0.827"
"1529","NCT00699816","Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients","Hepatocellular Carcinoma",0,"Immuncell-LC","Biological","Green Cross Cell Corporation","Industry",0,0,"All","20 Years","80 Years","230","July 2008","November 2012","Recurrence Free Survival(RFS)","0.01","0","Log Rank","0.63","Hazard Ratio (HR)","95","2-Sided","0.43","0.94"
"1530","NCT00699972","Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures","Refractory Partial Seizures",0,"E2007 (perampanel)","Drug","Eisai Inc.","Industry",0,0,"All","12 Years","99 Years","390","June 2008","October 2010","Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases)","0","0","0","0","0","0","0","0","0"
"1531","NCT00699998","A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects","Acute Coronary Syndrome",0,"Clopidogrel","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","9326","June 2008","April 2012","Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke","0.210","Two-sided p-value based on a log-rank test stratified by clopidogrel status at randomization.","Log Rank","0.915","Hazard Ratio (HR)","95","2-Sided","0.793","1.055"
"1532","NCT00700427","A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder",0,"atomoxetine hydrochloride","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","50 Years","2017","June 2008","August 2011","Percentage of Participants Who Maintain a Satisfactory Response During the Double-Blind Maintenance/Randomized Withdrawal Period","0.001","0","Fisher Exact","0","0","0","0","0","0"
"1533","NCT00700622","Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks","Diabetes, Type 1",0,"Technosphere Insulin","Drug","Mannkind Corporation","Industry",0,0,"All","18 Years","80 Years","130","May 2008","November 2009","Change From Baseline in HbA1c to Week 16","0","0","0","-0.07","Mean Difference (Net)","95","2-Sided","-0.31","0.17"
"1534","NCT00700817","The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus","Diabetes",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","80 Years","665","June 2008","June 2009","Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26","0.0001","Multiple comparisons not applicable due to the hieracheal testing.","ANCOVA","-0.6","Estimated treatment difference, LS Mean","95","0","-0.77","-0.43"
"1535","NCT00701623","Sodic Heparin Effectiveness of the Treatment of Burns","Burns",0,"heparin","Drug","Azidus Brasil","Industry",0,0,"All","12 Years","N/A","84","June 2008","June 2008","Primary: immediate decrease in pain. Secondary: analgesic request for 10 minutes after application of heparin, signs of intolerance and adverse events.","0","0","0","0","0","0","0","0","0"
"1536","NCT00701714","Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients","Anemia",0,"HX575 recombinant human erythropoietin alfa","Drug","Sandoz","Industry",0,0,"All","18 Years","N/A","337","September 2007","July 2009","change in hemoglobin level","0","0","0","0","0","0","0","0","0"
"1537","NCT00701974","Non-inferiority Clinic of Kollagenase® Compared Iruxol® in Treatment of Cutaneous Ulcers","Ulcers",0,"collagenase (IRUXOL)","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","66","February 2008","February 2008","Primary: Non-inferiority based on efficiency that will be evaluated by the general improvement of the injury; Secondary: tolerability assessed by the incidence of adverse events.","0","0","0","0","0","0","0","0","0"
"1538","NCT00702468","Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis","Spasticity",0,"Sativex","Drug","GW Pharmaceuticals Ltd.","Industry",0,0,"All","18 Years","N/A","36","November 2007","January 2009","Number of Subjects Who Experience Treatment Failure.","0.013","0","Chi-squared","0.335","Odds Ratio (OR)","90","2-Sided","0.162","0.691"
"1539","NCT00702650","A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations","Hypogonadism",0,"Testosterone MD-Lotion","Drug","Eli Lilly and Company","Industry",0,0,"Male","18 Years","N/A","155","June 2008","July 2009","Percentage of Participants With 24-Hour Average Concentration [Cavg(0-24h)] Total Testosterone Within Normal Range at Day 120","<0.001","0","One-Sample Binomial (Wald) test, 2-sided","0","0","0","0","0","0"
"1540","NCT00702702","Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids","Uterine Fibroids",0,"Proellex 25 mg","Drug","Repros Therapeutics Inc.","Industry",0,0,"Female","18 Years","45 Years","56","June 2008","August 2009","Change in Hemoglobin vs Placebo","0","0","0","0","0","0","0","0","0"
"1541","NCT00702715","Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)","Anesthesia",0,"sugammadex","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","69","September 24, 2008","March 15, 2010","Time to Recovery of the T4/T1 Ratio to 0.9.","0","0","0","78.0","Median Difference (Final Values)","95","2-Sided","36.0","143.0"
"1542","NCT00703118","A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Hepatitis C, Chronic",0,"Telaprevir","Drug","Tibotec BVBA","Industry",0,0,"All","18 Years","70 Years","663","October 2008","July 2010","Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After the Last Planned Dose of Study Medication - SVR24 Planned","<0.001","Overall significance level was set at 5% (two-sided). Adjustment of significance level for multiple comparisons was carried out using the Hochberg procedure","Regression, Logistic","46.8","Difference in percentage of response","95","2-Sided","36.8","56.7"
"1543","NCT00703781","Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","Cataract",0,"bromfenac ophthalmic solution","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","126","June 2008","November 2008","Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero","0","0","0","0","0","0","0","0","0"
"1544","NCT00703937","Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia","Anemia",0,"Ferric Carboxymaltose (FCM)","Drug","Luitpold Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","708","July 2008","July 2009","Safety, as Defined by the Occurence of Serious Adverse Events (SAE's), of FCM Compared to SMC","0","0","0","0","0","0","0","0","0"
"1545","NCT00704028","Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia","Anemia",0,"Ferric Carboxymaltose","Drug","Luitpold Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","161","June 2008","January 2010","The Number of Subjects Who Reported Treatment-emergent Adverse Events (AE's)","0","0","0","0","0","0","0","0","0"
"1546","NCT00704353","Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia","Anemia",0,"Ferric Carboxymaltose","Drug","Luitpold Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","735","June 2008","July 2009","Number of Participants With Treatment-emergent Serious Adverse Events (SAE's)","0","0","0","0","0","0","0","0","0"
"1547","NCT00704418","Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","Cataract",0,"Bromfenac","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","156","June 2008","January 2009","Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero","0","0","0","0","0","0","0","0","0"
"1548","NCT00704509","Efficacy of Bifeprunox in Patients With Schizophrenia","Schizophrenia",0,"Bifeprunox","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","346","June 2008","August 2009","The difference in change from baseline to the 12-week time point between bifeprunox and placebo using the Positive and Negative Syndrome Scale (PANSS).","0","0","0","0","0","0","0","0","0"
"1549","NCT00704730","Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer","Thyroid Cancer",0,"XL184","Drug","Exelixis","Industry",0,0,"All","18 Years","N/A","330","June 2008","October 2011","Progression-Free Survival (PFS)","0","0","0","0","0","0","0","0","0"
"1550","NCT00704847","Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)","Osteoarthritis",0,"Oral Salmon Calcitonin","Drug","Nordic Bioscience A/S","Industry",0,0,"All","51 Years","80 Years","1030","June 2008","May 2011","Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months","0","0","0","0","0","0","0","0","0"
"1551","NCT00705276","Dermacyd Femina Delicata (Lactic Acid)- Photo Dermatological Evaluation of the Irritation and Sensitivity Potential","Hygiene",0,"Lactic acid (Dermacyd Femina Delicata)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","26","April 2008","May 2008","The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale.","0","0","0","0","0","0","0","0","0"
"1552","NCT00705432","Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)","Hepatitis C, Chronic",0,"Peginterferon alfa-2b (PEG)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1472","August 2008","May 2010","Sustained Virologic Response (SVR) Rate","<0.0001","0","Cochran-Mantel Haenszel Chi-square test","26.6","The difference in SVR","95","2-Sided","19.1","34.1"
"1553","NCT00705575","Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension","Hypertension",0,"Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","688","June 2008","April 2009","Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 12)","0","0","0","0","0","0","0","0","0"
"1554","NCT00705744","Dermacyd Femina (Lactic Acid) - Photo Dermatological Evaluation of the Irritation and Sensitivity Potential.","Hygiene",0,"Lactic acid (Dermacyd Femina)","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","26","April 2008","May 2008","The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale","0","0","0","0","0","0","0","0","0"
"1555","NCT00705770","A Multi-Dose Study With a Treatment for Open-Angle Glaucoma","Open-Angle Glaucoma",0,"Anecortave Acetate","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","0","May 2008","July 2008","Mean Intraocular Pressure","0","0","0","0","0","0","0","0","0"
"1556","NCT00705783","Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia","Schizophrenia",0,"Aripiprazole depot","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","60 Years","843","July 2008","August 2010","Time to Exacerbation of Psychotic Symptoms/Impending Relapse","<0.0001","0","Log Rank","0.199","Hazard Ratio (HR)","95","2-Sided","0.125","0.317"
"1557","NCT00705861","Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus","Erectile Dysfunction",0,"Placebo","Drug","SK Chemicals Co.,Ltd.","Industry",0,0,"Male","19 Years","N/A","112","November 2007","July 2008","Erectile Function domain score (sum of Question 1,2,3,4,5 and 15) of the International Index of Erectile Function (IIEF) Questionnaire","0","0","0","0","0","0","0","0","0"
"1558","NCT00705939","Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial","Gaucher Disease",0,"Taliglucerase alfa","Drug","Protalix","Industry",0,0,"All","18 Years","N/A","45","June 2008","May 2012","Spleen Volume","0","0","0","0","0","0","0","0","0"
"1559","NCT00705978","Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis","Pancreatic Insufficiency",0,"Pancreatin","Drug","Abbott Products","Industry",0,0,"All","18 Years","N/A","62","June 2008","May 2010","Change in CFA from baseline to the end of double blind treatment","0","0","0","0","0","0","0","0","0"
"1560","NCT00706134","Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study","Hypertension",0,"Placebo","Drug","Novartis","Industry",0,0,"All","65 Years","N/A","756","May 2008","April 2009","Change in Mean Sitting Systolic Blood Pressure (msSBP)From Baseline to End of Study (Week 8)","0","0","0","0","0","0","0","0","0"
"1561","NCT00706394","34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms","Abdominal Aortic Aneurysm",0,"Endologix Powerlink 34 mm stent graft cuff","Device","Endologix","Industry",0,0,"All","18 Years","N/A","60","September 2005","September 2012","Proximal Type I endoleak","0","0","0","0","0","0","0","0","0"
"1562","NCT00706589","Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder","Chronic Motor or Vocal Tic Disorder",0,"aripiprazole","Drug","Korea Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","6 Years","18 Years","61","October 2008","April 2010","Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)","0","0","0","0","0","0","0","0","0"
"1563","NCT00706654","Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia","Schizophrenia",0,"Aripiprazole depot 300 or 400 mg","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","60 Years","937","September 2008","August 2012","Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26","0.7871","0","z-statistics","-0.64","Mean Difference (Final Values)","95","2-Sided","-5.26","3.99"
"1564","NCT00706849","Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease","Heterozygous Familial Hypercholesterolemia",0,"mipomersen sodium","Drug","Kastle Therapeutics, LLC","Industry",0,0,"All","18 Years","N/A","124","July 2008","December 2009","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point","<0.001","Statistical significance was concluded if p ≤ 0.05.","t-test, 2 sided","0","0","0","0","0","0"
"1565","NCT00707031","GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","639","June 2008","November 2010","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","0","0","0","0.17","Least squares (LS) mean difference","95","2-Sided","0.033","0.297"
"1566","NCT00707057","Ibuprofen Extended-Release Dental Pain Study","Pain",0,"Ibuprofen 600 mg Extended-Release Tablets","Drug","SCOLR Pharma, Inc.","Industry",0,0,"All","16 Years","45 Years","256","June 2008","October 2008","Analgesic Efficacy, as Measured by the Sum of Pain Intensity Differences (SPID) Scale","<0.0001","0","ANCOVA","0","0","0","0","0","0"
"1567","NCT00707304","Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer","Non Small Cell Lung Cancer",0,"Talactoferrin","Drug","Agennix","Industry",0,0,"All","18 Years","N/A","742","November 2008","March 2011","Overall survival","0","0","0","0","0","0","0","0","0"
"1568","NCT00707486","A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing","Tooth Extractions",0,"Hemcon Dental Dressing","Device","HemCon Medical Technologies, Inc","Industry",0,0,"All","14 Years","N/A","72","June 2008","January 2009","Time to Hemostasis","0","0","0","0","0","0","0","0","0"
"1569","NCT00707837","Nutritional Study in Preterm Infants","Preterm Infants",0,"Preterm infant formulas and discharge formulas","Other","Abbott Nutrition","Industry",0,0,"All","N/A","21 Days","206","May 2005","August 2008","The primary objective of this study is to compare the serum concentrations of fat soluble compounds in preterm infants fed a regimen of preterm formulas and in human milk fed infants","0","0","0","0","0","0","0","0","0"
"1570","NCT00707980","Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","Major Depressive Disorder",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","76 Years","836","June 2008","July 2010","Physical Examination Findings","0","0","0","0","0","0","0","0","0"
"1571","NCT00707993","Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics","Diabetes Mellitus",0,"Alogliptin","Drug","Takeda","Industry",0,0,"All","65 Years","90 Years","441","June 2008","August 2010","Change From Baseline in Glycosylated Hemoglobin at Week 52.","0","0","0","-0.05","Mean Difference (Final Values)","97.5","1-Sided","0","0.13"
"1572","NCT00708097","In Situ Caries Efficacy of Fluoride Toothpastes","Caries",0,"NaF","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","78 Years","57","April 2008","July 2008","Percentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF)","0.5757","No adjustment made for multiple comparisons as the primary comparison was pre-specified.","ANOVA","1.98","Adjusted Mean Difference","95","2-Sided","-5.00","8.97"
"1573","NCT00708123","In Situ Caries of Fluoride Toothpastes","Healthy Subjects",0,"Sodium fluoride toothpaste","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","78 Years","60","November 2007","April 2008","Mean Percentage Surface Microhardness Recovery (%SMHR) of Enamel Specimens Exposed to NaF/Carbopol Toothpaste (1400 ppmF), NaF Toothpaste (1350ppmF) Compared to NaMFP/NaF Toothpaste (1450ppmF)","0.0265","No adjustment was made for multiple comparisons as primary comparisons were pre-defined.","ANOVA","3.97","Adjusted mean difference","95","2-Sided","0.47","7.48"
"1574","NCT00708162","Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","HIV Infection",0,"Elvitegravir","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","724","July 2008","December 2010","Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 50 Copies/mL at Week 48","0","0","0","1.1","Difference in percentages","95","2-Sided","-6.0","8.2"
"1575","NCT00708305","Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes","Dental Caries",0,"Sodium Fluoride (NaF)","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","65 Years","65","June 2008","October 2008","Natural Log Transformed Area Under the Fluoride Concentration in Plaque Fluid by Time Curve (AUC) Between 0-4 Hours","0.9762","No adjustment was made for multiple comparisons as the primary comparison was predefined.","ANCOVA","0.00","Adjusted Mean Difference","95","0","-0.21","0.20"
"1576","NCT00708500","Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","Hepatitis C, Chronic",0,"Boceprevir (SCH 503034)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","404","August 2008","April 2010","Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population.","<0.0001","0","Cochran-Mantel-Haenszel","37.4","Treatment Difference","95","0","25.7","49.1"
"1577","NCT00708682","Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico","Vaccines, Pneumococcal",0,"13-valent pneumococcal conjugate vaccine","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","42 Days","98 Days","225","July 2008","May 2010","Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL), 1 Month After the Infant Series","0","0","0","0","0","0","0","0","0"
"1578","NCT00709098","Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension",0,"iloprost","Drug","Actelion","Industry",0,0,"All","18 Years","N/A","49","September 2008","June 2010","Treatment-emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"1579","NCT00709436","Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery","Pain, Postoperative",0,"PMI-150 (intranasal ketamine)","Drug","Hospira, now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","85 Years","250","June 2008","August 2011","Measures of pain intensity difference","0","0","0","0","0","0","0","0","0"
"1580","NCT00709579","Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids","Cortico Atrophy",0,"RV3391A","Drug","Pierre Fabre Dermo Cosmetique","Industry",0,0,"All","50 Years","N/A","60","June 2008","August 2010","20 Mhz echography : Dermal Thickness","0","0","0","0","0","0","0","0","0"
"1581","NCT00709852","Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging","Diagnostic Imaging",0,"Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","402","June 2008","April 2009","Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 1 (BR1)","< 0.0001","for contrast enhancement","paired t-test","1.26","Mean Difference (Final Values)","0","0","0","0"
"1582","NCT00709865","Phase 2b Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency","Renal Insufficiency",0,"tonapofylline","Drug","Biogen","Industry",0,0,"All","18 Years","N/A","420","July 2008","October 2009","Assess the safety andtolerability of intravenous tonapofylline, when added to standard therapy in subjects hospitalized with ADHF and renal insufficiency.","0","0","0","0","0","0","0","0","0"
"1583","NCT00709904","Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery","Venous Thromboembolism",0,"Open-label Semuloparin sodium","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","469","June 2008","January 2010","Percentage of Participants Who Experience Venous Thromboembolism Events (VTE) or Death From Any Cause During the Extension Treatment Period","0","0","0","0","0","0","0","0","0"
"1584","NCT00709956","Iloprost Power 15 in Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension",0,"iloprost (5 µg)","Drug","Actelion","Industry",0,0,"All","18 Years","N/A","64","July 2008","August 2009","6-minute-walk Distance (6MWD)","0.7883","If the primary endpoint reaches significance, treatment effect of the secondary endpoint is determined at a 2-sided nominal of 0.05. Since hierarchy of the endpoints to be tested has been predefined, no correction for multiple testing will be applied","Generalized linear model","-1.5","Difference in least squares mean","95","2-Sided","-12.3","9.4"
"1585","NCT00710580","Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","Moderate to Severe Plaque Psoriasis",0,"ABT-874","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","350","July 2008","April 2009","Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12","0","0","0","0","0","0","0","0","0"
"1586","NCT00711217","Evaluation of a Medical Food for Chronic Wounds","Foot Ulcer, Diabetic",0,"Medical Food","Other","Abbott Nutrition","Industry",0,0,"All","18 Years","N/A","271","June 2008","December 2010","Wound healing","0","0","0","0","0","0","0","0","0"
"1587","NCT00711295","Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups","Influenza",0,"H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted","Biological","Nanotherapeutics, Inc.","Industry",0,0,"All","18 Years","N/A","3583","August 2008","July 2009","Frequency and severity of systemic reactions until 21 days after the first and second vaccinations","0","0","0","0","0","0","0","0","0"
"1588","NCT00712166","Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa","Cystic Fibrosis",0,"AZLI 75 mg three times daily (TID)","Drug","Gilead Sciences","Industry",0,0,"All","6 Years","N/A","160","May 2008","June 2009","Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS) Score at Day 28","0.433","The primary endpoint analysis was based on a two-sided test with an 0.05 a priori threshold for statistical significance.
A gate-keeper approach was established a priori to control the type 1 error rate, however, the primary endpoint was not met.","ANCOVA","1.80","Mean Difference (Final Values)","95","2-Sided","-2.83","6.44"
"1589","NCT00712413","Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori","Helicobacter Pylori Infection",0,"OBMT","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","0","August 2008","December 2008","H. pylori status confirmed by Urea Breath Test","0","0","0","0","0","0","0","0","0"
"1590","NCT00712673","GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","680","June 2008","March 2011","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","<0.0001","Stepwise testing procedure applied to control type 1 error: lixisenatide (morning) compared with placebo (combined), if found statistically significant, then lixisenatide (evening) compared with placebo (combined).","ANCOVA","-0.48","Least squares (LS) mean difference","95","2-Sided","-0.657","-0.312"
"1591","NCT00712920","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies","Perennial Allergic Rhinitis",0,"0.15% azelastine hydrochloride","Drug","Meda Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","581","January 2007","May 2008","Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (AM and PM Combined) at 28 Days.","0.03","0","ANCOVA","-0.90","Mean Difference (Final Values)","95","0","-1.70","-0.10"
"1592","NCT00713011","Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients","Diabetic Nephropathies",0,"Adalat XL","Drug","Bayer","Industry",0,0,"All","18 Years","80 Years","0","November 2008","March 2009","Change in Proteinuria","0","0","0","0","0","0","0","0","0"
"1593","NCT00713310","Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis","Ulcerative Colitis",0,"Asacol 400 mg","Drug","Warner Chilcott","Industry",0,0,"All","5 Years","17 Years","83","December 2008","March 2011","Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population","0.9240","0","Cochran-Mantel-Haenszel","-1.1","High-Low Dose Difference Success Rates","95","2-Sided","-22.7","20.5"
"1594","NCT00713648","Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency","Congenital Bleeding Disorder",0,"catridecacog","Drug","Novo Nordisk A/S","Industry",0,0,"All","6 Years","N/A","41","August 2008","April 2010","Rate (Number Per Subject Year) of Bleeding Episodes Requiring Treatment With a FXIII Containing Product During the Treatment Period","0","0","0","0.048","Mean (Lambda)","95","0","0.0094","0.2501"
"1595","NCT00713830","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","Diabetes Mellitus, Type 2",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","859","July 2008","January 2011","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","<0.0001","Statistical testing: 2-sided at significance level=0.05. Analysis of co-variance (ANCOVA) included treatment arms, randomization strata of screening HbA1c (<8.0, >=8.0%), metformin use (yes, no), country as fixed effects, baseline HbA1c as covariate.","ANCOVA","-0.74","Least squares (LS) mean difference","95","2-Sided","-0.867","-0.621"
"1596","NCT00714597","Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility","Venous Thromboembolism",0,"Semuloparin sodium","Drug","Sanofi","Industry",0,0,"All","40 Years","N/A","421","July 2008","March 2009","Percentage of Participants Who Experienced Venous Thromboembolism Event (VTE) or VTE-related Death","0","0","0","0","0","0","0","0","0"
"1597","NCT00714688","A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder","Attention Deficit/ Hyperactivity Disorder",0,"prolonged release (PR) OROS methylphenidate 54 mg","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","65 Years","279","February 2008","April 2009","Attention Deficit/Hyperactivity Disorder (ADHD) Symptoms Total Score of the Conners Adult ADHD Rating Scale (CAARS)","0.136","The p value was adjusted for multiplicity via Dunnett's test procedure.","ANCOVA","-2.7","Difference in Least-Squares Means","95","0","-6.04","0.67"
"1598","NCT00715624","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","Diabetes Mellitus, Type 2",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","496","July 2008","February 2011","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","0.0002","Statistical testing: 2-sided at significance level=0.05. Analysis of co-variance (ANCOVA) included treatment arms, randomization strata of screening HbA1c (<8.0, >=8.0%), metformin use (yes, no), country as fixed effects, baseline HbA1c as covariate.","ANCOVA","-0.36","Least squares (LS) mean difference","95","2-Sided","-0.550","-0.174"
"1599","NCT00715637","Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study","Secondary Acute Myeloid Leukemia (Secondary AML, sAML)",0,"Daunorubicin and Cytarabine","Drug","Antisoma Research","Industry",0,0,"All","18 Years","N/A","420","June 2007","June 2010","Rate of CR + CRi (which includes CRc and CRd) will be determined by assessing the proportion of patients who achieved CR or CRi among all evaluable patients.","0","0","0","0","0","0","0","0","0"
"1600","NCT00715975","Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis","Psoriasis",0,"halobetasol","Drug","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","140","July 2008","May 2010","assess the improvement of symptoms of psoriasis","0","0","0","0","0","0","0","0","0"
"1601","NCT00716053","Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema","Advanced Upper Lobe Predominant Emphysema",0,"BLVR","Drug","Aeris Therapeutics","Industry",0,0,"All","N/A","N/A","225","December 2008","December 2009","Improvement in pulmonary function and respiratory symptoms","0","0","0","0","0","0","0","0","0"
"1602","NCT00716547","Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)","Osteoarthritis of the Knee",0,"ketoprofen in Diractin®","Drug","IDEA AG","Industry",0,0,"All","46 Years","N/A","1399","May 2008","March 2009","pain subscale of the WOMAC","0","0","0","0","0","0","0","0","0"
"1603","NCT00716859","A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.","Glaucoma",0,"Timolol","Drug","Pfizer","Industry",0,0,"All","36 Weeks","18 Years","139","July 2008","November 2009","Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)","0","0","0","1.46","Mean Difference (Net)","95","2-Sided","-0.81","3.74"
"1604","NCT00717236","Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Certolizumab pegol (CZP)","Drug","UCB Pharma","Industry",0,0,"All","18 Years","N/A","1648","July 2008","March 2010","American College of Rheumatology 20% (ACR20) Response at Week 12","0","0","0","0","0","0","0","0","0"
"1605","NCT00717561","A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia","Pneumonia",0,"Avelox (Moxifloxacin, BAY12-8039)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","60","February 2008","May 2009","Clinical response 20 days after completion of study treatment (Test-of-Cure visit)","0","0","0","0","0","0","0","0","0"
"1606","NCT00717652","Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma","Melasma",0,"arbutin, tretinoin, triamcinolone","Drug","Azidus Brasil","Industry",0,0,"Female","18 Years","N/A","110","July 2008","July 2008","evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone)in the treatment of epidermal melasma.","0","0","0","0","0","0","0","0","0"
"1607","NCT00717678","A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients","Kidney Transplantation",0,"Prograf-XL","Drug","Astellas Pharma Inc","Industry",0,0,"All","12 Years","N/A","73","December 2007","April 2010","The patient and graft survival rates at 6 month post-transplant","0","0","0","0","0","0","0","0","0"
"1608","NCT00718224","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery","Venous Thromboembolism",0,"Semuloparin sodium","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","1150","July 2008","May 2009","Percentage of Participants Who Experienced Venous Thromboembolism Event (VTE) or All-cause Death","0","0","0","0","0","0","0","0","0"
"1609","NCT00718965","Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia","Hypercholesterolemia",0,"AVE5530","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","826","July 2008","November 2008","percent change from baseline in calculated LDL-C","0","0","0","0","0","0","0","0","0"
"1610","NCT00719576","A Comparison Between the Performance of Chondrocytes Versus Microfracture Technique on Knee Symptoms","Repair of Articular Cartilage Defects",0,"Matrix-Induced Autologous Chondrocyte Implant (MACI)","Biological","Vericel Corporation","Industry",0,0,"All","18 Years","55 Years","144","July 2008","March 2012","Change from Baseline to week 104 for the patient's Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain and Function (Sports and Recreational activities) scores.","0","0","0","0","0","0","0","0","0"
"1611","NCT00719745","A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients","Liver Transplantation",0,"Prograf","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","74","February 2006","June 2008","Event rate of patients with biopsy-proven acute rejections","0","0","0","0","0","0","0","0","0"
"1612","NCT00719823","Maraviroc Compassionate Use","Human Immunodeficiency Virus Type 1",0,"Maraviroc","Drug","ViiV Healthcare","Industry",0,0,"All","16 Years","N/A","0","August 2008","May 2010","Safety analysis will include all subjects who receive at least one dose of study drug","0","0","0","0","0","0","0","0","0"
"1613","NCT00720057","Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.","Toothache",0,"Naproxen Sodium ER (BAYH6689)","Drug","Bayer","Industry",0,0,"All","16 Years","45 Years","312","June 2008","August 2008","Summed Pain Intensity Difference (SPID)","<0.001","0","ANCOVA","0","0","0","0","0","0"
"1614","NCT00720265","A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients","Kidney Transplantation",0,"Prograf","Drug","Astellas Pharma Inc","Industry",0,0,"All","19 Years","65 Years","135","February 2006","March 2008","Acute rejection within 24 weeks (6 months)","0","0","0","0","0","0","0","0","0"
"1615","NCT00720382","A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis","Perennial Allergic Rhinitis",0,"0.15% azelastine hydrochloride","Drug","Meda Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","703","March 2007","June 2008","Change From Baseline on Direct Visual Nasal Exams to 12 Months","0","0","0","0","0","0","0","0","0"
"1616","NCT00720408","A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.","Liver Transplantation",0,"Prograf-XL","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","70 Years","48","December 2007","September 2009","Incidence of biopsy confirmed acute rejection (local assessment of biopsies performed due to hepatic dysfunction) during the 6 months post-transplant.","0","0","0","0","0","0","0","0","0"
"1617","NCT00720941","Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell",0,"Pazopanib","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","927","August 14, 2008","May 21, 2012","Progression-free Survival (PFS)","0","0","0","1.0466","Hazard Ratio (HR)","95","2-Sided","0.8982","1.2195"
"1618","NCT00721149","NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study","Heart Diseases",0,"Radiofrequency Ablation","Device","Biosense Webster, Inc.","Industry",0,0,"All","18 Years","N/A","10","September 2008","December 2009","Percentage of Subjects Who Exhibited no Documented Symptomatic Paroxysmal Atrial Fibrillation (PAF) Episodes From Study Day 91 Through Day 361.","0","0","0","0","0","0","0","0","0"
"1619","NCT00721760","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery","Venous Thromboembolism",0,"Enoxaparin sodium","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","1003","July 2008","October 2009","Percentage of Participants Who Experienced Venous Thromboembolism Event [VTE] or All-cause Death","0","0","0","0","0","0","0","0","0"
"1620","NCT00721955","Staccato® Loxapine Treatment of Agitation in Bipolar Disorder Patients","Bipolar I Disorder",0,"loxapine","Drug","Alexza Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","65 Years","300","July 2008","October 2008","Change in PANSS Excited component (PEC) score from baseline following Dose #1 of Staccato Loxapine, compared with placebo","0","0","0","0","0","0","0","0","0"
"1621","NCT00721968","Safety and Efficacy of the GTS400 Stent in Conjunction With Cataract","Open-angle Glaucoma",0,"Glaucoma Stent Surgery (GTS400 Stent)","Device","Glaukos Corporation","Industry",0,0,"All","18 Years","N/A","62","March 2007","February 2012","Month 12 Intraocular Pressure ≤ 18 mmHg Without Topical Hypotensive Medications","0","0","0","0","0","0","0","0","0"
"1622","NCT00722371","MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","Type 2 Diabetes Mellitus",0,"Sitagliptin phosphate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","78 Years","1615","September 5, 2008","October 26, 2010","Change From Baseline in Hemoglobin A1C (A1C) at Week 24","0","0","0","0","0","0","0","0","0"
"1623","NCT00722566","A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma","Multiple Myeloma",0,"VELCADE Administered by subcutaneous injection","Drug","Millennium Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","222","July 2008","August 2010","Number of Patients With Overall Response (Complete Response + Partial Response)","0.00201","0","Farrrington and Manning","16.8","ORR_SQ - 0.6 ORR_IV","95","2-Sided","6.1","27.1"
"1624","NCT00722579","A Study of the Presillion Stent in de Novo Coronary Lesions","Coronary Artery Disease",0,"PRESILLION cobalt chromium stent","Device","Cordis Corporation","Industry",0,0,"All","18 Years","N/A","101","July 2008","December 2008","Composite of MACE which includes cardiac death, myocardial infarction (Q-wave and non Q-wave) and clinically driven target lesion revascularization (TLR).","0","0","0","0","0","0","0","0","0"
"1625","NCT00722852","Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee","Osteoarthritis of the Knee",0,"ketoprofen in Diractin®","Drug","IDEA AG","Industry",0,0,"All","46 Years","N/A","555","June 2008","February 2009","pain subscale of the WOMAC","0","0","0","0","0","0","0","0","0"
"1626","NCT00723190","Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder",0,"CLONICEL (Clonidine HCl sustained release)","Drug","Shionogi","Industry",0,0,"All","6 Years","17 Years","303","January 2008","March 2010","Safety Assessment in Terms of Adverse Events (Treatment-emergent [TEAEs] and Serious [SAEs])","0","0","0","0","0","0","0","0","0"
"1627","NCT00723411","A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)","Type 1 Diabetes Mellitus",0,"rhGAD65","Drug","Diamyd Therapeutics AB","Industry",0,0,"All","10 Years","20 Years","334","July 2008","May 2011","Meal stimulated C-peptide (area under the curve)","0","0","0","0","0","0","0","0","0"
"1628","NCT00723528","An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis","Psoriasis",0,"Placebo (CP)","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","158","March 2008","January 2009","Percentage of Participants With Greater Than or Equal to 75 Percent (%) Improvement in Psoriasis Area and Severity Index (PASI) Score","<0.0001","Fisher's exact test (using Holm's method)","Fisher Exact","0","0","0","0","0","0"
"1629","NCT00723554","Iloprost Power Disc-15 in Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension",0,"Iloprost PD-6","Drug","Actelion","Industry",0,0,"All","18 Years","85 Years","63","July 2008","August 2010","Number of Patients Reporting Treatment-emergent Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"1630","NCT00723606","A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation","Schizophrenia",0,"Intramuscular ziprasidone mesylate","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","376","September 2008","July 2009","Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Scores at 72 Hours","0","0","0","0","0","0","0","0","0"
"1631","NCT00724048","A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease","Huntington Disease",0,"ACR16 10 mg","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","30 Years","N/A","227","October 2008","June 2011","Sum score of items 4-10 and 13-15 of the UHDRS motor assessment","0","0","0","0","0","0","0","0","0"
"1632","NCT00724126","Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)","Non-Constipation Irritable Bowel Syndrome",0,"Rifaximin","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","637","July 2008","August 2009","Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).","0.03","0","Regression, Logistic","0","0","0","0","0","0"
"1633","NCT00724815","The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine","Migraine Disorders",0,"NP101 - Sumatriptan iontophoretic transdermal patch","Drug","NuPathe Inc.","Industry",0,0,"All","18 Years","65 Years","530","January 2009","July 2009","Pain Free at Two Hours","0","0","0","0","0","0","0","0","0"
"1634","NCT00724906","Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor","Parkinsonian Syndromes",0,"123 I - ALTROPANE®","Drug","Alseres Pharmaceuticals, Inc","Industry",0,0,"All","40 Years","80 Years","240","July 2010","July 2011","To evaluate the diagnostic accuracy of a single dose of 123 I-ALTROPANE® as an imaging agent to aid in the diagnosis of Parkinsonian syndromes (PS) in subjects with upper extremity tremor for less than 2 years.","0","0","0","0","0","0","0","0","0"
"1635","NCT00724932","Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)","Anesthesia, General",0,"Rocuronium","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","140","July 16, 2008","April 1, 2009","Time From Start of Administration of Investigational Medicinal Product (IMP, Sugammadex or Neostigmine) to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9","<0.0001","Testing was performed using a two-sided test at the 0.05 significance level. There was only one primary comparison, therefore no adjustment for multiplicity was required.","ANOVA","3.4","Geometric Mean Ratio (Final Values)","95","2-Sided","2.8","4.1"
"1636","NCT00725114","Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain","Pain",0,"Tetrodotoxin","Biological","Wex Pharmaceuticals Inc.","Industry",0,0,"All","18 Years","N/A","165","April 2008","November 2012","Efficacy: Composite-endpoint will be an evaluation that combines pain outcome and quality of life. Pain intensity will be used a co-primary endpoint. Safety as assessed by the analysis of AEs, 12-lead ECG, and abnormal lab values.","0","0","0","0","0","0","0","0","0"
"1637","NCT00725491","A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)","Controlled Ovarian Stimulation",0,"ganirelix","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","35 Years","259","May 2007","December 2008","The Amount of International Units (IU) of Recombinant Follicle Stimulating Hormone (recFSH) Needed in a Controlled Ovarian Stimulation (COS) Cycle up to the First Day the Human Chorionic Gonadotropin (hCG) Criterion is Met.","<0.001","0","Cochran-Whitehead","0","0","0","0","0","0"
"1638","NCT00725985","Oral Cladribine in Early Multiple Sclerosis (MS)","Multiple Sclerosis",0,"Cladribine","Drug","EMD Serono","Industry",0,0,"All","18 Years","55 Years","617","December 2008","July 2011","Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS","0.0001","The treatment effect was also assessed by hazard ratios using the Cox's proportional hazards model.","two-sided Wald test","0.381","Hazard Ratio (HR)","95","2-Sided","0.249","0.584"
"1639","NCT00726011","Tetrodotoxin Open-label Efficacy and Safety Continuation Study","Pain",0,"Tetrodotoxin","Biological","Wex Pharmaceuticals Inc.","Industry",0,0,"All","18 Years","N/A","113","July 2008","December 2011","Efficacy: long-term efficacy of tetrodotoxin (TTX) in reducing pain and improving quality of life. Safety: long-term safety and tolerability of s.c. TTX","0","0","0","0","0","0","0","0","0"
"1640","NCT00726388","An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain","Pain, Postoperative",0,"DIC075V (intravenous diclofenac sodium)","Drug","Javelin Pharmaceuticals","Industry",0,0,"All","18 Years","85 Years","850","September 2008","April 2009","Adverse Events","0","0","0","0","0","0","0","0","0"
"1641","NCT00727857","Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.","Diabetes Mellitus",0,"Pioglitazone and metformin","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","600","June 2007","August 2008","Percent Change From Baseline in Glycosylated Hemoglobin","<0.0001","0","ANCOVA","0.86","Mean Difference (Final Values)","95","0","0.51","1.22"
"1642","NCT00727987","A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","Rheumatoid Arthritis",0,"CNTO 148","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","74 Years","269","May 2008","December 2011","ACR 20% response","0","0","0","0","0","0","0","0","0"
"1643","NCT00728091","A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia","Hyponatremia",0,"Satavaptan","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","2","July 2008","December 2008","serum sodium change from baseline","0","0","0","0","0","0","0","0","0"
"1644","NCT00728351","Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)","Diabetes Mellitus, Type 2",0,"vildagliptin + metformin","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","78 Years","317","June 2008","February 2010","HbA1c reduction after 24 weeks of treatment in patients with T2DM inadequately controlled with metformin monotherapy","0","0","0","0","0","0","0","0","0"
"1645","NCT00728416","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)","Allergic Rhinitis",0,"Mometasone furoate nasal spray (MFNS)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","333","August 2008","October 2008","Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days","<0.001","0","ANCOVA","-0.31","Difference in LS Means","95","2-Sided","-0.43","-0.19"
"1646","NCT00729027","Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia","Hypercholesterolemia",0,"25 mg/day AVE5530","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","1015","July 2008","June 2009","Percent change from baseline in calculated LDL-C","0","0","0","0","0","0","0","0","0"
"1647","NCT00729183","Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)","Osteoporosis",0,"Odanacatib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","45 Years","85 Years","214","October 2008","March 2010","Percent Change From Baseline to Month 12 in Lumbar Spine Areal Bone Mineral Density (aBMD)","<0.001","0","Longitudinal Data Analysis (LDA) Model","3.49","Difference in LS Means","95","2-Sided","2.66","4.32"
"1648","NCT00729599","Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.","Hygiene",0,"Cetylpyridinium chloride","Drug","Sanofi","Industry",0,0,"All","10 Years","60 Years","31","July 2008","August 2008","Patients will be evaluated according to the adverse reactions and the intensity of them.","0","0","0","0","0","0","0","0","0"
"1649","NCT00730236","A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)","Homozygous Familial Hypercholesterolemia",0,"AEGR-733","Drug","Aegerion Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","29","December 2007","September 2010","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)","0","0","0","0","0","0","0","0","0"
"1650","NCT00730249","Quality Assurance of Administering Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) - QUMEA","Attention Deficit Hyperactivity Disorder",0,"methylphenidate hydrochloride","Drug","Medice Arzneimittel Pütter GmbH & Co KG","Industry",0,0,"All","18 Years","N/A","150","September 2008","January 2010","Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) in last study-week (Placebo vs. Verum, double-blind phase, week 6)","0","0","0","0","0","0","0","0","0"
"1651","NCT00730691","Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","Generalized Anxiety Disorder",0,"Placebo","Drug","Takeda","Industry",0,0,"All","18 Years","65 Years","781","June 2008","February 2009","Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8","0.255","This treatment arm is not in the pre-specified testing sequence, a nominal p-value is provided.","Mixed model for repeated measurements","-0.96","LS Mean Difference","95","2-Sided","-2.62","0.69"
"1652","NCT00731120","Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","Generalized Anxiety Disorder",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","457","June 2008","January 2009","Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score","0.279","Hierarchical testing stopped at 10 mg versus placebo for HAM-A total score at Week 8 in the testing sequence, a nominal p-value is provided.","ANCOVA","-0.87","LS Mean Difference","95","2-Sided","-2.45","0.71"
"1653","NCT00731679","Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)","Non-Constipation Irritable Bowel Syndrome",0,"Rifaximin","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","623","July 2008","August 2009","Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).","0.01","0","Regression, Logistic","0","0","0","0","0","0"
"1654","NCT00732225","DisCoVisc Comparative Evaluation","Cataracts",0,"DisCoVisc","Device","Alcon Research","Industry",0,0,"All","49 Years","N/A","173","May 2007","February 2008","Percent Loss of Endothelial Cells","0","0","0","0","0","0","0","0","0"
"1655","NCT00732381","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)","Allergic Rhinitis",0,"Mometasone furoate nasal spray (MFNS)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","351","August 2008","November 2008","The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days","0.006","0","ANCOVA","0","0","0","0","0","0"
"1656","NCT00732615","Use of NPSP558 in the Treatment of Hypoparathyroidism","Hypoparathyroidism",0,"Placebo","Drug","Shire","Industry",0,0,"All","18 Years","85 Years","124","December 2008","September 2011","The Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria at Week 24.","<0.001","A fixed sequence test procedure was used to control the study level type I error. Order of test sequence started with the primary efficacy endpoint and proceeded to the 3 secondary efficacy endpoints, in the order defined in the protocol.","Fisher Exact","52.3","Treatment difference","95","2-Sided","40.6","64.0"
"1657","NCT00732641","Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)","Multiple Myeloma",0,"Peginterferon","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","85 Years","244","December 2000","November 2010","Number of Days With Progression Free Survival (PFS)","0","0","0","0","0","0","0","0","0"
"1658","NCT00732875","A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)","Arthritis, Rheumatoid",0,"Infliximab + methotrexate (MTX)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","75 Years","92","August 2006","May 2008","Number of Subjects Experiencing Any Adverse Event","0","0","0","0","0","0","0","0","0"
"1659","NCT00733005","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)","Allergic Rhinitis",0,"Mometasone furoate nasal spray (MFNS)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","324","July 2008","October 2008","The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days.","0.102","0","ANCOVA","0","0","0","0","0","0"
"1660","NCT00733135","Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)","Peripheral Arterial Disease",0,"SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device","Device","Medtronic Endovascular","Industry",0,0,"All","18 Years","N/A","133","October 2008","November 2010","Successful Revascularization","<0.05","0","GEE","0","0","0","0","0","0"
"1661","NCT00733902","Tanezumab in Osteoarthritis of the Knee","Arthritis",0,"tanezumab","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","697","September 2008","September 2009","WOMAC function","0","0","0","0","0","0","0","0","0"
"1662","NCT00734058","SOLAR & ATRILAZE Atrial Fibrillation Trial","Atrial Fibrillation",0,"Laser MAZE by Ablation of Cardiac Tissue","Device","EndoPhotonix, Inc.","Industry",0,0,"All","18 Years","N/A","90","December 2008","January 2012","Freedom from atrial fibrillation by 24-hour 3-lead Holter Monitor at the 180 day evaluation. On or Off Class 1 and III anti-arrhythmic medication","0","0","0","0","0","0","0","0","0"
"1663","NCT00734071","An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","Generalized Anxiety Disorder",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","304","June 2008","January 2009","Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8","0.518","Pre-specified sequential statistical testing procedure indicates that when p-value >0.05, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.","Mixed model for repeated measurements","0.59","LS Mean Difference","95","2-Sided","-1.20","2.38"
"1664","NCT00734162","Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection","Hepatitis B Virus (HBV)",0,"Tenofovir disoproxil fumarate (TDF)","Drug","Gilead Sciences","Industry",0,0,"All","12 Years","17 Years","106","December 2008","March 2011","Percentage of Participants With HBV DNA < 400 Copies/mL at Week 72","< 0.001","A p-value of < 0.05 was considered statistically significant.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1665","NCT00734318","Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma","Asthma, Bronchial",0,"Flutiform 250/10 micrograms","Drug","Mundipharma Research Limited","Industry",0,0,"All","18 Years","N/A","1667","September 2008","June 2009","Comparison of FEV1 (Forced expiratory volume in the first second) values.","0","0","0","0","0","0","0","0","0"
"1666","NCT00734474","A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin","Diabetes Mellitus, Type 2",0,"LY2189265","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","75 Years","1202","August 2008","June 2011","Glycosylated Hemoglobin (HbA1c) Change From Baseline","<0.001","P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","ANCOVA","-0.71","LS Mean Difference","95","2-Sided","-0.87","-0.55"
"1667","NCT00734578","Efficacy and Safety of SPD503 in Combination With Psychostimulants","ADHD",0,"SPD503-AM","Drug","Shire","Industry",0,0,"All","6 Years","17 Years","461","September 2008","December 2009","Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF)","0.002","Both SPD503 groups were compared with placebo using Dunnett's adjustment. Each treatment comparison was evaluated at the 0.05 significance level (Dunnett's adjusted).","ANCOVA","-4.5","Placebo-adjusted difference in LS mean","95","0","-7.5","-1.4"
"1668","NCT00734604","A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.","Erectile Dysfunction",0,"tadalafil once a day [T(OaD)]","Drug","Eli Lilly and Company","Industry",0,0,"Male","18 Years","N/A","378","August 2008","September 2009","Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)","0.001","p-value is for difference in LS Means change from baseline between tadalafil OaD and Sildenafil PRN.","t-test","0.12","Mean Difference (Final Values)","95","2-Sided","0.04","0.19"
"1669","NCT00734708","Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)","Periodontitis",0,"Trafermin (genetical recombination)","Drug","Kaken Pharmaceutical","Industry",0,0,"All","20 Years","N/A","328","August 2008","March 2010","rate of increase in alveolar bone height","0","0","0","0","0","0","0","0","0"
"1670","NCT00734747","Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)","Gastroesophageal Reflux Disease (GERD)",0,"Medigus SRS endoscopic stapling system","Device","Aviel Roy-Shapira, M.D.","Industry",0,0,"All","18 Years","N/A","72","May 2008","May 2011","Percentage of Participants With >= 50% Improvement in GERD Health Related Quality of Life (GERD-HRQL - Velanovich) Score","0","0","0","0","0","0","0","0","0"
"1671","NCT00735007","12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.","Multiple Sclerosis",0,"Rebif® New Formulation (RNF) using RebiSmartTM","Drug","EMD Serono","Industry",0,0,"All","18 Years","65 Years","106","July 2008","January 2009","The Number of Subjects Rating the Suitability of RebiSmart at the End of 12-week Treatment Period for Self-injecting Rebif® New Formulation (RNF).","0","0","0","0","0","0","0","0","0"
"1672","NCT00735241","FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma","Colorectal Carcinoma",0,"SIR-Spheres microspheres","Device","Sirtex Medical","Industry",0,0,"All","18 Years","N/A","0","July 2008","March 2009","Toxicity and safety","0","0","0","0","0","0","0","0","0"
"1673","NCT00735267","A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)","Generalized Anxiety Disorder",0,"PD 0332334","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","468","October 2008","April 2009","The nature, incidence, and duration of adverse events monitored throughout the study by physical exam","0","0","0","0","0","0","0","0","0"
"1674","NCT00735371","Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder (ADHD)",0,"LDX 30 mg","Drug","Shire","Industry",0,0,"All","13 Years","17 Years","314","October 2008","April 2009","Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks","0.0056","0","ANCOVA","0","0","0","0","0","0"
"1675","NCT00735462","Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts","Genital Warts",0,"2.5% imiquimod cream","Drug","Graceway Pharmaceuticals, LLC","Industry",0,0,"All","12 Years","N/A","511","August 2008","July 2009","Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study.","0","0","0","0","0","0","0","0","0"
"1676","NCT00735553","Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids","Uterine Fibroids",0,"Proellex","Drug","Repros Therapeutics Inc.","Industry",0,0,"Female","18 Years","48 Years","77","August 2008","August 2009","To Determine the Efficacy of 50 mg Proellex® Versus Placebo in the Treatment of Subjects With Symptomatic Uterine Fibroids From Baseline to Month 4 as Determined by Scoring Changes in the Pictorial Blood Loss Assessment Chart (PBAC)","0","0","0","0","0","0","0","0","0"
"1677","NCT00735644","Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines","Japanese Encephalitis",0,"Japanese encephalitis vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","12 Months","18 Months","1200","August 2008","May 2009","Number of Participants With Seroconversion to Vaccine Antigens Following Vaccination With JE-CV by GPO MBP Lots","0","0","0","0","0","0","0","0","0"
"1678","NCT00735709","Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","Major Depressive Disorder",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","75 Years","560","August 2008","July 2009","Change From Baseline in the 24-item Hamilton Depression Scale Total Score At Week 8","<0.001","Pre-specified sequential statistical testing procedure indicates that when p-value <0.05, hierarchical testing continues.","Mixed model for repeated measurements","-4.93","LS Mean Difference","95","2-Sided","-6.99","-2.86"
"1679","NCT00736840","BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis","Chronic Liver Disease",0,"c13 methacetin solution with breath analyzer","Device","Exalenz Bioscience LTD.","Industry",0,0,"All","18 Years","N/A","414","August 2008","September 2009","Number of Subjects With Likelihood of Cirrhosis Based on ""Hepatic Impairment Score"" (HIS)","0.0924","0","Exact binomial test","0.74","Sensitivity","95","2-Sided","0.6607","0.8809"
"1680","NCT00736853","An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain","Pain",0,"Tramadol Hydrochloride Plus Acetaminophen (Open-Label)","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","321","June 2008","January 2009","Number of Participants With Insufficient Pain Relief After the Start of Double-Blind Period","0.0001","0","Log Rank","0.377","Hazard Ratio (HR)","95","2-Sided","0.221","0.641"
"1681","NCT00736879","Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","77 Years","497","September 22, 2008","December 29, 2009","Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants","<0.0001","Tested at alpha=0.019 applying Dunnett’s adjustment","ANCOVA","-0.69","Mean Difference (Final Values)","95","2-Sided","-1.02","-0.37"
"1682","NCT00736957","A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain","Chronic Pain",0,"Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","219","May 2008","October 2009","Change From Baseline in Visual Analogue Scale (VAS24) Score at Week 4","0","0","0","0","0","0","0","0","0"
"1683","NCT00737048","A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain","Pain",0,"Tramadol Hydrochloride","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","74 Years","328","March 2008","September 2008","Total Pain Relief Based on Numerical Rating Scale (NRS) Score","<0.0001","0","Fisher Least Signiﬁcant Diﬀerence Method","-5.3","Mean Difference (Final Values)","0","0","0","0"
"1684","NCT00737282","Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids","Uterine Fibroids",0,"Proellex 25 mg","Drug","Repros Therapeutics Inc.","Industry",0,0,"Female","18 Years","48 Years","175","October 2008","August 2009","To Assess the Safety of Proellex Administered Once Daily for Three Treatment Cycles (4 Months Each Cycle)","0","0","0","0","0","0","0","0","0"
"1685","NCT00737412","Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults","Diarrhea",0,"Probiotic: Bio-K+ CL1285","Other","Bio-K Plus International Inc.","Industry",0,0,"All","18 Years","N/A","277","April 2008","December 2009","To determine the efficacy of Bio-K+ CL1285 RX® in reducing traveler's diarrhea by comparing the incidence of diarrhea in travelers during their stay abroad and upon their return to Canada, following either BIO-K+CL1285 RX® or placebo prophylaxis.","0","0","0","0","0","0","0","0","0"
"1686","NCT00737568","Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine","Hepatitis B",0,"TDF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","75 Years","280","September 2008","November 2011","Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96","0.43","The p-value for the two-sided Cochran-Mantel-Haenszel test was controlled for strata (HBeAg status and ALT level).","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1687","NCT00737672","GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis","Renal Failure",0,"GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface","Device","W.L.Gore & Associates","Industry",0,0,"All","18 Years","N/A","293","September 2008","May 2011","Target Lesion Primary Patency at 6 Months","0","0","0","0","0","0","0","0","0"
"1688","NCT00737789","Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.","Ulcerative Colitis",0,"Mesalazine slow-release granules","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","206","November 2008","June 2010","Primary efficacy criterion: remission after 8 weeks of treatment, defined on the basis of the UC-DAI score less than or equal to 1","0","0","0","0","0","0","0","0","0"
"1689","NCT00738062","Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)","Neurogenic Orthostatic Hypotension",0,"Droxidopa","Drug","Chelsea Therapeutics","Industry",0,0,"All","18 Years","N/A","103","January 2008","December 2010","Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ)","0.438","0","Mantel Haenszel","0","0","0","0","0","0"
"1690","NCT00738738","6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)","Generalized Anxiety Disorder",0,"PD-0332334","Drug","Pfizer","Industry",0,0,"All","65 Years","N/A","0","January 2009","February 2009","Discontinuations due to adverse events or adverse events occurring during and after the discontinuation of trial medication","0","0","0","0","0","0","0","0","0"
"1691","NCT00739635","Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus","Subjective Tinnitus",0,"Neramexane mesylate","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","75 Years","411","September 2008","February 2010","TBF-12 (Tinnitus-Beeinträchtigungs-Fragebogen-12 ""Tinnitus Handicap Inventory-12"") total score change from baseline to end of treatment","0","0","0","0","0","0","0","0","0"
"1692","NCT00739973","Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension","Hypertension",0,"Placebo","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","2694","September 2008","May 2009","Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)","<0.001","0","ANCOVA","-9.97","Least Square Mean Difference","95","2-Sided","-12.81","-7.12"
"1693","NCT00740324","Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men","Healthy",0,"NPO-11","Drug","Nihon Pharmaceutical Co., Ltd","Industry",0,0,"Male","35 Years","65 Years","30","August 2008","March 2009","[Safety] (Evaluation by investigator or subinvestigator) Adverse events and ADRs observed between administration and 7 ± 3 days after administration","0","0","0","0","0","0","0","0","0"
"1694","NCT00740792","A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis",0,"azelastine HCl/fluticasone propionate","Drug","Meda Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","776","August 2008","November 2008","Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)","0","0","0","0","0","0","0","0","0"
"1695","NCT00740831","PGL4001 Versus GnRH-agonist in Uterine Myomas","Uterine Myomas",0,"PGL4001","Drug","PregLem SA","Industry",0,0,"Female","18 Years","50 Years","301","August 2008","January 2010","Percentage of Subjects With Reduction of Uterine Bleeding at Week 13 Visit Defined as Pictorial Blood-loss Assessment Chart (PBAC) Score < 75 at End-of-treatment Visit (Week 13 Visit)","0","0","0","1.2","Difference in proportions","97.5","1-Sided","-9.3","0"
"1696","NCT00741611","Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation","Paroxysmal Atrial Fibrillation",0,"HD Mesh Ablation System","Device","C. R. Bard","Industry",0,0,"All","21 Years","75 Years","44","July 2008","November 2009","Number of Participants With Major Complications","0","0","0","0","0","0","0","0","0"
"1697","NCT00741715","Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia","Hypercholesterolemia",0,"AVE5530","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","1736","August 2008","May 2009","Percent change from baseline in calculated LDL-C","0","0","0","0","0","0","0","0","0"
"1698","NCT00742391","A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","Actinic Keratoses",0,"PEP005 (ingenol mebutate) Gel","Drug","Peplin","Industry",0,0,"All","18 Years","N/A","255","September 2008","February 2009","Patients With Complete Clearance of Actinic Keratosis (AKs)","<0.0001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1699","NCT00742443","Juvista in Scar Revision Surgery of Disfiguring Scars","Cicatrix",0,"Juvista (avotermin)","Drug","Renovo","Industry",0,0,"All","18 Years","85 Years","350","December 2008","January 2011","Global Scar Comparison Scale as assessed by an Independent Clinical Scar Assessment Panel using photographs of the treated scars.","0","0","0","0","0","0","0","0","0"
"1700","NCT00742599","Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy","Patients Undergoing Gastric Endoscopy",0,"NPO-11","Drug","Nihon Pharmaceutical Co., Ltd","Industry",0,0,"All","20 Years","N/A","80","September 2008","April 2009","Presence or absence of gastric peristalsis (central evaluation by independent evaluator) No gastric peristalsis is defined as when patients have no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy.","0","0","0","0","0","0","0","0","0"
"1701","NCT00743652","Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.","Pneumococcal Disease",0,"13-valent Pneumococcal Conjugate Vaccine","Biological","Pfizer","Industry",0,0,"All","42 Days","5 Years","373","January 2009","September 2010","Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the Infant Series","0","0","0","0","0","0","0","0","0"
"1702","NCT00744471","Tanezumab in Osteoarthritis Of The Hip","Arthritis",0,"tanezumab","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","627","November 2008","March 2010","Womac Pain","0","0","0","0","0","0","0","0","0"
"1703","NCT00744497","Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer","Prostatic Neoplasms",0,"Placebo","Drug","Bristol-Myers Squibb","Industry",0,0,"Male","18 Years","N/A","1930","October 2008","August 2012","Overall Survival: Time From Randomization to Date of Death","0.9009","An interim analysis on survival was performed and the final test was corrected for multiplicity.","Log Rank","0.99","Hazard Ratio (HR)","95.53","2-Sided","0.87","1.13"
"1704","NCT00744627","Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.","Generalized Anxiety Disorder",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","301","September 2008","July 2009","Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8","<0.001","Pre-specified sequential statistical testing procedure indicates that when p-value <0.05, hierarchical testing continues.","Mixed model for repeated measurements","-3.81","LS Mean Difference","95","2-Sided","-5.74","-1.88"
"1705","NCT00744848","Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy","Hemorrhoids",0,"Bupivacaine HCl","Drug","Pacira Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","204","August 2008","February 2009","Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores","0","0","0","0","0","0","0","0","0"
"1706","NCT00745290","A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty","Postoperative Pain",0,"Bupivacaine HCl","Drug","Pacira Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","245","August 2008","January 2009","Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores","0","0","0","0","0","0","0","0","0"
"1707","NCT00745459","Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy","Stomach Diseases",0,"NPO-11","Drug","Nihon Pharmaceutical Co., Ltd","Industry",0,0,"All","20 Years","N/A","100","September 2008","April 2009","Presence or absence of gastric peristalsis (central evaluation by independent evaluator) No gastric peristalsis is defined as when patients have no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy.","0","0","0","0","0","0","0","0","0"
"1708","NCT00745823","A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)","HIV",0,"Comparator: Raltegravir 400 mg b.i.d.","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","775","September 2008","October 2010","Number of Participants With HIV Ribonucleic Acid (RNA) <50 Copies/mL at 48 Weeks","0.044","0","Miettinen and Nurminen","-5.7","Mean Difference (Final Values)","95","2-Sided","-10.7","-0.83"
"1709","NCT00746096","Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea","Dysmenorrhea",0,"IKH-01","Drug","Nobelpharma","Industry",0,0,"Female","16 Years","N/A","115","September 2008","September 2009","Patient Response to Treatment for Primary Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment)","0","0","0","0","0","0","0","0","0"
"1710","NCT00746616","Durom(R) Hip Resurfacing System Multicenter Trial","Advanced Hip Disease",0,"Durom Hip Resurfacing System","Device","Zimmer Biomet","Industry",0,0,"All","18 Years","65 Years","40","June 2007","March 2011","Device Survival","0","0","0","0","0","0","0","0","0"
"1711","NCT00747032","To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis","Plaque Psoriasis",0,"NYC 0462 Ointment","Drug","Fougera Pharmaceuticals Inc.","Industry",0,0,"All","18 Years","N/A","0","September 2010","February 2011","Reduction in plaque elevation score","0","0","0","0","0","0","0","0","0"
"1712","NCT00747110","Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)","Colitis, Ulcerative",0,"budesonide","Drug","Dr. Falk Pharma GmbH","Industry",0,0,"All","18 Years","75 Years","343","October 2007","August 2008","Rate of clinical remission (defined by CAI <= 4, with stool frequency and rectal bleeding subscores of ´0´) at week 8 (LOCF)","0","0","0","0","0","0","0","0","0"
"1713","NCT00747227","Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)","Cataract",0,"modified light transmission intraocular lens","Device","Abbott Medical Optics","Industry",0,0,"All","18 Years","N/A","250","December 2006","March 2009","Best Corrected Distance Visual Acuity","0","0","0","0","0","0","0","0","0"
"1714","NCT00747318","A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005","Asthma",0,"SKP FlutiForm HFA pMDI","Drug","SkyePharma AG","Industry",0,0,"All","18 Years","N/A","280","September 2008","May 2010","To assess the long-term safety and efficacy of FlutiForm HFA pMDI 250/10 mcg bid in adolescents and adults with moderate to severe asthma who have completed the study SKY2028-3-005","0","0","0","0","0","0","0","0","0"
"1715","NCT00747344","A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis","Psoriasis",0,"Placebo - Controlled Period (CP)","Drug","Centocor, Inc.","Industry",0,0,"All","20 Years","N/A","121","December 2008","September 2009","The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) at Week 12","<0.001","The study was designed to maintain a Type I error of 0.05 or less for the primary analysis.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1716","NCT00748098","Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance","Restless Legs Syndrome",0,"GSK1838262 Extended Release Tablets","Drug","XenoPort, Inc.","Industry",0,0,"All","18 Years","N/A","136","October 2008","July 2009","Adjusted Mean Change From Baseline in Wake Time During Sleep (WTDS) at Week 4/10 Measured by Polysomnography (PSG) (Sleep Study) Using Last Observation Carried Forward (LOCF)","<0.0001","0","ANCOVA","-26.00","Adjusted mean difference versus placebo","95","2-Sided","-35.64","-16.36"
"1717","NCT00748124","PleuraSeal Pivotal Study (US)","Open Thoracotomy",0,"PleuraSeal Sealant System","Device","Integra LifeSciences Corporation","Industry",0,0,"All","18 Years","N/A","230","August 2008","September 2010","Proportion of subjects remaining air leak free from time of skin closure to hospital discharge.","0","0","0","0","0","0","0","0","0"
"1718","NCT00750139","Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis","Tinea Pedis",0,"NAFT-500","Drug","Merz Pharmaceuticals, LLC","Industry",0,0,"All","12 Years","N/A","707","August 2008","August 2009","Percentage of Subjects With Complete Cure at Week 6.","0.010","The first primary efficacy analyses will use the Cochran-Mantel-Haenszel (CMH) test after stratification by pooled clinical site. The test will be conducted with the FAS at a one-sided level of significance of α = 0.025.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1719","NCT00750152","Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris","Tinea Cruris",0,"NAFT-500","Drug","Merz Pharmaceuticals, LLC","Industry",0,0,"All","12 Years","N/A","334","September 2008","August 2009","Percentage of Subjects","0.025","0","Cochran-Mantel-Haenszel","0.001","one-sided p-value from CMH test","95","1-Sided","0","0"
"1720","NCT00750165","Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)","Sleep Apnea, Obstructive",0,"SleepStyle 200 Auto Series CPAP Humidifier","Device","Fisher and Paykel Healthcare","Industry",0,0,"All","18 Years","N/A","30","May 2007","January 2008","Apnea Hypopnea Index (AHI)","0","0","0","0","0","0","0","0","0"
"1721","NCT00750633","A Phase III Study of an Otic Formulation in Acute Otitis Externa","Acute Otitis Externa",0,"Moxidex otic solution","Drug","Alcon Research","Industry",0,0,"All","6 Months","N/A","990","June 2008","January 2009","Clinical Cure","0","0","0","0","0","0","0","0","0"
"1722","NCT00750919","Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)","Sleep Initiation and Maintenance Disorders",0,"esmirtazapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","65 Years","184","October 2008","March 2010","Change From Baseline in Total Sleep Time (TST)","0","0","0","0","0","0","0","0","0"
"1723","NCT00751036","Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg","Gastrointestinal Stromal Tumors",0,"Nilotinib","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","94","June 2009","August 2012","Progression-free Survival (PFS)","0","0","0","0","0","0","0","0","0"
"1724","NCT00751179","Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)","Neuromuscular Blockade",0,"rocuronium","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","161","November 2008","December 2009","Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine","<0.0001","Significance level was set at 0.05.","ANOVA","0","0","0","0","0","0"
"1725","NCT00751283","Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities","Peripheral Vascular Disease",0,"GRST Peripheral Catheter System","Device","Vessix Vascular, Inc","Industry",0,0,"All","18 Years","N/A","0","August 2007","November 2010","Major adverse clinical events rate","0","0","0","0","0","0","0","0","0"
"1726","NCT00751400","Naproxen Sodium Extended-Release Actual Use Study","Pain",0,"Naproxen Sodium ER (BAYH6689)","Drug","Bayer","Industry",0,0,"All","12 Years","N/A","497","July 2008","November 2008","Use Days With One or More Misuse Occasions","0","0","0","0","0","0","0","0","0"
"1727","NCT00751621","Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)","Primary Immunodeficiency (PID)",0,"IgPro20","Biological","CSL Behring","Industry",0,0,"All","2 Years","65 Years","40","August 2008","December 2011","Total Serum IgG Trough Levels","0","0","0","0","0","0","0","0","0"
"1728","NCT00751842","A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT","Type 1 Diabetes Mellitus",0,"rhGAD65","Drug","Diamyd Therapeutics AB","Industry",0,0,"All","10 Years","20 Years","331","September 2008","March 2012","Meal Stimulated C-peptide (area under the curve)","0","0","0","0","0","0","0","0","0"
"1729","NCT00751881","An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis","Multiple Sclerosis",0,"Placebo","Drug","Sanofi","Industry",0,0,"All","18 Years","55 Years","1169","August 2008","April 2012","Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate","0.0001","Step down approach used to adjust for multiplicity:
H1 tested first
H2 tested only if the comparison H1 was statistically significant
A priori threshold for statistical significance for both comparisons ≤0.05","Regression, Poisson","36.3","Relative risk reduction (%)","95","2-Sided","0","0"
"1730","NCT00752050","Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows","Glabellar Rhytides",0,"Mentor Purified Toxin Botulinum Toxin Type A","Drug","Mentor Worldwide, LLC","Industry",0,0,"All","18 Years","N/A","699","November 2007","February 2009","Change in assessments of severity of glabellar rhytide by the investigator and the subject at maximum frown as a single composite effectiveness endpoint.","0","0","0","0","0","0","0","0","0"
"1731","NCT00752258","A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows","Glabellar Rhytides",0,"Mentor Purified Toxin Botulinum Toxin Type A","Drug","Mentor Worldwide, LLC","Industry",0,0,"All","18 Years","N/A","576","February 2008","May 2011","Estimation of the incidences of treatment-emergent adverse events, serious treatment-emergent adverse events, and treatment-emergent laboratory abnormalities, when PurTox is administered in repeated treatments.","0","0","0","0","0","0","0","0","0"
"1732","NCT00752297","Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows","Glabellar Rhytides",0,"Preservative-free Saline","Drug","Mentor Worldwide, LLC","Industry",0,0,"All","18 Years","N/A","402","June 2007","May 2008","Degree of glabellar rhytide reduction assessed by the investigator and the subject at maximum frown as a single composite effectiveness endpoint.","0","0","0","0","0","0","0","0","0"
"1733","NCT00752973","Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice","Pediculosis",0,"MALG (malathion) Treatment","Drug","Taro Pharmaceuticals USA","Industry",0,0,"All","6 Months","24 Months","12","September 2008","December 2011","Participants With a Change in Cholinesterase Level at 1 Hour (Day 0).","0","0","0","0","0","0","0","0","0"
"1734","NCT00753181","Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"Nutritional Formula","Other","Abbott Nutrition","Industry",0,0,"All","18 Years","75 Years","60","August 2008","December 2008","Average daily blood glucose level","0","0","0","0","0","0","0","0","0"
"1735","NCT00753454","Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)","Rheumatoid Arthritis",0,"Certolizumab pegol","Drug","UCB Pharma","Industry",0,0,"All","18 Years","N/A","168","September 2008","May 2011","Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period","0","0","0","0","0","0","0","0","0"
"1736","NCT00753688","Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy","Sarcoma, Soft Tissue",0,"PAZOPANIB","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","369","October 2008","November 2010","Progression-free Survival (PFS)","<0.001","Stratified two-sided log rank p-value","Log Rank","0.35","Hazard Ratio (HR)","95","2-Sided","0.26","0.48"
"1737","NCT00753896","Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin","Type 2 Diabetes",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","134","October 2008","July 2009","Percentage of Patients Experiencing Adverse Events","0","0","0","0","0","0","0","0","0"
"1738","NCT00753922","Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses","Breast Reconstruction",0,"Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface","Device","Mentor Worldwide, LLC","Industry",0,0,"Female","18 Years","N/A","1008","September 2000","June 2012","10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation","0","0","0","0","0","0","0","0","0"
"1739","NCT00754013","Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10","Down Syndrome",0,"Aricept (Donepezil hydrochloride)","Drug","Eisai Inc.","Industry",0,0,"All","6 Years","10 Years","9","September 2008","October 2008","Vineland-II Adaptive Behavior Scales (VABS-II) Parent/Caregiver Rating Form (PCRF) Sum of the 9 Sub-domain V-scores (3 Scores for Each of the Communication, Daily Living Skills, and Socialization Domains) Using Last Observation Carried Forward.","0","0","0","0","0","0","0","0","0"
"1740","NCT00754065","To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)","Contraception",0,"Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)","Drug","Bayer","Industry",0,0,"Female","18 Years","50 Years","409","September 2008","May 2011","The Change in Average of the 3 Highest Visual Analog Scale (VAS) Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28 From Baseline to Cycle 6","0.0024","Comparison of EV/DNG vs. EE/NGM","ANOVA","9.3218","F-statistic","0","0","0","0"
"1741","NCT00754221","Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia","Fibromyalgia",0,"[S,S]-Reboxetine","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","390","May 2008","May 2009","Vital Signs","0","0","0","0","0","0","0","0","0"
"1742","NCT00754689","Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"Rimonabant","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","0","September 2008","November 2008","Change from baseline in A1C","0","0","0","0","0","0","0","0","0"
"1743","NCT00755053","Comparative Efficacy of Ovule vs Tablet","Clotrimazole",0,"Clotrimazole, vaginal ovule","Drug","Bayer","Industry",0,0,"Female","14 Years","50 Years","466","September 2008","May 2009","Percentage of Subjects With Overall Response at Visit 2 (Day 10 to 14)","0","0","0","0","0","0","0","0","0"
"1744","NCT00755417","Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women","Hot Flashes",0,"Gabapentin Extended-Release (G-ER) 1200 mg","Drug","Depomed","Industry",0,0,"Female","18 Years","70 Years","541","September 2008","August 2009","Change From Baseline in Average Daily Frequency of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo","0.0117","Based on F test of type III analysis for pairwise comparison at 0.025 level.","ANCOVA","-0.96","Mean Difference (Final Values)","97.5","2-Sided","-1.81","-0.11"
"1745","NCT00755755","PGL4001 Versus Placebo in Uterine Myomas","Uterine Myomas",0,"PGL4001 (ulipristal) and iron","Drug","PregLem SA","Industry",0,0,"Female","18 Years","50 Years","241","October 2008","March 2010","Co-primary Endpoint: Percentage of Subjects With Reduction in Uterine Bleeding Defined as a Pictorial Blood-loss Assessment Chart (PBAC) Score <75 at End-of-treatment Visit (Week 13)","<0.001","As comparison involved two doses of PGL4001 vs Placebo, Bonferroni correction used with p-values doubled (threshold was 0.05) and confidence intervals adjusted","Cochran-Mantel-Haenszel","72.7","Difference in proportions","95","2-Sided","55.1","83.2"
"1746","NCT00755781","Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation","Lung Transplant",0,"Cyclosporine Inhalation Solution (CIS)","Drug","APT Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","284","September 2008","September 2011","Duration of BOS-free survival. Other causes for the decline should be excluded by bronchoscopy and other diagnostic testing performed at the discretion of the investigator. The diagnosis of BOS will be determined by the Outcomes Committee","0","0","0","0","0","0","0","0","0"
"1747","NCT00755807","Duloxetine for Multiple Sclerosis Pain","Multiple Sclerosis",0,"Duloxetine Hydrochloride (HCI)","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","239","October 2008","August 2010","Change From Baseline in the Weekly 24-Hour Average Pain Scores at Week 6 (Acute Phase)","0.001","The a priori threshold for statistical significance was 0.05.","Mixed Models Analysis","0","0","0","0","0","0"
"1748","NCT00756002","Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia","Sleep Initiation and Maintenance Disorders",0,"Ramelteon","Drug","Takeda","Industry",0,0,"All","18 Years","64 Years","259","August 2007","March 2008","Mean Latency to Persistent Sleep Via Polysomnography (Nights 1-2).","<0.001","P-values are from t-tests of the ANCOVA model for the overall treatment comparison. Statistical significance was determined at the 0.05 level.","ANCOVA","0","0","0","0","0","0"
"1749","NCT00756548","BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy","Colon Cancer",0,"BLI850","Drug","Braintree Laboratories","Industry",0,0,"All","18 Years","N/A","386","August 2008","November 2008","Efficacy - Preparation Quality Using a 4 Point Scale","0","0","0","0","0","0","0","0","0"
"1750","NCT00756938","Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)","Hypertension",0,"losartan potassium","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","6 Months","6 Years","101","March 1, 2009","August 14, 2012","Mean Change From Baseline in Systolic Blood Pressure","0.753","0","ANCOVA","1.22","Slope","95","2-Sided","-6.45","8.90"
"1751","NCT00756977","BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy","Colon Cancer",0,"BLI850","Drug","Braintree Laboratories","Industry",0,0,"All","18 Years","N/A","394","August 2008","November 2008","Efficacy - Preparation Quality Using a 4 Point Scale","0","0","0","0","0","0","0","0","0"
"1752","NCT00757237","Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa","Cystic Fibrosis",0,"Aztreonam for Inhalation Solution (AZLI)","Drug","Gilead Sciences","Industry",0,0,"All","6 Years","N/A","274","August 2008","May 2010","Relative Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28","0.0001","Based on the Benjamini & Hochberg method, non-inferiority at Day 28 for relative change in FEV1 percent predicted was assessed at the 0.05 level, given the significance of the coprimary endpoint (p<0.05).","ANCOVA","-7.80","Mean Difference (Final Values)","95","2-Sided","-11.73","-3.86"
"1753","NCT00757588","Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin","Type 2 Diabetes",0,"Saxagliptin, 5 mg + insulin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","78 Years","455","November 2008","April 2010","Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF])","<0.0001","Significance testing based on hierarchical testing. Primary and secondary endpoints are presented in order of testing.","ANCOVA","-0.41","Mean Difference (Final Values)","95","2-Sided","-0.59","-0.24"
"1754","NCT00758043","A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response","Hepatitis C",0,"telaprevir","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","18 Years","70 Years","540","October 2008","June 2010","Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24)","0","0","0","4.5","Difference in proportions","95","2-Sided","-2.1","11.1"
"1755","NCT00758290","Clinical Study to Evaluate Dental Plaque","Gingival Diseases",0,"Triclosan/Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","20 Years","51 Years","23","May 2008","July 2008","Dental Plaque Index","0.05","0","ANOVA","0","0","0","0","0","0"
"1756","NCT00758303","A Study to Evaluate the Lipid Regulating Effects of TRIA-662","Hyperlipidemia",0,"Low Dose TRIA-662","Drug","Cortria Corporation","Industry",0,0,"All","18 Years","N/A","211","September 2007","December 2008","The primary efficacy parameter is the percent change in total serum Triglycerides from baseline to end of study","0","0","0","0","0","0","0","0","0"
"1757","NCT00758407","Methylphenidate Treatment of Cancer-Related Fatigue","Cancer-related Fatigue",0,"Methylphenidate hydrochloride","Drug","Medice Arzneimittel Pütter GmbH & Co KG","Industry",0,0,"All","18 Years","60 Years","66","August 2006","January 2010","General Fatigue measured by the Multidimensional Fatigue Inventory (Subscale General Fatigue)","0","0","0","0","0","0","0","0","0"
"1758","NCT00758485","Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)","Anesthesia",0,"Sugammadex","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","140","October 2008","May 2009","Time From Start of Administration of Investigational Medicinal Product (IMP, Sugammadex or Placebo) to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9","0","0","0","0","0","0","0","0","0"
"1759","NCT00758498","Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder","Excessive Sleepiness",0,"armodafinil","Drug","Cephalon","Industry",0,0,"All","18 Years","65 Years","427","September 2008","February 2009","Mean Sleep Latency (Minutes) From the Multiple Sleep Latency Test (MSLT)- Average of Four Scheduled Naps Across Days 1 and 2","<0.0001","0","ANCOVA","2.9","Mean Difference (Final Values)","95","2-Sided","2.07","3.71"
"1760","NCT00758563","Train New Examiners Via Modified Gingival Margin Plaque","Dental Plaque",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","65 Years","15","March 2008","April 2008","Mean Gingival Plaque Units","0.05","0","ANOVA","0","0","0","0","0","0"
"1761","NCT00758758","Performance of the Hedrocel(R) Cervical Fusion Device","Symptomatic Cervical Disc Disease",0,"Anterior Cervical Discectomy and Fusion","Device","Zimmer Biomet","Industry",0,0,"All","18 Years","70 Years","231","December 2001","January 2009","Overall Clinical Success (NDI, Fusion, Additional Surgical Procedures)","0","0","0","0","0","0","0","0","0"
"1762","NCT00759031","Investigation of Dental Plaque and Gingival Index","Dental Plaque",0,"Sodium Monofluorophosphate","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","65 Years","19","February 2008","March 2008","Gingival Margin Plaque Index","0.05","0","ANOVA","0","0","0","0","0","0"
"1763","NCT00759109","Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","Carcinoma, Hepatocellular",0,"Peginterferon alfa-2b","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","70 Years","150","March 2002","November 2009","Number of Participants With the Development of Hepatocellular Carcinoma (HCC)","0","0","0","0","0","0","0","0","0"
"1764","NCT00759148","Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis","Bacterial Conjunctivitis",0,"Moxifloxacin eye drops","Drug","Alcon Research","Industry",0,0,"All","1 Month","N/A","1179","October 2008","March 2010","Clinical Cure of Bacterial Conjunctivitis","0","0","0","0","0","0","0","0","0"
"1765","NCT00759187","Evaluate Clinical Research From Commerical Oral Care Products","Gingival Diseases",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","65 Years","25","January 2008","April 2008","Dental Plaque Index","<0.05","Two way Anova general linear model (subject and treatment as factors)","ANOVA","0","0","0","0","0","0"
"1766","NCT00759421","Exploratory Cognition Study of Sertindole in Patients With Schizophrenia","Schizophrenia",0,"Sertindole","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","96","October 2006","March 2008","Global cognitive composite score","0","0","0","0","0","0","0","0","0"
"1767","NCT00759460","Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia","Schizophrenia",0,"Sertindole","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","250","March 2007","March 2008","Changes from baseline by treatment and between treatments for each of the components of the metabolic syndrome","0","0","0","0","0","0","0","0","0"
"1768","NCT00759655","Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age","Hemophilia A",0,"Moroctocog alfa","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"Male","N/A","5 Years","1","June 2009","December 2009","Percentage of Participants With Factor VIII (FVIII) Inhibitor Development","0","0","0","0","0","0","0","0","0"
"1769","NCT00759681","ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial","Vascular Disease",0,"ArterX Surgical Sealant","Device","Tenaxis Medical, Inc.","Industry",0,0,"All","18 Years","N/A","217","September 2008","December 2009","Immediate Sealing Evidenced by no Bleeding on Clamp Release.","0.05","0","Exact binomial confidence limit","0.208","Mean Difference (Final Values)","95","2-Sided","0.103","0.314"
"1770","NCT00760214","Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension","Hypertension",0,"Azilsartan medoxomil","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","885","January 2008","April 2009","Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.","<.001","Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.","ANCOVA","-8.41","Mean Difference (Final Values)","95","2-Sided","-11.04","-5.78"
"1771","NCT00760539","Safety and Efficacy of Travoprost/Timolol BAC-free","Open-Angle Glaucoma",0,"Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution","Drug","Alcon Research","Industry",0,0,"All","20 Years","N/A","87","June 2008","December 2008","Mean Intraocular Pressure (IOP) combined across all visits and timepoints","0","0","0","0","0","0","0","0","0"
"1772","NCT00760916","FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)","Pulmonary Hypertension",0,"UT-15C 1 mg","Drug","United Therapeutics","Industry",0,0,"All","18 Years","70 Years","0","December 2008","January 2009","Change in six-minute walk distance from Baseline to Week 12","0","0","0","0","0","0","0","0","0"
"1773","NCT00761150","Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)","Chronic Low Back Pain",0,"ABT-712","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","21 Years","75 Years","308","September 2008","March 2009","Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)","0","0","0","0","0","0","0","0","0"
"1774","NCT00761280","Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma","Anaplastic Astrocytoma",0,"trabedersen","Drug","Isarna Therapeutics GmbH","Industry",0,0,"All","18 Years","70 Years","27","December 2008","February 2012","Survival Rate at 24 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)","0","0","0","0","0","0","0","0","0"
"1775","NCT00761319","Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health","Open-angle Glaucoma",0,"Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","705","October 2008","September 2009","Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score","0","0","0","0","0","0","0","0","0"
"1776","NCT00761358","To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia","Functional Dyspepsia",0,"Z-338","Drug","Zeria Pharmaceutical","Industry",0,0,"All","20 Years","64 Years","820","September 2008","June 2010","General impression at last visit in treatment period","0","0","0","0","0","0","0","0","0"
"1777","NCT00761462","BAY 0 9867 Cipro Pediatric Use Study (QUIP)","Infectious Diseases",0,"Ciprofloxacin","Drug","Bayer","Industry",0,0,"All","2 Months","16 Years","1029","October 1999","January 2008","Incidence of Arthropathy (Cumulative)","0","0","0","0","0","0","0","0","0"
"1778","NCT00761631","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years","Healthy Subjects",0,"13 valent pneumococcal conjugate vaccine","Biological","Pfizer","Industry",0,0,"All","15 Months","17 Years","1200","December 2008","July 2010","Percentage of Participants Achieving Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL) Measured 1 Month After Vaccination in Group 1 and 2","0","0","0","0","0","0","0","0","0"
"1779","NCT00761748","Comparison of Two Urostomy Bags (2-piece).","Urostomy Patent",0,"Convatec Uro 2-piece","Device","Coloplast A/S","Industry",0,0,"All","18 Years","N/A","30","September 2008","January 2009","Preference of the Two Urostomy Products","0","0","0","0","0","0","0","0","0"
"1780","NCT00761800","Dermacyd Teen Care Tangerina Mix - Compatibility","Hygiene",0,"Lactic acid","Drug","Sanofi","Industry",0,0,"Female","18 Years","60 Years","51","May 2008","May 2008","The absence of primary and accumulated dermal irritability will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.","0","0","0","0","0","0","0","0","0"
"1781","NCT00761930","Compare the Clinical Efficacy of Prototype Toothpastes.","Gingival Diseases",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","65 Years","103","March 2008","June 2008","Dental Plaque","<0.05","0","ANCOVA","0","0","0","0","0","0"
"1782","NCT00762034","A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer","Non-small Cell Lung Cancer",0,"Pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","939","December 2008","April 2012","Overall Survival","0.94896","0","Log Rank","1.00","Hazard Ratio (HR)","95","2-Sided","0.86","1.16"
"1783","NCT00762177","Investigate Oral Bacteria in Adult Population","Oral Bacteria",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","70 Years","24","May 2008","September 2008","Antimicrobial Species in Plaque(Actinomyces)","0.05","0","ANCOVA","0","0","0","0","0","0"
"1784","NCT00762359","A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers","Stomach Ulcer",0,"Lansoprazole","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","461","May 2007","November 2008","Number of Participants With Gastric Ulcer and/or Duodenal Ulcer","<0.0001","0","Log Rank","0.0989","Hazard Ratio (HR)","95","2-Sided","0.0425","0.2300"
"1785","NCT00762372","Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane)","Anesthesia",0,"desflurane","Drug","Baxter Healthcare Corporation","Industry",0,0,"All","20 Years","69 Years","216","February 2008","August 2008","Anesthetic effectiveness (presence/absence of body movement, presence/absence of awakening, presence/absence of need for rescue medication, control of BP/heart rate, presence/absence of intraoperative recall)","0","0","0","0","0","0","0","0","0"
"1786","NCT00762411","Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo","Alzheimer's Disease",0,"LY450139","Drug","Eli Lilly and Company","Industry",0,0,"All","55 Years","N/A","1111","September 2008","April 2011","Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks","0.560","0","Mixed Models Analysis","0","0","0","0","0","0"
"1787","NCT00762450","Effect on Bacterial Glycolytic Acid Formation on Plaque","Dental Plaque",0,"Triclosan, Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","72 Years","79 Years","6","April 2008","August 2008","ph of Dental Plaque After Sucrose Challenge","0.05","0","ANOVA","0","0","0","0","0","0"
"1788","NCT00762463","Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis","Ankylosing Spondylitis",0,"Celecoxib","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","240","July 2009","June 2010","Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6","0.0085","0","ANCOVA","3.3","LS Mean Difference","95","2-Sided","-2.2","8.8"
"1789","NCT00762515","Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes","Dental Plaque",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","65 Years","44","February 2008","August 2008","Control Established Plaque in Adults","<0.05","0","ANCOVA","0","0","0","0","0","0"
"1790","NCT00762619","Clinical Study to Examine Brushing on Dental Implants","Gingival Diseases",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","76 Years","105","April 2007","August 2008","Mombelli Plaque Index (mPI) for Natural Teeth","0.05","0","ANCOVA","0","0","0","0","0","0"
"1791","NCT00762762","Investigate Plaque and Gingival Index","Periodontitis",0,"Triclosan and fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","65 Years","46","March 2006","December 2008","HbA1c Levels in Blood","0.05","0","ANOVA","0","0","0","0","0","0"
"1792","NCT00762853","Development of Clinical Method to Triclosan Retention in Plaque Following Brushing","Dental Plaque",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","65 Years","20","May 2008","June 2008","Triclosan Concentration in Dental Plaque","0.05","0","ANCOVA","0","0","0","0","0","0"
"1793","NCT00763048","Collection of Gingival Crevicular Fluid From Periodontitis Patients","Gingival Diseases",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","26 Years","68 Years","39","March 2008","April 2008","Metabolite Associated With Inflammation (Cadaverine)","<0.05","0","t-test, 1 sided","0","0","0","0","0","0"
"1794","NCT00763165","Periodontal Disease and Cardiovascular Disease","Periodontal Diseases",0,"Triclosan","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","75 Years","438","November 2000","December 2009","Periodontal disease","0","0","0","0","0","0","0","0","0"
"1795","NCT00763256","The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics","Periodontal Disease",0,"Triclosan, Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","75 Years","33","May 2006","August 2009","HbA1c Levels in Blood","0.05","0","t-test, 2 sided","0","0","0","0","0","0"
"1796","NCT00763269","The Efficacy of a Toothpaste to Reduce Sensitivity","Dentin Hypersensitivity",0,"Triclosan, Silicon dioxide, fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","12 Years","80 Years","626","September 2008","December 2008","Hypersensitivity Tactile(Yeaple Probe)","0.05","0","ANCOVA","0","0","0","0","0","0"
"1797","NCT00763321","Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)","Chronic Low Back Pain",0,"ABT-712","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","21 Years","75 Years","287","September 2008","April 2009","Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)","0","0","0","0","0","0","0","0","0"
"1798","NCT00763451","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","484","September 2008","January 2011","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","<0.0001","Stepwise testing procedure applied to control type 1 error: Lixisenatide (2-step titration) was compared with Placebo (combined), if found statistically significant, then Lixisenatide (1-step titration) arm compared with Placebo (combined).","ANCOVA","-0.41","Least squares (LS) mean difference","95","2-Sided","-0.583","-0.232"
"1799","NCT00763815","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","Diabetes Mellitus Type 2",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","484","September 2008","June 2011","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","<0.0001","Statistical testing: 2-sided at significance level=0.05. Analysis of co-variance (ANCOVA) included treatment arms; randomization strata of screening HbA1c (<8.0, >=8.0%), metformin use (yes, no); country as fixed effects; baseline HbA1c as covariate.","ANCOVA","-0.56","Least Squares (LS) Mean Difference","95","2-Sided","-0.731","-0.386"
"1800","NCT00764374","A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia","Dyspepsia",0,"YM443","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","79 Years","412","August 2008","December 2009","Subject's global assessment","0","0","0","0","0","0","0","0","0"
"1801","NCT00764504","Reverse Shoulder Prosthesis Study","Rotator Cuff Arthropathy",0,"Reverse Shoulder Prosthesis","Device","Encore Medical, L.P.","Industry",0,0,"All","18 Years","N/A","516","October 2002","June 2008","American Shoulder and Elbow Surgeons Shoulder Score","0","0","0","0","0","0","0","0","0"
"1802","NCT00764868","Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study","ADHD",0,"Lisdexamfetamine Dimesylate (LDX)","Drug","Shire","Industry",0,0,"All","13 Years","17 Years","269","October 2008","April 2010","Change From Baseline (From the Antecedent Study, SPD489-305) in the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at up to 52 Weeks","<0.001","0","t-test, 2 sided","0","0","0","0","0","0"
"1803","NCT00764881","Effects of SH T00658ID on Libido","Contraception",0,"EV/DNG (Qlaira, BAY86-5027, SH T00658ID)","Drug","Bayer","Industry",0,0,"Female","18 Years","50 Years","217","January 2009","July 2010","Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS)","0","0","0","0","0","0","0","0","0"
"1804","NCT00765063","The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)","Diabetic Foot Ulcer",0,"Fragmin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","62","October 2008","October 2010","Number of All Hemorrhages","0","0","0","0","0","0","0","0","0"
"1805","NCT00765206","A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)","Gastric Acid",0,"Omeprazole/sodium bicarbonate","Drug","Bayer","Industry",0,0,"All","18 Years","65 Years","60","May 2008","August 2008","Change From Baseline in Median 24-hour Intragastric pH on the 7th Day of Drug Administration","0","0","0","0","0","0","0","0","0"
"1806","NCT00765323","Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly","Acromegaly",0,"Octreotide Implant","Drug","Endo Pharmaceuticals","Industry",0,0,"All","18 Years","80 Years","169","September 2008","February 2011","Efficacy based on IGF-1, GH, signs and symptoms scores, tumor size, QoL and Patient Treatment Assessments","0","0","0","0","0","0","0","0","0"
"1807","NCT00765362","Mobile - Bearing Knee Study","Inflammatory Tissue Disorder",0,"Encore Mobile-Bearing Knee","Device","Encore Medical, L.P.","Industry",0,0,"All","18 Years","N/A","419","January 2000","June 2008","Knee Society Score Evaluation","0","0","0","0","0","0","0","0","0"
"1808","NCT00765674","Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension","Hypertension",0,"Aliskiren","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","1191","September 2008","August 2009","Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)","0","0","0","0","0","0","0","0","0"
"1809","NCT00765700","Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury","Sprain",0,"Topical Ketoprofen 10% Cream","Drug","Imprimis Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","70 Years","364","September 2008","August 2009","Assess the efficacy of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury (acute sprain or strain) of upper and lower extremities on the day 3 visit.","0","0","0","0","0","0","0","0","0"
"1810","NCT00765817","Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus","Type 2 Diabetes",0,"placebo","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","261","October 2008","January 2010","Change in Glycosylated Hemoglobin (HbA1c)","<0.001","0","ANCOVA","0","0","0","0","0","0"
"1811","NCT00765830","Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)","Diabetes Mellitus, Type 2",0,"vildagliptin","Drug","Novartis","Industry",0,0,"All","18 Years","85 Years","349","September 2008","April 2011","To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatment","0","0","0","0","0","0","0","0","0"
"1812","NCT00765856","Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects","Chronic Pain",0,"Oxymorphone IR - Opioid","Drug","Endo Pharmaceuticals","Industry",0,0,"All","6 Years","17 Years","27","October 2008","February 2010","Change in pain intensity from baseline to last assessment using the FPS-R.","0","0","0","0","0","0","0","0","0"
"1813","NCT00765999","An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation","Chronic Constipation",0,"Linaclotide 300 micrograms","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","1557","October 2008","January 2012","Safety will be assessed descriptively by summarizing AEs, clinical laboratory test results, vital sign measurements, and ECG measurements.","0","0","0","0","0","0","0","0","0"
"1814","NCT00766493","GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (EMBOLDEN)","Carotid Artery Stenosis",0,"GORE® Embolic Filter","Device","W.L.Gore & Associates","Industry",0,0,"All","18 Years","N/A","250","January 2009","July 2010","Composite Major Adverse Event (MAE) Rate of Death, Myocardial Infarction, and Stroke at 30 Days Postprocedure","0.0001","Reject H0 if z<-1.96, or 1-sided p<0.025.","One Sample Binomial","0.043","Proportion","95","2-Sided","0.021","0.077"
"1815","NCT00766688","Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia","Hypercholesterolemia",0,"AVE5530","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","643","October 2008","April 2009","Percent change from baseline in calculated LDL-C","0","0","0","0","0","0","0","0","0"
"1816","NCT00767325","A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography","Rheumatoid Arthritis",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","104","December 2008","October 2011","Mean Change From Baseline in Global Power Doppler Ultrasonography (PDUS) Score Assessing the Metacarpophalangeal (MCP) 2-5 Joints of Both Hands (LOCF Analysis)","0","0","0","-0.7","Mean Difference (Final Values)","95","2-Sided","-1.2","-0.1"
"1817","NCT00767481","1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT","Glaucoma",0,"Travoprost/Brinzolamide","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","6","October 2008","February 2009","Mean IOP","0","0","0","0","0","0","0","0","0"
"1818","NCT00767494","Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT","Glaucoma",0,"Travoprost/Brinzolamide fixed combination","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","17","October 2008","February 2009","Mean IOP","0","0","0","0","0","0","0","0","0"
"1819","NCT00767806","A Study for Patient With Chronic Low Back Pain","Chronic Low Back Pain",0,"Duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","401","September 2008","July 2009","Change From Baseline to 12 Weeks in Brief Pain Inventory 24-hour Average Pain Score","0.001","0","Mixed Models Analysis","0","0","0","0","0","0"
"1820","NCT00768287","Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B","Hemophilia B",0,"IB1001 (On-Demand)","Biological","Aptevo BioTherapeutics","Industry",0,0,"Male","5 Years","N/A","77","January 2009","November 2011","degree of hemorrhage control by treatment regimen","0","0","0","0","0","0","0","0","0"
"1821","NCT00768300","(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF","Idiopathic Pulmonary Fibrosis",0,"Ambrisentan","Drug","Gilead Sciences","Industry",0,0,"All","40 Years","80 Years","494","December 2008","February 2011","Time to Death or Disease (IPF) Progression.","0.010","P-value was based on a stratified log-rank test with strata of baseline presence of pulmonary hypertension and whether a surgical lung biopsy was performed with definite or probable usual interstitial pneumonia (UIP) based on core pathology review.","Log Rank","1.74","Hazard Ratio (HR)","95","2-Sided","1.14","2.66"
"1822","NCT00768482","A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence","Opioid Dependence",0,"Probuphine (buprenorphine implant)","Drug","Braeburn Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","9","September 2008","December 2008","Plasma BPN AUC(0-24)during 24 hours at steady state.","0","0","0","0","0","0","0","0","0"
"1823","NCT00769314","Phase 3 Clinical Study for the Treatment of Cold Sore","Herpes Labialis",0,"Acyclovir Lauriad","Drug","Onxeo","Industry",0,0,"All","18 Years","N/A","1727","May 2007","November 2008","Time to Healing (TTH) of Vesicular Primary Lesion","0.0419","p-value < 0.05 considered significant","Chi-squared","0.0685","Treatment difference","95","2-Sided","0.0025","0.1339"
"1824","NCT00769886","Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.","Allergic Conjunctivitis",0,"Ketotifen/naphazoline","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","6 Years","N/A","144","October 2008","December 2008","Ocular itching","0","0","0","0","0","0","0","0","0"
"1825","NCT00770029","IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2","Moderate to Severe Glabellar Frown Lines",0,"IncobotulinumtoxinA (Xeomin) (20 Units)","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","N/A","276","October 2008","March 2009","Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's Rating on Facial Wrinkle Scale (FWS) and by Patient's Assessment on 4-point Scale","<0.0001","0","Fisher Exact","0.60","Difference response rate","95","2-Sided","0.52","0.68"
"1826","NCT00770081","Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)","Diabetes Mellitus, Type 2",0,"vildagliptin","Drug","Novartis","Industry",0,0,"All","18 Years","85 Years","75","September 2008","April 2011","Assessment of treatment emergent adverse events (including hypoglycemia events and other events of special interest)","0","0","0","0","0","0","0","0","0"
"1827","NCT00770133","Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.","Allergic Conjunctivitis",0,"Ketotifen/naphazoline","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","6 Years","N/A","133","February 2010","April 2010","Ocular itching","0","0","0","0","0","0","0","0","0"
"1828","NCT00770146","Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients","Hypercholesterolemia",0,"Mipomersen sodium","Drug","Kastle Therapeutics, LLC","Industry",0,0,"All","18 Years","N/A","158","November 2008","May 2010","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point","<0.001","Statistical significance was concluded if p ≤ 0.05.","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"1829","NCT00770211","IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines","Moderate to Severe Glabellar Frown Lines",0,"IncobotulinumtoxinA (Xeomin) (20 Units)","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","N/A","271","October 2008","March 2009","Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's Rating on the Facial Wrinkle Scale and the Patient's Assessment on 4-point Scale","<0.0001","0","Fisher Exact","0.48","Difference response rate","95","2-Sided","0.40","0.56"
"1830","NCT00770315","Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)","Rhinitis, Allergic",0,"Ambrosia artemisiifolia allergen extract (Amb a 1-U)","Biological","ALK-Abelló A/S","Industry",0,0,"All","18 Years","50 Years","784","September 2009","May 2011","Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS)","0.2192","0","ANOVA","-0.76","Mean Difference (Final Values)","95","2-Sided","-1.98","0.45"
"1831","NCT00770510","A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)","Primary Insomnia",0,"Eszopiclone 1 mg","Drug","Eisai Co., Ltd.","Industry",0,0,"All","21 Years","64 Years","192","September 2008","May 2010","Latency To Persistent Sleep (LPS)","0","0","0","0","0","0","0","0","0"
"1832","NCT00770653","Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.","Diabetes Mellitus",0,"Pioglitazone and Metformin","Drug","Takeda","Industry",0,0,"All","18 Years","75 Years","305","April 2007","May 2009","The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.","0.0018","0","ANCOVA","3.2670","Mean Difference (Final Values)","95","2-Sided","1.2264","5.3076"
"1833","NCT00770952","Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.","Diabetes Mellitus",0,"Pioglitazone and Glimepiride","Drug","Takeda","Industry",0,0,"All","30 Years","75 Years","91","December 2006","December 2008","Change from Baseline in Homeostatic Model Assessment - Beta cell.","0","0","0","0","0","0","0","0","0"
"1834","NCT00771251","A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)","Rheumatoid Arthritis",0,"CNTO 148","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","74 Years","311","May 2008","October 2011","ACR 20% response","0","0","0","0","0","0","0","0","0"
"1835","NCT00771758","Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis","Back Pain",0,"oxycodone IR","Drug","Ortho-McNeil Janssen Scientific Affairs, LLC","Industry",0,0,"All","50 Years","85 Years","108","September 2008","December 2009","Sum of Pain Intensity Difference Over 3 Days (SPID72)","0","0","0","0","0","0","0","0","0"
"1836","NCT00772031","NINDS CRC Chronic Migraine Treatment Trial","Chronic Migraine",0,"propranolol LA","Drug","Anne Lindblad","Industry",0,0,"All","18 Years","N/A","191","October 2008","September 2010","Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline","0.77","0","ANCOVA","0.3","Mean Difference (Net)","95","2-Sided","-1.8","2.4"
"1837","NCT00772109","Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults","Orthomyxoviridae Infection",0,"Influenza Virus Vaccine USP Trivalent Types A and B","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","18 Years","64 Years","4292","October 2008","May 2009","Geometric Mean Titers (GMTs) at Baseline and Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccines","0","0","0","0","0","0","0","0","0"
"1838","NCT00772174","Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes","Diabetes Mellitus",0,"Pioglitazone and Metformin","Drug","Takeda","Industry",0,0,"All","35 Years","75 Years","418","January 2007","February 2008","Increase in High-Density Lipoprotein cholesterol levels.","0","0","0","0","0","0","0","0","0"
"1839","NCT00772382","Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia","Chronic Kidney Disease",0,"MCI-196","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","18 Years","N/A","116","December 2008","August 2010","Number of Adverse Events (AE)","0","0","0","0","0","0","0","0","0"
"1840","NCT00772447","China Registration Study in Patients With Skin Infections","Skin Diseases",0,"Daptomycin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","75 Years","265","September 2008","September 2010","Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood)","0","0","0","0","0","0","0","0","0"
"1841","NCT00772603","Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures","Epilepsies, Partial",0,"Placebo","Drug","Supernus Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","65 Years","366","November 2008","April 2010","PCH(T), ITT","=0.003","P values reported are not adjusted for multiple comparisons. To preserve the overall Type I error-rate at 0.050, a step-up Hochberg procedure was used for the pair-wise comparisons.","Wilcoxon (Mann-Whitney)","-18.30","Median Difference (Net)","95","2-Sided","-30.40","-5.80"
"1842","NCT00772785","Study of Probuphine in Patients With Opioid Dependence","Opioid Dependency",0,"Probuphine (buprenorphine implant)","Drug","Braeburn Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","16","September 2008","February 2009","Number of adverse events","0","0","0","0","0","0","0","0","0"
"1843","NCT00772980","Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus","Subjective Tinnitus",0,"Neramexane mesylate","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","75 Years","400","November 2008","June 2010","TBF-12 (Tinnitus-Beeinträchtigungs-Fragebogen-12 ""Tinnitus Handycap Inventory-12"") total score change from baseline to end of treatment","0","0","0","0","0","0","0","0","0"
"1844","NCT00773240","A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment","Grass Pollen Allergy",0,"Grazax","Drug","ALK-Abelló A/S","Industry",0,0,"All","18 Years","65 Years","276","April 2008","October 2008","Pharmacodynamics - Immunological assessments","0","0","0","0","0","0","0","0","0"
"1845","NCT00773279","Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics","Diabetes",0,"FlexTouch®","Device","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","242","September 2008","June 2009","HbA1c (Glycosylated Haemoglobin) for Participants Treated With PDS290 and FlexPen®","0","0","0","-0.047","Mean Difference (Final Values)","95","0","-0.127","0.032"
"1846","NCT00773747","Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)","Multiple Myeloma",0,"vorinostat","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","637","December 2008","September 2011","Duration of progression-free survival (PFS) in participants treated with vorinostat + bortezomib versus placebo + bortezomib","0","0","0","0","0","0","0","0","0"
"1847","NCT00774722","A Randomised Controlled Trial of the Use of Topical Metronidazole (10%) to Reduce Pain After Haemorrhoidectomy","Haemorrhoidectomy",0,"Metronidazole","Drug","S.L.A. Pharma AG","Industry",0,0,"All","18 Years","N/A","59","September 2006","March 2008","The primary objective is to evaluate the efficacy of 10% metronidazole ointment in reducing post-operative pain associated with haemorrhoidectomy as compared to placebo.","0","0","0","0","0","0","0","0","0"
"1848","NCT00774917","Numen Stent Assessment Using OCT Technique in a Single Center Study","Hyperplasia",0,"Numen","Device","International Biomedical Systems S.p.A.","Industry",0,0,"All","18 Years","N/A","60","October 2008","September 2009","The primary endpoint is the assessment of the development of neointimal hyperplasia by OCT in the stented segment at 6-month follow-up.","0","0","0","0","0","0","0","0","0"
"1849","NCT00775242","Efficacy and Safety of Estradiol and Progesterone Microspheres for the Treatment of Climacteric Symptoms.","Menopause",0,"Estradiol and Progesterone","Drug","Centro A.F. de Estudios Tecnologicos, S.A.","Industry",0,0,"Female","40 Years","65 Years","103","April 2007","November 2008","Change of frequency and intensity of vasomotor symptoms","0","0","0","0","0","0","0","0","0"
"1850","NCT00775528","Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis","Cystic Fibrosis",0,"Pancrelipase Delayed Release","Drug","Solvay Pharmaceuticals","Industry",0,0,"All","1 Month","6 Years","19","April 2009","June 2009","Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE)","0","0","0","0","0","0","0","0","0"
"1851","NCT00775840","Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.","Heart Failure",0,"Candesartan","Drug","Takeda","Industry",0,0,"All","45 Years","N/A","22","January 2008","December 2008","The change from Baseline in N-terminal pro-B-type Natriuretic Peptide biomarker.","0","0","0","0","0","0","0","0","0"
"1852","NCT00776165","Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)","Chemotherapy-Induced Neutropenia",0,"Recombinant Human GCSF (Shantha Biotechnics Limited)","Biological","Shantha Biotechnics Limited","Industry",0,0,"All","18 Years","N/A","126","October 2007","July 2009","Percentage of patients developing febrile neutropenia (defined as body temperature ≥ 38.2°C or developing a temperature of > 38°C twice in a 12-hour period and absolute neutrophil count < 0.5 x 10e9/L on the same day of the fever or the day after.","0","0","0","0","0","0","0","0","0"
"1853","NCT00776230","Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling","Japanese Encephalitis",0,"IC51","Biological","Valneva Austria GmbH","Industry",0,0,"All","18 Years","N/A","304","September 2008","June 2010","Primary: 1. Geometric Mean Titers (GMT) at Day 56","0","0","0","0","0","0","0","0","0"
"1854","NCT00776919","Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne","Acne Vulgaris",0,"clindamycin / benzoyl peroxide gel","Drug","Stiefel, a GSK Company","Industry",0,0,"All","12 Years","45 Years","1315","October 2008","September 2009","Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1855","NCT00777023","Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.","Hot Flashes",0,"Gabapentin Extended-Release (G-ER) 1200 mg","Drug","Depomed","Industry",0,0,"Female","18 Years","70 Years","565","October 2008","July 2009","Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment","0.0024","P value for pairwise test of difference of least square mean change from baseline between G-ER 1200 mg and placebo groups based on F test of type III analysis.","ANCOVA","-1.61","Mean Difference (Net)","97.5","2-Sided","-2.80","-0.42"
"1856","NCT00777153","Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","Recurrent Glioblastoma",0,"Cediranib","Drug","AstraZeneca","Industry",0,0,"All","18 Years","100 Years","423","October 2008","April 2010","Progression Free Survival (PFS)","0","0","0","0","0","0","0","0","0"
"1857","NCT00777556","Emergency Contraception Actual Use Study","Emergency Contraception",0,"DR-104","Drug","Duramed Research","Industry",0,0,"Female","11 Years","16 Years","343","October 2008","December 2010","Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions","0","0","0","0","0","0","0","0","0"
"1858","NCT00777803","NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines","Glabellar Frown Lines",0,"NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"Female","18 Years","50 Years","381","November 2008","April 2009","Responder by Independent Rater's Assessment at Maximum Frown at Week 4","0","0","0","0.7","difference of response rates","95","2-Sided","-3.2","7.1"
"1859","NCT00777946","Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone","Hypertension",0,"Aliskiren 300 mg","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","818","October 2008","May 2009","Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)","0","0","0","0","0","0","0","0","0"
"1860","NCT00778609","Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache","Oral Contraceptive",0,"EV/DNG (Qlaira, BAY86-5027)","Drug","Bayer","Industry",0,0,"Female","18 Years","50 Years","449","December 2008","December 2010","To compare SH T00658ID (Qlaira) to Microgynon with regard to changes in frequency and intensity of the hormone withdrawal associated symptoms headache and pelvic pain on cycle days 22-28 combined into a single endpoint","0","0","0","0","0","0","0","0","0"
"1861","NCT00778843","Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C","Chronic Hepatitis C",0,"Viusid","Dietary Supplement","Catalysis SL","Industry",0,0,"All","18 Years","65 Years","60","October 2008","May 2009","The improvement of serum parameters related to oxidative stress (SOD, AT, MDA, MDA/HNE, GPx, GR, AOP, MPO, PAOP, GSH) at 24 weeks (end of the treatment).","0","0","0","0","0","0","0","0","0"
"1862","NCT00778921","Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone","Hypertension",0,"Amlodipine 10 mg","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","847","October 2008","June 2009","Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study","0","0","0","0","0","0","0","0","0"
"1863","NCT00779103","Histrelin Subcutaneous Implant in Children With Central Precocious Puberty","Central Precocious Puberty",0,"Histrelin Subcutaneous Implant","Drug","Endo Pharmaceuticals","Industry",0,0,"All","2 Years","10 Years","36","September 2004","August 2011","LH suppression following stimulation with a GnRH analog (leuprolide acetate)","0","0","0","0","0","0","0","0","0"
"1864","NCT00780416","Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C","Hepatitis C",0,"MP-424","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","65 Years","189","November 2008","August 2010","The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","0","0","0","0","0","0","0","0","0"
"1865","NCT00780507","Fecal Biomarker Study for Patients With Ulcerative Colitis","Ulcerative Colitis",0,NA,NA,"Warner Chilcott","Industry",0,0,"All","18 Years","N/A","89","August 2007","July 2009","Compare the fecal biomarker calprotectin between the UC patients who relapse (flare) and the UC patients who remain in remission throughout the study while on Asacol regardless of the maintenance regimen.","0","0","0","0","0","0","0","0","0"
"1866","NCT00780910","Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy","Chronic Hepatitis C",0,"MP-424","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","65 Years","109","November 2008","October 2010","The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","0","0","0","0","0","0","0","0","0"
"1867","NCT00781274","Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy","Hepatitis C",0,"MP-424","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","65 Years","32","December 2008","July 2010","The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","0","0","0","0","0","0","0","0","0"
"1868","NCT00781820","Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste","Onychomycosis",0,"Bifonazole cream 1%","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","693","October 2008","January 2010","Overall cure rate comprising clinical cure and mycological cure microscopy + culture negative","0","0","0","0","0","0","0","0","0"
"1869","NCT00781859","Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.","Vitreomacular Adhesion",0,"125 µg Ocriplasmin","Drug","ThromboGenics","Industry",0,0,"All","18 Years","N/A","326","December 2008","March 2010","Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28.","0.003","comparing placebo and ocriplasmin","Fisher Exact","2.56","Odds Ratio (OR)","95","2-Sided","1.32","5.24"
"1870","NCT00781937","Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance","Metabolism and Nutrition Disorder",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","422","October 30, 2008","September 1, 2010","Mean Percentage Change in Fasting Body Weight From Baseline","<0.0001","Two sided, conducted at a 5% significance level","ANCOVA","-6.06","Treatment Contrast","95","0","-7.50","-4.62"
"1871","NCT00782184","Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)","Hypercholesterolemia",0,"ezetimibe/simvastatin 10/40","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","250","November 2008","September 2010","Percent Change From Baseline in Low Density Lipoprotein (LDL)-C","<0.001","0","Regression, Logistic","8.4","Odds Ratio (OR)","95","2-Sided","3.4","21.0"
"1872","NCT00782340","A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa","Symptomatic Neurogenic Orthostatic Hypotension (NOH)",0,"Placebo","Drug","Chelsea Therapeutics","Industry",0,0,"All","18 Years","N/A","263","September 2008","September 2010","Change in Orthostatic Hypotension Questionnaire Score (OHQ)","0.003","Statistical analysis plan involved a hierarchical assessment of secondary endpoints to prevent inflation of type I errors.","ANCOVA","0","0","0","0","0","0"
"1873","NCT00782431","Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","Influenza",0,"Vero cell derived, trivalent, seasonal influenza vaccine","Biological","Nanotherapeutics, Inc.","Industry",0,0,"All","50 Years","N/A","3195","November 2008","December 2008","Seroconversion at Day 21 after vaccination","0","0","0","0","0","0","0","0","0"
"1874","NCT00782769","A Safety Extension Study of DR-OXY-301","Overactive Bladder",0,"Oxybutinyn Vaginal Ring 4mg","Drug","Duramed Research","Industry",0,0,"Female","18 Years","N/A","240","September 2008","July 2010","Safety, by investigating post void residual volume, physical exams, vital signs, and clinical laboratory values. The outcome of any pregnancy will be followed and reported","0","0","0","0","0","0","0","0","0"
"1875","NCT00783198","Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)","Rhinitis; Allergic, With Asthma",0,"SCH 39641 6 Amb a 1-U","Biological","ALK-Abelló A/S","Industry",0,0,"All","18 Years","50 Years","565","September 2009","May 2011","Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS)","0.0039","0","ANOVA","-1.76","Mean Difference (Final Values)","95","2-Sided","-2.95","-0.57"
"1876","NCT00783263","A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)","Hypercholesterolemia",0,"Comparator: rosuvastatin 5 mg + ezetimibe 10 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","440","November 2008","May 2010","Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment","<0.001","0","Longitudinal Data Analysis (LDA)","-15.25","Mean Difference (Final Values)","95","2-Sided","-19.89","-10.60"
"1877","NCT00783692","Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease","Crohn's Disease",0,"vedolizumab","Drug","Millennium Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","80 Years","1116","December 2008","March 2012","Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6","0.0206","P-value is based on the Cochran-Mantel-Haenszel (CMH) chi-square test, with stratification according to: 1) concomitant use of oral corticosteroids (yes/no); 2) previous exposure to TNFα antagonists and/or concomitant immunomodulator use (yes/no).","Cochran-Mantel-Haenszel","7.8","Risk Difference (RD)","95","2-Sided","1.2","14.3"
"1878","NCT00783718","Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis","Ulcerative Colitis",0,"vedolizumab","Drug","Millennium Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","80 Years","895","January 2009","December 2011","Induction Phase: Percentage of Participants With a Clinical Response at Week 6","< 0.0001","0","Cochran-Mantel-Haenszel","21.7","Risk Difference (RD)","95","2-Sided","11.6","31.7"
"1879","NCT00783796","SPIRIT Small Vessel Registry","Coronary Artery Disease",0,"2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System","Device","Abbott Vascular","Industry",0,0,"All","18 Years","N/A","150","October 2008","October 2010","Composite Rate of Cardiac Death, Target Vessel Myocardial Infarction (MI) (Per Protocol Definition) & Clinically Indicated Target Lesion Revascularization (CI-TLR).","0","0","0","0","0","0","0","0","0"
"1880","NCT00784017","Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia","Acute Lymphoblastic Leukemia",0,"asparaginase","Drug","medac GmbH","Industry",0,0,"All","1 Year","18 Years","199","October 2008","October 2012","To determine the rate of patients with complete asparagine (ASN) depletion in serum during induction treatment and to demonstrate non-inferiority of rASNase compared to Asparaginase medac™ with respect to this parameter","0","0","0","0","0","0","0","0","0"
"1881","NCT00784277","A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease","Joint Diseases",0,"oxycodone CR","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","80 Years","597","October 2008","July 2009","5-Day Sum of Pain Intensity Difference (SPID5)","0.007","P-value is adjusted for multiplicity for comparison against placebo using Hochberg's test.","ANCOVA","55.1","Difference in Least-Squares Means","95","0","15.11","95.13"
"1882","NCT00784368","A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection","Mycoses",0,"ITCZ Oral Solution","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","18 Years","79 Years","55","January 2008","April 2009","Maximum Plasma Itraconazole Concentration (Cmax)","0","0","0","0","0","0","0","0","0"
"1883","NCT00784836","Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients","Multiple Sclerosis",0,"BG9418 (interferon beta 1-a)","Drug","Biogen","Industry",0,0,"All","18 Years","60 Years","3","October 2008","February 2009","Number of Participants Who Developed Neutralizing Antibodies (NAbs) to Interferon-beta (IFN-beta)","0","0","0","0","0","0","0","0","0"
"1884","NCT00785356","Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids","Uterine Fibroids",0,"Proellex 25 mg","Drug","Repros Therapeutics Inc.","Industry",0,0,"Female","18 Years","48 Years","8","October 2008","August 2009","The Comparison Between the 50 mg Proellex® Dose Level and Placebo in the Change in Hemoglobin From Baseline to 3 Months.","0","0","0","0","0","0","0","0","0"
"1885","NCT00787111","Extended Management and Measurement of Autism","Autistic Disorder",0,"Fluoxetine (prozac)","Drug","Neuropharm","Industry",0,0,"All","5 Years","18 Years","128","November 2008","April 2009","Safety Outcomes: Laboratory determinations, Urine drugs of abuse tests,Vital Signs,Physical Examinations, Adverse Events/Serious Adverse Events, Clinical Global Impression of Severity (CGI-S AD)","0","0","0","0","0","0","0","0","0"
"1886","NCT00787254","Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs","Stomach Ulcer",0,"Lansoprazole","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","366","April 2007","May 2009","Number of Participants With Gastric Ulcer and/or Duodenal Ulcer","<0.0001","0","Log Rank","0.2510","Hazard Ratio (HR)","95","2-Sided","0.1400","0.4499"
"1887","NCT00787878","Long Term Metabolic Safety of Norditropin® Treatment of Small for Gestational Age (SGA) Subjects","Foetal Growth Problem",0,"somatropin","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","24 Years","153","February 2009","January 2011","Insulin sensitivity","0","0","0","0","0","0","0","0","0"
"1888","NCT00787891","A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients","Gastroesophageal Reflux Disease (GERD)",0,"rabeprazole","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","1 Year","11 Years","127","January 2009","January 2011","The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)","0","0","0","0","0","0","0","0","0"
"1889","NCT00788034","Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder","Generalized Anxiety Disorder",0,"Lu AA21004","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","75 Years","459","October 2008","June 2010","Time to relapse","0","0","0","0","0","0","0","0","0"
"1890","NCT00788372","An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain","Chronic Pain",0,"Fentanyl","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","142","November 2008","November 2010","Questionnaire of Opioid Withdrawal Symptoms","0","0","0","0","0","0","0","0","0"
"1891","NCT00788515","Comparison of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties","Sleep Initiation and Maintenance Disorders",0,"Volinanserin (M100907)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","33","November 2008","January 2009","Sleepiness in the morning measured on a visual analog scale of the patient's sleep questionnaire","0","0","0","0","0","0","0","0","0"
"1892","NCT00788593","A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)","Chronic Pancreatitis",0,"Placebo","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","82","January 2008","March 2009","Percent Coefficient of Fat Absorption (CFA) of Participants Treated With High Dose EUR-1008 and Low Dose EUR-1008","0.228","0","ANCOVA","1.023","Least Square (LS) Mean Difference","95","2-Sided","-0.656","2.701"
"1893","NCT00788710","A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)","Acute Pain Following a Total Abdominal Hysterectomy",0,"etoricoxib (MK0663) 120 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","N/A","430","October 2008","July 2010","Average Pain Intensity at Rest Over Days 1 to 3","<0.001","0","ANOVA","0","0","0","0","0","0"
"1894","NCT00789191","Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes","Diabetes",0,"insulin detemir","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","222","November 2008","August 2009","HbA1c (Glycosylated Haemoglobin A1c)","0.0010","No corrections to adjust for multiplicity were performed. Statistical significance threshold was p<0.05.","ANCOVA","-0.55","Mean Difference (Final Values)","95","0","-0.77","-0.33"
"1895","NCT00789373","A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer",0,"Pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","939","November 2008","June 2010","Investigator-assessed Objective Progression-free Survival (PFS)","0.00006","0","Log Rank","0.62","Hazard Ratio (HR)","95","2-Sided","0.49","0.79"
"1896","NCT00789633","A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer","Pancreatic Cancer",0,"masitinib (AB1010)","Drug","AB Science","Industry",0,0,"All","18 Years","N/A","320","November 2008","December 2011","Overall survival","0","0","0","0","0","0","0","0","0"
"1897","NCT00789698","Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia","Chronic Schizophrenia",0,"Lurasidone HC1","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","240","December 2008","July 2011","Relapse of Psychotic Symptoms","0","0","0","0.728","Hazard Ratio (HR)","95","2-Sided","0.410","1.295"
"1898","NCT00789737","Welchol as Monotherapy for Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"Welchol","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","N/A","357","January 2009","December 2011","Percent Change in Hemoglobin A1c","0.0369","0","ANCOVA","0","0","0","0","0","0"
"1899","NCT00789750","Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"Welchol","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","N/A","562","April 2009","July 2012","mean change from baseline in HbA1C","0","0","0","0","0","0","0","0","0"
"1900","NCT00789854","Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients","Major Depressive Disorder",0,"Quetiapine XR","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","688","November 2008","August 2009","Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)","0","0","0","-2.322","Mean Difference (Final Values)","97.5","0","-4.6","-0.05"
"1901","NCT00790023","Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis","Seasonal Allergic Rhinitis",0,"80 mcg Ciclesonide","Drug","Sunovion","Industry",0,0,"All","12 Years","N/A","707","November 2008","February 2009","Change From Baseline in Daily Subject-reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Averaged Over the Two-week Treatment Period.","<0.0001","The p-value from primary outcome was adjusted at alpha=0.025.","ANCOVA","0.94","Mean Difference (Final Values)","95","2-Sided","0.57","1.32"
"1902","NCT00790192","Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.","Schizophrenia",0,"Lurasidone","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","488","October 2008","July 2010","Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase","<0.05","0","Mixed Models Analysis","0","0","0","0","0","0"
"1903","NCT00790283","Assessment of the Numen Stent With Evaluation in a Randomized Study","Lesion",0,"PTCA with stent implantation","Device","International Biomedical Systems S.p.A.","Industry",0,0,"All","18 Years","N/A","500","September 2008","September 2009","Cumulative incidence of Major Adverse Cardiac Events (MACE), Cerebrovascular Events CVE) and Major Bleedings (according to TIMI classification)","0","0","0","0","0","0","0","0","0"
"1904","NCT00790322","Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy","Head and Neck Cancer",0,"SBG","Drug","Biotec Pharmacon ASA","Industry",0,0,"All","18 Years","N/A","130","October 2008","February 2010","Compare the proportion of patients in the two arms who develop severe oral mucositis","0","0","0","0","0","0","0","0","0"
"1905","NCT00790400","Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)","Tuberous Sclerosis Complex (TSC)",0,"Everolimus (RAD001)","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","118","April 2009","June 2011","Angiomyolipoma Response Rate as Per Central Radiology Review","<0.0001","0","Clopper-Pearson","0","0","0","0","0","0"
"1906","NCT00790751","Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED","Erectile Dysfunction",0,"placebo","Drug","VIVUS, Inc.","Industry",0,0,"Male","18 Years","N/A","646","November 2008","August 2009","Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse","0","0","0","0","0","0","0","0","0"
"1907","NCT00791492","An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy","Familial Amyloid Polyneuropathy",0,"Fx-1006A","Drug","Pfizer","Industry",0,0,"All","18 Years","75 Years","86","July 2008","August 2008","Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6","0","0","0","0","0","0","0","0","0"
"1908","NCT00791921","Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)","Rheumatoid Arthritis",0,"CDP870","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","74 Years","230","November 2008","January 2010","American College of Rheumatology 20% (ACR20) Response at Week 12","<0.05","0","Regression, Logistic","0","0","0","0","0","0"
"1909","NCT00791934","Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide","Sinusitis",0,"Stratus Microflow Ethmoid Spacer","Device","Acclarent","Industry",0,0,"All","17 Years","N/A","63","August 2008","November 2011","Mean Intrapatient Change in Ethmoid Lund-MacKay CT Score (Ethmoid Score Only) at 10 Weeks Post-procedure Compared to Baseline.","0","0","0","0","0","0","0","0","0"
"1910","NCT00791999","Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)","Rheumatoid Arthritis",0,"CDP870 400mg","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","74 Years","316","November 2008","January 2010","American College of Rheumatology 20% (ACR20) Response at Week 12","<0.025","Wald p-values(vs. placebo) for the comparison of the treatment groups have been calculated using logistic regression with factors for treatment.","Regression, Logistic","0","0","0","0","0","0"
"1911","NCT00792103","An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months","Migraine Disorders",0,"NP101","Drug","NuPathe Inc.","Industry",0,0,"All","18 Years","65 Years","198","January 2009","September 2010","Subject Self-examination of Skin Irritation","0","0","0","0","0","0","0","0","0"
"1912","NCT00792727","HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain","Osteoarthritis of the Knee",0,"ketoprofen Patch","Drug","Hisamitsu Pharmaceutical Co., Inc.","Industry",0,0,"All","45 Years","N/A","380","September 2007","April 2008","Change from the baseline of the WOMAC pain subscale score at Visit 6 (Day 14 ± 2 days)","0","0","0","0","0","0","0","0","0"
"1913","NCT00793104","Evaluation of the CR Plug (Allograft) for the Treatment of a Cartilage Injury in the Knee.","Knee Injury",0,"Placement of allograft CR Plug in primary injury site","Procedure","RTI Surgical","Industry",0,0,"All","18 Years","N/A","10","November 2008","March 2012","The Knee Injury and Osteoarthritis Outcome Score (KOOS) at 24 Months","0","0","0","0","0","0","0","0","0"
"1914","NCT00793156","A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)","Uremic Pruritus",0,"Nalfurafine HCl 2.5 µg","Drug","Acologix, Inc.","Industry",0,0,"All","18 Years","80 Years","350","December 2009","December 2010","Primary efficacy endpoint is the change in worst itching intensity from baseline, compared to that in the last two weeks of the double blind, placebo controlled, randomized withdrawal period.","0","0","0","0","0","0","0","0","0"
"1915","NCT00793520","Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia","Fibromyalgia",0,"Milnacipran","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","70 Years","2","November 2008","April 2009","Change in Medium Pressure Pain Threshold From Baseline to End of Treatment.","0","0","0","0","0","0","0","0","0"
"1916","NCT00794482","Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.","Hepatic Cirrhosis",0,"NRL972","Drug","Norgine","Industry",0,0,"All","18 Years","80 Years","1200","March 2008","June 2009","Influence of CTP staging on the pharmacokinetics of NRL972 in patients with cirrhosis.","0","0","0","0","0","0","0","0","0"
"1917","NCT00794664","Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis","Hypercholesterolemia",0,"Mipomersen","Drug","Kastle Therapeutics, LLC","Industry",0,0,"All","18 Years","N/A","58","January 2009","May 2010","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point","<0.001","Statistical significance was concluded if p≤0.05","t-test, 2 sided","0","0","0","0","0","0"
"1918","NCT00794703","A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections","Fungemia",0,"micafungin (Mycamine)","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","70 Years","288","November 2008","November 2009","Treatment success rate (fungal breakthrough rate)","0","0","0","0","0","0","0","0","0"
"1919","NCT00795639","Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)","Pulmonary Arterial Hypertension",0,"Sitaxsentan","Drug","Pfizer","Industry",0,0,"All","16 Years","80 Years","183","December 2008","March 2011","Change From Baseline in Total Distance Walked During 6 Minute Walk Distance (6MWD) at Week 12","0.0104","Significance test performed using non-parametric analysis of covariance controlling for Baseline 6MWD and PAH etiology and PAH not secondary to a connective tissue disease (other).","ANCOVA","14","Mean Difference (Final Values)","95","2-Sided","3","26"
"1920","NCT00795821","A Study in Adult Patients With Major Depressive Disorder","Depressive Disorder, Major",0,"LY2216684","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","65 Years","495","December 2008","February 2010","The Montgomery-Asberg Depression Rating Scale (MADRS)","0","0","0","0","0","0","0","0","0"
"1921","NCT00796120","An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)","Sarcoma",0,"Trabectedin","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","121","November 2008","August 2012","Progression - Free Survival (PFS)","0","0","0","0","0","0","0","0","0"
"1922","NCT00796354","Constipation Associated With Irritable Bowel Syndrome (IBS-C)","Constipation",0,"MOVICOL","Drug","Norgine","Industry",0,0,"All","18 Years","80 Years","210","November 2008","February 2010","To evaluate the efficacy and safety of Movicol® versus placebo in the relief of constipation associated with IBS.","0","0","0","0","0","0","0","0","0"
"1923","NCT00796367","A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)","Obesity",0,"VI-0521","Drug","VIVUS, Inc.","Industry",0,0,"All","18 Years","70 Years","676","December 2008","June 2010","Percent Weight Change at End of Treatment, Week 108.","<0.0001","Intersection-union method applied in a step-down testing approach","ANCOVA","8.71","Mean Difference (Final Values)","95","2-Sided","7.39","10.03"
"1924","NCT00796510","Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety","Pulmonary Arterial Hypertension",0,"Sitaxsentan","Drug","Pfizer","Industry",0,0,"All","16 Years","80 Years","3","July 2010","January 2011","Overall Survival","0","0","0","0","0","0","0","0","0"
"1925","NCT00796601","Maintenance of Efficacy.","Fibromyalgia",0,"Esreboxetine","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","650","May 2009","May 2010","Change from baseline to 3 and 6 months in the mean daily pain rating score measured by the 11 point pain intensity Numerical Rating Scale (NRS).","0","0","0","0","0","0","0","0","0"
"1926","NCT00796614","Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder","Bladder, Neurogenic",0,"tamsulosin hydrochloride","Drug","Boehringer Ingelheim","Industry",0,0,"All","2 Years","16 Years","231","January 2008","February 2009","Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day.","0.5388","0","Regression, Logistic","1.38","Odds Ratio (OR)","95","2-Sided","0.50","3.80"
"1927","NCT00796666","Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil","Pulmonary Arterial Hypertension",0,"Sitaxsentan","Drug","Pfizer","Industry",0,0,"All","16 Years","80 Years","131","May 2009","March 2011","Time to Clinical Worsening (TTCW)","0.5416","0","Log Rank","0.8616","Cox Proportional Hazard","95","2-Sided","0.602","1.233"
"1928","NCT00797069","Comparison of Nutritional Products for People With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"standard nutritional product (medical food)","Other","Abbott Nutrition","Industry",0,0,"All","18 Years","75 Years","58","November 2008","February 2009","To compare the postprandial glycemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.","0","0","0","0","0","0","0","0","0"
"1929","NCT00797511","Immunogenicity and Safety of Adacel Polio Vaccine","Diphtheria",0,"TdcP-IPV vaccine","Biological","Sanofi","Industry",0,0,"All","6 Years","8 Years","132","November 2008","April 2009","Number of Participants With Seroprotection to Vaccine Antigens Following Vaccination With ADACEL Polio (TdcP-IPV) Vaccine.","0","0","0","0","0","0","0","0","0"
"1930","NCT00797797","Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia","Fibromyalgia",0,"No Treatment Added","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","70 Years","364","November 2008","November 2009","Patient Global Impression of Change (PGIC) Responder Rate at End of Study","<0.001","0","Regression, Logistic","0","0","0","0","0","0"
"1931","NCT00797862","Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension","Hypertension",0,"Amlodipine","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","1254","November 2008","November 2010","Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 Weeks","0","0","0","0","0","0","0","0","0"
"1932","NCT00798291","Evaluation of AN777 in Elderly Subjects","Aged",0,"Ad lib diet and Control placebo","Other","Abbott Nutrition","Industry",0,0,"All","65 Years","N/A","108","October 2008","December 2009","The primary objective is to evaluate the effect of AN777 on muscle mass change in an elderly population while on an adequate protein intake.","0","0","0","0","0","0","0","0","0"
"1933","NCT00798317","Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.","Vitreomacular Adhesion",0,"Ocriplasmin 125µg","Drug","ThromboGenics","Industry",0,0,"All","18 Years","N/A","326","December 2008","June 2010","Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28","<0.001","Comparing placebo and ocriplasmin","Fisher Exact","5.13","Odds Ratio (OR)","95","2-Sided","1.97","17.00"
"1934","NCT00798382","Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants","Infant, Newborn",0,"soy protein formula","Other","Abbott Nutrition","Industry",0,0,"All","N/A","8 Days","154","December 2008","April 2009","Gastrointestinal tolerance from Study Visit 1 to Study Visit 3 at 35 days of age.","0","0","0","0","0","0","0","0","0"
"1935","NCT00798447","Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery","GI Cancer",0,"MLF 541","Drug","B. Braun Melsungen AG","Industry",0,0,"All","18 Years","80 Years","100","November 2008","October 2010","reduction of pro inflammatory activity","0","0","0","0","0","0","0","0","0"
"1936","NCT00798707","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder","Major Depressive Disorder",0,"Desvenlafaxine Succinate Sustained-Release (DVS SR)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","709","December 2008","April 2010","Change From Baseline in HAM-D17 Total Score at the Final On-therapy (FOT)Evaluation (Week 8 or ET)","0.452","A Hochberg step-up procedure was used to control for the multiplicity associated with multiple active dose arms.","ANCOVA","0.47","Mean Difference (Final Values)","95","2-Sided","-0.75","1.69"
"1937","NCT00798967","Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects","Short Bowel Syndrome",0,"teduglutide","Drug","Shire","Industry",0,0,"All","18 Years","N/A","86","November 2008","January 2011","Responder","0.002","Cochran-Mantel-Haenszel (CMH) test adjusted for the randomization stratification variable (<= 6 or > 6 L/week of PN at baseline)","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1938","NCT00800605","Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection","Influenza",0,"Vero cell-derived, trivalent, seasonal influenza vaccine","Biological","Nanotherapeutics, Inc.","Industry",0,0,"All","18 Years","49 Years","7252","December 2008","May 2009","To demonstrate the efficacy of an investigational Vero cell-derived influenza vaccine to prevent infection with an influenza virus that is antigenically similar to one of the three strains in the vaccine","0","0","0","0","0","0","0","0","0"
"1939","NCT00800787","Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation","Hepatitis B, Chronic",0,"Nabi-HB","Biological","Biotest Pharmaceuticals Corporation","Industry",0,0,"All","18 Years","65 Years","0","April 2010","August 2010","To evaluate the efficacy of Nabi-HB administered subcutaneously weekly for a total of 14 weeks in patients who previously underwent a liver transplant. Levels will provide evidence if effective anti-HB levels >150 IU/ML can be maintained.","0","0","0","0","0","0","0","0","0"
"1940","NCT00800800","Effects of Rosuvastatin on Aortic Stenosis Progression","Aortic Stenosis",0,"Rosuvastatin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","82 Years","378","November 2002","September 2008","The changes in transvalvular aortic velocities and the changes in aortic valve area.","0","0","0","0","0","0","0","0","0"
"1941","NCT00801203","A Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence","Stress Urinary Incontinence",0,"IRCT","Drug","Pneumoflex Systems, LLC","Industry",0,0,"Female","25 Years","N/A","180","December 2008","July 2009","Sensitivity to identify SUI in women with a history of SUI and specificity to not identify SUI in healthy women without a history of SUI","0","0","0","0","0","0","0","0","0"
"1942","NCT00801242","Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer","Prostate Cancer",0,"Degarelix 240 mg / 80 mg","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","220","December 2008","June 2012","Median and Between Participant Variability of Time to Prostate-specific Antigen (PSA) >4 ng/mL During the First Cycle of Intermittent Androgen Deprivation (IAD) After 7 Monthly Injections of Degarelix Induction Treatment","0","0","0","0","0","0","0","0","0"
"1943","NCT00801398","Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.","Postoperative Pain",0,"Oxymorphone IR","Drug","Endo Pharmaceuticals","Industry",0,0,"All","12 Years","17 Years","60","December 2008","September 2011","During the Single-Dose Period, the safety of oxymorphone IR in children >12-17 years requiring an opioid to treat their acute postoperative pain of various etiologies will be assessed.","0","0","0","0","0","0","0","0","0"
"1944","NCT00801723","(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.","Ulcerative Colitis",0,"Budesonide MMX 6 mg Tablet","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","75 Years","123","December 2008","May 2011","Clinical remission at 1, 3, 6, 9, and 12 months, where clinical remission is defined as the combined absence of recurrence of rectal bleeding and absence of increased stool frequency.","0","0","0","0","0","0","0","0","0"
"1945","NCT00803023","Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia","Fibromyalgia",0,"Sodium Oxybate","Drug","Jazz Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","129","March 2010","July 2010","Summary of Most Frequent Adverse Events (Per Arm) Experienced by Study Subjects","0","0","0","0","0","0","0","0","0"
"1946","NCT00803205","Study of Ataluren (PTC124™) in Cystic Fibrosis","Cystic Fibrosis",0,"Ataluren (PTC124)","Drug","PTC Therapeutics","Industry",0,0,"All","6 Years","N/A","238","July 2009","November 2011","Forced expiratory volume in 1 second (FEV1)","0","0","0","0","0","0","0","0","0"
"1947","NCT00803244","Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis","Primary Disease",0,"300 IR","Drug","Stallergenes","Industry",0,0,"All","12 Years","65 Years","381","January 2009","August 2009","Average Adjusted Symptom Score (AAdSS)","0.2344","0","ANCOVA","-0.49","Difference in LS Means","95","0","-1.30","0.32"
"1948","NCT00803361","Duloxetine for the Treatment of Generalized Anxiety Disorder","Generalized Anxiety Disorder",0,"Duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","210","December 2008","January 2010","Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score at Endpoint","0.006","p-value is for Change from Baseline.","ANCOVA","-1.62","Mean Difference (Final Values)","95","2-Sided","-2.76","-0.48"
"1949","NCT00803595","A Multinational Phase III Study of CS-8958 (MARVEL)","Influenza, Human",0,"CS-8958","Drug","Daiichi Sankyo Co., Ltd.","Industry",0,0,"All","20 Years","N/A","1002","November 2008","March 2009","Time to Alleviation of Influenza Illness","0.748","2-sided p-value without adjustments for multiple testing","Generalized Wilcoxon Test","-0.6","Median Difference (Final Values)","95","2-Sided","-9.9","6.9"
"1950","NCT00803634","Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)","Hypertension",0,"Clevidipine","Drug","The Medicines Company","Industry",0,0,"All","18 Years","N/A","117","December 2008","February 2012","Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes","0","0","0","0","0","0","0","0","0"
"1951","NCT00804141","Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation","Constipation",0,"N-methylnaltrexone bromide (MOA-728)","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","1040","December 2008","September 2010","collection of safety data & assessments to include monitoring of treatment emergent adverse events, safety laboratory measurements, electrocardiograms and changes in the physical exam including vital signs while on therapy","0","0","0","0","0","0","0","0","0"
"1952","NCT00804271","Memantine and Validation of a New Alzheimer's Disease Scale","Alzheimer's Disease",0,"memantine","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","50 Years","N/A","487","December 2008","November 2009","Validation of new scale regarding content, reliability and responsiveness for DAT symptoms","0","0","0","0","0","0","0","0","0"
"1953","NCT00804414","Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers","Diabetes",0,"SBG","Drug","Biotec Pharmacon ASA","Industry",0,0,"All","18 Years","N/A","133","October 2008","August 2009","Compare the proportion of patients in the two arms who have complete healing of target ulcer","0","0","0","0","0","0","0","0","0"
"1954","NCT00805350","Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties","Primary Insomnia",0,"Eplivanserin","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","637","December 2008","June 2009","Change from baseline of mean PSG-WASO on N41/N42","0","0","0","0","0","0","0","0","0"
"1955","NCT00805740","An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida","Candidiasis",0,"Active anidulafungin","Drug","Pfizer","Industry",0,0,"All","16 Years","N/A","41","April 2009","June 2012","Percentage of Participants With Global Response at End of Treatment (Day 14 To Day 42)","0","0","0","21.8","Risk Difference (RD)","95","2-Sided","-12.3","53.3"
"1956","NCT00805766","Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)","Crohn's Disease",0,"TA-650","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","16 Years","75 Years","39","December 2008","November 2009","Median Crohn's Disease Activity Index (CDAI) Change From Week 0 to Week 8 in the Increased Dose Period","0","0","0","0","0","0","0","0","0"
"1957","NCT00806026","Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients","Idiopathic Restless Legs Syndrome",0,"placebo and pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","731","December 2008","May 2011","Restless Legs Syndrome (RLS) Symptom Severity","0","0","0","0","0","0","0","0","0"
"1958","NCT00806351","An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System","Fungemia",0,"Active Anidulafungin","Drug","Pfizer","Industry",0,0,"All","16 Years","N/A","21","August 2009","October 2011","Global Response at End of Intravenous Treatment (EOIVT)","0","0","0","-27.3","Risk Difference","95","2-Sided","-80.9","40.3"
"1959","NCT00806546","An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months","Migraine Disorders",0,"NP101","Drug","NuPathe Inc.","Industry",0,0,"All","18 Years","65 Years","514","February 2009","May 2011","Subject Self-examination of Skin Irritation","0","0","0","0","0","0","0","0","0"
"1960","NCT00807027","Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea","Glioblastoma",0,"Activated T lymphocyte(Immuncell-LC)","Drug","Green Cross Cell Corporation","Industry",0,0,"All","18 Years","70 Years","180","December 2008","October 2012","MRI","0","0","0","0","0","0","0","0","0"
"1961","NCT00807547","Intraseasonal Short-time Up-dosing With Alutard SQ Grasses","Allergy",0,"Allergy vaccination (Alutard SQ)","Biological","ALK-Abelló A/S","Industry",0,0,"All","18 Years","65 Years","149","April 2008","October 2008","Changes from baseline in Immuno globuline E (IgE)-blocking factor","0","0","0","0","0","0","0","0","0"
"1962","NCT00808132","Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis","Menopause",0,"bazedoxifene 20 mg/ conjugated estrogens 0.45 mg","Drug","Pfizer","Industry",0,0,"Female","40 Years","64 Years","1886","January 2009","February 2011","Percentage of Participants With Endometrial Hyperplasia at Month 12: Main Study","0","0","0","0","0","0","0","0","0"
"1963","NCT00809328","The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)","Community Acquired Pneumonia (CAP)",0,"Azithromycin","Drug","Pfizer","Industry",0,0,"All","16 Years","80 Years","102","February 2009","March 2010","Response Rate (Clinical Response, Data Review Committee Assessment)","0","0","0","0","0","0","0","0","0"
"1964","NCT00809354","Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip","Osteoarthritis",0,"NSAID","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","2720","February 2009","October 2010","WOMAC Physical Function subscale","0","0","0","0","0","0","0","0","0"
"1965","NCT00809471","Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)","Erectile Dysfunction",0,"placebo","Drug","VIVUS, Inc.","Industry",0,0,"Male","18 Years","N/A","390","December 2008","February 2010","Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse","0","0","0","0","0","0","0","0","0"
"1966","NCT00809497","A Clinical Study on Efficacy & Safety Profile of Propionyl-L-carnitine Tablets for Peripheral Arterial Diseases","Peripheral Arterial Disease",0,"Propionyl-L-carnitine Tablets","Drug","Lee's Pharmaceutical Limited","Industry",0,0,"All","40 Years","75 Years","239","May 2008","September 2009","To compare the difference between pre-and post-the treatment of each group","0","0","0","0","0","0","0","0","0"
"1967","NCT00809783","Extension Study Of Tanezumab In Osteoarthritis","Osteoarthritis",0,"tanezumab","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","2147","February 2009","October 2010","Hematology","0","0","0","0","0","0","0","0","0"
"1968","NCT00809965","An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome","Acute Coronary Syndrome",0,"Rivaroxaban 2.5 mg","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","15526","November 2008","September 2011","The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke","0.020","0","Log Rank","0.84","Hazard Ratio (HR)","95","2-Sided","0.72","0.97"
"1969","NCT00810004","Maintenance Treatment of Iron Deficiency in IBD Patients","Iron Deficiency",0,"Ferinject","Drug","Vifor Inc.","Industry",0,0,"All","18 Years","N/A","245","February 2009","October 2010","Efficacy of maintenance treatment of iron deficiency","0","0","0","0","0","0","0","0","0"
"1970","NCT00810030","FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR","Inflammatory Bowel Disease",0,"Ferric carboxymaltose","Drug","Vifor Inc.","Industry",0,0,"All","18 Years","N/A","484","October 2008","December 2009","Number of responders with respect to the baseline Hb value.","0","0","0","0","0","0","0","0","0"
"1971","NCT00810238","C-Cure Clinical Trial","Heart Failure Class II or III",0,"C-Cure","Biological","Celyad (formerly named Cardio3 BioSciences)","Industry",0,0,"All","18 Years","75 Years","240","December 2008","July 2010","Change in left ventricular ejection fraction","0","0","0","0","0","0","0","0","0"
"1972","NCT00810693","A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)","Pulmonary Hypertension",0,"Riociguat (Adempas, BAY63-2521)","Drug","Bayer","Industry",0,0,"All","18 Years","80 Years","445","December 2008","May 2012","6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12","<0.0001","Prespecified significance level for all significance tests was 5%. Primary analysis due to result of Shapiro-Wilk test.","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"1973","NCT00811018","A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension",0,"Sitaxsentan","Drug","Pfizer","Industry",0,0,"All","12 Years","75 Years","1192","March 2003","July 2011","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"1974","NCT00811174","Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases","Immunologic Deficiency Syndromes",0,"Octagam 10%","Drug","Octapharma","Industry",0,0,"All","2 Years","75 Years","5","January 2009","September 2010","Adverse events","0","0","0","0","0","0","0","0","0"
"1975","NCT00811252","Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients","Major Depressive Disorder",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","65 Years","N/A","453","January 2009","February 2010","Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment","0.0011","Since p-value <0.05, hierarchically testing continued","ANCOVA","-3.32","Mean Difference (Final Values)","95","2-Sided","-5.31","-1.34"
"1976","NCT00811447","Taxotere New Indication - Gastric Cancer Treatment Registration Trial","Stomach Neoplasms",0,"5-fluorouracil","Drug","Sanofi","Industry",0,0,"All","18 Years","70 Years","243","November 2008","June 2012","Time to progression","0","0","0","0","0","0","0","0","0"
"1977","NCT00811642","Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)","Fungal Infection",0,"Posaconazole","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","70 Years","63","November 2008","March 2010","Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment","0","0","0","0","0","0","0","0","0"
"1978","NCT00811720","Efficacy of Nalmefene in Patients With Alcohol Dependence","Alcohol Dependence",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","N/A","598","December 2008","October 2010","Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)","0.002","0","Adjusted change from Baseline to Month 6","-2.33","Mean Difference (Final Values)","95","2-Sided","-3.81","-0.85"
"1979","NCT00811928","Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)","Leukopenia",0,"Posaconazole","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","70 Years","252","November 2008","May 2010","Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period","0","0","0","-5.88","Difference for the incidence","95","2-Sided","-12.21","0.25"
"1980","NCT00811941","Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence","Alcohol Dependence",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","N/A","665","March 2009","November 2010","Number of Patients With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"1981","NCT00812006","A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis","Migraine",0,"rizatriptan benzoate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","108","March 24, 2009","October 22, 2009","Pain Relief (PR)","<0.001","0","Generalized Linear Mixed Model","0","0","0","0","0","0"
"1982","NCT00812461","Efficacy of Nalmefene in Patients With Alcohol Dependence","Alcohol Dependence",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","N/A","678","March 2009","March 2011","Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)","0.012","0","Adjusted change from Baseline to Month 6","-1.72","Mean Difference (Final Values)","95","2-Sided","-3.07","-0.38"
"1983","NCT00812799","A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis","Allergic Rhinoconjunctivitis",0,"Oralgen","Drug","Artu Biologicals","Industry",0,0,"All","18 Years","60 Years","374","December 2008","August 2011","Difference between active and placebo-group based on combined RTSS and RMS score","0","0","0","0","0","0","0","0","0"
"1984","NCT00812955","Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (""Bad Cholesterol"") and Triglycerides","Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia",0,"ABT-143","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","474","November 2008","June 2009","Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set)","0","0","0","0","0","0","0","0","0"
"1985","NCT00813111","Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation","Pain",0,"SKY0402","Drug","Pacira Pharmaceuticals, Inc","Industry",0,0,"Female","18 Years","N/A","136","November 2008","February 2009","Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores","0","0","0","0","0","0","0","0","0"
"1986","NCT00813995","A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)","Type 2 Diabetes Mellitus",0,"Comparator: Sitagliptin phosphate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","78 Years","395","December 9, 2008","August 9, 2010","Change From Baseline in Hemoglobin A1c (A1C) at Week 24","<.001","Pairwise comparison","ANCOVA","0","0","0","0","0","0"
"1987","NCT00814073","A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap","Smouldering Systemic Mastocytosis",0,"masitinib (AB1010)","Drug","AB Science","Industry",0,0,"All","18 Years","N/A","200","December 2008","December 2012","Responder rate at week 24","0","0","0","0","0","0","0","0","0"
"1988","NCT00814294","Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus","Diabetes",0,"placebo","Drug","Diasome Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","230","December 2008","September 2009","The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.","0","0","0","0","0","0","0","0","0"
"1989","NCT00814307","A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis","Arthritis, Rheumatoid",0,"CP-690,550","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","611","February 2009","June 2010","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3","<0.0001","A step-down procedure was used to control for multiple comparisons. In order for the comparison to 5 mg to be statistically significant, the comparison to 10 mg had to be statistically significant.","Normal approximation","39.04","Percent difference","95","2-Sided","29.12","48.95"
"1990","NCT00814320","Gammagard Liquid and rHuPH20 in PID","Primary Immunodeficiency Diseases (PID)",0,"Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)","Biological","Baxalta US Inc.","Industry",0,0,"All","2 Years","N/A","89","December 2008","November 2010","Validated Acute Serious Bacterial Infection (VASBI) Rate","<0.0001","Testing the null hypothesis of 1 VASBI/year against a one-sided alternative at the 0.01 level of statistical significance.","Poisson","0.025","Poisson","99","1-Sided","0","0.046"
"1991","NCT00814515","Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome","Moderate to Severe Dry Eye Syndrome",0,"NOVA22007 (Ciclosporin 0.1%)","Drug","Santen SAS","Industry",0,0,"All","18 Years","N/A","482","September 2007","September 2009","Corneal fluorescein staining (on modified Oxford scale)","0","0","0","0","0","0","0","0","0"
"1992","NCT00814580","Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery","Postoperative Pain",0,"Tapentadol IR","Drug","Ortho-McNeil Janssen Scientific Affairs, LLC","Industry",0,0,"All","18 Years","80 Years","382","December 2008","March 2010","Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 3 Days (72 Hours)","0.5265","Analysis of covariance (ANCOVA) model included baseline pain intensity score as the covariate and treatment and pooled center as class variables.","ANCOVA","9.0","Least square mean difference","95","2-Sided","-18.9","36.9"
"1993","NCT00814801","An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease","Alzheimer's Disease",0,"Placebo","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","45 Years","N/A","580","February 2007","September 2008","Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)","0.0113","0","Least Square Means","-1.49","Mean Difference (Final Values)","95","2-Sided","-2.64","-0.34"
"1994","NCT00815386","Safety and Efficacy Study of the PTMA Device to Reduce Mitral Valve Regurgitation in Patients With Heart Failure","Mitral Regurgitation",0,"Percutaneous transvenous mitral annuloplasty","Device","Viacor","Industry",0,0,"All","50 Years","N/A","20","February 2009","December 2010","Reduction of mitral regurgitation","0","0","0","0","0","0","0","0","0"
"1995","NCT00817063","Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema","Eczema",0,"alitretinoin","Drug","Stiefel, a GSK Company","Industry",0,0,"All","18 Years","75 Years","600","January 2009","April 2012","Response as assessed by Physicans Global Assessment (PGA)","0","0","0","0","0","0","0","0","0"
"1996","NCT00817206","Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily","Renal Failure",0,"LCP-Tacro","Drug","Veloxis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","326","December 2008","February 2011","Composite Endpoint for Efficacy Failure Within 12 Months of Randomization: Death, Graft Failure, Biopsy-proven Acute Rejection or Loss to Follow-up.","0","0","0","0","0","0","0","0","0"
"1997","NCT00818324","Long Term Administration Study of OPC-12759 Ophthalmic Suspension","Dry Eye Syndromes",0,"OPC-12759 Ophthalmic suspension","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","N/A","154","January 2009","September 2010","Change From Baseline (CFB) in Fluorescein Corneal Staining (FCS) Score","<0.001","The p value represents the comparison between baseline data and data at Week 2","t-test, 2 sided","0","0","0","0","0","0"
"1998","NCT00818519","GA YAZ ACNE in China Phase III","Acne Vulgaris",0,"EE20/Drospirenone (YAZ, BAY86-5300)","Drug","Bayer","Industry",0,0,"Female","14 Years","45 Years","179","December 2008","May 2010","Percent Change From Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the FAS (Full Analysis Set)","0","0","0","0","0","0","0","0","0"
"1999","NCT00818662","A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease","Alzheimer´s Disease",0,"Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg","Biological","Baxalta US Inc.","Industry",0,0,"All","50 Years","89 Years","390","December 2008","December 2012","Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)","0.476","0","ANCOVA","-0.8","Difference in least-square means","95","0","-3.1","1.5"
"2000","NCT00818883","Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","Essential Hypertension",0,"Azilsartan medoxomil and chlorthalidone","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","609","February 2009","November 2009","Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure","<0.001","Overall type I error rate controlled using stepwise testing procedure. First treatment test done at Week 6. If statistically significant at significance level of 5%, then treatment comparison at Week 10 was performed. Tested at 5% significance level.","ANCOVA","-5.6","Mean Difference (Final Values)","95","2-Sided","-8.3","-2.9"
"2001","NCT00819312","YAZ, Oral Contraceptive Registration in China","Contraception",0,"YAZ (SH T00186, BAY86-5300)","Drug","Bayer","Industry",0,0,"Female","18 Years","45 Years","675","December 2008","January 2011","The primary efficacy variable is the number of unintended pregnancies as measured by the Pearl Index (PI) during 13 cycles of treatment.","0","0","0","0","0","0","0","0","0"
"2002","NCT00820027","Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)","Pain, Postoperative",0,"Etoricoxib 90 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","776","December 2008","December 2010","Average Pain Intensity Difference at Rest (etoricoxib 120 mg/ 90 mg to placebo)","0","0","0","0","0","0","0","0","0"
"2003","NCT00820222","Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer","Metastases, Brain",0,"capecitabine","Drug","Novartis Pharmaceuticals","Industry",0,0,"Female","18 Years","N/A","546","April 2009","June 2012","Number of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse","0.360","0","Odds Ratio","0.65","Odds Ratio (OR)","95","2-Sided","0.26","1.63"
"2004","NCT00820651","Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis","Nonalcoholic Steatohepatitis",0,"Diamel","Dietary Supplement","Catalysis SL","Industry",0,0,"All","18 Years","70 Years","158","November 2009","April 2012","The histological improvement (steatosis, necro-inflammatory activity and fibrosis) at 52 weeks (end of the treatment) as compared with pre-treatment liver biopsy.","0","0","0","0","0","0","0","0","0"
"2005","NCT00821483","A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine","Migraine",0,"Frovatriptan","Drug","SK Chemicals Co.,Ltd.","Industry",0,0,"All","18 Years","65 Years","298","November 2006","February 2008","A comparison between Frovatriptan and placebo for the proportion of patients who have complete(grade 0) or almost complete(grade 1) relief of headache at 2 hours after taking Frovatriptan","0","0","0","0","0","0","0","0","0"
"2006","NCT00821717","EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure","Chronic Heart Failure",0,"Ferinject ® (Ferric carboxymaltose)","Drug","Vifor Inc.","Industry",0,0,"All","18 Years","N/A","35","December 2008","October 2009","The distance covered in six-minute walk tests performed at 4, 12 and 24 weeks","0","0","0","0","0","0","0","0","0"
"2007","NCT00821834","Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned","Stable Angina",0,"clopidogrel (SR25990)","Drug","Sanofi","Industry",0,0,"All","20 Years","N/A","1003","December 2008","August 2010","Time from randomization to first safety events of interest","0","0","0","0","0","0","0","0","0"
"2008","NCT00821873","Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site From an Autograft in the Knee.","Knee Injury",0,"CR Plug","Other","RTI Surgical","Industry",0,0,"All","18 Years","55 Years","9","December 2008","July 2012","MRI to Evaluate Success of Outcome.","0","0","0","0","0","0","0","0","0"
"2009","NCT00822237","Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)","Varicella",0,"Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Months","23 Months","598","January 2009","October 2009","Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process).","0","0","0","0","0","0","0","0","0"
"2010","NCT00822614","Safety of Fentanyl TAIFUN Treatment","Breakthrough Cancer Pain",0,"Fentanyl TAIFUN","Drug","Akela Pharma, Inc.","Industry",0,0,"All","18 Years","N/A","500","December 2008","December 2009","AE Profile","0","0","0","0","0","0","0","0","0"
"2011","NCT00822809","CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers","Cancer",0,"Catumaxomab","Drug","Neovii Biotech","Industry",0,0,"All","18 Years","N/A","230","December 2008","November 2010","Influence of prednisolone on the safety of 3 hours i.p. infusion of catumaxomab measured by a composite safety score","0","0","0","0","0","0","0","0","0"
"2012","NCT00823212","The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions","Coronary Artery Disease",0,"PROMUS Coronary Stent System","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","1530","January 2009","September 2010","Target Lesion Failure (TLF)","0.001","0","Farrington-Manning test","0.5","Difference in percent of participants","95","1-Sided","0","2.13"
"2013","NCT00823225","Urokinase Therapy in Patients With Diabetic Foot Syndrome","Diabetic Foot",0,"standard therapy","Procedure","medac GmbH","Industry",0,0,"All","18 Years","N/A","5","June 2008","June 2009","Major amputation free survival","0","0","0","0","0","0","0","0","0"
"2014","NCT00823836","Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease","Parkinson Disease",0,"ropinirole PR/XR","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","N/A","302","March 2009","December 2010","Mean Change From Week 0 (Baseline) in the Japanese Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score at the Final Assessment Point (FAP) (up to Week 24) in the Non-Inferiority Verification Phase","0.702","Analysis of covariance (ANCOVA) model: value of change from Week 0 at Week 24 = treatment group + Week 0 value","ANCOVA","0.34","Median Difference (Net)","95","2-Sided","-1.41","2.09"
"2015","NCT00824187","YAZ Premenstrual Dysphoric Disorder (PMDD) in China","Premenstrual Dysphoric Disorder ( PMDD)",0,"EE20/DRSP(YAZ, BAY86-5300)","Drug","Bayer","Industry",0,0,"Female","18 Years","45 Years","187","January 2009","January 2011","The difference in DRSP scale scores for the first 21 items, comparing average scores from the last 5 days before menses of the 3rd cycle in the treatment phase to average scores from the last 5 days before menses of the 2 run in cycles","0","0","0","0","0","0","0","0","0"
"2016","NCT00824291","Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","Depressive Disorder, Major",0,"desvenlafaxine succinate sustained release","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","19 Years","74 Years","437","February 2009","October 2009","Change From Baseline in Hamilton Depression Scale (HAM-D) at Week 12","0.002","0","ANCOVA","2.12","Mean Difference (Net)","95","2-Sided","0.78","3.46"
"2017","NCT00824434","A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)","Atherosclerosis",0,"PROMUS Element™","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","100","March 2009","September 2009","Cardiac Events (Composite)","0","0","0","0","0","0","0","0","0"
"2018","NCT00824447","Long-term Efficacy and Safety Study With Oralgen Grass Pollen","Allergic Rhinoconjunctivitis",0,"Oralgen","Drug","Artu Biologicals","Industry",0,0,"All","18 Years","51 Years","356","August 2007","August 2008","Pollen Season Rhinoconjunctivitis Total Symptom Score","0","0","0","0","0","0","0","0","0"
"2019","NCT00824473","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis",0,"Placebo","Drug","Meda Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","506","December 2008","February 2009","Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days","<0.001","0","ANCOVA","-1.4286","Mean Difference (Final Values)","95","0","-2.12","-0.74"
"2020","NCT00824655","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children","Pneumococcal Vaccines",0,"13vPnC","Biological","Pfizer","Industry",0,0,"All","140 Days","392 Days","234","March 2009","June 2010","Geometric Mean Concentration (GMC) of Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibodies 1 Month After the Toddler Dose","0","0","0","0","0","0","0","0","0"
"2021","NCT00825747","Evaluation of Seelens AF, an Aspheric Intra-Ocular Lens","Cataract",0,"SeeLens AF intra-ocular lens","Device","Hanita Lenses","Industry",0,0,"All","18 Years","90 Years","60","January 2009","January 2010","Best corrected visual acuity 3 months after SeeLens AF implantation","0","0","0","0","0","0","0","0","0"
"2022","NCT00825812","Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)","Anesthesia, General",0,"Sugammadex","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","64 Years","308","January 2010","September 2010","Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9.","0","0","0","5.7","ratio of geometric mean time to recovery","95","0","4.9","6.6"
"2023","NCT00825955","Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment","Liver Cancer",0,"Brivanib","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","414","February 2009","November 2011","To compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to Sorafenib and receive Brivanib plus best supportive care (BSC) to those receiving placebo plus BSC","0","0","0","0","0","0","0","0","0"
"2024","NCT00826176","Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)","Anesthesia, General",0,"Sugammadex","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","64 Years","164","January 2010","August 2010","Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.9","0","0","0","6.4","upper limit of tolerance interval (min.)","95","0","0","0"
"2025","NCT00826280","Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)","Coronary Artery Disease (CAD)",0,"regadenoson","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","347","March 2009","July 2010","Change in Number of Reversible Defects","<0.001","P-Value is from the primary analysis using ANCOVA.","ANCOVA","0","0","0","0","0","0"
"2026","NCT00826709","Prospective Evaluation of the Fluid Rapid Influenza Test","Influenza",0,"fluID Rapid Influenza Test","Device","Nanogen, Inc.","Industry",0,0,"All","N/A","N/A","1300","February 2009","October 2009","Sensitivity and specificity of influenza A and influenza B","0","0","0","0","0","0","0","0","0"
"2027","NCT00827008","Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus","Subjective Tinnitus",0,"Neramexane mesylate","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","75 Years","821","January 2009","December 2011","Descriptive analyses of TBF-12 (Tinnitus-Beeinträchtigungs-Fragebogen 12 ""Tinnitus Handicap Inventory 12"")total score and its subscores, of the Tinnitus Rating Scale and its single items as well as of SF-36 and safety/tolerability parameters","0","0","0","0","0","0","0","0","0"
"2028","NCT00827242","Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily","Benign Prostatic Hyperplasia",0,"Placebo","Drug","Eli Lilly and Company","Industry",0,0,"Male","45 Years","N/A","325","January 2009","November 2009","Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS)","0.004","The p-value associates with LS Mean difference of changes from baseline to 12 weeks between treatment groups for IPSS. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.","ANCOVA","-1.9","Mean Difference (Final Values)","95","0","0","0"
"2029","NCT00828100","Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B","Influenza",0,"fluID Rapid Influenza Test","Device","Nanogen, Inc.","Industry",0,0,"All","N/A","N/A","650","February 2009","May 2009","Positive percent agreement and negative percent agreement for both influenza A and influenza B.","0","0","0","0","0","0","0","0","0"
"2030","NCT00828204","Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects","Multiple Sclerosis",0,"single-use autoinjector with a prefilled liquid Avonex syringe","Device","Biogen","Industry",0,0,"All","18 Years","65 Years","95","January 2009","July 2010","Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector","0","0","0","0","0","0","0","0","0"
"2031","NCT00828295","Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients","Postoperative Nausea and Vomiting",0,"palonosetron","Drug","Helsinn Healthcare SA","Industry",0,0,"All","N/A","16 Years","150","August 2008","December 2008","Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively","0","0","0","0","0","0","0","0","0"
"2032","NCT00828776","Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure","Chronic Renal Failure",0,"Heparin sodic - Cristália","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","62","September 2007","February 2008","TTPA Anti-Xa Adverse Reactions","0","0","0","0","0","0","0","0","0"
"2033","NCT00828971","A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs","Infectious Diseases",0,"Avelox (Moxifloxacin, BAY12-8039)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","16","November 2008","September 2009","Clinical response up to 14-21 days after the completion of study drug therapy (Test-of-Cure visit [TOC]).","0","0","0","0","0","0","0","0","0"
"2034","NCT00829166","A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","Breast Cancer",0,"Trastuzumab emtansine","Drug","Hoffmann-La Roche","Industry",0,0,"All","18 Years","N/A","991","February 2009","July 2012","Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)","0","0","0","0","0","0","0","0","0"
"2035","NCT00829374","Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil","Alzheimer's Disease",0,"Dimebon","Drug","Medivation, Inc.","Industry",0,0,"All","50 Years","N/A","1003","March 2009","December 2011","Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)","0","0","0","0","0","0","0","0","0"
"2036","NCT00830063","Tanezumab In Osteoarthritis Of The Knee (2)","Arthritis",0,"tanezumab 10 mg","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","848","May 2009","May 2010","WOMAC function","0","0","0","0","0","0","0","0","0"
"2037","NCT00830128","A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia","Fibromyalgia",0,"pregabalin (Lyrica)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","106","July 2009","February 2011","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"2038","NCT00830154","A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering","Stuttering",0,"pagoclone","Drug","Endo Pharmaceuticals","Industry",0,0,"All","18 Years","80 Years","321","February 2009","January 2010","To assess whether treatment with pagoclone 0.30 mg BID or 0.60 mg BID reduces the percentage of syllables stuttered in people who stutter compared with placebo.","0","0","0","0","0","0","0","0","0"
"2039","NCT00830167","Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia","Fibromyalgia",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","498","March 2009","May 2011","Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline","0.0046","The analysis was conducted using 1-sided test with the significance level of 0.025. Actual significance level was calculated based on O’Brien-Fleming type alpha spending function of Lan and DeMets (1983).","ANCOVA","-0.44","Mean Difference (Final Values)","95","2-Sided","-0.78","-0.11"
"2040","NCT00830947","Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement","Malocclusion",0,"OrthoAccel Device","Device","OrthoAccel Technologies Inc.","Industry",0,0,"All","12 Years","40 Years","45","February 2009","November 2011","The Rate of Orthodontic Movement of a Maxillary Canine Tooth Being Distalized to Close an Extraction Space.","0","0","0","0","0","0","0","0","0"
"2041","NCT00830960","A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome","Acute Coronary Syndrome",0,"Prasugrel","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","720","February 2009","June 2010","Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units; PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours Post-Loading Dose (LD) in Primary Cohort (≥60 kg and <75 Years)","<0.0001","Linear mixed effects model: treatment, visit, treatment-by-visit interaction, gender, country as fixed effects, baseline PRU as covariate, participant as random effect was used.
Difference in PRU = prasugrel - clopidogrel.","Mixed Models Analysis","-183","Least Square (LS) Mean Difference in PRU","95","2-Sided","-229","-137"
"2042","NCT00831233","Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","42","April 2009","June 2010","Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12","0.1973","FAS.","ANCOVA","-2.95","Mean Difference (Final Values)","95","2-Sided","-7.51","1.61"
"2043","NCT00831415","Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)","Major Depressive Disorder",0,"desvenlafaxine succinate sustained release tablets","Drug","Pfizer","Industry",0,0,"All","20 Years","N/A","304","March 2009","March 2011","Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score","0","0","0","0","0","0","0","0","0"
"2044","NCT00831441","Phase III Acute Coronary Syndrome","Acute Coronary Syndrome",0,"Apixaban","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","7484","March 2009","March 2011","Event Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants","0.5094","0","Cox proportional hazard models","0.95","Hazard Ratio (HR)","95","2-Sided","0.80","1.11"
"2045","NCT00831753","Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants","Diphtheria",0,"DTaP IPV HB PRP~T vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","50 Days","71 Days","263","May 2008","May 2009","Number of Participants Achieving Seroprotection for Anti Hep-B After a Primary Series of Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™","0","0","0","0","0","0","0","0","0"
"2046","NCT00833001","Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse","Cystocele",0,"GYNECARE PROLIFT+M* Pelvic Floor Repair System","Device","Ethicon, Inc.","Industry",0,0,"Female","18 Years","N/A","126","April 2008","November 2009","Pelvic Organ Prolapse Quantification (POP-Q) score","0","0","0","0","0","0","0","0","0"
"2047","NCT00833053","Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)","Psoriasis",0,"Infliximab","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","39","October 2009","April 2011","Number of Participants With A Psoriasis Area and Sensitivity Index (PASI)-75 Response at Week 28","0","0","0","0","0","0","0","0","0"
"2048","NCT00833248","Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","246","April 2009","September 2011","Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set)","0.8942","0","ANCOVA","-0.3","Mean Difference (Final Values)","95","2-Sided","-4.74","4.14"
"2049","NCT00833703","Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation","Heart Defects, Congenital",0,"Clopidogrel","Drug","Sanofi","Industry",0,0,"All","12 Months","N/A","49","January 2009","July 2010","Number of Participants With Bleeding Events","0","0","0","0","0","0","0","0","0"
"2050","NCT00833768","A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis","Chronic Kidney Disease",0,"Sevelamer carbonate","Drug","Genzyme, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","5","January 2009","September 2009","To compare the efficacy and safety of sevelamer carbonate and placebo dosed three times per day (TID) on serum phosphorus levels","0","0","0","0","0","0","0","0","0"
"2051","NCT00834080","ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals","Opiate Dependence",0,"Medisorb naltrexone 380 mg","Drug","Alkermes, Inc.","Industry",0,0,"All","18 Years","N/A","38","March 2009","May 2012","Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study.","0","0","0","0","0","0","0","0","0"
"2052","NCT00834106","Prevention of HPV in 20 to 45 Year Old Chinese Women (V501-041)","HPV Infections",0,"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","20 Years","45 Years","3006","December 31, 2008","May 11, 2012","Number of participants with persistent HPV 6, 11, 16 or 18 infection, or HPV 6/11/16/18-related genital disease","0","0","0","0","0","0","0","0","0"
"2053","NCT00835380","A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)","Hepatitis A Virus Infection",0,"Hepatitis A Vaccine, Purified Inactivated (VAQTA™)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Months","23 Months","80","March 2008","October 2008","Hepatitis A Virus (HAV) Seroconversion Rate, i.e. the Percentage of Subjects Who Were Seronegative at Baseline and Developed Seropositive at Month 7 After Administration of a 2-dose Regime of Vaccines.","0","0","0","99","Seroconversion Rate","95","0","89","99"
"2054","NCT00836199","NicVAX/Placebo as an Aid for Smoking Cessation","Smoking Cessation",0,"NicVAX vaccine","Biological","Nabi Biopharmaceuticals","Industry",0,0,"All","18 Years","65 Years","1000","October 2009","July 2011","Evaluate NicVAX as an aid to smoking cessation for long term abstinence.","0","0","0","0","0","0","0","0","0"
"2055","NCT00836693","Effect of Tadalafil Once a Day in Men With Erectile Dysfunction","Erectile Dysfunction",0,"tadalafil","Drug","Eli Lilly and Company","Industry",0,0,"Male","18 Years","N/A","217","January 2009","January 2010","Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12","<0.001","p-value is for Week 12 Change. The null hypothesis concerning tadalafil versus placebo was to be rejected if, and only if, the three primary hypotheses (H01, H02, and H03) were all rejected therefore no adjustments for multiple comparisons were made.","ANCOVA","3.9","Mean Difference (Final Values)","95","2-Sided","2.2","5.5"
"2056","NCT00837265","Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel","Chemotherapy-induced Neutropenia",0,"Neugranin","Biological","Teva Pharmaceutical Industries","Industry",0,0,"All","18 Years","N/A","334","August 2008","September 2009","Duration of severe neutropenia","0","0","0","0","0","0","0","0","0"
"2057","NCT00837577","MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)","Diabetes Mellitus, Non-Insulin-Dependent",0,"Comparator: Placebo","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","N/A","133","February 5, 2009","August 11, 2010","Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12","<.001","Adjusted for other prior antihyperglycemic medications (absence, presence).","Longitudinal data analysis (LDA)","-0.92","Least squares mean difference","95","2-Sided","-1.09","-0.75"
"2058","NCT00837967","Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients","Asthma",0,"Symbicort Turbuhaler","Drug","AstraZeneca","Industry",0,0,"All","16 Years","65 Years","25","January 2009","July 2009","Adverse Events","0","0","0","0","0","0","0","0","0"
"2059","NCT00838110","A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease","Alzheimer's Disease",0,"Dimebon","Drug","Pfizer","Industry",0,0,"All","50 Years","N/A","742","February 2009","January 2010","Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 1","0","0","0","0","0","0","0","0","0"
"2060","NCT00838201","Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer","Cancer",0,"Denosumab","Drug","Amgen","Industry",0,0,"Male","18 Years","N/A","384","February 2009","July 2012","Overall Survival Through Month 24","0","0","0","0","0","0","0","0","0"
"2061","NCT00838214","Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis","Autoimmune Hepatitis",0,"budesonide","Drug","Dr. Falk Pharma GmbH","Industry",0,0,"All","10 Years","70 Years","208","March 2001","December 2008","Biochemical remission (=serum levels of ASAT and ALAT within normal ranges) at the individual last visit of Segment A and lack of steroid specific side effects","0","0","0","0","0","0","0","0","0"
"2062","NCT00838357","A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).","Lymphoma (Non-Hodgkin's Lymphoma)",0,"Generic = Plerixafor","Drug","Genzyme, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","118","September 2008","November 2010","To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplant","0","0","0","0","0","0","0","0","0"
"2063","NCT00838487","Evaluate Safety & Efficacy of Condroflex in Subjects With OA","Treatment",0,"condroflex and exercise","Other","Zodiac Produtos Farmaceuticos S.A.","Industry",0,0,"All","40 Years","70 Years","240","March 2009","July 2009","improvement of pain","0","0","0","0","0","0","0","0","0"
"2064","NCT00838812","Safety and Efficacy Study of Association Between Tretinoin and Clindamycin on the Treatment of Acne Mild and Moderate","Acne Vulgaris",0,"application of the topic gel","Drug","Igefarma Laboratorios S.A.","Industry",0,0,"All","12 Years","N/A","154","March 2009","January 2010","Evaluation of the efficacy, through number of lesions, and tolerability of the product.","0","0","0","0","0","0","0","0","0"
"2065","NCT00838903","Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"albiglutide","Biological","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","1049","February 2009","January 2012","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104","0","0","0","-0.91","Mean Difference (Net)","95","2-Sided","-1.16","-0.65"
"2066","NCT00838916","A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"albiglutide","Biological","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","779","February 2009","January 2012","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52","0","0","0","0.11","Mean Difference (Net)","95","2-Sided","-0.04","0.27"
"2067","NCT00839527","A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"placebo to match albiglutide","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","685","February 2009","January 2012","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52","<0.0001","0","ANCOVA","-0.87","Mean Difference (Net)","95","2-Sided","-1.07","-0.68"
"2068","NCT00839800","Study to Investigate the Efficacy of Symbicort® SMART.","Asthma",0,"Symbicort Turbuhaler","Drug","AstraZeneca","Industry",0,0,"All","16 Years","N/A","2091","February 2009","February 2011","The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study","0","0","0","0","0","0","0","0","0"
"2069","NCT00839917","A Study of ProQuad™ in Healthy Children in Korea (V221-023)","Measles",0,"Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Months","23 Months","30","February 2008","May 2008","Percentage of Participants With Measles Antibody Levels ≥255 mIU/mL","0","0","0","0","0","0","0","0","0"
"2070","NCT00840086","Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects","Congenital Bleeding Disorder",0,"turoctocog alfa","Drug","Novo Nordisk A/S","Industry",0,0,"Male","12 Years","65 Years","150","April 2009","September 2011","The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU))","0","0","0","0","0","0","0","0","0"
"2071","NCT00840645","A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients","Urinary Bladder, Overactive",0,"YM178","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","204","December 2008","March 2010","Vital signs, AEs, lab tests, ECG, post-void residual volume","0","0","0","0","0","0","0","0","0"
"2072","NCT00840671","Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke","Stroke",0,"Cerebrolysin","Drug","Ever Neuro Pharma GmbH","Industry",0,0,"All","18 Years","80 Years","119","October 2005","March 2008","Modified Rankin Scale score at day 90 (or earlier in the event of patient withdrawal).","0","0","0","0","0","0","0","0","0"
"2073","NCT00840801","Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children","Encephalitis, Tick-Borne",0,"Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)","Biological","Pfizer","Industry",0,0,"All","1 Year","11 Years","302","February 2009","May 2009","Seropositivity rate as determined by neutralization test (NT) 28 days after the second vaccination","0","0","0","0","0","0","0","0","0"
"2074","NCT00841126","Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate","Chronic Kidney Failure",0,"Magnesium iron hydroxycarbonate","Drug","Ineos Healthcare Limited","Industry",0,0,"All","18 Years","N/A","657","July 2009","July 2011","Stage 1: Control or not the level of serum phosphate","0","0","0","0","0","0","0","0","0"
"2075","NCT00841256","Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children","Allergic Rhinoconjunctivitis",0,"Grass pollen allergens in a water/glycerol solution","Biological","Allergopharma GmbH & Co. KG","Industry",0,0,"All","4 Years","11 Years","207","February 2008","June 2012","Changes of Symptom-Medication-Score","0","0","0","0","0","0","0","0","0"
"2076","NCT00842881","A Trial for Evaluation of Clinical Efficacy and Safety of Healing Stone Navel Belt in Patients With Primary Dysmenorrhea","Primary Dysmenorrhea",0,"Healingstone navel belt","Device","Healingstone Co., Ltd.","Industry",0,0,"Female","15 Years","45 Years","102","August 2008","March 2009","10cm VAS of pain(Dysmenorrhea)","0","0","0","0","0","0","0","0","0"
"2077","NCT00843024","Migraine Study in Adolescent Patients","Migraine Disorders",0,"Sumatriptan and Naproxen Sodium","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","17 Years","589","December 2008","May 2010","Number of Participants Who Were Pain Free at 2 Hours Post-dose","0.003","Adjusted for multiplicity according to the fixed sequence testing strategy","Cochran-Mantel-Haenszel","0.20","Mean Difference (Final Values)","95","2-Sided","0.09","0.30"
"2078","NCT00843154","Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure","Heart Failure",0,"Candesartan and standard chronic heart disease therapy","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","571","December 2005","July 2008","Change from baseline in Brain Natriuretic Peptide","0","0","0","0","0","0","0","0","0"
"2079","NCT00843492","A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery","Thrombosis, Venous",0,"Fondaparinux sodium","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","1351","December 2008","January 2010","Number of Participants With Venous Thromboembolism (VTE) or Death up to the Time of Complete Mobilization","<0.001","0","Fisher Exact","0.30","Odds Ratio (OR)","95","2-Sided","0.15","0.54"
"2080","NCT00843778","Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study","Rheumatoid Arthritis",0,"Certolizumab Pegol","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","131","January 2009","December 2012","Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period","0","0","0","0","0","0","0","0","0"
"2081","NCT00843986","Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)","Hyponatremia",0,"conivaptan","Drug","Cumberland Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","9","April 2009","August 2009","Change in Renal Function From Baseline at 72 Hours Assessed by Calculated Creatinine Clearance (MDRD Equation)","0","0","0","0","0","0","0","0","0"
"2082","NCT00844532","Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.","Peripheral Vascular Disease",0,"Absolute Pro™ Peripheral Self-Expanding Stent System","Device","Abbott Vascular","Industry",0,0,"All","18 Years","89 Years","151","March 2009","March 2011","Major Adverse Event (MAE) Rate","0","0","0","0","0","0","0","0","0"
"2083","NCT00844649","Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas","Metastatic Pancreatic Cancer",0,"Albumin-bound paclitaxel (ABI-007)","Drug","Celgene","Industry",0,0,"All","18 Years","79 Years","861","March 2009","September 2012","Overall Survival (OS)","<0.0001","P-value was based on a stratified log-rank test stratified by randomization strata of geographic region (North America versus Others), Karnofsky performance score (70 to 80 versus 90 to 100), and presence of liver metastasis","Stratified Log-rank Test","0.72","Hazard Ratio (HR)","95","2-Sided","0.617","0.835"
"2084","NCT00844662","Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride","Chronic Kidney Failure",0,"Fermagate","Drug","Ineos Healthcare Limited","Industry",0,0,"All","18 Years","N/A","1000","July 2009","September 2011","Control or not the level of serum phosphate","0","0","0","0","0","0","0","0","0"
"2085","NCT00844805","Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)","Ankylosing Spondylitis",0,"Infliximab","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","48 Years","158","September 2009","April 2011","Number of Participants Achieving the Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at Week 28","0","0","0","0","0","0","0","0","0"
"2086","NCT00845065","Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)","Hepatitis C, Chronic",0,"Boceprevir","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","202","February 2009","October 2010","Sustained Virologic Response (SVR) Rate in Full Analysis Set (FAS) Population.","0","0","0","0","0","0","0","0","0"
"2087","NCT00845702","Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)","Renal Artery Stenosis",0,"Gadoterate meglumine (Dotarem)","Drug","Guerbet","Industry",0,0,"All","18 Years","N/A","33","April 2009","February 2010","Percent of Non Assessable Renal Artery Segments","0","0","0","0","0","0","0","0","0"
"2088","NCT00845728","Exacerbation Study","Chronic Obstructive Pulmonary Disease",0,"Indacaterol 150 µg","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","3439","March 2009","July 2012","Trough Forced Expiratory Volume in 1 Second (FEV1).","0","0","0","0","0","0","0","0","0"
"2089","NCT00846157","Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients","Diffuse Large B-cell Lymphoma",0,"NKM injection","Biological","NKBio Co.Ltd.","Industry",0,0,"All","20 Years","70 Years","276","September 2007","September 2011","Event Free survival","0","0","0","0","0","0","0","0","0"
"2090","NCT00846365","Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","Essential Hypertension",0,"Azilsartan medoxomil and chlorthalidone","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","1085","March 2009","June 2010","Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.","<0.001","Statistical significance was set at the 0.05 level per the predefined stepwise testing strategy used.","ANCOVA","-6.1","Mean Difference (Final Values)","95","2-Sided","-8.4","-3.8"
"2091","NCT00846586","Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","Chronic Obstructive Pulmonary Disease (COPD)",0,"Indacaterol 150 μg","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","1134","March 2009","March 2010","Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of Treatment (Week 12)","0","0","0","0","0","0","0","0","0"
"2092","NCT00846781","Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)","Cystic Fibrosis",0,"Denufosol tetrasodium Inhalation Solution","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","5 Years","N/A","308","February 2009","February 2011","Rate of change in lung function, as measured by change in FEV1","0","0","0","0","0","0","0","0","0"
"2093","NCT00847379","Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)","Duchenne Muscular Dystrophy",0,"Ataluren (PTC124)","Drug","PTC Therapeutics","Industry",0,0,"Male","N/A","N/A","173","January 2009","May 2010","Long-term safety of PTC124 in boys with nonsense-mutation mediated DMD/BMD, as determined by adverse events and laboratory abnormalities","0","0","0","0","0","0","0","0","0"
"2094","NCT00847613","A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate","Arthritis, Rheumatoid",0,"CP-690,550","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","800","March 2009","April 2011","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6","<0.0001","A step-down procedure was used to control for multiple comparisons. In order for the comparison to 5 mg to be statistically significant, the comparison to 10 mg had to be statistically significant.","Normal approximation","36.48","Percent difference","95","2-Sided","27.73","45.23"
"2095","NCT00847626","Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","Hypertension",0,"Azilsartan medoxomil and chlorthalidone","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","1711","January 2009","May 2010","Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)","<0.001","Tested at 5% significance level.","ANCOVA","-13.0","Mean Difference (Net)","95","2-Sided","-15.8","-9.5"
"2096","NCT00847808","Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy","Gastroesophageal Reflux",0,"Dexlansoprazole MR QD","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","178","February 2009","April 2010","Proportion of Participants Who Remain Well Controlled After Switching From Their Current Twice-daily Proton Pump Inhibitor Therapy to Dexlansoprazole MR.","0","0","0","0","0","0","0","0","0"
"2097","NCT00847821","Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene","Postmenopause",0,"Bazedoxifene 10 mg/CE 0.625 mg","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"Female","40 Years","75 Years","185","May 2009","August 2010","Endometrial gene regulation at the level of mRNA expression in placebo, Bazedoxifene/CE, and raloxifene treated groups","0","0","0","0","0","0","0","0","0"
"2098","NCT00848081","A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers","Benign Prostatic Hyperplasia",0,"Tadalafil","Drug","Eli Lilly and Company","Industry",0,0,"Male","45 Years","N/A","318","March 2009","December 2009","Number of Men With Treatment-emergent Dizziness","0.403","1-sided test","Fisher Exact","0","0","0","0","0","0"
"2099","NCT00848536","Efficacy Study of Travoprost APS Versus TRAVATAN","Open Angle Glaucoma",0,"Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","371","March 2009","January 2010","Mean Intraocular Pressure at 9:00 am","0","0","0","-0.2","Mean Difference (Final Values)","95","2-Sided","-0.9","0.5"
"2100","NCT00849017","Safety and Efficacy Study of Albiglutide in Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"albiglutide","Biological","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","309","January 2009","November 2011","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52","<0.0001","0","ANCOVA","-0.84","Mean Difference (Net)","95","2-Sided","-1.11","-0.58"
"2101","NCT00849043","Extension Study of Original Protocol AERO C009 for Obstructive Sleep Apnea-hypopnea","Obstructive Sleep Apnea Hypopnea",0,NA,NA,"Ventus Medical, Inc.","Industry",0,0,"All","18 Years","N/A","65","February 2009","August 2010","To measure the percent change in the subject's apnea-hypopnea index (AHI) during the 12 month PSG while wearing the Provent device as compared to their AHI during the first week PSG when the subject did not wear the Provent device in the C009 study","0","0","0","0","0","0","0","0","0"
"2102","NCT00849056","Safety and Efficacy of Albiglutide in Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"albiglutide","Biological","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","310","January 2009","November 2011","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52","0","0","0","0","0","0","0","0","0"
"2103","NCT00849576","Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.","Type 2 Diabetes",0,"Regular Human Insulin","Drug","Biodel","Industry",0,0,"All","40 Years","75 Years","15","April 2008","August 2008","Postprandial time course of Asymmetric dimethyl arginine (ADMA) after injection of insulin VIAjectTM compared with regular human insulin and insulin lispro.","0","0","0","0","0","0","0","0","0"
"2104","NCT00849667","Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse","Ovarian Cancer",0,"MORAb-003 (farletuzumab)","Drug","Morphotek","Industry",0,0,"Female","18 Years","N/A","1100","April 2009","December 2012","Progression-free survival using by RECIST","0","0","0","0","0","0","0","0","0"
"2105","NCT00849693","A Study in the Treatment of Children and Adolescents With Major Depressive Disorder","Major Depressive Disorder",0,"Placebo","Drug","Eli Lilly and Company","Industry",0,0,"All","7 Years","17 Years","463","March 2009","February 2011","Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint","0.193","0","Mixed Models Analysis","0","0","0","0","0","0"
"2106","NCT00849901","A Study in the Treatment of Children and Adolescents With Major Depressive Disorder","Major Depressive Disorder",0,"duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","7 Years","17 Years","337","March 2009","March 2011","Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint","0.999","0","Mixed Models Analysis","0","0","0","0","0","0"
"2107","NCT00850239","Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin","Type 2 Diabetes Mellitus",0,"dutogliptin","Drug","Phenomix","Industry",0,0,"All","18 Years","85 Years","700","May 2009","October 2010","Primary objective is to demonstrate the efficacy of dutogliptin, as evidenced by placebo-corrected changes in HbA1c relative to baseline.","0","0","0","0","0","0","0","0","0"
"2108","NCT00851422","Accurate Measurement of Cardiac Output Using the Ultrasound Dilution Technique","Cardiac Output",0,NA,NA,"Transonic Systems Inc.","Industry",0,0,"All","N/A","18 Years","28","February 2008","May 2011","Validation of cardiac output measured by ultrasound dilution with cardiac output measured by thermodilution.","0","0","0","0","0","0","0","0","0"
"2109","NCT00851721","Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor","Hemophilia A or B With Inhibitors",0,"Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)","Biological","Baxalta US Inc.","Industry",0,0,"All","4 Years","65 Years","52","March 2009","October 2012","Reduction in Annualized Bleeding Episode Rate (ABR) Among Participants Receiving Prophylactic Treatment as Compared to Those Treated On-demand","0.0003","0","Two-sample, two-sided t-test","0","0","0","0","0","0"
"2110","NCT00852540","Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA","Skin Infections, Bacterial",0,"Retpamulin Ointment, 1%","Drug","Stiefel, a GSK Company","Industry",0,0,"All","2 Months","N/A","410","April 2009","July 2010","Number of Participants Achieving Clinical Response at Follow-up Who Had Methicillin-resistant Staphlococcus Aureus (MRSA) as a Baseline Pathogen","0","0","0","56.9","percentage of participants","95","2-Sided","45.5","68.4"
"2111","NCT00852631","Seroquel XR in Adults With Schizophrenia","Schizophrenia",0,"Quetiapine fumarate (Seroquel)","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","28","February 2009","May 2010","Change in Positive and Negative Syndrome Scale (PANSS) Total Score","0","0","0","0","0","0","0","0","0"
"2112","NCT00853099","A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","Ulcerative Colitis",0,"adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","15 Years","N/A","274","February 2009","May 2011","Percentage of Participants With Clinical Remission at 8 Weeks","0","0","0","0","0","0","0","0","0"
"2113","NCT00853385","A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis","Rheumatoid Arthritis",0,"CP 690,550","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","717","May 2009","March 2011","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6","<0.0001","A step-down procedure was used to control for multiple comparisons. In order for the comparison to 5 mg to be statistically significant, the comparison to 10 mg had to be statistically significant.","Normal approximation","24.24","Percent difference","95","2-Sided","13.18","35.31"
"2114","NCT00853567","Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids","Uterine Fibroids",0,"Proellex","Drug","Repros Therapeutics Inc.","Industry",0,0,"Female","18 Years","48 Years","71","February 2009","August 2009","To Determine the Efficacy of 50 mg Proellex® Versus Placebo in the Treatment of Subjects With Symptomatic Uterine Fibroids From Baseline to Month 4 as Determined by Scoring Changes in the Pictorial Blood Loss Assessment Chart (PBAC)","0","0","0","0","0","0","0","0","0"
"2115","NCT00853593","Model 4396 Left Ventricular (LV) Lead Study","Heart Failure",0,"Pacing Lead","Device","Medtronic Cardiac Rhythm and Heart Failure","Industry",0,0,"All","18 Years","N/A","197","March 2009","July 2009","Safety (Subjects Without a Model 4396 Lead Related Complication)","0","0","0",".951","One sample proportion","95","1-Sided",".906","0"
"2116","NCT00853606","Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction","Erectile Dysfunction",0,"avanafil","Drug","VIVUS, Inc.","Industry",0,0,"Male","18 Years","N/A","712","March 2009","April 2010","Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse.","0","0","0","0","0","0","0","0","0"
"2117","NCT00853749","Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine","Invasive Pneumococcal Disease",0,"13-valent pneumococcal conjugate vaccine (13vPnC)","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","5 Years","8 Years","89","May 2009","August 2010","Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per Milliliter (Mcg/mL) Measured 1 Month After Vaccination","0","0","0","2.7","Difference in proportions (percentage)","95","2-Sided","-5.0","14.2"
"2118","NCT00854061","Study of T-PRED(TM) Compared to Pred Forte(R) II","Cataract",0,"T-Pred","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","135","February 2009","August 2009","Ratio of means aqueous humor prednisolone acetate concentrations","0","0","0","0","0","0","0","0","0"
"2119","NCT00855166","Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","30 Years","75 Years","182","February 2009","June 2010","Adjusted Mean Change in Total Body Weight","<0.0001","Significant at alpha=0.05 (2-sided)","ANCOVA","-2.08","Mean Difference (Final Values)","95","2-Sided","-2.84","-1.31"
"2120","NCT00855465","A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.","Pulmonary Hypertension",0,"Riociguat (Adempas, BAY63-2521)","Drug","Bayer","Industry",0,0,"All","18 Years","80 Years","262","February 2009","June 2012","6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16","<0.0001","Prespecified significance level for all significance tests was 5%. Primary analysis, due to result of Shapiro-Wilk test.","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"2121","NCT00855582","A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia","Erectile Dysfunction",0,"Tadalafil","Drug","Eli Lilly and Company","Industry",0,0,"Male","45 Years","N/A","606","March 2009","July 2010","Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (5 mg)","<0.001","Statistical significance was assessed using a Dunnett-Bonferroni gatekeeping procedure for multiple hypothesis testing. The pre-specified alpha level of 0.0271 was used.","ANCOVA","-2.3","Median Difference (Final Values)","95","0","0","0"
"2122","NCT00855920","Study Utilizing Rilonacept in Gout Exacerbations","Acute Gout Flare",0,"Rilonacept","Drug","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","225","March 2009","February 2010","Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours","0","0","0","0","0","0","0","0","0"
"2123","NCT00855959","Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients","Asthma",0,"Budesonide","Drug","AstraZeneca","Industry",0,0,"All","16 Years","N/A","108","February 2009","August 2009","Morning Peak Expiratory Flow (mPEF)","0","0","0","0","0","0","0","0","0"
"2124","NCT00856206","Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)","Gout",0,"Rilonacept","Biological","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","80 Years","1315","March 2009","January 2011","Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)","0","0","0","0","0","0","0","0","0"
"2125","NCT00856284","Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"Alogliptin","Drug","Takeda","Industry",0,0,"All","18 Years","80 Years","2639","March 2009","October 2012","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52","0","0","0","-0.03","LS Mean Difference","98.75","1-Sided","0","0.059"
"2126","NCT00856544","A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications","Arthritis, Rheumatoid",0,"CP-690,550","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","795","May 2009","January 2011","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6","<0.0001","A step-down procedure was used to control for multiple comparisons. In order for the comparison to 5 mg to be statistically significant, the comparison to 10 mg had to be statistically significant.","Normal approximation","27.04","Percent difference","95","2-Sided","17.94","36.13"
"2127","NCT00856583","Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use","Schizophrenia",0,"Sertindole","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","N/A","9809","July 2002","February 2008","Number of Participants With All-cause Mortality","0.05","0","Cox Proportional Hazard","1.117","Hazard Ratio (HR)","90","2-Sided","0.831","1.500"
"2128","NCT00856843","BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects","Colonoscopy",0,"BLI800","Drug","Braintree Laboratories","Industry",0,0,"All","18 Years","N/A","136","February 2009","May 2009","Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale","0.038","0","Chi-squared","8.8","Difference in success rates","95","2-Sided","0.9","16.8"
"2129","NCT00856973","Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia","Insomnia",0,"eszopiclone","Drug","Sunovion","Industry",0,0,"All","6 Years","17 Years","486","May 2009","July 2011","Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS).",">0.05","0","ANCOVA","7.33","LS Mean Treatment Difference","97.5","2-Sided","-5.17","19.83"
"2130","NCT00856986","The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes","Diabetes",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","84 Years","987","March 2009","April 2010","Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.","0","0","0","-0.52","Estimated Treatment Difference, LSMean","95","0","-0.68","-0.36"
"2131","NCT00857220","Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia","Insomnia",0,"eszopiclone","Drug","Sunovion","Industry",0,0,"All","6 Years","17 Years","304","May 2009","October 2011","Overall Incidence of Adverse Events","0","0","0","0","0","0","0","0","0"
"2132","NCT00857233","Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease","Alzheimer's Disease",0,"Memantine","Drug","H. Lundbeck A/S","Industry",0,0,"All","50 Years","N/A","297","June 2004","July 2010","Number of Patients With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"2133","NCT00857415","Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain","Alzheimer's Disease",0,"florbetapir F 18","Drug","Avid Radiopharmaceuticals","Industry",0,0,"All","18 Years","N/A","226","December 2008","March 2010","Correlation of Florbetapir-PET Image and Amyloid Plaque Density","<0.0001","A one-sided test (rho > 0) was performed with a significance level of alpha=0.05 to assess a significant correlation.","Spearman's Rank Correlation test","0.78","Correlation coefficient","95","2-Sided","0.58","0.89"
"2134","NCT00857454","A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations","Hypogonadism",0,"Testosterone MD-Lotion","Drug","Eli Lilly and Company","Industry",0,0,"Male","18 Years","N/A","71","October 2008","August 2009","Change From Baseline MTE08 to MTE09 Endpoint in Draize Score","0","0","0","0","0","0","0","0","0"
"2135","NCT00857584","Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy","Bipolar Disorder",0,"Extended release quetiapine (quetiapine XR)","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","27","May 2009","February 2011","The Mean Change From Baseline to Week 2 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score","0","0","0","0","0","0","0","0","0"
"2136","NCT00857649","Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease","Alzheimer's Disease",0,"Memantine","Drug","H. Lundbeck A/S","Industry",0,0,"All","50 Years","N/A","369","December 2003","April 2010","Efficacy of Memantine on Behavioural Symptoms in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the NPI - 12 Items Version Total Score.","0.418","0","ANCOVA","1.23","Mean Difference (Final Values)","95","2-Sided","-1.75","4.21"
"2137","NCT00857688","Efficacy of the Combination Bismuth + Neomycin + Procaine in the Treatment of Recurrent Aphthous Ulceration","Aphtous Ulcers",0,"Bismu-Jet","Drug","Azidus Brasil","Industry",0,0,"All","12 Years","N/A","100","May 2011","June 2011","The pain will be assessed by visual analogue scale. Will evaluate the size of the lesion using a ruler created specifically for this study The number of lesions will be evaluated by counting.","0","0","0","0","0","0","0","0","0"
"2138","NCT00857818","Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome","Schizophrenia",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","64","April 2009","March 2010","Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Levels","0","0","0","0","0","0","0","0","0"
"2139","NCT00857987","Effectiveness and Safety of the of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improvement of Symptoms Resulting From Acute Respiratory Infections.","Upper Airway Infections",0,"EMS Expectorant","Drug","Azidus Brasil","Industry",0,0,"All","12 Years","N/A","174","April 2010","October 2011","- Decrease in nasal secretion - Decrease in sneezing - Reduction of edema of the nasal mucosa - Decreased frequency of cough - Decrease the frequency of dyspnea - Reduction of nasal obstruction","0","0","0","0","0","0","0","0","0"
"2140","NCT00858637","Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis","Chronic Kidney Disease",0,"MCI-196","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","18 Years","N/A","260","March 2009","March 2010","Percent Change in Serum LDL-cholesterol Levels From Week 16 to Week 20 (LOCF) (ITT2)","0","0","0","0","0","0","0","0","0"
"2141","NCT00858871","First Line Hepato Cellular Carcinoma (HCC)","Hepato Cellular Carcinoma (HCC)",0,"Brivanib","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","1714","May 2009","June 2012","To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatment","0","0","0","0","0","0","0","0","0"
"2142","NCT00859105","A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis","Actinic Keratosis",0,"Imiquimod 5%: manufactured by Apotex","Drug","Apotex Inc.","Industry",0,0,"All","N/A","N/A","497","February 2008","November 2008","The primary objectives are to establish the therapeutic equivalence of imiquimod cream 5%, manufactured by Apotex Inc. and two Aldara (imiquimod) creams, manufactured by 3M (US & Canada) , and to show superiority over vehicle in the treatment of AK.","0","0","0","0","0","0","0","0","0"
"2143","NCT00859599","Monochromatic Phototherapy on Diabetic Foot Ulcers","Diabetic Foot Ulcers",0,"Monochromatic phototherapy, Biolight®","Device","Biolight AB","Industry",0,0,"All","18 Years","N/A","107","August 2008","December 2011","Number of subjects who completely healed and time to 100% wound reduction.","0","0","0","0","0","0","0","0","0"
"2144","NCT00859898","Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","77 Years","1093","April 2009","May 2010","Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants","<0.0001","Dapagliflozin 10 mg plus metformin XR treatment group had to be superior to both monotherapy treatment groups to be considered significant. Two-sided significance level at α=0.05","ANCOVA","-0.53","Mean Difference (Final Values)","95","2-Sided","-0.74","-0.32"
"2145","NCT00860067","A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age","Healthy or Stable Underlying Chronic Medical Condition",0,"Q/LAIV (MEDI3250)","Biological","MedImmune LLC","Industry",0,0,"All","18 Years","49 Years","1800","March 2009","May 2009","The 4 Post-dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) in the Q/LAIV (MEDI3250) Arm Are Noninferior to Those in the Comparator FluMist Group.","0","0","0","1.09","Ratio of geometric mean","95","2-Sided","1.01","1.18"
"2146","NCT00860873","Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis","Osteoarthrosis",0,"EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)","Dietary Supplement","Azidus Brasil","Industry",0,0,"All","30 Years","80 Years","280","October 2009","November 2009","Decrease in pain.","0","0","0","0","0","0","0","0","0"
"2147","NCT00861497","Bifeprunox Extension to Extension Study in Patients With Schizophrenia","Schizophrenia",0,"Bifeprunox","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","N/A","11","January 2006","January 2008","Adverse events, clinical safety laboratory tests, vital signs, ECGs, physical and neurological examinations, abnormal movement scales (AIMS, BARS, SAS)","0","0","0","0","0","0","0","0","0"
"2148","NCT00861614","Study of Immunotherapy to Treat Advanced Prostate Cancer","Prostate Cancer",0,"Ipilimumab","Drug","Bristol-Myers Squibb","Industry",0,0,"Male","18 Years","N/A","988","May 2009","November 2012","Overall Survival (OS)","0.0127","0","Log Rank","0.83","Hazard Ratio (HR)","95","2-Sided","0.71","0.96"
"2149","NCT00861757","Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia","Benign Prostatic Hyperplasia",0,"Tadalafil","Drug","Eli Lilly and Company","Industry",0,0,"Male","45 Years","N/A","612","March 2009","June 2010","Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks","0.003","0","ANCOVA","-1.8","Mean Difference (Final Values)","95","2-Sided","-3.0","-0.6"
"2150","NCT00861926","Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics","Asthma",0,"Ventolin","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","18 Years","N/A","2079","March 2009","December 2010","Time to first severe asthma exacerbation","0","0","0","0","0","0","0","0","0"
"2151","NCT00862121","A Study With Pentasa in Patients With Active Crohn's Disease","Crohn´s Disease",0,"Pentasa","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","20","April 2009","October 2010","Percentage of Crohn's Disease Activity Index (CDAI) Responders at Week 10.","0.231","0","Regression, Logistic","0.212","Odds Ratio (OR)","95","2-Sided","0.017","2.683"
"2152","NCT00862251","Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)","Cardiovascular Disorder",0,"ezetimibe (+) simvastatin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","808","April 2009","March 2011","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).","<0.001","0","Longitudinal data analysis (LDA)","-14.76","Percent change in least-square means","95","2-Sided","-19.61","-9.91"
"2153","NCT00862394","A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma","Asthma",0,"BDP/Formoterol Next DPI","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","12 Years","N/A","783","February 2009","October 2009","Change from baseline measured at clinic to the end of treatment period in pre-dose morning FEV1 (L) measured at clinic","0","0","0","0","0","0","0","0","0"
"2154","NCT00862420","Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease","Peripheral Arterial Disease (PAD)",0,"clopidogrel (SR25990)","Drug","Sanofi","Industry",0,0,"All","20 Years","N/A","431","February 2009","May 2011","Safety events of interest including clinical significant bleeding, blood disorders, hepatic dysfunction and other serious adverse drug reactions (death, hospitalization...)","0","0","0","0","0","0","0","0","0"
"2155","NCT00862472","Safety and Efficacy Study of DuoTrav APS Versus DuoTrav","Open-angle Glaucoma",0,"DuoTrav APS","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","0","March 2009","June 2009","Mean Intraocular Pressure (IOP)","0","0","0","0","0","0","0","0","0"
"2156","NCT00862654","Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis","Scalp Seborrheic Dermatitis",0,"clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)","Drug","Galderma","Industry",0,0,"All","18 Years","N/A","326","March 2009","February 2010","Total Severity Score (TSS): Percent Change From Baseline at Week 4","<0.01","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"2157","NCT00863304","Tanezumab in Osteoarthritis of the Hip or Knee (2)","Osteoarthritis",0,"tanezumab 10 mg","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","849","May 2009","April 2010","WOMAC function","0","0","0","0","0","0","0","0","0"
"2158","NCT00863746","A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).","Carcinoma",0,"Sorafenib (Nexavar, BAY43-9006)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","703","April 2009","March 2012","Overall Survival","0.4687","p-value of one-sided test (significance level 2.5%)","Log Rank","0.9934","Hazard Ratio (HR)","95","2-Sided","0.8409","1.1735"
"2159","NCT00863772","Tanezumab and Nerve Function In Arthritis Patients","Osteoarthritis",0,"tanezumab","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","220","May 2009","November 2010","Change from Baseline in the composite measure (5NC [nd] + HRdb [nd])","0","0","0","0","0","0","0","0","0"
"2160","NCT00863798","Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder","Major Depressive Disorder",0,"Desvenlafaxine Succinate Sustained-Release 10mg","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","N/A","682","April 2009","March 2010","Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET)","0.175","A Hochberg step-up procedure was used to control for the multiplicity associated with multiple active dose arms.","ANCOVA","0.86","Mean Difference (Final Values)","95","2-Sided","-0.38","2.10"
"2161","NCT00864045","Sertindole in Asian Patients With Schizophrenia","Schizophrenia",0,"Sertindole","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","394","March 2007","March 2008","To evaluate the efficacy of 12 weeks treatment with flexible doses of sertindole in comparison to flexible doses of olanzapine in patients with schizophrenia.","0","0","0","0","0","0","0","0","0"
"2162","NCT00864097","Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip","Osteoarthritis",0,"tanezumab","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","607","August 2009","November 2010","Western Ontario and McMaster Universities (WOMAC) Pain Subscale","0","0","0","0","0","0","0","0","0"
"2163","NCT00864253","A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma","Malignant Melanoma",0,"ABI-007","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","529","April 2009","June 2012","Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines","0.044","An interim safety review was performed by DMC. An alpha spending function was utilized to preserve the overall Type 1 error at 0.050. The spending function allocated alpha of 0.001 and 0.049 to the interim and final analyses of PFS, respectively.","Log Rank","0.792","Hazard Ratio (HR)","95.1","2-Sided","0.631","0.992"
"2164","NCT00864851","Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease","Fabry Disease",0,"Replagal","Biological","Shire","Industry",0,0,"All","18 Years","N/A","44","December 2008","June 2012","Change From Baseline to Month 12 in Left Ventricular Mass Indexed to Height (LVMI)","0","0","0","0","0","0","0","0","0"
"2165","NCT00865280","Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)","Skin Diseases, Infectious",0,"PTK 0796","Drug","Paratek Pharmaceuticals Inc","Industry",0,0,"All","18 Years","N/A","143","March 2009","April 2010","Clinical success at follow-up","0","0","0","0","0","0","0","0","0"
"2166","NCT00865488","Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery","Ovarian Cysts",0,"ADHEXIL","Biological","OMRIX Biopharmaceuticals","Industry",0,0,"Female","18 Years","45 Years","80","May 2009","February 2010","Adhesions will be assessed according to incidence, extent and severity.","0","0","0","0","0","0","0","0","0"
"2167","NCT00865592","Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"dutogliptin","Drug","Phenomix","Industry",0,0,"All","18 Years","85 Years","450","March 2009","January 2011","To demonstrate safety and tolerability of dutogliptin","0","0","0","0","0","0","0","0","0"
"2168","NCT00866294","Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)","Depressive Disorder",0,"paroxetine IR 10mg tablet","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","N/A","416","April 2009","February 2010","Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8","<0.001","The hypothesis test was conducted with a two-sided significance level of 5% to show the superiority of paroxetine CR relative to placebo.","ANCOVA","-2.4","Mean Difference (Net)","95","2-Sided","-3.8","-1.1"
"2169","NCT00866606","Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects","Hemophilia B",0,"Benefix","Biological","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","6 Years","N/A","35","February 2009","December 2009","Investigator Hemostatic Efficacy Assessment of Participants After 8 Hours Post Infusion","0","0","0","0","0","0","0","0","0"
"2170","NCT00866658","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)","Diabetes Mellitus, Type 2",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","19 Years","N/A","311","March 2009","June 2010","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","<0.0001","Statistical testing: 2-sided at significance level=0.05. Analysis of co-variance(ANCOVA)included treatment arms, randomization strata of screening HbA1c (<8.0, >=8.0%),sulfonylurea use (yes, no), country as fixed effects, baseline HbA1c as covariate.","ANCOVA","-0.88","Least squares (LS) mean difference","95","2-Sided","-1.116","-0.650"
"2171","NCT00866697","Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Neoplasms, Ovarian",0,"Pazopanib","Drug","Novartis Pharmaceuticals","Industry",0,0,"Female","18 Years","N/A","940","May 26, 2009","July 8, 2012","Investigator-assessed Progression-free Survival (PFS)","0.0021","The P-value from the stratified log-rank test was adjusted for the two stratification factors.","Log Rank","0.766","Hazard Ratio (HR)","95","2-Sided","0.643","0.911"
"2172","NCT00867165","Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)","Primary Hypercholesterolemia",0,"ezetimibe","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","6 Years","10 Years","138","May 21, 2009","April 13, 2012","Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12","<0.001","0","ANCOVA","-26.74","Difference in least-squares means","95","2-Sided","-30.80","-22.69"
"2173","NCT00867724","Clinical Study-evaluate Performance&Safety ""Aer-O-Scope"" in Colon of Low Risk Patients","Colon Cancer",0,"aeroscopy (aer-o-scope)","Device","GI View Ltd.","Industry",0,0,"All","18 Years","70 Years","100","September 2009","December 2011","Ability to screen the entire length of the colon to the cecum.","0","0","0","0","0","0","0","0","0"
"2174","NCT00868166","Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)","Amyotrophic Lateral Sclerosis",0,"Olesoxime","Drug","Trophos","Industry",0,0,"All","18 Years","80 Years","512","April 2009","September 2011","The primary outcome measure will be the overall 18-month survival rate.","0","0","0","0","0","0","0","0","0"
"2175","NCT00868452","Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)","Bipolar Depression",0,"lurasidone + (lithium or divalproex)","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","348","April 2009","December 2011","Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)","0.005","0","Mixed Models Analysis","-3.6","Mean Difference (Final Values)","0","0","0","0"
"2176","NCT00868530","Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects","Hemophilia A",0,"Xyntha","Biological","Pfizer","Industry",0,0,"All","6 Years","N/A","53","September 2008","December 2009","Investigator Hemostatic Efficacy Assessment 8 Hours Post Infusion","0","0","0","0","0","0","0","0","0"
"2177","NCT00868699","Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)","Bipolar Depression",0,"lurasidone","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","505","April 2009","February 2012","Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)","<0.001","0","Mixed Models Analysis","-4.6","Mean Difference (Final Values)","0","0","0","0"
"2178","NCT00869063","Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion","Acute Pain",0,"Diclofenac Sodium Patch","Drug","Cerimon Pharmaceuticals","Industry",0,0,"All","17 Years","75 Years","214","February 2009","July 2009","Change in average pain during daily activity","0","0","0","0","0","0","0","0","0"
"2179","NCT00869180","Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain","Acute Pain",0,"Diclofenac Sodium","Drug","Cerimon Pharmaceuticals","Industry",0,0,"All","17 Years","75 Years","219","February 2009","June 2009","Change in average pain during daily activity at Day 3","0","0","0","0","0","0","0","0","0"
"2180","NCT00869674","GeneSearch™ Breast Lymph Node (BLN) Assay China Registration Study","Breast Cancer",0,"GeneSearch™ Breast Lymph Node (BLN) Assay","Procedure","Johnson & Johnson Medical, China","Industry",0,0,"All","18 Years","N/A","540","February 2009","October 2009","To compare GeneSearch™ BLN Test Kit to permanent pathological section to evaluate the clinical sensitivity and specificity of GeneSearch™ BLN Test Kit in detecting axillary sentinel lymph node metastases in breast cancer patients.","0","0","0","0","0","0","0","0","0"
"2181","NCT00869726","A Study for Patients With Secondary Progressive Multiple Sclerosis","Secondary Progressive Multiple Sclerosis",0,"dirucotide","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","65 Years","596","December 2004","May 2009","Increase in the time to worsening of disability by Kurtzke Expended Disability Status (EDSS).","0","0","0","0","0","0","0","0","0"
"2182","NCT00869856","Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)","Anemia",0,"HX575 solution for s.c. administration","Drug","Sandoz","Industry",0,0,"All","18 Years","N/A","0","April 2009","August 2009","Change in hemoglobin level","0","0","0","0","0","0","0","0","0"
"2183","NCT00869986","A Study for Patients With Relapsing Remitting Multiple Sclerosis","Relapsing Remitting Multiple Sclerosis",0,"dirucotide","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","50 Years","218","November 2006","September 2009","Annualized relapse rate","0","0","0","0","0","0","0","0","0"
"2184","NCT00870155","A Study for Patients With Multiple Sclerosis","Secondary Progressive Multiple Sclerosis",0,"dirucotide","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","65 Years","546","February 2007","September 2009","To assess clinically significant effects of MBP8298 synthetic peptide in all subjects by collecting adverse event, ECG, laboratory, and physical exam outcomes","0","0","0","0","0","0","0","0","0"
"2185","NCT00870818","Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)","Type 1 Diabetes Mellitus",0,"Teplizumab","Drug","MacroGenics","Industry",0,0,"All","10 Years","37 Years","219","February 2009","February 2011","Primary outcome measures will include the number and percentage of subjects who experience a SAE, Adverse Event of Special Interest (including Opportunistic Infection, Lymphopoliferative disease), or other Immediately Reportable Event.","0","0","0","0","0","0","0","0","0"
"2186","NCT00871494","Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan","Pelvic Inflammatory Disease",0,"Azithromycin","Drug","Pfizer","Industry",0,0,"Female","16 Years","80 Years","76","May 2009","November 2010","Response Rate (Clinical Response, Data Review Committee Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃ or Higher Was Option)","0","0","0","0","0","0","0","0","0"
"2187","NCT00872001","The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)","Coronary Artery Bypass",0,"Acadesine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","50 Years","N/A","3080","April 2009","October 2010","Incidence of All-cause Death, Non-fatal Stroke, and Need for Mechanical Support for Severe Left Ventricular Dysfunction (SLVD) (Intent-to-Treat Population)","0","0","0","0","0","0","0","0","0"
"2188","NCT00872651","Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension","Open-angle Glaucoma",0,"Travoprost 0.004%/Timolol 0.5%","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","242","January 2010","November 2011","Intraocular pressure (IOP)","0","0","0","0","0","0","0","0","0"
"2189","NCT00874120","Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)","Blood Pressure",0,"Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","116","December 2008","February 2009","Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).","0.5480","P-value is based on an ANOVA model including sequence, subject within sequence, period and treatment as factors.","ANOVA","-0.5","residual error term from the ANOVA","95","2-Sided","-2.0","1.1"
"2190","NCT00875108","An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 2 Diabetes Mellitus","Diabetes Mellitus",0,"VIAject™","Drug","Biodel","Industry",0,0,"All","30 Years","70 Years","116","July 2007","January 2010","The frequency of occurrence of hypoglycemia measured quarterly over one year.","0","0","0","0","0","0","0","0","0"
"2191","NCT00875394","Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)","Diabetes Mellitus, Non-Insulin-Dependent",0,"sitagliptin phosphate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","30 Years","78 Years","68","February 1, 2007","June 27, 2008","Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24","0","0","0","0","0","0","0","0","0"
"2192","NCT00875459","An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 1 Diabetes Mellitus","Diabetes Mellitus",0,"VIAject™","Drug","Biodel","Industry",0,0,"All","18 Years","70 Years","233","April 2007","February 2010","The frequency of occurrence of hypoglycemia measured quarterly over one year.","0","0","0","0","0","0","0","0","0"
"2193","NCT00875550","Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects","Sedation",0,"Dexmedetomidine","Drug","Hospira, now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","1 Month","16 Years","175","January 2010","January 2011","Percentage of Subjects That do Not Require Rescue Midazolam (MDZ) for Sedation Based on Achieving and Maintaining a Target University of Michigan Sedation Scale (UMSS) Score of 1 to 3 While Intubated.","0","0","0","0","0","0","0","0","0"
"2194","NCT00876343","Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder","Major Depressive Disorder",0,"Aripiprazole (Fixed dose)","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","74 Years","586","March 2009","July 2012","Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","0.006","0","ANCOVA","-2.2","Mean Difference (Final Values)","95","2-Sided","-3.7","-0.6"
"2195","NCT00876798","A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia","Euvolemic Hyponatremia",0,"Lixivaptan","Drug","CardioKine Inc.","Industry",0,0,"All","18 Years","N/A","206","June 2009","November 2010","To demonstrate that lixivaptan is safe and effective in achieving and maintaining increased serum sodium concentration in subjects with SIADH and other conditions of euvolemic hyponatremia.","0","0","0","0","0","0","0","0","0"
"2196","NCT00876824","To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar","Leishmaniasis, Visceral",0,"Amphotericin B Lipid emulsion","Drug","Bharat Serums and Vaccines Limited","Industry",0,0,"All","5 Years","65 Years","500","July 2009","January 2011","Clinical and parasitological cure at end of treatment and final cure (no relapse) at six months","0","0","0","0","0","0","0","0","0"
"2197","NCT00876850","Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)","Skin Structures and Soft Tissue Infections",0,"PTK 0796","Drug","Paratek Pharmaceuticals Inc","Industry",0,0,"All","18 Years","N/A","0","July 2009","July 2010","Clinical success at follow-up","0","0","0","0","0","0","0","0","0"
"2198","NCT00877006","Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study","Non-Hodgkin's Lymphoma",0,"bendamustine","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","18 Years","N/A","447","April 2009","March 2012","Percentage of Participants With Complete Response (CR) at End of Treatment Period","0","0","0","0","0","0","0","0","0"
"2199","NCT00877279","Multicenter Study of the Safety and Efficacy of Dermal Filler, Belotero® Soft","Facial Wrinkles",0,"CosmoDerm1","Device","Merz Pharmaceuticals, LLC","Industry",0,0,"All","18 Years","75 Years","64","November 2007","March 2008","The severity of the facial wrinkle","0","0","0","0","0","0","0","0","0"
"2200","NCT00877409","Safety and Efficacy Study of Acnase Creme in the Treatment of Acne Vulgaris I and II","Acne Vulgaris",0,"Benzoyl Peroxide 5% and Sulphur 2%","Drug","Zurita Laboratorio Farmaceutico Ltda.","Industry",0,0,"All","12 Years","35 Years","80","April 2009","July 2009","Average clinical development of target lesions of the groups for each experimental time.","0","0","0","0","0","0","0","0","0"
"2201","NCT00877890","A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)","Type 2 Diabetes Mellitus",0,"exenatide once weekly","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","254","March 2009","October 2009","Change in HbA1c From Baseline to Week 24","<.0001","0","ANOVA","-0.67","Least Squares Mean Difference","95","2-Sided","-0.94","-0.39"
"2202","NCT00878917","Equivalence Study of Dorzolamide 2% Eye Drops Solution","Open Angle Glaucoma",0,"Dorzolamide 2 % eye drops solution","Drug","Alfred E. Tiefenbacher (GmbH & Co. KG)","Industry",0,0,"All","18 Years","N/A","32","April 2009","February 2010","intraocular pressure (IOP)-lowering","0","0","0","0","0","0","0","0","0"
"2203","NCT00879229","ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis",0,"Ambrisentan","Drug","Gilead Sciences","Industry",0,0,"All","35 Years","80 Years","40","July 2009","February 2011","Change From Baseline in Six-minute Walk Distance (6MWD).","0.696","This is an exact Wilcoxon rank sum test p-value for testing equality of ambrisentan and placebo distributions.","Wilcoxon (Mann-Whitney)","-29","Mean Difference (Final Values)","95","2-Sided","-54","17"
"2204","NCT00880100","Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)","Cystic Fibrosis",0,"Ultrase® MT12","Drug","Forest Laboratories","Industry",0,0,"All","2 Years","6 Years","49","April 2009","November 2009","Percentage of Patients With Control of Steatorrhea","0","0","0","0","0","0","0","0","0"
"2205","NCT00880620","A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease","Parkinson's Disease",0,"placebo","Drug","IMPAX Laboratories, Inc.","Industry",0,0,"All","30 Years","N/A","381","April 2009","October 2010","Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30","0","0","0","0","0","0","0","0","0"
"2206","NCT00881257","Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System","Peripheral Vascular Disease",0,"GRST Peripheral Catheter System","Device","Vessix Vascular, Inc","Industry",0,0,"All","18 Years","N/A","78","August 2007","November 2009","Major Adverse Clinical Events Rate","0","0","0","0","0","0","0","0","0"
"2207","NCT00881452","A Trial of CM-AT in Children With Autism","Autism",0,"CM-AT","Drug","Curemark","Industry",0,0,"All","3 Years","8 Years","182","May 2009","June 2011","Evidence of changes in behavior scales associated with the core symptoms of autism","0","0","0","0","0","0","0","0","0"
"2208","NCT00881842","Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season","Influenza",0,"Trivalent influenza subunit vaccine Influvac","Biological","Abbott Biologicals","Industry",0,0,"All","18 Years","N/A","120","June 2009","July 2009","HI titers and its derived parameters after 2 weeks (seroprotection, seroconversion and mean fold increase), reactogenicity and inconvenience of Influvac® 2008/2009 as defined by the CHMP guideline for influenza vaccines.","0","0","0","0","0","0","0","0","0"
"2209","NCT00882219","Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period","Coronary Restenosis",0,"Xience V®","Device","Abbott Vascular","Industry",0,0,"All","18 Years","N/A","102","March 2009","March 2011","Evaluation by QCA (Quantitative Coronary Angiography) of in-stent late loss after the implantation of the stent XIENCE V®","0","0","0","0","0","0","0","0","0"
"2210","NCT00882362","Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder","Major Depressive Disorder",0,"OPC-14597 (Aripiprazole)","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","N/A","155","March 2009","July 2012","Montgomery-Asberg Depression Rating Scale (MADRS)","0","0","0","0","0","0","0","0","0"
"2211","NCT00882518","Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients","Schizophrenia",0,"Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","388","April 2009","July 2010","Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment at Day 42","0","0","0","0","0","0","0","0","0"
"2212","NCT00882531","Isotretinoin in Papular-Pustular Rosacea","Papular-pustular Rosacea",0,"isotretinoin","Drug","Laboratoires Bailleul-Biorga","Industry",0,0,"All","18 Years","N/A","156","February 2007","August 2009","To determine numbers of patients responding to treatment for 4 months with isotretinoin (patients were considered as responders if their number of papular-pustular lesions fell by at least 90% after 4 months of treatment)","0","0","0","0","0","0","0","0","0"
"2213","NCT00882609","F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets","Bone Metastases",0,"Bone Scan: F18-Fluoride PET/CT or TC-MDP","Device","American College of Radiology - Image Metrix","Industry",0,0,"All","18 Years","N/A","550","January 2009","December 2012","Analysis of the diagnostic performance of [18F]NaF fluoride PET/CT scanning","0","0","0","0","0","0","0","0","0"
"2214","NCT00883116","A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","Endometrial Cancer",0,"Ixabepilone","Drug","R-Pharm","Industry",0,0,"Female","18 Years","N/A","551","August 2009","June 2012","Overall Survival (OS)","0.0397","0","Log Rank","1.3","Hazard Ratio (HR)","95","2-Sided","1.0","1.7"
"2215","NCT00883168","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis",0,"Placebo","Drug","Meda Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","1791","April 2009","July 2009","Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)","0","0","0","0","0","0","0","0","0"
"2216","NCT00883233","Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris","Acne",0,"Adapalene BPO Gel standard daily overnight application","Drug","Galderma","Industry",0,0,"All","12 Years","35 Years","123","April 2009","September 2009","Local Tolerability Was Analyzed in Terms of Worst Score Post-Baseline.","0","0","0","0","0","0","0","0","0"
"2217","NCT00883337","A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis","Multiple Sclerosis",0,"Interferon β-1a","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","324","April 2009","September 2011","Core Treatment Period: Overview of Failures","0","0","0","0","0","0","0","0","0"
"2218","NCT00883493","Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression","Acute Bipolar Depression",0,"Quetiapine fumarate XR","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","421","April 2009","March 2011","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.","0","0","0","0","0","0","0","0","0"
"2219","NCT00883740","Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia","Fibromyalgia",0,"Pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","119","June 2009","June 2010","Wake After Sleep Onset (WASO) at Weeks 5 and 11","<0.0001","P-value is based on a linear mixed effects model including sequence, period, and treatment as fixed factors and participant within sequence and within participant error as random factors.","linear mixed effects model","-19.15","Mean Difference (Final Values)","95","2-Sided","-26.69","-11.61"
"2220","NCT00884000","A Study of Zomacton in Children With Growth Hormone Deficiency","Growth Hormone Deficiency",0,"Genotropin","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","3 Years","11 Years","165","January 2010","June 2012","Height Velocity","0","0","0","0","0","0","0","0","0"
"2221","NCT00884221","MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer","Infertility",0,"Highly purified menotrophin","Drug","Ferring Pharmaceuticals","Industry",0,0,"Female","21 Years","34 Years","749","July 2009","July 2010","Ongoing Pregnancy After One Fresh Embryo Replacement Cycle, Intention-to-treat (ITT) Analysis Set","0.499","Since there was only one primary endpoint, no adjustment for multiplicity was needed for the primary analysis.","Sign test","2.2","Difference in pregnancy rates, ITT","95","2-Sided","-4.2","8.6"
"2222","NCT00884273","Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","182","August 2009","March 2011","Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set)","0.36","FAS.","ANCOVA","2.37","Mean Difference (Final Values)","95","2-Sided","-2.78","7.52"
"2223","NCT00884585","Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis","Atopic Conjunctivitis",0,"Cyclosporine Vehicle","Drug","Allergan","Industry",0,0,"All","12 Years","N/A","176","May 2009","October 2010","Percentage of Treatment Responders","0","0","0","0","0","0","0","0","0"
"2224","NCT00885079","Confirmatory Study of OPC-12759 Ophthalmic Suspension","Dry Eye Syndromes",0,"OPC-12759 Ophthalmic suspension","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","N/A","188","May 2009","March 2010","Change in Fluorescein Corneal Staining (FCS) Score From Baseline","<0.05","An analysis of change from baseline of FCS was performed using t-test. The level of singnificanse was 5 % (2-sided).","t-test, 2 sided","-0.9","Mean Difference (Final Values)","95","2-Sided","-1.47","-0.24"
"2225","NCT00885352","Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","Type 2 Diabetes Mellitus",0,"Sitagliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","78 Years","313","April 15, 2009","November 10, 2010","Change From Baseline in Hemoglobin A1c (A1C) at Week 26","0","0","0","0","0","0","0","0","0"
"2226","NCT00885365","A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®","Cystic Fibrosis",0,"tobramycin / Bramitob","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","6 Years","N/A","324","April 2009","April 2010","Change From Baseline to End of the Treatment Period of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal","0.640","0","ANCOVA","-0.50","difference of least square means","95","2-Sided","-2.58","1.59"
"2227","NCT00885378","Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"Saxagliptin plus metformin IR","Drug","AstraZeneca","Industry",0,0,"All","18 Years","78 Years","166","May 2009","February 2010","Mean Hemoglobin A1C (A1c) and Change From Baseline to Week 12","0.1248","0","ANCOVA","-9.51","Mean Difference (Final Values)","95","2-Sided","-21.68","2.66"
"2228","NCT00885742","A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency","Factor XIII Deficiency",0,"FXIII Concentrate (Human)","Biological","CSL Behring","Industry",0,0,"All","N/A","N/A","41","August 2009","April 2011","The Incidence of Spontaneous Bleeding Events Requiring Treatment (Treatment is Defined as Administration of a FXIII‑Containing Product to Treat the Bleeding Event)","0","0","0","0","0","0","0","0","0"
"2229","NCT00887224","Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","Major Depressive Disorder",0,"Desvenlafaxine succinate sustained release 50 mg","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","874","June 2009","March 2011","Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185","<0.001","Significance declared if p-value ≤0.05. The estimated probability obtained via Kaplan-Meier estimate.","Log Rank","0","0","0","0","0","0"
"2230","NCT00887237","Triple Site Ventricular Stimulation for Cardiac Resynchronization Therapy (CRT) Candidates","Heart Failure",0,"CRT with triple site ventricular stimulation","Device","Medtronic Cardiac Rhythm and Heart Failure","Industry",0,0,"All","18 Years","N/A","76","May 2009","July 2012","Safety of triple site CRT compared to conventional CRT","0","0","0","0","0","0","0","0","0"
"2231","NCT00887978","Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension","Pulmonary Hypertension",0,"UT-15C SR","Drug","United Therapeutics","Industry",0,0,"All","18 Years","75 Years","310","June 2009","July 2011","6-minute Walk Distance (6MWD)","0.089","0","non-parametric ANCOVA","10.0","Hodges-Lehmann (H-L)","95","2-Sided","-2.0","22.0"
"2232","NCT00888082","Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy","Breast Cancer",0,"Goserelin acetate","Drug","AstraZeneca","Industry",0,0,"Female","18 Years","45 Years","102",NA,"April 2012","The ovarian function will be considered as regained, if E2 measurements return to premenopausal levels (equal to or above 20 pg/ml), FSH measurements return to premenopausal levels (less than or equal to 40 IU/L)","0","0","0","0","0","0","0","0","0"
"2233","NCT00888199","Clinical Trial of Tensegrity Prosthetics K3 Promoter Foot Prosthesis","Amputation",0,"Experimental prosthetic foot (K3 Promoter)","Device","Tensegrity Prosthetics","Industry",0,0,"All","18 Years","90 Years","80","January 2010","June 2010","Change in metabolic cost of transport","0","0","0","0","0","0","0","0","0"
"2234","NCT00889252","Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers","Allergic Conjunctivitis",0,"contact lens with ketotifen","Device","Vistakon Pharmaceuticals","Industry",0,0,"All","8 Years","N/A","250","April 2009","July 2009","Lid and Lid Margin Erythema, Change From Baseline","0","0","0","0","0","0","0","0","0"
"2235","NCT00889356","Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis","Candidiasis",0,"Clindamycin 100mg and Ketoconazole 400mg","Drug","Zodiac Produtos Farmaceuticos S.A.","Industry",0,0,"Female","18 Years","50 Years","160","September 2009","March 2010","Efficacy based on cure rate evaluated by clinical and laboratory criteria.","0","0","0","0","0","0","0","0","0"
"2236","NCT00890097","Geographic Atrophy Treatment Evaluation","Geographic Atrophy",0,"AL-8309B Ophthalmic Solution","Drug","Alcon Research","Industry",0,0,"All","55 Years","N/A","772","April 2009","May 2012","Mean Annualized Lesion Enlargement Rate From Baseline as Assessed With Fundus Autofluorescence Imaging","0","0","0","0","0","0","0","0","0"
"2237","NCT00890682","Study of Postoperative Analgesia in Bunionectomy","Bunion",0,"SKY0402","Drug","Pacira Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","193","April 2009","November 2009","Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores","0","0","0","0","0","0","0","0","0"
"2238","NCT00890721","Study of Pain Control in Hemorrhoidectomy","Hemorrhoid",0,"SKY0402","Drug","Pacira Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","189","May 2009","November 2009","The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo.","0","0","0","0","0","0","0","0","0"
"2239","NCT00890981","A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab","Low Bone Mass",0,"high-resolution peripheral quantitative computed tomography (HR-pQCT)","Procedure","Amgen","Industry",0,0,"Female","N/A","N/A","79","July 2009","June 2010","Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT","0.0766","0","ANCOVA","3.7","Mean Difference (Final Values)","95","0","-0.4","7.8"
"2240","NCT00891202","A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)","Gaucher Disease, Type 1",0,"Eliglustat tartrate","Drug","Genzyme, a Sanofi Company","Industry",0,0,"All","16 Years","N/A","40","November 2009","July 2012","PAP: Percent Change From Baseline in Spleen Volume (in Multiples of Normal [MN]) at Week 39 of the Primary Analysis Period With Eliglustat Tartrate Treatment as Compared to Placebo","<0.0001","0","ANCOVA","-30.03","Least Squares Mean Difference","95","2-Sided","-36.82","-23.24"
"2241","NCT00891267","Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome","Metabolic Syndrome",0,"Olmesartan medoxomil tablets low dose","Drug","Daiichi Sankyo Europe, GmbH","Industry",0,0,"All","18 Years","N/A","60","October 2008","April 2011","To investigate the anti-inflammatory effect of Olmesartan (OM) higher dose compared to Olmesartan (OM) lower dose and amlodipine (AML) on the change in levels of the inflammatory marker hs-CRP","0","0","0","0","0","0","0","0","0"
"2242","NCT00891306","Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects","Familial Lipoprotein Lipase Deficiency",0,"Alipogene Tiparvovec (AMT-011), Human LPL [S447X]","Genetic","Amsterdam Molecular Therapeutics","Industry",0,0,"All","18 Years","N/A","5","February 2009","August 2010","Reduction of triglyceride (TG) concentrations","0","0","0","0","0","0","0","0","0"
"2243","NCT00891371","Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea","Diarrhea",0,"lanreotide (Autogel formulation)","Drug","Ipsen","Industry",0,0,"All","18 Years","N/A","42","July 2009","August 2012","Percentage of Patients Having Minimum Reduction of 50% or Normalization (≤3 Stools/24hours) in the Mean Number of Stools (Mean of Last 7 Days)","0","0","0","0","0","0","0","0","0"
"2244","NCT00891462","Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)","Chronic Obstructive Pulmonary Disease",0,"Aclidinium bromide","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","561","April 2009","November 2009","Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1)","<0.0001","0","ANCOVA","0.086","Least Squares Mean Difference","95","2-Sided","0.05","0.13"
"2245","NCT00891982","A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash","Acne Vulgaris",0,"CTGel/ BPO Wash","Drug","Stiefel, a GSK Company","Industry",0,0,"All","12 Years","45 Years","60","April 1, 2009","June 1, 2009","Local Tolerability - Skin Dryness","0","0","0","0","0","0","0","0","0"
"2246","NCT00892749","Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis","Chronic Kidney Disease",0,"ASP1585","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","248","May 2009","September 2010","Changes in serum Phosphorus level","0","0","0","0","0","0","0","0","0"
"2247","NCT00892762","Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health","Open Angle Glaucoma",0,"Travoprost APS 40 micrograms/ml eye drop solution","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","434","June 2009","May 2011","Mean NEI VFQ-25 composite score at the end of the treatment period (Day 90)","0","0","0","0","0","0","0","0","0"
"2248","NCT00892957","FS VH S/D 500 S-apr in Vascular Surgery","Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses",0,"Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)","Biological","Baxter Healthcare Corporation","Industry",0,0,"All","N/A","N/A","176","July 2009","October 2010","Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application.","<0.0001","0","Likelihood ratio chi-square test","0","0","0","0","0","0"
"2249","NCT00893867","Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke","Acute Ischemic Stroke",0,"DP-b99","Drug","D-Pharm Ltd.","Industry",0,0,"All","18 Years","85 Years","446","December 2009","April 2012","Modified Rankin Scale (mRS) categorical analysis (""shift"")","0","0","0","0","0","0","0","0","0"
"2250","NCT00894556","A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)","Acute Migraine",0,"rizatriptan","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","109","June 2009","January 2010","Pain Relief (PR)","<0.001","0","Generalized Linear Mixed Model (GLIMMIX)","0","0","0","0","0","0"
"2251","NCT00894647","Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery","Actinic Keratosis",0,"imiquimod cream","Drug","Graceway Pharmaceuticals, LLC","Industry",0,0,"All","18 Years","N/A","247","May 2009","February 2010","Change From Baseline in Percentage of Lesion Count","0","0","0","0","0","0","0","0","0"
"2252","NCT00894673","Efficacy and Safety of Sodium Heparin (Hipolabor) in Patients","Cardiac Surgery",0,"Heparin sodium Hipolabor","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","104","July 2009","July 2011","Effectiveness of heparin of porcine origin in patients undergoing cardiovascular surgery","0","0","0","0","0","0","0","0","0"
"2253","NCT00894829","Efficacy and Safety of Sodium Heparin (Eurofarma)","Cardiac Surgery",0,"heparin sodium - Eurofarma","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","104","June 2009","September 2011","Comparison of TTPA, Anti-Xa and ACT","0","0","0","0","0","0","0","0","0"
"2254","NCT00894959","Efficacy and Safety of Sodium Heparin in Patients","Cardiac Surgery",0,"Heparin sodium Blausiegel 1","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","104","July 2009","September 2009","Comparison of TTPA, Anti-Xa and ACT","0","0","0","0","0","0","0","0","0"
"2255","NCT00894985","Efficacy and Safety of Sodium Heparin","Cardiac Surgery",0,"heparin sodium - blausiegel","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","104","June 2009","September 2009","Comparison of TTPA, Anti-Xa and ACT","0","0","0","0","0","0","0","0","0"
"2256","NCT00894998","Efficacy and Safety of Sodium Heparin in Patients (Cristália)","Cardiac Surgery",0,"heparin sodium - Cristália","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","104","June 2009","September 2009","Comparison of TTPA, Anti-Xa and ACT","0","0","0","0","0","0","0","0","0"
"2257","NCT00895011","Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy","Erectile Dysfunction",0,"Placebo","Drug","VIVUS, Inc.","Industry",0,0,"Male","18 Years","70 Years","298","April 2009","April 2011","Change in Percentage of Sexual Attempts in Which Subjects Are Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse","0","0","0","0","0","0","0","0","0"
"2258","NCT00895479","Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence","End Stage Renal Disease",0,"Graft placement surgery plus Trinam therapy","Procedure","Ark Therapeutics Ltd","Industry",0,0,"All","18 Years","N/A","250","April 2009","September 2011","Primary Unassisted Patency","0","0","0","0","0","0","0","0","0"
"2259","NCT00896337","EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries","Iliac Artery Stenosis",0,"Epic™ Nitinol Stent System","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","125","May 2009","September 2011","Device- and/or Procedure-related Major Adverse Events (MAE)","<0.0001","A one-sided exact-test was used to test the hypothesis that the primary endpoint rate in the Epic-treated cohort is less than the predefined performance goal of 17.0%.","One-sided exact-test","3.4","9-month major adverse event rate","95","2-Sided","0.9","8.5"
"2260","NCT00901901","Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma","Carcinoma, Hepatocellular",0,"Sorafenib (Nexavar, BAY43-9006)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","732","May 2009","April 2012","Overall Survival","0","0","0","0","0","0","0","0","0"
"2261","NCT00902252","Multi-National Phase III Vitala™ 12-Hour Wear Test","Colostomy",0,"Usual","Device","ConvaTec Inc.","Industry",0,0,"All","18 Years","N/A","78","April 2009","January 2010","Safety","0","0","0","0","0","0","0","0","0"
"2262","NCT00902538","Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension","Essential Hypertension",0,"Olmesartan medoxomil 40 mg - Amlodipine 10 mg","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","N/A","2204","April 2009","September 2010","Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg","0.1187","0","ANCOVA","0","0","0","0","0","0"
"2263","NCT00902746","Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis","Dysmenorrhea",0,"NPC-01","Drug","Nobelpharma","Industry",0,0,"Female","18 Years","N/A","149","May 2009","February 2012","Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment)","0","0","0","0","0","0","0","0","0"
"2264","NCT00902837","OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects","Chronic Osteoarthritis",0,"Oxycodone naloxone prolonged release tablets (OXN)","Drug","Mundipharma Research GmbH & Co KG","Industry",0,0,"All","18 Years","N/A","181","May 2009","April 2010","To demonstrate that treatment with OXN PR tablets is non-inferior to treatment with OxyPR with regards to analgesic efficacy & locomotor function. To demonstrate that subjects with moderate to severe OA pain taking oxycodone/naloxone prolonged re","0","0","0","0","0","0","0","0","0"
"2265","NCT00902928","A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery","Venous Thromboembolism",0,"YM150","Drug","Astellas Pharma Europe B.V.","Industry",0,0,"All","18 Years","N/A","1992","April 2009","June 2010","Incidence of symptomatic Venous Thromboembolisms and death from all causes","0","0","0","0","0","0","0","0","0"
"2266","NCT00903409","Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects","Hypertriglyceridemia",0,"Simvastatin + Lovaza® (omega-3-acid ethyl esters)","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","79 Years","0","November 15, 2005","June 1, 2008","Median Percent Change of Non-HDL-C (High Density Lipoprotein-Cholesterol) in Switchers vs. Non-Switchers Subjects From LOV111858 End-of-Treatment (Week 8) to Month 4 of Extension Study (LOV111818)","<0.001","The difference between Non-switchers and Switchers in the percent change in non-HDL-C level from the end of the OM6 double-blind study (average of Weeks 6 and 8 for the statistical analysis) to 4 months of OM6X open-label treatment (Month 4).","Kruskal-Wallis","0","0","0","0","0","0"
"2267","NCT00903981","Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil","Erectile Dysfunction",0,"Avanafil","Drug","JW Pharmaceutical","Industry",0,0,"Male","19 Years","70 Years","208","March 2009","October 2009","Change of EF domain score in the IIEF(The International Index of Erectile Function)","0","0","0","0","0","0","0","0","0"
"2268","NCT00904670","Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder",0,"Quillivant Oral Suspension XR","Drug","Pfizer","Industry",0,0,"All","6 Years","12 Years","45","April 2009","August 2009","Swanson, Kotin, Agler, M-Flynn, and Pelham Rating Scale (SKAMP)-Combined Scores at Hour 4 Post-Dose","<0.0001","0","ANOVA","-12.46","Least Square (LS) mean difference","95","2-Sided","-14.75","-10.17"
"2269","NCT00904683","Effect of LY2062430 on the Progression of Alzheimer's Disease","Alzheimer's Disease",0,"LY2062430","Drug","Eli Lilly and Company","Industry",0,0,"All","55 Years","N/A","1040","May 2009","June 2012","Change from Baseline to Week 80 in Alzheimer's Disease Assessment Scale - Cognitive Subscore 14-Item Scale (ADAS-Cog14)","0","0","0","0","0","0","0","0","0"
"2270","NCT00904969","A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence","Urinary Incontinence, Stress",0,"The AMS Male Transobturator Sling System","Device","American Medical Systems","Industry",0,0,"Male","40 Years","N/A","55","September 2005","May 2009","Improvement in patient continence status","0","0","0","0","0","0","0","0","0"
"2271","NCT00905216","Efficacy and Safety of Sodium Heparin in Patients Submitted to Heart Surgery Using Bypass","Cardiac Surgery",0,"heparin sodium - Bergamo","Drug","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","104","June 2009","September 2009","Comparison of TTPA, Anti-Xa and ACT Comparison of bleeding","0","0","0","0","0","0","0","0","0"
"2272","NCT00905255","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)","Diabetes Mellitus, Type 2",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","20 Years","N/A","69","May 2009","January 2011","Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital Signs, Electrocardiogram (ECG) and Laboratory Monitoring","0","0","0","0","0","0","0","0","0"
"2273","NCT00905268","A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients","Friedreich's Ataxia",0,"idebenone","Drug","Santhera Pharmaceuticals","Industry",0,0,"All","8 Years","N/A","232","April 2006","January 2010","Absolute Change in International Cooperative Ataxia Rating Scale (ICARS) Scores From Baseline Assessment to Week 52","0","0","0","0","0","0","0","0","0"
"2274","NCT00905372","Effect of LY2062430 on the Progression of Alzheimer's Disease","Alzheimer's Disease",0,"LY2062430","Drug","Eli Lilly and Company","Industry",0,0,"All","55 Years","N/A","1000","May 2009","April 2012","Change from baseline to endpoint in Alzheimer's Disease Assessment Scale—Cognitive subscore (ADAS-Cog11)","0","0","0","0","0","0","0","0","0"
"2275","NCT00905437","Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients Undergoing Total Hip Replacement","Pain, Perioperative",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","72","November 2009","July 2012","Mean Pain on Movement Score","0","0","0","0","0","0","0","0","0"
"2276","NCT00906399","Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis","Relapsing Multiple Sclerosis",0,"BIIB017 (peginterferon beta-1a)","Drug","Biogen","Industry",0,0,"All","18 Years","65 Years","1516","June 2009","October 2012","Annualized Relapse Rate (ARR) at 1 Year","0.0114","0","Negative Binomial Regression","0.725","Rate Ratio","95","2-Sided","0.565","0.930"
"2277","NCT00907426","Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin","Hypotrichosis",0,"Bimatoprost 0.03% solution","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","368","August 2009","November 2010","Percentage of Treatment Responders at Month 4","0","0","0","0","0","0","0","0","0"
"2278","NCT00908349","Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy","Partial Epilepsy",0,"Oxcarbazepine XR","Drug","Supernus Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","66 Years","214","June 2009","November 2011","Percent Change in Seizure Rate","0","0","0","0","0","0","0","0","0"
"2279","NCT00908453","The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin","Epilepsy",0,"fosphenytoin","Drug","Nobelpharma","Industry",0,0,"All","2 Years","N/A","40","May 2009","February 2010","Incidence of adverse events","0","0","0","0","0","0","0","0","0"
"2280","NCT00908752","Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC","Hepatocellular Carcinoma",0,"Brivanib","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","734","July 20, 2009","September 28, 2012","To compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy","0","0","0","0","0","0","0","0","0"
"2281","NCT00908778","A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects","Diabetic Retinopathy",0,"Vitreosolve","Drug","Vitreoretinal Technologies, Inc.","Industry",0,0,"All","50 Years","N/A","160","October 2008","July 2010","Ultrasound, OCT, and clinical exam","0","0","0","0","0","0","0","0","0"
"2282","NCT00909181","Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence","Urge Urinary Incontinence",0,"Oxybutynin","Drug","Antares Pharma Inc.","Industry",0,0,"All","18 Years","N/A","626","March 2009","July 2010","Change From Baseline in Mean Weekly Frequency of Urinary Incontinence Episodes at Week 12","0","0","0","0","0","0","0","0","0"
"2283","NCT00909532","Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation","Cystic Fibrosis",0,"Ivacaftor","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","12 Years","N/A","167","June 2009","July 2010","Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24","<0.0001","The primary and key secondary endpoints were analyzed using Hochberg’s step-up procedure: test 1, primary (α=0.05); test 2, CFQ-R resp domain (Wk24) and sweat chloride (Wk24)(α=0.05).","Mixed Models Analysis","10.6","Mean Difference (Final Values)","95","2-Sided","8.6","12.6"
"2284","NCT00909571","Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus","Liver Transplantation",0,"FK506E (modified release tacrolimus)","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","10","April 2009","March 2010","Assessment of pharmacokinetic parameters","0","0","0","0","0","0","0","0","0"
"2285","NCT00909727","Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation","Cystic Fibrosis",0,"Ivacaftor","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","6 Years","11 Years","52","August 2009","November 2010","Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24","<0.0001","The primary endpoint and key secondary endpoints were tested in sequence. test 1: primary (α=0.05); test 2: using Hochberg's step-up procedure on weight (Wk 24) and sweat chloride (Wk 24)(α=0.05); test 3: CFQ-R respiratory domain score (Wk 24).","Mixed Models Analysis","12.5","Mean Difference (Final Values)","95","2-Sided","6.6","18.3"
"2286","NCT00909779","Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects","Chronic Obstructive Pulmonary Disease",0,"Arformoterol","Drug","Sunovion","Industry",0,0,"All","40 Years","N/A","841","June 2009","June 2012","Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).","0","0","0","0.606","Hazard Ratio (HR)","95","2-Sided","0.425","0.864"
"2287","NCT00909857","Effect on Primary Dysmenorrhea","Primary Dysmenorrhea",0,"Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)","Drug","Bayer","Industry",0,0,"Female","14 Years","50 Years","507","April 2009","November 2010","Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain","0","0","0","0","0","0","0","0","0"
"2288","NCT00909870","Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers","Venous Leg Ulcer",0,"Dermagraft(R)","Device","Shire Regenerative Medicine, Inc.","Industry",0,0,"All","18 Years","N/A","537","June 2009","May 2011","Complete Healing of the Study Ulcer by Week 16.","0.1030","This p-value did not meet the prespecified threshold for statistical significance of < 0.05","Chi-squared","6.5","Difference in proportions","95","2-Sided","0","0"
"2289","NCT00910403","Multicenter Evaluation of Safety and Effectiveness of Presbyopic LASIK for Hyperopes","Presbyopia",0,"LASIK","Procedure","Technolas Perfect Vision GmbH","Industry",0,0,"All","18 Years","N/A","80","June 2009","May 2011","Binocular uncorrected VA better than 20/40","0","0","0","0","0","0","0","0","0"
"2290","NCT00910520","Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","Overactive Bladder",0,"onabotulinumtoxinA","Biological","Allergan","Industry",0,0,"All","18 Years","N/A","548","September 2009","August 2011","Change From Baseline in Number of Daily Episodes of Urinary Incontinence","0","0","0","0","0","0","0","0","0"
"2291","NCT00910624","Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)","Hepatitis C, Chronic",0,"Boceprevir","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","168","June 2009","December 2012","Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24);","0","0","0","0","0","0","0","0","0"
"2292","NCT00910637","Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles","Contraception",0,"Gestodene/EE Patch (BAY86-5016)","Drug","Bayer","Industry",0,0,"Female","18 Years","45 Years","1502","May 2009","December 2010","Occurrence of pregnancy (yes/no) while on treatment","0","0","0","0","0","0","0","0","0"
"2293","NCT00910845","Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","Overactive Bladder",0,"onabotulinumtoxinA","Biological","Allergan","Industry",0,0,"All","18 Years","N/A","557","September 2009","July 2011","Change From Baseline in Number of Daily Episodes of Urinary Incontinence","0","0","0","0","0","0","0","0","0"
"2294","NCT00911027","SonoVue Guided Prostate Biopsy","Prostate Cancer",0,"Contrast-enhanced ultrasound guided biopsy","Drug","Bracco Diagnostics, Inc","Industry",0,0,"Male","40 Years","N/A","282","February 2009","March 2011","Determination of potentiality of SonoVue to guide prostate biopsy increasing detection rate of malignant lesions of 6% points (absolute terms) compared to detection rate of conventional systematic biopsy on patients candidates to a bioptic procedure.","0","0","0","0","0","0","0","0","0"
"2295","NCT00911170","PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study","Cancer",0,"Pegfilgrastim","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","847","November 2009","September 2012","Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy","0.014","0","Cochran-Mantel-Haenszel","0.41","Odds Ratio (OR)","95","2-Sided","0.19","0.86"
"2296","NCT00912054","DuoTrav APS Versus XALACOM® in Ocular Surface Health","Open Angle Glaucoma",0,"DuoTrav APS","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","240","March 2010","May 2011","Mean change from baseline (Day 0) in Ocular Surface Disease at the end of the treatment period (Day 90)","0","0","0","0","0","0","0","0","0"
"2297","NCT00912093","A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)","Hereditary Angioedema",0,"Icatibant","Drug","Shire","Industry",0,0,"All","18 Years","N/A","98","June 2009","July 2012","Time to Onset of Symptom Relief for an Acute Attack, as Assessed by the Patient","<0.001","0","Peto-Peto Wilcoxon","0","0","0","0","0","0"
"2298","NCT00912288","A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease","Alzheimer Disease",0,"Dimebon 20 mg po TID","Drug","Pfizer","Industry",0,0,"All","50 Years","N/A","86","September 2009","August 2010","Change From Baseline in the Severe Impairment Battery (SIB) Score at Week 26","0","0","0","0","0","0","0","0","0"
"2299","NCT00912483","Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical Patients","Venous Thromboembolism",0,"heparin sodium - Blausiegel","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","60 Years","0","May 2010","November 2010","Incidence of venous thromboembolism during the 28 days of study","0","0","0","0","0","0","0","0","0"
"2300","NCT00912964","A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","Urinary Bladder, Overactive",0,"Mirabegron","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","2030","April 2009","April 2010","Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours","0.005","The response variable for the stratified rank ANCOVA was standardized ranks on change from Baseline to Final Visit value with baseline standardized ranks and gender as covariates and geographic region as a stratum.","Stratified rank ANCOVA","-0.40","LS Mean Difference","95","2-Sided","-0.74","-0.06"
"2301","NCT00913120","Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery","Venous Thromboembolism",0,"YM150","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","610","May 2009","March 2010","Overall incidence of venous thromboembolism","0","0","0","0","0","0","0","0","0"
"2302","NCT00914472","Comparison of Two Heparin Formulations in Patients With Chronic Renal Failure.","Thrombus",0,"heparin sodium - APP","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","120","April 2010","March 2011","Effectiveness of heparin in thrombi formation.","0","0","0","0","0","0","0","0","0"
"2303","NCT00914693","EU/LA Pearl Index Study - Transdermal Contraceptive Patch","Contraception",0,"Ethinylestradiol/Gestodene (BAY86-5016)","Drug","Bayer","Industry",0,0,"Female","18 Years","35 Years","1694","April 2009","September 2011","Occurrence of pregnancy","0","0","0","0","0","0","0","0","0"
"2304","NCT00915343","Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency","Adrenal Insufficiency",0,"hydrocortisone (modified release), oral tablet 20 and 5 mg","Drug","Shire","Industry",0,0,"All","18 Years","N/A","64","August 2007","July 2008","Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma After Multiple Doses During Part A","<0.0001","Comparison of log S-cortisol AUC between OD and TID regimens was adjusted for both period effect and subject effect using generalized linear model (GLM) in statistical analysis system (SAS).","ANOVA","0.806","Period-adjusted quotient","95","2-Sided","0.753","0.862"
"2305","NCT00915551","A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","Actinic Keratosis",0,"PEP005 (Ingenol Mebutate) gel, 0.015%","Drug","Peplin","Industry",0,0,"All","18 Years","N/A","278","June 2009","September 2009","Complete Clearance of Actinic Keratoses (AK) Lesions","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"2306","NCT00916006","A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","Actinic Keratosis",0,"PEP005 Gel","Drug","Peplin","Industry",0,0,"All","18 Years","N/A","269","June 2009","September 2009","Patients With Complete Clearance of Actinic Keratosis (AK) Lesions.","0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"2307","NCT00916370","SPIRIT PRIME Clinical Trial","Myocardial Ischemia",0,"Core size Xience Prime","Device","Abbott Vascular","Industry",0,0,"All","18 Years","N/A","525","June 2009","March 2011","Target Lesion Failure (TLF)","0","0","0","0","0","0","0","0","0"
"2308","NCT00917254","Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery","Venous Thromboembolism",0,"YM150","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","369","May 2009","January 2010","Overall incidence of venous thromboembolism","0","0","0","0","0","0","0","0","0"
"2309","NCT00917267","A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects","Type 2 Diabetes Mellitus",0,"exenatide once weekly","Drug","AstraZeneca","Industry",0,0,"All","20 Years","N/A","691","July 2009","September 2010","Change in HbA1c From Baseline to Week 26.","<.001","0","Mixed Models Analysis","-0.31","Least Squares Mean Difference","95","2-Sided","-0.49","-0.14"
"2310","NCT00917306","A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)","Actinic Keratosis",0,"PEP005 Gel","Drug","Peplin","Industry",0,0,"All","18 Years","N/A","102","June 2009","September 2009","Safety (Incidence of treatment related AEs, local skin reactions and pigmentation and scarring)","0","0","0","0","0","0","0","0","0"
"2311","NCT00917384","Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma","Gastric Cancer",0,"ramucirumab","Biological","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","355","August 2009","July 2012","Overall Survival (OS)","0.0473","0","Stratified Log-Rank Test","0.776","Hazard Ratio (HR)","95","0","0.603","0.998"
"2312","NCT00918138","Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg","Type 2 Diabetes",0,"Saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","78 Years","219","August 2009","May 2010","Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4","0.1278","Comparison between saxagliptin 5 mg + metformin 1500 mg and metformin 2000 mg significant at alpha =0.05 according to sequential testing procedure","ANCOVA","-10.8","Mean Difference (Final Values)","95","2-Sided","-24.8","3.2"
"2313","NCT00918879","Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control","Type 2 Diabetes",0,"Saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","213","May 2009","July 2010","Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)","0.0011","0","ANCOVA","-0.46","Mean Difference (Net)","95","0","-0.73","-0.18"
"2314","NCT00919126","General Anesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia.","Anaesthesia",0,"Xenon","Drug","Air Liquide SA","Industry",0,0,"All","50 Years","N/A","102","June 2009","January 2012","Dose of Propofol (mg) Administered During Maintenance Adjusted to Patient Body Surface Area (BSA in m²) and Maintenance Duration (Min)","<0.0001","0","ANCOVA","0","0","0","0","0","0"
"2315","NCT00919711","Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy","Osteoporosis",0,"Actonel®","Drug","Amgen","Industry",0,0,"Female","55 Years","N/A","870","September 2009","December 2011","Total Hip BMD Percent Change From Baseline at Month 12","<0.0001","0","ANCOVA","1.6","Mean Difference (Net)","95","2-Sided","1.2","2.0"
"2316","NCT00920166","Evaluation of Safety, Growth, Tolerance and Effects on the Intestinal Fora of a New Milk for Healthy Infants","Growth",0,"Pétunia 1","Dietary Supplement","Sodilac","Industry",0,0,"All","N/A","8 Days","97","February 2007","March 2008","Growth Parameters","0","0","0","0","0","0","0","0","0"
"2317","NCT00920582","Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus","Type 1 Diabetes Mellitus",0,"Teplizumab (MGA031)","Drug","MacroGenics","Industry",0,0,"All","8 Years","35 Years","254","September 2009","April 2012","Successful versus unsuccessful clinical responses. A successful response requires that both components of a composite endpoint are met. The composite endpoint includes both the subject's total daily insulin usage and his/her HbA1c levels.","0","0","0","0","0","0","0","0","0"
"2318","NCT00920816","Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer","Kidney Neoplasms",0,"Axitinib (AG-013736)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","492","August 25, 2009","July 27, 2012","Progression Free Survival (PFS): First-Line Participants","0","0","0","0.767","Hazard Ratio (HR)","95","2-Sided","0.559","1.053"
"2319","NCT00920946","A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease","Huntington Disease",0,"Dimebon","Drug","Medivation, Inc.","Industry",0,0,"All","30 Years","N/A","403","July 2009","July 2011","A comparison between the mean changes from baseline in the Dimebon 20 mg TID treatment group and the placebo group on the MMSE","0","0","0","0","0","0","0","0","0"
"2320","NCT00920985","US Cycle Control and Blood Pressure Study","Contraception",0,"Gestodene/EE (FC Patch Low, BAY86-5016)","Drug","Bayer","Industry",0,0,"Female","18 Years","45 Years","346","June 2009","August 2010","Cycle control parameters and bleeding pattern indices","0","0","0","0","0","0","0","0","0"
"2321","NCT00921375","Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia","Hyperuricemia",0,"TULY","Drug","Virchow Group","Industry",0,0,"All","1 Year","75 Years","100","February 2010","December 2011","Percentage of reduction in plasma uric acid at 4 hrs after uric acid-lowering therapy","0","0","0","0","0","0","0","0","0"
"2322","NCT00922480","Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients","Hypertension",0,"Fimasartan","Drug","Boryung Pharmaceutical Co., Ltd","Industry",0,0,"All","18 Years","70 Years","506","December 2008","July 2009","Diastolic Blood Pressure","0","0","0","0","0","0","0","0","0"
"2323","NCT00922636","A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder","Attention Deficit Hyperactivity Disorder",0,"LY2216684","Drug","Eli Lilly and Company","Industry",0,0,"All","6 Years","17 Years","340","June 2009","December 2010","Change From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored (ADHD-RS-IV-PV:IR) Total Score at Week 8","0.008","Statistical significance was assessed at an alpha level of 0.027 with a Dunnett adjustment for multiple comparisons.","Mixed Models Analysis","-5.74","Mean Difference (Final Values)","95","0","0","0"
"2324","NCT00923091","Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension","Essential Hypertension",0,"olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","N/A","2689","June 2009","January 2011","Change in Seated Diastolic Blood Pressure (SeDBP).","0.0071","0","ANCOVA","0","0","0","0","0","0"
"2325","NCT00924573","Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride","Type 2 Diabetes Mellitus",0,"Metformin","Drug","Sanofi","Industry",0,0,"All","20 Years","74 Years","189","May 2009","March 2010","Changes in HbA1c from baseline","0","0","0","0","0","0","0","0","0"
"2326","NCT00924664","Long Term Safety Study of Tanezumab in Chronic Low Back Pain","Low Back Pain",0,"Tanezumab 20 mg","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","849","August 2009","November 2010","Adverse events; Injection site assessments; Safety laboratory testing; Electrocardiogram; Neurological examination; Anti-drug antibody assessments; Physical examinations; Vital signs.","0","0","0","0","0","0","0","0","0"
"2327","NCT00924989","A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma","Adrenocortical Carcinoma",0,"OSI-906","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","139","September 2009","July 2012","Overall survival of single agent OSI-906 versus placebo","0","0","0","0","0","0","0","0","0"
"2328","NCT00925301","Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease","Fabry Disease",0,"migalastat hydrochloride","Drug","Amicus Therapeutics","Industry",0,0,"All","16 Years","74 Years","67","August 2009","July 2012","kidney GL-3 (assessed histologically in kidney biopsy samples)","0","0","0","0","0","0","0","0","0"
"2329","NCT00925548","STRIDE - STimulating Immune Response In aDvanced brEast Cancer","Breast Cancer",0,"Tecemotide (L-BLP25) and Hormonal Treatment","Biological","EMD Serono","Industry",0,0,"Female","18 Years","N/A","16","September 2009","August 2010","Progression-Free Survival (PFS)","0","0","0","0","0","0","0","0","0"
"2330","NCT00925587","Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease","Anemia",0,"darbepoetin alfa","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","358","June 2009","April 2012","Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33)","0","0","0","-0.188","Mean Difference (Final Values)","95","2-Sided","-0.427","0.052"
"2331","NCT00926029","Compare the Clinical Efficacy of Prototype Toothpastes","Dental Plaque",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","65 Years","98","January 2008","April 2008","Plaque Index","0.05","0","ANOVA","0","0","0","0","0","0"
"2332","NCT00926575","Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)","Acute Gastrointestinal Graft vs Host Disease",0,"oral beclomethasone 17,21-dipropionate","Drug","Soligenix","Industry",0,0,"All","18 Years","N/A","140","October 2009","December 2011","The Proportion of Subjects With GVHD Treatment Failure","0","0","0","0","0","0","0","0","0"
"2333","NCT00927173","Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder","Major Depressive Disorder",0,"Brainsway H-Coil Deep TMS System","Device","Brainsway","Industry",0,0,"All","22 Years","68 Years","233","September 2009","March 2012","HDRS-21","0","0","0","0","0","0","0","0","0"
"2334","NCT00927472","Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice","Pediculosis",0,"Malathion gel 0.5%","Drug","Taro Pharmaceuticals USA","Industry",0,0,"All","2 Years","N/A","254","August 2009","May 2010","Proportion of Index Subjects Free of Any of Lice 14 Days After Their Last Treatment.","0.0386","0","t-test, 2 sided","0","0","0","0","0","0"
"2335","NCT00927641","HKT-500 in the Treatment of Adult Patients With Ankle Sprain","Ankle Sprain",0,"Ketoprofen Patch","Drug","Hisamitsu Pharmaceutical Co., Inc.","Industry",0,0,"All","18 Years","N/A","240","July 2009","November 2010","Change from the baseline of the 100-mm VAS pain intensity score during monopodal weight bearing for 1 second at Visit 3 (Day 3 + 1 day)","0","0","0","0","0","0","0","0","0"
"2336","NCT00928122","Intrastromal Correction of Ametropia by a Femtosecond Laser","Presbyopia",0,"Intrastromal Correction of Presbyopia","Device","20/10 Perfect Vision","Industry",0,0,"All","18 Years","N/A","200","July 2008","January 2009","Prove safety and effectiveness as well as improvement in near visual acuity performance and increase in near visual acuity.","0","0","0","0","0","0","0","0","0"
"2337","NCT00928434","A Study of Degarelix in Patients With Prostate Cancer","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","409","May 2009","August 2012","Percentage of Patients With Serum PSA Levels ≤4.0 ng/mL","0","0","0","1.57","Percentage difference","95","2-Sided","-0.19","3.33"
"2338","NCT00928486","A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma","Multiple Myeloma",0,"Lenalidomide","Drug","Celgene Corporation","Industry",0,0,"All","20 Years","N/A","25","April 2009","September 2010","Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)","0","0","0","0","0","0","0","0","0"
"2339","NCT00928590","Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension","Open-angle Glaucoma",0,"Travoprost/Timolol Maleate Fixed Combination solution","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","155","July 2009","November 2010","Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"2340","NCT00928785","Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults","Healthy",0,"REPEVAX","Biological","MCM Vaccines B.V.","Industry",0,0,"All","18 Years","N/A","456","July 2009","December 2009","Anti-tetanus seroprotection rate (defined as the percentage of subjects with anti-tetanus antibody titre (ELISA) ≥ 0.1 IU/mL)","0","0","0","0","0","0","0","0","0"
"2341","NCT00929292","Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic","Growth",0,"Modilac Dahlia 1","Other","Sodilac","Industry",0,0,"All","N/A","3 Months","66","November 2006","July 2008","Crying duration per 24 hours","0","0","0","0","0","0","0","0","0"
"2342","NCT00929851","BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)","Pulmonary Disease, Chronic Obstructive",0,"CHF1535","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","40 Years","N/A","1199","October 2009","March 2012","Exacerbation rate Change in pre-dose FEV1","0","0","0","0","0","0","0","0","0"
"2343","NCT00929864","Abatacept Versus Adalimumab Head-to-Head","Rheumatoid Arthritis",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","869","October 2009","October 2011","The Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population","0","0","0","1.8","Difference from adalimumab at Day 365","95","2-Sided","-5.6","9.2"
"2344","NCT00930436","Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease","Contrast Induced Kidney Injury.",0,"sodium bicarbonate","Drug","MD Scientific","Industry",0,0,"All","18 Years","N/A","391","January 2010","August 2012","Death or renal replacement therapy or sustained kidney injury","0","0","0","0","0","0","0","0","0"
"2345","NCT00931866","Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)","Acute Pain",0,"Diclofenac Sodium","Drug","Cerimon Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","407","April 2009","September 2009","Change in average pain during daily activity at Day 7","0","0","0","0","0","0","0","0","0"
"2346","NCT00932893","An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","Carcinoma, Non-Small-Cell Lung",0,"PF-02341066","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","347","September 2009","March 2012","Progression-Free Survival (PFS)","<0.0001","To control family-wise Type 1 error, a step-down procedure was applied in following order: PFS, objective response rate (ORR), overall survival (OS), and disease control rate (DCR). Statistical significance: 1-sided at alpha=0.025.","Log Rank","0.487","Hazard Ratio (HR)","95","0","0.371","0.638"
"2347","NCT00933686","Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome","Fibromyalgia",0,"Saizen®","Drug","Merck KGaA","Industry",0,0,"Female","18 Years","N/A","113","December 2007","July 2010","Percentage of Participants With Less Than 11 Tender Points at Month 6","0","0","0","0","0","0","0","0","0"
"2348","NCT00933868","Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke","Stroke",0,"Magnesium Chloride","Drug","Relox Medical, LLC","Industry",0,0,"All","18 Years","90 Years","81","April 2009","May 2010","Barthel Index","0","0","0","0","0","0","0","0","0"
"2349","NCT00933933","Evaluation of Diagnostic HIV Ag/Ab Combo Assay","Human Immunodeficiency Viruses",0,"ARCHITECT HIV Ag/Ab Combo","Device","Abbott Diagnostics Division","Industry",0,0,"All","N/A","N/A","635","June 2009","October 2009","Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection","0","0","0","99.77","Clinical Specificity","95","2-Sided","99.62","99.88"
"2350","NCT00934154","Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma","Multiple Myeloma",0,"Thalidomide","Drug","Cigdem Sahinbas YILMAZ","Industry",0,0,"All","55 Years","N/A","122","March 2006","September 2009","response rate","0","0","0","0","0","0","0","0","0"
"2351","NCT00934167","Efficacy of Sodium Heparin for Prophylaxis of Venous Thromboembolism in Surgical Patients","Venous Thromboembolism",0,"heparin sodium - Hipolabor","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","60 Years","140","May 2010","November 2010","Non-appearance of venous thromboembolism","0","0","0","0","0","0","0","0","0"
"2352","NCT00934427","Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms","Raynaud Disease",0,"0.9% nitroglycerin in TAM cream","Drug","MediQuest Therapeutics","Industry",0,0,"All","18 Years","70 Years","100","June 2009","June 2010","Response rate as measured by changes in severity of the Raynaud's symptom most bothersome to the individual patient (Pain, Numbness, or Tingling)","0","0","0","0","0","0","0","0","0"
"2353","NCT00935532","Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"exenatide once weekly","Drug","AstraZeneca","Industry",0,0,"All","20 Years","N/A","427","July 2009","September 2010","Change in HbA1c From Baseline to Endpoint (Week 26)","<.001","No adjustments for multiplicity will be performed","ANCOVA","-0.43","Least Squares Mean Difference","95","2-Sided","-0.59","-0.26"
"2354","NCT00935649","PinPointe FootLaser for the Treatment of Onychomycosis","Infected Toenails",0,"PinPointe FootLaser","Device","PathoLase, Inc.","Industry",0,0,"All","18 Years","80 Years","134","June 2009","November 2010","Nail Bed Clearing","0","0","0","0","0","0","0","0","0"
"2355","NCT00936741","An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome","Cushing's Syndrome",0,"mifepristone","Drug","Corcept Therapeutics","Industry",0,0,"All","18 Years","N/A","30","July 2009","September 2012","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"2356","NCT00936897","A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates","Postmenopausal Osteoporosis",0,"Ibandronate","Drug","Amgen","Industry",0,0,"Female","55 Years","N/A","833","July 2009","November 2011","Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","<0.0001","0","ANCOVA","1.4","Mean Difference (Net)","95","2-Sided","1.0","1.8"
"2357","NCT00937378","Treatment of Patients With Nocturia (Non-PK Study)","Nocturia",0,"SER120","Drug","Serenity Pharmaceuticals, Inc.","Industry",0,0,"All","50 Years","N/A","326","June 2009","August 2010","Number of nocturic episodes","0","0","0","0","0","0","0","0","0"
"2358","NCT00937391","Contrast-enhanced MRI in Children 2 Months to <2 Years","Magnetic Resonance Imaging",0,"Gadopentetate dimeglumine (Magnevist, BAY86-6661)","Drug","Bayer","Industry",0,0,"All","2 Months","23 Months","54","January 2010","September 2010","Number of Participants With Diagnostic Adequacy - Open-label Clinical Investigators (Per Protocol Set)","0","0","0","0","0","0","0","0","0"
"2359","NCT00937820","Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism","Venous Thromboembolism",0,"YM150","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","87","June 2009","December 2010","Joint incidence of deep vein thromboembolism or pulmonary thromboembolism","0","0","0","0","0","0","0","0","0"
"2360","NCT00937859","Treatment of Patients With Nocturia","Nocturia",0,"SER120","Drug","Serenity Pharmaceuticals, Inc.","Industry",0,0,"All","50 Years","N/A","301","June 2009","July 2010","number of nocturic episodes","0","0","0","0","0","0","0","0","0"
"2361","NCT00937911","Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities","Venous Thromboembolism",0,"YM150","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","101","June 2009","April 2010","Incidence of venous thromboembolism","0","0","0","0","0","0","0","0","0"
"2362","NCT00938236","CIS001 Extension Study of Cyclosporine Inhalation Solution","Lung Transplant",0,"Cyclosporine Inhalation Solution (CIS)","Drug","APT Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","17","December 2009","September 2011","To assess the long-term safety of CIS administration","0","0","0","0","0","0","0","0","0"
"2363","NCT00938353","Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup","Croup",0,"beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","6 Months","3 Years","6","April 2010","September 2010","To demonstrate superiority of nebulized BDP vs placebo in Westley croup score at 6 h","0","0","0","0","0","0","0","0","0"
"2364","NCT00938652","A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer","Breast Cancer",0,"gemcitabine/carboplatin","Drug","Sanofi","Industry",0,0,"Female","18 Years","N/A","519","July 2009","January 2011","progression free survival","0","0","0","0","0","0","0","0","0"
"2365","NCT00939003","Study of Adalimumab in Patients With Axial Spondyloarthritis","Axial Spondyloarthritis",0,"Adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","192","July 2009","February 2011","Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response","<0.001","0","Chi-squared","0","0","0","0","0","0"
"2366","NCT00939055","StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight","Obesity",0,"StomaphyX","Device","EndoGastric Solutions","Industry",0,0,"All","18 Years","64 Years","112","July 2009","June 2012","Weight Loss","0","0","0","0","0","0","0","0","0"
"2367","NCT00939276","Macular Edema Incidence/Severity Reduction With Nevanac","Diabetic Retinopathy",0,"Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","175","August 2009","May 2011","Percentage of patients who develop macular edema within 90 days following cataract surgery","0","0","0","0","0","0","0","0","0"
"2368","NCT00939783","An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease","Alzheimer's Disease",0,"Dimebon","Drug","Pfizer","Industry",0,0,"All","50 Years","N/A","649","September 2009","August 2010","Percentage of Participants With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"2369","NCT00940095","Clazosentan in Aneurysmal Subarachnoid Hemorrhage","Aneurysmal Subarachnoid Hemorrhage",0,"Clazosentan","Drug","Actelion","Industry",0,0,"All","18 Years","75 Years","577","July 2009","October 2010","Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol","0","0","0","0","0","0","0","0","0"
"2370","NCT00940472","Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients","Diabetes Type 2",0,"DMMET-01","Drug","Laboratorios Silanes S.A. de C.V.","Industry",0,0,"All","40 Years","60 Years","20","March 2009","December 2009","Metabolic Control (Fasting glucose, postprandial glucose, HbA1C)","0","0","0","0","0","0","0","0","0"
"2371","NCT00940667","Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension","Hypertension",0,"Amlodipine plus Losartan","Drug","Hanmi Pharmaceutical Company Limited","Industry",0,0,"All","18 Years","N/A","185","May 2008","December 2008","Change from baseline in mean sitting diastolic blood pressure","0","0","0","0","0","0","0","0","0"
"2372","NCT00940680","Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension","Hypertension",0,"Amlodipine plus Losartan","Drug","Hanmi Pharmaceutical Company Limited","Industry",0,0,"All","18 Years","N/A","142","April 2008","November 2008","Change from baseline in mean sitting diastolic blood pressure","0","0","0","0","0","0","0","0","0"
"2373","NCT00941382","Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients","Obesity",0,"Sibutramine-Metformin","Drug","Laboratorios Silanes S.A. de C.V.","Industry",0,0,"All","30 Years","50 Years","60","November 2008","August 2009","improvement of body weight, adiposity and inflammation state defined by serum adiponectin, leptin and C reactive protein","0","0","0","0","0","0","0","0","0"
"2374","NCT00942396","Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography","Breast Cancer",0,"Full Field Digital Mammogram (Planmed Sophie Nuance)","Device","Planmed Oy","Industry",0,0,"Female","40 Years","85 Years","250","April 2008","March 2011","Area under ROC curve based on subjects' maximum POM scores; sensitivity based on subjects' maximum BI-RADS scores with 4 or higher as positive for cancer; and specificity based on subjects maximum BI-RADS scores with 4 or higher as positive for cancer","0","0","0","0","0","0","0","0","0"
"2375","NCT00942435","A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery","Venous Thromboembolism",0,"YM150","Drug","Astellas Pharma Inc","Industry",0,0,"All","40 Years","N/A","156","June 2009","April 2010","Composite assessment of venous thromboembolism events and all causes of death","0","0","0","0","0","0","0","0","0"
"2376","NCT00942448","Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery","Dental Pain",0,"Diclofenac HPBCD","Drug","IBSA Institut Biochimique SA","Industry",0,0,"All","18 Years","65 Years","306","September 2009","January 2010","Pain Intensity Difference (PID) on a 0-100 VAS","< 0.001","0","ANCOVA","24.2","Mean Difference (Final Values)","0","0","0","0"
"2377","NCT00942487","Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol","Primary Arterial Hypertension",0,"Nebilet","Drug","Berlin-Chemie Menarini","Industry",0,0,"All","18 Years","N/A","60","April 2005","December 2008","Changes of: longitudinal myocardial velocities at rest (assessed by TDE), systolic functional reserve (calculated as the absolute and relative increase of the myocardial systolic velocities at peak stress from rest), NT-proBNP","0","0","0","0","0","0","0","0","0"
"2378","NCT00942604","A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","Actinic Keratoses",0,"PEP005 (ingenol mebutate) Gel","Drug","Peplin","Industry",0,0,"All","18 Years","N/A","203","July 2009","October 2009","Proportion of Patients With Complete Clearance of Actinic Keratoses (AK) Lesions","0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"2379","NCT00943072","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)","Macular Edema Secondary to Central Retinal Vein Occlusion",0,"VEGF Trap-Eye 2.0mg","Biological","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","189","July 2009","October 2010","Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score","< 0.0001","P-value for the primary endpoint was calculated using 2-sided Cochran-Mantel-Haenszel test adjusted by regions (North America vs. Rest of World) and baseline BCVA (BCVA > 20/200 and BCVA ≤ 20/200)","Cochran-Mantel-Haenszel","44.8","Risk Difference (RD)","95","2-Sided","33.0","56.6"
"2380","NCT00943098","Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery","Dental Pain",0,"Diclofenac HPBCD s.c. 75mg/ml","Drug","IBSA Institut Biochimique SA","Industry",0,0,"All","18 Years","65 Years","142","September 2009","March 2010","Pain Intensity Difference (PID)","0.813","0","ANCOVA","-0.71","Mean Difference (Final Values)","95","2-Sided","-6.62","5.20"
"2381","NCT00943111","A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)","Gaucher Disease, Type 1",0,"Eliglustat tartrate","Drug","Genzyme, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","160","September 2009","November 2012","Percentage of Participants Who Remained Stable for 52 Weeks During the Primary Analysis Period","0","0","0","-8.8","Difference in Percentage Stable","95","2-Sided","-17.6","4.2"
"2382","NCT00943657","Yearly Strain Variation Study, 2009/2010","Influenza",0,"Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]","Biological","Nanotherapeutics, Inc.","Industry",0,0,"All","18 Years","N/A","110","June 2009","July 2009","Number of subjects demonstrating seroconversion to each of the three antigens contained in the vaccine 21 days after vaccination","0","0","0","0","0","0","0","0","0"
"2383","NCT00943722","A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)","Cervical Cancers",0,"V503","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","9 Years","26 Years","3074","August 27, 2009","April 30, 2011","Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])","<0.001","one-sided tests of non-inferiority conducted at the alpha=0.025 level","ANOVA","1.90","GMT ratio","95","2-Sided","1.70","2.14"
"2384","NCT00944268","Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety","Anxiety",0,"Passiflora, Crataegus e Salix","Drug","Ativus Farmaceutica Ltda","Industry",0,0,"All","18 Years","N/A","124","September 2009","December 2009","Hamilton Scales","0","0","0","0","0","0","0","0","0"
"2385","NCT00944502","To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins","Neuralgia",0,"Dexamethasone","Drug","Bunker Industria Farmaceutica Ltda.","Industry",0,0,"All","18 Years","N/A","104","October 2009","November 2009","Observation of adverse events related to medication. The causality of adverse events concerning the use of medication will be given after applying the Naranjo Algorythm","0","0","0","0","0","0","0","0","0"
"2386","NCT00944918","Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)","Progression-free Survival",0,"fulvestrant","Drug","AstraZeneca","Industry",0,0,"Female","18 Years","N/A","25","December 2008","June 2011","Progression-free survival","0","0","0","0","0","0","0","0","0"
"2387","NCT00945646","FST-201 In The Treatment of Acute Fungal Otitis Externa","Acute Fungal Otitis Externa",0,"FST-201 (dexamethasone 0.1%) Otic Suspension","Drug","Shire","Industry",0,0,"All","18 Years","N/A","6","July 2009","July 2010","Overall clinical cure as defined by absence of the signs and symptoms of AFOE including ear inflammation, edema, tenderness, pruritis and otic discharge.","0","0","0","0","0","0","0","0","0"
"2388","NCT00945906","An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency","Factor XIII Deficiency",0,"FXIII Concentrate (Human) (FXIII)","Biological","CSL Behring","Industry",0,0,"All","N/A","N/A","61","September 2009","August 2011","Adverse Events","0","0","0","0","0","0","0","0","0"
"2389","NCT00945945","A Study of Duloxetine in Patients With Osteoarthritis Knee Pain","Osteoarthritis Knee Pain",0,"Duloxetine (DLX)","Drug","Eli Lilly and Company","Industry",0,0,"All","40 Years","N/A","424","July 2009","May 2010","Change From Baseline to 13 Week Endpoint (Baseline Observation Carried Forward [BOCF]) in Brief Pain Inventory (BPI) ""24-Hour Average Pain"" Item (Question 3) of the BPI-Modified Short Form Score","0.105","P-value for Change from Baseline to Endpoint (BOCF).","ANCOVA","0.34","Least Squares Mean Difference","95","2-Sided","-0.07","0.75"
"2390","NCT00945958","Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension","Open Angle Glaucoma",0,"SPARC0913","Drug","Sun Pharma Advanced Research Company Limited","Industry",0,0,"All","18 Years","N/A","161","November 2010","June 2012","Number of Subjects With AEs","0","0","0","0","0","0","0","0","0"
"2391","NCT00946920","A Trial of Degarelix in Patients With Prostate Cancer","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","859","June 2009","March 2011","Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) With Degarelix","0","0","0","0","0","0","0","0","0"
"2392","NCT00947297","Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)","Urea Cycle Disorders",0,"HPN-100","Drug","Horizon Pharma Ireland, Ltd., Dublin Ireland","Industry",0,0,"All","6 Years","N/A","60","November 2009","September 2011","Rate of Adverse Events (Number of Participants Who Experienced Any AE Considered Related to Study Drug)","0","0","0","0","0","0","0","0","0"
"2393","NCT00947557","Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin","Diabetes Mellitus, Type II",0,"Dutogliptin","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","85 Years","677","July 2009","July 2010","Hemoglobin A1c (HbA1c)","0","0","0","0","0","0","0","0","0"
"2394","NCT00947752","Safety of New Formulation of Glatiramer Acetate","Relapsing Remitting Multiple Sclerosis",0,"Glatiramer Acetate","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","18 Years","N/A","147","July 2009","September 2009","Subject-reported Pain Associated Immediately After Each Injection","0","0","0","0","0","0","0","0","0"
"2395","NCT00948428","Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis","Actinic Keratoses",0,"imiquimod","Drug","Actavis Mid-Atlantic LLC","Industry",0,0,"All","18 Years","N/A","462","May 2008","March 2009","Primary - Proportion of subjects in each treatment group with Complete Clearance of AK lesions.","0","0","0","0","0","0","0","0","0"
"2396","NCT00948818","Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation","Irritable Bowel Syndrome Characterized by Constipation",0,"Linaclotide 290 micrograms","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","803","July 2009","July 2010","Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks","0.0004","The p-value is still less than 0.05 after adjusting multiplicity using a serial gatekeeping multiple comparison procedure.","Cochran-Mantel-Haenszel","2.60","Odds Ratio (OR)","95","2-Sided","1.51","4.47"
"2397","NCT00951587","Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Night Procedure","Colonic Diseases",0,"PillCam™ (Capsule Endoscopy)","Device","Given Imaging Ltd.","Industry",0,0,"All","18 Years","50 Years","49","February 2008","February 2010","Colon cleansing level score","0","0","0","0","0","0","0","0","0"
"2398","NCT00952289","COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial","Myelofibrosis",0,"Ruxolitinib","Drug","Incyte Corporation","Industry",0,0,"All","18 Years","N/A","309","August 2009","November 2010","Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24","<0.0001","0","Fisher Exact","0","0","0","0","0","0"
"2399","NCT00952341","Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)","Chemotherapy-induced Nausea and Vomiting (CINV)",0,"aprepitant","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","421","August 25, 2009","April 4, 2010","Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1","0.007","0","Regression, Logistic","0","0","0","0","0","0"
"2400","NCT00952705","A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age","Healthy or Stable Underlying Chronic Medical Condition",0,"Q/LAIV-BFS (MEDI8662)","Biological","MedImmune LLC","Industry",0,0,"All","18 Years","49 Years","1800","August 2009","January 2010","The Post Dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMTs) in the Q/LAIV-BFS (MEDI8662) Arm as Compared to Those in the Combined Flumist Arms (All Flumist Group).","0","0","0","0.95","Ratio of geometric mean titers","95","2-Sided","0.87","1.03"
"2401","NCT00952783","A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study","Actinic Keratosis",0,"Lesion count","Drug","Peplin","Industry",0,0,"All","18 Years","N/A","98","July 2009","October 2010","Summarize treatment area recurrence of AK lesions in the selected treatment area","0","0","0","0","0","0","0","0","0"
"2402","NCT00953147","A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","Allergic Rhinitis",0,"Ciclesonide HFA 80 mcg","Drug","Sunovion","Industry",0,0,"All","12 Years","N/A","1110","August 2009","January 2010","Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS (rTNSS) Averaged Over the First 6 Weeks of Double-blind Treatment","<0.0001","The p-value from primary outcome was adjusted at alpha=0.025.","ANCOVA","0.69","Mean Difference (Final Values)","95","2-Sided","0.35","1.04"
"2403","NCT00953732","A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies","Actinic Keratosis",0,"Lesion count","Drug","Peplin","Industry",0,0,"All","18 Years","N/A","117","August 2009","October 2010","Summarize treatment area recurrence of AK lesions, in the selected treatment area","0","0","0","0","0","0","0","0","0"
"2404","NCT00954590","A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease","Moderate to Severe Alzheimer",0,"Dimebon (latrepirdine)","Drug","Medivation, Inc.","Industry",0,0,"All","50 Years","N/A","89","October 2009","August 2010","Neuropsychiatric Inventory (NPI)","0","0","0","0","0","0","0","0","0"
"2405","NCT00955513","Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain","Grade I/II Ankle Sprain",0,"diclofenac diethylamine gel 2.32%","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","242","July 2009","December 2009","Measure: Pain on Movement on Day 5 (Change From Baseline).","0","0","0","0","0","0","0","0","0"
"2406","NCT00955526","Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa","Parkinson's Disease",0,"Istradefylline","Drug","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","20 Years","N/A","373","July 2009","February 2011","Reducing the mean total hours of awake time per day spent in the OFF state","0","0","0","0","0","0","0","0","0"
"2407","NCT00955552","Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee","Osteoarthritis of the Knee",0,"Glucosamine sulphate and chondroitin sulphate association","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","40 Years","N/A","100","April 2010","October 2010","To assess the efficacy and safety of the association of glucosamine sulphate 500 mg/chondroitin sulphate 400 mg (Eurofarma) in the treatment of osteoarthritis, compared to Condroflex® (Zodiac) in same presentation and pharmaceutical form","0","0","0","0","0","0","0","0","0"
"2408","NCT00955747","Naturlose (D-Tagatose) Efficacy Evaluation Trial","Type 2 Diabetes",0,"Tagatose","Drug","Robert Lodder","Industry",0,0,"All","18 Years","75 Years","494","April 2007","October 2010","Change in Hemoglobin A1C Level From Baseline","<0.05","0","ANCOVA","0.5","Mean Difference (Net)","95","2-Sided","0","0"
"2409","NCT00955799","Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus","Subjective Tinnitus",0,"Neramexane mesylate","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","75 Years","455","September 2009","May 2011","Absolute Change in TBF-12 (Tinnitus Handicap Inventory-12) Total Score from Baseline.","0","0","0","0","0","0","0","0","0"
"2410","NCT00955825","Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis","Allergic Rhinitis Due to Grass Pollens",0,"300 IR","Drug","Stallergenes","Industry",0,0,"All","18 Years","65 Years","473","October 2008","August 2009","Combined Score (CS)","0.0003","0","ANCOVA","-0.126","LS Mean difference vs. Placebo","95","0","-0.194","-0.058"
"2411","NCT00957073","Rheos HOPE4HF (Health Outcomes Prospective Evaluation for Heart Failure With Ejection Fraction (EF) ≥ 40%) Trial","Heart Failure",0,"Rheos Baroreflex Activation System","Device","CVRx, Inc.","Industry",0,0,"All","21 Years","N/A","19","August 2009","October 2012","Cardiovascular death or heart failure event","0","0","0","0","0","0","0","0","0"
"2412","NCT00957203","Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients","Parkinson's Disease",0,"Istradefylline","Drug","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","20 Years","N/A","308","October 2009","September 2011","Adverse events","0","0","0","0","0","0","0","0","0"
"2413","NCT00957372","Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy","Partial Epilepsy",0,"eslicarbazepine acetate","Drug","Bial - Portela C S.A.","Industry",0,0,"All","18 Years","N/A","253","December 2004","June 2008","Seizure Frequency","0","0","0","0","0","0","0","0","0"
"2414","NCT00957996","Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza","Seasonal Influenza",0,"Peramivir","Drug","BioCryst Pharmaceuticals","Industry",0,0,"All","6 Years","N/A","234","October 2009","October 2010","Change From Baseline in Influenza Virus Titer (48 Hours)","0","0","0","0","0","0","0","0","0"
"2415","NCT00958009","The Multicenter, Open-label, Single-use Autoinjector Convenience Study","Multiple Sclerosis",0,"Rebidose®","Device","EMD Serono","Industry",0,0,"All","18 Years","65 Years","109","October 2009","April 2010","Proportion of Relapsing Multiple Sclerosis (RMS) Subjects Rating the Single-use Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial Questionnaire","0","0","0","0.86","mean positive response","95","2-Sided","0.80","0.93"
"2416","NCT00958165","Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic AF","Paroxysmal Atrial Fibrillation",0,"CardioFocus EAS-AC","Device","CardioFocus","Industry",0,0,"All","18 Years","70 Years","81","August 2009","March 2012","Chronic Effectiveness in Treating PAF as Demonstrated by no AF Recurrences After the Blanking Period and During the 12-month Follow-up Period.","0","0","0","0","0","0","0","0","0"
"2417","NCT00958308","Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection","Antibiotic-Associated Diarrhea",0,"BIO-K+ CL-1285®","Other","Bio-K Plus International Inc.","Industry",0,0,"All","50 Years","70 Years","255","December 2008","March 2009","To Assess if Probiotic Prophylaxis (BIO-K+CL1285®) is Effective for the Prevention of AAD in Hospitalized Patients.","=0.02","0","Fisher Exact","0","0","0","0","0","0"
"2418","NCT00958568","A Study in Relapse Prevention of Treatment-Resistant Depression","Treatment Resistant Depression",0,"Olanzapine and Fluoxetine combination (OFC)","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","65 Years","892","August 2009","March 2012","Time to Relapse by Any Criteria","<0.001","The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.","Log Rank","0","0","0","0","0","0"
"2419","NCT00958776","A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza","Cough",0,"Peramivir+SOC","Drug","BioCryst Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","405","November 2009","November 2012","Time to Clinical Resolution (Kaplan-Meier Estimate)","0.973","0","Wilcoxon-Gehan statistic","1.03","Hazard Ratio (HR)","95","2-Sided","0.69","1.55"
"2420","NCT00959049","A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","Influenza",0,"CSL's Influenza Virus Vaccine (Afluria)","Biological","Seqirus","Industry",0,0,"All","6 Months","17 Years","1474","September 2009","December 2009","Geometric Mean Titer 30 Days After the Last Study Vaccination","0","0","0","0","0","0","0","0","0"
"2421","NCT00959153","Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney","Kidney Stones",0,"LithoSpace Extracorporeal Shockwave Lithotripter","Device","Advance Shockwave Technology GmbH","Industry",0,0,"All","18 Years","N/A","20","June 2010","August 2011","stone fragmentation","0","0","0","0","0","0","0","0","0"
"2422","NCT00959218","Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis","Central Neuropathic Pain in Multiple Sclerosis",0,"Dronabinol","Drug","Bionorica Research GmbH","Industry",0,0,"All","18 Years","70 Years","240","June 2007","March 2010","Mean change of baseline pain severity score on the 11-point Likert Numerical Rating Scale recorded in patient diary","0","0","0","0","0","0","0","0","0"
"2423","NCT00959764","A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women","Osteoporosis, Postmenopausal",0,"Oral Calcitonin Tablets","Drug","Tarsa Therapeutics, Inc.","Industry",0,0,"Female","45 Years","N/A","565","June 2009","February 2011","Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar Spine","0.002","The P-value was not adjusted for multiple comparisons. The a priori threshold for statistical significance was <0.05","ANCOVA","0.77","Mean Difference (Net)","95","2-Sided","0.08","1.45"
"2424","NCT00960076","An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes","Type 2 Diabetes",0,"Saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","78 Years","282","August 2009","October 2010","Change in HbA1c Level From Baseline to Week 18 (LOCF)","0","0","0","-0.52","Mean Difference (Net)","95","2-Sided","-0.73","-0.31"
"2425","NCT00960440","Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors","Arthritis, Rheumatoid",0,"CP-690,550","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","399","October 2009","March 2011","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3","<0.0001","A step-down procedure was used to control for multiple comparisons. In order for the comparison to 5 mg to be statistically significant, the comparison to 10 mg had to be statistically significant.","Normal Approximation","23.69","Percentage Difference","95","2-Sided","12.45","34.92"
"2426","NCT00960661","A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","1036","September 2009","August 2012","Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30","0.6273","The primary mixed-model repeated measures (MMRM) model included baseline HbA1c as covariate, treatment, country, prior use of SUs, week of visit, and treatment-by-week interaction as fixed effects and patient and error as random effects.","Mixed model repeated measures","-0.04","Mean Difference (Final Values)","95","2-Sided","-0.18","0.11"
"2427","NCT00960804","Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients","Osteoarthritis",0,"Tanezumab","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","21","February 2010","November 2010","Change from baseline in the composite measure (5NC [nd] + HRdb [nd])","0","0","0","0","0","0","0","0","0"
"2428","NCT00960869","Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","Gastric Ulcer",0,"PA32540","Drug","POZEN","Industry",0,0,"All","55 Years","N/A","519","October 2009","February 2012","Number of Participants With Gastric Ulcer Confirmed by Endoscopy","0.005","0","Cochran-Mantel-Haenszel","2.7","proportions","95","2-Sided","1.1","5.5"
"2429","NCT00961051","Evaluation of an Investigational Multi-Purpose Solution (MPS)","Study Focus is Healthy Contact Lens Wearers",0,"Investigational MPS","Device","Abbott Medical Optics","Industry",0,0,"All","18 Years","N/A","270","February 2009","August 2009","Mean Lens Cleanliness as Measured by Light Reflectance","0","0","0","0","0","0","0","0","0"
"2430","NCT00961350","A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","Gastric Ulcer",0,"PA32540","Drug","POZEN","Industry",0,0,"All","55 Years","N/A","530","October 2009","February 2012","Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg","0.020","0","Cochran-Mantel-Haenszel","3.8","Proportions","95","0","1.8","6.8"
"2431","NCT00961636","A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)","Dyslipidemia",0,"ER niacin (+) laropiprant (ERN/LRPT)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","75 Years","1152","October 2009","January 2011","Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period","<0.001","The closed ordered testing procedure was applied to the efficacy hypotheses. If statistical significance was achieved for the primary hypothesis, then the secondary hypothesis was tested. All tests were performed at significance level 0.05.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"2432","NCT00961675","FST-201 in the Treatment of Acute Otitis Externa","Acute Otitis Externa",0,"FST201 (dexamethasone 0.1% with povidone-iodine 1%)","Drug","Shire","Industry",0,0,"Male","18 Years","75 Years","70","August 2009","June 2010","Overall clinical cure as defined by absence of the signs and symptoms of AOE including ear inflammation, edema, tenderness and otic discharge.","0","0","0","0","0","0","0","0","0"
"2433","NCT00961714","OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture","Vertebral Compression Fractures",0,"OsseoFix Spinal Fracture Reduction System","Device","Alphatec Spine, Inc.","Industry",0,0,"All","50 Years","N/A","15","August 2009","December 2012","Reduction of back pain at 12-m f/u by ≥ 20mm from baseline measured by VAS","0","0","0","0","0","0","0","0","0"
"2434","NCT00962104","Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder","Attention Deficit Hyperactivity Disorder",0,"Atomoxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","391","August 2009","February 2011","Change From Baseline in the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) 18-Item Total Attention-Deficit/Hyperactivity Disorder (ADHD) Symptom Score up to 10 Weeks","<0.001","Statistical significance was assessed using an analysis of covariance (ANCOVA) with term for treatment, country, and baseline CAARS-Inv:SV 18-Item Total ADHD Symptom score .","ANCOVA","-5.78","Least Squares Mean Difference","95","2-Sided","-7.66","-3.91"
"2435","NCT00962741","Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis","Arthritis, Juvenile Idiopathic",0,"Etanercept","Drug","Pfizer","Industry",0,0,"All","2 Years","17 Years","127","September 2009","June 2011","Percentage of Participants With an American College of Rheumatology Pediatric 30 (ACR Pedi 30) Response at Week 12","0","0","0","0","0","0","0","0","0"
"2436","NCT00963235","Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS","HIV Infections",0,"13-valent pneumococcal conjugate vaccine","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","331","November 2009","May 2012","Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC","0","0","0","0","0","0","0","0","0"
"2437","NCT00963443","Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold","Common Cold",0,"Acetylsalicylic Acid (Aspirin, BAYE4465)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","833","September 2009","March 2012","Reduction of nasal congestion and relief of pain","0","0","0","0","0","0","0","0","0"
"2438","NCT00963508","Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice","Pediculosis",0,"Malathion gel 0.5%","Drug","Taro Pharmaceuticals USA","Industry",0,0,"All","2 Years","N/A","403","August 2009","March 2010","Proportion of Index Subjects Free of Any Lice 14 Days After Their Last Treatment in the Modified ITT (LOCF)","<0.0001","0","t-test, 2 sided","0","0","0","0","0","0"
"2439","NCT00963937","Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents","Migraine Disorders",0,"Sumatriptan 25 mg","Drug","GlaxoSmithKline","Industry",0,0,"All","10 Years","17 Years","178","September 2009","December 2010","Percentage of Participants Who Reported Pain Relief at 120 Minutes Post-Treatment","0.345","Multiplicity was not considered because the primary analysis included a single statistical comparison.","Chi-squared","-7.49","Percent Difference","95","2-Sided","-23.02","8.04"
"2440","NCT00964860","A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing","Gingivitis",0,"Glide dental floss","Device","Procter and Gamble","Industry",0,0,"All","18 Years","N/A","60","August 2009","August 2009","Mean Interproximal Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group","0.001","a priori threshold for statistical significance = 0.05","ANCOVA","0.24","Mean Difference (Final Values)","95","1-Sided","0","0"
"2441","NCT00965484","Genotropin Study Assessing Use of Injection Pen","Growth Hormone Deficiency",0,"New Genotropin Pen","Device","Pfizer","Industry",0,0,"All","8 Years","18 Years","136","October 2009","January 2010","Percentage of Dyads (Participant and Caregiver or Parent) Reporting no Difference or Easier to Use for New Genotropin Mark VII Injection Pen Compared to Pre-study Experience With the Genotropin Pen®","0","0","0","0","0","0","0","0","0"
"2442","NCT00966004","A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder","Urinary Bladder, Overactive",0,"YM178","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","1139","July 2009","February 2010","Change from baseline in the mean number of micturitions per 24 hours","0","0","0","0","0","0","0","0","0"
"2443","NCT00966212","Parent Education for Young Teen Females","Prevention",0,"parent education","Behavioral","Education Development Center, Inc.","Industry",0,0,"All","12 Years","N/A","500","September 2003","September 2009","positive parenting practices","0","0","0","0","0","0","0","0","0"
"2444","NCT00966628","Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)","Dengue Shock Syndrome",0,"Hypertonic sodium lactate","Drug","Innogene Kalbiotech Pte. Ltd","Industry",0,0,"All","2 Years","14 Years","50","May 2008","April 2009","To assess the effect of solution containing half molar sodium lactate (Totilac™) infusion on the plasma sVCAM-1 level","0","0","0","0","0","0","0","0","0"
"2445","NCT00966953","Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.","Gingival Diseases",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","65 Years","25","October 2007","January 2008","Plaque Index","0.05","0","ANOVA","0","0","0","0","0","0"
"2446","NCT00967018","A Long Term Safety Study of Degarelix in Patients With Prostate Cancer","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","77","August 2009","November 2011","Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables","0","0","0","0","0","0","0","0","0"
"2447","NCT00967317","Phase III Open Study, Prospective, Multicenter, Randomized, Comparative to the Positive Control for Evaluating the Efficacy and Safety of Auris-Sedina in the Symptomatic Control of Otalgy in Patients With or Without Acute External Otitis.","Otitis",0,"Auris-Sedina","Drug","Laboratorios Osorio de Moraes Ltda.","Industry",0,0,"All","6 Years","N/A","188","December 2009","March 2010","Visual Analogic Scale, by clinical examination and opinion of the investigator.","0","0","0","0","0","0","0","0","0"
"2448","NCT00967343","Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor","Myeloid Leukemia",0,"Donor lymphocyte preparation depleted of host functional alloreactive T-cells","Biological","Kiadis Pharma","Industry",0,0,"All","18 Years","65 Years","40","August 2009","February 2012","Transplant related mortality","0","0","0","0","0","0","0","0","0"
"2449","NCT00967681","Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic Disease","Breast Fibrocystic Disease",0,"Oncoxin","Dietary Supplement","Catalysis SL","Industry",0,0,"Female","20 Years","N/A","200","September 2009","April 2011","The ultrasonographic improvement at 24 weeks (end of the treatment)","0","0","0","0","0","0","0","0","0"
"2450","NCT00968812","CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride","Diabetes Mellitus, Type 2",0,"Glimepiride","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","80 Years","1452","September 2009","December 2011","Change in HbA1c From Baseline to Week 52","0","0","0","-0.01","Least-Squares Mean Difference","95","2-Sided","-0.109","0.085"
"2451","NCT00969150","Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","Major Depressive Disorder",0,"Levomilnacipran ER","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","80 Years","362","September 2009","November 2010","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","0.2492","0","Mixed Models Analysis","-1.49","Least squares mean difference","95","2-Sided","-4.02","1.05"
"2452","NCT00969254","Study to Assess the Efficacy and Safety of ""Pílulas de Lussen®"" Compared to the Pyridium® in the Symptomatic Control of Dysuria","Dysuria",0,"Pílulas de Lussen","Drug","Laboratorios Osorio de Moraes Ltda.","Industry",0,0,"All","18 Years","N/A","80","December 2009","February 2010","Visual Analogic Scale and opinion of the investigator.","0","0","0","0","0","0","0","0","0"
"2453","NCT00969527","Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Oncoxin + Viusid","Dietary Supplement","Catalysis SL","Industry",0,0,"All","18 Years","N/A","86","September 2009","March 2011","Disease Activity Score (DAS 28 score) at week 12.","0","0","0","0","0","0","0","0","0"
"2454","NCT00969618","A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder","Attention Deficit Hyperactivity Disorder",0,"Atomoxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","211","November 2009","January 2012","Number of Participants With Adverse Events Leading to Discontinuation","0","0","0","0","0","0","0","0","0"
"2455","NCT00969709","Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","Major Depressive Disorder",0,"Levomilnacipran ER","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","65 Years","724","September 2009","May 2011","Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","0.0186","0","Mixed Models Analysis","-3.23","Least squares mean difference","95","2-Sided","-5.92","-0.54"
"2456","NCT00970268","Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)","Chronic Obstructive Pulmonary Disease",0,"Aclidinium bromide","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","291","August 2009","October 2010","Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)","0","0","0","0","0","0","0","0","0"
"2457","NCT00970281","A Study of Olanzapine in Patients With Schizophrenia","Schizophrenia",0,"Rapid-Acting Intramuscular Olanzapine","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","64 Years","91","September 2009","April 2011","Change From Baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection","<0.001","The p-value was based on an analysis of variance (ANOVA) model that included treatment and site as a factor.","ANOVA","0","0","0","0","0","0"
"2458","NCT00970424","Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone","Diabetes Mellitus, Type II",0,"Placebo","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","85 Years","252","August 2009","August 2010","Hemoglobin A1c Level (HbA1c)","0","0","0","0","0","0","0","0","0"
"2459","NCT00970632","A Study of Tadalafil in Men With Benign Prostatic Hyperplasia","Benign Prostatic Hyperplasia (BPH)",0,"Tadalafil 5 mg","Drug","Eli Lilly and Company","Industry",0,0,"Male","45 Years","N/A","511","October 2009","January 2011","Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks","0.001","The p-value associated with LS Mean difference of changes from baseline to Week 12 endpoint between tadalafil and placebo treatment groups was for the primary comparison and assessed for significance at a level of 0.05.","ANCOVA","-2.1","Difference in LS Means","0","0","0","0"
"2460","NCT00970658","Efficacy and Safety of Salonsip Compared to Sabiá Plaster","Contusions",0,"Salonsip plaster","Drug","Hisamitsu Farmaceutica do Brasil Ltda","Industry",0,0,"All","12 Years","N/A","70","December 2009","January 2010","Likert Scales and Visual Analogue Scales","0","0","0","0","0","0","0","0","0"
"2461","NCT00972270","Trial Using Impella LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability","Acute Myocardial Infarction",0,"Impella LP 2.5","Device","Abiomed Inc.","Industry",0,0,"All","18 Years","90 Years","1","July 2008","August 2010","Composite rate of major adverse events within 30 days or hospital discharge.","0","0","0","0","0","0","0","0","0"
"2462","NCT00972283","Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","1006","September 1, 2009","October 28, 2010","Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"2463","NCT00972777","Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis","Bacterial Conjunctivitis",0,"Besifloxacin","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","1 Year","N/A","474","October 2009","October 2010","Clinical Resolution","0","0","0","0","0","0","0","0","0"
"2464","NCT00972816","Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)","Influenza",0,"MF59-eH1N1","Biological","Novartis Vaccines","Industry",0,0,"All","3 Years","8 Years","1357","September 2009","November 2009","Antibody Responses According to the Hemagglutinin Inhibition (HI) Assay After the First and Second Vaccinations","0","0","0","0","0","0","0","0","0"
"2465","NCT00973115","Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia","Hyperlipidemia",0,"Simvastatin CR","Drug","Hanmi Pharmaceutical Company Limited","Industry",0,0,"All","19 Years","75 Years","132","November 2007","August 2009","the percent change from baseline in LDL cholesterol","0","0","0","0","0","0","0","0","0"
"2466","NCT00973271","Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides","Hypertriglyceridemia",0,"290 mg DCCR","Drug","Essentialis, Inc.","Industry",0,0,"All","18 Years","N/A","0","March 2011","November 2011","The effect of DCCR on triglycerides in subjects without diabetes mellitus who have very high triglycerides over a period of 84 days","0","0","0","0","0","0","0","0","0"
"2467","NCT00973349","Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults","Influenza",0,"MF59-eH1N1_f","Biological","Novartis","Industry",0,0,"All","18 Years","N/A","2719","September 2009","November 2009","Immunogenicity Results After Each Vaccination by Vaccine Group, in Participants 18 to 64 Years of Age","0","0","0","0","0","0","0","0","0"
"2468","NCT00973479","An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy","Arthritis, Rheumatoid",0,"Golimumab","Drug","Centocor, Inc.","Industry",0,0,"All","18 Years","N/A","592","September 2009","March 2011","Proportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"2469","NCT00973817","Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis","Acute On Chronic Hepatitis",0,"ELAD plus standard of care treatment","Biological","Vital Therapies, Inc.","Industry",0,0,"All","18 Years","67 Years","62","September 2009","April 2011","Time to progression at which a 5-point or greater Model for End stage Liver Disease (MELD) score is recorded relative to baseline","0","0","0","0","0","0","0","0","0"
"2470","NCT00974090","Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","75 Years","194","September 2009","March 2011","Change From Baseline in HbA1c at Week 12","0","0","0","0","0","0","0","0","0"
"2471","NCT00974311","Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy","Castration-Resistant Prostate Cancer",0,"Enzalutamide","Drug","Medivation, Inc.","Industry",0,0,"Male","18 Years","N/A","1199","September 2009","November 2011","Overall Survival","<0.0001","0","Log Rank","0.63","Hazard Ratio (HR)","95","2-Sided","0.53","0.75"
"2472","NCT00974428","Multi-Center Study Evaluating the Efficacy of Wobenzym(R)N in Treating Knee Osteoarthritis","Knee Osteoarthritis",0,"Wobenzym® N","Dietary Supplement","Atrium Innovations","Industry",0,0,"All","45 Years","80 Years","0","October 2009","March 2010","Determination of the most effective dose of Wobenzym® N on the reduction of pain severity, measured by the WOMAC Osteoarthritis Index.","0","0","0","0","0","0","0","0","0"
"2473","NCT00974974","A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).","Parkinson's Disease",0,"IPX066","Drug","IMPAX Laboratories, Inc.","Industry",0,0,"All","30 Years","N/A","471","September 2009","January 2011","Percentage of ""Off"" Time During Waking Hours at End of Study","<.0001","0","ANCOVA","0","0","0","0","0","0"
"2474","NCT00975117","Spermotrend in the Treatment of Male Infertility","Male Infertility",0,"Placebo","Dietary Supplement","Catalysis SL","Industry",0,0,"Male","19 Years","60 Years","86","September 2009","March 2011","Parameters of seminal analysis at weeks 24","0","0","0","0","0","0","0","0","0"
"2475","NCT00975130","Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)","Arthritis, Rheumatoid",0,"SC golimumab","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","3366","September 2009","August 2011","Number of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Month 6","0","0","0","0","0","0","0","0","0"
"2476","NCT00975143","Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne","Severe Nodular Acne",0,"CIP-Isotretinoin","Drug","Cipher Pharmaceuticals Inc.","Industry",0,0,"All","12 Years","54 Years","925","September 2009","May 2011","Co-primary Outcome 1: Change From Baseline in Total Nodular Lesion Count (Facial and Truncal)","0.5077","P values are from analysis of covariance (ANCOVA) controlling for Baseline total nodular lesion count, gender and analysis site.","ANCOVA","0.1382","LS Mean Difference","95","2-Sided","-0.2712","0.5475"
"2477","NCT00975221","Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy","Hyperparathyroidism, Primary",0,"Cinacalcet","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","67","March 2010","December 2012","Percentage of Participants With Mean Corrected Total Serum Calcium Concentration ≤ 10.3 mg/dL (2.57 mmol/L) During the EAP","<0.001","0","Cochran-Mantel-Haenszel","39.866","Cochran-Mantel-Haenszel (CMH) statistic","0","0","0","0"
"2478","NCT00975286","24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","Type 2 Diabetes Mellitus",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","446","October 2009","August 2011","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","<0.0001","Statistical testing: 2-sided at significance level=0.05. Analysis of covariance (ANCOVA) included treatment arms; randomization strata of Week -1 HbA1c (<8.0,>=8.0%) and TZD use (yes/no); country as fixed effects; baseline HbA1c as covariate.","ANCOVA","-0.32","[Least squares (LS) mean difference","95","2-Sided","-0.463","-0.171"
"2479","NCT00975715","Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures","Partial Onset Seizures",0,"TRI476","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","4 Years","14 Years","99","September 2009","October 2012","Percent Change in Partial Onset Seizure Frequency Per 28 Days From Baseline to the Double-blind Phase, by Treatment Group","0","0","0","0","0","0","0","0","0"
"2480","NCT00976027","Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older","Influenza",0,"Trivalent inactivated influenza vaccine High Dose","Biological","Sanofi","Industry",0,0,"All","65 Years","N/A","9172","September 2009","May 2011","Efficacy of Fluzone High Dose Relative to Fluzone in the Prevention of Laboratory Confirmed Influenza Caused by Viral Types and Subtypes That Are Antigenically Similar to Those Contained in the Respective Annual Vaccine Formulations.","0","0","0","0","0","0","0","0","0"
"2481","NCT00976209","Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)","Vasomotor Rhinitis",0,"Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","331","August 2009","November 2009","Percentage of Participants That Preferred Phenylephrine HCl 30 mg Extended Release Tablets, as Compared to Phenylephrine HCl 10 mg Immediate Release Tablets for the Relief of Nasal Congestion","0","0","0","0","0","0","0","0","0"
"2482","NCT00976391","A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine","Diabetes Mellitus, Type 2",0,"albiglutide + insulin glargine","Biological","GlaxoSmithKline","Industry",0,0,"All","18 Years","75 Years","586","September 2009","October 2011","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26","<0.0001","0","t-test, 1 sided","-0.16","Mean Difference (Net)","95","2-Sided","-0.32","0.00"
"2483","NCT00976716","An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain","Pain",0,"Celecoxib","Drug","Pfizer","Industry",0,0,"All","20 Years","N/A","80","September 2009","November 2009","Patient Impressions at Final Visit (the Number of Participants Who Have Rated ""Excellent"" and ""Good"")","0","0","0","0","0","0","0","0","0"
"2484","NCT00976937","24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years","Type 2 Diabetes Mellitus",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","49 Years","319","August 2009","March 2011","Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24","0.1696","Cochran-Mantel-Haenszel (CMH) test stratified by randomization strata of screening HbA1c (<8.0 or >=8.0%) and randomization strata of screening BMI (<35 or >=35 kg/m^2) was used.","Cochran-Mantel-Haenszel","4.6","Response rate difference","95","2-Sided","-1.84","11.00"
"2485","NCT00977444","Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment","Osteoarthritis",0,"kondrium","Drug","Nucitec","Industry",0,0,"All","40 Years","N/A","114","November 2007","February 2009","The primary efficacy variable is the change from baseline to final assessment in the Western Ontario and McMastern University OA index (WOMAC), and Lequesne´s functional index.","0","0","0","0","0","0","0","0","0"
"2486","NCT00977925","The Severe Soft Tissue Bleeding Study","Soft Tissue Bleeding",0,"Fibrin Pad","Biological","Ethicon, Inc.","Industry",0,0,"All","18 Years","N/A","91","August 2009","January 2011","Proportion of subjects achieving hemostasis at the Target Bleeding Site. Hemostasis is defined as no detectable bleeding at the TBS.","0","0","0","0","0","0","0","0","0"
"2487","NCT00977964","Tolerance of Healthy Term Infants Fed Infant Formulas #3","Gastrointestinal Tolerance",0,"Experimental milk protein infant formula Process A","Other","Abbott Nutrition","Industry",0,0,"All","N/A","8 Days","270","September 2009","January 2010","The primary variable is Gastrointestinal tolerance.","0","0","0","0","0","0","0","0","0"
"2488","NCT00978224","Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment","Chronic Inflammatory Syndrome",0,"Viusid","Dietary Supplement","Catalysis SL","Industry",0,0,"All","18 Years","75 Years","152","October 2009","September 2011","Body mass index (BMI) at week 72 (end of the treatment)","0","0","0","0","0","0","0","0","0"
"2489","NCT00978627","Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","548","August 2009","May 2010","Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"2490","NCT00978705","Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood","Burn Wound",0,"Autologous cultured keratinocyte cell","Drug","Modern Cell and Tissue Technology","Industry",0,0,"All","1 Year","70 Years","19","November 2007","May 2008","engraftment assessment","0","0","0","0","0","0","0","0","0"
"2491","NCT00978861","Clinical Study to Evaluate of The Whitening Efficacy and Safety of REMEWHITE","Tooth Whitening",0,"Hydrogen Peroxide","Drug","JDC Tech","Industry",0,0,"All","20 Years","N/A","70","October 2008","June 2009","colorimeter","0","0","0","0","0","0","0","0","0"
"2492","NCT00978887","Retorna Facial Cream in the Treatment of Facial Wrinkles","Facial Wrinkles",0,"Retorna","Other","Catalysis SL","Industry",0,0,"Female","20 Years","60 Years","148","October 2009","May 2010","Total correction or improvement of facial wrinkles at the end of treatment (4 weeks)","0","0","0","0","0","0","0","0","0"
"2493","NCT00979745","Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)","Erythropoietic Protoporphyria",0,"Afamelanotide","Drug","Clinuvel Pharmaceuticals Limited","Industry",0,0,"All","18 Years","70 Years","70","September 2009","May 2011","Severity of phototoxic reaction measured by visual analogue scale","0","0","0","0","0","0","0","0","0"
"2494","NCT00980174","Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis","Low Bone Mass",0,"60 mg denosumab","Drug","Amgen","Industry",0,0,"Male","30 Years","85 Years","242","October 2009","July 2011","Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12","<0.0001","0","ANCOVA","4.8","Mean Difference (Net)","95","2-Sided","4.0","5.6"
"2495","NCT00980681","Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)","Renal Disease",0,"Dotarem","Drug","Guerbet","Industry",0,0,"All","18 Years","N/A","13","September 2009","December 2010","Percent of Non Assessable Renal Artery Segments","0","0","0","0","0","0","0","0","0"
"2496","NCT00980798","Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee","Pain",0,"OROS hydromorphone HCl","Drug","Janssen-Cilag International NV","Industry",0,0,"All","40 Years","N/A","288","October 2007","November 2008","Analgesic Effect as Assessed by Brief Pain Inventory (BPI) Item 5 Score (Pain on Average)","0.1212","No adjustment for multiple comparisons necessary, as only 1 primary hypothesis was tested. Threshold for statistical significance was 0.05.","Mixed-model regression analysis","-0.2365","Mean Difference (Net)","95","2-Sided","-0.5357","0.0627"
"2497","NCT00981045","Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function","Iron Deficiency Anemia",0,"Ferric Carboxymaltose (FCM)","Drug","Luitpold Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","2561","August 2009","July 2011","Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.","0","0","0","0","0","0","0","0","0"
"2498","NCT00981409","The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","Embolism, Pulmonary",0,"Fondaparinux sodium","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","N/A","41","July 2007","December 2008","The Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE)","0","0","0","0","0","0","0","0","0"
"2499","NCT00982007","Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)","Iron Deficiency Anemia",0,"Ferric Carboxymaltose (FCM)","Drug","Luitpold Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","997","September 2009","March 2011","Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.","0","0","0","0","0","0","0","0","0"
"2500","NCT00982111","First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin","Non Small Cell Lung Cancer",0,"Pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","633","November 2009","November 2012","Overall Survival Time (OS)","0.9561","0","Log Rank","1.01","Hazard Ratio (HR)","95","2-Sided","0.84","1.21"
"2501","NCT00982228","Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","629","September 1, 2009","November 8, 2010","Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"2502","NCT00982280","Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.","Chronic Pain",0,"Tapentadol PR","Drug","Grünenthal GmbH","Industry",0,0,"All","40 Years","N/A","82","September 2009","May 2010","Responder Rate","0","0","0","0","0","0","0","0","0"
"2503","NCT00982644","Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","1030","September 2009","December 2010","Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"2504","NCT00983073","Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic","Chronic Pain",0,"Tapentadol","Drug","Grünenthal GmbH","Industry",0,0,"All","40 Years","N/A","224","September 2009","June 2010","The Primary Endpoint is Defined as the Change From Week -1 of the Average Pain Intensity Score on an 11-point NRS-3 at Week 6.","0","0","0","0","0","0","0","0","0"
"2505","NCT00983151","Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation","Premature Ejaculation",0,"Tramadol Hydrochloride & Placebo","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"Male","18 Years","65 Years","1050","August 2009","September 2010","Increase in IELT (Intravaginal ejaculatory time)","0","0","0","0","0","0","0","0","0"
"2506","NCT00983385","Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics","Chronic Pain",0,"Tapentadol PR","Drug","Grünenthal GmbH","Industry",0,0,"All","18 Years","N/A","208","September 2009","May 2010","The Primary Endpoint is Defined as the Change of the Average Pain Intensity Score on an 11-point NRS-3 at Week 6 From Week -1 (Baseline).","0","0","0","0","0","0","0","0","0"
"2507","NCT00983736","Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation","Premature Ejaculation",0,"Tramadol Hydrochloride","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"Male","18 Years","65 Years","1050","October 2009","September 2010","Increase in IELT (Intravaginal ejaculatory time)","0","0","0","0","0","0","0","0","0"
"2508","NCT00984204","Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)","Typical Atrial Flutter",0,"Therapy Cool Path Duo","Device","St. Jude Medical","Industry",0,0,"All","18 Years","N/A","188","October 2009","August 2010","Primary Safety- Incidence of Intra Procedural Serious Cardiac Adverse Events Occuring Within 7 Days of Post-procedure, Regardless of Whether a Determination Can be Made Regarding Device Relatedness.","0","0","0","0","0","0","0","0","0"
"2509","NCT00984282","Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","Thyroid Neoplasms",0,"Sorafenib (Nexavar, BAY43-9006)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","417","October 2009","August 2012","Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation","<0.0001","stratified by age group (< 60 years, >= 60 years) and region (Europe, North-America, Asia)","Log Rank","0","0","0","0","0","0"
"2510","NCT00984568","Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)","Colitis, Ulcerative",0,"Infliximab","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","28","November 2009","March 2012","Number of Participants With Response at Week 4 and Steroid-Free Remission at Week 50","0","0","0","0","0","0","0","0","0"
"2511","NCT00984594","Evaluation of a Composite Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Knee Osteochondral Defects","Knee Injury",0,"Primary injury site","Other","RTI Surgical","Industry",0,0,"All","18 Years","55 Years","4","January 2009","February 2012","Knee Injury and Osteoarthritis Outcome Score (KOOS","0","0","0","0","0","0","0","0","0"
"2512","NCT00984789","Birth Control Patch Study","Contraception",0,"Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)","Drug","Bayer","Industry",0,0,"Female","18 Years","35 Years","393","May 2009","September 2010","Bleeding Patterns and cycle control","0","0","0","0","0","0","0","0","0"
"2513","NCT00984815","Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment","Osteoarthritis",0,"HZT-501","Drug","Horizon Pharma Ireland, Ltd., Dublin Ireland","Industry",0,0,"All","40 Years","80 Years","86","September 2009","July 2011","Number of Participants With Treatment Emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"2514","NCT00985426","Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in Chronic Kidney Disease (CKD) Patients","Chronic Kidney Disease",0,"HEPLISAV and Placebo","Biological","Dynavax Technologies Corporation","Industry",0,0,"All","18 Years","75 Years","521","September 2009","January 2012","Proportion of subjects who have a seroprotective immune response (anti-HBsAg antibody≥ 10 milli-international unit (mlU)/mL) at week 28.","0","0","0","0","0","0","0","0","0"
"2515","NCT00985621","Tanezumab In Osteoarthritis Of The Hip Or Knee","Osteoarthritis",0,"tanezumab 10 mg","Biological","Pfizer","Industry",0,0,"All","18 Years","75 Years","600","October 2009","December 2010","WOMAC pain","0","0","0","0","0","0","0","0","0"
"2516","NCT00985985","Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation","Smoking",0,"Nicotine","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","723","May 2009","March 2011","Rate of Successful Smoking Cessation at Week 6","0.3851","0","Cochran-Mantel-Haenszel","1.22","Odds Ratio (OR)","95","2-Sided","0.78","1.92"
"2517","NCT00986180","NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain","Pain",0,"NUCYNTA","Drug","Ortho-McNeil Janssen Scientific Affairs, LLC","Industry",0,0,"All","18 Years","N/A","667","September 2009","December 2010","Sum of Pain Intensity Difference (SPID) for Low Back Pain - Summary Statistics at 120 Hours (With Imputation)","0.9703","0","ANCOVA","-0.6","Mean Difference (Final Values)","95","2-Sided","-32.1","30.9"
"2518","NCT00986258","Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability","Pain",0,"Tapentadol Prolonged Release","Drug","Grünenthal GmbH","Industry",0,0,"All","18 Years","N/A","136","October 2009","December 2010","Number of Participants That Responded to Treatment","0","0","0","0","0","0","0","0","0"
"2519","NCT00986323","Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma","Asthma",0,"Temperature controlled Laminar Airflow (TLA)","Device","Airsonett AB","Industry",0,0,"All","7 Years","70 Years","312","April 2008","February 2010","miniAQLQ (Mini Asthma Quality of Life Questionnaire, Appendix 1) and the corresponding paediatric PAQLQ score.","0","0","0","0","0","0","0","0","0"
"2520","NCT00986570","Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face","Skin Aging",0,"Botulinum Toxin A","Biological","Biolab Sanus Farmaceutica","Industry",0,0,"Female","30 Years","50 Years","121","September 2009","June 2010","Treatment Success","0","0","0","0","0","0","0","0","0"
"2521","NCT00987246","Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis","Actinic Keratosis",0,"Placebo Gel","Drug","Almirall, S.A.","Industry",0,0,"All","18 Years","85 Years","470","June 2008","June 2009","Histological status of AK target lesion","0","0","0","0","0","0","0","0","0"
"2522","NCT00987272","Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects","Allergic Conjunctivitis",0,"Olopatadine Hydrochloride Ophthalmic Solution, 0.2%","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","267","October 2009","November 2009","Mean Ocular Itching Score","0","0","0","0","0","0","0","0","0"
"2523","NCT00988091","Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee","Osteoarthritis of the Knee",0,"1.2% Sodium Hyaluronate","Device","Ferring Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","596","September 2009","October 2010","Change From Baseline in the Visual Analogue Score (VAS) Pain Score of the 50-foot Walk Test at Week 26","0.034","The p-value was not adjusted for multiple comparisons because there was a single treatment comparison for the primary endpoint. The a priori threshold for statistical significance was p <0.05.","Mixed Models Repeated Measures ANCOVA","5.33","Adjusted mean difference","95","2-Sided","0.41","10.24"
"2524","NCT00988156","Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children","Partial Epilepsy in Children and Adolescents",0,"Eslicarbazepine acetate (BIA 2-093)","Drug","Bial - Portela C S.A.","Industry",0,0,"All","2 Years","16 Years","304","December 2007","August 2012","Change From Baseline in Seizure Frequency","0.2490","0","ANCOVA","0","0","0","0","0","0"
"2525","NCT00988208","Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer","Prostate Cancer",0,"Lenalidomide","Drug","Celgene","Industry",0,0,"Male","18 Years","N/A","1059","November 11, 2009","January 13, 2012","Overall Survival (OS)","0.0017","p-value is based on unstratified log-rank test","Log Rank","1.53","Hazard Ratio (HR)","95","2-Sided","1.17","2.00"
"2526","NCT00988247","Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis","Rhinitis, Allergic, Perennial",0,"Beclomethasone dipropionate","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","N/A","529","October 2009","February 2011","Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 30 Weeks","<0.001","0","ANCOVA","-0.97","LS mean treatment diff from placebo]","95","2-Sided","-1.5","-0.5"
"2527","NCT00988429","Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures","Partial Epilepsy",0,"800 mg QD Eslicarbazepine acetate","Drug","Bial - Portela C S.A.","Industry",0,0,"All","16 Years","N/A","653","December 2008","January 2012","Seizure Frequency Over the 12-week Maintenance Period.","0.058","0","ANCOVA","0","0","0","0","0","0"
"2528","NCT00988884","A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)","Human Papillomavirus Infection",0,"V503","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","11 Years","15 Years","1241","October 1, 2009","February 22, 2011","Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503","<0.001","0","ANOVA","0.97","Fold difference in GMT","95","2-Sided","0.88","1.08"
"2529","NCT00989001","A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)","Atrial Fibrillation",0,"Vernakalant","Drug","Cardiome Pharma","Industry",0,0,"All","18 Years","85 Years","217","October 2009","November 2010","Number of Participants who Experience Hypotension, Ventricular Arrhythmias and/or Death","0","0","0","0","0","0","0","0","0"
"2530","NCT00989235","Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","108","April 2007","October 2009","Time to Disease Relapse Through Month 12 (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse)","0","0","0","0","0","0","0","0","0"
"2531","NCT00989313","A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study","Actinic Keratosis",0,"Lesion count","Drug","Peplin","Industry",0,0,"All","18 Years","N/A","43","September 2009","October 2010","Summarize treatment area recurrence of AK lesions, in the selected treatment area during a 12 month follow-up period for patients with complete clearance, who have completed Day 57 in Study PEP005-028.","0","0","0","0","0","0","0","0","0"
"2532","NCT00989573","A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease","Crohn's Disease",0,"Placebo","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","18 Years","64 Years","191","October 2009","August 2012","Clinical improvement rate (number of subjects showing clinical improvement / number of subjects evaluated x 100)","0","0","0","0","0","0","0","0","0"
"2533","NCT00990327","Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI","Coronary Artery Disease",0,"Apadenoson SPECT-MPI","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","863","November 2009","April 2012","Presence of myocardial perfusion defect as based on SPECT-MPI","0","0","0","0","0","0","0","0","0"
"2534","NCT00990847","Nebulized Procaterol Versus Nebule Salbutamol for the Treatment of Moderate Acute Asthma","Moderate Acute Asthma",0,"Procaterol, Salbultamol","Drug","PT Otsuka Indonesia","Industry",0,0,"All","15 Years","60 Years","140","June 2007","April 2008","Difference 5% from baseline in peak expiratory flow rate (PEFR)","0","0","0","0","0","0","0","0","0"
"2535","NCT00991276","Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance","Restless Legs Syndrome",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","85","December 2009","June 2011","Wake After Sleep Onset (WASO)","<0.0001","This analysis was step 1 in a step-down procedure (if p-value < 0.05, then continue to next step) used to control the Type I error rate.","Mixed Models Analysis","-27.10","LS Mean Difference","95","2-Sided","-35.78","-18.42"
"2536","NCT00991367","CICATRIX in the Treatment of Recent Post-surgical Scars","Post-surgical Scars",0,"Cicatrix","Other","Catalysis SL","Industry",0,0,"All","18 Years","55 Years","90","October 2009","December 2010","Length of the post-surgical scar(s) measured by a millimetric ruler at week 4 (end of the treatment)","0","0","0","0","0","0","0","0","0"
"2537","NCT00992459","Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders","Urea Cycle Disorders",0,"HPN-100","Drug","Horizon Pharma Ireland, Ltd., Dublin Ireland","Industry",0,0,"All","18 Years","N/A","46","October 2009","September 2010","The Primary Endpoint Was the 24-hour Area Under the Curve for Blood Ammonia (NH324-hour AUC) on Days 14 and 28.","0","0","0","0","0","0","0","0","0"
"2538","NCT00992589","Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)","Gastroesophageal Reflux",0,"Rabeprazole sodium 5 mg","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","1 Month","11 Months","344","November 2009","November 2011","Change From Baseline in Average Daily Frequency of Regurgitation (Double-blind Phase/ Baseline Observation Carried Forward)","0.168","0","ANCOVA","-0.449","Least-Squares Mean Difference","95","2-Sided","-1.087","0.190"
"2539","NCT00993005","CICATRIX in the Treatment of Hypertrophic Scars and Keloids Scars","Hypertrophic Scars",0,"Cicatrix","Other","Catalysis SL","Industry",0,0,"All","18 Years","55 Years","90","October 2009","December 2010","Length of the hypertrophic scar(s) and keloids measured by a millimetric ruler at week 12 (end of the treatment)","0","0","0","0","0","0","0","0","0"
"2540","NCT00993317","A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Placebo of CDP870","Drug","Korea Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","18 Years","75 Years","127","October 2009","August 2011","ACR20 Responses at Week 24","0","0","0","0","0","0","0","0","0"
"2541","NCT00993473","6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes","Type 1 Diabetes Mellitus",0,"Insulin glargine (HOE901)","Drug","Sanofi","Industry",0,0,"All","1 Year","6 Years","125","October 2009","March 2011","Event Rate of ""All Hypoglycemia"" Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)","0","0","0","1.18","Risk Ratio (RR)","95","2-Sided","0.97","1.44"
"2542","NCT00993681","Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study","Travelers' Diarrhea",0,"TD Vaccine System","Biological","Intercell USA, Inc.","Industry",0,0,"All","18 Years","64 Years","2036","October 2009","November 2010","Incidence of cases with vaccine preventable outcome","0","0","0","0","0","0","0","0","0"
"2543","NCT00993967","Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)","Freidreich's Ataxia",0,"idebenone","Drug","Santhera Pharmaceuticals","Industry",0,0,"All","9 Years","N/A","204","June 2007","June 2012","Measures of safety and tolerability: nature and frequency of adverse events (AEs)","0","0","0","0","0","0","0","0","0"
"2544","NCT00994266","Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy","Type 2 Diabetes",0,"Diamel","Dietary Supplement","Catalysis SL","Industry",0,0,"All","40 Years","65 Years","116","October 2009","April 2011","Difference of insulin daily doses at week 24 and at the beginning of the study","0","0","0","0","0","0","0","0","0"
"2545","NCT00995410","Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers","Aspirin-Associated Gastric Ulcers",0,"PA32540","Drug","POZEN","Industry",0,0,"All","55 Years","N/A","380","October 2009","May 2011","Number of Subjects Monitored for Long-term Safety of PA32540","0","0","0","0","0","0","0","0","0"
"2546","NCT00996164","Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder","Sexual Dysfunctions, Psychological",0,"Flibanserin","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","18 Years","55 Years","1090","October 2009","December 2010","The Change From Baseline to Week 24 in the Score of the Female Sexual Function Index Desire Domain.","0","0","0","0","0","0","0","0","0"
"2547","NCT00996281","Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","Essential Hypertension",0,"Azilsartan medoxomil and chlorthalidone","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","837","October 2009","November 2011","Percentage of Participants With at Least 1 Adverse Event","0","0","0","0","0","0","0","0","0"
"2548","NCT00996307","Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months","Influenza",0,"MF59-eH1N1_f","Biological","Novartis Vaccines","Industry",0,0,"All","6 Months","35 Months","654","October 2009","December 2009","Antibody Responses After the First and Second Vaccinations","0","0","0","0","0","0","0","0","0"
"2549","NCT00996372","Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women","Sexual Dysfunctions, Psychological",0,"flibanserin","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","35 Years","N/A","949","October 2009","March 2011","Change From Baseline in the Number of Satisfying Sexual Events","0","0","0","0","0","0","0","0","0"
"2550","NCT00996580","A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy","Pregnancy Prevention",0,"DR-103","Drug","Teva Women's Health","Industry",0,0,"Female","18 Years","40 Years","3597","October 2009","September 2011","All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight","0","0","0","0","0","0","0","0","0"
"2551","NCT00996788","Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis","Dyspepsia",0,"Rebamipide","Drug","PT Otsuka Indonesia","Industry",0,0,"All","18 Years","80 Years","55","October 2007","January 2012","To assess the efficacy of Rebamipide 100 mg t.i.d. in reducing gastric mucosal damage due to free radical and inflammation","0","0","0","0","0","0","0","0","0"
"2552","NCT00996918","A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients","Alzheimer Disease",0,"Bapineuzumab 0.5 mg/kg","Drug","Pfizer","Industry",0,0,"All","51 Years","N/A","198","December 2009","November 2012","Number of Participants Reporting a Serious Adverse Event.","0","0","0","0","0","0","0","0","0"
"2553","NCT00997204","EASSI - Evaluation of the Safety of Self-Administration With Icatibant","Hereditary Angioedema",0,"Icatibant","Drug","Shire","Industry",0,0,"All","18 Years","N/A","151","September 2009","June 2011","Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant","0","0","0","0","0","0","0","0","0"
"2554","NCT00997282","A Study of OPC-262 in Patients With Type 2 Diabetes","Diabetes Type 2",0,"OPC-262 2.5 mg","Drug","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","20 Years","74 Years","255","September 2009","October 2010","Changes in HbA1C from baseline","0","0","0","0","0","0","0","0","0"
"2555","NCT00997971","Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein","Growth",0,"Modilac Rose 1","Other","Sodilac","Industry",0,0,"All","N/A","1 Month","86","September 2007","August 2009","Growth parameters","0","0","0","0","0","0","0","0","0"
"2556","NCT00998686","Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin","Type 2 Diabetes Mellitus",0,"dutogliptin","Drug","Phenomix","Industry",0,0,"All","18 Years","85 Years","650","November 2009","October 2011","To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG","0","0","0","0","0","0","0","0","0"
"2557","NCT00998764","A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients","Alzheimer Disease",0,"Bapineuzumab 0.5 mg/kg","Drug","Pfizer","Industry",0,0,"All","51 Years","90 Years","494","December 2009","October 2012","Number of Participants Reporting a Serious Adverse Event","0","0","0","0","0","0","0","0","0"
"2558","NCT00998881","Monotherapy Study of MP-513 in Patients With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"Teneligliptin 20 mg","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","75 Years","203","September 2009","June 2010","Change From Baseline in HbA1c at Week 12","0","0","0","0","0","0","0","0","0"
"2559","NCT00999141","Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy","Face-lift",0,"FS VH S/D 4 s-apr","Biological","Baxter Healthcare Corporation","Industry",0,0,"All","18 Years","75 Years","75","September 2009","December 2009","Total Volume of Drainage on Each Side of the Face","<0.0001","0","two-sided paired t-test","0","0","0","0","0","0"
"2560","NCT00999206","Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine","Influenza",0,"Influenza Vaccine","Biological","Abbott Biologicals","Industry",0,0,"All","18 Years","N/A","3138","January 2010","August 2010","Anti-HA antibody titers and derived parameters seroprotection, seroconversion and fold increase","0","0","0","0","0","0","0","0","0"
"2561","NCT00999596","Image Evaluation of Philips Philips MammoDiagnost DR Full Field Digital Mammography System (FFDM)","Breast Cancer",0,NA,NA,"Philips Healthcare","Industry",0,0,"Female","40 Years","N/A","107","April 2010","January 2011","FFDM (Full Field Digital Mammography) Mammogram Scores","0","0","0","0","0","0","0","0","0"
"2562","NCT01000207","Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects","Swine-Origin Influenza A H1N1 Virus",0,"Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine","Biological","Novartis Vaccines","Industry",0,0,"All","6 Months","19 Years","123","October 2009","December 2009","Seroprotection, GMRs and Seroconversion rate at Weeks 0, 3 and 6","0","0","0","0","0","0","0","0","0"
"2563","NCT01000792","3-D Visualization of the Anti-Obstructive Effect of Levocetirizine","Allergic Rhinitis",0,"Levocetirizine","Drug","Clinical Research International Limited","Industry",0,0,"All","18 Years","65 Years","1","November 2009","January 2010","Improvement of nasal flow","0","0","0","0","0","0","0","0","0"
"2564","NCT01000961","Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis","Cystinosis",0,"Cystagon® (Cysteamine Bitartrate)","Drug","Horizon Pharma USA, Inc.","Industry",0,0,"All","6 Years","N/A","43","June 2010","June 2011","The Steady-state White Blood Cell Cystine Levels of RP103 Compared to Cystagon®","0.0001","0","t-test, 1 sided","0.0785","Mean Difference (Final Values)","95.8","2-Sided","0.0107","0.1464"
"2565","NCT01001117","Laser Treatment of the Crystalline Lens","Cataract",0,"LensAR laser surgery","Device","LensAR Incorporated","Industry",0,0,"All","N/A","N/A","75","October 2008","October 2009","Capsulotomy a. Ease of opening b. Achievement of intended shape and size","0","0","0","0","0","0","0","0","0"
"2566","NCT01001234","A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)","Migraine, Acute",0,"rizatriptan","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","6 Years","17 Years","1382","November 30, 2009","April 21, 2011","Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age","0.025","The statistical significance level for the primary endpoint was α=0.0477, and had been adjusted to account for the interim sample size adjustment.","Regression, Logistic","1.55","Odds Ratio (OR)","95","2-Sided","1.06","2.26"
"2567","NCT01001364","A Comparative Study Between Foraseq And Formoterol/Budesonide Inhalation Capsules in Patients With Asthma","ASTHMA",0,"Formoterol/Budesonide","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","12 Years","N/A","88","February 2010","April 2011","The study primary endpoint will be the forced expiratory volume in 1 second (FEV1) at the final visit (FV) at each study arm.","0","0","0","0","0","0","0","0","0"
"2568","NCT01001494","Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients","Chronic Obstructive Pulmonary Disease (COPD)",0,"Aclidinium bromide 200 μg bid","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","828","October 2009","November 2010","Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment","0","0","0","0","0","0","0","0","0"
"2569","NCT01001611","An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2",0,"CKD-501 0.5mg","Drug","Chong Kun Dang Pharmaceutical","Industry",0,0,"All","18 Years","80 Years","173","October 2009","January 2012","Change from baseline in Glycosylated Hemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"2570","NCT01001624","Melanil in the Treatment of Melasma","Melasma",0,"Melanil facial cream","Other","Catalysis SL","Industry",0,0,"All","18 Years","75 Years","150","October 2009","October 2010","MASI score, at the beginning of the study and at weeks 4, 8 (end of the treatment), 12 and 52.","0","0","0","0","0","0","0","0","0"
"2571","NCT01001832","Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients","Rheumatoid Arthritis",0,"Intravenous (IV) abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","20 Years","N/A","118","December 2009","February 2011","Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Day 169 in Short Term Period","0","0","0","0","0","0","0","0","0"
"2572","NCT01001975","Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)","Sun Protection",0,"Sunscreen Test Code: V53-028","Drug","Bayer","Industry",0,0,"All","18 Years","70 Years","10","July 2009","August 2009","Determination of Sunscreen Protection Factor (SPF)","0","0","0","0","0","0","0","0","0"
"2573","NCT01003184","Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"exenatide once weekly","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","222","October 2009","July 2011","Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26)","<.0001","0","Regression, Logistic","6.60","Odds Ratio (OR)","95","2-Sided","3.17","13.73"
"2574","NCT01004185","Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis","Ulcerative Colitis",0,"Asacol 400 mg","Drug","Warner Chilcott","Industry",0,0,"All","5 Years","17 Years","39","October 2009","March 2011","Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population","0","0","0","0","0","0","0","0","0"
"2575","NCT01004263","A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)","Acute Migraine With or Without Aura in Adolescents",0,"rizatriptan benzoate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","17 Years","674","December 2009","April 2011","Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any Dose","0","0","0","0","0","0","0","0","0"
"2576","NCT01004575","Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease","Coronary Artery Disease",0,"Kaname cobalt-chromium coronary stent","Device","Terumo Europe N.V.","Industry",0,0,"All","18 Years","N/A","280","October 2009","July 2011","Freedom from Target vessel failure TVF defined as composite of clinically driven target vessel revascularization (TVR)myocardial infarction or cardiac death that could not be clearly attributed to a vessel other than the target vessel.","0","0","0","0","0","0","0","0","0"
"2577","NCT01005407","Safety, Immunogenicity, Lot-to-lot Consistency Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine","Healthy",0,"HEPLISAV and Placebo","Biological","Dynavax Technologies Corporation","Industry",0,0,"All","40 Years","70 Years","2452","February 2010","January 2011","Proportion of subjects who have a seroprotective immune response (anti-HBsAg antibody≥ 10 milli-international unit (mIU)/mL) 8 weeks after the last active dose of HEPLISAV™ compared to 8 weeks after the last active dose of Engerix-B®","0","0","0","0","0","0","0","0","0"
"2578","NCT01005680","A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer","Non Small Cell Lung Cancer",0,"Pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","256","November 2009","November 2012","Overall Survival (OS)","0.822","HR adjusted for treatment, disease stage, Eastern Cooperative Oncology Group Performance Status (ECOG PS), sex, and basis for initial pathological diagnosis.","Cox Proportional Hazard","1.03","Hazard Ratio (HR)","95","2-Sided","0.77","1.39"
"2579","NCT01005719","Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)","Human Experimentation",0,"Zegerid","Drug","Bayer","Industry",0,0,"All","18 Years","65 Years","63","September 2009","January 2010","Achievement of Sustained Difference in Inhibition of Intragastric Acidity Based on Median pH Values Between the Two Active Study Treatments at Steady-state on Day 7","0.0242","p-value for 10-15 mins Post-dose on Day 7. No adjustments were made for multiple comparisons. P-values <= 0.05 were reported as statistically significant.","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"2580","NCT01005966","In Situ Caries Model of Fluoride Toothpastes","Caries",0,"Sodium Fluoride Toothpaste","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","80 Years","65","November 2008","March 2009","Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF)","0.2117","No adjustment made for multiple comparisons as the primary comparison was pre-specified.","ANOVA","-3.01","Adjusted Mean Difference","95","2-Sided","-7.75","1.73"
"2581","NCT01006252","A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma","Melanoma",0,"Tasisulam","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","323","December 2009","March 2011","Overall survival","0","0","0","0","0","0","0","0","0"
"2582","NCT01006291","Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","687","November 2009","September 2010","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"2583","NCT01007591","A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas","Psoriasis Vulgaris",0,"LEO 80190","Drug","LEO Pharma","Industry",0,0,"All","6 Years","17 Years","40","October 2009","June 2010","The percentage change in PASI of the face from baseline to week 8","0","0","0","0","0","0","0","0","0"
"2584","NCT01007708","The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis","Onychomycosis",0,"IDP-108","Drug","Dow Pharmaceutical Sciences","Industry",0,0,"All","18 Years","70 Years","780","November 2009","December 2011","Percentage of patients who achieve clinical cure","0","0","0","0","0","0","0","0","0"
"2585","NCT01007864","Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists","Idiopathic Parkinson's Disease",0,"piribedil","Drug","Desitin Arzneimittel GmbH","Industry",0,0,"All","35 Years","80 Years","80","January 2010","December 2011","The primary efficacy variable will be the 'median reaction time during the second 15 minutes (minutes 16-30)' of the subtest 'vigilance', visual test condition 'moving bar', of the Test battery for Attention Performances (TAP) at end of treatment.","0","0","0","0","0","0","0","0","0"
"2586","NCT01007890","Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer","Breast Cancer",0,"ChemoFX Assay","Other","Precision Therapeutics","Industry",0,0,"Female","18 Years","N/A","134","November 2009","October 2012","Primary clinical endpoint pCR will be a dichotomous outcome variable with two levels: complete response and no complete response.","0","0","0","0","0","0","0","0","0"
"2587","NCT01008085","STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)","STEMI",0,"Stentys coronary stent","Device","Stentys","Industry",0,0,"All","18 Years","N/A","80","November 2009","June 2010","Stent strut apposition measured by optical coherence tomography (OCT)","0","0","0","0","0","0","0","0","0"
"2588","NCT01008293","Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life","Chronic Liver Disease",0,"VSL#3","Drug","CD Pharma India Pvt. Ltd.","Industry",0,0,"All","15 Years","80 Years","120","October 2009","June 2012","To compare the effect of probiotics and lactulose based on normalization of the abnormal test parameters, Neuropsychometric tests, P3ERP, EEG, venous ammonia levels, Development of overt encephalopathy and other complications and HRQOL","0","0","0","0","0","0","0","0","0"
"2589","NCT01008553","A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome","Postherpetic Neuralgia",0,"Fentanyl","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","258","December 2008","March 2010","Time From the Initial Day of Application in Double-Blind Period to Withdrawal Because of Insufficient Analgesic Efficacy","0.0003","0","Log Rank","0","0","0","0","0","0"
"2590","NCT01008605","Caverject User Study","Erectile Dysfunction",0,"delivery system","Other","Pfizer","Industry",0,0,"Male","40 Years","70 Years","48","February 2011","February 2011","Percentage of Participants Who Successfully Operated the Caverject Impulse Delivery System","0","0","0","95.83","Lower limit, 95% one-sided CI","95","1-Sided","87.46","0"
"2591","NCT01008618","A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain","Chronic Pain",0,"Fentanyl","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","218","January 2009","February 2010","Time From the Initial Day of Application in Double-Blind Period to Withdrawal Because of Insufficient Analgesic Efficacy","0.0846","0","Log Rank","0","0","0","0","0","0"
"2592","NCT01008995","A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis","Psoriasis",0,"placebo","Drug","Centocor, Inc.","Industry",0,0,"All","18 Years","N/A","322","October 2009","July 2011","The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) From Baseline at Week 12.","<0.001","The study was designed to maintain a Type I error of 0.05 or less for the primary analysis.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"2593","NCT01009047","An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia","Schizophrenia",0,"Paliperidone extended release (ER)","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","12 Years","17 Years","228","December 2009","June 2012","Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56","0.935","Analysis of covariance (ANCOVA) model with treatment (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.","ANCOVA","0.1","Least-squares (LS) mean difference","95","2-Sided","-3.46","3.76"
"2594","NCT01009086","A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis","Arthritis, Psoriatic",0,"Placebo","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","N/A","615","December 2009","October 2011","Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24.","<0.001","0","re-randomization test","0","0","0","0","0","0"
"2595","NCT01009463","A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"FF/GW642444 Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","1626","September 25, 2009","October 1, 2011","Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean","0.181","0","Generalized Linear Model","0.87","Risk Ratio (RR)","95","2-Sided","0.72","1.06"
"2596","NCT01009580","Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","447","November 2009","August 2010","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"2597","NCT01009671","Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee","Knee Osteoarthritis",0,"ART 44","Drug","Laboratoires NEGMA","Industry",0,0,"All","40 Years","80 Years","210","November 2009","August 2010","To demonstrate the better digestive tolerability of ART44 versus ART 50 over a 1-month period, based on a clinically predetermined difference","0","0","0","0","0","0","0","0","0"
"2598","NCT01010022","Trial of 6% HES130/0.4","Hypovolemia",0,"6% hydroxyethyl starch 130/0.4","Drug","Fresenius Kabi Japan","Industry",0,0,"All","20 Years","N/A","64","November 2009","July 2010","Volume of colloid solution infused during investigational period (= intra-operatively)","0","0","0","0","0","0","0","0","0"
"2599","NCT01010633","Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","Inflammation",0,"Vehicle of Loteprednol Etabonate","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","406","November 2009","June 2010","Resolution of Anterior Chamber Cells (ACC).","<0.001","0","Chi-squared","14.3","Mean Difference (Final Values)","95","2-Sided","5.7","22.9"
"2600","NCT01010932","Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)","Cerebral Arterial Diseases",0,"Dotarem","Drug","Guerbet","Industry",0,0,"All","18 Years","N/A","222","October 2009","December 2010","Technical Failure Rate","0","0","0","0","0","0","0","0","0"
"2601","NCT01010971","Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older","Seasonal Allergic Rhinitis",0,"Ciclesonide HFA 160 μg","Drug","Sunovion","Industry",0,0,"All","12 Years","N/A","671","December 2009","February 2010","Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over the Two-week Treatment Period.","<0.0001","The p-value from primary outcome was adjusted at alpha=0.025.","ANCOVA","1.02","Mean Difference (Final Values)","95","2-Sided","0.59","1.45"
"2602","NCT01011608","Effect of a Medical Food Supplement in Hospitalized Patients Recovering From Surgery","Hip Fracture",0,"Medical Food Supplement","Other","Abbott Nutrition","Industry",0,0,"All","45 Years","N/A","127","November 2009","August 2010","Blood chemistry","0","0","0","0","0","0","0","0","0"
"2603","NCT01011621","Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis","Dermatitis, Atopic",0,"0.5% prednisolone acetate cream","Drug","Mantecorp Industria Quimica e Farmaceutica Ltd.","Industry",0,0,"All","12 Years","60 Years","170","February 2010","February 2012","Evaluate efficacy and safety of 0.5% prednisolone cream in comparison to 0.1% betamethasone cream in the treatment of corticosensitive dermatosis.","0","0","0","0","0","0","0","0","0"
"2604","NCT01011816","Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System","Back Pain",0,"BIOSTAT BIOLOGX","Biological","Spinal Restoration, Inc.","Industry",0,0,"All","18 Years","N/A","220","March 2010","December 2012","Subject Composite Success","0.52","0","Fisher Exact","0","0","0","0","0","0"
"2605","NCT01012258","Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects","Squamous Cell Carcinoma of the Head and Neck",0,"Cetuximab + concomitant boost radiotherapy","Biological","Merck KGaA","Industry",0,0,"All","18 Years","N/A","70","February 2009","September 2010","Best Overall Response (BOR)","0","0","0","0","0","0","0","0","0"
"2606","NCT01012323","A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases","Primary Immunodeficiency Diseases",0,"NewGam","Biological","Octapharma","Industry",0,0,"All","2 Years","75 Years","51","January 2010","June 2012","Number of Serious Bacterial Infections Per Person-year of Treatment","0","0","0","0","0","0","0","0","0"
"2607","NCT01012349","Efficacy and Safety Clinical Trial of the Combination of Acetylsalicylic Acid, Sodium Bicarbonate and Citric Acid, Produced by Geolab Pharmaceutical Industries Ltd., Compared to Acetylsalicylic Acid (Aspirin ® - Bayer) in Patients With Episodic Tension-type Headache.","Treatment of Episodic Tension Headache",0,"Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)","Drug","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","152","February 2011","May 2011","The primary efficacy endpoint is the rate of sustained response (percentage of subjects who have no pain) two hours after the drug administration.","0","0","0","0","0","0","0","0","0"
"2608","NCT01012674","Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)","Cerebral Arterial Diseases",0,"Dotarem","Drug","Guerbet","Industry",0,0,"All","18 Years","N/A","211","October 2009","December 2010","Technical Failure Rate","0","0","0","0","0","0","0","0","0"
"2609","NCT01012908","Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency","Pancreatic Insufficiency",0,"Norzyme - Bergamo","Dietary Supplement","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","25","March 2010","April 2010","Amount of fat in the stools of 72 hours of medication use between the two treatments.","0","0","0","0","0","0","0","0","0"
"2610","NCT01012973","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)","Retinal Vein Occlusion",0,"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","Biological","Bayer","Industry",0,0,"All","18 Years","N/A","177","October 2009","February 2011","Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures","<.0001","0","Cochran-Mantel-Haenszel","38.3","CMH adjusted difference","95","2-Sided","24.4","52.1"
"2611","NCT01014013","Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)","Urinary Tract Infection",0,"ertapenem sodium (MK0826)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","271","April 2008","February 2009","Microbiological Response Assessment Profile","0","0","0","-0.8","the difference between two response rate","95","0","-11.7","10.2"
"2612","NCT01014390","WallFlex Biliary Fully Covered (FC) Benign Stricture Study","Biliary Stricture",0,"WallFlex Biliary RX Fully Covered Stent System","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","187","December 2009","November 2012","Stent Removability, defined as ability to remove the stent endoscopically without serious stent-removal related adverse events as assessed from the time of stent removal to 1 month post-stent removal.","0","0","0","0","0","0","0","0","0"
"2613","NCT01014559","Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients","Constipation",0,"Oxycodone Naloxone","Drug","Mundipharma SAS","Industry",0,0,"All","18 Years","N/A","225","February 2010","June 2011","Change of intensity of constipation symptoms, as assessed by the BFI from baseline to Day 28. The BFI is the mean value of 3 single items: Ease of defecation; Feeling of incomplete bowel evacuation; Personal judgement of constipation.","0","0","0","0","0","0","0","0","0"
"2614","NCT01014689","Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris","Acne Vulgaris",0,"Adapalene/ BPO gel with Lymecycline capsules","Drug","Galderma","Industry",0,0,"All","12 Years","35 Years","378","August 2009","April 2010","Percent Change From Baseline in Total Lesion Count","0","0","0","0","0","0","0","0","0"
"2615","NCT01014702","Prospective Clinical Trial of the LensAR Laser System","Cataract",0,"LensAR Laser System","Device","LensAR Incorporated","Industry",0,0,"All","21 Years","N/A","100","November 2009","June 2011","Completeness and ease of opening of capsulotomy","0","0","0","0","0","0","0","0","0"
"2616","NCT01015404","A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)","Periodontitis",0,"Trafermin","Drug","Kaken Pharmaceutical","Industry",0,0,"All","20 Years","N/A","25","November 2009","March 2010","serum Trafermin level","0","0","0","0","0","0","0","0","0"
"2617","NCT01016119","Efficacy of Folrex in the Superior Extremity Rehabilitation After Acute Stroke","Stroke",0,"Folrex","Drug","Catalysis SL","Industry",0,0,"All","20 Years","90 Years","40","October 2009","March 2010","Periodical measures of the motor recovery, of the upper extremity, by Fugl-Meyer score, it will be done at the beginning, at fifth day and at month (4 weeks).","0","0","0","0","0","0","0","0","0"
"2618","NCT01016262","Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis","Ulcerative Proctitis",0,"MAX-002","Drug","Axcan Pharma","Industry",0,0,"All","18 Years","N/A","549","September 2009","July 2011","The responder rate at Week 6","0","0","0","0","0","0","0","0","0"
"2619","NCT01016470","Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease","Parkinson`s Disease",0,"VIUSID/ALZER","Dietary Supplement","Catalysis SL","Industry",0,0,"All","20 Years","90 Years","100","October 2009","May 2011","Periodical measures of the clinical features with Unified Parkinson Disease Rating Scale (UPDRS) will be done at the beginning, every three months until one year (end of the treatment)","0","0","0","0","0","0","0","0","0"
"2620","NCT01016808","Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients","Moderate to Severe Postoperative Pain",0,"Q8003","Drug","QRxPharma Inc.","Industry",0,0,"All","18 Years","N/A","522","December 2009","March 2010","Difference in pain intensity scores from baseline","0","0","0","0","0","0","0","0","0"
"2621","NCT01017120","A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne","Acne Vulgaris",0,"Tazarotene Foam","Drug","Stiefel, a GSK Company","Industry",0,0,"All","12 Years","45 Years","742","October 1, 2009","November 1, 2010","Absolute Change in Lesion Counts (LCs) From Baseline to Week 12","<0.001","The p-value indicates treatment differences between tazarotene foam and vehicle foam for ILs","ANCOVA","0","0","0","0","0","0"
"2622","NCT01017146","A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301","Acne Vulgaris",0,"Tazarotene foam","Drug","Stiefel, a GSK Company","Industry",0,0,"All","12 Years","45 Years","744","October 2009","November 2010","Absolute Change in Lesion Counts (LCs) From Baseline to Week 12","<0.001","The p-value indicates treatment differences between tazarotene foam and vehicle foam for ILs","ANCOVA","0","0","0","0","0","0"
"2623","NCT01017276","A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis","Chronic Kidney Disease",0,"ASP1585","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","35","November 2009","September 2010","Serum phosphorus level at treatment discontinuation","0","0","0","0","0","0","0","0","0"
"2624","NCT01017614","Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia","Inflammatory Bowel Disease",0,"Monofer","Drug","Pharmacosmos A/S","Industry",0,0,"All","18 Years","N/A","350","October 2009","July 2012","Change in Hb concentration from baseline to week 8.","0","0","0","0","0","0","0","0","0"
"2625","NCT01017952","A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"FF/GW642444 Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","1635","September 2009","October 2011","Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean","0.040","0","Generalized Linear Model","0.81","Risk Ratio (RR)","95","2-Sided","0.66","0.99"
"2626","NCT01018186","Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study","Asthma",0,"Fluticasone Furoate/GW642444","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","503","October 2009","May 2011","Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period","0","0","0","0","0","0","0","0","0"
"2627","NCT01018511","Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms","Benign Prostatic Hyperplasia",0,"Placebo tamsulosin hydrochloride OCAS 0.4 mg","Drug","Astellas Pharma Europe B.V.","Industry",0,0,"Male","45 Years","N/A","1334","January 2010","March 2011","Change From Baseline to End of Treatment in Total International Prostate Symptom Score","0.001","The primary analysis was adjusted for multiplicity for IPSS using the Hochberg procedure involving 2 stages: Stage 1, superiority to placebo and Stage 2: non-inferiority to tamsulosin alone, with a switch to superiority where applicable.","Mixed Models Analysis","-0.8","Least Squares Mean Difference","97.5","2-Sided","-1.73","0.11"
"2628","NCT01018680","A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis","Osteoarthritis Knee Pain",0,"Duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","40 Years","N/A","524","November 2009","April 2011","Change From Baseline in the Weekly Mean of the 24-Hour Average Pain Score at 8 Weeks","<0.001","A 0.05 level of significance was pre-specified for use in treatment group comparisons.","Mixed Models Analysis","-0.91","Mean Difference (Final Values)","95","0","0","0"
"2629","NCT01018862","A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis","Perennial Allergic Rhinitis",0,"Azelastine hydrochloride nasal spray 0.15%","Drug","Meda Pharmaceuticals","Industry",0,0,"All","6 Years","12 Years","489","November 2009","April 2011","Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) for the Entire 28-day Study Period Compared to Placebo","0","0","0","0","0","0","0","0","0"
"2630","NCT01019824","Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain","Pain",0,"Ralfinamide","Drug","Newron","Industry",0,0,"All","18 Years","85 Years","400","January 2009","April 2010","The primary efficacy variable will be the change from baseline in the mean weekly pain score (11-point Likert scale).","0","0","0","0","0","0","0","0","0"
"2631","NCT01020448","Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","Prostate Cancer",0,"Triptorelin (Decapeptyl®)","Drug","Ipsen","Industry",0,0,"Male","18 Years","N/A","339","November 2009","November 2011","PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA","0","0","0","0","0","0","0","0","0"
"2632","NCT01020838","Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology","Alzheimer Disease",0,"Florbetaben (BAY94-9172)","Drug","Piramal Imaging SA","Industry",0,0,"All","21 Years","N/A","218","November 2009","September 2011","Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem Specimens","0","0","0","0.774","Sensitivity","95","2-Sided","0.654","0.894"
"2633","NCT01021332","Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms","Lower Urinary Tract Symptoms",0,"tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)","Drug","Astellas Pharma Europe B.V.","Industry",0,0,"Male","45 Years","N/A","1067","April 2010","December 2011","Number of Participants With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"2634","NCT01021423","A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).","Mantle Cell Lymphoma",0,"Lenalidomide","Drug","Celgene Corporation","Industry",0,0,"All","18 Years","N/A","9","April 2010","March 2011","Progression-free Survival (PFS)","0","0","0","0","0","0","0","0","0"
"2635","NCT01021813","A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)","Insomnia",0,"Suvorexant","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","781","December 2009","May 2011","Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs) During the Double-Blind (DB) Treatment Phase","0","0","0","0","0","0","0","0","0"
"2636","NCT01022047","Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis","Allergic Rhinitis",0,"Noex","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","12 Years","N/A","280","February 2010","February 2010","The primary objective of the study is to evaluate the efficiency of Noex","0","0","0","0","0","0","0","0","0"
"2637","NCT01022060","Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis","Recurrent Calcic Urolithiasis",0,"Renalof","Dietary Supplement","Catalysis SL","Industry",0,0,"All","18 Years","65 Years","110","November 2009","February 2010","Size of calculi at week 12 (end of the treatment); week 0 refers to the beginning of treatment)","0","0","0","0","0","0","0","0","0"
"2638","NCT01023035","Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","Hepatitis C, Chronic",0,"Boceprevir","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","687","December 2009","October 2011","Percentage of Participants With Sustained Virologic Response (SVR)","0","0","0","-0.7","Mean Difference (Final Values)","95","2-Sided","-8.6","7.2"
"2639","NCT01023412","Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery","Gastrointestinal Cancer",0,"Immunonutrition","Dietary Supplement","Nestlé","Industry",0,0,"All","18 Years","N/A","107","January 2006","May 2008","Rate of post-operative complications","0","0","0","0","0","0","0","0","0"
"2640","NCT01023581","Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"Alogliptin","Drug","Takeda","Industry",0,0,"All","18 Years","80 Years","784","November 2009","June 2011","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26","<0.001","For each set of comparisons in the primary analysis, the null hypothesis was rejected only if both comparisons between a combination and its constituent doses were statistically significant at the 2-sided 2.5% level.","ANCOVA","-0.67","LS mean difference","95","2-Sided","-0.96","-0.37"
"2641","NCT01024491","Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation","Premature Ejaculation",0,"paroxetine","Drug","MorePharma Corporation","Industry",0,0,"Male","20 Years","70 Years","174","August 2008","March 2009","Intravaginal Ejaculatory Latency Time (IELT)","0","0","0","0","0","0","0","0","0"
"2642","NCT01024608","Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","Seasonal Allergic Rhinitis",0,"Beclomethasone dipropionate","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","N/A","340","December 2009","February 2010","Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period","<0.001","A priori threshold for statistical significance is p<0.05.","ANCOVA","-0.91","LS mean treatment diff from placebo","95","2-Sided","-1.3","-0.5"
"2643","NCT01024738","Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse","Dental Plaque",0,"Fluoride","Drug","Colgate Palmolive","Industry",0,0,"All","18 Years","65 Years","22","March 2008","April 2008","Plaque Index","0.05","0","ANOVA","0","0","0","0","0","0"
"2644","NCT01025050","Intrastromal Presbyopia Correction by Means of a Femtosecond Laser","Presbyopia",0,"Intrastromal Correction of Presbyopia","Procedure","Technolas Perfect Vision GmbH","Industry",0,0,"All","18 Years","N/A","58","December 2009","May 2010","The proportion of treated eyes who gained uncorrected near visual acuity of at least 2 lines. This proportion should be greater than 70%.","0","0","0","0","0","0","0","0","0"
"2645","NCT01025115","Diamel in the Treatment of Metabolic Syndrome","Metabolic Syndrome",0,"Diamel","Dietary Supplement","Catalysis SL","Industry",0,0,"All","19 Years","70 Years","100","March 2009","March 2010","Blood concentrations of glucose at months 0,3,6,9,12.","0","0","0","0","0","0","0","0","0"
"2646","NCT01025336","Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated","Healthy",0,"Blood draw","Other","Pfizer","Industry",0,0,"All","60 Years","N/A","962","December 2009","October 2010","Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)","0","0","0","0","0","0","0","0","0"
"2647","NCT01026038","Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.","13-valent Pneumococcal Vaccine",0,"13-valent pneumococcal conjugate vaccine","Biological","Pfizer","Industry",0,0,"All","3 Years","N/A","263","April 2010","November 2010","Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine","0","0","0","0.81","GMC ratio","95","2-Sided","0.61","1.07"
"2648","NCT01026194","Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"Placebo / Teneli (Teneligliptin) + pio (pioglitazone)","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","75 Years","204","December 2009","June 2011","Change From Baseline in HbA1c at Week 12","0","0","0","0","0","0","0","0","0"
"2649","NCT01026831","Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)","Open-angle Glaucoma",0,"Preservative-Free Tafluprost","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","643","January 2010","September 2010","Mean Intraocular Pressure (IOP) Change From Baseline at All 9 Time Points During the Study (0800, 1000 and 1600 Hrs at Weeks 2, 6, and 12)","0","0","0","0","0","0","0","0","0"
"2650","NCT01027364","Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B","Severe Hemophilia B",0,"Factor IX (rFIXFc)","Drug","Bioverativ Therapeutics Inc.","Industry",0,0,"Male","12 Years","N/A","123","December 2009","July 2012","Number of Participants With Potentially Clinically Significant Laboratory Abnormalities","0","0","0","0","0","0","0","0","0"
"2651","NCT01027494","Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora","Acute Otitis Media",0,"Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension","Drug","Alcon Research","Industry",0,0,"All","6 Months","4 Years","318","December 2009","November 2012","Change in microbial organism susceptibility and fluoroquinolone resistant flora at sites distal to the original infection.","0","0","0","0","0","0","0","0","0"
"2652","NCT01028027","Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis","Conjunctivitis",0,"Loteprednol and tobramycin","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","357","October 2009","February 2010","Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population","0","0","0","0","0","0","0","0","0"
"2653","NCT01028378","Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia","Myopia",0,"T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser","Device","Clinical Research Consultants, Inc.","Industry",0,0,"All","18 Years","N/A","212","October 2009","April 2012","Percentage of Eyes With Manifest Refraction Spherical Equivalent (MRSE) +/- 0.50 D","0","0","0","0","0","0","0","0","0"
"2654","NCT01028586","MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)","Idiopathic Parkinson's Disease",0,"Safinamide, MAO-B inhibitor","Drug","Newron","Industry",0,0,"All","30 Years","80 Years","507","October 2009","May 2012","Time from baseline to first intervention, i.e., change in the dose of Dopamine (DA) agonist, addition of another DA-agonist, levodopa, or other Parkinson Disease (PD) therapy, or discontinuation due to lack of efficacy","0","0","0","0","0","0","0","0","0"
"2655","NCT01028950","YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness","Venous Thromboembolism",0,"YM150","Drug","Astellas Pharma Inc","Industry",0,0,"All","40 Years","N/A","52","May 2009","April 2010","Composite assessment of VTE events and all cause death","0","0","0","0","0","0","0","0","0"
"2656","NCT01029340","Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A","Blood Coagulation Disorders",0,"Recombinant Factor VIII (BAY81-8973)","Biological","Bayer","Industry",0,0,"Male","12 Years","65 Years","74","December 2009","June 2012","Part A - Area Under the Drug Concentration-time Curve (AUC)","0","0","0","0","0","0","0","0","0"
"2657","NCT01029886","Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"exenatide once weekly","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","912","January 2010","January 2011","Change in HbA1c From Baseline to Week 26","0.002","0","Mixed Models Analysis","0.21","Least Squares Mean Difference","95","2-Sided","0.08","0.33"
"2658","NCT01030185","Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance","Ascites",0,"NovaShunt's Automated Fluid Shunt implantation","Device","NovaShunt AG","Industry",0,0,"All","18 Years","N/A","40","February 2010","November 2011","The safety of the NovaShunt AFS will be evaluated by the incidence and severity of device- and procedure-related serious adverse events","0","0","0","0","0","0","0","0","0"
"2659","NCT01030380","Determination of the Efficacy of Slendertone® Face to Tone the Muscles of the Face and Reduce the Signs of Facial Aging","Facial Muscle Toning",0,"Slendertone Face","Device","Bio-Medical Research, Ltd.","Industry",0,0,"Female","25 Years","55 Years","108","February 2009","May 2009","Ultrasound measurements of the zygomaticus major muscle","0","0","0","0","0","0","0","0","0"
"2660","NCT01030783","A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma","Advanced Renal Cell Carcinoma",0,"tivozanib (AV-951)","Drug","AVEO Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","517","December 2009","July 2012","To compare the progression-free survival (PFS) of subjects with advanced renal cell cancer (RCC) randomized to treatment with tivozanib or sorafenib","0","0","0","0","0","0","0","0","0"
"2661","NCT01032499","Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir","Acne Vulgaris II or III Degree",0,"oxytetracycline, taro elixir","Drug","Laboratorios Goulart S.A.","Industry",0,0,"All","14 Years","N/A","120","May 2010","July 2010","Measure the efficacy in the treatment of boils or acne vulgaris II and III degree with taro elixir compared with Oxytetracycline.","0","0","0","0","0","0","0","0","0"
"2662","NCT01032915","Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis","Non-infectious Uveitis",0,"AIN457","Biological","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","125","February 2010","June 2011","Time to First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline","0","0","0","0","0","0","0","0","0"
"2663","NCT01033071","Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","Essential Hypertension",0,"Azilsartan medoxomil and chlorthalidone","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","1071","January 2010","October 2010","Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.","<0.001","Overall Type 1 error rate of 0.05 controlled using 'Closed Testing' principle (hypothesis of “all treatment groups equal” first tested at 0.05 significance level; upon rejection of this hypothesis, pairwise comparison was tested at the 0.05 level.","ANCOVA","-5.3","Mean Difference (Final Values)","95","0","-7.6","-3.1"
"2664","NCT01033825","Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis","Perennial Allergic Rhinitis",0,"Ciclesonide HFA Nasal Aerosol 320 mcg","Drug","Sunovion","Industry",0,0,"All","12 Years","N/A","310","January 2010","May 2010","Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-24h) at Baseline","0","0","0","0","0","0","0","0","0"
"2665","NCT01034111","A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)","Type 2 Diabetes",0,"Sitagliptin phosphate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","30","March 1, 2010","October 4, 2010","Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"2666","NCT01034163","A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)","Hodgkin's Lymphoma",0,"Panobinostat","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","41","June 2010","May 2012","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"2667","NCT01034267","Safety Study of F2695 SR in Major Depressive Disorder","Major Depressive Disorder",0,"F2695 SR","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","80 Years","828","December 2009","June 2012","Adverse events, clinical laboratory tests, vital sign measurements, electrocardiograms, physical examinations, Columbia-Suicide Severity Rating Scale","0","0","0","0","0","0","0","0","0"
"2668","NCT01034462","Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","Major Depressive Disorder",0,"Levomilnacipran ER","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","80 Years","442","December 2009","December 2011","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","0.0051","0","Mixed Models Analysis","-3.095","Least squares mean difference","95","2-Sided","-5.256","-0.935"
"2669","NCT01034488","Pharmacodynamics Aspects Of Porcine Heparin Sodium, Produced by Eurofarma, Compared Heparin Sodium, Produced by APP Pharmaceuticasls, in Patients With Chronic Renal Failure","Pharmacodynamics",0,"Suine","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","128","August 2010","December 2011","Effect (activity) of heparin observed for markers for aPTT and anti-Xa.","0","0","0","0","0","0","0","0","0"
"2670","NCT01035138","A Study of Semagacestat for Alzheimer's Patients","Alzheimer's Disease",0,"semagacestat","Drug","Eli Lilly and Company","Industry",0,0,"All","55 Years","N/A","180","December 2009","April 2011","Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog11) at Week 16 After Cessation of Study Drug","0","0","0","0","0","0","0","0","0"
"2671","NCT01035346","Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection","Infection",0,"Ibuprofen","Drug","Pfizer","Industry",0,0,"All","12 Years","65 Years","16","January 2010","May 2011","Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)","0.228","p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).","ANOVA","8.33","Least-squares (LS) mean difference","95","2-Sided","-7.94","24.60"
"2672","NCT01036165","A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study","Multiple Sclerosis",0,"RebiSmart™","Device","EMD Serono","Industry",0,0,"All","18 Years","65 Years","103","January 2010","August 2010","The Primary Endpoint is the Proportion of RMS Subjects Rating the RebiSmart™ Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial Questionnaire.","0","0","0","0.78","Mean positive response","95","2-Sided","0.70","0.86"
"2673","NCT01037179","An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis","Allergic Conjunctivitis",0,"Olopatadine Hydrochloride Ophthalmic Solution, 0.2%","Drug","Alcon Research","Industry",0,0,"All","12 Years","N/A","110","February 2010","May 2010","Mean Itching Score by Visit","0","0","0","0","0","0","0","0","0"
"2674","NCT01037218","Treatment of Erectile Dysfunction II","Erectile Dysfunction",0,"Udenafil","Drug","Warner Chilcott","Industry",0,0,"Male","19 Years","N/A","601","September 2009","April 2010","Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF), Baseline to Final Visit/Week 12, mITT (Modified Intent-to-Treat), LOCF (Last Observation Carried Forward)","<0.0001","0","ANCOVA","3.38","Difference in LS Means","95","2-Sided","1.70","5.07"
"2675","NCT01037231","Phase 2/3 Oxabact Study","Primary Hyperoxaluria",0,"Oxalobacter formigenes","Biological","OxThera","Industry",0,0,"All","2 Years","N/A","36","December 2009","January 2011","Percentage change in urinary oxalate levels (expressed as molar oxalate to creatinine ratio) from Baseline to Week 24","0","0","0","0","0","0","0","0","0"
"2676","NCT01037244","Treatment of Erectile Dysfunction I","Erectile Dysfunction",0,"Udenafil","Drug","Warner Chilcott","Industry",0,0,"Male","19 Years","N/A","618","September 2009","March 2010","Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF), Baseline to Final Visit/Week 12, mITT (Modified Intent-to-Treat), LOCF (Last Observation Carried Forward)","<0.0001","0","ANCOVA","5.04","Difference in Least Square (LS) Means","95","2-Sided","3.36","6.73"
"2677","NCT01038661","Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy","Lung Neoplasms",0,"Docetaxel","Drug","Sanofi","Industry",0,0,"All","18 Years","75 Years","375","November 2009","August 2012","Progression-free survival (PFS) during the maintenance treatment phase","0","0","0","0","0","0","0","0","0"
"2678","NCT01040052","A Study to Assess the Safety of Adacel® Vaccine","Diphtheria",0,"Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","18 Years","45 Years","30","December 2009","February 2010","Number of Participants Reporting at Least One Solicited Local or Systemic Reaction Post-Vaccination With ADACEL® Vaccine","0","0","0","0","0","0","0","0","0"
"2679","NCT01040208","12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress","Sexual Dysfunctions, Psychological",0,"flibanserin 50 mg to 100 mg qhs","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","18 Years","50 Years","111","January 2010","January 2011","The Primary Safety Endpoint is the Occurrence of Adverse Events During the Treatment and Post Treatment Period.","0","0","0","0","0","0","0","0","0"
"2680","NCT01040780","Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients","Non-small Cell Lung Cancer",0,"Icotinib","Drug","Betta Pharmaceuticals Co.,Ltd.","Industry",0,0,"All","18 Years","75 Years","399","February 2009","March 2010","Progression Free Survival","0","0","0","0","0","0","0","0","0"
"2681","NCT01041001","Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury","Cartilage Injury",0,"Cartistem","Biological","Medipost Co Ltd.","Industry",0,0,"All","18 Years","N/A","104","February 2009","December 2010","ICRS Cartilage Repair Assessment will follow to determine the appropriate grade. The treatment will be considered efficacious if the ICRS grade drops by at least 1 grade or more from baseline to week 48.","0","0","0","0","0","0","0","0","0"
"2682","NCT01041573","Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","Encephalitis",0,"IC51 Japanese Encephalitis","Biological","Valneva Austria GmbH","Industry",0,0,"All","2 Months","18 Years","1869","March 2010","February 2011","Rate of Subjects With Serious Adverse Events and Medically Attended Adverse Events Until Day 56 After First Vaccination","0.641","0","Fisher Exact","0","0","0","0","0","0"
"2683","NCT01041859","A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy","Diabetic Peripheral Neuropathy",0,"Tapentadol extended release (ER)","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","460","December 2009","March 2011","Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12","<0.001","Analysis of covariance (ANCOVA) model was used with treatment, dose level, and pooled analysis center as factors and baseline pain intensity score as a covariate","ANCOVA","-0.95","Mean Difference (Final Values)","95","2-Sided","-1.415","-0.493"
"2684","NCT01043367","Deprexil in Subjects With Signs and Symptoms of Depression","Depression",0,"Deprexil","Dietary Supplement","Catalysis SL","Industry",0,0,"All","18 Years","59 Years","200","January 2010","January 2011","Functional capabilities at week 24 (end of the treatment)","0","0","0","0","0","0","0","0","0"
"2685","NCT01043666","A Study of YM178 in Subjects With Symptoms of Overactive Bladder","Urinary Bladder, Overactive",0,"YM178","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","1126","December 2009","September 2011","Change in mean number of micturitions per 24 hrs","0","0","0","0","0","0","0","0","0"
"2686","NCT01044459","Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)","Chronic Obstructive Pulmonary Disease",0,"Aclidinium Bromide 200 µg","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","605","November 2009","April 2011","Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)","0","0","0","0","0","0","0","0","0"
"2687","NCT01045018","A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis","Mild to Moderate Ulcerative Colitis",0,"Placebo","Drug","EMET Pharmaceuticals, LLC","Industry",0,0,"All","18 Years","N/A","0","January 2008","June 2009","Treatment Success: Responders are patients in remission or who do not require use of rescue medication for symptomatic relief of UC at week 6 Treatment benefit: Improvement at endpoint compared to baseline Treatment Failure: Increase or no improvement","0","0","0","0","0","0","0","0","0"
"2688","NCT01045161","Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)","Chronic Obstructive Pulmonary Disease",0,"Aclidinium bromide","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","544","March 2009","June 2011","Part A: Morning Predose (Trough) Forced Expiratory Volume in 1 Second (FEV1)","0.019","0","ANCOVA","0.051","Least Squares Mean Difference","95","2-Sided","0.01","0.09"
"2689","NCT01045447","Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","465","January 2010","October 2010","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"2690","NCT01045707","Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","530","January 2010","October 2010","Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"2691","NCT01046110","Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","458","January 2010","November 2010","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"2692","NCT01046318","A Study of OPC-262 in Patients With Type 2 Diabetes","Type 2 Diabetes",0,"OPC-262","Drug","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","20 Years","74 Years","100","November 2009","July 2011","Changes in HbA1C from baseline to each visit (OC) and Week 52 (LOCF)","0","0","0","0","0","0","0","0","0"
"2693","NCT01046383","Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients","NON-SMALL CELL LUNG CANCER",0,"IMN1207","Dietary Supplement","Immunotec Inc.","Industry",0,0,"All","18 Years","N/A","16","June 2010","June 2012","The primary endpoint of the study is the % change in body weight in the IMN1207 group compared to casein over a 40 weeks treatment period.","0","0","0","0","0","0","0","0","0"
"2694","NCT01047345","A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)","Cervical Cancers",0,"V503","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","12 Years","26 Years","924","February 24, 2010","June 10, 2011","Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study","0","0","0","0","0","0","0","0","0"
"2695","NCT01047501","Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","Hypertriglyceridemia",0,"AMR101 (ethyl icosapentate)","Drug","Amarin Pharma Inc.","Industry",0,0,"All","18 Years","N/A","702","December 2009","February 2011","Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in triglyceride lowering effect","0","0","0","0","0","0","0","0","0"
"2696","NCT01047553","Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients","Chronic Obstructive Pulmonary Disease",0,"Formoterol (OT)","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","251","December 2009","January 2011","Clinical Laboratory Test: Haematology -Erythrocytes","0","0","0","0","0","0","0","0","0"
"2697","NCT01047683","Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","Hypertriglyceridemia",0,"AMR101 (ethyl icosapentate)","Drug","Amarin Pharma Inc.","Industry",0,0,"All","18 Years","N/A","229","December 2009","October 2010","Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in triglyceride lowering effect","0","0","0","0","0","0","0","0","0"
"2698","NCT01048541","Bladder Scan of Residual Urine With New Catheter","Urinary Incontinence",0,"Test Catheter - SpeediCath Compact Male","Device","Coloplast A/S","Industry",0,0,"Male","18 Years","N/A","37","January 2010","June 2010","Mean Residual Urine Volume","0","0","0","0","0","0","0","0","0"
"2699","NCT01048788","A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg","Cirrhosis",0,"OPC-41061","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","80 Years","51","December 2009","August 2011","Body Weight","0","0","0","0","0","0","0","0","0"
"2700","NCT01048866","A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis","Pharyngitis",0,"Placebo","Drug","Reckitt Benckiser LLC","Industry",0,0,"All","18 Years","N/A","300","November 2009","March 2011","The primary Outcome Measure in this trial will be efficacy for Sore Throat Pain during the first 24 hours.","0","0","0","0","0","0","0","0","0"
"2701","NCT01049217","Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy","Neuropathy",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","377","April 2010","May 2012","Change From Baseline in Mean Pain Score at Endpoint (up to Week 16)","0.7090","0","ANCOVA","0.07","Least Squares (LS) Mean Difference","95","2-Sided","-0.30","0.45"
"2702","NCT01049334","A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis","Pharyngitis",0,"Placebo","Drug","Reckitt Benckiser LLC","Industry",0,0,"All","18 Years","N/A","300","November 2009","March 2011","The primary Outcome Measure in this trial will be efficacy for Sore Throat Pain during the first 24 hours.","0","0","0","0","0","0","0","0","0"
"2703","NCT01050218","Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy","Diabetic Neuropathy, Painful",0,"Desvenlafaxine Succinate Sustained-Release (DVS SR)","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","N/A","237","July 2006","January 2009","Change From Baseline in Mean Pain Score on the Numeric Rating Scale (NRS).","0","0","0","0","0","0","0","0","0"
"2704","NCT01050530","A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema","Cirrhosis",0,"OPC-41061","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","80 Years","162","December 2009","February 2012","Body ｗeight","<0.0001","0","t-test, 2 sided","-1.51","Mean Difference (Final Values)","95","2-Sided","-2.08","-0.93"
"2705","NCT01050543","Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)","Neuromuscular Blockade",0,"sugammadex","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","128","February 1, 2010","August 20, 2010","Time From Start of Study Drug Administration to Recovery of the T4/T1 Ratio to 0.9","<0.0001","0","ANOVA","8.1","Mean Difference (Final Values)","95","2-Sided","6.8","9.6"
"2706","NCT01050816","Effects of CHONDRON (Autologous Chondrocytes) With Ankle Cartilage Defect","Articular Cartilage Defects of Ankle Joint",0,"Chondron(autologous chondrocyte) Implantation","Procedure","Sewon Cellontech Co., Ltd.","Industry",0,0,"All","15 Years","65 Years","30","January 2006","January 2009","Average Change From Baseline in American Orthopedic Foot and Ankle Society(AOFAS) at 12 Months Post-surgery","0","0","0","0","0","0","0","0","0"
"2707","NCT01050829","Gadobutrol Magnevist-controlled Body Study","Magnetic Resonance Imaging",0,"Gadobutrol (Gadovist, BAY86-4875)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","370","January 2010","April 2011","The total score of the following 3 visualization parameters is used for primary variable: Degree of contrast enhancement; Border delineation; Internal morphology.","0","0","0","0","0","0","0","0","0"
"2708","NCT01051024","Diamel in the Treatment of Polycystic Ovary Syndrome","Polycystic Ovary Syndrome",0,"Diamel","Dietary Supplement","Catalysis SL","Industry",0,0,"Female","18 Years","40 Years","110","November 2009","April 2011","Normalization of blood concentrations of androgens at week 24","0","0","0","0","0","0","0","0","0"
"2709","NCT01051128","Continuous Intrathecal Baclofen Infusion for Chronic Spasticity","Spasticity",0,"Prometra Programmable Implantable Pump System","Device","Flowonix Medical","Industry",0,0,"All","22 Years","N/A","0","January 2010","June 2010","The primary endpoint is: A change in the average lower extremity spasticity score as measured by the Modified Ashworth Scale","0","0","0","0","0","0","0","0","0"
"2710","NCT01051518","Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)","Aortic Valve Stenosis",0,"Medtronic CoreValve System","Device","Medtronic Bakken Research Center","Industry",0,0,"All","75 Years","N/A","126","May 2006","February 2009","Composite Major Adverse Events (MAE)","0","0","0","0","0","0","0","0","0"
"2711","NCT01052012","Bupivacaine Effectiveness and Safety in SABER™ Trial","Postoperative Pain",0,"SABER™-Bupivacaine","Drug","Durect","Industry",0,0,"All","18 Years","N/A","305","December 2009","September 2011","Pain intensity on movement","0","0","0","0","0","0","0","0","0"
"2712","NCT01053143","Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India","Influenza",0,"A/H1N1 pandemic influenza vaccine (non- adjuvanted)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","100","January 2010","August 2010","To provide information concerning the safety profile in terms of solicited injection site reactions, systemic events, and serious adverse events after administration of A/H1N1 pandemic influenza vaccine.","0","0","0","0","0","0","0","0","0"
"2713","NCT01053247","Study of 0416 Ointment in the Treatment of Atopic Dermatitis","Atopic Dermatitis",0,"0416","Drug","Fougera Pharmaceuticals Inc.","Industry",0,0,"All","18 Years","N/A","793","January 2008","August 2009","Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment","0","0","0","0","0","0","0","0","0"
"2714","NCT01053312","PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus","Normal Pressure Hydrocephalus",0,"[18F] Flutemetamol","Drug","GE Healthcare","Industry",0,0,"All","50 Years","N/A","7","December 2009","July 2010","Quantitative Estimates of Brain Uptake [18F]Flutemetamol and the Quantitative Immunohistochemical (IHC) Estimates of Amyloid Levels in Biopsy Samples Previously Obtained.","0","0","0","0","0","0","0","0","0"
"2715","NCT01053988","A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"FF/GW642444 Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","1031","October 5, 2009","February 1, 2011","Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours Post-dose at Day 168","0.040","Nominal p-value","Mixed Models Analysis","0.053","Least squares mean difference","95","2-Sided","0.003","0.104"
"2716","NCT01054092","A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients","Type 2 Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","182","December 2009","July 2011","HbA1c","0","0","0","0","0","0","0","0","0"
"2717","NCT01054573","VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo","Hepatitis C, Chronic",0,"Telaprevir","Drug","Janssen Infectious Diseases BVBA","Industry",0,0,"All","18 Years","70 Years","90","April 2010","March 2012","The Percentage of Participants Achieving a Sustained Virologic Response (SVR) 24 Weeks After the Last Dose of Study Drug (SVR24 Actual)","0","0","0","0","0","0","0","0","0"
"2718","NCT01054885","Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"FF Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","1226","October 2009","February 2011","Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours (h) Post-dose at Day 168","0.085","0","Mixed Models Analysis","0.046","Least squares mean difference","95","2-Sided","-0.006","0.098"
"2719","NCT01055015","Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty","Postoperative Pain",0,"Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)","Drug","QRxPharma Inc.","Industry",0,0,"All","18 Years","N/A","141","February 2010","December 2010","Difference in pain intensity scores from baseline","0","0","0","0","0","0","0","0","0"
"2720","NCT01055262","Safety, Tolerability And On-Body Temperature Of A Disposable Heatwrap Device For The Lower Back","Healthy",0,"Heatwrap 1","Device","Pfizer","Industry",0,0,"All","35 Years","N/A","169","January 2010","February 2010","Percentage of Participants With a Significant Skin Event (Day 5 Cumulative)","0","0","0","0","0","0","0","0","0"
"2721","NCT01056341","Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy","Infantile Hemangioma",0,"Propranolol","Drug","Pierre Fabre Dermatology","Industry",0,0,"All","35 Days","150 Days","512","January 2010","May 2012","Interim Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at Week 24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of Week 24 Photographs.","< 0.0001","P-value not adjusted for multiplicity. An Independent Committee conducted this analysis to determine the most efficacious of all arms with a good safety profile.
P-value linked to the 3 mg/kg/day 6 months selected arm .","One-sided Z-tests","0","0","0","0","0","0"
"2722","NCT01057407","A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis","Chronic Kidney Disease",0,"ASP1585","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","110","January 2010","September 2010","Serum phosphorus level at the end of treatment","0","0","0","0","0","0","0","0","0"
"2723","NCT01057628","A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients","Type 2 Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","130","January 2010","December 2010","change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"2724","NCT01057693","Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy","Diabetic Neuropathy, Painful",0,"pregabalin (Lyrica)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","665","March 2010","January 2012","Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase","0.1221","0","ANCOVA","-0.32","Least Squares Mean Difference","95","2-Sided","-0.74","0.09"
"2725","NCT01057901","Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America","Sexual Dysfunctions, Psychological",0,"Flibanserin","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","35 Years","N/A","748","January 2010","January 2011","Change From Baseline in the Number of Satisfying Sexual Events","0","0","0","0","0","0","0","0","0"
"2726","NCT01058096","Safety and Efficacy of Cariprazine for Mania","Bipolar Disorder",0,"Cariprazine","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","65 Years","323","February 2010","July 2011","Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3","0.0004","0","Mixed Models Analysis","-4.3","Least Squares Mean Difference","95","2-Sided","-6.7","-1.9"
"2727","NCT01058174","Liver Transplant European Study Into the Prevention of Fungal Infection","Liver Transplantation",0,"micafungin","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","350","December 2009","May 2012","'Clinical success' at the End of Prophylaxis as assessed by the Independent Data Review Board (IDRB).","0","0","0","0","0","0","0","0","0"
"2728","NCT01058668","Safety and Efficacy of Cariprazine for Bipolar I Disorder","Mania",0,"Cariprazine","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","65 Years","497","February 2010","December 2011","Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3","<0.001","0","Mixed Models Analysis","-6.1","Least Squares Mean Difference","95","2-Sided","-8.4","-3.8"
"2729","NCT01059344","Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis","Ulcerative Colitis",0,"Mesalamin","Drug","Tillotts Pharma AG","Industry",0,0,"All","18 Years","N/A","281","November 2009","July 2011","To Achieve Clinical Remission in Subjects With Active Ulcerative Colitis (UC).","0.069","0","Chi-squared","0","0","0","0","0","0"
"2730","NCT01059539","Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder","Bipolar I Disorder",0,"cariprazine","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","65 Years","403","January 2010","March 2012","Clinical laboratory","0","0","0","0","0","0","0","0","0"
"2731","NCT01059565","Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection","Cystic Fibrosis",0,"AZLI","Drug","Gilead Sciences","Industry",0,0,"All","6 Years","N/A","102","February 2010","September 2011","AUCave of Relative Change in FEV1 % Predicted From Baseline to Week 24","0.663","To correct for multiplicity, a family alpha spending rule was used to control the type 1 error rate of alpha=0.05.
A gate-keeping procedure to control family-wise Type 1 error was established a priori for primary and key secondary endpoints.","ANCOVA","0.91","Difference in least squares mean (LSM)","95","2-Sided","-3.24","5.06"
"2732","NCT01059799","Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","435","February 1, 2010","December 16, 2010","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"2733","NCT01059812","A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","424","February 2010","December 2010","Change in HbA1c (Glycosylated Haemoglobin) After 26 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"2734","NCT01060072","Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","Inflammation",0,"Loteprednol etabonate","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","407","February 2010","September 2010","Resolution of Anterior Chamber Cells.","0","0","0","0","0","0","0","0","0"
"2735","NCT01060592","LapBand Adjustment to Improve Early Weight Loss","Obesity",0,"EndoFLIP device (FDA Device Listing Number : D091203)","Device","Crospon","Industry",0,0,"All","18 Years","N/A","35","October 2009","December 2010","%Excess Weight Loss 4-6 Weeks After Surgery (Large and Small Bands)","0","0","0","0","0","0","0","0","0"
"2736","NCT01060943","An Efficacy and Safety Study of TheraFill® Versus KOKEN for 3 Months on Nasolabial Folds","Nasolabial Folds",0,"KOKEN","Device","Sewon Cellontech Co., Ltd.","Industry",0,0,"All","20 Years","N/A","73","May 2008","January 2009","Efficacy: Wrinkle Severity Rating Scale - Primary endpoint","0","0","0","0","0","0","0","0","0"
"2737","NCT01061372","12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects","Restless Legs Syndrome",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","0","May 2010","August 2011","Changes from baseline in RLS symptom severity using the International Restless Leg Group Rating Scale (IRLS) total score for efficacy assessment","0","0","0","0","0","0","0","0","0"
"2738","NCT01062477","A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants","Diphtheria",0,"DTaP//PRP-T Combined Vaccine","Biological","Sanofi","Industry",0,0,"All","60 Days","89 Days","1056","January 2010","September 2011","Immunogenicity: To provide information concerning the immunogenicity of ACTACEL vaccine after primary and booster vaccination.","0","0","0","0","0","0","0","0","0"
"2739","NCT01063036","Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment","Chronic Hepatitis B",0,"Entecavir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","144","May 2010","November 2012","Percentage of Participants With a Virologic Response at Week 48 - Treated Population","0","0","0","0","0","0","0","0","0"
"2740","NCT01063088","Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine","Influenza",0,"Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)","Biological","Nanotherapeutics, Inc.","Industry",0,0,"All","18 Years","59 Years","211","February 2010","March 2010","To assess the safety of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2009/2010 season in an adult population through the first seven post vaccination days","0","0","0","0","0","0","0","0","0"
"2741","NCT01063231","Evaluation of PillCam™ Colon 2 in Visualization of the Colon","Colonic Diseases",0,"PillCam™ (Capsule Endoscopy) Colon 2 capsule","Device","Given Imaging Ltd.","Industry",0,0,"All","18 Years","80 Years","119","September 2009","September 2010","Accuracy parameters of PillCam™ COLON 2 in detecting patients with colonic polyps ≥6mm and ≥10 mm as compared to conventional colonoscopy","0","0","0","0","0","0","0","0","0"
"2742","NCT01063764","An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures","Epilepsy",0,"Levetiracetam","Drug","UCB Japan Co. Ltd.","Industry",0,0,"All","4 Years","16 Years","73","January 2010","April 2011","Change From Baseline in Partial Seizure Frequency Per Week Over the 14-weeks Treatment Period","0","0","0","0","0","0","0","0","0"
"2743","NCT01063855","Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction","Erectile Dysfunction",0,"Placebo","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"Male","18 Years","N/A","495","April 2010","August 2011","The Average Intravaginal Ejaculatory Latency Time (IELT) at Week 12","<0.001","To properly adjust for multiplicity, a hierarchical (step-down) testing procedure with a priori ordered hypothesis was used to control the family-wise type I error was rate.","ANCOVA","1.69","Median Difference (Final Values)","95","2-Sided","0.837","2.542"
"2744","NCT01063868","A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)","Diabetic Neuropathy, Painful",0,"Tapentadol extended release (ER)","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","47","January 2010","April 2010","Number of Subjects With Treatment-emergent Adverse Events (TEAE)","0","0","0","0","0","0","0","0","0"
"2745","NCT01063920","Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®","Osteoarthritis",0,"LT-NS001","Drug","Logical Therapeutics","Industry",0,0,"All","45 Years","80 Years","534","February 2010","November 2010","Gastric Ulcer by Endoscopy","0","0","0","0","0","0","0","0","0"
"2746","NCT01064024","Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo","Pain",0,"Phenazopyridine Hydrochloride","Drug","Amneal Pharmaceuticals, LLC","Industry",0,0,"Female","18 Years","N/A","233","December 2009","December 2010","proportion of subjects in each treatment group who demonstrate reduction in pain or burning when passing urine.","0","0","0","0","0","0","0","0","0"
"2747","NCT01064310","Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer","Carcinoma, Renal Cell",0,"pazopanib","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","169","May 17, 2010","October 19, 2011","Number of Participants With Preference for Pazopanib Versus Sunitinib as Assessed by the Patient Preference Questionnaire (PPQ)","<0.001","The p value indicates the difference in preference for pazopanib versus sunitinib treatment","Prescotts test","49.26","Percentage of participants","90","2-Sided","37.0","61.5"
"2748","NCT01064414","An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","Diabetes Mellitus, Type 2",0,"Canagliflozin","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","25 Years","N/A","272","June 2010","December 2011","Change in HbA1c From Baseline to Week 26","0.012","0","ANCOVA","-0.30","Least-Squares Mean Difference","95","2-Sided","-0.529","-0.066"
"2749","NCT01064687","A Study in Participants With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2",0,"LY2189265","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","978","February 2010","November 2011","Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)","<0.001","P-value is adjusted for multiplicity based on a tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","ANCOVA","-1.05","LS Mean Difference","95","2-Sided","-1.22","-0.88"
"2750","NCT01064856","Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)","Peripheral Spondyloarthritis",0,"Adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","165","February 2010","August 2011","Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12","0.006","0","Pearson's chi-square","0","0","0","0","0","0"
"2751","NCT01064960","Therapeutic MRI-HIFU Ablation of Uterine Fibroids in a 3T MRI Scanner","Uterine Leiomyomas",0,"Philips MR-guided HIFU system","Device","Philips Healthcare","Industry",0,0,"Female","18 Years","59 Years","7","January 2010","July 2011","Safety of HIFU for treatment of the uterine fibroids as determined by adverse event reporting.","0","0","0","0","0","0","0","0","0"
"2752","NCT01065012","Treatment of Erectile Dysfunction - Long Term Safety and Efficacy","Erectile Dysfunction",0,"Udenafil 50 mg","Drug","Warner Chilcott","Industry",0,0,"Male","19 Years","N/A","1027","January 2010","February 2011","International Index of Erectile Function (IIEF) score","0","0","0","0","0","0","0","0","0"
"2753","NCT01065857","Safety and Efficacy Study of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.","Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time.",0,"Sodium picosulphate, light magnesium oxide and anhydride citric acid.","Drug","Laboratorios Casen-Fleet S.L.U.","Industry",0,0,"All","18 Years","80 Years","547","January 2010","June 2010","Percentage of subjects that achieve 'excellent' or 'good' cleansing in the Fleet® Grading Scale for Bowel Cleansing.","0","0","0","0","0","0","0","0","0"
"2754","NCT01066520","TAASS-Traumeel Ointment and Gel Compared With a Topical NSAID in Athletes With Acute Ankle Sprain","Sprain of Ankle",0,"Traumeel S ointment","Drug","Biologische Heilmittel Heel GmbH","Industry",0,0,"All","18 Years","40 Years","449","August 2009","September 2011","Patient's Assessment of Ankle Pain (VAS)- Absolute Value Decrease on Day 7","0","0","0","0","0","0","0","0","0"
"2755","NCT01066546","An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease","Alzheimer's Disease",0,"Dimebon tablet for oral administration","Drug","Pfizer","Industry",0,0,"All","50 Years","N/A","5","April 2010","July 2010","Number of Participants With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"2756","NCT01066585","A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation","Head Lice",0,"Ivermectin Cream","Drug","Topaz Pharmaceuticals Inc","Industry",0,0,"All","6 Months","N/A","410","March 2010","June 2010","Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)","0","0","0","0","0","0","0","0","0"
"2757","NCT01067105","A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","Perennial Allergic Rhinitis",0,"ciclesonide HFA 160 μg","Drug","Sunovion","Industry",0,0,"All","12 Years","N/A","824","February 2010","November 2010","Percentage of Subjects Experiencing Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"2758","NCT01067313","Continuous Hemodialysis With an Enhanced Middle Molecule Clearance Membrane","Septic Shock",0,"Dialyzer Ultraflux EMiC2","Device","Fresenius Medical Care France","Industry",0,0,"All","18 Years","N/A","24","July 2008","July 2010","Clearance of Urea","0","0","0","0","0","0","0","0","0"
"2759","NCT01067976","Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI","Breast Cancer",0,"Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","446","February 2010","July 2011","Difference for Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader","0","0","0","0","0","0","0","0","0"
"2760","NCT01068158","A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects","Head Lice",0,"0.5% Ivermectin Cream","Drug","Topaz Pharmaceuticals Inc","Industry",0,0,"All","5 Months","N/A","371","March 2010","June 2010","Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)","0","0","0","0","0","0","0","0","0"
"2761","NCT01068665","Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","460","March 2010","November 2010","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"2762","NCT01068678","Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","460","February 2010","November 2010","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"2763","NCT01069120","Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids","Uterine Fibroids",0,"Proellex","Drug","Repros Therapeutics Inc.","Industry",0,0,"Female","18 Years","N/A","27","April 2009","August 2009","To Assess the Incidence of Adverse Events (AE) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"2764","NCT01069172","Study of the Femtosecond Laser System as Compared to Continuous Curvilinear Capsulorhexis for Cataract Surgery","Cataract",0,"FS Laser Surgery","Device","Abbott Medical Optics","Industry",0,0,"All","50 Years","80 Years","30","February 2010","July 2010","Deviation From Intended Capsulotomy Diameter","0","0","0","0","0","0","0","0","0"
"2765","NCT01069289","Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients","Chronic Obstructive Pulmonary Disease",0,"Budesonide/formoterol (Symbicort Turbuhaler)","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","1293","January 2010","March 2011","Pre-dose Forced Expiratory Volume in One Second (FEV1)","0","0","0","0","0","0","0","0","0"
"2766","NCT01069939","Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin","Prevention",0,"Esomeprazole","Drug","AstraZeneca","Industry",0,0,"All","20 Years","N/A","427","February 2010","November 2011","Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis.","<0.001","An interim analysis was done so that the significance level was adjusted using the Pocock-like alpha-spending function with Lan-DeMets approach. The adjusted significance level was the two-sided 3.35%.","Log Rank","0.09","Hazard Ratio (HR)","96.65","2-Sided","0.02","0.41"
"2767","NCT01070303","Remission in Subjects With Crohn's Disease, Open Label Extension","Crohn's Disease",0,"Adalimumab 40 mg eow or ew","Biological","Abbott","Industry",0,0,"All","18 Years","75 Years","177","August 2002","December 2008","Number of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] <150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303).","0","0","0","0","0","0","0","0","0"
"2768","NCT01070784","A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan","Chronic Obstructive Pulmonary Disease",0,"Symbicort Turbuhaler (Budesonide/formoterol)","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","328","January 2010","October 2011","Clinical Laboratory Test: Haematology -Erythrocytes","0","0","0","0","0","0","0","0","0"
"2769","NCT01071902","Safety and Efficacy of Moxidex Otic","Acute Otitis Media",0,"Moxidex otic solution","Drug","Alcon Research","Industry",0,0,"All","6 Months","12 Years","400","February 2010","October 2011","Clinical Cure at End of Treatment","0","0","0","0","0","0","0","0","0"
"2770","NCT01071915","Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer","Prostate Cancer",0,"Degarelix 240/80 mg","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","157","March 2010","November 2011","Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) From Day 28 to Day 196","0","0","0","0","0","0","0","0","0"
"2771","NCT01072149","A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo","Pulmonary Disease, Chronic Obstructive",0,"Fluticasone Furoate (FF)/GW642444 Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","54","January 2010","July 2010","Time-adjusted Area Under the Curve (AUC) (i.e., Weighted Mean) for 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at the End of Each 28-day Treatment Period","<0.001","0","Mixed Models Analysis","0.233","Median Difference (Final Values)","95","2-Sided","0.179","0.287"
"2772","NCT01072188","Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste","Hypersensitivity",0,"Arginine/Calcium Carbonate","Device","Colgate Palmolive","Industry",0,0,"All","18 Years","70 Years","45","July 2008","August 2008","Hypersensitivity to Touch (Tactile)","0.05","0","ANCOVA","0","0","0","0","0","0"
"2773","NCT01072331","Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"MP-513","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","75 Years","99","February 2010","August 2010","Change From Baseline in 2-h Postprandial Glucose (Breakfast, Lunch and Dinner)","0","0","0","0","0","0","0","0","0"
"2774","NCT01072630","Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder","Depression",0,"Armodafinil","Drug","Cephalon","Industry",0,0,"All","18 Years","65 Years","492","March 2010","November 2012","Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)","0.1302","All statistical tests were 2-tailed at the 0.05 level of significance.","mixed-model repeated measures (MMRM)","-2.1","Mean Difference (Final Values)","95","2-Sided","-4.67","0.60"
"2775","NCT01072747","Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass","Prevention of Venous Thromboembolism",0,"bovine heparin","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","104","April 2010","August 2011","Coagulometric parameters markers heparin activity: ACT, APTT and Anti - Xa","0","0","0","0","0","0","0","0","0"
"2776","NCT01072929","A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder","Depression",0,"Armodafinil","Drug","Cephalon","Industry",0,0,"All","18 Years","65 Years","433","January 2010","March 2012","Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)","0.0097","All statistical tests were 2-tailed at the 0.05 level of significance.","mixed-model repeated measures (MMRM)","-3.8","Mean Difference (Final Values)","95","2-Sided","-6.58","-0.92"
"2777","NCT01072955","Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass","Prevention of Venous Thromboembolism",0,"Bovine Heparin","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","104","April 2010","August 2010","Coagulometric parameters markers heparin activity: ACT, APTT and Anti - Xa","0","0","0","0","0","0","0","0","0"
"2778","NCT01073293","A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)","Papillomavirus Infections",0,"V503 Vaccine","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","11 Years","15 Years","1054","April 22, 2010","June 16, 2011","Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503","<0.001","0","ANOVA","0.95","Fold difference in GMT","95","2-Sided","0.86","1.05"
"2779","NCT01073605","Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation","Growth Disorders",0,"Genotonorm","Drug","Pfizer","Industry",0,0,"All","3 Years","12 Years","208","July 1993","May 2009","Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm","0.02922","P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"2780","NCT01073865","Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer","Breast Cancer",0,"ZD9393 (Zoladex)","Drug","AstraZeneca","Industry",0,0,"Female","20 Years","130 Years","286","February 2010","September 2012","Number of Patients With Progression-free Survival (PFS) at 24 Weeks","0","0","0","1.29","Risk Difference (RD)","95","2-Sided","-11.40","13.90"
"2781","NCT01073930","Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep","Bowel Preparation",0,"PicoPrep","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","80 Years","608","May 2010","October 2010","Percentage of Participants Classified as Successes (Excellent and Good Ratings) According to the Aronchick Scale As Assessed by a Blinded Gastroenterologist","0","0","0","9.8","Mean Difference (Net)","97.5","1-Sided","3.4","0"
"2782","NCT01073943","Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep","Bowel Preparation",0,"PicoPrep","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","80 Years","603","May 2010","October 2010","Percentage of Participants Classified as Successes (Excellent and Good Ratings) According to the Aronchick Scale As Assessed by a Blinded Gastroenterologist","0","0","0","3.3","Mean Difference (Net)","97.5","1-Sided","-2.9","0"
"2783","NCT01074125","A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease","Hyperphosphatemia",0,"ferric citrate","Drug","Keryx Biopharmaceuticals","Industry",0,0,"All","18 Years","N/A","154","May 2010","November 2010","Change in Serum Phosphorus From Baseline to End of Treatment","<0.0001","0","Regression, Linear","-0.3376","Mean Difference (Final Values)","0","2-Sided","0","0"
"2784","NCT01074268","Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","456","February 2010","December 2010","Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"2785","NCT01075282","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)","Diabetes Mellitus, Type 2",0,"Insulin Glargine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","810","February 2010","May 2012","Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)","<0.001","P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","ANCOVA","-0.45","LS Mean Difference","95","2-Sided","-0.60","-0.29"
"2786","NCT01076075","A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","Type 2 Diabetes Mellitus",0,"Sitagliptin phosphate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","78 Years","427","June 3, 2010","July 11, 2011","Change From Baseline in Hemoglobin A1C (%) at Week 24","<0.001","0","ANCOVA","-0.68","Difference in Least Squares Means","95","2-Sided","-0.87","-0.50"
"2787","NCT01076088","Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)","Type 2 Diabetes Mellitus",0,"Sitagliptin 50 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","78 Years","744","November 15, 2010","December 24, 2012","Change From Baseline in Hemoglobin A1C (A1C) at Week 24","0.087","Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.","ANCOVA","-0.27","Difference in Least Squares Mean","95","2-Sided","-0.58","0.04"
"2788","NCT01076322","A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients","Asthma",0,"Meptin® Swinghaler","Drug","Taiwan Otsuka Pharm. Co., Ltd","Industry",0,0,"All","16 Years","N/A","17","March 2009","June 2010","The change in Forced Expiratory Volume in 1 second (FEV1) value.","0","0","0","0","0","0","0","0","0"
"2789","NCT01076582","Comparative Trial in Hormone Withdrawal Associated Symptoms","Oral Contraceptive",0,"EE20/DRSP (YAZ, BAY86-5300)","Drug","Bayer","Industry",0,0,"Female","18 Years","35 Years","592","April 2010","October 2011","Change from baseline to cycle 4 in the sum of composite score during cycle days 22 - 28. The composite score comprises headache, pelvic pain and bloating (each measured by 7-point Likert scales).","0","0","0","0","0","0","0","0","0"
"2790","NCT01076647","Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","467","March 2010","December 2010","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"2791","NCT01077076","Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)","Intragastric Acidity",0,"Zegerid","Drug","Bayer","Industry",0,0,"All","18 Years","65 Years","30","December 2008","March 2009","Percent Time With Intragastric pH>4 During the First 4 Hours Following Administration on Day 4 of Treatment","0","0","0","0","0","0","0","0","0"
"2792","NCT01077362","A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents","Arthritis, Psoriatic",0,"placebo","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","N/A","312","March 2010","March 2012","Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24.","<0.001","0","re-randomization test","0","0","0","0","0","0"
"2793","NCT01077973","Study Evaluating A Novel Ibuprofen Formulation In Episodic Tension-Type Headache","Pain",0,"Novel Ibuprofen","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","200","March 2010","October 2010","Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet","0.299","p-value was calculated using ANOVA model with treatment, baseline Pain Severity Rating (PSR), gender and treatment-by-baseline PSR terms.","ANOVA","-1.12","Least-square (LS) mean difference","95","2-Sided","-3.23","1.00"
"2794","NCT01078753","Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis","Nocturnal Enuresis",0,"Desmopressin","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","6 Years","15 Years","89","January 2010","September 2010","Change in the Number of Wet Nights Between Baseline and Treatment Period II","0.009","Desmopressin was considered to be superior to Placebo if the p-value for the comparison was < 0.05 and the reduction from Baseline in number of wet nights was larger in the FE992026 group than in the Placebo group.","ANCOVA","1.813","Least Squares Mean Difference","95","2-Sided","0.462","3.163"
"2795","NCT01079117","Morphine Slow-release Capsules in Substitution Therapy","Opiate Dependent",0,"Sevre-Long™","Drug","Mundipharma Medical Company","Industry",0,0,"All","18 Years","N/A","276","October 2006","June 2011","Proportion of positive urine tests for by-consumption of target substances per subject","0","0","0","0","0","0","0","0","0"
"2796","NCT01079234","Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","493","March 2010","November 2010","Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"2797","NCT01079676","A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer","Neutropenia in Breast Cancer",0,"Filgrastim (Eurofarma)","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"Female","18 Years","N/A","220","March 2011","April 2011","The study primary endpoint will be the rate of grade 4 neutropenia after the first cycle of chemotherapy, according to the classification Common Terminology Criteria for Adverse Events (CTC-AE)","0","0","0","0","0","0","0","0","0"
"2798","NCT01080261","PROMUS Element Japan Small Vessel Trial","Atherosclerosis",0,"PROMUS Element","Device","Boston Scientific Corporation","Industry",0,0,"All","20 Years","N/A","60","February 2010","March 2011","Major Adverse Cardiac Events (MACE) (Percentage of Participants With an Event)","<0.0001","0","One-group exact binomial test","0","Percent of patients experiencing a MACE","95","1-Sided","0","4.9"
"2799","NCT01080300","Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women","Hot Flashes",0,"Gabapentin Extended Release","Drug","Depomed","Industry",0,0,"Female","18 Years","70 Years","600","August 2010","September 2011","Evaluate Efficacy of G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.","<0.0001","P-value for the test of difference of the least square mean change from baseline between Gabapentin ER 1800 mg and placebo group is based on the F-test of Type III analysis.","ANCOVA","-1.70","Mean Difference (Net)","95","0","-2.31","-1.09"
"2800","NCT01081834","The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial","Diabetes Mellitus, Type 2",0,"Canagliflozin","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","80 Years","678","March 2010","August 2011","Change in HbA1c From Baseline to Week 26 (Main Study)","<0.001","0","ANCOVA","-0.91","Least-Squares Mean Difference","95","2-Sided","-1.088","-0.729"
"2801","NCT01081912","Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain","Back Pain Lower Back Chronic",0,"Placebo","Drug","Zogenix, Inc.","Industry",0,0,"All","18 Years","75 Years","510","March 2010","October 2011","Mean Change in 24-hour Pain Intensity Ratings Scale (NRS).","0","0","0","0","0","0","0","0","0"
"2802","NCT01084148","Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis","Uremic Xerosis",0,"V0034CR01B","Drug","Orfagen","Industry",0,0,"All","18 Years","N/A","237","January 2007","January 2009","Treatment Response of Xerosis","0","0","0","0","0","0","0","0","0"
"2803","NCT01084551","Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)","Idiopathic Restless Legs Syndrome",0,"SPM 962","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","79 Years","284","February 2010","September 2011","International Restless Legs Syndrome Rating Scale (IRLS) Total Score","0","0","0","0","0","0","0","0","0"
"2804","NCT01084876","Demonstrate Efficacy and Safety of Metastatic Breast Cancer","Metastatic Breast Cancer",0,"CT-P6","Drug","Celltrion","Industry",0,0,"Female","18 Years","N/A","383","June 2010","December 2011","To Compare Efficacy","0","0","0","0","0","0","0","0","0"
"2805","NCT01085812","Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder","Depression",0,"F2695 SR","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","65 Years","348","March 2010","October 2011","The primary outcome measure is the time to relapse (in days) during the double-blind treatment phase","0","0","0","0","0","0","0","0","0"
"2806","NCT01086384","Asthma Exacerbation Study","Asthma",0,"Fluticasone Furoate/GW642444","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","2020","February 2010","September 2011","Number of Participants With 1 or More Severe Asthma Exacerbations","0","0","0","0.795","Regression Cox","95","2-Sided","0.642","0.985"
"2807","NCT01086410","Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis","Asthma",0,"Placebo Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","65 Years","185","March 2010","September 2010","Ratio From Baseline of the Serum Cortisol Weighted Mean (0-24 Hours) on Day -1/1 (Baseline) and Day 42","0","0","0","0.99","Ratio of least square gometric mean","95","2-Sided","0.87","1.12"
"2808","NCT01086553","9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease","Crohn´s Disease",0,"budesonide","Drug","Dr. Falk Pharma GmbH","Industry",0,0,"All","18 Years","75 Years","471","November 2009","May 2012","Rate of clinical remission, defined as a CDAI < 150, at week 8 (LOCF)","0","0","0","0","0","0","0","0","0"
"2809","NCT01086865","Clinical Study Phase III, Randomized, Double-blind, Prospective and Comparative to Evaluate the Efficacy and Tolerability of Using APETIVITON BC Compared to Petivit BC in Appetite Stimulate.","Inappetence",0,"Apetiviton BC","Drug","Cifarma Cientifica Farmaceutica Ltda","Industry",0,0,"All","2 Years","80 Years","150","August 2010","November 2010","Evaluate the effectiveness of apetiviton BC compared to Petivit BC in appetite stimulation in children, adults and seniors.","0","0","0","0","0","0","0","0","0"
"2810","NCT01086969","A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India","Meningococcal Infection",0,"Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)","Biological","Sanofi","Industry",0,0,"All","2 Years","55 Years","300","June 2010","February 2011","Number of Participants With Vaccine Antibody Titers at ≥ 8 Before and After Menactra Vaccination","0","0","0","0","0","0","0","0","0"
"2811","NCT01087528","Evaluation of PillCam™ Colon 2 in Visualization of the Colon","Colonic Diseases",0,"PillCam™ (Capsule Endoscopy) Colon 2 capsule","Device","Given Imaging Ltd.","Industry",0,0,"All","18 Years","70 Years","51","July 2009","May 2010","Sensitivity of Capsule Endoscopy for Indicated Polyps","0","0","0","0","0","0","0","0","0"
"2812","NCT01087671","Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops","Ocular Hypertension",0,"tafluprost","Drug","Santen Oy","Industry",0,0,"All","18 Years","N/A","185","April 2010","October 2010","Assessment of changes in ocular symptoms and signs","0","0","0","0","0","0","0","0","0"
"2813","NCT01087762","Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis","Spondyloarthropathies",0,"CZP 200 mg Q2W","Biological","UCB BIOSCIENCES GmbH","Industry",0,0,"All","18 Years","N/A","325","March 2010","October 2011","Assessment in Axial Spondyloarthritis International Society 20 % (ASAS20) Response Criteria at Week 12","=0.004","Difference of Certolizumab Pegol 200 mg versus Placebo (and corresponding 95 % Confidence Interval and p-value) were estimated using a standard two-sided Wald asymptotic test with a 5 % alpha level.","Wald-test, 2-sided","19.3","Mean Difference (Final Values)","95","2-Sided","6.3","32.4"
"2814","NCT01087788","Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis","Arthritis, Psoriatic",0,"CZP 200 mg Q2W","Biological","UCB BIOSCIENCES GmbH","Industry",0,0,"All","18 Years","N/A","409","March 2010","November 2011","American College of Rheumatology 20 (ACR20) Response at Week 12","<0.001","Difference of Certolizumab Pegol 200 mg versus Placebo (and corresponding 95 % Confidence Interval and p-value) were estimated using a standard two-sided Wald asymptotic test with a 5 % alpha level.","Wald-test, 2-sided","33.7","Difference in Percentages","95","2-Sided","22.8","44.6"
"2815","NCT01087801","A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers","Pancreatic Disease",0,"ChiRhoStim","Drug","ChiRhoClin, Inc.","Industry",0,0,"All","18 Years","N/A","64","October 2007","November 2009","Endoscopic Sample","0","0","0","0","0","0","0","0","0"
"2816","NCT01089348","A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial Vaginosis","Bacterial Vaginosis",0,"Lactofiltrum + Metronidazole","Drug","Avva Rus, JSC","Industry",0,0,"Female","18 Years","45 Years","90","July 2010","October 2010","Self-reported complaints","0","0","0","0","0","0","0","0","0"
"2817","NCT01089556","A Study in Painful Diabetic Neuropathy","Diabetic Neuropathy, Painful",0,"Duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","811","March 2010","November 2011","Change From Week 8 to Week 16 Endpoint in 24 Hour Average Pain Item Score on the Brief Pain Inventory (BPI) Modified Short Form","0.370","0","Mixed Models Analysis","-0.192","LS Mean Differences (Final Values)","95","0","0","0"
"2818","NCT01089725","Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study","Osteoarthritis",0,"Placebo IV","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","385","March 2010","November 2010","Change from Baseline to Week 16 in the Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain subscale","0","0","0","0","0","0","0","0","0"
"2819","NCT01089790","Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone","Diabetes Mellitus, Type 2",0,"Dutogliptin","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","86 Years","141","March 2010","August 2010","To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG","0","0","0","0","0","0","0","0","0"
"2820","NCT01090310","Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis","Non-infectious Uveitis",0,"AIN457","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","86","August 2010","July 2011","The Time to the First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline","0","0","0","0","0","0","0","0","0"
"2821","NCT01091246","A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children","Healthy or Stable Chronic Illness",0,"Q/LAIV (MEDI3250)","Biological","MedImmune LLC","Industry",0,0,"All","2 Years","17 Years","2312","March 2010","July 2010","The 4 Post-dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) in the Q/LAIV (MEDI3250) Arm Are Noninferior to Those in the Comparator FluMist Group.","0","0","0","1.07","Ratio of geometric mean","95","2-Sided","0.98","1.16"
"2822","NCT01091662","Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic","Epilepsy",0,"Eslicarbazepine acetate 1600 mg","Drug","Sunovion","Industry",0,0,"All","16 Years","70 Years","172","June 2010","November 2012","Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method","0","0","0","0","0","0","0","0","0"
"2823","NCT01092507","A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers","Encephalitis",0,"Japanese encephalitis chimeric virus vaccine (JE-CV)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","9 Months","18 Months","300","March 2010","September 2011","Number of Participants With Japanese Encephalitis Seroconversion After Vaccination With One Dose of Either Japanese Encephalitis Chimeric Vaccine (JE-CV) or Japanese Encephalitis Live Vaccine (SA14-14-2) (CD.JEVAX®)","0","0","0","0","0","0","0","0","0"
"2824","NCT01092546","Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus","Normal Pressure Hydrocephalus",0,"[18F]Flutemetamol","Drug","GE Healthcare","Industry",0,0,"All","50 Years","N/A","12","March 2010","April 2011","Standard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the ""Cerebellum"" (CER) as the Reference Region.","0","0","0","0","0","0","0","0","0"
"2825","NCT01094886","Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement","Arthritis",0,"Rivaroxaban","Drug","Ortho-McNeil Janssen Scientific Affairs, LLC","Industry",0,0,"All","18 Years","99 Years","56","March 2010","December 2010","Summary of Change From Day 3 to Day 1 in Maximum Anti-Factor Xa (aFXa)",".008","0","t-test, 2 sided","0.20","Mean Difference (Final Values)","95","2-Sided","-0.05","0.34"
"2826","NCT01095003","Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer","Breast Cancer",0,"Vinflunine plus Capecitabine","Drug","Pierre Fabre Medicament","Industry",0,0,"Female","21 Years","N/A","770","May 2009","December 2011","Progression Free Survival","0","0","0","0","0","0","0","0","0"
"2827","NCT01095016","A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients","Asthma",0,"Meptin swinghaler","Drug","Taiwan Otsuka Pharm. Co., Ltd","Industry",0,0,"All","18 Years","N/A","32","March 2010","September 2012","The change of Forced Expiratory Volume in 1 second (FEV1) value","0","0","0","0","0","0","0","0","0"
"2828","NCT01095653","A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","1179","June 2010","March 2012","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])","<0.0001","Primary endpoints were tested at alpha=0.027 applying Dunnett’s adjustment","ANCOVA","-0.75","Mean Difference (Final Values)","95","2-Sided","-0.94","-0.56"
"2829","NCT01095796","Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","HIV",0,"Stribild","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","707","March 2010","August 2011","The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48","0","0","0","3.6","Difference in response rates","95.2","2-Sided","-1.6","8.8"
"2830","NCT01096017","To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study","Asthma",0,"Terbutaline Turbuhaler®","Drug","AstraZeneca","Industry",0,0,"All","16 Years","N/A","24","March 2010","April 2010","FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation","0","0","0","0","0","0","0","0","0"
"2831","NCT01096186","An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease","Parkinson's Disease",0,"IPX066 95 mg","Drug","IMPAX Laboratories, Inc.","Industry",0,0,"All","30 Years","N/A","617","March 2010","October 2011","Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III","0","0","0","0","0","0","0","0","0"
"2832","NCT01096615","Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens","Rhinitis",0,"Placebo","Dietary Supplement","Merck Medication Familiale","Industry",0,0,"All","18 Years","60 Years","500","April 2010","September 2011","The primary criterion is the RQLQ global score measured at the end of Week 0 and Week 5.","0","0","0","0","0","0","0","0","0"
"2833","NCT01097018","Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer","Colorectal Cancer",0,"Capecitabine","Drug","AEterna Zentaris","Industry",0,0,"All","18 Years","N/A","468","April 2010","April 2012","Overall Survival","0","0","0","0","0","0","0","0","0"
"2834","NCT01097616","Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)","Primary Insomnia",0,"Suvorexant High Dose (HD)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1023","May 2010","September 2011","Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1","<0.00001","By multiplicity strategy above, overall Type I error among primary hypotheses was controlled at two-sided 5% significance level.","Longitudinal Data Analysis","19.6","Difference in Least Squares Means","95","2-Sided","12.0","27.1"
"2835","NCT01097629","Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)","Primary Insomnia",0,"Suvorexant High Dose (HD)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1020","May 2010","November 2011","Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1","<0.00001","By multiplicity strategy above, overall Type I error among primary hypotheses was controlled at two-sided 5% significance level.","Longitudinal Data Analysis","26.3","Difference in Least Squares Means","95","2-Sided","18.3","34.3"
"2836","NCT01098539","A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.","Diabetes Mellitus, Type 2",0,"albiglutide","Biological","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","507","May 2010","November 2012","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26","<0.0001","0","t-test, 1 sided","-0.32","Median Difference (Final Values)","95","2-Sided","-0.49","-0.15"
"2837","NCT01098747","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain","Pain",0,"Novel Ibuprofen","Drug","Pfizer","Industry",0,0,"All","16 Years","40 Years","335","April 2010","July 2010","Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-8 Hours (SPRID 0-8)","<0.001","p-value was calculated using ANOVA model with treatment, baseline Pain Severity Rating (PSR) and gender terms.","ANOVA","24.21","Least-square (LS) mean difference","95","2-Sided","19.32","29.09"
"2838","NCT01098812","Clinical Evaluation of a 1-Piece Intraocular Lens","Cataract",0,"Tecnis ZCB00 IOL (control)","Device","Abbott Medical Optics","Industry",0,0,"All","18 Years","N/A","269","March 2010","October 2011","Mean Percent Reduction in Cylinder","<0.0001","Primary study endpoint; therefore, no adjustment for multiple comparisons. The planned alpha level for testing was 0.025.","t-test, 1 sided","43","Mean Difference (Final Values)","90","1-Sided","25","0"
"2839","NCT01099319","Renalof in the Treatment of Elderly Patients With Gallstones","Cholelithiasis",0,"Renalof","Dietary Supplement","Catalysis SL","Industry",0,0,"All","65 Years","N/A","40","January 2010","June 2011","Size of calculi at month 0 and 6 (month 0 refers to the beginning of treatment and month 6 refers to the end of the treatment)","0","0","0","0","0","0","0","0","0"
"2840","NCT01099579","PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)","HIV Infections",0,"Atazanavir powder","Drug","Bristol-Myers Squibb","Industry",0,0,"All","3 Months","66 Months","82","November 2011","October 2012","Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation","0","0","0","0","0","0","0","0","0"
"2841","NCT01099722","Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma","Asthma",0,"Flutiform","Drug","Mundipharma Research Limited","Industry",0,0,"All","12 Years","N/A","261","April 2010","November 2010","non-inferiority in the efficacy of FlutiForm®","0","0","0","0","0","0","0","0","0"
"2842","NCT01099774","Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","Glaucoma",0,"Bimatoprost 0.03% Formulation B Ophthalmic Solution","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","597","May 2010","April 2011","Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12","0","0","0","0","0","0","0","0","0"
"2843","NCT01100112","(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets","Colitis, Ulcerative",0,"Budesonide","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","75 Years","61","February 2010","July 2010","The Percentage of Patients Achieving Clinical Remission","0","0","0","0","0","0","0","0","0"
"2844","NCT01100164","A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia","INSOMNIA",0,"Eszopiclone","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","20 Years","64 Years","263","March 2011","March 2012","Latency to persistent sleep measured by polysomnography","0","0","0","0","0","0","0","0","0"
"2845","NCT01100307","A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema","Macular Edema",0,"pegaptanib sodium","Drug","Pfizer","Industry",0,0,"All","20 Years","N/A","243","May 2010","August 2012","Number of Participants Who Experience a ≥10 Letter Improvement of Visual Acuity (VA) in Early Treatment Diabetic Retinopathy Study (ETDRS) Chart From Baseline at Week 24: Double Masked Phase","0.0003","Significance level of test in the comparison between pegaptanib sodium 0.3 mg and sham was set to 0.05.","Cochran-Mantel-Haenszel","4.85","Odds Ratio (OR)","95","2-Sided","1.92","12.28"
"2846","NCT01101399","Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy","Iron-Deficiency Anemia",0,"Ferric carboxymaltose","Drug","Vifor Inc.","Industry",0,0,"All","18 Years","N/A","19","May 2010","November 2012","Change in haemoglobin from baseline to Week 4","0","0","0","0","0","0","0","0","0"
"2847","NCT01101841","24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms","Hot Flashes",0,"Brisdelle (paroxetine mesylate)","Drug","Noven Therapeutics","Industry",0,0,"Female","40 Years","N/A","570","March 2010","September 2011","Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12.","<0.0001","Week 4 frequency","Rank transformed ANCOVA","0","0","0","0","0","0"
"2848","NCT01102114","A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation","Smoking Cessation",0,"NicVAX Vaccine","Biological","Nabi Biopharmaceuticals","Industry",0,0,"All","18 Years","65 Years","1000","March 2010","November 2011","Evaluate NicVAX as an aid to smoking cessation for long term abstinence (by subject self-report and carbon monoxide confirmation).","0","0","0","0","0","0","0","0","0"
"2849","NCT01102244","A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis","Blepharitis",0,"Tobradex ST","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","122","April 2010","June 2010","Global sign and symptom score for blepharitis","0","0","0","0","0","0","0","0","0"
"2850","NCT01103323","Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","Metastatic Colorectal Cancer",0,"Regorafenib (Stivarga, BAY73-4506)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","760","April 2010","July 2011","Overall Survival","0.005178","According to protocol specified O'Brien-Fleming type alpha spending function and 432 death events at 2nd IA, the pre-specified alpha (false positive rate) for this analysis was 0.009279 (1-sided).","Log Rank","0.774","Hazard Ratio (HR)","95","0","0.636","0.942"
"2851","NCT01103362","A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder","Sexual Dysfunctions, Psychological",0,"flibanserin","Drug","Sprout Pharmaceuticals, Inc","Industry",0,0,"Female","18 Years","N/A","596","April 2010","January 2011","The Frequency of Adverse Events","0","0","0","0","0","0","0","0","0"
"2852","NCT01104584","Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)","Breast Cancer",0,"Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","460","May 2010","September 2011","Difference of Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader","0","0","0","0","0","0","0","0","0"
"2853","NCT01104766","Safety and Efficacy of Cariprazine in Patients With Schizophrenia","Schizophrenia",0,"Cariprazine","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","60 Years","617","April 2010","December 2011","Measurement of schizophrenia symptoms: Positive and Negative Syndrome Scale (PANSS) total score","0","0","0","0","0","0","0","0","0"
"2854","NCT01104779","Safety and Efficacy of Cariprazine in Schizophrenia","Schizophrenia",0,"Cariprazine","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","60 Years","459","April 2010","December 2011","Measurement of schizophrenia symptoms: Positive and Negative Syndrome Scale (PANSS) total score","0","0","0","0","0","0","0","0","0"
"2855","NCT01105013","Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections","Fungal Infections",0,"Clotrimazole","Drug","Laboratório Teuto Brasileiro S/A","Industry",0,0,"All","12 Years","N/A","90","April 2012","July 2012","Evaluate the efficacy and safety of the tolnaftate cream 10 mg / g.","0","0","0","0","0","0","0","0","0"
"2856","NCT01105559","Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine","Diphtheria",0,NA,NA,"Sanofi","Industry",0,0,"All","41 Months","43 Months","455","April 2010","November 2011","The antibody titers for each valence of DTaP-IPV-Hep B-PRP-T vaccine (except poliovirus) post-primary and booster vaccination.","0","0","0","0","0","0","0","0","0"
"2857","NCT01106040","Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes","Breast Cancer",0,"Lymphoseek","Drug","Navidea Biopharmaceuticals","Industry",0,0,"All","18 Years","N/A","163","June 2010","April 2011","Concordance of Blue Dye and Lymphoseek","0","0","0","0","0","0","0","0","0"
"2858","NCT01106131","Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin","Type 2 Diabetes Mellitus",0,"CKD-501 0.5mg","Drug","Chong Kun Dang Pharmaceutical","Industry",0,0,"All","18 Years","80 Years","253","May 2010","April 2012","Change from baseline in Glycosylated Hemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"2859","NCT01106430","Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate","Attention-Deficit/Hyperactivity Disorder",0,"Lisdexamfetamine Dimesylate","Drug","Shire","Industry",0,0,"All","6 Years","17 Years","267","June 2010","July 2012","Time to First Response","=0.001","0","Peto-Peto-Prentice Wilcoxon Test","0","0","0","0","0","0"
"2860","NCT01106586","Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","HIV",0,"Stribild","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","708","April 2010","September 2011","The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48","0","0","0","3.0","Difference in response rates","95.2","2-Sided","-1.9","7.8"
"2861","NCT01106625","The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)","Diabetes Mellitus, Type 2",0,"Canagliflozin","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","80 Years","469","May 2010","September 2011","Change in HbA1c From Baseline to Week 26","<0.001","0","ANCOVA","-0.71","Least-Squares Mean Difference","95","2-Sided","-0.904","-0.524"
"2862","NCT01106651","A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2",0,"Canagliflozin 100 mg","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","55 Years","80 Years","716","June 2010","November 2011","Change in HbA1c From Baseline to Week 26","<0.001","0","ANCOVA","-0.57","Least-Squares Mean Difference","95","2-Sided","-0.708","-0.436"
"2863","NCT01106677","The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","Diabetes Mellitus, Type 2",0,"Placebo","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","80 Years","1284","May 2010","October 2011","Change in HbA1c From Baseline to Week 26","<0.001","0","ANCOVA","-0.62","Least-Squares Mean Difference","95","2-Sided","-0.758","-0.481"
"2864","NCT01106690","The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)","Diabetes Mellitus, Type 2",0,"Placebo","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","80 Years","344","June 2010","November 2011","Change in HbA1c From Baseline to Week 26","<0.001","0","ANCOVA","-0.62","Least-Squares Mean Difference","95","2-Sided","-0.811","-0.437"
"2865","NCT01108510","Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","HIV",0,"COBI","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","698","April 2010","November 2011","Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48","0","0","0","-2.2","Difference in percentages","95.2","2-Sided","-7.4","3.0"
"2866","NCT01109173","Confirmatory Study Nepafenac 0.3%","Cataract",0,"Nepafenac Ophthalmic Suspension, 0.3%","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","2120","June 2010","May 2011","Percentage of Patients Cured at Day 14","0","0","0","0","0","0","0","0","0"
"2867","NCT01109316","Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","Diabetes Mellitus, Type 1",0,"Insulin lispro 2 day reservoir in-use","Drug","Eli Lilly and Company","Industry",0,0,"All","13 Years","N/A","132","April 2010","August 2011","Mean of Last Five 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Day 2 for Insulin Lispro 2D and Day 6 for Insulin Aspart 6D Pump Reservoir In-use","0","0","0","0.48","Least Squares Mean Difference","95","2-Sided","0.20","0.76"
"2868","NCT01110330","An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot","Tinea Pedis",0,"Placebo cream","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","N/A","583","July 2007","October 2008","The Number of Patients in the Positive Baseline Culture Set (PBCS) With Mycological Cure (MC) at Week 6","0","0","0","0","0","0","0","0","0"
"2869","NCT01110421","A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia","Pneumonia, Bacterial",0,"Cefepime placebo","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","3 Months","18 Years","7","December 2010","March 2012","The Number of Participants With Clinical Cure Rate at Test Of Cure (TOC) Visit","0","0","0","0","0","0","0","0","0"
"2870","NCT01110512","Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)","Venous Insufficiency",0,"Flavonid","Drug","Azidus Brasil","Industry",0,0,"All","18 Years","75 Years","140","October 2010","December 2010","Improvement of the parameters of CVI, such as edema of lower members.","0","0","0","0","0","0","0","0","0"
"2871","NCT01110629","Study in Chronic Kidney Disease (CKD) Not on Dialysis","Hyperphosphatemia",0,"Fosrenol (Lanthanum Carbonate, BAY77-1931)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","143","June 2010","November 2011","The change from baseline in serum phosphate concentrations","0","0","0","0","0","0","0","0","0"
"2872","NCT01110720","Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy","Progressive Supranuclear Palsy",0,"Davunetide","Drug","Allon Therapeutics","Industry",0,0,"All","41 Years","85 Years","313","October 2010","November 2012","Efficacy, as measured by change from baseline scores of the Progressive Supranuclear Palsy Rating Scale (PSPRS) at 52 weeks","0","0","0","0","0","0","0","0","0"
"2873","NCT01110746","To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy","Type 1 Diabetes Mellitus",0,"Viaject 7","Drug","Biodel","Industry",0,0,"All","18 Years","75 Years","20","February 2010","June 2010","3 hour incremental area under the glucose curve after a standardized high glycemic index meal.","0","0","0","0","0","0","0","0","0"
"2874","NCT01111344","Glizigen-Viudid-External Anogenital Warts in Children and Adolescents","External Anogenital Warts",0,"Glizigen + Viusid","Dietary Supplement","Catalysis SL","Industry",0,0,"All","10 Years","18 Years","76","December 2010","September 2011","Time to lesion regression","0","0","0","0","0","0","0","0","0"
"2875","NCT01111383","A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®","Cystic Fibrosis",0,"tobramycin","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","6 Years","N/A","209","September 2009","May 2011","to assess safety profile in terms of incidence of adverse events/adverse drug reactions, frequency of cystic fibrosis exacerbations, audiometric test, laboratory parameters (hematology and blood chemistry), vitals signs (hr and bp), physical examination.","0","0","0","0","0","0","0","0","0"
"2876","NCT01111539","Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)","Major Depressive Disorder (MDD)",0,"Escitalopram","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","84","July 2010","July 2011","Mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","0","0","0","0","0","0","0","0","0"
"2877","NCT01111552","Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)","Major Depressive Disorder (MDD)",0,"Escitalopram","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","66","July 2010","July 2011","Mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","0","0","0","0","0","0","0","0","0"
"2878","NCT01112267","An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain","Low Back Pain",0,"Tramadol HCl/acetaminophen Extended Release","Drug","Janssen Korea, Ltd., Korea","Industry",0,0,"All","25 Years","75 Years","248","May 2009","October 2009","Percentage of Participants With Reduction in Pain Intensity","0.0367","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"2879","NCT01112644","Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms","Moderate to Severe Idiopathic RLS With Daytime Symptoms",0,"Oxycodone naloxone prolonged release tablets (OXN PR)","Drug","Mundipharma Research GmbH & Co KG","Industry",0,0,"All","18 Years","N/A","205","April 2010","June 2011","Changes in the IRLS score between the two treatment arms will be compared","0","0","0","0","0","0","0","0","0"
"2880","NCT01112696","An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor","Type 1 Diabetes Mellitus",0,"Sensor wear","Device","Medtronic Diabetes","Industry",0,0,"All","18 Years","75 Years","100","April 2010","November 2010","Glucose Sensor Accuracy When Compared to Laboratory Standard (YSI): Proportion of Glucose Sensor Readings That Met Accuracy Criteria","0","0","0","0","0","0","0","0","0"
"2881","NCT01112865","Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects","Growth Hormone Deficiency",0,"Genotropin Pen","Device","Pfizer","Industry",0,0,"All","4 Years","N/A","120","August 2010","October 2011","Percentage of Dyads (Participant and Caregiver or Parent) and Adult Participants Reporting no Difference or Easier to Use for the New Genotropin Mark VII Injection Pen Compared to the Genotropin Pen®","0","0","0","0","0","0","0","0","0"
"2882","NCT01113346","A Pilot Study of Filtrum-STI in Children With Viral Gastroenteritis","Viral Gastroenteritis",0,"Filtrum-STI (lignin hydrolytic)","Drug","Avva Rus, JSC","Industry",0,0,"All","1 Month","4 Years","150","June 2010","December 2010","Severity of gastroenteritis","0","0","0","0","0","0","0","0","0"
"2883","NCT01113541","One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome","Bipolar Disorder",0,"Ziprasidone HCL (oral)","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","13","July 2010","February 2011","Percentage of Participants Who Achieved a Reduction From Baseline of at Least 1 Risk Factor for Metabolic Syndrome (MS) at Week 52 or Premature Discontinuation","0","0","0","0","0","0","0","0","0"
"2884","NCT01113931","Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin","Urogential Chlamydia Trachomatis Infection",0,"Doxycyline Hyclate tablet","Drug","Warner Chilcott","Industry",0,0,"All","19 Years","45 Years","495","April 2010","October 2010","Microbiological Cure Rate","0","0","0","0.3","Difference in Percent Cure Rates","95","2-Sided","-4.6","5.1"
"2885","NCT01114139","A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia","Iron Deficiency Anemia",0,"Ferumoxytol","Drug","AMAG Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","812","June 2010","February 2012","Hemoglobin changes","0","0","0","0","0","0","0","0","0"
"2886","NCT01114204","A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia","Iron Deficiency Anemia",0,"Ferumoxytol","Drug","AMAG Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","605","June 2010","November 2011","Hemoglobin changes","0","0","0","0","0","0","0","0","0"
"2887","NCT01114217","Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia","Iron Deficiency Anemia",0,"Ferumoxytol","Drug","AMAG Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","634","July 2010","September 2012","Hemoglobin changes","0","0","0","0","0","0","0","0","0"
"2888","NCT01114308","A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction","Opioid Dependency",0,"Probuphine (buprenorphine implant)","Drug","Braeburn Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","287","April 2010","May 2011","CDF of the percent of urine samples negative for opioids in Probuphine and Placebo groups from weeks 1-24","0","0","0","0","0","0","0","0","0"
"2889","NCT01114828","A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema","Cirrhosis",0,"OPC-41061","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","80 Years","40","February 2010","October 2011","Body Weight","0","0","0","0","0","0","0","0","0"
"2890","NCT01114880","Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis","Ankylosing Spondylitis",0,"adalimumab","Biological","Abbott","Industry",0,0,"All","18 Years","65 Years","344","January 2010","September 2010","Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria","< 0.001","0","Chi-squared","0","0","0","0","0","0"
"2891","NCT01115569","Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain","Chronic Pain",0,"Hydrocodone Bitartrate","Drug","Zogenix, Inc.","Industry",0,0,"All","18 Years","75 Years","424","May 2010","January 2012","Mean Change in Average Daily Pain","0","0","0","0","0","0","0","0","0"
"2892","NCT01115582","Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis","Inborn Errors of Bile Acid Synthesis",0,"Cholic acid","Drug","Retrophin, Inc.","Industry",0,0,"All","N/A","N/A","16","April 2010","August 2010","Serum Transaminases","0","0","0","0","0","0","0","0","0"
"2893","NCT01115673","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery","Pain",0,"Acetaminophen","Drug","McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.","Industry",0,0,"All","16 Years","50 Years","540","June 2010","January 2011","Overall Analgesic Efficacy - Sum of Pain Intensity Difference and Pain Relief Scores Over Six Hours (SPRID6)","<0.001","0","ANOVA","469.37","Mean Difference (Final Values)","0","0","0","0"
"2894","NCT01116206","An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation","Constipation",0,"Prucalopride","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","65 Years","507","May 2010","March 2011","Percentage of Participants With an Average of 3 or More Spontaneous Complete Bowel Movements (SCBMs)","0","0","0","0","0","0","0","0","0"
"2895","NCT01116778","the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis","Perennial Allergic Rhinitis",0,"eN-Lac®","Biological","GenMont Biotech Incorporation","Industry",0,0,"All","5 Years","16 Years","236","May 2010","January 2012","Evaluate the efficacy profile of probiotics Lactobacillus paracasei GMNL-32 (eN-Lac®) in children with perennial allergic rhinitis.","0","0","0","0","0","0","0","0","0"
"2896","NCT01117051","Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation","Non-cancer Pain",0,"placebo","Drug","Shire","Industry",0,0,"All","18 Years","N/A","174","May 2010","August 2012","Percent of Subjects With an Average Frequency of >=3 Spontaneous Bowel Movements Per Week","0.305","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"2897","NCT01117220","Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196)","Bipolar Disorder",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","10 Years","17 Years","0","June 2010","April 2011","Change from baseline to Week 4 in Young Mania Rating Scale (YMRS) total score.","0","0","0","0","0","0","0","0","0"
"2898","NCT01117636","Evaluate Analgesic Efficacy of Fast Release Aspirin","Drugs, Investigational",0,"Acetylsalicylic acid (Fast release Aspirin, BAY1019036)","Drug","Bayer","Industry",0,0,"All","16 Years","45 Years","514","April 2010","July 2010","Time to First Perceptible Pain Relief (PR)","0","0","0","0","0","0","0","0","0"
"2899","NCT01118572","A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients","Post Operative Pain",0,"YM177","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","616","February 2010","November 2010","Patient impressions (4-categorical assessments)","0","0","0","0","0","0","0","0","0"
"2900","NCT01118663","Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection","Acetaminophen Overdose",0,"Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)","Drug","Cumberland Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","17","September 2010","November 2012","The Incidence of Hepatoxicity as Measured by the Percentage of Subjects With an Alanine Transaminase (ALT) or Aspartate Transaminase (AST) Value > 1000 U/L Versus Those With an ALT and AST < 1000 U/L","0","0","0","0","0","0","0","0","0"
"2901","NCT01119534","Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin","Cough",0,"Guaiacol, eucalyptol, menthol and camphor suppository","Drug","Azidus Brasil","Industry",0,0,"All","2 Years","6 Years","270","May 2011","October 2011","Improvement of cough of infectious origin.","0","0","0","0","0","0","0","0","0"
"2902","NCT01120301","Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)","Acute Ischemic Stroke",0,"NeuroThera® Laser System","Device","PhotoThera, Inc","Industry",0,0,"All","40 Years","80 Years","1000","September 2010","September 2012","Disability assessed using the dichotomous modified Rankin Scale (mRS)","0","0","0","0","0","0","0","0","0"
"2903","NCT01120340","Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis Flares","Diverticular Disease",0,"mesalamine","Drug","SOFAR S.p.A.","Industry",0,0,"All","18 Years","N/A","105","October 2005","November 2011","diverticulitis relapse","0","0","0","0","0","0","0","0","0"
"2904","NCT01120405","Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery","Elevated Cardiac Risk",0,"Xenon","Drug","Air Liquide Santé International","Industry",0,0,"All","18 Years","N/A","600","May 2010","July 2012","Number of Participants With Myocardial Necrosis (MN)","0.0052","0","Difference of proportion","0.19","Difference of proportion","95","2-Sided","-6.70","7.07"
"2905","NCT01120509","Crux Biomedical Vena Cava Filter Study - United States","Pulmonary Embolism",0,"Inferior Vena Cava Filter","Device","Crux Biomedical","Industry",0,0,"All","18 Years","N/A","88","June 2010","June 2011","Clinical Success","0","0","0","0","0","0","0","0","0"
"2906","NCT01120522","Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3 (""RETRIEVE 3"")","Pulmonary Embolism",0,"Inferior Vena Cava Filter","Device","Crux Biomedical","Industry",0,0,"All","18 Years","N/A","17","May 2010","June 2011","Clinical Success","0","0","0","0","0","0","0","0","0"
"2907","NCT01120535","Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter 4","Pulmonary Embolism",0,"Inferior Vena Cava Filter","Device","Crux Biomedical","Industry",0,0,"All","18 Years","N/A","20","May 2010","June 2011","Clinical Success","0","0","0","0","0","0","0","0","0"
"2908","NCT01120717","A Study to Assess the Long-term Safety of QVA149","Chronic Obstructive Pulmonary Disease",0,"QVA149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","339","April 2010","December 2011","Number of Participants With Adverse Events, Serious Adverse Events or Death","0","0","0","0","0","0","0","0","0"
"2909","NCT01121666","Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment","Infertility",0,"Follitropin alfa","Drug","Finox AG","Industry",0,0,"Female","20 Years","38 Years","460","June 2010","December 2011","Number of Oocytes Retrieved (Per Protocol Population)","0.0003","This study was powered to test equivalence using a two one-sided test (TOST) with a power of 90%, an alpha error of 2.5% and a pre-determined clinical equivalence margin of +/-2.9 oocytes for the relevant population.","Shuirmann’s TOST","0","0","0","0","0","0"
"2910","NCT01121822","Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)","Influenza",0,"Influenza virus vaccine (split virion, inactivated)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","129","May 2010","June 2010","To provide information concerning the immunogenicity of the Influenza virus vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation.","0","0","0","0","0","0","0","0","0"
"2911","NCT01122121","Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer","Prostatic Neoplasms, Locally Advanced",0,"Leuprorelin SR","Drug","Takeda","Industry",0,0,"Male","18 Years","80 Years","273","March 2000","December 2008","Progression-free survival at 5 years","0","0","0","0","0","0","0","0","0"
"2912","NCT01122602","Evaluate Analgesic Efficacy of Fast Release Aspirin","Drugs, Investigational",0,"Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)","Drug","Bayer","Industry",0,0,"All","16 Years","45 Years","500","April 2010","July 2010","Time to First Perceptible Pain Relief (PR)","0","0","0","0","0","0","0","0","0"
"2913","NCT01123083","Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2","Diabetes Mellitus, Type 1",0,"Otelixizumab","Biological","GlaxoSmithKline","Industry",0,0,"All","12 Years","17 Years","179","May 2010","March 2012","Amount of C-peptide (a protein that shows how much insulin the body is producing) during a mixed meal stimulation test.","0","0","0","0","0","0","0","0","0"
"2914","NCT01124045","Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery","Cataracts",0,"Difluprednate ophthalmic emulsion, 0.05%","Drug","Alcon Research","Industry",0,0,"All","N/A","3 Years","80","August 2010","April 2012","Percentage of Patients With an Anterior Cell Grade of 0 (no Cells) at Day 15 ± 2 Days","0","0","0","0","0","0","0","0","0"
"2915","NCT01124097","Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia","Post Herpetic Neuralgia",0,"Eslicarbazepine acetate (BIA 2-093)","Drug","Bial - Portela C S.A.","Industry",0,0,"All","18 Years","N/A","240","September 2010","April 2012","Change From Baseline to Endpoint in Mean Pain","0.9321","0","Dunnett's test","0","0","0","0","0","0"
"2916","NCT01124318","A Pilot Study of Lactofiltrum to Treat Atopic Dermatitis in Adults","Atopic Dermatitis",0,"Lactofiltrum","Drug","Avva Rus, JSC","Industry",0,0,"All","18 Years","60 Years","90","May 2010","September 2010","SCORAD Index","0","0","0","0","0","0","0","0","0"
"2917","NCT01124877","Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)","Bipolar Disorder",0,"ziprasidone oral capsules","Drug","Pfizer","Industry",0,0,"All","10 Years","17 Years","0","July 2010","October 2011","Change from Baseline in blood pressure and pulse Change from baseline in electrocardiogram (QTc) Change from Baseline in Clinical Global Impression of Severity Scale (CGI-S)","0","0","0","0","0","0","0","0","0"
"2918","NCT01125410","Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis","Bacterial Vaginosis",0,"Dequalinium chloride","Drug","Medinova AG","Industry",0,0,"Female","18 Years","55 Years","321","January 2007","July 2008","clinical cure rate","0","0","0","0","0","0","0","0","0"
"2919","NCT01125644","Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis","Cryptococcosis or Aspergillosis Infections",0,"SPK-843","Drug","Proaparts srl","Industry",0,0,"All","18 Years","75 Years","10","May 2010","October 2011","Evaluation of the overall global clinical response","0","0","0","0","0","0","0","0","0"
"2920","NCT01125761","Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis","Dermatitis",0,"dexamethasone 0.5 mg and 1.0 mg clemastine cream","Drug","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","104","November 2010","November 2010","Through clinical examinations, evaluating the efficacy of the cream composed by 0.5 mg dexamethasone and clemastine 1mg compared with the cream of 0.5 mg dexamethasone in improving the signs and symptoms associated with allergic dermatitis.","0","0","0","0","0","0","0","0","0"
"2921","NCT01125774","Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)","Migraine",0,"Telcagepant","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","N/A","4548","June 2010","April 2011","Number of Participants With Clinical Adverse Events (AEs)","0","0","0","-1.2","Difference in percent incidence","95","2-Sided","-4.4","2.1"
"2922","NCT01125813","Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A","Severe Hemophilia A",0,"recombinant Factor VIII","Biological","Octapharma","Industry",0,0,"Male","12 Years","N/A","32","June 2010","January 2012","Efficacy Assessment After a Total of at Least 50 EDs Per Subject at the End of the Study at 6 Months","0","0","0","0","0","0","0","0","0"
"2923","NCT01126190","Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003)","Chemotherapy-induced Neutropenia",0,"Neugranin","Biological","Teva Pharmaceutical Industries","Industry",0,0,"All","18 Years","N/A","381","June 2010","February 2012","Duration of severe neutropenia","0","0","0","0","0","0","0","0","0"
"2924","NCT01126580","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)","Diabetes Mellitus, Type 2",0,"Metformin","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","807","May 2010","November 2011","Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)","<0.001","The p-value is adjusted for multiplicity using a tree-gatekeeping strategy. To determine significance, the p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.","ANCOVA","-0.22","LS Mean Difference","95","2-Sided","-0.36","-0.08"
"2925","NCT01127217","Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension","Hypertension",0,"amlodipine/losartan","Drug","Hanmi Pharmaceutical Company Limited","Industry",0,0,"All","18 Years","N/A","149","May 2009","March 2010","Change from baseline in MSSBP","0","0","0","0","0","0","0","0","0"
"2926","NCT01127477","Study to Obtain Volume Effect and Safety Data on 6 % Hydroxyethyl Starch 130/0.4 in Pediatric and Adult Patients Undergoing Major Elective Surgery","Plasma Volume Substitution (Hypovolemia) Including Massive Hemorrhage",0,"1: Hydroxyethyl starch 130/0.4, 6 %","Drug","Fresenius Kabi Japan","Industry",0,0,"All","N/A","N/A","20","May 2010","December 2010","Volume Effect","0","0","0","0","0","0","0","0","0"
"2927","NCT01127581","Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery","Reducing Time to Vaginal Delivery",0,"MVI 200","Drug","Ferring Pharmaceuticals","Industry",0,0,"Female","18 Years","N/A","1358","September 2010","March 2012","Time to Vaginal Delivery During the First Hospital Admission","<0.001","0","Log Rank","-677","Median Difference (Net)","95","2-Sided","0","0"
"2928","NCT01127893","Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis","Osteoarthritis",0,"Tanezumab","Biological","Pfizer","Industry",0,0,"All","18 Years","N/A","1","June 2010","September 2010","Hematology","0","0","0","0","0","0","0","0","0"
"2929","NCT01128153","Saxagliptin Triple Oral Therapy","Type 2 Diabetes",0,"Saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","257","June 2010","June 2011","Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF)","<0.0001","0","ANCOVA","-0.66","Mean Difference (Final Values)","95","2-Sided","-0.86","-0.47"
"2930","NCT01128738","GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis","Hyperhidrosis",0,"GSK1358820","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","75 Years","152","April 2010","August 2011","Percentage of Responders Assessed by Gravimetric Measurement at Week 4 in the First Treatment Phase","<0.001","0","Fisher Exact","50.2","Percentage difference","95","2-Sided","38.1","62.3"
"2931","NCT01128894","A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.","Diabetes Mellitus, Type 2",0,"albiglutide","Biological","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","841","May 2010","September 2011","Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32","0.0846","0","ANCOVA","0.21","Mean Difference (Final Values)","95","2-Sided","0.08","0.34"
"2932","NCT01129011","Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","Gastric Ulcer",0,"PN400 (VIMOVO)","Drug","POZEN","Industry",0,0,"All","18 Years","N/A","420","September 2007","September 2008","Number of Participants With Gastric Ulcer Confirmed by Endoscopy","0.001","0","Cochran-Mantel-Haenszel","11.9","proportions","95","2-Sided","7.9","17.1"
"2933","NCT01129102","Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea","Dysmenorrhea",0,"NPC-01","Drug","Nobelpharma","Industry",0,0,"Female","16 Years","N/A","215","May 2010","April 2011","Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment)","0","0","0","0","0","0","0","0","0"
"2934","NCT01129674","A Long-Term, Open-Label, Study on Schizophrenia","Schizophrenia",0,"LY2140023","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","65 Years","1210","June 2010","October 2012","Time to discontinuation due to adverse events","0","0","0","0","0","0","0","0","0"
"2935","NCT01129856","Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye","Dry Eye",0,"Dexamethasone phosphate ophthalmic solution","Drug","Eyegate Pharmaceuticals, Inc.","Industry",0,0,"All","12 Years","N/A","198","June 2010","January 2011","Sign: Differences in corneal fluorescein staining (inferior region, Ora Scale) Visit 1 Pre-CAE to Visit 6 compared to placebo; Symptom: Ocular discomfort at Visit 5 as compared to placebo","0","0","0","0","0","0","0","0","0"
"2936","NCT01129960","Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain","Painful Diabetic Neuropathy",0,"Eslicarbazepine acetate (BIA 2-093)","Drug","Bial - Portela C S.A.","Industry",0,0,"All","18 Years","N/A","332","November 2010","April 2012","Change From Baseline to Endpoint in Mean Pain","0.3726","0","Dunnett's test (analysis of covariance)","0","0","0","0","0","0"
"2937","NCT01130246","VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome","Acute Coronary Syndrome",0,"A-002, varespladib methyl","Drug","Anthera Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","5189","May 2010","March 2012","Primary Objective of the Study","0","0","0","0","0","0","0","0","0"
"2938","NCT01130493","A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066","Parkinson's Disease",0,"IPX066","Drug","IMPAX Laboratories, Inc.","Industry",0,0,"All","30 Years","N/A","74","May 2010","January 2012","Parkinson's Disease Patient Diary","0","0","0","0","0","0","0","0","0"
"2939","NCT01131026","Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication","Helicobacter Pylori Infection",0,"Levofloxacin","Drug","Deva Holding A.S.","Industry",0,0,"All","18 Years","N/A","60","June 2010","August 2011","Helicobacter pylori infection eradication","0","0","0","0","0","0","0","0","0"
"2940","NCT01131637","Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients","Chronic Heart Failure",0,"rhNRG-1","Drug","Zensun Sci. & Tech. Co., Ltd.","Industry",0,0,"All","18 Years","80 Years","331","April 2010","June 2012","all cause mortality","0","0","0","0","0","0","0","0","0"
"2941","NCT01133626","Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)","Perennial Allergic Rhinitis",0,"Placebo Nasal Aerosol","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","45 Years","107","June 2010","September 2010","The 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment","0","0","0","0.96","geometric mean ratio","95","2-Sided","0.87","1.06"
"2942","NCT01134042","Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics","Asthma",0,"Fluticasone Furoate/Vilanterol Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","587","June 2010","October 2011","Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period","<0.001","0","ANCOVA","0.193","Median Difference (Final Values)","95","2-Sided","0.108","0.277"
"2943","NCT01134107","Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","Diabetes Mellitus, Type 1",0,"Insulin Lispro 6 Day (6D)","Drug","Eli Lilly and Company","Industry",0,0,"All","13 Years","N/A","133","November 2010","December 2011","Mean of Last Six 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Insulin Aspart 6D Pump Reservoir In-use","0","0","0","0.36","Least Squares Mean Difference","95","2-Sided","0.06","0.66"
"2944","NCT01134263","Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia","Dengue Fever",0,"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","18 Years","60 Years","712","October 2010","November 2012","Information concerning the immunogenicity of different lots of CYD Dengue vaccine in terms of antibody levels against each of the four dengue virus serotype strains contained in the CYD dengue vaccine.","0","0","0","0","0","0","0","0","0"
"2945","NCT01134705","Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)","Rhinitis, Allergic, Perennial",0,"Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","N/A","474","May 2010","October 2010","Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period","<0.001","A priori threshold for statistical significance is p<0.05","Repeated measures Analysis of covariance","-0.84","LS Mean Difference","95","2-Sided","-1.2","-0.5"
"2946","NCT01135069","Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo","Acne",0,"Tretinoin microsphere 0.1%","Drug","Spear Pharmaceuticals","Industry",0,0,"All","12 Years","40 Years","480","October 2009","April 2010","Improvement in Acne","0","0","0","0","0","0","0","0","0"
"2947","NCT01135134","Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)","Rhinitis, Allergic, Perennial",0,"Mometasone furoate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","5 Years","15 Years","333","June 2010","October 2010","Change From Baseline in the Total Nasal Symptom Score at 2 Weeks","<0.0001","0","ANCOVA","0","0","0","0","0","0"
"2948","NCT01135212","The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension","Hypertension",0,"Fimasartan 60mg","Drug","Boryung Pharmaceutical Co., Ltd","Industry",0,0,"All","19 Years","75 Years","290","April 2010","April 2011","Sitting Diastolic Blood Pressure","0","0","0","0","0","0","0","0","0"
"2949","NCT01135433","A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients","Type 2 Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","168","May 2010","December 2011","Change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"2950","NCT01135992","Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","143","June 2010","November 2010","HbA1c (Glycosylated Haemoglobin)","0","0","0","0","0","0","0","0","0"
"2951","NCT01136746","Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin","Hyperglycemia",0,"Human regular insulin","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","16","March 2011","November 2011","Mean Plasma Glucose (MPG) Throughout Hospital Study Period","0","0","0","0","0","0","0","0","0"
"2952","NCT01136954","A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)","Partial Seizures",0,"Zonisamide","Drug","Eisai Limited","Industry",0,0,"All","6 Years","18 Years","144","July 2008","January 2012","Treatment Emergent Non-Serious Adverse Events With Greater Than 5% Frequency","0","0","0","0","0","0","0","0","0"
"2953","NCT01137331","K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp","Seborrhoeic Eczema of the Scalp",0,"K301","Drug","Moberg Pharma AB","Industry",0,0,"All","18 Years","70 Years","201","February 2008","April 2008","Erythema and desquamation scores","0","0","0","0","0","0","0","0","0"
"2954","NCT01137877","Growth and Tolerance of Healthy Term Infants to a New Infant Formula","Healthy Term Infants",0,"Milk based infant formula powder","Other","Abbott Nutrition","Industry",0,0,"All","N/A","11 Days","399","May 2010","October 2010","weight gain","0","0","0","0","0","0","0","0","0"
"2955","NCT01138007","A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)","Depressive Disorder, Major",0,"323U66 SR 150 mg tablet","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","64 Years","572","June 2010","August 2012","Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal","0.853","The p-value was estimated based on the ANCOVA model including Baseline MADRS score and region as covariates. The multiplicity was adjusted by Dunnett’s step-down procedure.","ANCOVA","-0.5","Least Squared Mean Difference","95","2-Sided","-2.7","1.7"
"2956","NCT01138397","Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)","Influenza",0,"Influenza virus vaccine (split virion, inactivated)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","129","June 2010","July 2010","Information concerning the immunogenicity of the Influenza virus vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation.","0","0","0","0","0","0","0","0","0"
"2957","NCT01138501","Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A","Congenital Bleeding Disorder",0,"turoctocog alfa","Drug","Novo Nordisk A/S","Industry",0,0,"Male","N/A","11 Years","65","June 2010","November 2011","The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU))","0","0","0","0","0","0","0","0","0"
"2958","NCT01138514","Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels","Acne Vulgaris",0,"Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)","Drug","Perrigo Company","Industry",0,0,"All","12 Years","65 Years","1555","October 2009","October 2010","Percent Change From Baseline in Inflammatory Lesions","0.05","0","Fieller's method","98.77","equivalence ratio","90","2-Sided","95.2","102.5"
"2959","NCT01139021","One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age","Meningococcal Disease",0,"rMenB+OMV NZ","Biological","Novartis Vaccines","Industry",0,0,"All","23 Months","27 Months","508","June 2010","November 2010","Geometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.","0","0","0","0","0","0","0","0","0"
"2960","NCT01139450","Study of 0417 Ointment in the Treatment of Atopic Dermatitis","Atopic Dermatitis",0,"0417","Drug","Fougera Pharmaceuticals Inc.","Industry",0,0,"All","8 Years","N/A","899","January 2008","August 2009","Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment","0","0","0","0","0","0","0","0","0"
"2961","NCT01139580","The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis","Psoriasis",0,"Calcipotriene Foam","Drug","Stiefel, a GSK Company","Industry",0,0,"All","12 Years","N/A","363","May 2010","December 2010","Number of Participants With an Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using the Failure Method","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"2962","NCT01139762","A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms","Benign Prostatic Hyperplasia",0,"Tadalafil","Drug","Eli Lilly and Company","Industry",0,0,"Male","45 Years","N/A","696","September 2010","February 2012","Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks","0.001","0","Mixed Model Repeated Measures Analysis","-1.41","LS Mean Difference","95","2-Sided","-2.27","-0.55"
"2963","NCT01140217","Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception","Contraceptive Usage",0,"Norethindrone Acetate","Drug","Watson Pharmaceuticals","Industry",0,0,"Female","18 Years","45 Years","1659","May 2010","March 2012","Pregnancy Rate","0","0","0","0","0","0","0","0","0"
"2964","NCT01140906","Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults","Major Depressive Disorder",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","75 Years","607","May 2010","September 2011","Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.","<0.0001","Since p-value <0.025, hierarchically testing continued.","MMRM","-5.53","Mean Difference (Final Values)","95","2-Sided","-7.66","-3.40"
"2965","NCT01141062","Therapeutic MRI Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids","Uterine Leiomyomas",0,"Philips MR-guided HIFU","Device","Philips Healthcare","Industry",0,0,"Female","18 Years","59 Years","15","June 2010","October 2011","Safety of HIFU for treatment of the uterine fibroids as determined by adverse event reporting.","0","0","0","0","0","0","0","0","0"
"2966","NCT01142089","Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)","Traveler's Diarrhea",0,"Placebo","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","264","May 2010","June 2012","Time to Last Unformed Stool (TLUS)","0","0","0","0","0","0","0","0","0"
"2967","NCT01143077","A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents","Schizophrenia",0,"Lurasidone HCl","Drug","Sunovion","Industry",0,0,"All","18 Years","N/A","244","June 2010","May 2011","Time to Relapse of Psychotic Symptoms During 6 Weeks","0","0","0","0","0","0","0","0","0"
"2968","NCT01143090","A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder","Schizophrenia",0,"Lurasidone HCl","Drug","Sunovion","Industry",0,0,"All","18 Years","N/A","149","August 2010","November 2011","Adverse Events","0","0","0","0","0","0","0","0","0"
"2969","NCT01144416","Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)","Infertility",0,"SCH 900962 / Corifollitropin alfa / Org 36286","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","35 Years","42 Years","1424","June 2010","July 2011","Percentage of Participants With a Vital Pregnancy","0","0","0","-3.0","Difference in percentage vital pregnancy","95","2-Sided","-7.4","1.4"
"2970","NCT01144650","Dapsone for Acute Ischemia Stroke Study","Cerebral Stroke",0,"Dapsone","Drug","Cidat, S.A. de C.V.","Industry",0,0,"All","18 Years","N/A","300","July 2009","August 2010","Shift across the board of National Institute of Health stroke scale (NIHSS) and Modified Rankin Scale (mRS)","0","0","0","0","0","0","0","0","0"
"2971","NCT01145339","A Non-inferiority, Multicenter and Randomized, Single-Dose Study About a Treatment to Hypolactasia (LAILAI)","Hypolactasia",0,"Lactase","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","18 Years","60 Years","140","July 2011","November 2011","Hydrogen value in the air expired","0","0","0","0","0","0","0","0","0"
"2972","NCT01145417","Pregabalin Trial In HIV Neuropathic Pain","HIV-1 Infection",0,"pregabalin (Lyrica)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","217","July 2010","May 2012","Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"2973","NCT01145586","A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia","Lactose Intolerance",0,"Lactase Oral Tablets","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","18 Years","60 Years","140","June 2011","March 2012","Hydrogen value in the expired air","0","0","0","0","0","0","0","0","0"
"2974","NCT01145625","Clinical Trial in Females With Female Pattern Hair Loss","Alopecia",0,"5% Minoxidil","Drug","Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","Industry",0,0,"Female","18 Years","N/A","322","June 2010","February 2012","Target Area Hair Count (TAHC)","0.9170","0","ANCOVA","-0.3","Mean Difference (Final Values)","95","2-Sided","-6.0","5.4"
"2975","NCT01145807","TDT 067 Onychomycosis Study","Onychomycosis",0,"TDT067","Drug","Celtic Pharma Development Services","Industry",0,0,"All","18 Years","75 Years","738","April 2010","February 2012","Cure Rate","0","0","0","0","0","0","0","0","0"
"2976","NCT01146015","Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season","Influenza",0,"Trivalent influenza subunit vaccine Influvac","Biological","Abbott Biologicals","Industry",0,0,"All","18 Years","N/A","121","June 2010","July 2010","HI titers and its derived parameters after 2 weeks (seroprotection, seroconversion and mean fold increase), reactogenicity and inconvenience of Influvac® 2010/2011 as defined by the CHMP guideline for influenza vaccines","0","0","0","0","0","0","0","0","0"
"2977","NCT01146860","Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis","Acute Rhinosinusitis",0,"BNO 1016","Drug","Bionorica SE","Industry",0,0,"All","18 Years","75 Years","386","January 2010","April 2010","Major Symptom Score (MSS) Assessed by the Investigator","0","0","0","0","0","0","0","0","0"
"2978","NCT01147081","Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011","Seasonal Influenza",0,"BEGRIVAC","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","N/A","142","June 2010","July 2010","Evaluation of antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 1 and on Day 22, and evaluation of safety of Begrivac","0","0","0","0","0","0","0","0","0"
"2979","NCT01147289","Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain","Lumbar Sciatic Pain",0,"Dextralgen","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","18 Years","75 Years","280","February 2011","November 2011","efficacy","0","0","0","0","0","0","0","0","0"
"2980","NCT01147848","HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents","Asthma",0,"Fluticasone furoate/Vilanterol Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","810","June 2010","July 2011","Change From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 24","0.162","0","ANCOVA","-0.037","Least Squares Mean Difference","95","2-Sided","-0.088","0.015"
"2981","NCT01150162","Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation","Gastric Ulcer",0,"Rebamipide and Omeprazole","Drug","Otsuka Pakistan Limited","Industry",0,0,"All","18 Years","65 Years","129","October 2010","June 2012","Healing rates for gastric ulcer patients via endoscopic examination","0","0","0","0","0","0","0","0","0"
"2982","NCT01150942","Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea","Japanese Encephalitis",0,"JE vaccine","Biological","Boryung Pharmaceutical Co., Ltd","Industry",0,0,"All","12 Months","23 Months","205","August 2010","September 2012","immunogenicity","0","0","0","0","0","0","0","0","0"
"2983","NCT01151137","Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy","Atrial Fibrillation",0,"Dronedarone","Drug","Sanofi","Industry",0,0,"All","65 Years","N/A","3236","July 2010","September 2011","Overview of the Two Co-primary Outcomes","0","0","0","0","0","0","0","0","0"
"2984","NCT01151202","Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of ""AG NPP709 Syrup""","Acute Upper Respiratory Tract Infections",0,"AG NPP709syrup","Drug","Ahn-Gook Pharmaceuticals Co.,Ltd","Industry",0,0,"All","24 Months","75 Years","236","February 2010","May 2010","improvement by global assessment","0","0","0","0","0","0","0","0","0"
"2985","NCT01152190","A Study in Benign Prostatic Hyperplasia","Benign Prostatic Hyperplasia",0,"Tadalafil","Drug","Eli Lilly and Company","Industry",0,0,"Male","45 Years","N/A","97","September 2010","July 2012","Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone","0.121","The p-value associated with the LS mean difference of change from baseline to Week 8 between the tadalafil and placebo treatment groups was tested at a significance level of 0.05 with no adjustments for multiplicity.","Mixed-Model Repeated Measures","0.01","Difference in LS Means","95","0","0","0"
"2986","NCT01152489","A Test of the Effectiveness of a Device and Distraction for Pediatric Immunization Pain","Procedural Pain",0,"Device: Buzzy","Device","MMJ Labs LLC","Industry",0,0,"All","4 Months","12 Years","345","April 2010","April 2011","Pain of immunization","0","0","0","0","0","0","0","0","0"
"2987","NCT01152554","A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","Major Depressive Disorder",0,"TC-5214","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","813","June 2010","February 2012","Frequency of Patients Experiencing at Least One Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"2988","NCT01153009","Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","Depressive Disorder, Major",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","75 Years","614","June 2010","March 2012","Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","0.224","Pre-specified sequential statistical testing procedure indicates that when p-value >0.025, hierarchical testing stops for this dose and for subsequent endpoints in the sequence a nominal p-value is provided.","Mixed model for repeated measurements","-1.5","LS mean difference","95","2-Sided","-3.86","0.91"
"2989","NCT01153347","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","Major Depressive Disorder",0,"TC-5214","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","2409","June 2010","January 2012","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.","1.000","The adjusted p-value protects the overall family-wise error rate by taking into account the multiple comparisons between the TC-5214 doses for both the primary efficacy variable (MADRS) and the key secondary efficacy variable (SDS).","MMRM","-0.9","LS mean","95","2-Sided","-2.96","1.24"
"2990","NCT01153815","A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity","Cerebrovascular Accident",0,"GSK1358820(Botulinum toxin type A)","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","75 Years","170","April 2010","June 2011","Change From Baseline at Week 6 for Wrist Flexor Muscle Tone as Measured on the Modified Ashworth Scale (MAS)","<0.001","0","Exact Smirnov test","0","0","0","0","0","0"
"2991","NCT01154036","MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)","Hypercholesterolemia",0,"ezetimibe 10 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","1547","July 2010","September 2012","Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)","<0.001","The primary hypotheses were tested at 0.045, applying Hochberg’s procedure.","Multiple Imputation Robust Regression","-12.7","Difference in M-estimates","95","2-Sided","-16.6","-8.7"
"2992","NCT01154166","A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa","Parkinson Disease",0,"ReQuip PR","Drug","GlaxoSmithKline","Industry",0,0,"All","30 Years","N/A","347","February 2010","September 2011","Mean Change From Baseline in Total Awake Time Spent ""Off"" at Week 24 Using Last Observation Carried Forward (LOCF)","<0.001","0","ANCOVA","-1.76","Adjusted mean for treatment difference","95","2-Sided","-2.27","-1.26"
"2993","NCT01155414","Tolerance of Healthy Term Infants Fed Infant Formulas #4","Healthy Term Infants",0,"Hydrolysate based infant formula","Other","Abbott Nutrition","Industry",0,0,"All","N/A","8 Days","168","March 2010","July 2010","GI tolerance via stool consistency","0","0","0","0","0","0","0","0","0"
"2994","NCT01155466","A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)","Parkinson Disease",0,"Preladenant 2 mg tablet","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","30 Years","85 Years","778","July 2010","December 2012","Change From Baseline in Mean ""Off"" Time","0.8700","0","Mixed Models Analysis","0.0","Mean Difference (Final Values)","95","2-Sided","-0.62","0.53"
"2995","NCT01155661","A Safety Study in Patients With Major Depressive Disorder","Depressive Disorder, Major",0,"LY2216684","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","600","October 2010","December 2012","The number of participants experiencing clinically significant effects","0","0","0","0","0","0","0","0","0"
"2996","NCT01156857","PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata","Uterine Fibroids",0,"PGL4001, placebo","Drug","PregLem SA","Industry",0,0,"Female","18 Years","48 Years","209","July 2010","November 2011","Efficacy endpoints","0","0","0","0","0","0","0","0","0"
"2997","NCT01157078","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)","Major Depressive Disorder",0,"TC-5214","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","319","June 2010","November 2011","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.","0.349","The adjusted p-value protects the overall family-wise error rate by taking into account the multiple comparisons between the TC-5214 doses for both the primary efficacy variable (MADRS) and the key secondary efficacy variable (SDS).","MMRM","-1.0","LS mean","95","2-Sided","-3.14","1.11"
"2998","NCT01157702","Yearly Strain Variation Study, 2010/2011","Influenza",0,"Inactivated influenza vaccine (split virus, Vero cell-derived)","Biological","Baxter Healthcare Corporation","Industry",0,0,"All","18 Years","N/A","110","July 2010","August 2010","To assess the immunogenicity to each of the three antigens contained in a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2010/2011 season in an adult and elderly population","0","0","0","0","0","0","0","0","0"
"2999","NCT01159015","Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers","Allergic Conjunctivitis",0,"KetoNaph","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","2 Years","N/A","501","July 2010","September 2010","Adverse Events","0","0","0","0","0","0","0","0","0"
"3000","NCT01159262","Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age","Sedation",0,"Midazolam","Drug","Hospira, now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","28 Weeks","44 Weeks","36","July 2010","August 2011","Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion","0","0","0","0","0","0","0","0","0"
"3001","NCT01159912","Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents","Asthma",0,"Fluticasone propionate","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","350","June 2010","January 2012","Mean Change From Baseline in Clinic Visit Trough Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24 Week Treatment Period","0.009","0","ANCOVA","0.146","Mean Difference (Final Values)","95","2-Sided","0.036","0.257"
"3002","NCT01160198","A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.","Haematopoiesis",0,"ferrous ascorbate","Drug","GlaxoSmithKline","Industry",0,0,"Female","18 Years","55 Years","271","October 2010","March 2011","Rise of haemoglobin from baseline to 8 weeks in each ferrous bisglycinate chelate group (1 tablet daily and 2 tablets daily).","0","0","0","0","0","0","0","0","0"
"3003","NCT01160692","A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment","Age-Related Memory Disorders",0,"Multivitamin/Multimineral/Ginkgo (BAY 81-2775)","Dietary Supplement","Bayer","Industry",0,0,"All","60 Years","N/A","132","February 2006","July 2008","The effect of the multi-vitamin/-mineral preparation containing gingko on major aspects of human cognitive function employing a computerized cognitive assessment system.","0","0","0","0","0","0","0","0","0"
"3004","NCT01160770","Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome","Lennox-Gastaut Syndrome",0,"Clobazam","Drug","Lundbeck LLC","Industry",0,0,"All","2 Years","60 Years","267","December 2005","February 2012","Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment","0","0","0","0","0","0","0","0","0"
"3005","NCT01160796","Lcr35® for Bacterial Vaginosis Prevention","Bacterial Vaginosis",0,"placebo","Drug","Laboratoires Lyocentre","Industry",0,0,"Female","18 Years","N/A","352","June 2010","May 2011","mean time before the onset of first clinical recurrence confirmed by laboratory tests","0","0","0","0","0","0","0","0","0"
"3006","NCT01161498","Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer","Squamous Cell Carcinoma",0,"Talimogene Laherparepvec","Biological","BioVex Limited","Industry",0,0,"All","18 Years","N/A","5","February 2011","October 2011","2-year Event-free Survival","0","0","0","0","0","0","0","0","0"
"3007","NCT01161615","MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder","Acute Tendonitis",0,"MRX-7EAT","Drug","MEDRx USA, Inc.","Industry",0,0,"All","14 Years","N/A","350","July 2010","June 2011","Mean of all 24 Current Pain Intensity scores collected on Days 2 through 7 on a 0-10 NPRS.","0","0","0","0","0","0","0","0","0"
"3008","NCT01162876","A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus","Diabetes",0,"saxaglipitin","Drug","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","20 Years","65 Years","20","July 2010","November 2010","Pharmacokinetics","0","0","0","0","0","0","0","0","0"
"3009","NCT01163032","Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder","Non-24-Hour Sleep-Wake Disorder",0,"tasimelteon","Drug","Vanda Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","136","August 2010","November 2012","Proportion of Patients Entrained as Assessed by Urinary aMT6","0","0","0","0","0","0","0","0","0"
"3010","NCT01163266","Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","Depressive Disorder, Major",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","75 Years","462","July 2010","January 2012","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","0.058","Pre-specified sequential statistical testing procedure indicates that when p-value >0.025, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.","Mixed model for repeated measurements","-2.19","LS Mean Difference","95","2-Sided","-4.45","0.08"
"3011","NCT01165138","Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics","Asthma",0,"Fluticasone furoate/Vilanterol Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","612","August 20, 2010","October 1, 2011","Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12","0.002","0","ANCOVA","0.136","Median Difference (Final Values)","95","2-Sided","0.051","0.222"
"3012","NCT01165424","A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)","Rhinitis, Allergic, Perennial",0,"mometasone furoate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","3 Years","15 Years","80","April 2010","December 2010","Number of Participants With Adverse Events and Adverse Drug Reactions","0","0","0","0","0","0","0","0","0"
"3013","NCT01165554","Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels","Brain Fibrillarab Levels",0,"[18F] Flutemetamol","Drug","GE Healthcare","Industry",0,0,"All","55 Years","N/A","203","May 2010","November 2011","The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain Fibrillar Amyloid β.","0","0","0","0","0","0","0","0","0"
"3014","NCT01166243","The Fibrin Pad Liver Study","Hemorrhage",0,"Fibrin Pad","Biological","Ethicon, Inc.","Industry",0,0,"All","18 Years","N/A","84","July 2010","August 2011","Proportion of subjects achieving hemostasis at the Target Bleeding Site (TBS).","0","0","0","0","0","0","0","0","0"
"3015","NCT01166282","A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis","Enthesitis Related Arthritis (ERA)",0,"adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","6 Years","17 Years","46","September 2010","November 2012","Percent Change in Number of Active Joints With Arthritis From Baseline to Week 12","=0.039","0","ANCOVA","-51.17","Mean Difference (Final Values)","95","2-Sided","-99.69","-2.66"
"3016","NCT01166542","Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers","Carcinoma, Squamous Cell of the Head and Neck",0,"REOLYSIN","Biological","Oncolytics Biotech","Industry",0,0,"All","18 Years","N/A","167","June 2010","April 2012","Overall survival","0","0","0","0","0","0","0","0","0"
"3017","NCT01167010","A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma","Asthma",0,"Formoterol/Budesonide","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","12 Years","N/A","552","April 2011","August 2011","forced expiratory volume in 1 second (FEV1) at the final visit (FV)","0","0","0","0","0","0","0","0","0"
"3018","NCT01167322","Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas","Malignant Glioma",0,"NPC-07 for oral administration","Drug","Nobelpharma","Industry",0,0,"All","18 Years","70 Years","45","August 2010","December 2011","Positive predictive value of tissue fluorescence","0","0","0","0","0","0","0","0","0"
"3019","NCT01167426","Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients","Multiple Sclerosis",0,"Glatiramer Acetate 20 mg/0.5 mL","Drug","Teva Neuroscience, Inc.","Industry",0,0,"All","18 Years","N/A","148","July 2010","November 2010","Change From Week 2 to Week 6 in Composite Score of Patient Satisfaction With Injection Experience","<0.0001","0","Wilcoxon Signed-Rank","79.6","Difference in mean ranks","95","0","0","0"
"3020","NCT01168206","Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy","Cancer",0,"TK3","Dietary Supplement","Lavilabor Natural Products Ltd","Industry",0,0,"All","30 Years","80 Years","80","December 2010","December 2011","Assessment of Quality of Life","0","0","0","0","0","0","0","0","0"
"3021","NCT01169272","Clinical Evaluation Of The SonR Atrial Lead In Paradym RF Device","Heart Failure",0,"CRT-SonR 9770","Device","LivaNova","Industry",0,0,"All","18 Years","N/A","100","October 2010","June 2011","Evaluation of the SonR lead safety","0","0","0","0","0","0","0","0","0"
"3022","NCT01169779","Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin","Type 2 Diabetes Mellitus",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","391","July 2010","December 2011","Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","0.0004","Statistical testing:2-sided at significance level=0.05. Analysis of co-variance (ANCOVA) included treatment arms, randomization strata of screening HbA1c (<8.0,>=8.0%), sulfonylurea use (Yes,No), country as fixed effects, baseline HbA1c as covariate.","ANCOVA","-0.36","Least squares (LS) mean difference","95","2-Sided","-0.551","-0.162"
"3023","NCT01170221","TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.","Skin and Subcutaneous Tissue Bacterial Infections",0,"TR-701 FA","Drug","Trius Therapeutics LLC","Industry",0,0,"All","18 Years","N/A","667","August 1, 2010","September 1, 2011","Early Clinical Response Rate","0","0","0","0.1","Risk Difference (RD)","95","0","-6.1","6.2"
"3024","NCT01171014","Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms","Gastrointestinal Symptoms",0,"Bifidobacterium lactis HN019","Dietary Supplement","Fonterra Research Centre","Industry",0,0,"All","25 Years","65 Years","100","June 2009","December 2009","Colonic transit time","0","0","0","0","0","0","0","0","0"
"3025","NCT01172119","BioFreedom FIM Clinical Trial.","Treatment Of Stenotic Lesions In Native Coronary Arteries.",0,"Biofreedom Drug Eluting Stent","Device","Biosensors Europe SA","Industry",0,0,"All","18 Years","N/A","182","August 2008","June 2010","In-Stent Late Lumen Loss at 12 months post-procedure.","0","0","0","0","0","0","0","0","0"
"3026","NCT01172405","Efficacy and Safety Study to Compare Ibuprofen + Caffeine With Ibuprofen Alone in the Treatment of Headache","Headache",0,"Ibuprofen plus caffeine","Drug","Mantecorp Industria Quimica e Farmaceutica Ltd.","Industry",0,0,"All","18 Years","65 Years","144","October 2010","October 2012","Efficacy of study treatment compared with control to relieve headache symptoms.","0","0","0","0","0","0","0","0","0"
"3027","NCT01172444","Clinical Trial With Mesalamine 1g Suppositories","Proctitis",0,"Mesalamine","Drug","Sandoz","Industry",0,0,"All","18 Years","65 Years","158","June 2010","December 2012","DAI Score","0","0","0","0","0","0","0","0","0"
"3028","NCT01172938","Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","Psoriatic Arthritis",0,"Apremilast 20mg","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","504","June 2010","April 2012","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16","0.0001","0","Cochran-Mantel-Haenszel","19.0","Adjusted Difference","95","2-Sided","9.7","28.3"
"3029","NCT01173120","Methotrexate - Inadequate Response Device Sub-Study","Rheumatoid Arthritis (RA)",0,"Abatacept combination product (ACP)","Device","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","62","November 2009","February 2010","Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, and AEs Leading to Discontinuation","0","0","0","0","0","0","0","0","0"
"3030","NCT01173718","Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access","End Stage Renal Disease",0,"GORE® ACUSEAL Vascular Graft","Device","W.L.Gore & Associates","Industry",0,0,"All","18 Years","N/A","138","July 2010","September 2012","Cumulative Patency at 6 Months","0","0","0","0","0","0","0","0","0"
"3031","NCT01174004","A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis","Parkinson's Disease Psychosis",0,"pimavanserin tartrate","Drug","ACADIA Pharmaceuticals Inc.","Industry",0,0,"All","40 Years","N/A","199","July 2010","November 2012","Antipsychotic Efficacy","0","0","0","0","0","0","0","0","0"
"3032","NCT01174160","A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)","Atrial Fibrillation",0,"vernakalant hydrochloride","Drug","Cardiome Pharma","Industry",0,0,"All","18 Years","85 Years","123","August 2010","September 2012","Proportion of Patients With Treatment-induced Conversion of Atrial Fibrillation to Sinus Rhythm","0","0","0","0","0","0","0","0","0"
"3033","NCT01174446","Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients","Hemophilia B",0,"BAX 326","Biological","Baxalta US Inc.","Industry",0,0,"All","12 Years","65 Years","86","July 2010","May 2012","Study Part 1- Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Per Dose","0","0","0","1.063","Ratio of Geometric Means","90","2-Sided","1.03","1.09"
"3034","NCT01174992","A Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair","Dura Defects",0,"Evicel","Biological","Ethicon, Inc.","Industry",0,0,"All","18 Years","N/A","139","July 2010","September 2011","Proportion of success","0","0","0","0","0","0","0","0","0"
"3035","NCT01175590","Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle","Bacterial Conjunctivitis",0,"Besivance","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","1 Year","N/A","518","June 2010","December 2011","Ocular Treatment Emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"3036","NCT01176058","A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis","Candidemia",0,"Anidulafungin/Fluconazole","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","17","December 2010","November 2011","Percentage of Participants With Global Response at End of Intravenous Treatment (EOIT)","0","0","0","0","0","0","0","0","0"
"3037","NCT01176240","A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease","Orthostatic Hypotension",0,"Droxidopa","Drug","Chelsea Therapeutics","Industry",0,0,"All","18 Years","N/A","225","June 2010","October 2012","306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)","0.978","0","ANCOVA","0","0","0","0","0","0"
"3038","NCT01176695","Efficacy and Safety of a Fish Oil Containing Lipid Emulsion","Parenteral Nutrition",0,"fish oil containing lipid emulsion","Drug","B. Braun Melsungen AG","Industry",0,0,"All","18 Years","85 Years","240","April 2010","April 2011","To investigate on the efficacy of fish oil on the nutrition status","0","0","0","0","0","0","0","0","0"
"3039","NCT01177098","Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","Glaucoma",0,"bimatoprost /timolol formulation A fixed combination ophthalmic solution","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","561","October 2010","February 2012","Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12","0","0","0","0","0","0","0","0","0"
"3040","NCT01177722","A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants","Diphtheria",0,"DTaP-IPV-Hep B-PRP-T Vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","55 Days","65 Days","1375","August 2010","October 2011","Geometric Mean Titers (GMTs) of Anti-Hepatitis B Before and After 3 Dose Primary Vaccination With Either DTaP-IPV-Hep B-PRP~T Batch A, B, or C, or Infanrix Hexa™","0","0","0","0","0","0","0","0","0"
"3041","NCT01177800","A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis","Psoriasis",0,"Placebo","Drug","Xian-Janssen Pharmaceutical Ltd.","Industry",0,0,"All","18 Years","65 Years","129","February 2009","February 2010","Percentage of Participants Who Achieved a Greater Than Equal to 75 Percent Response in Psoriasis Area and Severity Index (PASI)","<0.001","0","Fisher Exact","0","0","0","0","0","0"
"3042","NCT01177852","Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis","Inflammation",0,"diphenhydramine + dropropizine + pseudoephedrine","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"All","2 Years","12 Years","0","October 2011","April 2012","Improvement of nasal congestion and cough","0","0","0","0","0","0","0","0","0"
"3043","NCT01177956","A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck","Squamous Cell Carcinoma of the Head and Neck",0,"Cetuximab","Biological","Merck KGaA","Industry",0,0,"All","18 Years","N/A","73","December 2009","January 2011","Best Overall Response (BOR) Until Cut-off Date 25 January 2011","0","0","0","0","0","0","0","0","0"
"3044","NCT01178346","Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies","Smoking Cessation",0,"NicVAX vaccine","Biological","Nabi Biopharmaceuticals","Industry",0,0,"All","18 Years","65 Years","500","July 2010","November 2011","To evaluate the effect of NicVAX vs. placebo on HRQoL over the study period.","0","0","0","0","0","0","0","0","0"
"3045","NCT01178632","Therapeutic Effect of an Herbal Medicine on Anxiety","Anxiety Disorders",0,"Passiflora","Drug","Millet Roux","Industry",0,0,"All","18 Years","65 Years","136","October 2010","December 2011","Hamilton anxiety scale score","0","0","0","0","0","0","0","0","0"
"3046","NCT01178996","Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.","Chronic Hepatitis C",0,"Thymosin alpha 1","Biological","sigma-tau i.f.r. S.p.A.","Industry",0,0,"All","18 Years","70 Years","552","December 2004","May 2008","Sustained Virological Response (SVR)","0","0","0","0","0","0","0","0","0"
"3047","NCT01179516","Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","Depressive Disorder, Major",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","75 Years","469","August 2010","May 2012","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","0.597","Pre-specified sequential statistical testing procedure indicates that when p-value >0.025, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.","Mixed model for repeated measurements","-0.79","LS Mean Difference","95","2-Sided","-3.71","2.14"
"3048","NCT01180348","Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines","Wrinkles",0,"Botulift","Drug","Azidus Brasil","Industry",0,0,"Female","18 Years","65 Years","192","August 2011","October 2011","overall improved assessment of hyperkinetic facial lines in a state of relaxation and maximal contraction through the Honeck's scale and photographic images obtained by equipment Visia Digital Compexton Analysis (Canfield Imaging Systems, version 4.0.2)","0","0","0","0","0","0","0","0","0"
"3049","NCT01180400","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","Major Depressive Disorder",0,"TC-5214","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","295","September 2010","September 2011","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.","0.944","The adjusted p-value protects the overall family-wise error rate by taking into account the multiple comparisons between the TC-5214 doses for both the primary efficacy variable (MADRS) and the key secondary efficacy variable (SDS).","MMRM","-0.1","LS mean","95","2-Sided","-1.86","1.73"
"3050","NCT01180634","MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis","Cystic Fibrosis",0,"MP-376 (Levofloxacin solution for Inhalation)","Drug","Forest Laboratories","Industry",0,0,"All","12 Years","N/A","330","November 2010","July 2012","Time to an exacerbation","0","0","0","0","0","0","0","0","0"
"3051","NCT01181102","A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty","Venous Thromboembolism",0,"edoxaban","Drug","Daiichi Sankyo Co., Ltd.","Industry",0,0,"All","20 Years","84 Years","716","March 2009","September 2009","Incidence of Subjects With Venous Thromboembolism Events.","<0.001","non-inferiority:P < 0.001 superiority:P = 0.010","non-inferiority:Z test. superiority:χ2 t","-6.5","Cox Proportional Hazard","95","2-Sided","-11.5","-1.6"
"3052","NCT01181115","Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)","Multiple Sclerosis",0,"Avonex","Drug","Biogen","Industry",0,0,"All","18 Years","55 Years","60","April 2010","October 2011","The number and proportion of subjects with adverse events (AEs)","0","0","0","0","0","0","0","0","0"
"3053","NCT01181128","Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A","Severe Hemophilia A",0,"Factor VIII (rFVIIIFc)","Drug","Bioverativ Therapeutics Inc.","Industry",0,0,"Male","12 Years","N/A","165","November 2010","August 2012","Incidence Rate of FVIII Inhibitor Development","0","0","0","0","0","0","0","0","0"
"3054","NCT01181141","Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery","Venous Thromboembolism",0,"DU-176b (edoxaban)","Drug","Daiichi Sankyo Co., Ltd.","Industry",0,0,"All","20 Years","N/A","92","October 2008","August 2009","The Incidence of Major or Clinically Relevant Non-major Bleeding","0","0","0","-3.5","Cox Proportional Hazard","95","2-Sided","-18.8","6.0"
"3055","NCT01181466","AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema","Pulmonary Emphysema",0,"AeriSeal System","Device","Aeris Therapeutics","Industry",0,0,"All","40 Years","N/A","20","August 2010","May 2011","Change in Percent Volume of Lung","0","0","0","0","0","0","0","0","0"
"3056","NCT01181479","Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System","Contraception",0,"AG200-15 transdermal patch","Drug","Agile Therapeutics","Industry",0,0,"Female","17 Years","40 Years","1504","August 2010","December 2011","Pregnancy","0","0","0","0","0","0","0","0","0"
"3057","NCT01181895","Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma","Asthma",0,"Vilanterol","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","348","September 2010","August 2011","Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12","0.244","P-value for the adjusted treatment difference for Vilanterol 25 µg OD versus Placebo.","ANCOVA","0.070","Mean Difference (Final Values)","95","2-Sided","-0.048","0.188"
"3058","NCT01183117","A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease","Peripheral Vascular Diseases",0,"SM-01","Device","Johnson & Johnson K.K. Medical Company","Industry",0,0,"All","20 Years","N/A","105","July 2010","September 2012","Non-TVF(Target-vessel failure) rate","0","0","0","0","0","0","0","0","0"
"3059","NCT01183741","Accuracy of Non-Invasive Blood Pressure Measurement in Adults","Hypertension",0,NA,NA,"Sotera Wireless, Inc.","Industry",0,0,"All","12 Years","N/A","150","September 2010","October 2010",NA,"0","0","0","0","0","0","0","0","0"
"3060","NCT01184846","Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy","Chronic Inflammatory Demyelinating Polyneuropathy",0,"10% liquid formulation of human immunoglobulin","Biological","CSL Behring","Industry",0,0,"All","18 Years","N/A","31","November 2010","November 2011","Responder Rate","0","0","0","0","0","0","0","0","0"
"3061","NCT01185002","Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen","Colonoscopy",0,"PillCam® COLON 2 procedure using MgC boosts","Other","Given Imaging Ltd.","Industry",0,0,"All","50 Years","75 Years","80","July 2010","June 2011","Capsule excretion rate","0","0","0","0","0","0","0","0","0"
"3062","NCT01185223","Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation","Allogeneic Stem Cell Transplantation",0,"Valganciclovir","Drug","Pierrel Research Europe GmbH","Industry",0,0,"All","18 Years","N/A","212","September 2010","December 2012","Efficacy and Safety of oral valganciclovir versus intravenous ganciclovir","0","0","0","0","0","0","0","0","0"
"3063","NCT01185301","Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)","Early Rheumatoid Arthritis",0,"adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","395","October 2010","September 2012","Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26","0","0","0","0","0","0","0","0","0"
"3064","NCT01185704","Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)","Polycystic Ovarian Syndrome",0,"Cetrorelix acetate","Drug","Merck KGaA","Industry",0,0,"Female","18 Years","35 Years","136","November 2008","October 2011","Estradiol (E2) Levels on r-hCG Day","0","0","0","0","0","0","0","0","0"
"3065","NCT01186198","A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions","Ischemic Heart Disease",0,"MINI TREK RX 1.20 mm Coronary Dilatation Catheter","Device","Abbott Vascular","Industry",0,0,"All","18 Years","N/A","71","August 2010","January 2011","Procedure Success","0","0","0","0","0","0","0","0","0"
"3066","NCT01186770","A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain","Opioid-Induced Constipation",0,"Methylnaltrexone bromide","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","700","September 2010","May 2012","Proportion of subjects with rescue-free laxation","0","0","0","0","0","0","0","0","0"
"3067","NCT01186926","Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep Apnea","Obstructive Sleep Apnea",0,"HGNS Treatment","Device","Apnex Medical, Inc.","Industry",0,0,"All","21 Years","70 Years","40","March 2009","December 2010","Mean change in AHI measured with in-lab nighttime polysomnography (PSG) compared to baseline","0","0","0","0","0","0","0","0","0"
"3068","NCT01186939","An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)","Myelodysplastic Syndromes",0,"Azacitidine","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","40","April 2007","September 2009","Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period","0","0","0","0","0","0","0","0","0"
"3069","NCT01187966","Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease","Parkinson's Disease",0,"Safinamide","Drug","Newron","Industry",0,0,"All","30 Years","80 Years","669","January 2007","October 2008","Increase in mean daily ""on"" time","0","0","0","0","0","0","0","0","0"
"3070","NCT01188200","Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"Experimental nutritional formula #M979","Other","Abbott Nutrition","Industry",0,0,"All","18 Years","N/A","168","December 2009","June 2010","The primary variable is glucose concentration","0","0","0","0","0","0","0","0","0"
"3071","NCT01188343","Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers","Japanese Encephalitis",0,"Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","12 Months","18 Months","542","August 2010","July 2012","Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or Single Administration of JE-CV and MMR Vaccine at 42 Days Following First Vaccination","0","0","0","0","0","0","0","0","0"
"3072","NCT01188564","Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks","Hereditary Angioedema",0,"rhC1INH","Drug","Pharming Technologies B.V.","Industry",0,0,"All","13 Years","N/A","75","January 2011","December 2012","Time to Beginning of Relief of Symptoms","0","0","0","0","0","0","0","0","0"
"3073","NCT01188928","LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)","Psoriasis Vulgaris",0,"Calcipotriol plus betamethasone","Drug","LEO Pharma","Industry",0,0,"All","18 Years","N/A","1152","September 2010","March 2011","Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4","0","0","0","0","0","0","0","0","0"
"3074","NCT01189461","Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema","Anti- VGF Inhibitor",0,"pegaptanib sodium","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","46","January 2011","July 2012","Incidence of Ocular and Non-Ocular Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"3075","NCT01189487","The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)","Pneumonia, Bacterial",0,"ampicillin sodium/sulbactam sodium","Drug","Pfizer","Industry",0,0,"All","16 Years","79 Years","47","October 2010","April 2011","Response Rate (Clinical Response, Data Review Committee Assessment)","0","0","0","0","0","0","0","0","0"
"3076","NCT01189747","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines","Lateral Canthus Rhytides",0,"onabotulinumtoxinA","Biological","Allergan","Industry",0,0,"All","18 Years","N/A","446","October 2010","April 2011","Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile","0","0","0","0","0","0","0","0","0"
"3077","NCT01189760","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","Facial Rhytides",0,"onabotulinumtoxinA 24 U","Biological","Allergan","Industry",0,0,"All","18 Years","N/A","917","September 2010","March 2011","Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile","0","0","0","0","0","0","0","0","0"
"3078","NCT01189890","Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)","Type 2 Diabetes Mellitus",0,"sitagliptin phosphate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","65 Years","85 Years","480","August 16, 2010","October 31, 2012","Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30","0","0","0","0.19","Difference in LS Means","95","2-Sided","0.03","0.34"
"3079","NCT01190228","Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV","Japanese Encephalitis",0,"Japanese encephalitis chimeric virus","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","36 Months","42 Months","454","August 2010","May 2012","Information concerning the immunogenicity of Japanese encephalitis chimeric virus vaccine","0","0","0","0","0","0","0","0","0"
"3080","NCT01190306","Safety Study of the VEGA UV-A System to Treat Keratoconus","Keratoconus",0,"The VEGA UV-A Illumination System","Device","Topcon Medical Systems, Inc.","Industry",0,0,"All","12 Years","N/A","118","August 2010","December 2011","Changes in Corneal Curvature","0","0","0","0","0","0","0","0","0"
"3081","NCT01191112","Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population","Gastrointestinal Diseases",0,"Peptide based enteral formula","Other","Abbott Nutrition","Industry",0,0,"All","1 Year","13 Years","27","January 2011","November 2011","Stool frequency","0","0","0","0","0","0","0","0","0"
"3082","NCT01191125","Evaluation of an Oral Nutritional Supplement Containing AN777","Malnutrition",0,"medical food with AN777","Other","Abbott Nutrition","Industry",0,0,"All","65 Years","90 Years","331","February 2011","September 2012","Knee extensor strength","0","0","0","0","0","0","0","0","0"
"3083","NCT01191268","A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)","Diabetes Mellitus, Type 2",0,"Insulin Glargine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","884","November 2010","February 2012","Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)","<0.001","Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.","ANCOVA","-0.22","LS Mean Difference","95","2-Sided","-0.38","-0.07"
"3084","NCT01191450","Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension","Arterial Hypertension",0,"Chlorthalidone 25 mg + amiloride hydrochloride 5 mg","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","60 Years","N/A","280","August 2011","November 2012","Potassium level","0","0","0","0","0","0","0","0","0"
"3085","NCT01192191","A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD","Pulmonary Disease, Chronic Obstructive",0,"Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","187","August 2010","January 2012","Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period","0","0","0","0","0","0","0","0","0"
"3086","NCT01193179","A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes","Diabetes, Type 2",0,"OPC-262","Drug","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","20 Years","N/A","450","July 2010","April 2012","Adverse events, clinical laboratory tests","0","0","0","0","0","0","0","0","0"
"3087","NCT01193634","Clinical Evaluation Of The PARADYM RF Device","Heart Failure",0,"VR 9250 / DR 9550 / CRT 9750","Device","LivaNova","Industry",0,0,"All","18 Years","N/A","75","October 2010","March 2012","Demonstration of the Right ventricular (RV) autothreshold algorithm performances","0","0","0","0","0","0","0","0","0"
"3088","NCT01193894","Trial on Profermin and Fresubin in Ulcerative Colitis","Ulcerative Colitis",0,"Profermin","Other","Nordisk Rebalance A/S","Industry",0,0,"All","18 Years","N/A","73","August 2010","September 2012","Development in Simple Clinical Colitis Activity Index (SCCAI) score","0","0","0","0","0","0","0","0","0"
"3089","NCT01194219","Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis","Plaque Psoriasis",0,"Apremilast","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","844","September 2010","February 2012","Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline","<0.0001","0","Chi-squared","27.8","Risk Difference (RD)","95","2-Sided","23.1","32.5"
"3090","NCT01195246","Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis","End Stage Renal Disease",0,"HEPLISAV","Biological","Dynavax Technologies Corporation","Industry",0,0,"All","18 Years","N/A","155","December 2010","February 2012","Proportion of subjects with seroprotection rate (SPR), defined as the percentage of subjects with anti-HBsAg serum concentration of 10 milli-international unit (mIU)/mL or higher, measured at Week 4","0","0","0","0","0","0","0","0","0"
"3091","NCT01195831","Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis","Scalp Psoriasis",0,"Xamiol® gel","Drug","LEO Pharma","Industry",0,0,"All","18 Years","65 Years","244","September 2010","March 2011","Patients With ""Controlled Disease"" in Terms of ""Clear"" or ""Minimal"" According to Investigator's Global Assessment of Disease Severity at Week 4.","0","0","0","0","0","0","0","0","0"
"3092","NCT01196104","Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler","Type 2 Diabetes",0,"Technosphere® Insulin Inhalation Powder","Drug","Mannkind Corporation","Industry",0,0,"All","18 Years","80 Years","39","September 2010","August 2011","Change in HbA1c (%) From Baseline to Week 16","0.8283","0","ANCOVA","-0.0473","Mean Difference (Final Values)","95","2-Sided","-0.4901","0.3956"
"3093","NCT01196819","Randomized MicroPort's Firehawk DES Versus Xience V","Coronary Artery Disease",0,"DES implantation","Procedure","Shanghai MicroPort Medical (Group) Co., Ltd.","Industry",0,0,"All","18 Years","75 Years","510","September 2010","September 2012","9 months in-stent late lumen loss","0","0","0","0","0","0","0","0","0"
"3094","NCT01197521","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.","Rheumatoid Arthritis",0,"fostamatinib","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","923","September 2010","November 2012","Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo.","<0.001","Week 24","Mantel Haenszel","0.15","Weighted difference in proportions","95","2-Sided","0.08","0.22"
"3095","NCT01198002","A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate","Rheumatoid Arthritis",0,"LY2127399","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","990","December 2010","December 2012","Percentage of patients with American College of Rheumatology 20% response (ACR20) at Week 24","0","0","0","0","0","0","0","0","0"
"3096","NCT01198834","MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains","Ankle Sprains",0,"MRX-7EAT","Drug","MEDRx USA, Inc.","Industry",0,0,"All","14 Years","N/A","600","September 2010","June 2011","Mean of All Current Pain Intensity During Point and Flex Scores on Days 2 Through 7 on a 0-10 Numeric Pain Rating Scale (NPRS).","0","0","0","0","0","0","0","0","0"
"3097","NCT01199133","Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children","Allergic Rhinitis Due to Dust Mite",0,"Dpte and Dfar Allergen Extracts","Drug","Stallergenes","Industry",0,0,"All","5 Years","17 Years","471","October 2009","January 2011","Efficacy Assessment","0","0","0","0","0","0","0","0","0"
"3098","NCT01199705","Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)","Primary Immune Deficiency",0,"Immune Globulin Subcutaneous (Human) (SCIG)","Biological","CSL Behring","Industry",0,0,"All","N/A","75 Years","25","September 2010","August 2011","IgG Trough Level","0","0","0","0","0","0","0","0","0"
"3099","NCT01200368","Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants","Healthy Subjects",0,"13-valent pneumococcal conjugate vaccine (13vPnC)","Biological","Pfizer","Industry",0,0,"All","3 Months","6 Months","551","September 2010","November 2011","Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series","0","0","0","0.0","Percent difference","95","2-Sided","-2.2","2.1"
"3100","NCT01200758","A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous (IV) in Participants With Follicular Non-Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma",0,"Rituximab SC","Drug","Hoffmann-La Roche","Industry",0,0,"All","18 Years","N/A","410","February 2011","June 2012","Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab","0","0","0","1.62","Geometric mean ratio","90","2-Sided","1.36","1.94"
"3101","NCT01201187","Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD","Mental Disorders",0,"YY-162","Drug","Yuyu Pharma, Inc.","Industry",0,0,"All","6 Years","12 Years","144","March 2010","April 2010","Korea-ADHD Rating scale","0","0","0","0","0","0","0","0","0"
"3102","NCT01201798","Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis","Endogenous Anterior Uveitis",0,"Difluprednate 0.05% ophthalmic emulsion","Drug","Alcon Research","Industry",0,0,"All","2 Years","N/A","111","October 2010","August 2011","Change From Baseline (Day 0) in Anterior Chamber Cell Grade at Day 14","0","0","0","-0.22","Mean Difference (Net)","95","2-Sided","-0.53","0.09"
"3103","NCT01201902","A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine","Influenza Infection",0,"Adjuvanted influenza A(H1N1) vaccine","Biological","Green Cross Corporation","Industry",0,0,"All","18 Years","N/A","592","October 2009","December 2009","HI antibody responses after 1 and/or 2 vaccinations","0","0","0","0","0","0","0","0","0"
"3104","NCT01201928","Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166","Type 1 Diabetes Mellitus",0,"Comparator administered in parent trial","Drug","Mannkind Corporation","Industry",0,0,"All","18 Years","80 Years","3","October 2010","March 2011","Comparison of change from baseline to final treatment visit in pulmonary function (FEV1 FVC, TLC and DLco) between treatment Groups (TI vs comparator arms) using ANCOVA models.","0","0","0","0","0","0","0","0","0"
"3105","NCT01202058","An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)","Atherosclerotic Coronary Artery Disease",0,"NEVO™ Sirolimus-eluting Coronary Stent System","Device","Cordis Corporation","Industry",0,0,"All","18 Years","N/A","156","August 2010","November 2011","Twelve month composite clinical endpoint of all death, all MI and all revascularizations.","0","0","0","0","0","0","0","0","0"
"3106","NCT01202084","A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients","Asthma",0,"Formoterol/Fluticasone","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","12 Years","N/A","222","January 2012","November 2012","Forced expiratory volume in 1 second (FEV1) at final visit.","0","0","0","0","0","0","0","0","0"
"3107","NCT01202227","An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain","Spinal Cord Diseases",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","104","September 2010","March 2012","Number of Participants With Peripheral Edema","0","0","0","0","0","0","0","0","0"
"3108","NCT01202578","Evaluation of the Tympanostomy Tube Delivery System","Otitis Media With Effusion",0,"tympanostomy tube","Device","Acclarent","Industry",0,0,"All","6 Months","N/A","53","September 2010","November 2010","Safety of Tympanostomy Tube (TT) Delivery System","0","0","0","0","0","0","0","0","0"
"3109","NCT01202747","Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction","Chalazion",0,"LipiFlow System","Device","TearScience, Inc.","Industry",0,0,"All","18 Years","N/A","50","September 2010","January 2011","Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score)","0.0005","p<0.05 considered statistically significant","Regression, Linear","0","0","0","0","0","0"
"3110","NCT01202760","A Rheumatoid Arthritis Study in Patients","Rheumatoid Arthritis",0,"LY2127399","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1002","January 2011","December 2012","Percentage of patients with American College of Rheumatology 20% response (ACR20)","0","0","0","0","0","0","0","0","0"
"3111","NCT01203371","Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS","Hyperplasia",0,"Naftopidil","Drug","Apsen Farmaceutica S.A.","Industry",0,0,"Male","50 Years","90 Years","250","January 2011","September 2011","International Prostate Symptom Score","0","0","0","0","0","0","0","0","0"
"3112","NCT01204853","A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients","Hypertension, Pulmonary",0,"Sitaxentan","Drug","Pfizer","Industry",0,0,"All","16 Years","80 Years","2","August 2010","November 2010","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"3113","NCT01205048","Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds","Skin Wrinkling",0,"Emervel Classic Lidocaine","Device","Galderma","Industry",0,0,"All","18 Years","N/A","171","September 2010","January 2012","Mean change in wrinkle severity score from baseline to 24 weeks after final initial injection","0","0","0","0","0","0","0","0","0"
"3114","NCT01205061","Emervel Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds","Skin Wrinkling",0,"Emervel Deep Lidocaine","Device","Galderma","Industry",0,0,"All","18 Years","N/A","162","September 2010","January 2012","Mean change in wrinkle severity score from baseline to 24 weeks after final initial injection","0","0","0","0","0","0","0","0","0"
"3115","NCT01205126","An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain","Pain",0,"Hydromorphone HCl","Drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Industry",0,0,"All","18 Years","70 Years","260","December 2009","February 2011","Change From Baseline in Worst Pain in the Past 24 Hours Assessed by Brief Pain Inventory (BPI) Short Form Questionnaire Score at Day 29","0.855","P-value was calculated by ANCOVA model using Baseline as covariate for change at Day 29.","ANCOVA","-0.1","Least square mean difference","95","2-Sided","-1.3","1.1"
"3116","NCT01205932","Dose-confirmatory Bridging Study in Total Hip Replacement","Venous Thromboembolism",0,"Rivaroxaban (BAY59-7939)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","402","September 2010","June 2011","A composite endpoint of any deep vein thrombosis (proximal and/or distal), non-fatal pulmonary embolism and death from all causes","0","0","0","0","0","0","0","0","0"
"3117","NCT01206387","Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis","Psoriasis",0,"Desoximetasone Spray 0.25%","Drug","Taro Pharmaceuticals USA","Industry",0,0,"All","18 Years","N/A","120","August 2010","December 2010","Clinical Success","0.0003","0","t-test, 2 sided","0","0","0","0","0","0"
"3118","NCT01206660","Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis","Psoriasis",0,"Desoximetasone Spray 0.25%","Drug","Taro Pharmaceuticals USA","Industry",0,0,"All","18 Years","N/A","120","August 2010","December 2010","Clinical Success ITT","<0.0001","0","t-test, 2 sided","0","0","0","0","0","0"
"3119","NCT01206972","Dose-confirmatory Bridging Study in Total Knee Replacement","Venous Thromboembolism",0,"Rivaroxaban (BAY59-7939)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","302","October 2010","May 2011","A composite endpoint of any deep vein thrombosis (proximal and/or distal), non-fatal pulmonary embolism and death from all causes","0","0","0","0","0","0","0","0","0"
"3120","NCT01208129","Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails","Onychomycosis",0,"NAB001","Drug","Promius Pharma, LLC","Industry",0,0,"All","18 Years","70 Years","458","September 2010","July 2012","Complete cure rate at Week 56. Complete cure defined as clinically clear nail and mycological cure.","0","0","0","0","0","0","0","0","0"
"3121","NCT01208168","Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails","Onychomycosis",0,"NAB001","Drug","Promius Pharma, LLC","Industry",0,0,"All","18 Years","70 Years","468","September 2010","July 2012","Complete cure rate at Week 56. Complete cure defined as clinically clear nail and mycological cure.","0","0","0","0","0","0","0","0","0"
"3122","NCT01209364","Durolane Versus Methylprednisolone in Knee Osteoarthritis","Knee Osteoarthritis",0,"Durolane is a device, methylprednisolone in a drug","Device","Q-Med AB","Industry",0,0,"All","35 Years","80 Years","442","March 2007","January 2008","Pain level and responder rate","0","0","0","0","0","0","0","0","0"
"3123","NCT01210443","Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients","Hypertension, Pulmonary",0,"Sitaxentan","Drug","Pfizer","Industry",0,0,"All","16 Years","80 Years","2","November 2010","December 2010","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"3124","NCT01210716","Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device","Autoimmune Diseases",0,"Therapeutic plasma exchange","Device","Fenwal, Inc.","Industry",0,0,"All","18 Years","N/A","37","September 2010","May 2011","Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange Procedure","<0.001","0","paired t-test","6.69","Mean Difference (Final Values)","95","1-Sided","4.0","0"
"3125","NCT01211834","Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","Rheumatoid Arthritis",0,"tocilizumab","Drug","JW Pharmaceutical","Industry",0,0,"All","18 Years","N/A","90","October 2009","October 2010","Proportion of patients with ACR20 responses","0","0","0","0","0","0","0","0","0"
"3126","NCT01211873","Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions","Diagnostic Self Evaluation",0,"Dotarem (gadoterate meglumine)","Drug","Guerbet","Industry",0,0,"All","2 Years","N/A","416","September 2010","November 2011","MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both ""Pre"" and ""Paired"" Evaluation, Each Lesion is Scored With 3-point Scales.","0","0","0","0","0","0","0","0","0"
"3127","NCT01212471","A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease","Dry Eye Syndrome",0,"Bromfenac Ophthalmic Solution A","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","840","September 2010","August 2011","Sign and symptom measures of dry eye disease","0","0","0","0","0","0","0","0","0"
"3128","NCT01212757","PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","Psoriatic Arthritis",0,"Apremilast 20mg","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","488","September 27, 2010","July 26, 2012","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16","0.0060","0","Cochran-Mantel-Haenszel","13.4","Adjusted Difference","95","2-Sided","4.0","22.7"
"3129","NCT01212770","PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","Psoriatic Arthritis",0,"Apremilast 20mg","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","505","September 30, 2010","August 21, 2012","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16","<0.0001","0","Cochran-Mantel-Haenszel","22.3","Adjusted Difference","95","2-Sided","13.0","31.6"
"3130","NCT01214291","Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer","Risk of Bone Fracture Occurrences",0,"Toremifene","Drug","GTx","Industry",0,0,"Male","50 Years","80 Years","0","March 2011","September 2011","To confirm the efficacy of toremifene 80mg compared with placebo in the reduction in the risk of new bone fracture occurrences in men with prostate cancer on androgen deprivation therapy as measured by semiquantitative assessment of vertebral fractures","0","0","0","0","0","0","0","0","0"
"3131","NCT01214811","Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing","Inflammation",0,"Mepilex Border Ag","Device","Molnlycke Health Care AB","Industry",0,0,"All","18 Years","N/A","27","September 2010","September 2011","Wound Are at Baseline","0","0","0","0","0","0","0","0","0"
"3132","NCT01214889","Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.","Diphtheria",0,"PENTAXIM™: DTacP IPV//PRP~T combined vaccine","Biological","Sanofi","Industry",0,0,"All","56 Days","70 Days","370","September 2010","November 2011","Non-inferiority in terms of seroprotection rates (Diphtheria, Tetanus, Polio types 1, 2 and 3, Polyribosyl Ribitol Phosphate conjugated to Tetanus protein) of PENTAXIM™ Vaccine to the Tetraxim™ and PRP~T conjugate (Act-HIB™) vaccines.","0","0","0","0","0","0","0","0","0"
"3133","NCT01215513","Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","127","September 2010","April 2012","Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables","0","0","0","0","0","0","0","0","0"
"3134","NCT01215656","Effect of a Follow on Formula With Lactobacillus Fermentum on the Incidence of Infections","Incidence of Infectious Diseases",0,"Lactobacillus fermentum","Dietary Supplement","Puleva Biotech","Industry",0,0,"All","6 Months","7 Months","188","May 2008","January 2010","Incidence of infectious diseases","0","0","0","0","0","0","0","0","0"
"3135","NCT01216163","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain","Pain",0,"Novel Ibuprofen","Drug","Pfizer","Industry",0,0,"All","16 Years","40 Years","218","October 2010","January 2011","Time-weighted Sum of Pain Relief Rating With Pain Intensity Difference From 0 to 6 Hours (SPRID 0-6)","<0.001","p-value was calculated using ANOVA model with treatment, baseline Pain Severity Rating (PSR), gender and treatment-by-baseline PSR terms.","ANOVA","17.68","Least-squares (LS) mean difference","95","2-Sided","13.08","22.27"
"3136","NCT01216618","Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies","Diabetes Mellitus, Insulin-Dependent",0,"InsuPatch","Device","Insuline Medical Ltd.","Industry",0,0,"All","18 Years","65 Years","55","October 2010","June 2011","Efficacy","0","0","0","0","0","0","0","0","0"
"3137","NCT01216943","Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension","Glaucoma",0,"bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","126","November 2010","August 2012","Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye","0","0","0","0","0","0","0","0","0"
"3138","NCT01217086","Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)","Rheumatoid Arthritis",0,"Infliximab","Drug","Celltrion","Industry",0,0,"All","18 Years","75 Years","617","October 2010","November 2011","PK equivalence to remicade","0","0","0","0","0","0","0","0","0"
"3139","NCT01217190","Cross-over Bioequivalence Fasting Study to Compare Ondansetron Oral Soluble Film (OSF)With Zofran Orally Disintegrating Tablets(ODT)","Healthy Volunteers",0,"Ondansetron Orally Dissolving Film","Drug","Par Pharmaceutical, Inc.","Industry",0,0,"All","18 Years","45 Years","48","September 2008","September 2008","Two-wy Cross-over study to Compare Ondansetron ODSF with Zofran ODT","0","0","0","0","0","0","0","0","0"
"3140","NCT01217463","The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study","Diabetic Foot Ulcer of Neuropathic Origin",0,"Trafermin 0.01% spray","Drug","Olympus Biotech Corporation","Industry",0,0,"All","18 Years","N/A","201","November 2010","March 2012","Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition","0.4109","0","Regression, Logistic","1.44","Odds Ratio (OR)","95","2-Sided","0.60","3.43"
"3141","NCT01217476","The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study","Diabetic Foot Ulcer of Neuropathic Origin",0,"Trafermin 0.01% spray","Drug","Olympus Biotech Corporation","Industry",0,0,"All","18 Years","N/A","207","December 2010","May 2012","Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Origin After a Maximum of 12 Weeks Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition to Best Local Cares","0.4039","0","Regression, Logistic","1.36","Odds Ratio (OR)","95","2-Sided","0.66","2.80"
"3142","NCT01217515","Diltiazem Hydrochloride Cream for Anal Fissure","Chronic Anal Fissure",0,"Diltiazem hydrochloride 4% cream","Drug","S.L.A. Pharma AG","Industry",0,0,"All","18 Years","N/A","465","October 2010","March 2012","Change From Baseline in Average of Worst Anal Pain Associated With or Following Defaecation for Week 4 (for the 7 Treatment Days Immediately Preceding the Week 4 Visit).","0","0","0","0","0","0","0","0","0"
"3143","NCT01217892","Evaluation of Dapagliflozin Taken Twice-daily","Type 2 Diabetes",0,"dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","77 Years","400","November 2010","August 2011","Adjusted Mean Change in HbA1c Levels","0.0106","significant at alpha=0.05 (2-sided) applying Hochberg's method across the two Dapagliflozin BID groups.","ANCOVA","-0.22","Mean Difference (Final Values)","95","2-Sided","-0.38","-0.05"
"3144","NCT01218009","A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing","Asthma",0,"Placebo Spiromax","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","N/A","331","October 2010","December 2010","Participants With Treatment-Emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"3145","NCT01218451","NeisVac-C Single Prime Study in Infants","Neisseria Meningitidis",0,"Meningococcal group C polysaccharide conjugate vaccine","Biological","Pfizer","Industry",0,0,"All","8 Weeks","11 Weeks","956","September 2010","January 2012","Number of subjects with seroprotective antibody titers (rSBA titers >= 8) 1 month after completion of the primary vaccination in single-dose groups compared to the two-dose group","0","0","0","0","0","0","0","0","0"
"3146","NCT01218646","Study of Quadrivalent Influenza Vaccine Among Adults","Influenza",0,"Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","739","October 2010","March 2011","Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding B Strain in Participants Aged 65 Years and Older.","0","0","0","0","0","0","0","0","0"
"3147","NCT01219621","Comparison of AAIsafeR and DDD Modes in Non-selected Patients","Any Patient Who Fulfills the Inclusion Criteria to be Implanted With a Dual Chamber Pacemaker Maybe Included in the Study as Per ACC/AHA Guidelines",0,"Symphony Dual Chamber Rate Responsive Device","Procedure","Sorin Group Canada","Industry",0,0,"All","18 Years","N/A","450","April 2006","April 2009","Percentage of ventricular pacing","0","0","0","0","0","0","0","0","0"
"3148","NCT01219855","Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)","Chronic Kidney Disease",0,"Cohort 1 CTAP101 Capsules- 60µg","Drug","OPKO Health, Inc.","Industry",0,0,"All","18 Years","85 Years","78","October 2010","November 2011","Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP).","<0.0001","0","Z-test cmpared 2 independ. proportions","0","0","0","0","0","0"
"3149","NCT01219959","Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients","End Stage Renal Disease (ESRD)",0,"Dianeal","Drug","Baxter Healthcare Corporation","Industry",0,0,"All","18 Years","N/A","71","October 2010","July 2011","Change from the baseline value in HbA1c between the Dianeal, Extraneal, Nutrineal (D-E-N) group compared to the Dianeal only group.","0","0","0","0","0","0","0","0","0"
"3150","NCT01220869","A Study of Degarelix in Taiwanese Patients With Prostate Cancer","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","20 Years","N/A","110","December 2010","October 2012","Cumulative Probability of Participants With Testosterone at Castrate Level <= 0.5 ng/mL From Day 28 to Day 168","0","0","0","0","0","0","0","0","0"
"3151","NCT01221597","Study of AA4500 in the Treatment of Peyronie's Disease","Peyronie's Disease",0,"AA4500","Biological","Endo Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","418","September 2010","April 2012","Percentage Change From Baseline in Penile Curvature","0.0005","0","ANOVA","0","0","0","0","0","0"
"3152","NCT01221623","Study of AA4500 in the Treatment of Peyronie's Disease","Peyronie's Disease",0,"AA4500","Biological","Endo Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","418","October 2010","March 2012","Percentage Change From Baseline in Penile Curvature",".0059","0","ANOVA","0","0","0","0","0","0"
"3153","NCT01223365","Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time","Chronic Pain",0,"Hydrocodone ER","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","18 Years","80 Years","330","October 2010","September 2012","Participants With Adverse Experiences","0","0","0","0","0","0","0","0","0"
"3154","NCT01223937","Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients","Nocturia",0,"Desmopressin","Drug","Ferring Pharmaceuticals","Industry",0,0,"Female","18 Years","N/A","268","November 2010","November 2011","Change From Baseline in Mean Number of Nocturnal Voids Averaged Over a 3-Month Period","0.0280","A priori threshold for significance was p<=0.05.","ANCOVA","-0.22","Mean Difference (Final Values)","95","2-Sided","-0.42","-0.02"
"3155","NCT01224015","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","Facial Rhytides",0,"normal saline","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","684","May 2011","October 2011","Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines","0","0","0","0","0","0","0","0","0"
"3156","NCT01224171","Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease","Crohn's Disease",0,"vedolizumab","Drug","Millennium Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","80 Years","416","November 2010","February 2012","Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation","0.4332","0","Cochran-Mantel-Haenszel","3.0","Risk Difference (RD)","95","2-Sided","-4.5","10.5"
"3157","NCT01224353","Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy","Diabetics",0,"lipoic acid","Drug","NovaMed Pharmaceuticals Inc.","Industry",0,0,"All","18 Years","75 Years","200","November 2010","May 2011","To evaluate the efficacy on overall neuropathic sensory symptom improvement of Thioctacid tablet 600mg once daily vs. placebo in 6-weeks' treatment in Chinese diabetic patients with distal symmetric polyneuropathy (DSP)","0","0","0","0","0","0","0","0","0"
"3158","NCT01224795","A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.","Influenza",0,"Peramivir","Drug","BioCryst Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","1","October 2010","November 2010","To evaluate the efficacy of peramivir administered intravenously compared to placebo on the time to alleviation of clinical symptoms with acute uncomplicated influenza.","0","0","0","0","0","0","0","0","0"
"3159","NCT01225081","A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients","Type 2 Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","152","October 2010","April 2012","Change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"3160","NCT01225276","Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP","Chronic Inflammatory Demyelinating Polyradiculoneuropathy",0,"NewGam 10%","Drug","Octapharma","Industry",0,0,"All","18 Years","N/A","2","October 2011","October 2012","Adjusted INCAT disability score","0","0","0","0","0","0","0","0","0"
"3161","NCT01226459","Clinical Trial in Females for Female Pattern Hair Loss","Androgenetic Alopecia",0,"5% Minoxidil Topical Foam","Drug","Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","Industry",0,0,"Female","18 Years","N/A","404","September 2010","August 2011","Target Area Hair Count","<0.0001","0","ANCOVA","9.1","Mean Difference (Final Values)","95","2-Sided","5.0","13.1"
"3162","NCT01227421","Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza","Influenza",0,"Nitazoxanide","Drug","Romark Laboratories L.C.","Industry",0,0,"All","12 Years","65 Years","624","December 2010","April 2011","Time to Resolution of All Clinical Symptoms of Influenza as Reported by the Subjects","0","0","0","0","0","0","0","0","0"
"3163","NCT01227655","Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.","Parkinson's Disease",0,"BIA 9-1067","Drug","Bial - Portela C S.A.","Industry",0,0,"All","30 Years","83 Years","427","March 2011","July 2012","Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)","0","0","0","0","0","0","0","0","0"
"3164","NCT01227824","A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","Infection, Human Immunodeficiency Virus I",0,"GSK1349572 (dolutegravir)","Drug","ViiV Healthcare","Industry",0,0,"All","18 Years","N/A","827","October 2010","March 2012","Percentage of Participants With HIV-1RNA <50 Copies (c)/Milliliter (mL) Through Week 48.","0","0","0","2.5","Difference in percentage","95","2-Sided","-2.2","7.1"
"3165","NCT01227889","A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma","Cancer",0,"GSK2118436","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","250","December 2010","December 2011","Progression-free Survival (PFS) as Assessed by the Investigator","<0.0001","The p value from a stratified log-rank test was adjusted for disease stage at screening.","Log Rank","0.37","Hazard Ratio (HR)","96","2-Sided","0.23","0.58"
"3166","NCT01227902","Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures","Epilepsy",0,"Retigabine IR","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","203","July 2010","December 2012","Number of Participants With a >=50% Reduction in Partial-onset Seizure (POS) Frequency From Baseline","0","0","0","40.0","percentage of participants","95","2-Sided","27.1","52.9"
"3167","NCT01228006","Study for Effectiveness Evaluation of Panax Ginseng, Vitamins and Minerals (Natugerin®) in Improvement of Stress and Fatigue","Stress",0,"NatusGerin","Dietary Supplement","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","300","September 2011","December 2011","To evaluate the efficacy of the product Natus Gerin, compared to placebo, ® in improving symptoms of stress and fatigue in patients with clinical diagnosis of mild to moderate stress","0","0","0","0","0","0","0","0","0"
"3168","NCT01228071","Time to Eugonadal Range, Time to Steady State and Drying Time","Male Hypogonadism",0,"testosterone gel 2%","Drug","Endo Pharmaceuticals","Industry",0,0,"Male","18 Years","65 Years","34","November 2010","May 2011","Time to Target Eugonadal Range","0","0","0","0","0","0","0","0","0"
"3169","NCT01228630","Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.","Perennial Allergic Rhinitis",0,"Cloratadd-D","Drug","Azidus Brasil","Industry",0,0,"All","12 Years","N/A","156","August 2011","April 2012","Signs and symptoms evaluated by a PHYSICIAN","0","0","0","0","0","0","0","0","0"
"3170","NCT01228643","Effectiveness of Pancreatic Enzymes in Patients Pancreatic Insufficient: Comparison of Two Drugs","Chronic Renal Failure",0,"Pancreatic enzimes","Biological","Azidus Brasil","Industry",0,0,"All","14 Years","65 Years","5","June 2007","November 2011","Balance of fat in feces.","0","0","0","0","0","0","0","0","0"
"3171","NCT01229072","Safe Use of Heparin Sodium Laboratory Blausiegel Compared to Liquemine ® Laboratory Roche in Patients With Chronic Renal Failure.","Chronic Renal Failure",0,"Heparin sodic","Biological","Azidus Brasil","Industry",0,0,"All","18 Years","N/A","60","July 2008","July 2008","Safety use of the heparin in patients with renal failure.","0","0","0","0","0","0","0","0","0"
"3172","NCT01229371","Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers","Influenza",0,"Inflexal V influenza vaccine (CSL HA Antigen) 2010","Biological","Crucell Holland BV","Industry",0,0,"All","18 Years","N/A","440","October 2010","December 2010","Immunogenicity - Geometric Mean Titer Fold Increase From Baseline","0","0","0","0","0","0","0","0","0"
"3173","NCT01229397","Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V","Influenza",0,"Inflexal V","Biological","Crucell Holland BV","Industry",0,0,"All","6 Months","35 Months","205","October 2010","November 2010","Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza Vaccine in Adults (Aged ≥18 to ≤60 Years) as Reference","0","0","0","0","0","0","0","0","0"
"3174","NCT01229436","Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)","Dupuytren's Contracture",0,"Xiapex","Drug","Pfizer","Industry",0,0,"All","18 Years","70 Years","254","December 2010","October 2012","Total Passive Extension Deficit (TPED) at Baseline for First Injection","0","0","0","0","0","0","0","0","0"
"3175","NCT01229449","Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study","Post-operative Pain",0,"Ibuprofen/acetaminophen","Drug","Reckitt Benckiser LLC","Industry",0,0,"All","16 Years","N/A","678","January 2009","September 2009","SPRID (the sum of the pain intensity difference (PID) and the pain relief (PR) score)","0","0","0","0","0","0","0","0","0"
"3176","NCT01229566","Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia","Severe Hypertriglyceridemia",0,"AKR-963","Drug","Trygg Pharma, Inc.","Industry",0,0,"All","18 Years","79 Years","240","October 2010","July 2012","Difference between AKR963 and Control [placebo or active control] treatment groups in triglyceride lowering effect [ Time Frame: 12 weeks ]","0","0","0","0","0","0","0","0","0"
"3177","NCT01230021","Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency","Congenital Bleeding Disorder",0,"catridecacog","Drug","Novo Nordisk A/S","Industry",0,0,"All","1 Year","6 Years","6","November 2010","January 2012","Area Under the Concentration vs. Time Curve (AUC)","0","0","0","0","0","0","0","0","0"
"3178","NCT01230060","One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction","Aphakia",0,"enVista","Device","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","122","October 2010","January 2011","Visual Acuity","0","0","0","0","0","0","0","0","0"
"3179","NCT01230125","Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery","Cataract",0,"Mapracorat","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","250","November 2010","June 2011","Resolution of anterior chamber (AC) cells","0","0","0","0","0","0","0","0","0"
"3180","NCT01231321","A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis","Rheumatoid Arthritis",0,"adalimumab","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","100","December 2007","February 2010","Frequency of Adverse Events","0","0","0","0","0","0","0","0","0"
"3181","NCT01231347","QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","Adenocarcinoma of the Pancreas",0,"AMG 479","Drug","NantCell, Inc.","Industry",0,0,"All","18 Years","N/A","800","April 2011","December 2012","To determine if AMG 479 in combination with gemcitabine improves overall survival as compared with placebo in combination with gemcitabine in subjects with metastatic adenocarcinoma of the pancreas","0","0","0","0","0","0","0","0","0"
"3182","NCT01231607","Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia","Androgenetic Alopecia",0,"1mg Finasteride active","Drug","GlaxoSmithKline","Industry",0,0,"Male","20 Years","50 Years","917","October 2010","February 2012","Change From Baseline (BL) in Target Area Hair Count (HC) Within a 2.54 Centimeter (cm) (1 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by Macrophotographic Technique (MT)","0.046","0","General linear model","22","Least-squares (LS) mean difference","98.33","2-Sided","-4.4","48.4"
"3183","NCT01232283","Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.","Plaque Psoriasis",0,"Apremilast","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","413","November 2010","March 2012","Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline","<0.0001","0","Chi-squared","23.0","Risk Difference (RD)","95","2-Sided","16.3","29.6"
"3184","NCT01232894","12-week Open-label Evaluation of Efficacy and Safety of Indacaterol","Chronic Obstructive Pulmonary Disease (COPD)",0,"Indacaterol","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","90","March 2011","May 2012","Change From Baseline on Clinical COPD Questionnaire (CCQ) Score","0","0","0","0","0","0","0","0","0"
"3185","NCT01233258","A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A","Hemophilia A",0,"rFVIII (BAY81-8973) on demand","Biological","Bayer","Industry",0,0,"Male","12 Years","65 Years","80","January 2011","December 2012","Annualized Number of All Bleeds","0.0001","No multiplicity adjustment as only 1 primary endpoint.","ANOVA","0","0","0","0","0","0"
"3186","NCT01233349","Safety and Efficacy of Litramine in Overweight and Obese Subjects","Overweight",0,"Litramine","Device","InQpharm Group","Industry",0,0,"All","18 Years","60 Years","125","July 2010","December 2010","weight loss (kg)","0","0","0","0","0","0","0","0","0"
"3187","NCT01233934","Comparative Study of Two Forms of Topical Dexchlorpheniramine Maleate (Cream Versus Gel) for Insect Bites","Insect Bites",0,"Dexchlorpheniramine 1% Gel","Drug","Mantecorp Industria Quimica e Farmaceutica Ltd.","Industry",0,0,"All","2 Years","60 Years","90","February 2011","July 2011","Pruritus Intensity at Insect Bite Site, Evaluated With a 10 Point Visual Analogic Scale (VAS)","0","0","0","0","0","0","0","0","0"
"3188","NCT01235221","Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.","Multiple Sclerosis",0,"BIIB041 (Fampridine-SR)","Drug","Biogen","Industry",0,0,"All","18 Years","70 Years","38","December 2010","June 2012","Adverse events (AEs) and serious adverse events (SAEs) as well as Changes in vital signs and clinical laboratory assessments","0","0","0","0","0","0","0","0","0"
"3189","NCT01235442","Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis","Psoriasis",0,"1=Etanercept","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","592","September 2010","October 2011","PASI 75 at Week 12","<0.001","Overall significance level for primary and secondary endpoints controlled based on a combination of sequential testing and Hommel procedures.","Cochran-Mantel-Haenszel","2.05","Odds Ratio (OR)","95","2-Sided","1.46","2.87"
"3190","NCT01235598","Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)","Rheumatoid Arthritis",0,"Placebo","Other","UCB Pharma","Industry",0,0,"All","18 Years","N/A","41","December 2010","September 2012","Change in Synovitis Measured by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Image Scoring System (RAMRIS) Score at Week 16 Compared to Baseline for Certolizumab Pegol Arm","0.049","Two-sided p-value is presented, with p < 0.05 as the threshold for statistical significance.","Permutation test with general scores","-1.5","Median difference within group changes","95","2-Sided","-3.0","0.0"
"3191","NCT01235754","Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)","Hypoactive Sexual Desire Disorder",0,"transdermal testosterone gel 1%","Drug","BioSante Pharmaceuticals","Industry",0,0,"Female","30 Years","66 Years","626","October 2010","December 2011","Change in the 4-week total number of days with at least one satisfying sexual event from the baseline period (during the previous study) to weeks 9-12 of the current study","0","0","0","0","0","0","0","0","0"
"3192","NCT01236768","Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm","Contraception",0,"Study Drug AG200-15, Contraceptives, Hormonal","Drug","Agile Therapeutics","Industry",0,0,"Female","18 Years","40 Years","407","October 2010","June 2011","Pregnancy","0","0","0","0","0","0","0","0","0"
"3193","NCT01237223","Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension","Essential Hypertension",0,"Aliskiren/Amlodipine 150/2.5 mg","Drug","Novartis","Industry",0,0,"All","20 Years","N/A","1342","October 2010","May 2011","Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)","0","0","0","0","0","0","0","0","0"
"3194","NCT01237340","Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study","Growth Hormone Deficiency (GHD)",0,"Saizen®","Drug","EMD Serono","Industry",0,0,"All","18 Years","60 Years","59","October 2010","December 2011","Number of Participants Who Developed Positive Binding Antibodies (BAbs+) to Saizen®","0","0","0","0","0","0","0","0","0"
"3195","NCT01237860","Evaluation of the Safety and Performance of the NESS L300 Plus System","Foot Drop",0,"NESS L300 Plus System","Device","Bioness Inc","Industry",0,0,"All","18 Years","80 Years","45","September 2010","January 2011","Occurence of anticipated and unanticipated adverse events","0","0","0","0","0","0","0","0","0"
"3196","NCT01237977","Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines","Skin Aging",0,"Botulinum Toxin Type A(Meditoxin®)","Drug","Medy-Tox","Industry",0,0,"All","20 Years","65 Years","314","November 2009","September 2010","Glabellar line improvement rate at maximum frown confirmed with investigator's live assessment severity","0","0","0","0","0","0","0","0","0"
"3197","NCT01239030","Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD","Attention Deficit Hyperactivity Disorder",0,"Methylphenidate Hydrochloride Extended Release Capsules","Drug","Rhodes Pharmaceuticals, L.P.","Industry",0,0,"All","6 Years","18 Years","236","November 2010","February 2012","Efficacy of Biphentin compared to placebo","0","0","0","0","0","0","0","0","0"
"3198","NCT01239147","Effects of Whole Grain on Weight Maintenance","Abdominal Fat",0,"Diet rich in whole grain","Other","Cereal Partners Worldwide","Industry",0,0,"Female","20 Years","55 Years","186","October 2010","September 2012","Abdominal fat","0","0","0","0","0","0","0","0","0"
"3199","NCT01240746","Study of Quadrivalent Influenza Vaccine Among Children","Influenza",0,"Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","6 Months","8 Years","4363","November 2010","December 2011","Geometric Mean Titers Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants","0","0","0","0","0","0","0","0","0"
"3200","NCT01240863","Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time","Chronic Pain",0,"Hydrocodone ER","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","18 Years","80 Years","391","November 2010","August 2011","Change From Baseline to Week 12 in Weekly Average Pain Intensity (wAPI)","0.134","statistical significance level of 0.05.","ANCOVA","0.35","Mean Difference (Final Values)","95","2-Sided","-0.11","0.82"
"3201","NCT01241760","VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection","Genotype 1 Chronic Hepatitis C",0,"Ribavirin","Drug","Janssen Infectious Diseases BVBA","Industry",0,0,"All","18 Years","70 Years","744","December 2010","August 2012","Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)","0","0","0","1.5","Difference in proportion of response, %","95","0","-4.9","12"
"3202","NCT01242202","A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients","Type 2 Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","113","October 2010","May 2012","Change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"3203","NCT01242215","A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients","Type 2 Diabetes Mellitus",0,"ASP1941","Device","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","243","October 2010","April 2012","Change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"3204","NCT01242228","A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","Type 2 Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","106","October 2010","June 2012","Change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"3205","NCT01242527","Epanova® for Lowering Very High Triglycerides","Severe Hypertriglyceridemia",0,"placebo","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","399","January 2011","March 2012","Fasting Serum Triglycerides","0.005","P-value adjusted with Dunnett’s procedure for multiple comparisons of Epanova vs olive oil","ANCOVA p-value on ranked data","-21.68","Placebo adjusted % change from baseline","95","2-Sided","-40.70","-2.89"
"3206","NCT01242670","Ross River Virus (RRV) Vaccine Study","Prophylaxis of Ross River Virus Infection",0,"Ross River Virus Vaccine","Biological","Nanotherapeutics, Inc.","Industry",0,0,"All","16 Years","N/A","1968","April 2011","October 2012","Immune response measured by Ross River Vaccine (RRV)-specific neutralizing titer 21 days after the 3rd vaccination as determined by RRV microneutralization (μNT) assay","0","0","0","0","0","0","0","0","0"
"3207","NCT01242748","A Degarelix Trial in Patients With Prostate Cancer","Prostate Cancer",0,"Degarelix","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","288","October 2010","December 2011","Hazard Ratio of Prostate-specific Antigen (PSA) Progression-free Survival (PFS) Failure Rates During 3 Years' Treatment Between Degarelix and Goserelin","0.1589","0","Cox proportional hazard model","0.774","Hazard Ratio (HR)","95","2-Sided","0.542","1.106"
"3208","NCT01243294","Study Evaluating a New Ostomy Appliance With Regard to Leakage, Handling and Comfort","Colostomy",0,"SS","Device","Coloplast A/S","Industry",0,0,"All","18 Years","N/A","56","August 2010","November 2010","Leakage (Percent of All Base Plates With Leakage)","0","0","0","0","0","0","0","0","0"
"3209","NCT01243411","A Study of AA4500 in Men With Peyronie's Disease","Peyronie's Disease",0,"AA4500","Biological","Endo Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","348","November 2010","August 2012","Percentage Change From Baseline in Penile Curvature","0","0","0","0","0","0","0","0","0"
"3210","NCT01243450","Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo","Acne",0,"Tretinoin","Drug","Spear Pharmaceuticals","Industry",0,0,"All","12 Years","40 Years","958","October 2009","October 2010","Acne Lesion Percent Reduction","0","0","0","0","0","0","0","0","0"
"3211","NCT01243671","A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease","Intestinal Behçet's Disease",0,"Adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","15 Years","N/A","20","October 2010","March 2012","Number of Participants With Marked Improvement at Week 24","0","0","0","0","0","0","0","0","0"
"3212","NCT01243983","Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis","Noninfectious Uveitis",0,"LX211","Drug","Lux Biosciences, Inc.","Industry",0,0,"All","18 Years","N/A","155","February 2011","December 2012","The change from baseline in graded vitreous haze in the study eye at 12 weeks of therapy or at the time of treatment failure, if earlier.","0","0","0","0","0","0","0","0","0"
"3213","NCT01244217","Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)","Rhinitis Perennial",0,"fexofenadine/Allegra (M016455)","Drug","Sanofi","Industry",0,0,"All","6 Months","11 Years","100","October 2010","July 2011","Number of patients with adverse events","0","0","0","0","0","0","0","0","0"
"3214","NCT01244230","Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)","Atopic Dermatitis",0,"fexofenadine/Allegra (M016455)","Drug","Sanofi","Industry",0,0,"All","6 Months","11 Years","100","November 2010","July 2011","Number of patients with adverse events","0","0","0","0","0","0","0","0","0"
"3215","NCT01244984","A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma","Asthma",0,"Fluticasone Furoate/GW642444 Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","243","July 2010","January 2012","Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)","0","0","0","0","0","0","0","0","0"
"3216","NCT01245062","GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma","Melanoma",0,"GSK1120212","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","322","November 2010","October 2011","Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review","<0.0001","Investigator-Assessed PFS","Log Rank","0.44","Hazard Ratio (HR)","95","2-Sided","0.31","0.64"
"3217","NCT01245166","A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus","The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg",0,"Acarbose","Drug","Lotus Pharmaceutical","Industry",0,0,"All","20 Years","80 Years","220","November 2010","June 2011","The changes from baseline in HbA1c to the end of treatment period","0","0","0","0","0","0","0","0","0"
"3218","NCT01245530","An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia","Alzheimer Type Dementia",0,"Aricept","Drug","Whanin Pharmaceutical Company","Industry",0,0,"All","50 Years","80 Years","280","June 2008","February 2011","Change in cognition as assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) total score","0","0","0","0","0","0","0","0","0"
"3219","NCT01245569","A Study in Patients With Chronic Obstructive Pulmonary Disease","Chronic Obstructive Pulmonary Disease",0,"Foster® 100/6 µg/unit dose","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","40 Years","N/A","373","April 2011","March 2012","Transition Dyspnoea Index (TDI) score","0","0","0","0","0","0","0","0","0"
"3220","NCT01245751","Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)","Herpes Zoster",0,"Zoster Vaccine, Live","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","50 Years","N/A","600","April 2011","July 2012","Geometric Mean Titer (GMT) of the Antibody Responses to Varicella-Zoster Virus (VZV)","<0.001","The alpha threshold for statistical significance is 0.025 (1-sided)","Longitudinal regression model","1.05","GMT Ratio","95","2-Sided","0.97","1.15"
"3221","NCT01246479","Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study","Japanese Encephalitis",0,"Blood draw","Procedure","Valneva Austria GmbH","Industry",0,0,"All","9 Months","20 Years","23","October 2010","October 2012","Rate of Subjects With PRNT50 Titers of ≥ 1:10 at Month 12 After the First IC51 Vaccination (in Study IC51-322)","0","0","0","0","0","0","0","0","0"
"3222","NCT01246505","Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions","Chronic Total Occlusion",0,"CTO Crossing and Percutaneous transluminal angioplasty","Device","BridgePoint Medical","Industry",0,0,"All","18 Years","N/A","105","July 2011","December 2011","Incidence of Patients with a Major Adverse Events (MAE)","0","0","0","0","0","0","0","0","0"
"3223","NCT01246791","Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers","Healthy",0,"NPC-01","Drug","Nobelpharma","Industry",0,0,"Female","20 Years","35 Years","12","November 2010","May 2011","Area Under the Plasma Concentration Versus Time Curve (AUC) on Norethisterone of NPC-01","0","0","0","0","0","0","0","0","0"
"3224","NCT01247740","Comparison of Three-chamber-bag Versus Compounded Bag","Parenteral Nutrition for Patients With Proven Insufficient Enteral Resorption",0,"NuTRIflex Lipid peri","Drug","B. Braun Melsungen AG","Industry",0,0,"All","18 Years","85 Years","240","October 2010","October 2011","Course of prealbumin (from day 1 to day 7)","0","0","0","0","0","0","0","0","0"
"3225","NCT01248325","A Study of Luffa Operculate Nasal Solution 5mg/mL Compared With Saline (NaCl 09%) for the Relief of Nasal Obstruction","Rhinitis",0,"Luffa Operculate Nasal Solution 5mg/mL","Drug","Zurita Laboratorio Farmaceutico Ltda.","Industry",0,0,"All","18 Years","90 Years","60","January 2011","July 2011","Improvement of nasal congestion","0","0","0","0","0","0","0","0","0"
"3226","NCT01248780","Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","Rheumatoid Arthritis",0,"Golimumab","Drug","Centocor, Inc.","Industry",0,0,"All","18 Years","N/A","264","September 2010","October 2011","American College of Rheumatology (ACR) 20 Response, Using CRP (C-reactive Protein), at Week 14","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"3227","NCT01248793","Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis","Ankylosing Spondylitis",0,"Placebo","Drug","Centocor, Inc.","Industry",0,0,"All","18 Years","N/A","213","October 2010","May 2011","Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 14","0","0","0","0","0","0","0","0","0"
"3228","NCT01249183","Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old","Diphtheria",0,"Concomitant administration","Biological","MCM Vaccines B.V.","Industry",0,0,"All","60 Years","99 Years","954","October 2010","September 2011","Diphtheria seroprotection rate","0","0","0","0","0","0","0","0","0"
"3229","NCT01250249","A Study of Comparing Safety and Reactogenicity, of Lyophilized BCG Vaccine IP of Green Signal Bio Pharma Private Limited, India With BCG Vaccine of Serum Institute of India Limited in 120 Healthy Children.","Healthy",0,"BCG Vaccine IP - Serum Institute of India","Biological","Green Signal Biopharma Private Limited","Industry",0,0,"All","N/A","14 Years","120","November 2008","June 2009",NA,"0","0","0","0","0","0","0","0","0"
"3230","NCT01251133","Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study","Infectious Disease by Haemophilus Influenzae Type b",0,"LBVH0101 (Hib vaccine)","Biological","LG Life Sciences","Industry",0,0,"All","12 Months","15 Months","122","July 2008","March 2009","Percentage of the subjects who obtained protective Ab response with anti-PRP Ab titer ≥ 1 ㎍/mL after 4th vaccination","0","0","0","0","0","0","0","0","0"
"3231","NCT01251276","Hepatitis B Challenge Dose in Adults","Hepatitis B",0,"1 dose at Day 1","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","50 Years","N/A","204","November 2010","June 2011","Pre-challenge anti HBs seroprotection rate (percentage of subjects with titre >=10 mIU/mL)","0","0","0","0","0","0","0","0","0"
"3232","NCT01251822","Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic Constipation","Constipation",0,"PEG 3350 plus electrolytes","Drug","Norgine","Industry",0,0,"Female","18 Years","75 Years","240","November 2010","September 2011","Number of spontaneous bowel movements","0","0","0","0","0","0","0","0","0"
"3233","NCT01252719","Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection","Wound Infection",0,"Single-Dose IV Oritavancin Diphosphate","Drug","The Medicines Company","Industry",0,0,"All","18 Years","N/A","960","December 2010","October 2012","Cessation of spread or reduction in size of baseline lesion, absence of fever, and no rescue antibiotic medication at ECE (48 to 72 hours)","0","0","0","0","0","0","0","0","0"
"3234","NCT01252940","Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","HIV-1 Infection",0,"FTC/RPV/TDF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","482","November 2010","January 2012","Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 (FDA Snapshot Analysis)","0","0","0","3.8","Mean Difference (Net)","95","2-Sided","-1.6","9.1"
"3235","NCT01253824","Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers","Healthy",0,"NPC-01","Drug","Nobelpharma","Industry",0,0,"Female","20 Years","35 Years","14","January 2011","July 2011","Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))","0","0","0","0","0","0","0","0","0"
"3236","NCT01254344","Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)","Infection",0,"ertapenem sodium","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","80 Years","599","December 2010","December 2011","Percentage of Participants With Success of Prophylaxis","0","0","0","0.1","Difference in percentage of prophylaxis","95","2-Sided","-5.2","5.5"
"3237","NCT01254422","Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia","Dengue Fever",0,"Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus","Biological","Sanofi","Industry",0,0,"All","2 Years","11 Years","250","December 2010","September 2012","Information concerning the safety of CYD Dengue vaccine following each dose of vaccine","0","0","0","0","0","0","0","0","0"
"3238","NCT01255423","Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain","Ankle Sprain",0,"Diclofenac sodium topical gel 1%","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","206","November 2010","June 2011","Pain on Movement","0","0","0","0","0","0","0","0","0"
"3239","NCT01255787","Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder","Depressive Disorder, Major",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","20 Years","64 Years","600","November 2010","March 2012","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","0.9070","Adjustment for multiplicity for the comparisons was based on the Dunnett-Hsu procedure.","ANCOVA","-0.61","LS Mean Difference","95","2-Sided","-3.258","2.035"
"3240","NCT01256177","Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression","Bipolar Depression",0,"Quetiapine Fumarate (SEROQUEL) Extended Release","Drug","AstraZeneca","Industry",0,0,"All","18 Years","65 Years","361","December 2010","November 2012","Change From Baseline (Visit 2) to End of Study (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","0.004","0","Mixed Model Repeated Measures (MMRM)","-3.22","Least Square Mean difference vs Placebo","95","2-Sided","-5.39","-1.04"
"3241","NCT01256450","Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain","Pain",0,"Buprenorphine","Drug","BioDelivery Sciences International","Industry",0,0,"All","18 Years","N/A","334","November 2010","July 2011","Change in Pain Intensity From Baseline to Week 12",".5870","0","ANCOVA","-0.14","Mean Difference (Net)","95","2-Sided","-0.646","0.366"
"3242","NCT01256671","DHEA Against Vaginal Atrophy - Safety Study of 12 Months","Vaginal Atrophy",0,"DHEA","Drug","EndoCeutics Inc.","Industry",0,0,"Female","40 Years","75 Years","530","December 2010","July 2012","Change from baseline over time of clinical safety data: adverse event (AE) reporting, vital signs, physical examination findings, gynecological examination findings, clinical laboratory tests, endometrial biopsy, mammography and Pap smear.","0","0","0","0","0","0","0","0","0"
"3243","NCT01256684","DHEA Against Vaginal Atrophy - 3-Month Efficacy Study","Vaginal Atrophy",0,"Placebo","Drug","EndoCeutics Inc.","Industry",0,0,"Female","40 Years","75 Years","255","December 2010","August 2011","Co-primary Endpoint: Change From Baseline Over Time of Vaginal Cell Maturation (Percentage of Parabasal Cells).","0","0","0","0","0","0","0","0","0"
"3244","NCT01256736","To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Tocilizumab","Drug","JW Pharmaceutical","Industry",0,0,"All","18 Years","N/A","89","March 2010","December 2011","Safety results","0","0","0","0","0","0","0","0","0"
"3245","NCT01257074","Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis","Herpes Labialis",0,"Acyclovir 50mg/g","Drug","EMS","Industry",0,0,"All","18 Years","N/A","76","February 2012","March 2012","Efficacy will be evaluated by the proportion of subjects with non herpes labialis manifestation","0","0","0","0","0","0","0","0","0"
"3246","NCT01257386","Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis","Active Ulcerative Colitis",0,"Asacol®","Drug","Tillotts Pharma AG","Industry",0,0,"All","18 Years","64 Years","251","November 2010","August 2012","Reduction degree of UC-DAI","0","0","0","0","0","0","0","0","0"
"3247","NCT01257984","Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function","Contraception",0,"BAY86-5300","Drug","Bayer","Industry",0,0,"Female","18 Years","35 Years","508","December 2010","August 2012","Mean daily delay of tablet release, i.e. the time of tablet-release which will be compared to the reference tablet release time","0","0","0","0","0","0","0","0","0"
"3248","NCT01258049","Superiority of ArTiMist Versus Quinine in Children With Severe Malaria","Plasmodium Falciparum Malaria",0,"Artemether Sublingual Spray","Drug","Proto Pharma Ltd","Industry",0,0,"All","N/A","N/A","151","December 2010","August 2012","Parasitological Success (MITT)","<0.005","0","Regression, Logistic","54.85","Percentage Difference","95","2-Sided","42.25","67.45"
"3249","NCT01258309","Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis","Rhinitis, Allergic, Seasonal",0,"olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","129","December 2010","January 2011","Ocular Itching","0","0","0","0","0","0","0","0","0"
"3250","NCT01258673","A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy","Essential Hypertension",0,"Fimasartan/HCTZ combination","Drug","Boryung Pharmaceutical Co., Ltd","Industry",0,0,"All","18 Years","N/A","263","November 2010","December 2011","Diastolic Blood Pressure","0","0","0","0","0","0","0","0","0"
"3251","NCT01258686","Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy","Hepatitis C",0,"Silymarin","Drug","Bukwang Pharmaceutical","Industry",0,0,"All","18 Years","N/A","53","November 2010","November 2012","The proportion of patient with serum ALT less than or equal to 40 IU/L or achieves at least 50% decline to less than 60 IU/L","0","0","0","0","0","0","0","0","0"
"3252","NCT01258712","Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients","Rheumatoid Arthritis (RA)",0,"Tocilizumab + methotrexate(MTX)","Drug","Chugai Pharma Taiwan","Industry",0,0,"All","20 Years","75 Years","86","December 2010","October 2012","Proportion of patients with an American College of Rheumatology 20(ACR20) response","0","0","0","0","0","0","0","0","0"
"3253","NCT01258738","Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes","Spondylitis, Ankylosing",0,"etanercept","Biological","Pfizer","Industry",0,0,"All","18 Years","49 Years","225","February 2011","November 2012","Percentage of Participants Achieving Ankylosing Spondylitis (ASAS) 40 Response at Week 12","0.0062","P-value <0.05 was required to declare statistical significance.","Cochran-Mantel-Haenszel","16.64","Mean Difference (Final Values)","95","2-Sided","5.36","27.92"
"3254","NCT01258842","Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults","Influenza",0,"Bifidobacterium lactis HN019","Dietary Supplement","Fonterra Research Centre","Industry",0,0,"All","18 Years","60 Years","426","December 2010","May 2011","Influenza infection","0","0","0","0","0","0","0","0","0"
"3255","NCT01258920","A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia","Schizophrenia",0,"Paliperidone palmitate","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","201","October 2010","November 2012","Incidence of adverse events as a measure of safety and tolerability","0","0","0","0","0","0","0","0","0"
"3256","NCT01259128","Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia","Nocturia",0,"SER120 Nasal Spray 500 ng/day","Drug","Serenity Pharmaceuticals, Inc.","Industry",0,0,"All","75 Years","95 Years","32","April 2010","November 2010","Safety and tolerability of SER120 nasal spray in 75 years or older nocturic patients in terms of serum sodium levels and adverse events.","0","0","0","0","0","0","0","0","0"
"3257","NCT01259674","Evaluation of the Efficacy and Tolerability of ABO/MEG-B-09 in Children With Acute Cough","Cough",0,"AboMeg-B-09","Device","Aboca Spa Societa' Agricola","Industry",0,0,"All","3 Years","6 Years","102","October 2010","April 2011","Cough score variation","0","0","0","0","0","0","0","0","0"
"3258","NCT01260636","Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries","Carotid, Aortic, Renal or Peripheral Artery Disease",0,"Gadobenate Dimeglumine","Drug","Bracco Diagnostics, Inc","Industry",0,0,"All","18 Years","N/A","120","September 2009","December 2011","Diagnostic Preference","0","0","0","0","0","0","0","0","0"
"3259","NCT01261611","Study Comparing Short Term Efficacy of Dysport® and Dysport RU® to Placebo, and to Assess Efficacy and Safety of Dysport RU® of Subjects With Cervical Dystonia","Cervical Dystonia",0,"Botulinum type A toxin (Dysport RU®)","Drug","Ipsen","Industry",0,0,"All","18 Years","N/A","333","April 2011","May 2012","Change in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score following first treatment","0","0","0","0","0","0","0","0","0"
"3260","NCT01262261","Re-Treatment Study of Probuphine in Opioid Addiction","Opioid Dependency",0,"Probuphine (buprenorphine implant)","Drug","Braeburn Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","85","November 2010","November 2011","Number of subjects with Adverse Events (AEs) as a measure of safety","0","0","0","0","0","0","0","0","0"
"3261","NCT01262456","Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients","Nocturia",0,"Desmopressin","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","395","February 2011","January 2012","Change From Baseline in Mean Number of Nocturnal Voids Averaged Over a 3-Month Period","<0.0001","A priori threshold for significance was p<=0.05.","ANCOVA","-0.41","Mean Difference (Final Values)","95","2-Sided","-0.61","-0.22"
"3262","NCT01262677","Once-A-Day Pregabalin For Partial Seizures","Partial Seizures",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","334","January 2011","August 2012","The primary endpoint will be the log transformed (loge) 28 day seizure rate for all partial onset seizures collected during the double blind treatment phase.","0","0","0","0","0","0","0","0","0"
"3263","NCT01263015","A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","Infection, Human Immunodeficiency Virus I",0,"Dolutegravir","Drug","ViiV Healthcare","Industry",0,0,"All","18 Years","N/A","844","February 2011","May 2012","Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48","0.003","P-value is for the test of superiority.","Wilcoxon (Mann-Whitney)","7.3","Difference in percentage","95","2-Sided","2.3","12.2"
"3264","NCT01263132","Neuropathic Pain Management","Diabetic Neuropathies",0,"F0434","Drug","Merck KGaA","Industry",0,0,"All","18 Years","70 Years","104","February 2008","February 2010","Mean Neuropathic Pain Score at Visit 3 (Week 1)","0","0","0","0","0","0","0","0","0"
"3265","NCT01263483","Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan","Type 2 Diabetes Mellitus",0,"Alogliptin and voglibose","Drug","Takeda","Industry",0,0,"All","33 Years","85 Years","230","January 2007","April 2008","Change From Baseline in Glycosylated Hemoglobin (Week 12).","0","0","0","-1.002","Mean Difference (Final Values)","95","2-Sided","-1.166","-0.838"
"3266","NCT01263509","Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan","Type 2 Diabetes Mellitus",0,"Alogliptin and voglibose","Drug","Takeda","Industry",0,0,"All","33 Years","85 Years","179","June 2007","October 2008","Number of Participants With Adverse Events.","0","0","0","0","0","0","0","0","0"
"3267","NCT01263925","Prostaglandin E1 in Outpatients With Intermittent Claudication","Stage II Peripheral Arterial Occlusive Disease",0,"Alprostadil (Prostaglandin E1)","Drug","UCB Pharma","Industry",0,0,"All","40 Years","N/A","561","April 2001","April 2011","Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline","0","0","0","0","0","0","0","0","0"
"3268","NCT01264419","Silk Road Medical First in Man Study - Neuroprotection During Carotid Stenting and Angioplasty","Carotid Artery Diseases",0,"Carotid angioplasty and stenting with Silk Road Embolic Protection System","Device","Silk Road Medical","Industry",0,0,"All","21 Years","N/A","75","March 2009","June 2012","Perioperative Major Adverse Events (stroke, death, MI) through 30 days","0","0","0","0","0","0","0","0","0"
"3269","NCT01265394","Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects","Healthy",0,"[18F] Flutemetamol","Drug","GE Healthcare","Industry",0,0,"All","18 Years","40 Years","218","December 2010","March 2011","Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid","0","0","0","0","0","0","0","0","0"
"3270","NCT01265446","Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.","Sore Throat Due to a Common Cold",0,"Lidocaine 8mg + CPC 2mg","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","250","December 2010","April 2011","Change From Baseline Sore Throat Pain Intensity","0","0","0","0","0","0","0","0","0"
"3271","NCT01266161","Multiple Dose Dental Pain Study Of Ibuprofen Extended Release","Pain",0,"Ibuprofen 600 mg ER","Drug","Pfizer","Industry",0,0,"All","16 Years","40 Years","139","November 2010","March 2011","Sum of pain relief and pain intensity difference scores from 0-12 hours after the first dose (SPRID 0-12)","0","0","0","0","0","0","0","0","0"
"3272","NCT01268098","Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)","Hypoparathyroidism",0,"NPSP558","Drug","Shire","Industry",0,0,"All","18 Years","85 Years","42","January 2011","September 2011","Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 8, Based on Investigator Prescribed Data.",">0.999","All hypothesis testings in this study were based on type I error of 0.05. Adjustment for multiplicity was not applied.","Fisher Exact","5.0","Treatment difference","95","2-Sided","-20.6","30.7"
"3273","NCT01268891","Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea","Parkinson's Disease",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","30 Years","N/A","132","January 2011","June 2012","Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary","0.3257","The threshold for statistical significance in showing a trend for this study is 0.10.","ANCOVA","-0.35","Mean Difference (Final Values)","90","2-Sided","-0.93","0.23"
"3274","NCT01269437","Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma","Asthma",0,"Budesonide dry powder inhaler","Drug","NovaMed Pharmaceuticals Inc.","Industry",0,0,"All","12 Years","70 Years","332","December 2010","October 2011","To demonstrate the non-inferiority of budesonide delivered by Novolizer to that delivered by Turbuhaler in terms of mPEF （morning peak expiratory flow） in Chinese mild to moderate asthma patients","0","0","0","0","0","0","0","0","0"
"3275","NCT01269463","Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting","Attention Deficit Hyperactivity Disorder",0,"Methylphenidate Hydrochloride Extended Release Capsules","Drug","Rhodes Pharmaceuticals, L.P.","Industry",0,0,"All","6 Years","12 Years","27","December 2010","June 2011","Comparison following treatment between drug and placebo using evaluation by SKAMP Combined, Attention, and Deportment Scales","0","0","0","0","0","0","0","0","0"
"3276","NCT01270347","Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients","Cystic Fibrosis",0,"MP-376 (Levofloxacin Solution for Inhalation)","Drug","Forest Laboratories","Industry",0,0,"All","12 Years","N/A","267","January 2011","October 2012","Safety","0","0","0","0","0","0","0","0","0"
"3277","NCT01270971","Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","Onychomycosis of Toenails",0,"AN2690 Topical Solution, 5%","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","594","December 2010","November 2012","Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52","0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"3278","NCT01270997","Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients","Rheumatoid Arthritis",0,"Etanercept","Biological","Hanwha Chemical","Industry",0,0,"All","20 Years","N/A","294","December 2010","May 2012","To prove the equivalence between two groups by comparing the ACR20 of W24 with the baseline after injecting HD203 and Enbrel® into rheumatoid arthritis patients for 24 weeks.","0","0","0","0","0","0","0","0","0"
"3279","NCT01271712","Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)","Gastrointestinal Stromal Tumors",0,"Regorafenib (Stivarga, BAY73-4506)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","199","January 2011","January 2012","Progression-free Survival","<0.000001","0","Log Rank","0","0","0","0","0","0"
"3280","NCT01271933","Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients","Fibromyalgia",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","777","March 2011","July 2012","Time to loss of therapeutic response based on pain response relative to baseline or patient discontinuation.","0","0","0","0","0","0","0","0","0"
"3281","NCT01272193","Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","20 Years","N/A","296","January 2011","September 2011","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"3282","NCT01272947","Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma Injuries","Acute Blunt Soft Tissue Injuries/Contusions",0,"Diclofenac sodium","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","204","January 2011","July 2011","Pain on Movement","0","0","0","0","0","0","0","0","0"
"3283","NCT01272986","Trial of Screening for ALOA-IgG AtheroAbzyme Test","Myocardial Ischemia",0,"ALOA IgG-Elisa","Device","Omicron Pharmaceuticals","Industry",0,0,"All","N/A","N/A","100","January 2011","March 2011","Measuring the degree of oxidized low-density lipoprotein (LDL) by ALOA- IgG AtheroAbzyme in healthy and cardiovascular disease patients","0","0","0","0","0","0","0","0","0"
"3284","NCT01274221","Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","ADHD",0,"SPD489","Drug","Shire","Industry",0,0,"All","13 Years","17 Years","0","February 2011","May 2011","Permanent Product Measure of Performance (PERMP) Total Score","0","0","0","0","0","0","0","0","0"
"3285","NCT01274897","A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea","Meningococcal Disease",0,"Novartis MenACWY-CRM","Biological","Novartis Vaccines","Industry",0,0,"All","11 Years","55 Years","450","December 2010","March 2011","Percentages of Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.","0","0","0","71","Lower limit of the two-sided 95% CI","95","2-Sided","71","81"
"3286","NCT01275066","A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","MPS IV A",0,"BMN 110 Weekly","Drug","BioMarin Pharmaceutical","Industry",0,0,"All","5 Years","N/A","177","February 2011","August 2012","Change From Baseline in Endurance as Measured by the 6-minute Walk Test","0.0174","Hochberg multiplicity adjustment - results considered statistically significant if both of p-values are p<0.05 or either of p-values is p<0.025.","ANCOVA","22.5","Mean Difference (Final Values)","95","0","0","0"
"3287","NCT01277172","TREatment of degeNerative and Neoplastic Diseases With Rituximab","Diffuse Large B Cell Lymphoma",0,"Rituximab","Biological","Probiomed S.A. de C.V.","Industry",0,0,"All","18 Years","80 Years","54","October 2010","September 2011","Basal and final serum CD 20 levels comparison.","0","0","0","0","0","0","0","0","0"
"3288","NCT01277289","Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease","Crohn's Disease",0,"Dexamethasone","Drug","Erydel","Industry",0,0,"All","18 Years","80 Years","51","April 2009","December 2011","proportion of patients maintaining steroids-free clinical remission (CDAI<150) without surgery for 12 months","0","0","0","0","0","0","0","0","0"
"3289","NCT01280188","A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).","Central Diabetes Insipidus",0,"Desmopressin Oral Melt","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","6 Years","75 Years","20","January 2011","August 2011","Change from Baseline in 24-hour Urine Volume","0","0","0","0","0","0","0","0","0"
"3290","NCT01280331","Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients","Postoperative Pain",0,"Q8003 (morphine sulfate and oxycodone hydrochloride)","Drug","QRxPharma Inc.","Industry",0,0,"All","18 Years","N/A","375","January 2011","April 2011","Differences in desaturation events per standardized time unit","0","0","0","0","0","0","0","0","0"
"3291","NCT01280591","Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain","Pain, Postoperative",0,"Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)","Drug","Bayer","Industry",0,0,"All","12 Years","45 Years","712","October 2010","January 2011","Wake Time After Sleep Onset (WASO) Measured by Actigraphy","0.0002","0","ANCOVA","-70.3","Mean Difference (Final Values)","95","2-Sided","-106.8","-33.7"
"3292","NCT01280981","A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding","Menorrhagia",0,"Tranexamic acid","Drug","Ferring Pharmaceuticals","Industry",0,0,"Female","18 Years","49 Years","288","April 2007","May 2009","Participants With Treatment-Emergent Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"3293","NCT01281189","Phase 3 Study of Dexpramipexole in ALS","Amyotrophic Lateral Sclerosis",0,"Dexpramipexole","Drug","Knopp Biosciences","Industry",0,0,"All","18 Years","80 Years","943","March 2011","November 2012","A joint rank of functional outcomes adjusted for mortality.","0","0","0","0","0","0","0","0","0"
"3294","NCT01281202","Vigabatrin for the Treatment of Cocaine Dependency","Cocaine Addiction",0,"Vigabatrin","Drug","Catalyst Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","207","January 2011","October 2012","Abstinence","0","0","0","0","0","0","0","0","0"
"3295","NCT01281527","Paliperidone Palmitate Flexible Dosing in Schizophrenia","Schizophrenia",0,"Paliperidone Palmitate","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","N/A","1044","November 2010","November 2012","Improved efficacy for non-acute patients transitioned due to lack of efficacy, as measured by the total PANSS score at endpoint versus baseline.","0","0","0","0","0","0","0","0","0"
"3296","NCT01282268","Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome","Fragile X Syndrome",0,"arbaclofen","Drug","Seaside Therapeutics, Inc.","Industry",0,0,"All","12 Years","50 Years","125","May 2011","December 2012","Aberrant Behavior Checklist - FXS Social Avoidance Subscale","0","0","0","0","0","0","0","0","0"
"3297","NCT01282619","Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease","Alzheimer's Disease",0,"Huperzine A","Drug","Shandong Luye Pharmaceutical Co., Ltd.","Industry",0,0,"All","50 Years","85 Years","390","May 2010","June 2012","Alzheimer's Disease Assessment Scale - Cognitive Subscale","0","0","0","0","0","0","0","0","0"
"3298","NCT01283594","Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off","Parkinson's Disease",0,"Tozadenant (SYN115) 60 mg BID","Drug","Biotie Therapies Inc.","Industry",0,0,"All","30 Years","80 Years","420","March 2011","October 2012","Assess efficacy of different doses of SYN115 for reducing the mean total hours of awake time per day spent in the off state","0","0","0","0","0","0","0","0","0"
"3299","NCT01283646","Efficacy and Tolerability of Apevitin BC Comparing to Vitamin Complex in Stimulating the Appetite","Lack or Loss Appetite Nonorganic Origin",0,"Apevitin BC","Drug","EMS","Industry",0,0,"All","5 Years","15 Years","51","October 2011","May 2012","Evaluate the effectiveness of Apevitin BC in appetite stimulation compared to vitamin complex.","0","0","0","0","0","0","0","0","0"
"3300","NCT01284517","Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression","Bipolar Depression",0,"Lurasidone","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","356","November 2010","August 2012","Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)","0.176","0","Mixed Models Analysis","-1.5","Mean Difference (Final Values)","0","0","0","0"
"3301","NCT01285583","Safety Extension Study of TRO19622 in ALS","Amyotrophic Lateral Sclerosis",0,"TRO19622","Drug","Hoffmann-La Roche","Industry",0,0,"All","N/A","N/A","271","October 2010","March 2012","The primary outcome measure will be the safety assessment.","0","0","0","0","0","0","0","0","0"
"3302","NCT01286857","An Investigation to Evaluate the Function of a New Silicon Cover Film and an On-top Suction Device to be Used in a NPWT System in the Treatment of Acute and Chronic Wounds","Acute and Chronic Wounds",0,"External Suction Interface and a Silicon Film","Device","Molnlycke Health Care AB","Industry",0,0,"All","18 Years","N/A","15","September 2010","May 2011","To evaluate the transport of exudate from the wound bed to canister and thus distribute negative pressure in the wound site","0","0","0","0","0","0","0","0","0"
"3303","NCT01286909","Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)","Metabolic Disease",0,"LaFlavon","Dietary Supplement","Omicron Pharmaceuticals","Industry",0,0,"All","45 Years","75 Years","40","January 2011","June 2011","Increase in High-Density Lipoprotein (HDL)","0","0","0","0","0","0","0","0","0"
"3304","NCT01286935","18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD","Parkinson's Disease",0,"Safinamide","Drug","Newron","Industry",0,0,"All","30 Years","80 Years","544","August 2007","April 2010","Mean change in the dyskinesias rating scale (DRS) during ""on"" time","0","0","0","0","0","0","0","0","0"
"3305","NCT01287182","Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis","Atherosclerosis",0,"Ateronon","Drug","Omicron Pharmaceuticals","Industry",0,0,"All","35 Years","75 Years","100","May 2011","December 2011","to evaluate the effectiveness of Ateronon in inhibiting atherogenic lipid oxidation in patients with demonstrated coronary disease","0","0","0","0","0","0","0","0","0"
"3306","NCT01287260","High Dose BAYA1040_Nifedipine: a Dose-comparative Study","Hypertension",0,"Nifedipine (Adalat, BAYA1040)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","352","January 2011","August 2011","Efficacy changes measured by sitting diastolic blood pressure (DBP)","0","0","0","0","0","0","0","0","0"
"3307","NCT01287364","Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis","Perennial Allergic Rhinitis",0,"ciclesonide hydrofluoroalkane (HFA) nasal aerosol","Drug","Sunovion","Industry",0,0,"All","12 Years","N/A","185","February 2011","April 2011","Treatment Satisfaction Subscales (Interference, Regimen Adaptation, Role Limitations, Sensory Impact, Regimen Difficulties, Burden, Hassle, Regimen Management, and Perceived Relief)Reliability Statistics","0","0","0","0","0","0","0","0","0"
"3308","NCT01287949","Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older","Diphtheria",0,"Diphtheria, tetanus, polio and pertussis vaccination","Biological","MCM Vaccines B.V.","Industry",0,0,"All","40 Years","N/A","342","January 2011","May 2012","Diphtheria seroprotection rate","0","0","0","0","0","0","0","0","0"
"3309","NCT01288209","A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy","Hepatitis C, Chronic",0,"TMC435","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","70 Years","106","February 2011","September 2012","The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)","0","0","0","0","0","0","0","0","0"
"3310","NCT01289015","Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis","Tinea Pedis",0,"NAFT-600 ( naftin 2 % gel )","Drug","Merz Pharmaceuticals, LLC","Industry",0,0,"All","12 Years","N/A","855","February 2011","November 2011","Complete Cure of Interdigital Tinea Pedis","<0.025","0","Cochran-Mantel-Haenszel","0.001","p-value","95","0","0","0"
"3311","NCT01289119","Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"Alogliptin","Drug","Takeda","Industry",0,0,"All","18 Years","75 Years","506","December 2010","December 2011","Change From Baseline in Glycosylated Hemoglobin (HbA1c)","<0.001","0","ANCOVA","-0.58","LS Mean Difference","95","2-Sided","-0.78","-0.37"
"3312","NCT01290341","Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis","Tinea Pedis",0,"NAFT-600 (naftin 2 % gel)","Drug","Merz Pharmaceuticals, LLC","Industry",0,0,"All","12 Years","N/A","860","February 2011","November 2011","Complete Cure of Interdigital Tinea Pedis","<0.025","0","Cochran-Mantel-Haenszel","0.001","p-value","95","0","0","0"
"3313","NCT01290731","A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy","Hepatitis C, Chronic",0,"TMC435","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","70 Years","49","January 2011","August 2012","The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)","0","0","0","0","0","0","0","0","0"
"3314","NCT01292239","A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients","Hepatitis C, Chronic",0,"Placebo","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","70 Years","183","February 2011","October 2012","The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)","<0.0001","The p-value was based on the asymptomatic distribution of the generalized Cochran-Mantel-Haenszel (CMH) statistic controlling for stratification factors.","Cochran-Mantel-Haenszel","27.5","(see comment)","95","2-Sided","14.38","40.56"
"3315","NCT01292265","A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)","Rheumatoid Arthritis",0,"Certolizumab Pegol","Biological","UCB Pharma","Industry",0,0,"All","18 Years","N/A","3","February 2011","January 2012","Change From Baseline (Week 0) in the Modified Ultrasound-7 Joint (mUS7) Sumscore at Week 12","0","0","0","0","0","0","0","0","0"
"3316","NCT01292460","Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies","Ocular Hypertension",0,"Timolol/ FDC/ Placebo/ Tafluprost","Drug","Santen Oy","Industry",0,0,"All","18 Years","N/A","600","February 2011","September 2012","Change from baseline in the average diurnal Intraocular Pressure (IOP) at 3 months","0","0","0","0","0","0","0","0","0"
"3317","NCT01292473","A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)","Chronic Idiopathic Urticaria",0,"Placebo","Drug","Genentech, Inc.","Industry",0,0,"All","12 Years","75 Years","323","March 2011","June 2012","Change From Baseline in the Weekly Itch Severity Score at Week 12","0.4637","Refer to the Type-I error control plan.","ANCOVA","-0.69","Least Squares Mean Difference","95","2-Sided","-2.54","1.16"
"3318","NCT01293201","Trial of STAHIST in Seasonal Allergic Rhinitis","Seasonal Allergic Rhinitis",0,"STAHIST","Drug","Magna Pharmaceuticals, Inc.","Industry",0,0,"All","12 Years","60 Years","290","March 2011","June 2011","Total Symptom Scores (TSS)","0","0","0","0","0","0","0","0","0"
"3319","NCT01293305","Study With Chondroitin Sulfate and Glucosamine Sulfate (in Dosage Capsule and Sachet) in Treating Osteoarthritis","Osteoarthritis",0,"Chondroitin sulfate + Glucosamine sulfate","Drug","Azidus Brasil","Industry",0,0,"All","40 Years","N/A","320","November 2011","August 2012","Promotion of pain relief in patients with osteoarthritis.","0","0","0","0","0","0","0","0","0"
"3320","NCT01293643","A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)","Vaginosis, Bacterial",0,"100 mg clindamycin /800 mg ketoconazole vaginal ovule","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","45 Years","99","May 2010","January 2011","Percentage of participants that obtain clinical cure","0","0","0","0","0","0","0","0","0"
"3321","NCT01294215","High Dose BAYA1040_Nifedipine: a Long Term Combination Study","Hypertension",0,"Nifedipine (Adalat, BAYA1040)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","72","February 2011","November 2011","Efficacy changes measured by sitting diastolic blood pressure (DBP)","0","0","0","0","0","0","0","0","0"
"3322","NCT01294384","Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease","Dry Eye Syndromes",0,"carboxymethylcellulose sodium based New Eye Drop Formulation 1","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","305","May 2011","September 2012","Change From Baseline in Ocular Surface Disease Index© (OSDI) Score","0","0","0","0","0","0","0","0","0"
"3323","NCT01294423","Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","20 Years","N/A","261","February 2011","March 2012","Adjusted Mean Change in HbA1c Levels","<0.0001","significant at alpha=0.027 (2-sided) applying Dunnett's adjustment. A hierarchical closed testing procedure was used to control the Type I error rate across the primary and key secondary endpoints.","ANCOVA","-0.35","Mean Difference (Final Values)","95","2-Sided","-0.52","-0.18"
"3324","NCT01294462","Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)","Acute Coronary Syndrome",0,"Ticagrelor","Drug","AstraZeneca","Industry",0,0,"All","20 Years","N/A","801","February 2011","July 2012","Major Bleeding","0","0","0","1.54","Hazard Ratio (HR)","95","2-Sided","0.94","2.53"
"3325","NCT01294644","Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat","Moderate or Severe Submental Fullness",0,"Deoxycholic acid injection","Drug","Kythera Biopharmaceuticals","Industry",0,0,"All","18 Years","65 Years","360","January 2011","February 2012","Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response","<0.001","0","Regression, Logistic","2.60","Odds Ratio (OR)","95","2-Sided","1.52","4.43"
"3326","NCT01294683","A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)","Primary Hypercholesterolemia",0,"Simvastatin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","85 Years","977","February 2011","January 2012","Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)","0","0","0","0","0","0","0","0","0"
"3327","NCT01295060","Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly","Acromegaly",0,"Octreotide","Drug","Endo Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","12","February 2011","April 2012","Long term safety and tolerability of the Octreotide Implant","0","0","0","0","0","0","0","0","0"
"3328","NCT01295372","Safety and Efficacy of Zicronapine in Patients With Schizophrenia","Schizophrenia",0,"Zicronapine","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","160","April 2011","October 2012","To assess the effect of zicronapine versus risperidone on body weight (and BMI)","0","0","0","0","0","0","0","0","0"
"3329","NCT01295450","Study to Evaluate the Efficacy and Tolerability of Apevinat BC Compared to Vitamin Complex","Lack of Appetite",0,"Apevinat BC","Drug","MDCPharma Produtos Farmaceuticos LTDA","Industry",0,0,"All","7 Years","14 Years","74","April 2011","August 2011","Evaluate the effectiveness of Apevinat BC in appetite stimulation.","0","0","0","0","0","0","0","0","0"
"3330","NCT01295580","Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis","Knee Osteoarthritis",0,"Hyaluronic acid, stabilized","Device","Bioventus LLC","Industry",0,0,"All","40 Years","80 Years","350","January 2011","August 2011","WOMAC(Western Ontario and McMaster Osteoarthritis Index) Pain","0","0","0","0","0","0","0","0","0"
"3331","NCT01296360","Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country","Japanese Encephalitis",0,"IXIARO","Biological","Valneva Austria GmbH","Industry",0,0,"All","9 Months","18 Years","300","December 2010","November 2011","SCRs (Seroconversion Rate) as Defined by Percentage of Subjects With Plaque Reduction Neutralization Test Titers of>1:10 at 1 Month After the Booster Dose","0","0","0","0","0","0","0","0","0"
"3332","NCT01296412","Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","Diabetes Mellitus, Type 2",0,"sitagliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","653","March 11, 2011","February 29, 2012","Change From Baseline in Hemoglobin A1c (A1C)","0","0","0","0.09","Difference in least squares mean","95","2-Sided","-0.05","0.23"
"3333","NCT01296698","Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking","Tobacco Dependence",0,"Placebo","Drug","McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.","Industry",0,0,"All","18 Years","N/A","257","March 2011","April 2011","Number of Participants With Continuous Smoking Abstinence","0","0","0","0","0","0","0","0","0"
"3334","NCT01297517","Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%","Open-Angle Glaucoma",0,"Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","1001","February 2011","March 2012","Mean IOP at Month 3 for Each Assessment Timepoint (8 AM, + 2 h, + 7 h, and + 9 h)","0","0","0","0","0","0","0","0","0"
"3335","NCT01297920","Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%","Open-Angle Glaucoma",0,"Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","1062","March 2011","June 2012","Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3","0","0","0","0","0","0","0","0","0"
"3336","NCT01298219","Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)","Opioid-induced Bowel Dysfunction",0,"Lubiprostone","Drug","Sucampo Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","447","December 2010","November 2011","Overall SBM response rate","0","0","0","0","0","0","0","0","0"
"3337","NCT01298752","Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery","Inflammation",0,"Mapracorat","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","142","February 2011","September 2011","Inflammation","0","0","0","0","0","0","0","0","0"
"3338","NCT01298765","Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain","Pain",0,"BEMA Buprenorphine","Drug","BioDelivery Sciences International","Industry",0,0,"All","18 Years","N/A","434","March 2011","August 2012","Mean change in pain intensity","0","0","0","0","0","0","0","0","0"
"3339","NCT01299376","MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)","Hypertension",0,"L50/H12.5/A5","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","80 Years","286","January 2011","November 2011","Change in Trough Sitting Diastolic Blood Pressure (SiDBP)-Double-Blind Treatment Period","<0.001","0","Contrained Longitudinal Data Analysis","-5.9","Difference in Least-squares Means","95","2-Sided","-7.5","-4.2"
"3340","NCT01299389","An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia","Schizophrenia",0,"Paliperidone palmitate","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","323","October 2010","May 2012","Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation","<0.0001","0","ANCOVA","-9.7","Least squares (LS) means difference","95","2-Sided","-14.0","-5.4"
"3341","NCT01300234","Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)","Hepatitis B",0,"Tenofovir disoproxil fumarate (TDF) tablets","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","69 Years","512","March 2011","October 2012","Participants With Hepatitis B Virus (HBV) DNA <400 Copies/Milliliter (mL) at Week 48","<0.0001","HBeAg-positive participants","Roche COBAS Taqman HBV test","58.5","percentage of participants","97.5","2-Sided","45.8","71.3"
"3342","NCT01301469","Comparison of HES 130 in Balanced and in Unbalanced Solution","Decreased and Nonspecific Blood Pressure Disorders and Shock",0,"6% HES 130/0.42 in plasma adapted Ringer's solution","Drug","B. Braun Melsungen AG","Industry",0,0,"All","18 Years","70 Years","240","February 2011","July 2011","Maximum difference of the mean arterial blood pressure","0","0","0","0","0","0","0","0","0"
"3343","NCT01301833","Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"teneligliptin","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","N/A","462","February 2011","September 2012","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"3344","NCT01302119","Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","Onychomycosis of Toenails",0,"AN2690 Topical Solution, 5%","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","604","February 2011","December 2012","Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"3345","NCT01302691","MK-0954E Study in Participants With Hypertension (MK-0954E-357)","Hypertension",0,"losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","80 Years","327","January 2011","April 2012","Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)","0.205","0","Constrained Longitudinal Data Analysis","-1.1","Difference in Least Squares Means","95","2-Sided","-2.7","0.6"
"3346","NCT01303406","Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)","Friedreich's Ataxia",0,"Idebenone","Drug","Santhera Pharmaceuticals","Industry",0,0,"All","10 Years","N/A","29","April 2011","July 2012","Patient Assessment of Treatment Assignment: Comparison of the Proportions of Patients Randomised to Idebenone and Placebo Who Assessed That They Received Idebenone","0","0","0","0","0","0","0","0","0"
"3347","NCT01304134","Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment","Other Acute Postoperative Pain",0,"Oxycodone","Drug","Mundipharma (China) Pharmaceutical Co. Ltd","Industry",0,0,"All","18 Years","65 Years","240","March 2010","August 2010","Measuring VAS","0","0","0","0","0","0","0","0","0"
"3348","NCT01304394","Safety During Use of Paediatric Triple Chamber Bag Formulas","Infant Nutrition Disorders",0,"Ped3CB","Drug","Baxter Healthcare Corporation","Industry",0,0,"All","N/A","18 Years","161","February 2008","December 2008","Practical handling,ease of use and safety information (number of participants with adverse events)","0","0","0","0","0","0","0","0","0"
"3349","NCT01304498","Immunogenicity and Tolerability of V503 Versus GARDASIL","Human Papillomavirus",0,"1 dose at Day 1, 1 dose at Month 2 and 1 dose at Month 6","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","9 Years","15 Years","600","February 2011","December 2011","HPV 16 GMTs","0","0","0","0","0","0","0","0","0"
"3350","NCT01304810","A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation","Smoking Cessation",0,"NicVAX vaccine","Biological","Nabi Biopharmaceuticals","Industry",0,0,"All","18 Years","65 Years","300","January 2011","August 2011","Antibody Levels","0","0","0","0","0","0","0","0","0"
"3351","NCT01305083","Efficacy and Safety Study of Udenafil Tablets in Erectile Dysfunction.","Erectile Dysfunction",0,"Udenafil","Drug","Abdi Ibrahim Ilac San. ve Tic A.S.","Industry",0,0,"Male","18 Years","60 Years","118","October 2010","August 2011","IIEF","0","0","0","0","0","0","0","0","0"
"3352","NCT01305226","A Trial Using Double-Bolus THR-100 Versus Streptokinase","Acute Myocardial Infarction",0,"THR-100","Drug","Bharat Biotech International Limited","Industry",0,0,"All","30 Years","75 Years","120","October 2010","August 2011","To demonstrate efficacy of THR100 as compared with streptokinase by assessment of 12-lead Electrocardiogram, specific cardiac Enzymes levels, pain relief and TIMI-90. (Non-Inferiority study)","0","0","0","0","0","0","0","0","0"
"3353","NCT01305577","Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat","Moderate or Severe Submental Fullness",0,"Deoxycholic acid injection","Drug","Kythera Biopharmaceuticals","Industry",0,0,"All","18 Years","65 Years","363","December 2010","January 2012","Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response","<0.001","0","Regression, Logistic","4.73","Odds Ratio (OR)","95","2-Sided","2.70","8.28"
"3354","NCT01306461","Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations","Ocular Hypertension",0,"Timolol and Tafluprost","Drug","Santen Oy","Industry",0,0,"All","18 Years","N/A","401","March 2011","April 2012","Change from baseline in the average diurnal intra-ocular pressure (IOP) at 6 months","0","0","0","0","0","0","0","0","0"
"3355","NCT01306721","Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis","Rhinitis Seasonal",0,"fexofenadine HCL (M016455)","Drug","Sanofi","Industry",0,0,"All","12 Years","N/A","520","February 2011","April 2011","Changes in the nasal congestion score based on the patient's symptom diary","0","0","0","0","0","0","0","0","0"
"3356","NCT01307033","A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","Hypertension",0,"MK-0954A","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","80 Years","278","March 29, 2011","December 4, 2012","Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)","0","0","0","0.2","Difference in least squares means","95","2-Sided","-1.7","2.2"
"3357","NCT01307046","MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","Hypertension",0,"MK-0954A","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","80 Years","336","March 29, 2011","February 7, 2012","Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP)","<.001","0","constrained longitudinal data analysis","-5.1","Difference in least square means","95","2-Sided","-6.8","-3.4"
"3358","NCT01307319","Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies","Seasonal Allergic Rhinitis",0,"BDP HFA","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","6 Years","11 Years","715","March 2011","July 2011","Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment","<0.001","a priori statistical significance is <0.05.","mixed-model for repeated measures (MMRM)","-0.63","LSM treatment difference from placebo","95","2-Sided","-1.0","-0.3"
"3359","NCT01307800","A Study of LY2140023 in Patients With Schizophrenia","Schizophrenia",0,"LY2140023","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","65 Years","1100","March 2011","September 2012","Change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score","0","0","0","0","0","0","0","0","0"
"3360","NCT01308060","A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)","Canthal Lines",0,"Botulinum Toxin Type A","Drug","Galderma R&D","Industry",0,0,"All","18 Years","65 Years","335","January 2011","May 2012","Primary efficacy criteria","0","0","0","0","0","0","0","0","0"
"3361","NCT01308853","NASHA BE for Enhancement of the Shape and Fullness of the Female Breast","Breast Enhancement",0,"NASHA BE","Device","Q-Med AB","Industry",0,0,"Female","25 Years","50 Years","24","March 2007","February 2008","The primary objective is to develop an injection technique for placement of the implant posterior to the mammary gland. This will be documented through MRI 1-5 days after the injection and evaluated by the Expert Group 6 weeks after treatment.","0","0","0","0","0","0","0","0","0"
"3362","NCT01309243","Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","HIV-1 Infection",0,"FTC/RPV/TDF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","799","February 2011","September 2012","Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48","0","0","0","4.1","Difference in the response rates","95","2-Sided","-1.1","9.2"
"3363","NCT01309386","A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants","Neoplasms",0,"Tapentadol ER","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","100","August 2010","January 2012","Percentage of Participants Who Achieved Pain Control","0","0","0","0","0","0","0","0","0"
"3364","NCT01309828","Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","Safety",0,"Azilsartan medoxomil and chlorthalidone","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","153","March 2011","October 2012","Number of Participants With at Least 1 Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"3365","NCT01309841","Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation","Opioid-Induced Constipation (OIC)",0,"NKTR-118","Drug","AstraZeneca","Industry",0,0,"All","18 Years","84 Years","652","March 2011","August 2012","Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12","0.015","0","Cochran-Mantel-Haenszel","1.380","Risk Ratio (RR)","95","2-Sided","1.062","1.795"
"3366","NCT01310400","Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children","Influenza",0,"Inflexal V","Biological","Crucell Holland BV","Industry",0,0,"All","6 Months","35 Months","1356","October 2009","January 2010","Immunogenicity, Assessed by the Haemagglutination (HI) Test","0.0036","The significance level α = 0.05 (one-sided) was adjusted to α = 0.025 (one-sided) for the primary endpoint","Chi-squared","4.5","Difference in seroconversion rates","95","2-Sided","1.4","7.5"
"3367","NCT01312922","Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)","Major Depressive Disorder",0,"PNB01 fixed dose combination of pipamperone and citalopram","Drug","PharmaNeuroBoost N.V.","Industry",0,0,"All","18 Years","N/A","555","September 2011","November 2012","Early and Sustained (antidepressant) Response (ESR) rate","0","0","0","0","0","0","0","0","0"
"3368","NCT01313507","High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)","Primary Immunodeficiency Disease",0,"NewGam","Biological","Octapharma","Industry",0,0,"All","2 Years","75 Years","21","May 2011","September 2012","Percentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug","0","0","0","0","0","0","0","0","0"
"3369","NCT01313572","Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI","Coronary Artery Disease",0,"Apadenoson SPECT-MPI","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","197","August 2011","April 2012","Presence of myocardial perfusion defect based on SPECT-MPI","0","0","0","0","0","0","0","0","0"
"3370","NCT01313637","A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD","Pulmonary Disease, Chronic Obstructive",0,"GSK573719/GW642444 125/25mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","1493","March 1, 2011","March 1, 2012","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)","<0.001","0","Mixed Models Analysis","0.160","Least squares mean difference","95","2-Sided","0.122","0.198"
"3371","NCT01313650","A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD","Pulmonary Disease, Chronic Obstructive",0,"62.5/25mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","1538","March 2011","April 2012","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)","<0.001","0","Mixed Models Analysis","0.115","Least squares mean difference","95","2-Sided","0.076","0.155"
"3372","NCT01313767","MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity","Spasticity",0,"Botulinum toxin type A","Drug","Medy-Tox","Industry",0,0,"All","20 Years","N/A","196","March 2011","January 2012","MAS(Modified Ashworth Scale)of wrist flexor","0","0","0","0","0","0","0","0","0"
"3373","NCT01314170","Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma.","Glaucoma",0,"Susanna Implant","Device","Adapt Produtos Oftalmológicos Ltda.","Industry",0,0,"All","18 Years","N/A","76","May 2011","October 2011","Study clinical multicenter, phase III, open-label, prospective character to evaluate the efficacy and safety Susanna implant in patients with refractory glaucoma.","0","0","0","0","0","0","0","0","0"
"3374","NCT01315249","QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease (COPD)",0,"indacaterol and glycopyrronium (QVA149)","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","523","March 2011","March 2012","Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12","0","0","0","0","0","0","0","0","0"
"3375","NCT01316094","A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment","Type 2 Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","74 Years","165","February 2011","November 2012","changes in Hemoglobin A1c (HbA1c)","0","0","0","0","0","0","0","0","0"
"3376","NCT01316107","A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients","Type 2 Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","122","February 2011","December 2012","change from baseline in hemoglobin A1c (HbA1c)","0","0","0","0","0","0","0","0","0"
"3377","NCT01316887","A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"125/25 mcg once-daily GSK573719/GW642444","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","120 Years","563","January 2011","July 2012","Number of Participants With Any On-treatment Adverse Event (AE) or Any Serious Adverse Event (SAE)","0","0","0","0","0","0","0","0","0"
"3378","NCT01316900","24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive",0,"GSK573719/GW642444 125/25","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","846","March 2011","April 2012","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)","<0.001","0","Mixed Models Analysis","0.090","Least squares mean difference","95","2-Sided","0.039","0.142"
"3379","NCT01316913","24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive",0,"GSK573719/GW642444 125/25","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","872","March 2011","April 2012","Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169","0.377","0","Mixed Models Analysis","0.022","Least squares mean difference","95","2-Sided","-0.027","0.072"
"3380","NCT01318070","Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan","Type 2 Diabetes Mellitus",0,"Alogliptin and pioglitazone","Drug","Takeda","Industry",0,0,"All","33 Years","88 Years","339","November 2007","October 2008","Change From Baseline in Glycosylated Hemoglobin (Week 12).","0","0","0","-0.179","Mean Difference (Final Values)","95","2-Sided","-0.224","-0.135"
"3381","NCT01318083","Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan","Type 2 Diabetes Mellitus",0,"Alogliptin and glimepiride","Drug","Takeda","Industry",0,0,"All","20 Years","64 Years","312","August 2008","April 2009","Change From Baseline in Glycosylated Hemoglobin (Week 12).","0","0","0","-0.936","Mean Difference (Final Values)","95","2-Sided","-1.097","-0.775"
"3382","NCT01318109","Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan","Type 2 Diabetes Mellitus",0,"Alogliptin and metformin","Drug","Takeda","Industry",0,0,"All","26 Years","64 Years","288","August 2008","April 2009","Change From Baseline in Glycosylated Hemoglobin (Week 12).","0","0","0","-0.751","Mean Difference (Final Values)","95","2-Sided","-0.923","-0.579"
"3383","NCT01318122","Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan","Type 2 Diabetes Mellitus",0,"Alogliptin and pioglitazone","Drug","Takeda","Industry",0,0,"All","33 Years","88 Years","336","May 2008","August 2009","Number of Participants With Adverse Events.","0","0","0","0","0","0","0","0","0"
"3384","NCT01318135","Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan","Type 2 Diabetes Mellitus",0,"Alogliptin and glimepiride","Drug","Takeda","Industry",0,0,"All","20 Years","64 Years","576","January 2009","January 2010","Number of Participants With Adverse Events.","0","0","0","0","0","0","0","0","0"
"3385","NCT01318733","Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","Rosacea",0,"CD07805/47 gel 0.5%","Drug","Galderma","Industry",0,0,"All","18 Years","N/A","449","March 2011","June 2012","Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea.","0","0","0","0","0","0","0","0","0"
"3386","NCT01320566","A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema","Pulmonary Emphysema",0,"AeriSeal System","Device","Aeris Therapeutics","Industry",0,0,"All","40 Years","N/A","18","March 2011","January 2012","Change from baseline in Percent Volume of Lung","0","0","0","0","0","0","0","0","0"
"3387","NCT01321359","A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis","Recurrent Herpes Simplex Labialis",0,"Vehicle versus NB-001","Drug","NanoBio Corporation","Industry",0,0,"All","18 Years","N/A","907","April 2011","January 2012","Time of Healing of the primary lesion complex","0","0","0","0","0","0","0","0","0"
"3388","NCT01321489","A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies","Erectile Dysfunction",0,"Sildenafil Citrate 20mg Tablet Sublingual","Drug","Laboratório Teuto Brasileiro S/A","Industry",0,0,"Male","18 Years","N/A","78","September 2011","January 2012","Evaluate a possible superiority expressed by the faster onset of action.","0","0","0","0","0","0","0","0","0"
"3389","NCT01321619","Efficacy and Tolerability of the Use of Varicell Compared With Daflon","Chronic Venous Insufficiency",0,"Daflon","Drug","Vidfarma Indústria de Medicamentos Ltda.","Industry",0,0,"All","18 Years","65 Years","102","July 2011","December 2011","Study to evaluate the efficacy and tolerability of the Use of Varicell Compared with Daflon.","0","0","0","0","0","0","0","0","0"
"3390","NCT01322919","Safety and Efficacy Study to Evaluate the Treatment of Both Near and Distance Vision in a Simultaneous Laser Procedure","Myopia",0,"Supracor","Procedure","Technolas Perfect Vision GmbH","Industry",0,0,"All","45 Years","85 Years","61","April 2010","February 2012","The percentage of treated patients with an uncorrected monocular high contrast Near VA of 20/40 or better","0","0","0","0","0","0","0","0","0"
"3391","NCT01323192","An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder","Attention-Deficit Hyperactivity Disorder",0,"JNS001","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","18 Years","64 Years","284","March 2011","April 2012","Change From Baseline to Endpoint in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Total Attention Deficit-Hyperactivity Disorder (ADHD) Symptoms Scores of Conners' Adult ADHD Rating Scale - Observer Screening Version (CAARS-O: SV)","<0.0001","0","ANCOVA","-4.5","Difference in least square means","95","2-Sided","-6.7","-2.4"
"3392","NCT01323478","Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","Major Depressive Disorder",0,"Vortioxetine (Lu AA21004)","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","75 Years","71","April 2011","September 2012","Number of Patients With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"3393","NCT01323621","Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","512","March 2011","January 2012","Change From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 84","0.267","0","ANCOVA","0.029","Least squares mean difference","95","0","-0.022","0.080"
"3394","NCT01323634","Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive",0,"Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","519","March 18, 2011","December 14, 2011","Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84","<0.001","0","ANCOVA","0.080","Least square mean difference","95","2-Sided","0.037","0.124"
"3395","NCT01323660","An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B","Pulmonary Disease, Chronic Obstructive",0,"GSK573719/GW642444 125/25","Drug","GlaxoSmithKline","Industry",0,0,"Male","40 Years","N/A","307","March 2011","July 2012","Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period","0.456","Nominal p-value","Mixed Models Analysis","25.0","Least squares mean difference","95","2-Sided","-41.0","91.0"
"3396","NCT01323790","Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation","Opioid-Induced Constipation (OIC)",0,"NKTR-118","Drug","AstraZeneca","Industry",0,0,"All","18 Years","84 Years","700","March 2011","September 2012","Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12","0.202","0","Cochran-Mantel-Haenszel","1.188","Risk Ratio (RR)","95","2-Sided","0.911","1.548"
"3397","NCT01324128","A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients","Chronic Kidney Disease Requiring Chronic Dialysis",0,"PA21 (2.5 g tablet containing 500 mg iron)","Drug","Vifor Inc.","Industry",0,0,"All","18 Years","N/A","1059","March 2011","April 2012","Change in Serum Phosphorus Levels From Week 24 to Week 27","0","0","0","0","0","0","0","0","0"
"3398","NCT01324466","A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)","Recurrent Herpes Labialis",0,"NB-001","Drug","NanoBio Corporation","Industry",0,0,"All","18 Years","N/A","847","April 2011","January 2012","Time of Healing of the primary lesion complex","0","0","0","0","0","0","0","0","0"
"3399","NCT01324921","Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics","Diabetes Mellitus, Type 2",0,"No breakfast/beverage only","Other","Abbott Nutrition","Industry",0,0,"All","18 Years","75 Years","37","August 2010","September 2010","Positive AUC for plasma glucose concentration","0","0","0","0","0","0","0","0","0"
"3400","NCT01324934","Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids","Renal Transplant Rejection",0,"ATG-Fresenius S","Drug","Neovii Biotech","Industry",0,0,"All","18 Years","75 Years","40","October 2006","January 2011","The primary endpoint is the incidence of biopsy-proven acute allograft rejection after 12 months, including all types of rejections like: • acute rejection • chronic rejection • subclinical rejection","0","0","0","0","0","0","0","0","0"
"3401","NCT01326026","Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","222","March 2011","December 2011","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"3402","NCT01326078","Use of Lipid Emulsion or Nanoemulsion of Propofol on Children Undergoing Ambulatory Invasive Procedures.","Leukemia",0,"propofol","Drug","Cristália Produtos Químicos Farmacêuticos Ltda.","Industry",0,0,"All","6 Years","12 Years","0","June 2011","July 2011","Classification of the sedation level","0","0","0","0","0","0","0","0","0"
"3403","NCT01326299","Post Prandial Glucose Control Proof-of-Principle","Diabetes Mellitus, Type 2",0,"Carbohydrate placebo","Other","Abbott Nutrition","Industry",0,0,"All","21 Years","75 Years","50","August 2010","September 2010","Positive AUC from 0 to 240 minutes for plasma glucose.","0","0","0","0","0","0","0","0","0"
"3404","NCT01327729","Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C","Self Efficacy",0,"pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg","Drug","BioGeneric Pharma","Industry",0,0,"All","18 Years","65 Years","300","November 2010","April 2011","viral clearance at 72 weeks","0","0","0","0","0","0","0","0","0"
"3405","NCT01328041","A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.","Infection, Human Immunodeficiency Virus",0,"dolutegravir","Drug","ViiV Healthcare","Industry",0,0,"All","18 Years","N/A","183","May 2011","May 2012","Mean Change From Baseline in Plasma HIV-1 RNA at Day 8","<0.001","The P value was derived by the null hypothesis testing of no change from Baseline in HIV-1 RNA at Day 8 at the two-sided 5% significance level using a single sample t-test.","t-test, 2 sided","-1.432","T distribution","95","2-Sided","-1.520","-1.343"
"3406","NCT01328093","A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients","Schizophrenia",0,"LY2140023","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","65 Years","670","April 2011","October 2012","Change from baseline to 24 weeks in body weight","0","0","0","0","0","0","0","0","0"
"3407","NCT01328379","Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis","Multiple Sclerosis",0,"Dalfampridine-ER 5mg","Drug","Acorda Therapeutics","Industry",0,0,"All","18 Years","70 Years","430","March 2011","April 2012","Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).","0.457","To demonstrate study sensitivity with respect to efficacy and maintain an overall alpha level ≤ 0.05, a stepwise procedure was performed.","ANOVA","0.054","least squares mean","95","2-Sided","-0.088","0.196"
"3408","NCT01328444","An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A","Pulmonary Disease, Chronic Obstructive",0,"GSK 573719 +GW642444 125/25","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","349","March 2011","June 2012","Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period","0.321","Nominal p-value","Mixed Models Analysis","26.5","Least squares mean difference","95","2-Sided","-25.9","78.9"
"3409","NCT01328938","GCPGC in Chemotherapy-induced Neutropenia","Chemotherapy Induced Neutropenia",0,"GCPGC 3.6mg","Biological","Green Cross Corporation","Industry",0,0,"All","18 Years","N/A","177","October 2010","November 2012","Duration of grade 4 neutropenia(ANC<500mm3) for cycle 1","0","0","0","0","0","0","0","0","0"
"3410","NCT01332188","Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model","Allergic Conjunctivitis",0,"AC-170 0.05%","Drug","Aciex Therapeutics, Inc.","Industry",0,0,"All","10 Years","N/A","100","April 2011","June 2011","Ocular Itching at defined timepoints up to 3 weeks","0","0","0","0","0","0","0","0","0"
"3411","NCT01332253","Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy","Tonsillectomy",0,"Intravenous ibuprofen","Drug","Cumberland Pharmaceuticals","Industry",0,0,"All","6 Years","17 Years","161","July 2011","July 2012","Number of Doses of Fentanyl Administered in the Postoperative Period Prior to Discharge.","0","0","0","0","0","0","0","0","0"
"3412","NCT01332643","Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy","Infertility",0,"Preimplantation Genetic Diagnosis","Genetic","Reprogenetics","Industry",0,0,"Female","30 Years","42 Years","120","April 2011","August 2012","Implantation rate","0","0","0","0","0","0","0","0","0"
"3413","NCT01333592","Long-term Study of KAD-1229 in Type 2 Diabetes Patients","Type 2 Diabetes",0,"KAD-1229","Drug","Kissei Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","N/A","136",NA,"August 2012","Incidences of Adverse Events","0","0","0","0","0","0","0","0","0"
"3414","NCT01333761","Cardiox Shunt Detection Technology Study","Patent Foramen Ovale",0,"Cardiox FDS","Device","Cardiox Corporation","Industry",0,0,"All","18 Years","N/A","71","April 2011","July 2012","To evaluate the Cardiox FDS system using TCD as a non-reference standard for positive percent agreement for accurately detecting a RTLS and negative percent agreement for accurately detecting the absence of RTLS","0","0","0","0","0","0","0","0","0"
"3415","NCT01335997","Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","Primary Hypercholesterolemia",0,"ER niacin/laropiprant (ERN/LRPT)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","85 Years","1139","May 2011","January 2012","Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Blood Levels","0","0","0","0","0","0","0","0","0"
"3416","NCT01336023","Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec/liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","1663","May 23, 2011","May 24, 2012","Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.","<0.0001","0","ANCOVA","-0.47","Treatment Contrast","95","2-Sided","-0.58","-0.36"
"3417","NCT01336205","Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation","Opioid-Induced Constipation (OIC)",0,"NKTR-118","Drug","AstraZeneca","Industry",0,0,"All","18 Years","84 Years","844","April 2011","December 2012","Incidence of Patients Experiencing at Least One Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"3418","NCT01339091","Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","Abscess",0,"Dalbavancin","Drug","Durata Therapeutics Inc., an affiliate of Allergan plc","Industry",0,0,"All","18 Years","85 Years","573","March 2011","September 2012","Early Clinical Efficacy","0","0","0","1.5","Difference in Proportions","95","2-Sided","-4.6","7.9"
"3419","NCT01339260","An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting","Chemotherapy-Induced Nausea and Vomiting",0,"Netupitant and Palonosetron","Drug","Helsinn Healthcare SA","Industry",0,0,"All","18 Years","N/A","1455","April 2011","November 2012","Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1","0.001","If superiority of netupitant/palonosetron was established for the CR delayed, CR acute and then CR overall at cycle 1 were to be tested according to a hierarchical procedure;no adjustment for multiplicity was needed.The a priori threshold was 0.050","Cochran-Mantel-Haenszel","1.48","Odds Ratio (OR)","95","2-Sided","1.16","1.87"
"3420","NCT01339312","Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine","Rabies",0,"Purified inactivated rabies vaccine, serum free","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","10 Years","N/A","816","April 2011","March 2012","Information on the rabies virus neutralizing antibody (RVNA) titer post vaccination","0","0","0","0","0","0","0","0","0"
"3421","NCT01340768","Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","Type 2 Diabetes Mellitus",0,"Sitagliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","870","June 22, 2010","September 21, 2011","Percentage of Participants With at Least One Symptomatic Hypoglycemic Event","0.028","P-value for association between treatment groups and proportions controlling for prior therapy (monotherapy or combination therapy).","Cochran-Mantel-Haenszel","0.52","Risk Ratio (RR)","95","2-Sided","0.29","0.94"
"3422","NCT01340937","A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","Bacterial Infections",0,"V419","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","46 Days","89 Days","2808","May 2011","December 2012","Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen","0","0","0","0.91","GMC Ratio (Lot A/Lot B)","95","2-Sided","0.77","1.08"
"3423","NCT01341782","Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism","Secondary Hyperparathyroidism",0,"paricalcitol","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","20 Years","N/A","255","May 2011","April 2012","Percentage of Participants With Target Intact Parathyroid Hormone (iPTH) and Without Hypercalcemia","0","0","0","0","0","0","0","0","0"
"3424","NCT01341912","Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)","Severe Hemophilia A",0,"Human-cl rhFVIII","Biological","Octapharma","Industry",0,0,"Male","12 Years","65 Years","3","June 2011","August 2012","Long-term Immunogenicity","0","0","0","0","0","0","0","0","0"
"3425","NCT01342315","Topical Antifungal Treatment for Tinea Cruris","Tinea Cruris",0,"33525","Drug","Medicis Global Service Corporation","Industry",0,0,"All","12 Years","N/A","483","May 2011","March 2012","Proportion of patients achieving complete clearance","0","0","0","0","0","0","0","0","0"
"3426","NCT01342913","A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))","Pulmonary Disease, Chronic Obstructive",0,"Fluticasone Furoate 100mcg/Vilanterol 25mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","528","February 2011","October 2011","Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84","0.282","0","ANCOVA","0.022","Least squares mean difference","95","2-Sided","-0.018","0.063"
"3427","NCT01344460","Gadobutrol Enhanced MRA of the Renal Arteries","Renal Artery Obstruction",0,"Gadobutrol (Gadovist, BAY86-4875)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","317","May 2011","July 2012","Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA","<0.000","0","McNemar","18.3","Percentage difference","95","2-Sided","15.2","Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."
"3428","NCT01345916","Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients","Asthma",0,"CHF 1535 100/6 NEXT DPI® 2 months","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","18 Years","N/A","932","March 2011","August 2011","Change from baseline to the entire treatment period in average pre-dose morning Peak Expiratory Flow.","0","0","0","0","0","0","0","0","0"
"3429","NCT01346215","Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure","Chronic Renal Failure",0,"heparin sodium","Biological","Laboratório Químico Farmacêutico Bergamo Ltda.","Industry",0,0,"All","18 Years","N/A","132","October 2011","December 2011","Effectiveness in prevention of clotting in the extracorporeal circuit during hemodialysis","0","0","0","0","0","0","0","0","0"
"3430","NCT01349010","Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia","Hyperlipidemia",0,"Probucol","Drug","Otsuka Beijing Research Institute","Industry",0,0,"All","20 Years","N/A","264","April 2011","July 2012","TC and LDL-C","0","0","0","0","0","0","0","0","0"
"3431","NCT01349283","Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns","Hepatitis B",0,"HepavaxGene (thiomersal free)","Biological","Crucell Holland BV","Industry",0,0,"All","N/A","1 Day","1738","May 2011","November 2012","Seroconversion rate for subjects in Stratum 2","0","0","0","0","0","0","0","0","0"
"3432","NCT01349348","Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites","Ascites",0,"Tolvaptan","Drug","Otsuka Beijing Research Institute","Industry",0,0,"All","18 Years","75 Years","535","October 2010","May 2012","Change from baseline in body weight after 7 days randomized treatment (Day 8).","0","0","0","0","0","0","0","0","0"
"3433","NCT01349998","Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis","Tinea Pedis",0,"Product 33525","Drug","Tinea Pharmaceuticals","Industry",0,0,"All","12 Years","N/A","604","May 2011","September 2012","Number of Subjects with Adverse Events","0","0","0","0","0","0","0","0","0"
"3434","NCT01350973","Efficacy of TAK-085 in Participants With Hypertriglyceridemia","Hypertriglyceridemia",0,"Omega-3-acid ethyl esters 90 (TAK-085)","Drug","Takeda","Industry",0,0,"All","20 Years","74 Years","611","November 2009","December 2010","Percent Change From Baseline in Triglyceride Level at the Final Visit","0.8760","An ANCOVA model was employed, using the baseline triglyceride level as covariate and the treatment group as an independent variable.","ANCOVA","0.37","LS Mean Difference","95","2-Sided","-4.2491","4.9830"
"3435","NCT01350999","Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia","Hypertriglyceridemia",0,"omega-3-acid ethyl esters 90 (TAK-085)","Drug","Takeda","Industry",0,0,"All","20 Years","74 Years","503","November 2009","January 2011","Number of Participants With Treatment Emergent Adverse Events (TEAEs)","0","0","0","0","0","0","0","0","0"
"3436","NCT01351675","Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes","Renal Insufficiency, Chronic",0,"Placebo","Drug","Reata Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","2185","June 2011","October 2012","Time-to-first event of the composite endpoint","0","0","0","0","0","0","0","0","0"
"3437","NCT01351792","A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)","Chronic Obstructive Pulmonary Disease",0,"Foster® 100/6 µg/unit dose","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","40 Years","N/A","113","September 2011","November 2012","Change from baseline to end of treatment in post-dose residual volume.","0","0","0","0","0","0","0","0","0"
"3438","NCT01352039","A Non-inferiority Study Comparing Two Heparin Sodium Preparations in Hip Fracture Surgery","Hip Fracture Surgery",0,"Heparin Sodium - Eurofarma","Biological","Eurofarma Laboratorios S.A.","Industry",0,0,"All","60 Years","85 Years","544","October 2011","October 2011","The Primary endpoint will be frequency of deep venous thrombosis (DVT) determined by Doppler ultrasound (DUS).","0","0","0","0","0","0","0","0","0"
"3439","NCT01353079","Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy","Allergy",0,"Short Ragweed Pollen Allergenic Extract","Biological","Greer Laboratories","Industry",0,0,"All","18 Years","55 Years","429","April 2011","November 2011","Scores on a Scale [Net Average Combined Daily Rhinoconjunctivitis Symptom (RSS) and Medication Scores]","<0.05","0","ANCOVA","-0.834","Mean Difference (Net)","95","2-Sided","-1.298","-0.369"
"3440","NCT01353469","Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy","Type 2 Diabetes Mellitus",0,"Insulin human/Insuman Comb 25 (HR1799)","Drug","Sanofi","Industry",0,0,"All","18 Years","75 Years","485","May 2011","November 2012","Change in HbA1c from baseline to the end of treatment","0","0","0","0","0","0","0","0","0"
"3441","NCT01353495","Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers","Diabetic Foot Ulcers",0,"APM Graft (BIOTAPE XMTM)","Device","Wright Medical Technology","Industry",0,0,"All","18 Years","N/A","40","April 2010","October 2010","Mann Whitney U Test","0","0","0","0","0","0","0","0","0"
"3442","NCT01353755","2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma","Rhinoconjunctivitis",0,"Grass pollen specific immunotherapy","Drug","Allergopharma GmbH & Co. KG","Industry",0,0,"All","12 Years","65 Years","195","October 2009","August 2012","Rhinoconjunctivitis Symptom-Medication-Score","0","0","0","0","0","0","0","0","0"
"3443","NCT01353976","Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis","Tinea Pedis",0,"Econazole Nitrate Foam 1%","Drug","AmDerma","Industry",0,0,"All","12 Years","N/A","264","May 2011","April 2012","Complete Cure","0","0","0","0","0","0","0","0","0"
"3444","NCT01354717","Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo","Actinic Keratoses",0,"Brand Carac","Drug","Spear Pharmaceuticals","Industry",0,0,"All","45 Years","85 Years","377","September 2010","March 2011","Percent of patients with clearing","0","0","0","0","0","0","0","0","0"
"3445","NCT01355081","Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder","Major Depressive Disorder",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","20 Years","75 Years","366","May 2011","December 2012","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment","0.1031","0","ANCOVA","-2.03","Least square means difference","95","2-Sided","-4.467","0.413"
"3446","NCT01355367","High Dose BAYA1040 CR: a Long Term Extension Study","Hypertension",0,"Nifedipine (Adalat, BAYA1040)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","120","January 2011","September 2011","Safety variables will be summarized using descriptive statistics based on adverse events collection","0","0","0","0","0","0","0","0","0"
"3447","NCT01355458","Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","Rosacea",0,"CD07805/47 gel","Drug","Galderma","Industry",0,0,"All","18 Years","N/A","260","May 2011","September 2011","Composite Success","<0.001","0","GEE: Logit link function","0","0","0","0","0","0"
"3448","NCT01355471","Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","Rosacea",0,"CD07805/47 Gel","Drug","Galderma","Industry",0,0,"All","18 Years","N/A","293","May 2011","November 2011","Composite Success","<0.001","0","GEE: Logit link function","0","0","0","0","0","0"
"3449","NCT01355874","Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids","Internal Hemorrhoids",0,"Iferanserin","Drug","Ventrus Biosciences, Inc","Industry",0,0,"All","18 Years","75 Years","403","July 2011","June 2012","Proportion of subjects with cessation of bleeding by the end of Day 7 that persists for the remainder of the treatment period (through Day 14) will be analyzed as the primary endpoint","0","0","0","0","0","0","0","0","0"
"3450","NCT01356407","Investigation of PICOPREP and PEG-ELS for Bowel Preparation for Colonoscopy","Colonoscopy",0,"PICOPREP","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","300","January 2011","May 2011","The Ottawa Scale Score of Patients Who Had Successfully Completed the Colonoscopy Examination After Having Completed the Study Bowel Preparation","0","0","0","0","0","0","0","0","0"
"3451","NCT01356498","Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout","Gout",0,"pegloticase","Biological","Savient Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","151","December 2006","January 2010","Uric Acid (mg/dL)","0","0","0","0","0","0","0","0","0"
"3452","NCT01357356","Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia","Nocturia",0,"SER120 (750 ng/day)","Drug","Serenity Pharmaceuticals, Inc.","Industry",0,0,"All","50 Years","N/A","816","May 2011","October 2012","# of nocturic episodes during treatment compare to baseline","0","0","0","0","0","0","0","0","0"
"3453","NCT01357642","Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients","Asthma",0,"Epinephrine inhalation aerosol","Drug","Amphastar Pharmaceuticals, Inc.","Industry",0,0,"All","12 Years","75 Years","373","July 2011","November 2011","Change in Area Under the Curve (AUC) versus placebo","0","0","0","0","0","0","0","0","0"
"3454","NCT01358240","Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis","Tinea Pedis",0,"Econazole Nitrate Foam 1%","Drug","AmDerma","Industry",0,0,"All","12 Years","N/A","336","June 2011","April 2012","Complete Cure","0","0","0","0","0","0","0","0","0"
"3455","NCT01358526","Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain","Low Back Pain",0,"Oxycodone/Naloxone Controlled-release","Drug","Purdue Pharma LP","Industry",0,0,"All","18 Years","N/A","1095","May 2011","October 2012","The ""Average Pain Over the Last 24 Hours"" at Week 12 of the Double-blind Period","0.0055","A gate-keeping strategy and a Bonferroni-Holm method was used to control the family-wise (primary and secondary efficacy analysis) error rate at the 5% level.","Mixed Models Analysis","0.45","Mean Difference (Final Values)","95","2-Sided","0.13","0.77"
"3456","NCT01358708","Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg","Diarrhea-predominant Irritable Bowel Syndrome",0,"LACTEOL® 340 mg","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","100 Years","26","June 2010","September 2011","Global Assessment of Relief During the Double-Blind Treatment Phase Using the Subject Global Assessment (SGA)","0","0","0","0","0","0","0","0","0"
"3457","NCT01358760","Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy","Vaginal Atrophy",0,"Placebo","Drug","EndoCeutics Inc.","Industry",0,0,"Female","40 Years","75 Years","450","June 2011","April 2012","Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear","0","0","0","0","0","0","0","0","0"
"3458","NCT01359449","Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations","Meningitis",0,"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","12 Months","18 Months","123","May 2011","July 2012","Geometric Mean Titers of Serum Bovine Albumin Baby Rabbit Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.","0","0","0","0","0","0","0","0","0"
"3459","NCT01361308","Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)","Postmenopausal Symptoms",0,"Brisdelle (paroxetine mesylate)","Drug","Noven Therapeutics","Industry",0,0,"Female","40 Years","N/A","614","May 2011","December 2011","Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12.","<0.0001","Week 4 frequency","Rank transformed ANCOVA","0","0","0","0","0","0"
"3460","NCT01362491","Ibuprofen Sodium Tension Headache Study","Pain",0,"Ibuprofen Sodium","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","226","June 2011","March 2012","Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet","<0.001","p-value was calculated using ANOVA model with treatment, baseline Pain Severity Rating (PSR) and gender terms.","ANOVA","6.11","Least-Square (LS) mean difference","95","2-Sided","4.49","7.73"
"3461","NCT01362517","Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B","Diphtheria",0,"Quinvaxem","Biological","Crucell Holland BV","Industry",0,0,"All","60 Days","120 Days","131","April 2010","July 2010","Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component","0","0","0","0","0","0","0","0","0"
"3462","NCT01363479","An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting","Chemotherapy-Induced Nausea and Vomiting",0,"Oral palonosetron","Drug","Helsinn Healthcare SA","Industry",0,0,"All","18 Years","N/A","743","July 2011","November 2012","Proportion of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication","0","0","0","3.21","Risk Difference (RD)","99","2-Sided","-2.74","9.17"
"3463","NCT01364428","Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","373","June 2011","January 2012","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"3464","NCT01365052","Safety Trial of Naproxen Sodium/ Diphenhydramine","Pain",0,"Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)","Drug","Bayer","Industry",0,0,"All","12 Years","N/A","326","May 2011","July 2011","Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product","0","0","0","0","0","0","0","0","0"
"3465","NCT01365507","Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","276","June 2011","April 2012","Change in Glycosylated Haemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"3466","NCT01366638","A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection","Hepatitis C, Chronic",0,"TMC435","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","70 Years","79","May 2011","November 2012","The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)","0","0","0","0","0","0","0","0","0"
"3467","NCT01367249","Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","Pain",0,"Bromfenac Ophthalmic Solution","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","440","May 2011","July 2011","Ocular Inflammation","0","0","0","0","0","0","0","0","0"
"3468","NCT01368211","Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)","Thrombocytopenia",0,"2-4-day-old Mirasol-treated Platelets Transfusion","Biological","Terumo BCTbio","Industry",0,0,"All","18 Years","N/A","16","September 2010","April 2011","Change in Maximum Amplitude at 1-hour Post-transfusion","0","0","0","0","0","0","0","0","0"
"3469","NCT01368978","Pediatric Diabetics Type 1 Using InsuPatch","Type 1 Diabetes Mellitus",0,"InsuPatch","Device","Insuline Medical Ltd.","Industry",0,0,"All","12 Years","17 Years","27","December 2009","May 2012","Efficacy","0","0","0","0","0","0","0","0","0"
"3470","NCT01370590","A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)","Hypercholesterolemia",0,"Atorvastatin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","406","September 2011","April 2012","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment","0","0","0","-0.2","Difference in Least-square Means","97.5","2-Sided","-1.7","3.3"
"3471","NCT01370603","A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)","Hypercholesterolemia",0,"Atorvastatin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","328","September 2011","May 2012","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment","0","0","0","-0.2","Difference in Least-squares means","97.5","2-Sided","-1.9","1.4"
"3472","NCT01370707","A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients","Diabetes Mellitus",0,"Metformin","Drug","CJ HealthCare Corporation","Industry",0,0,"All","20 Years","69 Years","187","April 2011","July 2012","Change from baseline in HbA1c at week 24","0","0","0","0","0","0","0","0","0"
"3473","NCT01371565","Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome","Cushing's Disease",0,"Mifepristone","Drug","Corcept Therapeutics","Industry",0,0,"All","18 Years","N/A","4","November 2010","June 2012","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"3474","NCT01372423","Evaluation of Clinical Equivalence Between Two Lubiprostone Products","Chronic Idiopathic Constipation",0,"Lubiprostone","Drug","Anchen Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","808","May 2011","June 2012","Primary Analysis","0","0","0","0","0","0","0","0","0"
"3475","NCT01372475","Hymovis™ Versus Placebo in Knee Osteoarthritis","Knee Osteoarthritis",0,"Hymovis Intra-articular Injection","Device","Fidia Farmaceutici s.p.a.","Industry",0,0,"All","40 Years","N/A","800","March 2011","November 2012","Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain sub-score","0","0","0","0","0","0","0","0","0"
"3476","NCT01372865","A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)","Mild to Moderate Persistent Allergic Rhinitis",0,"Mometasone furoate","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","12 Years","N/A","364","December 2011","June 2012","Nasal Index Score (NIS) scale that evaluates nasal obstruction, coryza, and sneezing","0","0","0","0","0","0","0","0","0"
"3477","NCT01373073","Evaluation of a Novel Human Milk Fortifier in Preterm Infants","Preterm Infants",0,"Experimental human milk fortifier","Other","Abbott Nutrition","Industry",0,0,"All","N/A","21 Days","147","August 2011","December 2012","Weight gain","0","0","0","0","0","0","0","0","0"
"3478","NCT01373502","International Randomized Comparison Between DES Limus Carbostent and Taxus Drug Eluting Stents in the Treatment of De-novo Coronary Lesions","Stable Angina",0,"DES Limus Carbostent","Device","CID - Carbostent & Implantable Devices","Industry",0,0,"All","18 Years","N/A","323","October 2009","April 2011","angiographic efficacy measurement (mm)","0","0","0","0","0","0","0","0","0"
"3479","NCT01373697","Study to Assess the Efficacy and Safety of Ibuprofen 50 mg/g Gel Compared to Profenid 25mg/g Gel","Muscular Atrophy",0,"Ibuprofen","Drug","Laboratório Teuto Brasileiro S/A","Industry",0,0,"All","12 Years","65 Years","144","June 2011","August 2011","Clinical study evaluating the efficacy and safety of Ibuprofen 50mg / g gel in the treatment of patients with muscle pain, joint, or pain caused by sprains, contusions, tendinitis, or myofascial compared to Profenid ® 25mg / g gel. ""","0","0","0","0","0","0","0","0","0"
"3480","NCT01373853","A Single Centre Study to Compare the Efficacy and Safety of Femtosecond Laser-Assisted Versus Manual Cataract Surgery","Cataract",0,"Lens Fragmentation by means of a femtosecondlaser","Procedure","Technolas Perfect Vision GmbH","Industry",0,0,"All","18 Years","N/A","131","April 2011","September 2011","Observation of the applied Effective Phaco Time (EPT) for Pahcoemulsifikation during surgery. The observed Effective Phaco Time in Group A should be significantly lower than in group B. Statistically significant difference at p<0.05.","0","0","0","0","0","0","0","0","0"
"3481","NCT01374490","Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea","HIV Enteropathy",0,"Crofelemer","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","251","June 2011","October 2012","Incidence of treatment-emergent AEs and serious adverse events (SAEs).","0","0","0","0","0","0","0","0","0"
"3482","NCT01375933","A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers","Smoking",0,"NicVAX Vaccine","Biological","Nabi Biopharmaceuticals","Industry",0,0,"All","18 Years","55 Years","260","May 2011","October 2011","Immunogenicity","0","0","0","0","0","0","0","0","0"
"3483","NCT01376245","A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD","Pulmonary Disease, Chronic Obstructive",0,"fluticasone furoate/vilanterol","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","646","April 2011","September 2012","Mean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169","<0.001","0","Mixed Models Analysis","0.140","Least Squares Mean Difference","95","2-Sided","0.089","0.191"
"3484","NCT01376297","A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting","Chemotherapy-Induced Nausea and Vomiting",0,"Netupitant and Palonosetron","Drug","Helsinn Healthcare SA","Industry",0,0,"All","18 Years","N/A","413","July 2011","September 2012","Percentage of Patients With Adverse Events","0","0","0","0","0","0","0","0","0"
"3485","NCT01376388","Long-term Safety Study for GSK573719/GW642444 in Japanese","Pulmonary Disease, Chronic Obstructive",0,"GSK573719/GW642444 Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","131","August 2011","December 2012","Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period","0","0","0","0","0","0","0","0","0"
"3486","NCT01376700","Early Prophylaxis Immunologic Challenge (EPIC) Study","Hemophilia A",0,"Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)","Biological","Baxalta US Inc.","Industry",0,0,"Male","N/A","1 Year","22","August 2011","November 2012","Number of Participants With Severe and Moderately Severe Hemophilia A (FVIII ≤ 2%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE","0","0","0","0","0","0","0","0","0"
"3487","NCT01377194","Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder","Major Depressive Disorder",0,"Levomilnacipran ER","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","75 Years","568","June 2011","March 2012","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.","0.0027","0","mixed-model for repeated measures","-3.303","Least squares mean difference","95","2-Sided","-5.457","-1.148"
"3488","NCT01378390","Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease","Complex Perianal Fistula",0,"Expanded autologous adipose-derived adult stem cells (eASCs)","Drug","Cellerix","Industry",0,0,"All","18 Years","N/A","56","December 2008","February 2010","Percentage of subjects in whom the external openings of the treated perianal fistula have closed","0","0","0","0","0","0","0","0","0"
"3489","NCT01378429","Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis","Perennial Allergic Rhinitis",0,"ciclesonide nasal aerosol","Drug","Sunovion","Industry",0,0,"All","6 Years","11 Years","89","July 2011","November 2011","The Change in Serum Cortisol Area Under the Curve (AUC) From Time 0 to 24 Hours (0-24), Calculated Using a Trapezoidal Rule, From Baseline to the End of the 6 Week Treatment Period","0","0","0","7.6","LS Mean Difference","95","2-Sided","-7.4","22.6"
"3490","NCT01378611","Does VNS Interact With the Serotonergic and Immune System in Children With Intractable Epilepsy?","Refractory Epilepsy in Children",0,"Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA","Device","Epilepsiecentrum Kempenhaeghe","Industry",0,0,"All","4 Years","18 Years","45","March 2006","March 2012","seizure frequency reduction of 50% or more","0","0","0","0","0","0","0","0","0"
"3491","NCT01380886","Growth and Tolerance of Young Infants Fed Infant Formulas","Infant Newborn",0,"experimental infant formula with alternate protein source","Other","Abbott Nutrition","Industry",0,0,"All","N/A","8 Days","209","June 2011","December 2011","Weight gain","0","0","0","0","0","0","0","0","0"
"3492","NCT01381900","A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea","Diabetes Mellitus, Type 2",0,"Placebo","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","80 Years","678","August 2011","November 2012","Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18","<0.001","0","ANCOVA","-0.51","Least-Squares Mean Difference","95","2-Sided","-0.644","-0.367"
"3493","NCT01382225","Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome","Dry Eye Syndrome",0,"Sodium Hyaluronate Ophthalmic Solution, 0.18%","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","1936","July 2011","May 2012","Change From Baseline in Lissamine Green Staining (LGS) Total Score at Day 7","0","0","0","0","0","0","0","0","0"
"3494","NCT01382329","H5N1 Vaccine Study in Japanese Adults","H5N1 Influenza",0,"H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)","Biological","Nanotherapeutics, Inc.","Industry",0,0,"All","18 Years","59 Years","340","June 2011","August 2011","Number of subjects with antibody response to the vaccine strain","0","0","0","0","0","0","0","0","0"
"3495","NCT01383486","Self Selection Trial of Naproxen Sodium","Pain",0,"Naproxen sodium ER (BAYH6689)","Drug","Bayer","Industry",0,0,"All","12 Years","N/A","253","July 2011","August 2011","The Percentage of Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours","0","0","0","0","0","0","0","0","0"
"3496","NCT01385371","A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)","Rhinitis Allergic",0,"Grass (Phleum pratense) pollen allergen extract","Biological","ALK-Abelló A/S","Industry",0,0,"All","5 Years","65 Years","1501","June 2011","August 2012","Average Total Combined Rhinoconjunctivitis Daily Symptom Score (DSS) and Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire Grass Pollen Season (GPS)","<0.001","0","Wilcoxon Rank Sum Test","-0.98","Median Difference (Final Values)","95","0","-1.2","-0.4"
"3497","NCT01386853","Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients","Hyperlipidemia",0,"Pitavastatin","Drug","Tai Tien Pharmaceuticals Co., Ltd.","Industry",0,0,"All","20 Years","75 Years","200","July 2011","March 2012","The change of LDL-C","0","0","0","0","0","0","0","0","0"
"3498","NCT01387230","Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD","Pulmonary Disease, Chronic Obstructive",0,"GSK573719","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","206","July 2011","February 2012","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85","<0.001","0","Mixed Models Analysis","0.127","Least squares mean difference","95","2-Sided","0.052","0.202"
"3499","NCT01387737","Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"TA-7284-Low","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","N/A","1299","May 2011","November 2012","Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events","0","0","0","0","0","0","0","0","0"
"3500","NCT01388361","Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","413","September 2011","July 2012","Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)","0","0","0","0","0","0","0","0","0"
"3501","NCT01389284","Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium","Pain, Postoperative",0,"Naproxen Sodium ER (BAYH6689)","Drug","Bayer","Industry",0,0,"All","15 Years","N/A","300","June 2011","September 2011","Summed, Time-weighted Pain Intensity Difference From 0 to 24 Hours Postdose (SPID0-24)","0","0","0","0","0","0","0","0","0"
"3502","NCT01389687","Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan","Poliomyelitis",0,"Inactive Poliovirus Vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","3 Months","68 Months","74","July 2011","January 2012","A description of the anti-Polio 1, 2 and 3 antibody titers post-vaccination","0","0","0","0","0","0","0","0","0"
"3503","NCT01390324","Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine","Migraine",0,"Fixed-dose combination of naratriptan+naproxen","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"All","18 Years","65 Years","0","December 2011","March 2012","Headache relief 2 hours after dosing, without use of rescue medication.","0","0","0","0","0","0","0","0","0"
"3504","NCT01391273","Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis","Eyelash Hypotrichosis",0,"bimatoprost solution 0.03%","Drug","Allergan","Industry",0,0,"All","20 Years","N/A","173","July 2011","May 2012","Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)","0","0","0","0","0","0","0","0","0"
"3505","NCT01391286","Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis","Eyelash Hypotrichosis",0,"bimatoprost solution 0.03%","Drug","Allergan","Industry",0,0,"All","20 Years","N/A","36","July 2011","May 2012","Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)","0","0","0","0","0","0","0","0","0"
"3506","NCT01392469","Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients","Pulmonary Arterial Hypertension",0,"Imatinib","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","21","April 20, 2011","December 24, 2012","Measure: To evaluate the effect of QTI571 on pharmacokinetics of of sildenafil and bosentan in terms of the changes in AUCtau and Cmax in patients with Pulmonary Arterial Hypertension","0","0","0","0","0","0","0","0","0"
"3507","NCT01392547","Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors","Congenital Bleeding Disorder",0,"vatreptacog alfa (activated)","Drug","Novo Nordisk A/S","Industry",0,0,"Male","12 Years","N/A","72","July 2011","August 2012","Effective Bleeding Control Defined as no Additional Haemostatic Medication (Other Than Trial Product) Given","0","0","0","0","0","0","0","0","0"
"3508","NCT01392573","A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec/liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","413","November 28, 2011","October 1, 2012","Change From Baseline in HbA1c (Glycosylated Haemoglobin)","<0.0001","0","ANCOVA","-1.05","Treatment contrast","95","2-Sided","-1.25","-0.84"
"3509","NCT01393145","Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD","Chronic Obstructive Pulmonary Disease",0,"Combination Fluticasone /Formoterol 12/250 μg","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"All","40 Years","N/A","0","August 2011","August 2012","Changes in pre-bronchodilator forced expiratory volume in first second (FEV1)","0","0","0","0","0","0","0","0","0"
"3510","NCT01395524","A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation","Opioid-Induced Constipation (OIC)",0,"NKTR-118","Drug","AstraZeneca","Industry",0,0,"All","18 Years","84 Years","302","July 2011","September 2012","Incidence of Patients Experiencing at Least One Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"3511","NCT01395888","A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD","Pulmonary Disease, Chronic Obstructive",0,"fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","80 Years","260","June 2011","August 2012","Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 12-week Treatment Period (Day 84)","0.484","0","Mixed Models Analysis","0.259","Least Squares Mean Difference","95","2-Sided","-0.468","0.986"
"3512","NCT01395901","Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients","Postoperative Nausea and Vomiting",0,"Palonosetron","Drug","Helsinn Healthcare SA","Industry",0,0,"All","N/A","16 Years","670","June 2011","March 2012","Proportion of Patients With Complete Response","0","0","0","-4.4","Risk Difference (RD)","95","2-Sided","-10.5","1.7"
"3513","NCT01396525","Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery","Peripheral Vascular Disease",0,"Omnilink Elite™ Peripheral Balloon-Expandable Stent System","Device","Abbott Vascular","Industry",0,0,"All","18 Years","89 Years","153","March 2009","September 2011","Major Adverse Event (MAE)","0","0","0","0","0","0","0","0","0"
"3514","NCT01396785","Topical Antifungal Treatment for Tinea Pedis","Tinea Pedis",0,"33525","Drug","Medicis Global Service Corporation","Industry",0,0,"All","12 Years","N/A","321","July 2011","January 2012","Proportion of patients achieving complete clearance","0","0","0","0","0","0","0","0","0"
"3515","NCT01396811","Topical Antifungal Treatment for Tinea Pedis","Tinea Pedis",0,"33525","Drug","Medicis Global Service Corporation","Industry",0,0,"All","12 Years","N/A","322","July 2011","January 2012","Proportion of patients achieving complete clearance","0","0","0","0","0","0","0","0","0"
"3516","NCT01397461","Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo","Impetigo",0,"ozenoxacin placebo","Drug","Ferrer Internacional S.A.","Industry",0,0,"All","2 Years","N/A","465","March 2012","December 2012","Clinical Success","0.003","0","Chi-squared","0","0","0","0","0","0"
"3517","NCT01398839","Safety Study of the VEGA UV-A System to Treat Ectasia","Ectasia",0,"VEGA UV-A Illumination System","Device","Topcon Medical Systems, Inc.","Industry",0,0,"All","18 Years","N/A","103","December 2010","July 2012","Changes in Corneal Curvature","0","0","0","0","0","0","0","0","0"
"3518","NCT01398852","Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia","Keratoconus and Ectasia",0,"Riboflavin","Drug","Topcon Medical Systems, Inc.","Industry",0,0,"All","12 Years","N/A","500","December 2010","July 2012","Changes in Corneal Curvature","0","0","0","0","0","0","0","0","0"
"3519","NCT01400425","Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline","Progressive Cognitive Decline",0,"florbetapir F 18","Drug","Avid Radiopharmaceuticals","Industry",0,0,"All","50 Years","N/A","239","July 2011","July 2012","Percentage of Subjects Who Undergo a Hypothetical Change in Clinical Diagnosis and Physician Management Plan After Obtaining a Negative Florbetapir F 18 PET Scan.","0","0","0","0","0","0","0","0","0"
"3520","NCT01400776","Safety & Efficacy WC3011 in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women","Postmenopausal Vulvovaginal Atrophy",0,"WC3011 Vaginal Gel","Drug","Warner Chilcott","Industry",0,0,"Female","35 Years","N/A","722","July 2011","February 2012","Change in Vaginal Cytology (Maturation Index; Percentage of Basal and Superficial Cells) from Baseline to Week 12/Final Visit","0","0","0","0","0","0","0","0","0"
"3521","NCT01400932","Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects","Acne Vulgaris",0,"GI148512","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","45 Years","360","July 2011","April 2012","Absolute Change in Total Lesion Counts From Baseline to Week 12","<0.001","0","ANCOVA","-21.0","Mean Difference (Net)","95","2-Sided","-26.2","-15.8"
"3522","NCT01400945","Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease","Gastroesophageal Reflux Disease",0,"AGSPT201 Tab contains S-pantoprazole","Drug","Ahn-Gook Pharmaceuticals Co.,Ltd","Industry",0,0,"All","18 Years","75 Years","154","December 2009","August 2011","Number of patients with healing of erosive esophagitis(The absence of esophageal lesions)","0","0","0","0","0","0","0","0","0"
"3523","NCT01401361","Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System","Typical Atrial Flutter",0,"Treatment Arm","Device","St. Jude Medical","Industry",0,0,"All","18 Years","N/A","150","October 2011","April 2012","Primary Safety:Incidence of Composite, Serious Adverse Events Within 7 Days Post Procedure","0","0","0","0","0","0","0","0","0"
"3524","NCT01401465","Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray","Perennial Allergic Rhinitis",0,"ciclesonide","Drug","Sunovion","Industry",0,0,"All","12 Years","N/A","327","July 2011","November 2011","Total Preference Composite Score Assessed at the End of the Study. The Total Preference Score is the Standardized Sum of 17 Individual Preference Items","<0.0001","The significance level was set at 0.025 to adjust for the fact that two co-primary endpoints were being tested.","Two-sided Signed Rank Test","88.235","Slope","0","0","0","0"
"3525","NCT01402843","Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia","Hypertension",0,"pitavastatin, valsartan, placebo","Drug","JW Pharmaceutical","Industry",0,0,"All","20 Years","N/A","150","June 2011","June 2012","The experimental group should be compared with control group in the change of DBP and LDL-C on the basis of the baseline.","0","0","0","0","0","0","0","0","0"
"3526","NCT01402921","Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema","Chronic Venous Insufficiency (CVI)",0,"V0322 BC","Device","Pierre Fabre Medicament","Industry",0,0,"All","18 Years","N/A","92","January 2011","January 2012","Volume reduction of the target leg presenting the most important initial volume (by Volumetry using water displacement)","0","0","0","0","0","0","0","0","0"
"3527","NCT01405508","Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy","Epilepsy",0,"Brivaracetam tablets","Drug","UCB Pharma","Industry",0,0,"All","16 Years","70 Years","105","August 2011","July 2012","Number of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days)","0","0","0","0","0","0","0","0","0"
"3528","NCT01406561","Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy","Meniscal Tear",0,"OMS103HP-S","Drug","Omeros Corporation","Industry",0,0,"All","18 Years","75 Years","344","August 2011","November 2012","KOOS Symptoms Subscale","0","0","0","0","0","0","0","0","0"
"3529","NCT01407068","Administration of Two Injections for Multiple Dupuytren's Contractures","Dupuytren's Contracture",0,"AA4500 collagenase clostridium histolyticum","Biological","Endo Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","60","September 2011","February 2012","Percent Change From Baseline in Total Fixed Flexion","0","0","0","0","0","0","0","0","0"
"3530","NCT01408173","Clinical Study of Caffeine for Apnea of Prematurity","Apnea of Prematurity",0,"NPC-11 for intravenous or oral administration.","Drug","Nobelpharma","Industry",0,0,"All","28 Weeks","33 Weeks","24","August 2011","October 2012","Success rates for controlling of apnea episode in each observation day (at least 50% reduction of apnea episodes from baseline)","0","0","0","0","0","0","0","0","0"
"3531","NCT01408303","[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL","Hypertriglyceridemia",0,"Olive oil, 4g","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","646","August 2011","June 2012","Serum Non-HDL Cholesterol","<0.05","0","ANCOVA","-2.95","LS mean difference relative to olive oil","0","0","0","0"
"3532","NCT01410916","Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)","Shiga-like Toxin-producing Escherichia Coli",0,"Eculizumab (Soliris®)","Drug","Alexion Pharmaceuticals","Industry",0,0,"All","2 Months","N/A","198","July 2011","January 2012","Improvement in Systemic TMA & Vital Organ Involvement at 8 weeks of treatment defined as either complete or partial responder based on hematologic normalization/improvement & clinically important improvement in Vital Organs: Brain, Kidney, and Thrombosis","0","0","0","0","0","0","0","0","0"
"3533","NCT01411176","Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy","Gastric Cancer",0,"Menthol","Drug","Nihon Pharmaceutical Co., Ltd","Industry",0,0,"All","20 Years","N/A","85","September 2011","May 2012","The proportion of patients had no or mild peristalsis during the therapeutic procedures","0","0","0","0","0","0","0","0","0"
"3534","NCT01411189","Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy","Gastric Cancer",0,"Menthol","Drug","Nihon Pharmaceutical Co., Ltd","Industry",0,0,"All","20 Years","N/A","33","September 2011","May 2012","The proportion of patients had no or mild peristalsis during the therapeutic procedures","0","0","0","0","0","0","0","0","0"
"3535","NCT01412281","Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers","Influenza",0,"Virosomal influenza vaccine (AdImmune HA Antigen)","Biological","Crucell Holland BV","Industry",0,0,"All","18 Years","N/A","440","October 2011","December 2011","Geometric Mean Titer","0","0","0","0","0","0","0","0","0"
"3536","NCT01413048","Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension","Essential Hypertension",0,"Carvedilol 25mg","Drug","Ahn-Gook Pharmaceuticals Co.,Ltd","Industry",0,0,"All","19 Years","N/A","260","January 2011","March 2012","Change from baseline in diastolic blood pressure (DBP)","0","0","0","0","0","0","0","0","0"
"3537","NCT01413204","Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"TA-7284 Low","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","N/A","272","July 2011","August 2012","Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value)","0","0","0","0","0","0","0","0","0"
"3538","NCT01413386","Efficacy and Safety of the Paclitaxel Eluting Covered Biliary Stent to the Common Covered Metallic Biliary Stent","Biliary Stricture",0,"biliary stent","Device","Jong Taek, Lee","Industry",0,0,"All","19 Years","90 Years","150","September 2011","October 2012","Accumulative Patency Rate","0","0","0","0","0","0","0","0","0"
"3539","NCT01413958","Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)","Seasonal Allergic Rhinitis",0,"Phenylephrine","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","575","August 2011","October 2011","Mean Change From Baseline in Daily Reflective Nasal Congestion Score","0","0","0","0","0","0","0","0","0"
"3540","NCT01416480","Clinical Trial to Evaluate the Safety and Efficacy of ""Theobromine Capsule"" as an Antitussive in Acute Cougher","Acute Bronchitis",0,"Theobromine 300mg","Drug","Ahn-Gook Pharmaceuticals Co.,Ltd","Industry",0,0,"All","18 Years","N/A","332","May 2010","February 2011","cough remission rate","0","0","0","0","0","0","0","0","0"
"3541","NCT01416896","New Needle for Two-Needle Hemodialysis","End Stage Renal Disease",0,"Hemodialysis using the standard venous needle","Procedure","Biomedical Enterprises Inc","Industry",0,0,"All","18 Years","80 Years","70","August 2011","September 2012","Net change in intracellular oxidative stress and intracellular proinflammatory cytokines levels","0","0","0","0","0","0","0","0","0"
"3542","NCT01420094","Evaluate Onset of Action of a Fast Release Aspirin","Healthy Subjects",0,"Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)","Drug","Bayer","Industry",0,0,"All","16 Years","45 Years","510","June 2011","September 2011","Time to Meaningful Pain Relief (PR)","0","0","0","0","0","0","0","0","0"
"3543","NCT01420159","Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma","Acute Pain Due to Trauma",0,"Methoxyflurane","Drug","Medical Developments International Limited","Industry",0,0,"All","12 Years","N/A","300","August 2011","July 2012","VAS Score","0","0","0","0","0","0","0","0","0"
"3544","NCT01421147","A Study in Adults With Type 1 Diabetes","Diabetes Mellitus, Type 1",0,"LY2963016","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","536","August 2011","August 2012","Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)","0.055","0","ANCOVA","0.108","LS Mean Difference","95","2-Sided","-0.002","0.219"
"3545","NCT01421433","A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol","Low Back Pain",0,"Tandrilax","Drug","Farmoquimica S.A.","Industry",0,0,"All","18 Years","65 Years","160","May 2012","August 2012","Pain average reduction","0","0","0","0","0","0","0","0","0"
"3546","NCT01421459","A Study in Adults With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"LY2963016","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","759","September 2011","September 2012","Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)","0.403","0","ANCOVA","0.052","Mean Difference (Final Values)","95","2-Sided","-0.070","0.175"
"3547","NCT01421498","Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE)","Dry Eye",0,"Lifitegrast","Drug","Shire","Industry",0,0,"All","18 Years","N/A","588","August 2011","May 2012","Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84","0.0007","0","t-test, 2 sided","0.24","Treatment difference","95","2-Sided","0.10","0.38"
"3548","NCT01422304","Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)","Neuromuscular Blockade",0,"Sugammadex","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1198","October 12, 2011","September 26, 2012","Number of Participants With One or More Adjudicated Events of Bleeding (Major or Non-major) With Onset Within 24 Hours After Study Drug Administration","0","0","0","0.70","Risk Ratio (RR)","95","2-Sided","0.38","1.29"
"3549","NCT01422434","LEO 90105 Ointment in Japanese Subjects With Psoriasis","Psoriasis",0,"LEO 90105 = calcipotriol + betamethasone dipropionate","Drug","LEO Pharma","Industry",0,0,"All","20 Years","N/A","676","July 2011","April 2012","Change From Baseline in Modified Psoriasis Area and Severity Index (mPASI)","0","0","0","0","0","0","0","0","0"
"3550","NCT01422512","Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects","Influenza",0,"seasonal influenza vaccine","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","N/A","126","September 2011","October 2011","Antibody response as measured by hemagglutination inhibition (HI) assay","0","0","0","0","0","0","0","0","0"
"3551","NCT01423084","Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years","Meningococcal Disease",0,"Serogroup B meningococcal vaccine","Biological","Novartis","Industry",0,0,"All","11 Years","17 Years","344","August 2011","December 2011","Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains.","0","0","0","1","between groups ratio","95","2-Sided","0.82","1.23"
"3552","NCT01423240","Major Depressive Disorder With Mixed Features","Major Depressive Disorder",0,"Lurasidone 20 mg","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","0","January 2012","December 2012","MADRS","0","0","0","0","0","0","0","0","0"
"3553","NCT01423617","Efficacy and Safety of Zenoctil in Reducing Body Weight","Overweight",0,"Zenoctil","Dietary Supplement","InQpharm Group","Industry",0,0,"All","18 Years","60 Years","92","July 2011","December 2011","Change in Mean Body Weight (kg)","0","0","0","0","0","0","0","0","0"
"3554","NCT01425632","A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","Perennial Allergic Rhinitis",0,"TAU-284","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","7 Years","15 Years","490","August 2011","December 2011","Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] (at Final Evaluation)","0","0","0","0","0","0","0","0","0"
"3555","NCT01425983","Dietary Intervention of Stress-Induced Neurovegetative Disorders With a Specific Amino Acid Composition (asn01)","Nervous System Disorder",0,"amino acid composition (asn01)","Dietary Supplement","Kyberg Vital GmbH","Industry",0,0,"All","18 Years","65 Years","80","March 2011","May 2012","Psychological neurological questionnaire (PNF)","0","0","0","0","0","0","0","0","0"
"3556","NCT01426854","Nepafenac Compared to Placebo for Ocular Pain and Inflammation","Cataract",0,"Nepafenac Ophthalmic Suspension, 0.1%","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","260","July 2011","April 2012","Proportion of Subjects With Clinical Cure at Day 14","<0.0001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"3557","NCT01427491","Compare Aquacel® Ag Versus Mepilex® Border Ag to Manage Bioburden in Leg Ulcers","Leg Ulcers",0,"Aquacel® Ag","Device","ConvaTec Inc.","Industry",0,0,"All","18 Years","N/A","18","August 2011","January 2012","Microbial load reduction","0","0","0","0","0","0","0","0","0"
"3558","NCT01427803","Actual Use Trial of Naproxen Sodium","Pain",0,"Naproxen Sodium ER (BAYH6689)","Drug","Bayer","Industry",0,0,"All","12 Years","N/A","778","September 2011","December 2011","Estimated Percentage of Misuse for Non-Therapeutic Reasons","0","0","0","0","0","0","0","0","0"
"3559","NCT01428583","Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain","Chronic Noncancer Pain",0,"oxycodone HCl and naltrexone HCl extended-release capsules","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","395","December 2010","May 2012","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Adverse Reactions","0","0","0","0","0","0","0","0","0"
"3560","NCT01429701","Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous","Eczema",0,"polymyxin B sulphate + prednisolone + benzocaine + clioquinol","Drug","EMS","Industry",0,0,"All","18 Years","40 Years","76","May 2012","June 2012","Reduction / improvement of signs and symptoms","0","0","0","0","0","0","0","0","0"
"3561","NCT01429987","The Plecanatide Chronic Idiopathic Constipation (CIC) Study","Chronic Idiopathic Constipation",0,"plecanatide","Drug","Synergy Pharmaceuticals Inc.","Industry",0,0,"All","18 Years","75 Years","951","October 2011","December 2012","Complete Spontaneous Bowel Movement (CSBM)","0","0","0","0","0","0","0","0","0"
"3562","NCT01430754","Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder","Non-24-Hour Sleep-Wake Disorder",0,"tasimelteon","Drug","Vanda Pharmaceuticals","Industry",0,0,"All","N/A","N/A","20","September 2011","December 2012","Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.","0","0","0","0","0","0","0","0","0"
"3563","NCT01431339","Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","Abscess",0,"IV Dalbavancin","Drug","Durata Therapeutics Inc., an affiliate of Allergan plc","Industry",0,0,"All","18 Years","85 Years","739","July 2011","November 2012","Early Clinical Efficacy","0","0","0","-1.5","Difference in Proportions","95","0","-7.4","4.6"
"3564","NCT01431716","Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension",0,"EFI/ACT-385781A","Drug","Actelion","Industry",0,0,"All","18 Years","N/A","42","March 2011","February 2012","Change in Pulmonary Vascular Resistance From Baseline to End of Treatment (EOT).","0","0","0","0","0","0","0","0","0"
"3565","NCT01431950","Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents","Asthma",0,"fluticasone furoate","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","100 Years","238","September 2011","October 2012","Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period","0","0","0","0.077","Mean Difference (Final Values)","95","0","-0.039","0.192"
"3566","NCT01432262","13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico","Pneumococcal Infections",0,"vaccine-13vPnC","Biological","Pfizer","Industry",0,0,"All","50 Years","N/A","324","July 2011","December 2011","Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination","0","0","0","0","0","0","0","0","0"
"3567","NCT01433107","Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis","Tinea Pedis",0,"Terbinafine","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","290","August 2011","February 2012","Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)","0","0","0","0","0","0","0","0","0"
"3568","NCT01433276","Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock","Hemorrhagic Shock",0,"Hyperosmolar sodium lactate","Drug","Innogene Kalbiotech Pte. Ltd","Industry",0,0,"All","18 Years","65 Years","71","July 2009","January 2011","Urinary output (UOP)","0","0","0","0","0","0","0","0","0"
"3569","NCT01433562","Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients","Breast Cancer",0,"DLBS1425","Drug","Dexa Medica Group","Industry",0,0,"Female","18 Years","65 Years","40","August 2011","November 2012","Clinical response as measured by RECIST","0","0","0","0","0","0","0","0","0"
"3570","NCT01435460","Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)","Seasonal Allergic Conjunctivitis",0,"Loteprednol etabonate 0.2%","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","300","August 2010","April 2011","Bulbar Conjunctival Injection","0","0","0","0","0","0","0","0","0"
"3571","NCT01435902","A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise","Asthma",0,"Fluticasone Furoate/Vilanterol Inhalation Powder","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","50 Years","0","January 2012","August 2012","Maximal percent decrease from baseline in FEV1 following exercise challenge at 12 hours post-dose","0","0","0","0","0","0","0","0","0"
"3572","NCT01436032","Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery","Laparoscopic Surgery",0,"N1539","Drug","Alkermes, Inc.","Industry",0,0,"All","18 Years","80 Years","50","October 2011","March 2012","Sum of the time-weighted pain intensity differences (SPID) as recorded on the Visual Analog Scale (VAS) from baseline (time 0) to 24 hours following the first dose of study medication (SPID 24)","0","0","0","0","0","0","0","0","0"
"3573","NCT01436071","Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma","Asthma",0,"Fluticasone furoate 50mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","248","September 2011","June 2012","Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period","0.012","0","ANCOVA","0.120","Median Difference (Final Values)","95","2-Sided","0.026","0.213"
"3574","NCT01436110","Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma","Asthma",0,"Fluticasone furoate 50mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","351","September 2011","September 2012","Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period","0.430","0","ANCOVA","0.037","Mean Difference (Final Values)","95","2-Sided","-0.055","0.128"
"3575","NCT01437111","Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)","Osteoporosis",0,"MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","50 Years","N/A","200","October 26, 2011","December 5, 2012","Number of Participants With Serum 25-hydroxyvitamin D >=50 ng/mL at Week 26","0","0","0","0","0","0","0","0","0"
"3576","NCT01438060","Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type","Dementia, Alzheimer Type",0,"Aripiprazole (BMS-337039)","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","55 Years","95 Years","232","August 2000","July 2010","Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase","0.802","Baseline data was evaluated by analysis of variance (ANOVA) with treatment and study center as main effects.","ANOVA","0.17","Mean Difference (Final Values)","95","2-Sided","-1.15","1.49"
"3577","NCT01438710","Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)","Renal Failure",0,"Prograf","Drug","Veloxis Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","44","December 2011","August 2012","Evaluation of Hand Tremor and Stable Kidney Transplant Patients When Switched From Prograf to LCP-Tacro.","0.0048","0","t-test, 2 sided","0","0","0","0","0","0"
"3578","NCT01438931","Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation","Sedation",0,"DA-9501","Drug","Hospira, now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","20 Years","N/A","162","July 2011","February 2012","Incidence of patients who did not require rescue administration of propofol to achieve and maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 during the study drug administration","0","0","0","0","0","0","0","0","0"
"3579","NCT01438957","Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation","Sedation",0,"Dexmedetomidine hydrochloride","Drug","Hospira, now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","20 Years","N/A","120","June 2011","November 2011","Incidence of patients who did not require rescue administration of propofol to achieve and maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 during the study drug administration.","0","0","0","0","0","0","0","0","0"
"3580","NCT01439789","Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients","Chronic Heart Failure",0,"rhNRG-1","Drug","Zensun Sci. & Tech. Co., Ltd.","Industry",0,0,"All","18 Years","75 Years","146","June 2011","June 2012","NT-proBNP","0","0","0","0","0","0","0","0","0"
"3581","NCT01439893","Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients","Chronic Systolic Heart Failure",0,"rhNRG-1","Drug","Zensun Sci. & Tech. Co., Ltd.","Industry",0,0,"All","18 Years","75 Years","14","June 2011","June 2012","Left Ventricular Ejection Fraction","0","0","0","0","0","0","0","0","0"
"3582","NCT01439984","Trial of PED-1 in Male Patients With Premature Ejaculation","Premature Ejaculation",0,"Clomipramine","Drug","Symyoo","Industry",0,0,"Male","20 Years","65 Years","159","September 2011","June 2012","Intravaginal ejaculation latency time (IELT)(seconds)","0","0","0","0","0","0","0","0","0"
"3583","NCT01440101","Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)","Multiple Sclerosis",0,"Natalizumab (BG00002)","Drug","Biogen","Industry",0,0,"All","18 Years","65 Years","106","November 2010","August 2012","Part A: Number of Participants With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"3584","NCT01440569","Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults","Acquired Immunodeficiency Syndrome",0,"COBI","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","314","September 2011","August 2012","Percentage of Participants With Onset of Any Treatment-emergent Grade 3 or 4 Adverse Event Between Baseline and Week 24","0","0","0","0","0","0","0","0","0"
"3585","NCT01442376","Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients","Chemotherapy-Induced Nausea and Vomiting",0,"Palonosetron","Drug","Helsinn Healthcare SA","Industry",0,0,"All","N/A","16 Years","502","September 2011","October 2012","Proportion of Patients With Complete Response 0 to 24 Hours (Acute Phase) in Cycle 1","0","0","0","0.36","Risk Difference (RD)","97.5","2-Sided","-11.7","12.4"
"3586","NCT01445301","Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects","Acne Vulgaris",0,"GSK2585823(CLDM 1%-BPO 3% gel)","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","45 Years","800","September 27, 2011","August 2, 2012","Absolute change from Baseline to Week 12 in total lesion counts.","0","0","0","0","0","0","0","0","0"
"3587","NCT01446042","Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism","Male Hypogonadism",0,"Testosterone","Drug","Trimel Biopharma SRL","Industry",0,0,"Male","18 Years","80 Years","280","September 2011","September 2012","Serum testosterone Cavg","0","0","0","0","0","0","0","0","0"
"3588","NCT01446211","Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis","Wegeners Granulomatosis",0,"Gusperimus + glucocorticoids","Drug","Nordic Pharma SAS","Industry",0,0,"All","18 Years","75 Years","4","November 2011","November 2012","Response rate","0","0","0","0","0","0","0","0","0"
"3589","NCT01447342","A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines","Facial Wrinkles",0,"Cryo-Touch II","Device","MyoScience, Inc","Industry",0,0,"All","30 Years","70 Years","54","September 2011","January 2012","Effectiveness success","0","0","0","0","0","0","0","0","0"
"3590","NCT01447719","Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07","Alzheimer's Disease",0,"florbetapir F 18","Drug","Avid Radiopharmaceuticals","Industry",0,0,"All","18 Years","N/A","110","March 2010","March 2011","Sensitivity Analysis in All Autopsy Population","0","0","0","92","Sensitivity","95","2-Sided","78","98"
"3591","NCT01450228","Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients","Sleep Initiation and Maintenance Disorders",0,"KI1001","Drug","Kuhnil Pharmaceutical Co., Ltd.","Industry",0,0,"All","55 Years","N/A","170","March 2011","March 2012","QOS in LSEQ","0","0","0","0","0","0","0","0","0"
"3592","NCT01451385","Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain","Osteoarthritis",0,"COV795","Drug","Mallinckrodt","Industry",0,0,"All","18 Years","N/A","376","September 2011","June 2012","Treatment Adverse Events","0","0","0","0","0","0","0","0","0"
"3593","NCT01451541","A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).","Perennial Allergic Rhinitis",0,"Ciclesonide nasal aerosol 37 mcg","Drug","Sunovion","Industry",0,0,"All","6 Years","11 Years","848","October 2011","December 2012","The Change From Baseline in Average Daily Subject-reported AM and PM Reflective Total Nasal Symptom Scores (rTNSS) Averaged Weekly Over the First 6 Weeks of the Double-blind Treatment.","<0.05","Multiple comparisons were adjusted for the primary and key secondary endpoints","Bonferroni-based gatekeeping method","0.59","LS Means with adjusted pvalues","0","0","0","0"
"3594","NCT01451749","Efficacy and Safety Study of Shenwu Capsule","Mild Cognitive Impairment",0,"Shenwu Capsule","Drug","North China Pharmaceutical Group Corporation","Industry",0,0,"All","55 Years","80 Years","324","September 2008","May 2009","Change in Cognitive Scores: Alzheimer Disease Assessment Scale-cognitive. Subscale (ADAS-cog)","0","0","0","0","0","0","0","0","0"
"3595","NCT01452009","Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%","Open Angle Glaucoma",0,"Travoprost Ophthalmic Solution, 0.004% (New Formulation)","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","0","November 2011","December 2011","Efficacy: mean IOP Efficacy as measured by mean IOP","0","0","0","0","0","0","0","0","0"
"3596","NCT01452295","Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion","Acute Liver Failure",0,"ELAD (Extracorporeal Liver Assist System)","Drug","Vital Therapies, Inc.","Industry",0,0,"All","18 Years","65 Years","0","June 2010","September 2012","Gather data","0","0","0","0","0","0","0","0","0"
"3597","NCT01452373","Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women","Vasomotor Symptoms",0,"Placebo","Drug","EndoCeutics Inc.","Industry",0,0,"Female","40 Years","75 Years","238","October 2011","December 2012","Co-primary endpoint: change from baseline to week 12 in frequency of moderate to severe hot flushes.","0","0","0","0","0","0","0","0","0"
"3598","NCT01452698","Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis","Erosive Esophagitis",0,"TAK-438","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","409",NA,"August 2012","Endoscopic Healing Rate Over 8 Weeks of Erosive Esophagitis","0","0","0","0","0","0","0","0","0"
"3599","NCT01452711","Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer","Gastric Ulcer",0,"TAK-438","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","482","November 2011","December 2012","Endoscopic Healing Rate of Gastric Ulcer Over 8 weeks","0","0","0","0","0","0","0","0","0"
"3600","NCT01452919","A Physical Dependence Study in Schizophrenia","Schizophrenia",0,"LY2140023","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","65 Years","150","November 2011","September 2012","Maximum Discontinuation Symptom Checklist-Modified Rickels Total Score","0","0","0","0","0","0","0","0","0"
"3601","NCT01453049","An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients","Diabetes Mellitus, Type 2",0,"rosiglitazone/glimepiride fix dose combination","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","75 Years","86","April 2010","October 2010","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","0","0","0","0","0","0","0","0","0"
"3602","NCT01453348","Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine","Meningococcal Disease",0,"MenACWY-CRM","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","64 Years","252","October 2011","January 2012","Geometric Mean antiHAV and antiHBV Concentrations (GMCs), 28 Days After Primary and Booster Vaccination","0","0","0","0.89","Ratio of GMC","95","2-Sided","0.6","1.32"
"3603","NCT01453400","Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain","Pharyngitis",0,"Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","177","September 2011","April 2012","Time to meaningful pain relief from the Sore Throat Pain Intensity Scale (STPIS) 100 mm visual analog scale","0","0","0","0","0","0","0","0","0"
"3604","NCT01453582","Efficacy and Safety Study of Total Flavonoids of Propolis Dropping Pill to Treat Angina Pectoris","Stable Angina Pectoris",0,"Total Flavonoids of Propolis dropping pill","Drug","Shanghai Greenvalley Pharmaceutical Co., Ltd.","Industry",0,0,"All","35 Years","70 Years","480","December 2011","August 2012","Improvement of total exercise time of treadmill exercise test","0","0","0","0","0","0","0","0","0"
"3605","NCT01453855","Travoprost 3-Month Safety and Efficacy Study","Open-Angle Glaucoma",0,"Travoprost ophthalmic solution, 0.003%","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","1099","November 2011","August 2012","Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)","0","0","0","0","0","0","0","0","0"
"3606","NCT01454063","Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification","Intraocular Lens Replacement",0,"OMS302","Drug","Omeros Corporation","Industry",0,0,"All","18 Years","N/A","405","September 2011","March 2012","Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm) During Surgery","<0.0001","p-value based on the generalized Cochran-Mantel-Haenszel (CMH) test stratified by randomization strata.","Cochran-Mantel-Haenszel","0.577","Mean Difference (Final Values)","95","0","0.475","0.678"
"3607","NCT01454531","An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy","Allergic Rhinoconjunctivitis",0,"AVANZ Phleum pratense","Drug","ALK-Abelló A/S","Industry",0,0,"All","18 Years","65 Years","199","June 2011","March 2012","Frequency of Subjects With Adverse Drug Reactions","0","0","0","0","0","0","0","0","0"
"3608","NCT01455181","A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary","Hypoparathyroidism",0,"NPSP558","Drug","Shire","Industry",0,0,"All","18 Years","85 Years","24","August 2011","May 2012","Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 24, Based on Investigator Prescribed Data.","0","0","0","0","0","0","0","0","0"
"3609","NCT01455597","Evaluate Long-Term Safety and Efficacy WC3011","Vulvovaginal Atrophy",0,"Estradiol Vaginal Gel","Drug","Warner Chilcott","Industry",0,0,"Female","35 Years","N/A","309","October 2011","December 2012","Number of Subjects without Endometrial Hyperplasia or Worse at Visit 7/Final Visit","0","0","0","0","0","0","0","0","0"
"3610","NCT01456169","A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone","Essential Hypertension",0,"Azilsartan medoxomil/placebo","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","507","October 2011","December 2012","Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure","<0.001","0","ANCOVA","-14.7","LS mean difference","95","2-Sided","-17.6","-11.8"
"3611","NCT01456611","Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%","Osteo Arthritis of the Knee",0,"Diclofenac","Drug","Anchen Pharmaceuticals, Inc","Industry",0,0,"All","35 Years","N/A","749","September 2011","April 2012","Mean Change from Baseline in WOMAC Pain Scale","0","0","0","0","0","0","0","0","0"
"3612","NCT01457950","A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab","Osteoporosis, Postmenopausal",0,"denosumab","Drug","GlaxoSmithKline","Industry",0,0,"Female","60 Years","90 Years","135","November 2011","December 2012","Mean Percent Change From Baseline in Lumbar Spine BMD at Month 6","<0.0001","0","ANCOVA","3.21","Mean Difference (Final Values)","95","2-Sided","2.06","4.36"
"3613","NCT01458561","Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery","Intraoperative Bleeding",0,"BioFoam Surgical Matrix","Device","CryoLife, Inc.","Industry",0,0,"All","18 Years","N/A","1","October 2010","September 2012","Time to Achieve Intraoperative Hemostasis Following Open Liver Resection Surgery in Subjects Receiving an Application of BioFoam or a Standard Topical Hemostatic Agent","0","0","0","0","0","0","0","0","0"
"3614","NCT01459081","Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China","Influenza A Virus Infection",0,"Zanamivir","Drug","Jiangsu Simcere Pharmaceutical Co., Ltd.","Industry",0,0,"All","18 Years","65 Years","298","October 2011","December 2012","Time to alleviation of clinically important symptoms","0","0","0","0","0","0","0","0","0"
"3615","NCT01459588","Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease","Dry Eye Syndromes",0,"Carboxymethylcellulose Based Eye Drop Formulation A","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","315","October 2011","February 2012","Change From Baseline in Ocular Surface Disease Index© Questionnaire Score","0","0","0","0","0","0","0","0","0"
"3616","NCT01459887","Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma","Diffuse Large B Cell Lymphoma",0,"CHOP combined with CMAB304","Drug","Shanghai CP Guojian Pharmaceutical Co.,Ltd.","Industry",0,0,"All","18 Years","70 Years","278","September 2006","December 2010","overall response rate","0","0","0","0","0","0","0","0","0"
"3617","NCT01459939","A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip","Pain",0,"Rose-hip powder capsules","Dietary Supplement","Hyben Vital ApS","Industry",0,0,"All","40 Years","N/A","120","October 2011","February 2012","difference in the effect by using WOMAC-pain score.","0","0","0","0","0","0","0","0","0"
"3618","NCT01459952","A Double-blind, Randomised, Parallel Group,Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold","Flu",0,"Rose hip Liquid","Dietary Supplement","Hyben Vital ApS","Industry",0,0,"All","50 Years","N/A","120","November 2011","April 2012","Frequency and duration of colds and flu attacks","0","0","0","0","0","0","0","0","0"
"3619","NCT01460342","Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Hyperplasia",0,"Tadalafil","Drug","Eli Lilly and Company","Industry",0,0,"Male","45 Years","N/A","610","December 2011","October 2012","Change From Baseline in Total Score of International Prostate Symptom Score (IPSS) at 12 Weeks","<0.001","0","Mixed Models Analysis","-1.5","Mean Difference (Final Values)","95","2-Sided","-2.4","-0.6"
"3620","NCT01460511","Evaluation of Efficacy and Safety of E004 in Children With Asthma","Asthma",0,"Epinephrine Inhalation Aerosol","Drug","Amphastar Pharmaceuticals, Inc.","Industry",0,0,"All","4 Years","11 Years","70","October 2011","March 2012","Primary Efficacy Endpoint AUC of FEV1's relative change","0","0","0","0","0","0","0","0","0"
"3621","NCT01461369","Study of Diclofenac Capsules to Treat Osteoarthritis Pain","Osteoarthritis",0,"Diclofenac","Drug","Iroko Pharmaceuticals, LLC","Industry",0,0,"All","40 Years","N/A","305","October 2011","March 2012","Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.","0.0024","0","Mixed Models Analysis","-11.68","Difference in Least Squares Mean","95","2-Sided","-19.17","-4.19"
"3622","NCT01462370","Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)","Dysmenorrhea",0,"Etoricoxib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","N/A","139","November 2011","June 2012","Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose","0.043","A priori threshold for statistical significance = <0.025 (one-sided).","ANOVA","0.89","Difference in LS Means","95","2-Sided","0.03","1.76"
"3623","NCT01462435","Study of Diclofenac Capsules to Treat Pain Following Bunionectomy","Other Acute Postoperative Pain",0,"Diclofenac Test (lower dose)","Drug","Iroko Pharmaceuticals, LLC","Industry",0,0,"All","18 Years","65 Years","428","October 2011","February 2012","The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48), ANCOVA Model.","<0.001","0","ANCOVA","446.946","Difference in Least Squares Mean","95","2-Sided","206.567","687.324"
"3624","NCT01462812","Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine","Migraine Headache",0,"Sumatriptan","Drug","Optinose US Inc.","Industry",0,0,"All","18 Years","65 Years","223","January 2011","June 2012","Headache Relief","0","0","0","0","0","0","0","0","0"
"3625","NCT01462929","Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease (COPD)",0,"Aclidinium bromide","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","414","November 2011","March 2012","Change From Baseline in Normalised Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over the 24-h Period After 6 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"3626","NCT01463683","Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)","Hepatitis B",0,"2XP HEPTAVAX™-II SC","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","35 Years","722","November 2011","November 2012","Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection","0","0","0","7.6","Difference in percentage of participants","95","2-Sided","1.9","13.6"
"3627","NCT01464190","A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients","Chronic Kidney Disease Requiring Chronic Dialysis",0,"PA21 (2.5 g tablet containing 500 mg iron)","Drug","Vifor Inc.","Industry",0,0,"All","18 Years","N/A","659","September 2011","October 2012","Change From Baseline and Levels at Each Time Point for Serum Phosphorus","0","0","0","0","0","0","0","0","0"
"3628","NCT01464372","Electromagnetic Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder","Urinary Incontinence, Urge",0,"Electrical Field Stimulation Device","Device","EMKinetics, Inc","Industry",0,0,"Female","18 Years","N/A","130","October 2011","October 2012","Reduction of incontinence episodes from baseline to follow-up greater for device arm than sham arm","0","0","0","0","0","0","0","0","0"
"3629","NCT01464853","Effect of Enteral Nutrition Support for Critically Ill Patients","Respiratory Distress Syndrome,Adult",0,"Enteral nutrition with fatty acids","Other","Abbott Nutrition","Industry",0,0,"All","18 Years","70 Years","84","April 2010","April 2011","Oxygenation status improvement","0","0","0","0","0","0","0","0","0"
"3630","NCT01464866","Effect of Nutritional Supplementation on Pediatric Burn Patients","Burns",0,"Nutritional Supplement","Other","Abbott Nutrition","Industry",0,0,"All","1 Year","10 Years","116","February 2010","July 2011","prealbumin","0","0","0","0","0","0","0","0","0"
"3631","NCT01466062","Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions","Respiratory Syncytial Virus Infection",0,"Palivizumab","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","N/A","24 Months","28","August 2011","April 2012","Serum Palivizumab Trough Concentrations at Day 1, Day 31, and Day 121","0","0","0","0","0","0","0","0","0"
"3632","NCT01466387","A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults","Meningococcal Disease",0,"Typhoid Vi Polysaccharide Vaccine","Biological","Novartis","Industry",0,0,"All","18 Years","60 Years","552","November 2011","April 2012","Geometric Mean Anti-typhoid Vi Antibody Concentrations","0","0","0","1.14","Ratio of GMC","95","2-Sided","0.81","1.6"
"3633","NCT01467362","Efficacy Emollient on Xerosis in Children With Atopic Dermatitis","Atopic Dermatitis",0,"V0034CR01B","Drug","Pierre Fabre Medicament","Industry",0,0,"All","2 Years","6 Years","251","November 2011","May 2012","Xerosis score: mean evolution over the different time-points of double-blind period","0","0","0","0","0","0","0","0","0"
"3634","NCT01468025","Effectiveness of Theramine on Chronic Back Pain","Low Back Pain",0,"Active Theramine and Active Naproxen","Drug","Targeted Medical Pharma","Industry",0,0,"All","18 Years","75 Years","127","February 2009","July 2009","Roland-Morris Lower Back Pain Scale","0","0","0","0","0","0","0","0","0"
"3635","NCT01468038","A Double-blind Placebo Controlled Trial of Sentra PM, a Medical Food","Sleep Disorder",0,"Trazodone","Drug","Targeted Medical Pharma","Industry",0,0,"All","18 Years","75 Years","111","April 2008","October 2008","Time to fall asleep","0","0","0","0","0","0","0","0","0"
"3636","NCT01469182","A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)","Allergy",0,"SCH 39641","Biological","ALK-Abelló A/S","Industry",0,0,"All","18 Years","N/A","914","November 2011","April 2012","Number of Participants With Treatment-emergent Adverse Events (AEs)","0.005","0","Stratified Miettinen and Nurminen","9.95","Percent Difference","95","2-Sided","3.1","16.7"
"3637","NCT01470053","Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis","Perennial Allergic Rhinitis",0,"mometasone furoate plus azelastine HCl","Drug","Hanlim Pharm. Co., Ltd.","Industry",0,0,"All","12 Years","N/A","347","March 2011","December 2011","change from baseline in rTNSS(reflective Total Nasal Symptom Score)","0","0","0","0","0","0","0","0","0"
"3638","NCT01471171","Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease (COPD)",0,"Aclidinium Bromide","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","112","November 2011","June 2012","Change From Baseline in Endurance Time (Seconds)","0","0","0","0","0","0","0","0","0"
"3639","NCT01473836","A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection","Intra-abdominal Infections",0,"Metronidazole","Drug","Pfizer","Industry",0,0,"All","16 Years","79 Years","38","November 2011","October 2012","Clinical Response: Response Rate (Data Review Committee Assessment)","0","0","0","0","0","0","0","0","0"
"3640","NCT01474499","A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation","Constipation",0,"Glycerine","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","300","September 2011","March 2012","Overall efficacy rate of the enema in treating the symptoms of constipation","0","0","0","0","0","0","0","0","0"
"3641","NCT01475032","Efficacy Study of the Product ""CHF 1535"" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children","Asthma",0,"CHF 1535","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","5 Years","11 Years","638","September 2011","September 2012","pre-dose FEV1 (forced expiratory volume in the first second)","0","0","0","0","0","0","0","0","0"
"3642","NCT01475071","Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses","Actinic Keratoses",0,"Metvix and natural daylight PDT","Drug","Galderma","Industry",0,0,"All","18 Years","N/A","100","March 2012","November 2012","Lesion Response","0.0345","0","paired Student's t statistic","-3.5","Mean Difference (Final Values)","95","1-Sided","-6.8","0"
"3643","NCT01476774","NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain","Disease (or Disorder); Intervertebral Disc, With Myelopathy (Manifestation)",0,"Buprenorphine Transdermal System","Drug","Mundipharma (China) Pharmaceutical Co. Ltd","Industry",0,0,"All","20 Years","80 Years","280","August 2009","June 2010","The primary Efficacy Variable is the change of Pain Intensity (Patients Visual Analogue Scale) from baseline","0","0","0","0","0","0","0","0","0"
"3644","NCT01476904","Safety Study in Adolescent and Adult Patients With Asthma","Asthma",0,"Placebo","Drug","Amphastar Pharmaceuticals, Inc.","Industry",0,0,"All","12 Years","75 Years","208","November 2011","April 2012","Adverse Events","0","0","0","0","0","0","0","0","0"
"3645","NCT01476917","The ATLAST Long-Term Study","Obstructive Sleep Apnea (OSA)",0,"Attune Sleep Apnea System","Device","ApniCure, Inc.","Industry",0,0,"All","18 Years","80 Years","39","November 2011","June 2012","Mean number of hours per night of device use over a 3-month period","0","0","0","0","0","0","0","0","0"
"3646","NCT01477281","Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon","Chronic Venous Insufficiency",0,"Daflon","Drug","Laboratório Teuto Brasileiro S/A","Industry",0,0,"All","18 Years","65 Years","82","February 2012","July 2012","Improves the symptoms of chronic venous insufficiency with classification CEAP 0-3","0","0","0","0","0","0","0","0","0"
"3647","NCT01477723","Evaluation of an Oral Nutritional Supplement in Older Hospitalized Patients","Pneumonia",0,"Experimental Oral Nutritional Supplement","Other","Abbott Nutrition","Industry",0,0,"All","55 Years","N/A","17","October 2011","November 2012","Leg Lean Mass","0","0","0","0","0","0","0","0","0"
"3648","NCT01477853","A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","Type 2 Diabetes Mellitus",0,"Sitagliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","166","October 2011","December 2012","Change From Baseline in Hemoglobin A1C (A1C) at Week 16","0","0","0","0","0","0","0","0","0"
"3649","NCT01479374","Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model","Allergic Conjunctivitis",0,"AL-4943A ophthalmic solution","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","397","January 2012","March 2012","Mean Ocular Itching at Onset of Action","0","0","0","0","0","0","0","0","0"
"3650","NCT01479764","Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)","Surgical Procedures, Elective",0,"Sugammadex","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","154","December 2, 2011","October 26, 2012","Incidence of Residual Neuromuscular Blockade (NMB) as Defined by a Train-of-Four (TOF) Ratio <0.9 at Post Anesthesia Care Unit (PACU) Entry","<0.0001","0","Pearson's Chi-square test","0.0","Odds Ratio (OR)","95","2-Sided","0.000","0.059"
"3651","NCT01481454","Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults","Influenza",0,"Quadrivalent Influenza Vaccine (split virion, inactivated)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","9 Years","60 Years","1701","March 2012","October 2012","Percentage of participants reporting solicited injection site reactions and solicited systemic reactions during the trial","0","0","0","0","0","0","0","0","0"
"3652","NCT01483976","Comparison of Medical Nutritional Supplements","Elderly",0,"Oral medical nutritional supplement","Other","Abbott Nutrition","Industry",0,0,"Male","60 Years","90 Years","27","October 2011","March 2012","Change in protein metabolism","0","0","0","0","0","0","0","0","0"
"3653","NCT01484119","Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis","Seasonal Allergic Rhinitis",0,"ACT-129968","Drug","Actelion","Industry",0,0,"All","12 Years","76 Years","630","December 2011","February 2012","The mean change in Daytime Nasal Symptom Score","0","0","0","0","0","0","0","0","0"
"3654","NCT01484210","Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®","Asthma",0,"Elpenhaler active - Diskus placebo","Drug","Elpen Pharmaceutical Co. Inc.","Industry",0,0,"All","N/A","N/A","28","March 2008","August 2008","The primary variable will be the 12-hour average FEV1 [area under the FEV1 versus time curve divided by 12 (FEV1 AUC0-12/12)].","0","0","0","0","0","0","0","0","0"
"3655","NCT01484652","Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension","Pain, Postoperative",0,"COV795","Drug","Mallinckrodt","Industry",0,0,"All","18 Years","75 Years","329","November 2011","August 2012","SPID48 (Summed Pain Intensity Difference)","0","0","0","0","0","0","0","0","0"
"3656","NCT01485328","Protocol: Phytomedicine-AMARGOL®, Clinical Trial for Efficacy Proof on Therapeutics","Digestive System Disorders",0,"AMARGOL®","Drug","Laboratorio Saude Ltda.","Industry",0,0,"Male","18 Years","45 Years","60","December 2008","April 2009","VAS - visual analogue scale","0","0","0","0","0","0","0","0","0"
"3657","NCT01487083","A Long-Term Study in Schizophrenia","Schizophrenia",0,"Pomaglumetad methionil","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","65 Years","282","December 2011","October 2012","Categorical change from baseline up to 5 years in Barnes Akathisia Scale (BAS)","0","0","0","0","0","0","0","0","0"
"3658","NCT01488071","A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication","Major Depressive Disorder",0,"Vortioxetine (Lu AA21004)","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","75 Years","495","January 2012","December 2012","Change From Baseline in MADRS Total Score at Week 8","0.0018","Under established non-inferiority the p-value is not adjusted.","Mixed Models Analysis","-2.16","Mean Difference (Final Values)","95","2-Sided","-3.51","-0.81"
"3659","NCT01490125","The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease",0,"QVA149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","247","October 2011","August 2012","Total Total Transient Dyspnea Index (TDI) Score After 6 Weeks of Treatment QVA149 Compared to Placebo","0","0","0","0","0","0","0","0","0"
"3660","NCT01491607","Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults","Anthrax",0,"BioThrax","Biological","Emergent BioSolutions","Industry",0,0,"All","18 Years","65 Years","200","November 2011","May 2012","Percentage of Subjects Achieving a TNA Response of a Predefined Threshold Value at Day 63 (5 Weeks Following the Third Vaccination on Day 28).","0","0","0","0","0","0","0","0","0"
"3661","NCT01493089","Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease","Gastroesophageal Reflux",0,"Zegerid","Drug","Norgine","Industry",0,0,"All","18 Years","75 Years","239","April 2011","October 2011","Determination of Median Time to Sustained Partial Response as Defined by Reduction in Likert Severity Scale Used to Assess Pain Associated With Heartburn in the Patient","0.563","0","Regression, Cox","1.097","Hazard Ratio (HR)","95","0","0","0"
"3662","NCT01495468","Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children","Growth Hormone Deficiency",0,"PEG-somatropin","Biological","GeneScience Pharmaceuticals Co., Ltd.","Industry",0,0,"All","8 Years","15 Years","343","March 2007","January 2008","yearly growth velocity","0","0","0","0","0","0","0","0","0"
"3663","NCT01495858","Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain","Pain, Postoperative",0,"Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)","Drug","Bayer","Industry",0,0,"All","12 Years","N/A","267","December 2011","February 2012","Wake Time After Sleep Onset (WASO) Measured by Actigraphy","0.3047","0","ANCOVA","0","0","0","0","0","0"
"3664","NCT01498068","Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C","Genotype 1 Chronic Hepatitis C",0,"Telaprevir","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","70 Years","36","January 2012","April 2012","Number of Participants With Extended Rapid Virologic Response (eRVR)","0","0","0","0","0","0","0","0","0"
"3665","NCT01498224","ReSure Sealant Pivotal Study","Cataract Surgery Incision Leak",0,"ReSure Sealant","Device","Ocular Therapeutix, Inc.","Industry",0,0,"All","22 Years","N/A","488","December 2011","November 2012","Proportion of eyes with any clear corneal incision/suture leakage as determined by positive Seidel test indicating fluid egress within first 7 days after surgery.","0","0","0","0","0","0","0","0","0"
"3666","NCT01499199","A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects","Infection, Human Immunodeficiency Virus",0,"Dolutegravir","Drug","ViiV Healthcare","Industry",0,0,"All","18 Years","N/A","13","January 2012","October 2012","The Ratio of Total and Unbound DTG Concentrations Between Cerebrospinal Fluid (CSF) and Plasma at Week 2 and Week 16","0","0","0","0","0","0","0","0","0"
"3667","NCT01499368","A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients","Erosive Esophagitis",0,"Lafutidine","Drug","Boryung Pharmaceutical Co., Ltd","Industry",0,0,"All","20 Years","75 Years","495","November 2011","November 2012","Healing rate of erosive esophagitis","0","0","0","0","0","0","0","0","0"
"3668","NCT01499667","Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod","Relapsing Remitting Multiple Sclerosis (RRMS)",0,"Fingolimod","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","142","September 2011","November 2012","Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment","0","0","0","0","0","0","0","0","0"
"3669","NCT01500434","The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)","Coronary Artery Disease",0,"PROMUS Element Coronary Stent System","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","102","February 2009","March 2011","Target Lesion Failure (TLF)","<0.0001","0","One-group exact binomial test","3.2","Target Lesion Failure Rate","95","1-Sided","0","7.96"
"3670","NCT01501253","CKD-828 S-Amlodipine Non-Responder Trial","Hypertension",0,"CKD-828 2.5/40mg","Drug","Chong Kun Dang Pharmaceutical","Industry",0,0,"All","18 Years","N/A","187","August 2011","September 2012","Mean Sitting Diastolic Blood Pressure (MSDBP)","0","0","0","0","0","0","0","0","0"
"3671","NCT01501695","Phase III Study of 5LGr to Treat Tic Disorder","Tic Disorder",0,"5LGr","Drug","Tasly Pharmaceuticals, Inc.","Industry",0,0,"All","5 Years","18 Years","603","January 2008","November 2010","Yale Global Tic Severity Scale(YGTSS) score change from baseline at 8 weeks","0","0","0","0","0","0","0","0","0"
"3672","NCT01503736","A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease","Hyperphosphatemia",0,"ferric citrate","Drug","Panion & BF Biotech Inc.","Industry",0,0,"All","18 Years","N/A","183","June 2010","June 2012","Change in serum phosphorus at Day 56 as compared to baseline","0","0","0","0","0","0","0","0","0"
"3673","NCT01503957","Nasya in Allergic Rhinitis","Allergic Rhinitis",0,"Nasya","Device","InQpharm Group","Industry",0,0,"All","18 Years","60 Years","20","January 2012","September 2012","Difference in Total Nasal Symptom Score","0","0","0","0","0","0","0","0","0"
"3674","NCT01505647","Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)","Herpes Zoster",0,"Zoster Vaccine, Live (AMP)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","50 Years","N/A","498","April 2012","July 2012","Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody","<0.001","The threshold for statistical significance is 0.025 (1-sided). The P-value was not adjusted.","Longitudinal regression model","1.08","GMT Ratio","95","2-Sided","0.98","1.20"
"3675","NCT01506154","Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the Shoulder","Bursitis",0,"MRX-7EAT","Drug","MEDRx USA, Inc.","Industry",0,0,"All","14 Years","N/A","210","December 2011","October 2012","Mean of all 16 Current Pain Intensity scores collected on Days 4 through 7 on a 0-10 NPRS.","0","0","0","0","0","0","0","0","0"
"3676","NCT01507727","Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia","Non-hypovolemic Non-acute Hyponatremia",0,"Tolvaptan","Drug","Jiangsu HengRui Medicine Co., Ltd.","Industry",0,0,"All","18 Years","80 Years","240","January 2012","September 2012","The change of average daily Area Under the Curve (AUC) of serum sodium by day 4 and 7 comparing with baseline serum sodium level within the double-blind therapy period","0","0","0","0","0","0","0","0","0"
"3677","NCT01508455","Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age","Anesthesia",0,"Dexmedetomidine","Drug","Hospira, now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","28 Weeks","36 Weeks","6","March 2012","May 2012","Percent of Subjects Requiring Rescue Midazolam for Sedation","0","0","0","0","0","0","0","0","0"
"3678","NCT01509053","Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole","Schizophrenia",0,"Aripiprazole (Abilify®) IM Depot Injection","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","30","January 2012","October 2012","Comparison of Inpatient Psychiatric Hospitalization Rates","0","0","0","0","0","0","0","0","0"
"3679","NCT01509261","Efficacy Study of Ilaprazole to Treat Erosive Esophgitis","Erosive Esophagitis",0,"Ilaprazole","Drug","Il-Yang Pharm. Co., Ltd.","Industry",0,0,"All","18 Years","75 Years","292","July 2010","June 2011","The crude healing rate of EE at Week 8 of treatment as assessed by endoscopy","0","0","0","0","0","0","0","0","0"
"3680","NCT01510327","PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)","Coronary Artery Disease",0,"PROMUS Element Everolimus-Eluting Coronary Stent System","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","22","October 2009","February 2010","Maximum Observed Everolimus Blood Concentration (Cmax)","0","0","0","0","0","0","0","0","0"
"3681","NCT01512004","Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder","Overactive Bladder",0,"Propiverine Hydrochloride","Drug","Lee's Pharmaceutical Limited","Industry",0,0,"All","18 Years","65 Years","324","January 2010","January 2010","Alteration of mean micturition frequency within 24h on the basis of continuous 3-day record","0","0","0","0","0","0","0","0","0"
"3682","NCT01512017","Clinical Study on Veloderm for the Treatment of Split-thickness Skin Graft Donor Sites","Split-thickness Skin Graft Donor Sites",0,"Crystalline cellulose simple occlusive dressing","Device","Lee's Pharmaceutical Limited","Industry",0,0,"All","18 Years","65 Years","96","June 2008","April 2010","Response Criteria","0","0","0","0","0","0","0","0","0"
"3683","NCT01512563","Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent","Biliary Stricture",0,"Biliary stent","Device","Taewoong Medical Co., Ltd.","Industry",0,0,"All","19 Years","90 Years","106","February 2007","February 2010","Accumulative Patency Rate","0","0","0","0","0","0","0","0","0"
"3684","NCT01513161","Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis","Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis",0,"nalfurafine hydrochloride (TRK-820)","Drug","SK Chemicals Co.,Ltd.","Industry",0,0,"All","20 Years","N/A","104","April 2008","October 2009","Change in pruritus degree measured by VAS(Visual Analogue Scale) score","0","0","0","0","0","0","0","0","0"
"3685","NCT01513590","A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","394","January 2012","November 2012","Change From Baseline in HbA1c (Glycosylated Haemoglobin)","0","0","0","0","0","0","0","0","0"
"3686","NCT01514838","A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus","Type II Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","46","January 2012","October 2012","Change in HbA1c from baseline to end of treatment","0","0","0","0","0","0","0","0","0"
"3687","NCT01515657","Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients","Diabetes Mellitus, Type 2",0,"PL2200 Aspirin Capsules","Drug","PLx Pharma","Industry",0,0,"All","21 Years","79 Years","40","January 2012","June 2012","Time to 99% Inhibition of Serum Thromboxane (TxB2)","0","0","0","0","0","0","0","0","0"
"3688","NCT01517178","Multi-national, Safety and Performance Study of New Ostomy Product Compared to Standard Care","Leakage",0,"New ostomy base plate (SS)","Device","Coloplast A/S","Industry",0,0,"All","18 Years","N/A","33","May 2011","June 2011","Degree of Output Under the Base Plate (Leakage).","0","0","0","0","0","0","0","0","0"
"3689","NCT01519713","Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects","Meningitis",0,"Meningococcal polysaccharide diphtheria toxoid conjugate","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","2 Years","55 Years","200","January 2012","September 2012","Number of Participants With Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers of >=1:128 Following Vaccination With One Dose of Menactra® Vaccine","0","0","0","0","0","0","0","0","0"
"3690","NCT01526564","Clinical Study on Acetyl-L-Carnitine","Peripheral Sensory Neuropathy",0,"Acetylcarnitine","Drug","Lee's Pharmaceutical Limited","Industry",0,0,"All","18 Weeks","75 Years","239","August 2008","April 2011","Changes in peripheral sensory neuropathy grades","0","0","0","0","0","0","0","0","0"
"3691","NCT01527019","Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)","Cystitis",0,"Norfloxacin","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","18 Years","N/A","0","October 2012","October 2012","Bacteriological Eradication","0","0","0","0","0","0","0","0","0"
"3692","NCT01528332","Blue Light Device for Pain Therapy","Low Back Pain",0,"Pain Relief Patch","Device","Philips Light and Health","Industry",0,0,"All","18 Years","65 Years","171","February 2012","August 2012","Change From Baseline (Mean of Three Measurements at Screening, Prior to Treatment Visit 1 and Treatment Visit 1 Pretreatment) in the Average Visual Analog Scale (VAS) Pain Intensity Over the 5 Treatment Days","0","0","0","0","0","0","0","0","0"
"3693","NCT01529359","Irritable Bowel Syndrome and Lactibiane Tolerance","Irritable Bowel Syndrome",0,"Lactibiane Tolerance","Dietary Supplement","Pileje","Industry",0,0,"All","18 Years","70 Years","94","April 2010","July 2012","Severity of bowel symptoms according to the Francis Score","0","0","0","0","0","0","0","0","0"
"3694","NCT01529476","Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP","Pneumonia",0,"Levofloxacin","Drug","TaiGen Biotechnology Co., Ltd.","Industry",0,0,"All","18 Years","70 Years","540","April 2011","August 2012","Per subject clinical cure rate","0","0","0","0","0","0","0","0","0"
"3695","NCT01529528","A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients","Type 2 Diabetes Mellitus",0,"Anagliptin","Drug","JW Pharmaceutical","Industry",0,0,"All","19 Years","75 Years","117","May 2011","September 2012","The Change in HbA1c from baseline to week24","0","0","0","0","0","0","0","0","0"
"3696","NCT01529632","Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease",0,"QVA149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","N/A","N/A","193","May 2012","December 2012","Trough Forced Expiratory Volume in 1 Second (FEV1) After 28 Days of Blinded Treatment","0","0","0","0","0","0","0","0","0"
"3697","NCT01529710","Safety and Efficacy of Mirazid for Schistosomiasis Treatment","Schistosoma Hematobium Infection",0,"Myrrh","Drug","Pharco Pharmaceuticals","Industry",0,0,"All","15 Years","30 Years","200","December 2011","September 2012","Compare Mirazid and Praziquantel cure rates for both Schistosoma species, and effect in lowering the intensity of infection for both Schistosoma species.","0","0","0","0","0","0","0","0","0"
"3698","NCT01529944","Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658","Genetic Disorder",0,"somatropin","Drug","Novo Nordisk A/S","Industry",0,0,"All","N/A","N/A","22","September 2008","October 2008","Change in height SDS (Standard Deviation Score) (referenced to normal population)","0","0","0","0","0","0","0","0","0"
"3699","NCT01531335","Hypocaloric Nutrition in Critically Ill Patients","Critically Ill",0,"Hypocaloric hyperproteic nutrition","Dietary Supplement","Lafrancol S.A.","Industry",0,0,"All","18 Years","N/A","80","August 2011","August 2012","SOFA (Sequential Organ Failure Assessment) Score","0","0","0","0","0","0","0","0","0"
"3700","NCT01531517","Study of the Efficacy of PedyPhar® Ointment on the Diabetic Foot Ulcers","Diabetic Foot Ulcer",0,"Royal Jelly and Panthenol (PedyPhar® Ointment)","Drug","European Egyptian Pharmaceutical Industries","Industry",0,0,"All","18 Years","70 Years","47","July 2011","July 2012","Healing of the Ulcer","0","0","0","0","0","0","0","0","0"
"3701","NCT01531699","Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers","Infection Secondary to Surgical Procedure",0,"ALT005 Ophthalmic Prep Solution","Drug","Altacor Ltd.","Industry",0,0,"All","18 Years","N/A","54","February 2012","October 2012","3 log10 reduction in microbial load","0","0","0","0","0","0","0","0","0"
"3702","NCT01531933","Efficacy and Safety of DLBS3233 in Prediabetic Patients","Prediabetic",0,"DLBS3233","Drug","Dexa Medica Group","Industry",0,0,"All","18 Years","60 Years","80","November 2011","July 2012","Change in 15-minute post prandial insulin level","0","0","0","0","0","0","0","0","0"
"3703","NCT01532180","Safety and Efficacy of a Hypoglossal Nerve Implant for the Treatment of Obstructive Sleep Apnea (OSA)","Sleep Apnea Syndromes",0,"aura6000 System","Device","ImThera Medical, Inc.","Industry",0,0,"All","25 Years","70 Years","14","November 2009","December 2011","Mean change in AHI measured through in-lab polysomnography (PSG) compared to baseline.","0","0","0","0","0","0","0","0","0"
"3704","NCT01533259","Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","Acquired Immunodeficiency Syndrome",0,"Stribild","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","48","January 2012","November 2012","Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12","0","0","0","0","0","0","0","0","0"
"3705","NCT01535417","Efficacy and Safety of Shinbaro Capsule","Osteoarthritis",0,"Shinbaro Capsule","Drug","Green Cross Corporation","Industry",0,0,"All","35 Years","80 Years","198","May 2009","December 2009","WOMAC change","0","0","0","0","0","0","0","0","0"
"3706","NCT01535560","Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa","Acute Otitis Externa",0,"AL-60371, 0.3% otic suspension","Drug","Alcon Research","Industry",0,0,"All","6 Months","N/A","589","April 2012","October 2012","Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit","0","0","0","0","0","0","0","0","0"
"3707","NCT01536210","Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)","Mental Disorders",0,"YY-162","Drug","Yuyu Pharma, Inc.","Industry",0,0,"All","6 Years","15 Years","144","December 2011","August 2012","Korea-ADHD Rating scale","0","0","0","0","0","0","0","0","0"
"3708","NCT01536574","Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528","Parkinson Disease",0,"Requip PR","Drug","GlaxoSmithKline","Industry",0,0,"All","30 Years","N/A","295","September 2010","March 2012","Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase)","0","0","0","0","0","0","0","0","0"
"3709","NCT01537081","Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections","Acute Upper Respiratory Tract Infection",0,"Mucinex","Drug","Reckitt Benckiser LLC","Industry",0,0,"All","12 Years","N/A","2810","September 2011","March 2012","Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 4","0","0","0","0","0","0","0","0","0"
"3710","NCT01537718","Evaluation of the Performances of the Sleep Disordered Breathing Monitoring Function in Pacemaker","Bradycardia",0,"REPLY 200","Device","LivaNova","Industry",0,0,"All","18 Years","N/A","40","March 2012","November 2012","Event-based sensitivity of breathing troubles","0","0","0","0","0","0","0","0","0"
"3711","NCT01539538","A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain","Post-Operative Pain",0,"Sufentanil NanoTab PCA System/15 mcg","Drug","AcelRx Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","357","April 2012","December 2012","Patient Global Satisfaction","<0.001","0","one-sided, z-test","12.90","difference in proportion","95","2-Sided","3.69","22.11"
"3712","NCT01541371","A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia","Schizophrenia",0,"Paliperidone ER","Drug","Xian-Janssen Pharmaceutical Ltd.","Industry",0,0,"All","18 Years","65 Years","405","July 2008","September 2009","Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12","0","0","0","0","0","0","0","0","0"
"3713","NCT01541930","An Open, Uncontrolled Study of GK567 in the Deodorization of Malodorous Fungating Neoplastic Tumours","Malodorous Infected Cutaneous Ulcer",0,"GK567","Drug","Galderma R&D","Industry",0,0,"All","20 Years","N/A","21","April 2012","December 2012","The Success Rate","0","0","0","0","0","0","0","0","0"
"3714","NCT01542788","Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon","Chronic Hepatitis C",0,"SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","278","March 2012","November 2012","Percentage of Participants Achieving SVR12","< 0.001","P-value is from the Cochran-Mantel-Haenszel test stratified by presence or absence of cirrhosis for the superiority of SOF+RBV over placebo.","Cochran-Mantel-Haenszel","77.3","Proportion difference","95","2-Sided","71.0","83.6"
"3715","NCT01543685","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy","Other Acute Postoperative Pain",0,"Indomethacin","Drug","Iroko Pharmaceuticals, LLC","Industry",0,0,"All","18 Years","65 Years","462","February 2012","June 2012","The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48)","<0.001","0","ANCOVA","441.8","Difference in Least Squares Mean","95","2-Sided","187.1","696.5"
"3716","NCT01551056","A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)","Allergic Conjunctivitis",0,"AC-170 0.24%","Drug","Aciex Therapeutics, Inc.","Industry",0,0,"All","10 Years","N/A","91","March 2012","June 2012","Ocular Itching at defined time points up to 2 weeks","0","0","0","0","0","0","0","0","0"
"3717","NCT01552343","Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary","Nocturia",0,"Desmopressin","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","56","March 2012","May 2012","The Pearson Correlation Coefficient Between Change From Baseline to Month 1 in Number of Nocturnal Voids and Change From Baseline to Month 1 in Nocturia Impact (NI) Diary Total Score","0.0187","The a priori threshold for statistical significance was 0.05.","t-test, 2 sided","0","0","0","0","0","0"
"3718","NCT01552798","Efficacy of a Single Dose of Aspirin vs. Acetaminophen in Tension Type Headache","Headache",0,"Acetylsalicylic acid (Aspirin, BAY1019036)","Drug","Bayer","Industry",0,0,"All","18 Years","65 Years","9","March 2012","June 2012","Time to meaningful pain relief (defined as the time when the subject indicates pain relief that is meaningful to the subject)","0","0","0","0","0","0","0","0","0"
"3719","NCT01554826","Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)","Influenza",0,"Influenza Split Vaccine","Biological","Hualan Biological Engineering, Inc.","Industry",0,0,"All","6 Months","36 Months","810","March 2009","May 2009","Number of subjects with adverse reactions as a measure of safety study","0","0","0","0","0","0","0","0","0"
"3720","NCT01559701","Long-term Safety of PF-00345439 (Oxycodone)","Pain",0,"PF-00345439","Drug","Pain Therapeutics","Industry",0,0,"All","18 Years","75 Years","823","April 2006","February 2008","Number and Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"3721","NCT01561521","An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis","Allergic Conjunctivitis",0,"AKF-1","Drug","Akorn, Inc.","Industry",0,0,"All","10 Years","N/A","90","March 2012","April 2012","Ocular Itching at defined time points up to 2 weeks","0","0","0","0","0","0","0","0","0"
"3722","NCT01561898","A Long-Term Study of JNS007ER in Patients With Schizophrenia","Schizophrenia",0,"Paliperidone extended-release (JNS007ER)","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","228","June 2006","October 2008","Incidence of Adverse Events","0","0","0","0","0","0","0","0","0"
"3723","NCT01562080","Combined Effects of Bioactive Compounds in Lipid Profile","Hyperlipidemia",0,"Armolipid Plus","Dietary Supplement","Rottapharm Spain","Industry",0,0,"All","18 Years","N/A","118","January 2012","June 2012","investigate whether the addition of Armolipid Plus ® decreases by 20% LDL-C levels compared to baseline in patients with initial levels of LDL-C ≥ 130 mg / dL.","0","0","0","0","0","0","0","0","0"
"3724","NCT01562717","Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries","Pain",0,"Ibuprofen","Drug","Orion Corporation, Orion Pharma","Industry",0,0,"All","18 Years","45 Years","62","February 2012","October 2012","Efficacy: VAS","0","0","0","0","0","0","0","0","0"
"3725","NCT01563081","Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics","Rhinitis",0,"Levocetirizine","Drug","GlaxoSmithKline","Industry",0,0,"All","6 Months","23 Months","60","April 2012","August 2012","Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"3726","NCT01563289","Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries","Pain",0,"Ibuprofen","Drug","Orion Corporation, Orion Pharma","Industry",0,0,"All","18 Years","45 Years","62","February 2012","July 2012","Efficacy: visual analog scale (VAS)","0","0","0","0","0","0","0","0","0"
"3727","NCT01566149","Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)","Asthma",0,"Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","49","March 2012","September 2012","Number of Participants With At Least One Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"3728","NCT01567995","Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety","Dermatitis, Eczematous",0,"Clobetasone Butyrate 0.05% Cream","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","65 Years","240","February 2008","January 2009","Change from baseline Eczema Area and Severity Index (EASI)","0","0","0","0","0","0","0","0","0"
"3729","NCT01568112","Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate","Healthy",0,"BG00012 (dimethyl fumarate)","Drug","Biogen","Industry",0,0,"All","25 Years","55 Years","173","April 2012","October 2012","Percentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Flushing Severity Scale (MFSS)","0","0","0","-9","Difference in percentage","95","2-Sided","-30.8","12.9"
"3730","NCT01568190","An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy","Allergic Rhinitis Due to Dust Mite",0,"AVANZ MITE","Biological","ALK-Abelló A/S","Industry",0,0,"All","18 Years","65 Years","102","December 2011","July 2012","Frequency of patients with adverse reactions.","0","0","0","0","0","0","0","0","0"
"3731","NCT01568892","Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir","Infection, Human Immunodeficiency Virus",0,"dolutegravir 50 mg twice daily","Drug","ViiV Healthcare","Industry",0,0,"All","18 Years","N/A","30","April 2012","October 2012","Mean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8","<0.001","0","ANCOVA","-1.16","Mean Difference (Final Values)","95","2-Sided","-1.52","-0.80"
"3732","NCT01569841","A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","75 Years","24","April 2012","November 2012","Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL)","0","0","0","0","0","0","0","0","0"
"3733","NCT01570049","Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma","Non-Hodgkin Lymphoma by Clinical Course",0,"Bendamustine","Drug","Shandong Lanjin Pharmaceuticals Co.,Ltd","Industry",0,0,"All","18 Years","75 Years","100","April 2010","September 2012","Overall response rate (ORR=CR+PR) of bendamustine hydrochloride in patients who are refractory to rituximab therapy.","0","0","0","0","0","0","0","0","0"
"3734","NCT01572740","Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes","Diabetes",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","20 Years","N/A","257","April 2012","November 2012","Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16","<0.0001","0","ANCOVA","-1.30","Estimated treatment difference, Mean","95","0","-1.47","-1.13"
"3735","NCT01573871","Tolerance and Compliance of Infants Fed an Hydrolyzed Infant Formula","Infant",0,"Experimental Hydrolyzed infant formula","Other","Abbott Nutrition","Industry",0,0,"All","N/A","180 Days","25","February 2012","September 2012","Weight maintenance","0","0","0","0","0","0","0","0","0"
"3736","NCT01574612","Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old","Herpes Labialis",0,"acyclovir/hydrocortisone cream","Drug","Meda Pharmaceuticals","Industry",0,0,"All","6 Years","11 Years","54","March 2012","December 2012","Reporting of Adverse Events","0","0","0","0","0","0","0","0","0"
"3737","NCT01576419","Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients","Osteoarthritis of the Knee",0,"PG201 tablet","Drug","PMG Pharm Co., Ltd","Industry",0,0,"All","40 Years","80 Years","309","January 2010","March 2011","100mm Pain VAS reduction","0","0","0","0","0","0","0","0","0"
"3738","NCT01576809","Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)","Upper Respiratory Infections",0,"IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin","Drug","Novartis","Industry",0,0,"All","12 Years","N/A","51","March 2012","May 2012","Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Per 30 ml Syrup","0","0","0","0","0","0","0","0","0"
"3739","NCT01577082","Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","Asthma",0,"CHF1535 200/6 µg","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","18 Years","N/A","542","April 2012","November 2012","Pre-dose morning PEF","0","0","0","0","0","0","0","0","0"
"3740","NCT01577238","A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis","Bacterial Vaginosis",0,"1% SPL7013 Gel","Drug","Starpharma Pty Ltd","Industry",0,0,"Female","12 Years","N/A","250","March 2012","December 2012","Number of women with Clinical Cure at the Test of Cure visit (TOC)","0","0","0","0","0","0","0","0","0"
"3741","NCT01577537","A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis","Bacterial Vaginosis",0,"1% SPL7013 Gel","Drug","Starpharma Pty Ltd","Industry",0,0,"Female","12 Years","N/A","251","March 2012","December 2012","Number of women with Clinical Cure at the Test of Cure visit (TOC)","0","0","0","0","0","0","0","0","0"
"3742","NCT01577667","Intellivent Versus Conventional Ventilation","Respiratory Failure",0,"Intellivent; automatic mode implemented on a S1 ventilator","Device","Hamilton Medical AG","Industry",0,0,"All","18 Years","90 Years","80","February 2011","April 2012","Safety","0","0","0","0","0","0","0","0","0"
"3743","NCT01578785","An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)","Relapsing-Remitting Multiple Sclerosis",0,"Glatiramer Acetate","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","18 Years","55 Years","178","March 2012","October 2012","The Annualized Relapse Rate During the Placebo Controlled Period","0","0","0","0","0","0","0","0","0"
"3744","NCT01579097","Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation","Nutrition Support",0,"Oliclinomel N4","Other","Baxter Healthcare Corporation","Industry",0,0,"All","18 Years","80 Years","458","December 2011","November 2012","Serum Prealbumin","0","0","0","0","0","0","0","0","0"
"3745","NCT01579565","Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification","Intraocular Lens Replacement",0,"OMS302","Drug","Omeros Corporation","Industry",0,0,"All","18 Years","N/A","416","April 2012","November 2012","Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter (mm) During Surgery","0.0001","p-value based on the generalized Cochran-Mantel-Haenszel (CMH) test stratified by the randomization strata.","Cochran-Mantel-Haenszel","0.590","Mean Difference (Final Values)","95","0","0.494","0.686"
"3746","NCT01580553","The Clinical Study of the Efficacy and Safety of L-Carnitine Injection in Treatment of Heart Failure","Heart Failure,",0,"Levocarnitine Injection","Drug","Lee's Pharmaceutical Limited","Industry",0,0,"All","18 Years","N/A","268","January 2011","March 2012","NYHA cardiac functional grading","0","0","0","0","0","0","0","0","0"
"3747","NCT01581320","Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis","Postmenopausal Women With Osteoporosis",0,"Test group","Drug","Alvogen Korea","Industry",0,0,"Female","40 Years","N/A","201","December 2011","September 2012","A ratio of subject whose 25 OHD concentration is less than 15ng/mL","0","0","0","0","0","0","0","0","0"
"3748","NCT01582594","A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection","Hepatitis C",0,NA,NA,"Johnson & Johnson Medical, China","Industry",0,0,"All","1 Year","90 Years","795","February 2012","August 2012","To evaluate the accuracy of the CHIRON® RIBA® HCV 3.0","0","0","0","0","0","0","0","0","0"
"3749","NCT01585220","Efficacy and Safety Study of Neuramis in Correction of Nasolabial Fold","Nasolabial Fold",0,"HA filler","Device","Medy-Tox","Industry",0,0,"All","30 Years","75 Years","69","February 2012","August 2012","WSRS","0","0","0","0","0","0","0","0","0"
"3750","NCT01586962","Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI","Upper Respiratory Infections",0,"IFF flavor 316 282, Paracetamol, Pseudoephedrine","Drug","Novartis","Industry",0,0,"All","12 Years","N/A","56","May 2012","May 2012","Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Pseudoephedrine 30 mg Per 30 ml Syrup","0","0","0","0","0","0","0","0","0"
"3751","NCT01590368","A Comparative Wear Test of Two Adhesives on the Unilect ™ Biotab Short Term Monitoring Electrode","Healthy Subjects",0,"Marketed electrode","Device","ConvaTec Inc.","Industry",0,0,"All","N/A","N/A","20","June 2012","June 2012","Product Performance : Remain in place","0","0","0","0","0","0","0","0","0"
"3752","NCT01591434","Study to Evaluate the Performance of AQUACEL® Extra™ in Venous Leg Ulcers","Leg Ulcer",0,"AQUACEL®","Device","ConvaTec Inc.","Industry",0,0,"All","18 Years","N/A","65","May 2012","September 2012","Wear Time","0","0","0","0","0","0","0","0","0"
"3753","NCT01592851","Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity","Dentine Hypersensitivity",0,"Stannous Fluoride","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","65 Years","113","April 2012","May 2012","Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Day 14","<0.0001","No adjustment made for multiple comparisons, as primary comparison was pre-specified.","ANCOVA","-0.83","Adjusted Mean Difference","95","2-Sided","-1.03","-0.63"
"3754","NCT01592864","The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity","Dentine Hypersensitivity",0,"Stannous Fluoride","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","65 Years","120","March 2012","May 2012","Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 8","<0.0001","No adjustment made for multiple comparisons, as primary comparison was pre-specified.","ANCOVA","-0.4","Adjusted Mean Difference","95","2-Sided","-0.6","-0.2"
"3755","NCT01597570","Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable VCD and Perclose® ProGlide SMC System","The Patients Who Needed Hemostasis at the Puncture Site of Common Femoral Artety(CFA) Caused by Femoral Angiogram or Intervention After the Catheter Removal",0,"Vascular Closure Device","Device","Taewoong Medical Co., Ltd.","Industry",0,0,"All","20 Years","85 Years","116","May 2012","November 2012","TTH; Time to hemostasis","0","0","0","0","0","0","0","0","0"
"3756","NCT01600365","Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus","Conjunctivitis",0,"Ophthalmic gel (placebo)","Drug","Adapt Produtos Oftalmológicos Ltda.","Industry",0,0,"All","18 Years","65 Years","22","May 2012","June 2012","time to regression of the ocular symptomatology","0","0","0","0","0","0","0","0","0"
"3757","NCT01603030","Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation","Eye Infection/Inflammation Other",0,"moxifloxacin 0,5% + prednisolone 1%","Drug","Adapt Produtos Oftalmológicos Ltda.","Industry",0,0,"All","18 Years","50 Years","66","June 2012","August 2012","Day 15 Evaluation of Anterior Chamber","0","0","0","0","0","0","0","0","0"
"3758","NCT01603056","Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis","Allergic Rhinitis",0,"Pangramin SLIT HDM mix.","Biological","ALK-Abelló A/S","Industry",0,0,"All","5 Years","55 Years","617","October 2009","February 2012","The Change From Baseline in Rhinoconjunctivitis Symptoms Score at 11 - 12 Months Between the Actively Treated Patients and the Placebo Treated.","0.743","0","t-test, 2 sided","0","0","0","0","0","0"
"3759","NCT01606228","A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia","Schizophrenia",0,"Paliperidone ER","Drug","Janssen Pharmaceutica","Industry",0,0,"All","18 Years","65 Years","188","December 2007","December 2008","The Proportion of Patients Improving 20% in Total Positive and Negative Syndrome Scale (PANSS) at Endpoint (Day 90)","0","0","0","0","0","0","0","0","0"
"3760","NCT01607411","A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model","Dental Caries",0,"Fluoride","Drug","GlaxoSmithKline","Industry",0,0,"All","11 Years","14 Years","55","February 2012","May 2012","Percentage Surface Microhardness Recovery of Test Dentifrices Relative to Placebo Dentifrice","<0.0001","No adjustment was required for multiple comparisons as the primary comparison was pre-specified.","ANOVA","5.59","Adjusted Mean Difference","95","2-Sided","3.60","7.58"
"3761","NCT01608815","Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects","Salmonella Infections",0,"Typhoid Vi polysaccharide","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","2 Years","N/A","200","May 2012","September 2012","Number of Participants With At Least a 4-Fold Rise in Vi Antibody Titers Following Vaccination With a Typhoid Vi Polysaccharide Vaccine","0","0","0","0","0","0","0","0","0"
"3762","NCT01617889","Healthy Term Infants Fed Milk-Based Formulas","Healthy Term Infant",0,"Experimental powdered milk-based infant formula with an alternate fat blend","Other","Abbott Nutrition","Industry",0,0,"All","53 Days","115 Days","17","March 2011","August 2012","calcium absorption","0","0","0","0","0","0","0","0","0"
"3763","NCT01621399","Safety and Efficacy Study to Treat Bacterial Vaginosis","Bacterial Vaginosis",0,"Product 55394","Drug","Medicis Global Service Corporation","Industry",0,0,"Female","18 Years","N/A","651","May 2012","October 2012","Clinical Cure","0","0","0","0","0","0","0","0","0"
"3764","NCT01626118","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy","Other Acute Postoperative Pain",0,"Indomethacin","Drug","Iroko Pharmaceuticals, LLC","Industry",0,0,"All","18 Years","65 Years","373","May 2012","August 2012","The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48)","0.034","0","ANCOVA","317.612","Difference in Least Squares Mean","95","2-Sided","23.297","611.926"
"3765","NCT01627327","Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease","Pulmonary Disease, Chronic Obstructive",0,"fluticasone furoate/vilanterol 100/25mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","623","April 2012","December 2012","Change From Baseline Trough in 24-hour Weighted Mean FEV1 on Treatment Day 84","0.201","0","ANCOVA","0.022","Median Difference (Net)","95","2-Sided","-0.012","0.055"
"3766","NCT01628926","A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients","Parkinson's Disease",0,"SPM 962","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","30 Years","79 Years","420","June 2009","May 2011","Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score","0","0","0","0","0","0","0","0","0"
"3767","NCT01628965","A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients","Parkinson's Disease",0,"SPM 962","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","N/A","N/A","143","January 2008","October 2010","Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters","0","0","0","0","0","0","0","0","0"
"3768","NCT01631110","Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains","Influenza",0,"Inflexal V","Biological","Crucell Holland BV","Industry",0,0,"All","18 Years","N/A","110","July 2012","August 2012","Seroprotection","0","0","0","0","0","0","0","0","0"
"3769","NCT01631825","A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients","Parkinson's Disease",0,"SPM 962","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","N/A","N/A","321","October 2009","June 2012","Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters","0","0","0","0","0","0","0","0","0"
"3770","NCT01633749","Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season","Prophylaxis of Influenza",0,"Trivalent influenza subunit vaccine Influvac","Biological","Abbott Biologicals","Industry",0,0,"All","18 Years","N/A","120","July 2012","July 2012","Antihemagglutinin antibody titers and the derived parameters seroprotection, seroconversion and mean fold increase","0","0","0","0","0","0","0","0","0"
"3771","NCT01634282","Along-term Study of OPC-262 in Patients With Type 2 Diabetes","Diabetes, Type 2",0,"OPC-262","Drug","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","20 Years","74 Years","222","August 2009","June 2011","Change in HBA1c form baseline","0","0","0","0","0","0","0","0","0"
"3772","NCT01635881","Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter","Coronary Artery Disease",0,"Emerge™ 1.20 mm PTCA Dilatation Catheter","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","60","July 2012","December 2012","Device Procedural Success","0","0","0","0","0","0","0","0","0"
"3773","NCT01636245","Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine","Hand, Foot and Mouth Disease",0,"three consecutive lots of EV71 vaccine","Biological","Sinovac Biotech Co., Ltd","Industry",0,0,"All","6 Months","5 Years","1400","July 2012","September 2012","The GMT of anti-EV71 antibodies in serum 28 days after the two-dose regimen","0","0","0","0","0","0","0","0","0"
"3774","NCT01639638","Recurrent and Nonrecurrent Condyloma Treatment","Recurrent Condyloma",0,"PROAPOPTOTIC PEPTIDE CIGB 300","Drug","Laboratorio Elea S.A.C.I.F. y A.","Industry",0,0,"Female","18 Years","65 Years","132","June 2010","December 2012","Number of patients with complete response of target lesion in each study group","0","0","0","0","0","0","0","0","0"
"3775","NCT01640314","Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above","Influenza",0,"Cell derived subunit trivalent nonadjuvanted vaccine","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","N/A","126","July 2012","August 2012","Percentages of Subjects With Seroconversion or Significant Increase in HI Titer Against Each of Three Vaccine Strains After One Vaccination of TIVc","0","0","0","0","0","0","0","0","0"
"3776","NCT01640327","Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above","Human",0,"Trivalent influenza virus vaccine (TIVf)","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","N/A","126","July 2012","August 2012","Percentage of Subjects With Seroconversion or Significant Increase in HI Titer Against Each of Three Vaccine Strains After One Vaccination of TIVf","0","0","0","0","0","0","0","0","0"
"3777","NCT01641237","Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions","Enamel Erosion",0,"sodium fluoride","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","65 Years","72","March 2012","May 2012","Percentage Surface Microhardness Recovery (%SMHR) Dose Response Relationship","<0.0001","0","ANOVA","0","0","0","0","0","0"
"3778","NCT01641770","Oral Nutritional Supplementation in Hospital Patients","Malnutrition",0,"Nutritional beverage 10003RF","Other","Abbott Nutrition","Industry",0,0,"All","18 Years","N/A","212","October 2010","July 2011","Changes from baseline in Body weight","0","0","0","0","0","0","0","0","0"
"3779","NCT01643967","Clinical Trial to Evaluate the Efficacy and Safety of the Use of Ozone Versus Sunflower Oil in Treating Diabetic Foot","Diabetes Mellitus",0,"sunflower oil","Other","Philozon Geradores de Ozonio LTDA","Industry",0,0,"All","18 Years","N/A","100","June 2012","December 2012","Evaluate the efficacy and safety of ozone released by the device Philozon Medplus in the treatment of patients with diabetic foot.","0","0","0","0","0","0","0","0","0"
"3780","NCT01646398","A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older","Pneumococcal Vaccines",0,"13-valent pneumococcal conjugate vaccine","Biological","Pfizer","Industry",0,0,"All","65 Years","N/A","764","June 2012","October 2012","Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes 1 Month After Vaccination","0","0","0","1.3","GMT Ratio","95","2-Sided","0.99","1.75"
"3781","NCT01654250","NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder",0,"NWP09","Drug","Pfizer","Industry",0,0,"All","6 Years","12 Years","90","July 2012","October 2012","Swanson, Kotin, Agler, M-Flynn, and Pelham Rating Scale (SKAMP)-Combined Scores-Average of All Post-Dose Time-Points","<0.001","0","Mixed Models Analysis","-7.0","Least Square(LS) Mean Difference","95","2-Sided","-10.9","-3.1"
"3782","NCT01658267","Compliance With Dietary Recommendations in Children at Risk for Undernutrition","Children",0,"nutritional supplement","Other","Abbott Nutrition","Industry",0,0,"All","36 Months","48 Months","200","October 2011","October 2012","Compliance with recommendation of a nutritional supplement consumption","0","0","0","0","0","0","0","0","0"
"3783","NCT01659853","Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea","Erythema",0,"CD07805/47 gel 0.5%/CD07805/47 Vehicle","Drug","Galderma Laboratories, L.P.","Industry",0,0,"All","18 Years","N/A","70","September 2012","December 2012","Composite Success","0","0","0","0","0","0","0","0","0"
"3784","NCT01660893","Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth","Anesthesia",0,"Tetracaine HCl 3% and oxymetazoline HCl 0.05%","Drug","St. Renatus, LLC","Industry",0,0,"All","18 Years","N/A","26","August 2012","September 2012","Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic (yes/no).","0","0","0","0","0","0","0","0","0"
"3785","NCT01662440","Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects","Rabies",0,"Rabies","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","65 Years","661","August 2012","December 2012","Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 7 Days After Last Active Vaccination","0","0","0","0","Difference in percentages of subjects","97.5","2-Sided","-2.8","2.8"
"3786","NCT01662648","Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia","Schizophrenia",0,"Paliperidone ER","Drug","Janssen Pharmaceutica","Industry",0,0,"All","18 Years","N/A","1117","June 2007","April 2008","Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26","0","0","0","0","0","0","0","0","0"
"3787","NCT01665170","Pilot Study on the Efficacy of Pascoflair in an Acute Stressful Situation (TSST)","Healthy",0,"Passiflora incarnata","Drug","Pascoe Pharmazeutische Praeparate GmbH","Industry",0,0,"All","25 Years","45 Years","60","May 2012","August 2012","VAS Insecurity (During)","0","0","0","0","0","0","0","0","0"
"3788","NCT01672827","Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images","Alzheimer's Disease",0,"[18F]Flutemetamol","Drug","GE Healthcare","Industry",0,0,"All","18 Years","N/A","276","July 2012","August 2012","Summary of Sensitivity of the Blinded Visual PET Image Interpretations Without Anatomic Images.","0","0","0","0","0","0","0","0","0"
"3789","NCT01673620","A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)","Allergic Rhinitis",0,"Montelukast 10 mg/loratadine 10 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","15 Years","65 Years","69","July 2012","October 2012","Number of Participants Experiencing at Least One Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"3790","NCT01673659","A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 Mcg/Actuation Compared With Nasonex® Nasal Spray 50 Mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)","Seasonal Allergic Rhinitis",0,"Mometasone furoate","Drug","Perrigo Company","Industry",0,0,"All","12 Years","65 Years","1220","August 2012","October 2012","Mean Change from Baseline for mean reflective Total Nasal Symptom Score (rTNSS)","0","0","0","0","0","0","0","0","0"
"3791","NCT01675622","Immediate-Release Oxycodone Capsules Study in Cancer Pain","Cancer",0,"Oxycodone","Drug","Mundipharma (China) Pharmaceutical Co. Ltd","Industry",0,0,"All","18 Years","80 Years","240","December 2010","June 2012","Numerical Rating Scale (NRS)","0","0","0","0","0","0","0","0","0"
"3792","NCT01675635","OxyNorm Capsules in Post-Operative Pain Study","Postoperative Pain",0,"OxyNorm Capsules","Drug","Mundipharma (China) Pharmaceutical Co. Ltd","Industry",0,0,"All","18 Years","65 Years","240","July 2011","June 2012","Resting Visual Analogue Scale (VAS) at 6h after administration of first dose","0","0","0","0","0","0","0","0","0"
"3793","NCT01676987","Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma","Asthma",0,"Fixed combination of budesonide and formoterol","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"All","18 Years","77 Years","181","April 2009","September 2010","Evaluation of the efficacy and safety of a fixed-dose, single capsule budesonide-formoterol combination in comparison with budesonide alone in patients with uncontrolled asthma","0","0","0","0","0","0","0","0","0"
"3794","NCT01685242","A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","Allergic Conjunctivitis",0,"AC-170 0.24%","Drug","Aciex Therapeutics, Inc.","Industry",0,0,"All","10 Years","N/A","100","September 2012","November 2012","Ocular Itching at defined time points up to 2 weeks","0","0","0","0","0","0","0","0","0"
"3795","NCT01686646","Effects of Two Doses of a Common Cold Treatment on Alertness","Common Cold",0,"paracetamol + caffeine","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","240","November 2011","November 2012","Change From Baseline in Number of Accurate Responses to Rapid Visual Information Processing (RVIP) Cognitive Test","0.0248","A hierarchical testing procedure was used such that p-values were only presented if the preceding treatment comparison was statistically significant (p<0.05).","ANCOVA","3.5","LS Mean DIfference","95","2-Sided","0.4","6.5"
"3796","NCT01695902","Therapeutic Equivalence Trial of Two Hormonal-IUDs in Patients With Heavy Menstrual Bleeding","Heavy Menstrual Bleeding",0,"Levosert-20","Drug","Uteron Pharma S.A.","Industry",0,0,"Female","18 Years","N/A","280","December 2007","January 2010","Mean change from baseline to Year 1 in the mean menstrual blood loss volume measured using the modified Wyatt pictogram in the two treatment groups","0","0","0","0","0","0","0","0","0"
"3797","NCT01702532","Nicotine Mouth Film for Craving Relief.","Smoking Cessation",0,"Nicotine","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","320","September 2012","December 2012","The Change From Pre-dose Post-provocation in Craving Score at 50 Seconds","0.0141","The comparison between treatments was conducted in a hierarchical order; consequently no adjustment of the significance level (5%) for multiplicity was needed.","ANCOVA","-4.90","LS Means Difference","95","2-Sided","-8.80","-0.99"
"3798","NCT01710007","Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia","Hypercholesterolemia",0,"1PC002","Drug","Orient Pharma Co., Ltd.","Industry",0,0,"All","20 Years","80 Years","202","November 2011","September 2012","LDL-C","0","0","0","0","0","0","0","0","0"
"3799","NCT01722604","Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","Glaucoma",0,"brinzolamide 1% ophthalmic suspension","Drug","InnoPharma Inc.","Industry",0,0,"All","18 Years","N/A","258","January 2012","September 2012","Intraocular pressure (IOP) at baseline (Eligibility Visit 2) weeks and after treatment.","0","0","0","0","0","0","0","0","0"
"3800","NCT01724008","The Efficacy of a Dentifrice in Providing Relief From Dentinal Hypersensitivity","Dentine Hypersensitivity",0,"Stannous Fluoride","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","65 Years","120","March 2012","June 2012","Schiff Sensitivity Score","0","0","0","0","0","0","0","0","0"
"3801","NCT01728285","Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis","Allergic Rhinitis",0,"Electronic compliance device (Memozax®)","Device","ALK-Abelló A/S","Industry",0,0,"All","18 Years","65 Years","261","March 2007","June 2009","To evaluate if compliance with grass Allergy Immunotherapy Tablet can be increased by providing an electronic compliance device (CED) (Memozax; a tablet-container with a programmable daily acoustic alarm)","0","0","0","0","0","0","0","0","0"
"3802","NCT01731249","Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis","Hypersensitivity",0,"Placebo","Biological","Stallergenes","Industry",0,0,"All","18 Years","65 Years","574","November 2010","July 2012","Average Adjusted Symptom Score","0","0","0","0","0","0","0","0","0"
"3803","NCT01733966","A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults","Diverticular Sigmoïditis",0,"Secnidazole, ciprofloxacine","Drug","Quanta Medical","Industry",0,0,"All","18 Years","75 Years","100","May 2010","March 2012","to compare efficacy of an association of Secnidazol(2g)-Ciprofloxacin(1g) (during 3 days) versus 3g of Amoxicillin-Clavulanic Acid during 10 days for clinical and biological cure","0","0","0","0","0","0","0","0","0"
"3804","NCT01735045","LSH Silicone Hydrogel Soft Hydrophilic Contact Lens for Daily Wear","Myopia",0,"Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens","Device","Szabocsik and Associates, Inc.","Industry",0,0,"All","18 Years","N/A","76","May 2010","December 2011","Visual Acuity","0","0","0","0","0","0","0","0","0"
"3805","NCT01736150","Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis","Chronic Kidney Disease",0,"Placebo","Drug","Genzyme, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","205","March 2010","September 2010","Change from baseline to Visit 6/Early Termination (ET) in serum phosphorous.","0","0","0","0","0","0","0","0","0"
"3806","NCT01736514","A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout","Gout",0,"febuxostat","Drug","Astellas Pharma Taiwan, Inc.","Industry",0,0,"All","20 Years","65 Years","109","March 2011","February 2012","Proportion of subjects whose serum urate level decreases to < 6.0 mg/dL","0","0","0","0","0","0","0","0","0"
"3807","NCT01740089","Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C","Hepatitis",0,"Algeron","Drug","Biocad","Industry",0,0,"All","18 Years","70 Years","150","November 2011","July 2012","Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) or ≥ 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment.","0","0","0","0","0","0","0","0","0"
"3808","NCT01740284","A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine","Allergic Rhinoconjunctivitis",0,"Grazax + Aerius","Drug","ALK-Abelló A/S","Industry",0,0,"All","18 Years","65 Years","46","September 2008","January 2009","To evaluate whether intake of antihistamine in connection with Grazax treatment results in a reduction in number of subjects reporting treatment related AEs the first day of Grazax exposure","0","0","0","0","0","0","0","0","0"
"3809","NCT01747330","Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency","Pancreatic Exocrine Insufficiency",0,"Pancreatin","Drug","Abbott Products","Industry",0,0,"All","N/A","4 Years","40","June 2012","December 2012","Body Weight","0","0","0","0","0","0","0","0","0"
"3810","NCT01751867","An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome","Myelodysplastic Syndrome",0,"Decitabine at 15 mg/m2","Drug","Xian-Janssen Pharmaceutical Ltd.","Industry",0,0,"All","18 Years","N/A","135","August 2009","May 2011","Overall Response Rate (ORR): Number of Participants Who Achieved Either Complete Remission (CR), Partial Remission (PR), or Marrow Complete Remission (mCR) - International Working Group (IWG) 2006 Response Criteria","0.003","0","Exact binomial proportion test","29.4","ORR %","95","2-Sided","15.1","47.5"
"3811","NCT01755702","Paracetamol With Caffeine to Treat Episodic Tension Type Headache","Headache, Tension-Type",0,"Placebo","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","65 Years","66","July 2009","March 2010","Time to First Perceptible Headache Relief","0.2840","0","Cox Proportional Hazard Model","1.25","Hazard Ratio (HR)","95","2-Sided","0.83","1.90"
"3812","NCT01759654","A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects","Influenza",0,"AdimFlu-V","Biological","Adimmune Corporation","Industry",0,0,"All","18 Years","N/A","120","October 2012","December 2012","The primary objective is to evaluate the immune response (i.e. HAI titer) in subjects after administration of influenza vaccine for 2012-2013 season.","0","0","0","0","0","0","0","0","0"
"3813","NCT01767922","Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life","Life Stress",0,"Extramel 10 mg - 140 UI SOD","Dietary Supplement","Bionov","Industry",0,0,"All","30 Years","65 Years","61","September 2008","May 2009","Perceived Stress : Change from base line in Cohen PSS 14 scale at V2 and V3","0","0","0","0","0","0","0","0","0"
"3814","NCT01774864","Efficacy and Safety Study of Udenafil to Treat Erectile Dysfunction","Erectile Dysfunction",0,"DA-8159 (Udenafil)","Drug","Dong-A Pharmaceutical Co., Ltd.","Industry",0,0,"Male","20 Years","N/A","349","April 2011","May 2012","IIEF EF domain score","0","0","0","0","0","0","0","0","0"
"3815","NCT01779947","Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo","Atrophic Vaginitis Due to Menopause",0,"Estradiol Vaginal Tablets 10 mcg","Drug","Amneal Pharmaceuticals, LLC","Industry",0,0,"Female","30 Years","75 Years","519","March 2012","September 2012","Responders","0","0","0","0","0","0","0","0","0"
"3816","NCT01781702","Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients","Pelubiprofen",0,"Pelubiprofen 30 mg","Drug","Daewon Pharmaceutical Co., Ltd.","Industry",0,0,"All","18 Years","80 Years","120","October 2010","October 2011","Changes in '100 mm pain VAS' value from baseline","0","0","0","0","0","0","0","0","0"
"3817","NCT01788384","Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris","Acne Vulgaris",0,"Clindamycin Phosphate / Benzoyl Peroxide Gel","Drug","Watson Laboratories, Inc.","Industry",0,0,"All","12 Years","40 Years","708","July 2012","December 2012","The evaluation of the primary endpoint will be based on the mean percent changes from baseline to week 12 in the inflammatory (papules and pustules) lesion counts and in the non-inflammatory (comedones) lesion counts.","0","0","0","0","0","0","0","0","0"
"3818","NCT01791881","Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of ""Hugeltox Inj."" in Essential Blepharospasm","Essential Blepharospasm",0,"Hugeltox","Drug","Hugel","Industry",0,0,"All","18 Years","75 Years","172","April 2008","May 2009","Rate of patients with an improvement more than one Grade of Severity of Spasm (by Scott's Method)","0","0","0","0","0","0","0","0","0"
"3819","NCT01791920","To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines","Skin Aging",0,"Botulinum toxin type A(Botulax®)","Drug","Hugel","Industry",0,0,"All","18 Years","65 Years","262","August 2011","December 2011","Responder rate of improvement in glabellar lines with Physician's rating of line severity","0","0","0","0","0","0","0","0","0"
"3820","NCT01801436","A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma","Multiple Myeloma",0,"Bortezomib","Drug","Johnson & Johnson Taiwan Ltd","Industry",0,0,"All","18 Years","65 Years","14","December 2006","April 2008","Number of Participants With Response to Treatment at Day 1 of Cycle 5","0","0","0","0","0","0","0","0","0"
"3821","NCT01806792","Post-menopausal Women Osteoporosis(Phase III)","Postmenopausal Women Osteoporosis",0,"risedronate combine","Drug","Hanlim Pharm. Co., Ltd.","Industry",0,0,"Female","N/A","N/A","150","November 2009","August 2010","proportion of patients with 25(OH)D level < 20 ng/mL at 16 weeks.","0","0","0","0","0","0","0","0","0"
"3822","NCT01814878","A Study Comparing the Effectiveness and Safety of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen With Immediate Release (IR) Tramadol HCl/Acetaminophen in Participants With Moderate to Severe Postoperative Pain","Pain, Postoperative",0,"Tramadol HCl/Acetaminophen ER","Drug","Janssen Korea, Ltd., Korea","Industry",0,0,"All","25 Years","80 Years","320","November 2009","January 2011","Sum of Pain Intensity Difference (SPID) at Hour 48","0.1648","Hour 48: P-value was calculated using Student's t-test","Student's t-test","-4.68","Mean Difference (Final Values)","95","2-Sided","-11.29","1.93"
"3823","NCT01820728","A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F®","Infertility",0,"DA-3801 Injection","Drug","Dong-A Pharmaceutical Co., Ltd.","Industry",0,0,"Female","20 Years","38 Years","93","January 2007","October 2012","The ovulation rate after 3 cycles of the injection","0","0","0","0","0","0","0","0","0"
"3824","NCT01842893","Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer","Breakthrough Pain",0,"Fentanyl Ethypharm","Drug","Ethypharm","Industry",0,0,"All","18 Years","N/A","91","November 2011","July 2012","Summed Pain Intensity Difference at 30 minutes (SPID30).","0","0","0","0","0","0","0","0","0"
"3825","NCT01846442","Topical DHEA Against Vaginal Atrophy","Vaginal Atrophy",0,"Placebo","Drug","EndoCeutics Inc.","Industry",0,0,"Female","40 Years","75 Years","218","June 2007","May 2008","Co-primary Endpoint: Change From Baseline Over Time of Vaginal Cell Maturation (Percentage of Parabasal Cells)","0","0","0","0","0","0","0","0","0"
"3826","NCT01857583","Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs","Venous Thromboembolism",0,"15mg DU-176b","Drug","Daiichi Sankyo Co., Ltd.","Industry",0,0,"All","20 Years","N/A","80","March 2012","December 2012","Incidence of Any Adjudicated Bleeding Events","0","0","0","12.6","Cox Proportional Hazard","95","2-Sided","-10.0","33.6"
"3827","NCT01861600","Stool Composition and Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas","Stool Composition",0,"S-26 Gold","Other","Nestlé","Industry",0,0,"All","N/A","14 Days","375","April 2009","August 2009","Stool Composition in Healthy Term Infants Fed Human Milk or Infant Formulas","0","0","0","0","0","0","0","0","0"
"3828","NCT01867164","A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis","Vaginitis",0,"Gynoclin V","Drug","Janssen-Cilag, S.A.","Industry",0,0,"Female","18 Years","75 Years","160","December 2007","December 2008","Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment","0","0","0","0","0","0","0","0","0"
"3829","NCT01876849","An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"exenatide","Drug","AstraZeneca","Industry",0,0,"All","30 Years","75 Years","275","December 2003","July 2008","Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events.","0","0","0","0","0","0","0","0","0"
"3830","NCT01884038","Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients","Liver Transplant",0,"treprostinil sodium","Drug","United Therapeutics","Industry",0,0,"All","18 Years","75 Years","0","June 2008","June 2010","Duration of the initial hospitalization (days) following transplantation","0","0","0","0","0","0","0","0","0"
"3831","NCT01886898","Synbiotics and Growth","Infants Growth",0,"Infant formula","Other","Nestlé","Industry",0,0,"All","N/A","14 Days","311","June 2007","February 2009","mean weight gain (g/day)","0","0","0","0","0","0","0","0","0"
"3832","NCT01896739","A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants","Healthy Infants",0,"Eutravac","Biological","LG Life Sciences","Industry",0,0,"All","N/A","6 Months","289","August 2009","November 2011","Seroprotection rate","0","0","0","0","0","0","0","0","0"
"3833","NCT01901640","Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction","Erectile Dysfunction",0,"DA-8159 (Udenafil)","Drug","Dong-A Pharmaceutical Co., Ltd.","Industry",0,0,"Male","20 Years","N/A","302","November 2011","November 2012","Safety","0","0","0","0","0","0","0","0","0"
"3834","NCT01902992","Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch","Allergic Rhinoconjunctivitis",0,"Depiquick Birch (DPG103)","Drug","Novartis","Industry",0,0,"All","12 Years","70 Years","202","March 2012","July 2012","Combined Symptom and Medication Score (SMS)","0","0","0","0","0","0","0","0","0"
"3835","NCT01964768","Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick Testing","Allergy",0,"Skin prick-test","Other","Stallergenes","Industry",0,0,"All","5 Years","60 Years","324","December 2010","June 2011","Skin wheal measure for each tested solution. For each allergen tested, 2 variables, positive SPT and negative SPT were defined. A SPT reaction was considered positive when the mean wheal diameter was >3 mm. A SPT reaction ≤3 mm was considered negative.","0","0","0","0","0","0","0","0","0"
"3836","NCT01996748","Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema","Otic Eczema",0,"DF277","Drug","Salvat","Industry",0,0,"All","12 Years","N/A","135","February 2012","March 2012","Analysis of the Itching Change at the End of Treatment.","0","0","0","0","0","0","0","0","0"
"3837","NCT02010918","Efficacy and Safety of Glucosamine Sulfate and Chondroitin Sulfate Combination in Treatment of Knee Osteoarthritis","Knee Osteoarthritis",0,"glucosamine sulfate /chondroitin sulfate - capsules","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"All","40 Years","N/A","922","February 2009","November 2010","Change from baseline in pain intensity in the affected knee and variation of Lequesne's index and VAS at week 16 .","0","0","0","0","0","0","0","0","0"
"3838","NCT02016963","An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection","Therapeutic Treatment of Inhalation Anthrax",0,"Raxibacumab","Biological","Human Genome Sciences Inc.","Industry",0,0,"All","18 Years","64 Years","20","January 2008","May 2008","Number of Participants Who Developed a Positive Anti-raxibacumab Antibody Response","0","0","0","0","0","0","0","0","0"
"3839","NCT02054338","A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer","Advanced Breast Cancer",0,"vinflunine 320 mg/m² as a 20-minute infusion on day 1 of each cycle repeated every 3 weeks gemcitabine 1000 mg/m² IV on day 1 and 8 repeated every 3 weeks","Drug","Pierre Fabre Medicament","Industry",0,0,"Female","18 Years","75 Years","1004","June 2006","June 2011","Progression Free Survival","0","0","0","0","0","0","0","0","0"
"3840","NCT02110212","Femtosecond Laser for Cataract Surgery","Cataract",0,"U/S Surgery and CCC","Procedure","Abbott Medical Optics","Industry",0,0,"All","50 Years","80 Years","17","April 2011","December 2011","Capsulotomy Dimension","0","0","0","0","0","0","0","0","0"
"3841","NCT02118896","Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant","Kidney Transplantation",0,"FK506E","Drug","Astellas Pharma Europe Ltd.","Industry",0,0,"All","18 Years","N/A","850","January 2003","October 2009","Participant Survival","0","0","0","0","0","0","0","0","0"
"3842","NCT02273817","A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis","Seasonal Allergic Rhinitis",0,"Ciclesonide nasal spray, 50 μg per actuation.","Drug","Apotex Inc.","Industry",0,0,"All","18 Years","65 Years","580","March 2011","August 2011","Treatment Of Seasonal Allergic Rhinitis","0","0","0","0","0","0","0","0","0"
"3843","NCT02285036","Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children","Pneumococcal Infectious Diseases",0,"vaccination PPV23","Biological","Walvax Biotechnology Co., Ltd.","Industry",0,0,"All","2 Years","N/A","1660","September 2012","December 2012","the rate of 2-fold increase of anti-pneumococcal antibody","0","0","0","0","0","0","0","0","0"
"3844","NCT02314637","Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients","Type 2 Diabetes Mellitus",0,"Teneligliptin","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","75 Years","240","August 2009","July 2011","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"3845","NCT02360514","Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS","Infection",0,"Hantavax injection","Drug","Green Cross Corporation","Industry",0,0,"All","19 Years","75 Years","226","December 2007","October 2012","Antibody seroconversion rates at 1 month after the booster vaccination and its retention rates","0","0","0","0","0","0","0","0","0"
"3846","NCT02435836","A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia","Schizophrenia",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","N/A","631","April 1998","December 2012","Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score by Week","0","0","0","0","0","0","0","0","0"
"3847","NCT02441218","Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study","Chronic Heart Failure",0,"Ivabradine","Drug","Servier","Industry",0,0,"All","18 Years","N/A","6505","September 2006","April 2010","Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.","<0.0001","0","Regression, Cox","0.82","Hazard Ratio (HR)","95","2-Sided","0.75","0.90"
"3848","NCT02449044","International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia","Hyponatremia",0,"Tolvaptan","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","N/A","111","May 2004","October 2009","Participants With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"3849","NCT02486354","Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy","Non-small Cell Lung Cancer",0,"icotinib","Drug","Betta Pharmaceuticals Co.,Ltd.","Industry",0,0,"All","18 Years","75 Years","128","March 2010","October 2011","progression-free survival","0","0","0","0","0","0","0","0","0"
"3850","NCT02525549","Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris","Acne",0,"Adapalene and Benzoyl Peroxide Gel","Drug","Perrigo Company","Industry",0,0,"All","12 Years","40 Years","903","December 2011","August 2012","Mean percent change from Baseline in inflammatory (papules and pustules) lesions","0","0","0","0","0","0","0","0","0"
"3851","NCT02616042","The Effect of New Dentifrices Containing Centella Asiatica and Bamboo Salt on Reducing Plaque and Gingivitis","Labor Trial Refused",0,"Centella asiatica and bamboo salt","Other","LG Household & Health Care Ltd.","Industry",0,0,"All","18 Years","40 Years","33","March 2009","July 2009","Gingivitis","0","0","0","0","0","0","0","0","0"
"3852","NCT02658188","Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients","Restless Legs Syndrome",0,"ASP8825","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","80 Years","182","December 2007","April 2009","Change from baseline in IRLS score","0","0","0","0","0","0","0","0","0"
"3853","NCT02799069","Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy","Actinic Keratosis",0,"BF-200 ALA","Drug","Biofrontera Bioscience GmbH","Industry",0,0,"All","18 Years","85 Years","571","April 2008","August 2009","Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), ITT","0","0","0","14.0","Difference to BF-200 ALA","97.5","1-Sided","5.9","0"
"3854","NCT02799082","Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.","Actinic Keratosis",0,"Vehicle","Drug","Biofrontera Bioscience GmbH","Industry",0,0,"All","18 Years","85 Years","122","December 2007","October 2008","Total Patient Clearance Rate 12 Weeks After the Last Photodynamic Therapy (PDT)","<0.0001","The percentages stated relate to the total number of subjects for the respective week and treatment.
Cochran-Mantel-Haenszel Test stratified by center","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"3855","NCT02847455","Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients","Duodenal Ulcer",0,"5 mg ilaprazole","Drug","Livzon Pharmaceutical Group Inc.","Industry",0,0,"All","18 Years","65 Years","408","August 2008","October 2009","The primary endpoint was the healing rate of ulcers, which based on post-treatment (week 4) endoscopic changes in stage of the ulcer relative to baseline (week 0) levels.","0","0","0","0","0","0","0","0","0"
"3856","NCT03072719","The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity","Dentine Hypersensitivity",0,"Stannous Fluoride","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","65 Years","120","March 1, 2012","June 1, 2012","Change From Baseline in Schiff Sensitivity Score on Day 14","0.1774","From ANCOVA model: Treatment as fixed factor, baseline Schiff Sensitivity score as covariate.","ANCOVA","-0.19","Least square (LS) mean difference","95","2-Sided","-0.46","0.09"
